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Foreword 
 
This publication includes papers presented at the 58th 
semiannual meeting of the Community Epidemiology 
Work Group (CEWG) held in Denver, Colorado, on 
June 14–17, 2005, under the sponsorship of the Na-
tional Institutes of Health, National Institute on Drug 
Abuse (NIDA).  
 
Representing 21 sentinel areas in the United States, 
CEWG representatives presented reports, citing the 
most recent data on drug abuse patterns, trends, and 
emerging problems in their areas. To enhance nonur-
ban representation, guest researchers from Maine and 
Ohio presented information on drug abuse patterns and 
trends in their areas. The meeting also included presen-
tations by two panels. One, comprised of NIDA- 
 
supported researchers, presented findings on metham-
phetamine/stimulant abuse among youth and young 
adults.  A second panel was comprised of international 
researchers who presented findings on drug abuse pat-
terns and emerging trends in Australia, Europe, Mex-
ico, Southern Africa, and Taiwan.   
 
Information reported at each CEWG meeting is dis-
seminated to drug abuse prevention and treatment 
agencies, public health officials, researchers, and poli-
cymakers. The information is intended to alert authori-
ties at the local, State, regional, and national levels and 
the general public to current drug abuse patterns and 
trends and emerging drug problems so that appropriate 
and timely action can be taken. Researchers also use 
this information to develop research hypotheses that 
might explain social, behavioral, and biological issues 
related to drug abuse.  
 
 
 
Moira P. O’Brien 
Division of Epidemiology, Services and Prevention Research 
National Institute on Drug Abuse 
National Institutes of Health 
Department of Health and Human Services 
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Introduction 
 
This publication includes papers based on informa-
tion and findings on drug abuse that were presented 
at the June 2005 Community Epidemiology Work 
Group meeting in Denver, Colorado. 
The papers of the CEWG representatives provided 
the most recent indicator data on the abuse of co-
caine/crack, heroin, methamphetamine, narcotic an-
algesics/other opiates, and marijuana in 21 CEWG 
areas and in the guest States of Ohio and Maine. The 
meeting also included two panel presentations. One 
panel focused on methamphetamine/stimulant abuse 
among youth and young adults, based on findings 
from NIDA-supported community-based research 
studies. The second focused on drug abuse patterns 
and emerging trends in other countries, namely Aus-
tralia, Europe, Mexico, Southern Africa, and Taiwan. 
Timothy Condon, Ph.D., Deputy Director, NIDA, 
welcomed participants and provided an update on 
NIDA research activities. The update included infor-
mation on NIDA’s collaboration with other Federal 
agencies in building partnerships to test NIDA’s re-
search findings at the community level. 
Wilson Compton, M.D., M.P.E., NIDA, led the dis-
cussion for the Panel on Methamphetamine and Other 
Stimulant Abuse among Youth and Young Adults. 
The Panel on International Drug Abuse Emerg-
ing/Current Trends was led by Steve Gust, Ph.D., 
NIDA. 
At the June meeting, updates were presented on the 
Drug Abuse Warning Network by Judy Ball, Ph.D., 
and on the National Forensic Laboratory Information 
System, by James Tolliver, Ph.D. A session by Ed-
ward Boyer, M.D., focused on Using the Internet as a 
Tool for Identifying and Monitoring Drugs of Abuse. 
Jamie Van Leeuwan, M.D., M.P.H., C.A.C. II, Direc-
tor of Development and Public Affairs, Urban Peak, 
addressed the problem of homeless and runaway 
youth and hosted a field trip for participants to visit 
Urban Peak. 
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The CEWG Network: Goals, 
Functions, and Data Sources 
The CEWG is a unique epidemiologic network that 
informs drug abuse prevention and treatment agen-
cies, public health officials, policymakers, and the 
general public about current and emerging drug abuse 
patterns. The network is comprised of researchers 
from 21 areas: Atlanta, Baltimore, Boston, Chi-
cago, Denver, Detroit, Honolulu, Los Angeles, Mi-
ami/Ft. Lauderdale, Minneapolis/St. Paul, New 
Orleans, New York City, Newark, Philadelphia, 
Phoenix, St. Louis, San Diego, San Francisco, Se-
attle, Texas, and Washington, DC.  
Interactive semiannual meetings are a major and dis-
tinguishing feature of the CEWG and provide a foun-
dation for continuity in monitoring and surveillance 
of current and emerging drug problems and related 
health and social consequences. Through the meet-
ings, the CEWG… 
• Identifies changing drug abuse patterns within 
and across CEWG areas 
• Plans followup on problems identified, e.g., 
emerging drug problems 
• Disseminates information on drug abuse patterns 
and trends in each CEWG area 
Papers presented by CEWG representatives include 
quantitative and qualitative drug abuse indicator data. 
Representatives go beyond publicly accessible data 
and provide a broader perspective obtained from both 
public records and qualitative research. Information 
is most often obtained from local substance abuse 
treatment providers and administrators, personnel of 
other health-related agencies, law enforcement offi-
cials, and drug abusers. 
Time at each meeting is devoted to presentations 
by… 
• Guest researchers, including NIDA grantees, 
who provide data/findings on a current or emerg-
ing drug problem identified in prior CEWG 
meetings 
• Federal personnel who provide updates on data 
sets used by CEWG members 
• Researchers from other countries who provide 
recent drug abuse data/findings 
The primary data sources used by CEWG representa-
tives and cited in this report include the following: 
• National Forensic Laboratory Information 
System (NFLIS) data, maintained by the Drug 
Enforcement Administration (DEA) 
• Treatment data from State and local sources and 
the Treatment Episode Data Set (TEDS), main-
tained by the Office of Applied Studies (OAS), 
Substance Abuse and Mental Health Services 
Administration (SAMHSA) 
• Drug Abuse Warning Network (DAWN) 
emergency department data, accessed through 
DAWN Live!, a restricted-access online service 
administered by OAS, SAMHSA 
• DAWN and local drug-related mortality data 
from OAS, SAMHSA, and/or local medical ex-
aminers/coroners 
• Law enforcement data from various sources, 
e.g., DEA’s Domestic Monitor Program, local 
DEA offices, Threat Assessment data from the 
Nation Drug Intelligence Center (NDIC), U.D. 
Department of Justice, and price and purity data 
from Narcotics Digest Weekly, and local police 
and sheriff’s offices 
Other data sources used by CEWG representatives, 
when available, include poison control centers, help-
lines, and surveys. 
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Drug Trends in Metropolitan 
Atlanta 
 
Brian J. Dew, Ph.D.,1 Claire E. Sterk, 
Ph.D.,2 and Kirk W. Elifson, Ph.D.1 
 
ABSTRACT 
 
Drug abuse indicators showed that cocaine/crack 
remained a primary drug of abuse in Atlanta during 
2004, with the drug dominant among ED reports, 
treatment admissions, and seized items analyzed by 
NFLIS. Marijuana use was widespread as well, with 
the drug accounting for 21.7 percent of public 
treatment admissions. This proportion, however, 
was consistent with previous years. Methampheta-
mine abuse appeared to be increasing, with treat-
ment admissions continuing to rise faster than for 
any other classification of drug. Treatment admis-
sions for methamphetamine remained low, at 8.5 
percent, however, compared to admissions for other 
drugs. Heroin indicators continued to reflect low 
levels of use of this drug in the metropolitan Atlanta 
area.  
 
INTRODUCTION 
 
Area Description 
 
The metropolitan Atlanta area is located in the 
northwest corner of the State of Georgia and includes 
20 of the State’s 159 counties. The metropolitan area 
comprises more than 6,100 square miles, or 10.5 per-
cent of Georgia’s total size. Currently, Georgia is the 
10th most populous State in the Nation. From April 
2000 to July 2002, the State’s population grew 4.6 
percent, ranking fourth among all States.    
 
With an estimated 4.4 million residents, the metro-
politan Atlanta area includes nearly 52 percent of the 
State’s population of nearly 8.4 million residents 
(U.S. Bureau of the Census, 2003). The Atlanta met-
ropolitan area ranks ninth among the Nation’s major 
population centers. The city of Atlanta, with a popu-
lation of approximately 369,000, represents 8.2 per-
cent of the overall metropolitan population (Ameri-
can Community Survey, 2003). The city is divided 
into two counties, Fulton County and DeKalb 
County, which include 18.8 and 15.9 percent of the 
metropolitan population, respectively.  
                                                 
1 Drs. Brian Dew and Kirk Elifson are affiliated with Georgia State 
University, Atlanta, Georgia. 
2Dr. Claire Sterk is affiliated with Emory University, Atlanta, 
Georgia. 
There are demographic differences between the city 
of Atlanta and the larger metropolitan area, which 
more closely reflects the State as a whole. African-
Americans are the largest ethnic group within the city 
(60 percent), followed by Whites (37 percent), His-
panics (6 percent), and Asians (2 percent). When 
examining the overall metropolitan Atlanta area, 
those numbers reverse. Whites account for the major-
ity (62.5 percent), followed by African-Americans 
(29 percent), Hispanics (7.9 percent), and Asians (3.7 
percent). Per capita family income in 2003 for the 
city of Atlanta was higher at $32,635 than in the met-
ropolitan area, at $26,145. The poverty rate inside the 
city is 24 percent, compared with only 9.6 percent in 
the metropolitan area. The housing vacancy rate out-
side the city (8.9 percent) is much lower than in the 
city (17.5 percent).  
 
In fiscal year (FY) 2004, the Georgia Bureau of In-
vestigation (GBI)’s statewide drug enforcement ef-
forts were led by 3 regional drug offices and 13 mul-
tijurisdictional task force programs. As a result of 
these combined efforts, 2,979 drug offenders were 
arrested. As of December 2004, there were 23 exist-
ing drug courts in Georgia (of these, 13 were for 
adult felony drug offenses, 3 were for adult misde-
meanor drug offenses, and 7 were for juvenile drug 
offenses). One adult felony drug court was located in 
Atlanta. In 2004, 34 percent of those on probation in 
Georgia, 19 percent of prisoners, and 37 percent of 
parolees had been convicted of a drug-related of-
fense.  
 
Additional factors that influence substance use in the 
State: 
  
• Georgia is both a final destination point for drug 
shipments and a smuggling corridor for drugs 
transported along the east coast. Extensive inter-
state highway, rail, and bus transportation net-
works, as well as international, regional, and pri-
vate air and marine ports of entry, serve the 
State. 
 
• The State is strategically located on the I-95 cor-
ridor between New York City and Miami, the 
key wholesale-level drug distribution centers on 
the east coast and major drug importation hubs. 
In addition, Interstate Highway 20 runs directly 
into Georgia from drug entry points along the 
southwest border and gulf coast.   
 
• The city of Atlanta has become an important 
strategic point for drug trafficking organizations, 
as it is the largest city in the South. It is consid-
ered a convenient nexus for all east/west and 
north/south travel. The city’s major international 
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airport also serves as a distribution venue for il-
licit substances.   
 
• The entire State, Atlanta in particular, has ex-
perienced phenomenal growth over the last sev-
eral years, with a corresponding increase in drug 
crime and violence. With Georgia bordering 
North Carolina, South Carolina, Tennessee, Ala-
bama, and Florida, Atlanta is the base for several 
major dealers who maintain trafficking cells in 
these States, especially Mexican-based traffick-
ers who hide within legitimate Hispanic en-
claves. 
 
Data Sources 
 
Principal data sources for this report include the fol-
lowing: 
 
• Emergency department (ED) data were de-
rived for calendar year 2004 from the Drug 
Abuse Warning Network (DAWN) Live! re-
stricted-access online query system administered 
by the Office of Applied Studies (OAS), Sub-
stance Abuse and Mental Health Services Ad-
ministration (SAMHSA). Eligible hospitals in 
the Atlanta area totaled 39; hospitals in the 
DAWN sample numbered 30, with the number 
of emergency departments in the sample totaling 
33. (Some hospitals have more than one emer-
gency department.) During this 12-month period, 
between 16 and 18 EDs reported data each 
month. The completeness of data reported by 
participating EDs varied by month (see exhibit 
1). Exhibits in this paper primarily reflect cases 
that were received by DAWN as of April 14, 
2005; an update on June 4, 2005, was also ac-
cessed for selected data (as shown in exhibit 3). 
All DAWN cases are reviewed for quality con-
trol. Based on this review, cases may be cor-
rected or deleted. Therefore, these data are sub-
ject to change. Data derived from DAWN Live! 
represent drug reports in drug-related ED visits. 
Drug reports exceed the number of ED visits, 
since a patient may report use of multiple drugs 
(up to six drugs and alcohol). The DAWN Live! 
data are unweighted, and, thus, are not estimates 
for the reporting area. These data cannot be 
compared to DAWN data from 2002 and before, 
nor can preliminary data be used for comparison 
with future data. Only weighted DAWN data re-
leased by SAMHSA can be used for trend analy-
sis. A full description of the DAWN system can 
be found at <http://dawninfo.samhsa.gov>.  
 
• Drug abuse treatment program data are from 
the Georgia Department of Human Resources for 
primary drugs of abuse among clients admitted 
to Atlanta’s public drug treatment programs be-
tween January and December 2004. Data for 
non-metropolitan Atlanta counties of Georgia 
were also reported.    
 
• Drug price, purity, and trafficking data are 
from the Drug Enforcement Administration 
(DEA), the National Drug Intelligence Center 
(NDIC), and the Office of National Drug Control 
Policy (ONDCP).  Information for 2004 on the 
price, purity, and source of heroin was provided 
by the DEA’s Domestic Monitoring Program 
(DMP). Additional information came from Nar-
cotics Digest Weekly published by the NDIC. 
Other data are from the Atlanta High Intensity 
Drug Trafficking Area (HIDTA) Task Force, a 
coordination unit for drug-related Federal, State, 
and local law enforcement agencies. 
 
• Forensic drug analysis data are from the Na-
tional Forensic Laboratory Information System 
(NFLIS) and represent evidence in suspected 
drug cases throughout metropolitan Atlanta that 
were tested by the GBI Forensic Laboratory from 
January through December 2004.  
 
• Ethnographic information was collected from 
local drug use researchers and is used for several 
purposes: (1) to corroborate the epidemiologic 
drug indicators, (2) to signal potential drug 
trends, and (3) to place the epidemiologic data in 
a social context.  
 
• Acquired immunodeficiency syndrome (AIDS) 
data are from the Department of Human Re-
sources and represent AIDS cases in Georgia and 
a 20-county Atlanta metropolitan from January 
1981 through August 2004. Additional informa-
tion was provided by the Centers for Disease Con-
trol and Prevention (CDC).   
 
DRUG ABUSE PATTERNS AND TRENDS 
 
Cocaine/Crack 
 
With 5,758 reports in 2004, cocaine continues to be 
the most frequently reported ED drug in the metro-
politan Atlanta area according to unweighted DAWN 
Live! data (exhibit 2). Cocaine ED reports were 
higher among men than women (exhibit 3), with a 
ratio of 2.4:1. There were 991 cocaine ED reports by 
White patients, 3,714 by African-Americans, 65 by 
Hispanics, and 988 by persons of unknown 
race/ethnicity. ED cocaine reports among patients 
between the ages of 35 and 54 totaled 3,838 (67 per-
cent of all ED reports).   
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In 2004, cocaine continued to be the primary drug of 
choice for individuals seeking assistance at publicly 
funded treatment centers in metropolitan Atlanta. 
However, the number of primary admissions in met-
ropolitan Atlanta for cocaine (n=3,162) in this period 
reflects a continuing downward trend (exhibit 4). In 
2000 and 2001, more than one-half of all treatment 
admissions in metropolitan Atlanta were cocaine-
related. In 2003, this percentage decreased to 42.8 
percent, and in 2004, cocaine-related admissions de-
clined to 39.5 percent. The ratio of men to women in 
treatment for cocaine was 1.27:1, a proportion that 
was considerably lower than the 1.65:1 found in 
2003. A smaller percentage of African-Americans 
entered treatment for cocaine-related issues in 2004 
than in previous years. Approximately 7 out of every 
10 cocaine-related admissions were African-
American in 2004 (exhibit 5).  In 2002–2003, Afri-
can-Americans accounted for 75 percent of treatment 
admissions. Whites accounted for a larger proportion 
of statewide cocaine treatment admissions outside 
metropolitan Atlanta. Whites represented 45 percent 
of the treatment population outside the Atlanta area, 
and African-Americans represented 55 percent. In 
2004, those older than 35 accounted for the largest 
number of both metropolitan and non-metropolitan 
cocaine admissions (80 percent).  In Atlanta, there 
was a 31-percent increase in admissions among those 
age 18–25 and an 18-percent increase in admissions 
among those age 26–34 from 2003 to 2004. In met-
ropolitan Atlanta, smoking continued to be the most 
preferred route of administration (77 percent), fol-
lowed by inhalation (13 percent), oral (3 percent), 
and injection (2 percent).  
 
According to the DEA and Atlanta HIDTA, cocaine 
remains readily available in Atlanta. Atlanta is a 
growing distribution hub for surrounding States and 
Europe. Atlanta also serves as part of a smuggling 
corridor along the east coast. Powder cocaine and 
crack dominate the Georgia drug scene. The primary 
sources for cocaine are Texas and California. HIDTA 
intelligence analysts implicate Mexico-based drug 
trafficking organizations, whose members blend 
within enclaves of Hispanic workers. According to 
HIDTA and NDIC, cocaine prices remain relatively 
stable in Atlanta. Powdered cocaine typically sells for 
$75–$100 per gram. Crack rocks sell for as little as 
$3. In 2003, members of the Atlanta HIDTA Task 
Force seized 186.69 kilograms of powdered cocaine 
and 7.56 kilograms of crack cocaine. Both quantities 
were similar to what was seized in 2002.  
 
The Georgia Threat Assessment (DEA 2003) reports 
that other than marijuana, crack is the most available 
drug in the city. Officials estimate that 75 percent of 
all drug-related arrests involve crack cocaine. How-
ever, crack has become more difficult for undercover 
officers to purchase, and it seems to have decreased 
somewhat in popularity. Powder cocaine availability 
at the retail level in Georgia is limited, except in large 
cities such as Atlanta. NFLIS reported that cocaine 
accounted for more than 44 percent of confiscated 
substances in suspected drug cases that were tested in 
forensic laboratories in 2004 (exhibit 6). In 2003, 
cocaine had accounted for nearly 40 percent of all 
confiscated substances in suspected drug cases.  
 
Heroin 
 
Heroin indicators for Atlanta are mixed. However, 
ethnographic data obtained through corroboration 
with local street outreach workers suggests that her-
oin use is increasing.  
 
According to unweighted data accessed from DAWN 
Live!, the number of ED reports of heroin in 2004 
(n=483) was less than reports for cocaine, marijuana, 
methamphetamine, and benzodiazepines (exhibit 2).  
A sizeable majority of these patients were males (ex-
hibit 3), with a 3.4:1 male-to-female ratio. African-
American heroin ED patients exceeded White pa-
tients (1.6:1). The ED heroin reports that involved 
Hispanics represented approximately 1 percent (n=5).  
More than one-half of all patients were age 35–54 
(n=274). Twelve percent of reports occurred among 
18–24-year-olds.  Although injection remains by far 
the most frequent route of heroin administration (74.4 
percent), approximately 10 percent of those with a 
documented route of administration reported inhal-
ing, sniffing, or snorting their heroin. 
 
In 2004, treatment admissions for individuals who 
reported heroin as their primary drug of choice ac-
counted for 2.5 percent of all treatment admissions in 
the State; these admissions were mostly concentrated 
in metropolitan regions.  Nearly 6 percent of metro-
politan Atlanta admissions in 2004 were for heroin 
(exhibit 4), compared with 1.3 percent in non-
metropolitan areas. Admission rates for men were 
double those for women in metropolitan regions, with 
a non-metropolitan male-to-female ratio of 1.3:1. 
African-Americans outnumbered Whites (230 to 206) 
in metropolitan Atlanta treatment admissions (exhibit 
5). Outside of metropolitan Atlanta, Whites repre-
sented an overwhelmingly high percentage (87 per-
cent) of heroin-related treatment admissions, fol-
lowed by African-Americans (9 percent) and Hispan-
ics (2.2 percent). A significant majority of heroin 
treatment admissions in both metropolitan (81 per-
cent) and non-metropolitan (79 percent) Atlanta were 
age 35 and older, as in previous reporting periods.  
While treatment admissions for heroin are relatively 
low for persons younger than 35, it is important to 
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note that 8 percent of heroin treatment admissions 
were for individuals younger than 17.  
 
Treatment data suggest that oral and inhalation ad-
ministration rates may be on the rise in both metro-
politan and non-metropolitan regions and that injec-
tion use of heroin may be declining. More than 35 
percent of all individuals admitted for heroin treat-
ment report smoking, oral, or inhalation as their pri-
mary method of administration.  Nevertheless, anec-
dotal reports from non-profit street outreach workers 
suggest that rates of heroin injection, particularly in 
metropolitan Atlanta, may be on the rise and are 
likely underreported. Most heroin users admitted to 
treatment did not report having a secondary drug of 
choice, although metropolitan users were overall 
more likely than non-metropolitan users to report a 
secondary drug of choice. Among heroin users in 
metropolitan Atlanta, 32 percent reported cocaine as 
a secondary drug of choice, compared with 14.6 per-
cent for non-metropolitan users. The Georgia De-
partment of Public Health estimates the rate of heroin 
addicts in Atlanta to be 159 per 100,000 population 
(n=approximately 7,000). 
 
The NDIC’s Georgia Threat Assessment (April 2003) 
reports that heroin is readily available in metropolitan 
Atlanta and that the city is a high traffic area for her-
oin distribution.  The majority of heroin available in 
Atlanta is South American, followed by heroin from 
southwest Asia. The DEA (February, 2005) reported 
that local purity ranged from 31 to 57 percent in 
2003. According to the ONDCP, in the first half of 
2003 heroin sold for $10–$20 per bag, $462 per 
gram, $6,160 per ounce, and $112,000 per kilogram 
in Atlanta. Law enforcement groups, including 
HIDTA and the DEA, report local heroin is supplied 
via sources in Chicago, New York, and the southwest 
border, and that there has been increased Hispanic 
involvement in trafficking. Reports from outlying 
metropolitan Atlanta counties suggest an increase in 
heroin traffic in their jurisdictions.  Approximately 1 
percent (n=194) of NFLIS seized drug items tested 
positive for heroin in 2004 (exhibit 6). 
 
Law enforcement groups, including HIDTA and the 
DEA, report that Mexican criminal groups are pri-
marily responsible for the trafficking of South 
American heroin in Georgia. These groups use com-
mercial and private vehicles to bring the drugs into 
the State. Heroin also enters the State through Co-
lombian and Nigerian groups that transport the drug 
via airline couriers. Additionally, NDIC and the DEA 
mention that Dominican criminal groups drive heroin 
into Georgia from New York and Philadelphia. Some 
of that heroin is sold in Atlanta and some is shipped 
elsewhere.  
Other Opiates/Narcotics 
 
Most indicators suggest that narcotic pain relievers 
are growing in popularity in metropolitan Atlanta. 
Unweighted DAWN Live! data show 212 ED oxy-
codone/combinations reports and 268 hydro-
codone/combinations reports in 2004 (exhibit 7). A 
greater percentage of oxycodone/combinations ED 
reports involved men and Whites than other groups 
(exhibit 3). African-Americans represented 16 per-
cent of all opiate/opioid ED reports (exhibit 3).  
 
Treatment data for other opiates or narcotics were 
only available for secondary and tertiary drug abuse 
categories. Continuing a stable trend, other opiates 
accounted for about 2–3 percent of secondary drugs 
abused statewide and about 1 percent of tertiary 
drugs abused in 2004. The use of opiates as a secon-
dary abuse category was cited more often in non-
metropolitan areas (2.6 percent) than in metropolitan 
Atlanta (1 percent).  
 
According to NFLIS data, oxycodone and hydro-
codone each accounted for about 1–2 percent of lab 
identifications of drugs seized by law enforcement 
from January through December 2004 (exhibit 6). 
OxyContin, the most widely recognized oxycodone 
product, is a growing drug threat in Georgia, accord-
ing to the DEA. Twenty-milligram tablets sold in the 
illegal market for $20 in 2004. Hydrocodone (Vi-
codin) and hydromorphone (Dilaudid) are also 
abused in Atlanta. These drugs are obtained by “doc-
tor-shopping” or by purchasing from dealers. Some 
dealers steal prescription pads or rob pharmacies. 
Several such incidents were reported in Georgia in 
2004.  
 
Marijuana 
 
Ethnographic sources consistently confirm that mari-
juana is the most commonly abused drug in Atlanta. 
Most epidemiological indicators show an upward 
trend in marijuana use, particularly among individu-
als younger than 17. 
 
According to unweighted data accessed from DAWN 
Live!, there were 2,001 marijuana ED reports in 2004 
(exhibit 2). There were more than twice as many 
marijuana reports for men as for women. The number 
of ED reports involving African-Americans was 
higher than that of Whites (1.4:1). Sixty-two percent 
of all ED reports for marijuana were distributed 
evenly among individuals age 18–35, with 35–44 
year-olds representing the largest percentage by age 
group (27 percent of all ED reports). Eight percent of 
reports were among 12–17-year-olds, and no reports 
occurred among those younger than 12 (exhibit 3).  
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Nearly 22 percent of public treatment admissions in 
2004 in metropolitan Atlanta were for those who 
considered marijuana their primary drug of choice 
(exhibit 4). Male admissions were just slightly less 
than double those of females in metropolitan Atlanta 
(1.9:1), with the gap narrowing in non-metropolitan 
regions (1.6:1). In 2004, the proportion of African-
Americans who identified marijuana as their primary 
drug of choice increased in metropolitan Atlanta (56 
percent vs. 46 percent in 2003) (exhibit 5) and de-
creased in non-metropolitan Atlanta (24 percent vs. 
39 percent in 2003). Similar to 2003, the vast major-
ity of users (81 percent) in 2004 were at least 35 
years old.  In metropolitan Atlanta, treatment admis-
sions of individuals 17 and younger (n=112) were 
more frequent than admissions age 18–25 (109). This 
trend was consistent in non-metropolitan public 
treatment facilities where individuals 17 and younger 
(n=401) were more likely to enter treatment than in-
dividuals 18–25 (391). Alcohol was the most popular 
secondary drug of choice for marijuana users, fol-
lowed by cocaine and methamphetamine for both 
metropolitan and non-metropolitan Atlanta admis-
sions.  
 
Marijuana, which is readily available in Atlanta and 
the rest of Georgia, retails for about $10–$20 per 
gram and $100–$350 per ounce, according to the 
DEA. Atlanta serves as a regional distribution center 
for marijuana. Most of the marijuana in Georgia 
comes from Mexico, although locally grown mari-
juana is also on the market. Colombian and Jamaican 
marijuana are purportedly present but less available. 
Mexican drug cartels are the primary transporters and 
wholesale distributors of Mexican-grown marijuana. 
Local gangs (African-American and Hispanic) and 
local independent dealers (African-American and 
White) are the primary resale distributors. 
 
Marijuana seizures increased 150 percent between 
2002 and 2003, with HIDTA Task Force officers 
confiscating 1,741.17 kilograms of bulk marijuana 
and 210 cannabis plants. The NFLIS report for 2004 
indicates that 14.4 percent of all drug-related items 
confiscated test positive for marijuana (exhibit 6). 
This proportion indicates a decrease from 2003, when 
23 percent of all drug-related items tested positive for 
marijuana. According to The Georgia Governor's 
Task Force on Drug Suppression, 58 percent of 
Georgia’s 159 counties have been reported as signifi-
cant locations for marijuana cultivation. 
 
Ethnographic data continue to support treatment and 
law enforcement data that indicate the widespread 
availability and use of marijuana in Atlanta. Hydro-
ponic cultivation of marijuana has become more 
popular due in part to the DEA’s eradication pro-
gram. 
 
Stimulants 
 
Methamphetamine is the most abused stimulant in 
Atlanta, and its use is increasing. Law enforcement 
efforts to stop the spread of this drug have involved 
seizures and closures of clandestine labs. Metham-
phetamine is an increasing threat in the suburban 
areas because of the drug’s price and ease of avail-
ability, and it is replacing some traditional drugs as a 
less expensive, more potent alternative. Moreover, 
frequent media reports; recent strengthening of crimi-
nal penalties for the manufacture, transfer, and 
possession of methamphetamine; and the statewide 
illegalization of transporting materials used in its 
production have fueled the growing concerns over the 
dangers the drug poses. Methamphetamine is not 
only a party drug, but it is also used for weight loss or 
as a way to keep up with demanding work schedules.  
 
There were 567 ED reports of methamphetamine in 
the Atlanta metropolitan area from January through 
December 2004 according to unweighted data ac-
cessed from DAWN Live! (exhibit 2). During this 
same period, the ratio of men to women among 
methamphetamine ED reports was nearly 2:1. Al-
though race/ethnicity was not documented for 19 
percent of these patients, Whites represented nearly 
70 percent of the methamphetamine ED reports (ex-
hibit 3).  ED reports among patients between the ages 
of 25 and 44 totaled 346 (61 percent of all metham-
phetamine ED reports).   
 
There were 367 ED amphetamine reports in the At-
lanta metropolitan area in 2004 (exhibit 2). The gap 
between male and female ED reports for ampheta-
mine was narrow (exhibit 3), with a male-to-female 
ratio of 1.3:1. More than three out of four ampheta-
mine-related ED patients were White, while African-
Americans represented 8 percent of these patients.  
 
The proportion of treatment admissions in metropoli-
tan and non-metropolitan areas for methamphetamine 
continues to rise faster than for any other classifica-
tion of drug. In 2004, 8.5 percent (n=680) of public 
treatment admissions reported methamphetamine as 
the primary drug of choice, compared with 5.1 per-
cent (543) in 2003 and 3.1 percent (377) in 2002 (ex-
hibit 4). The proportion of admissions for metham-
phetamine in non-metropolitan Atlanta was more 
than 14 percent, the highest percentage ever reported. 
The number of women in metropolitan Atlanta who 
reported to treatment for methamphetamine-related 
causes increased in 2004 and represented more than 
53 percent of all admissions. In treatment centers 
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outside of metropolitan Atlanta, the percentage of 
women entering treatment (56 percent) remained 
nearly identical to 2003. Most users were White; in 
fact, Whites accounted for 96 percent of treatment 
admissions in metropolitan Atlanta during 2004 (ex-
hibit 5). Nevertheless, the proportions of African-
American and Hispanic users are growing. Regard-
less of demographic area, more than 78 percent of 
statewide treatment admissions were individuals 
older than 35. Metropolitan Atlanta treatment admis-
sions were most likely to smoke methamphetamine 
(47 percent), followed by snort (23 percent), and in-
ject (13 percent). Non-metropolitan Atlanta treatment 
admissions preferred to smoke (56 percent), inject 
(15 percent), and orally consume methamphetamine 
(14 percent). 
 
According to the DEA and HIDTA, methampheta-
mine popularity continues to rise, in part because of 
its low price and ready availability. In 2004, 
methamphetamine typically sold for $110 per gram, 
$1,316 per ounce, and $8,250 per pound. 
 
Law enforcement officials report that methampheta-
mine has emerged as the primary drug threat in sub-
urban communities in neighboring Fulton and 
DeKalb Counties. The Atlanta HIDTA task force 
found that more than 68 percent of participating law 
enforcement agencies identified methamphetamine as 
posing the greatest threat to their areas. Metham-
phetamine accounted for more than 30 percent of 
NFLIS tests of seized drugs in 2004, compared with 
23 percent in 2003. In 2004, the proportion of posi-
tive methamphetamine tests among seized drugs 
ranked second behind only cocaine (exhibit 6). In 
2003, the proportion of methamphetamine-related 
items had ranked third behind cocaine and marijuana.  
The HIDTA task force seized more methampheta-
mine in 2004 than in previous years. These seizures 
in 2004 included 14.6 kilograms of methampheta-
mine and 11.4 kilograms of crystal methamphetamine 
or “ice.” HIDTA investigators also report an increase 
among African-Americans using methamphetamine 
in Atlanta. Ethnographic data from Atlanta-area drug 
research studies among individuals age 18–25 sup-
port this trend. 
 
Depressants 
 
The use of depressants, especially benzodiazepines, 
is on the rise in Atlanta. The most commonly abused 
benzodiazepine is alprazolam (Xanax). Only a few 
people admitted for drug treatment chose benzodi-
azepines as their secondary or tertiary drug of choice, 
but ME reports for these drugs continued to increase.  
 
The number of unweighted ED reports in metropoli-
tan Atlanta consists of the following: 96 barbiturates, 
814 benzodiazepines, and 268 miscellaneous other 
depressants.   
 
The treatment data from publicly funded programs 
included depressants such as barbiturates and benzo-
diazepines only as secondary and tertiary drug 
choices for 2004. In metropolitan Atlanta, nearly 1 
percent of primary heroin and methamphetamine 
users chose benzodiazepines as a secondary drug 
choice. These percentages are consistent with the 
figures from the previous 3 years.  
 
The DEA considers benzodiazepines and other pre-
scription depressants to be a minor threat in Georgia. 
The pills are widely available on the street, but their 
abuse does not seem to have reached the levels of 
oxycodone and hydrocodone abuse. According to the 
NDIC and DEA Georgia Threat Assessment (April 
2003), local dealers tend to work independently and 
typically sell to “acquaintances and established cus-
tomers.” These primarily White dealers and abusers 
steal prescription pads, rob pharmacies, and attempt 
to convince doctors to prescribe the desired pills.  
 
Hallucinogens 
 
The epidemiological indicators and law enforcement 
data do not indicate much hallucinogen use in At-
lanta. Despite these data, there was an increase in 
ethnographic reports of phencyclidine (PCP) in the 
past 12 months.  
 
In 2004, there were 24 total ED reports for lysergic 
acid diethylamide (LSD) according to the unweighted 
DAWN Live! data. Most of the 2004 ED reports in-
volved men rather than women, with a ratio of 5:1. 
Whites and African-Americans represented equal 
numbers (n=9) of ED patients for LSD. In 2004, the 
majority of LSD patients were age 18–29 (67 per-
cent). The total number of ED reports for PCP in 
2004 was 47. PCP reports were highest among White 
males between the ages of 35 and 44 and 18 and 24. 
 
Treatment data for hallucinogens are only available 
for secondary and tertiary drug abuse categories, and 
these are listed as PCP and “other hallucinogens.” In 
2004, hallucinogens were listed 14 times as a secon-
dary or tertiary drug of choice in metropolitan At-
lanta. “Other hallucinogens” were listed 30 times as a 
secondary drug of abuse and 41 times as a tertiary 
drug in non-metropolitan areas, also consistent with 
previous years.  
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In 2004, LSD accounted for only 0.04 percent of 
drugs analyzed by NFLIS. The DEA reports an in-
crease in the availability of LSD, especially among 
White traffickers/users age 18–25. LSD is usually 
encountered in school settings and is imported 
through the U.S. Postal Service. No PCP items were 
reported by NFLIS in FY 2004.  
 
Club Drugs 
 
While so-called club drugs—methylenedioxymeth-
amphetamine (MDMA or ecstasy), gamma hydroxy-
butyrate (GHB), and ketamine—appear relatively 
infrequently in epidemiological data, ethnographic 
and sociologic research suggests continued frequency 
in use, particularly among metropolitan Atlanta’s 
young adult population.   
 
According to unweighted data accessed from DAWN 
Live!, there were 75 ED MDMA reports in 2004 (ex-
hibit 2). MDMA reports by males exceeded those by 
females by almost double (1.6:1 ratio) (exhibit 3). 
There was an approximately even ratio (1:1.1) among 
Whites and African-Americans; there were no ED 
MDMA reports involving Hispanics. Young adults 
(age 21–29) represent 56 percent of ED MDMA pa-
tients.  The reported route of administration for 
MDMA was almost exclusively oral. More than one-
half of ED MDMA cases were referred to other treat-
ment or admitted for detoxification or psychiatric 
treatment.   
 
Atlanta serves as a distribution point for MDMA to 
other U.S. cities.  According to the NDIC, most of 
the MDMA available in Georgia is produced in 
northern Europe and flown into major U.S. cities, 
including Atlanta.  The NFLIS reported that in 2004, 
MDMA accounted for 2.0 percent of substances 
tested in suspected drug cases (exhibit 6); methyl-
enedioxyamphetamine (MDA) accounted for another 
0.4 percent.  The April 2003 NDIC and DEA Geor-
gia Threat Assessment indicated that most dealers are 
White middle and upper class high school and col-
lege students between the ages of 18 and 25.  The 
drug retails at $20–$30 per tablet, according to a July 
2003 report by the NDIC, although ethnographic data 
indicate that many users buy ecstasy in bulk. Users 
report that bulk ecstasy rates are $5–$10 per pill.  An 
emerging trend among young adults is “candy flip-
ping,” or combining MDMA and LSD, according to a 
local university report. 
 
There were a total of 50 unweighted GHB ED reports 
in 2004. GHB reports for males exceeded those for 
females (exhibit 3), at a ratio of 4.6:1. GHB ED re-
ports were also predominantly White (8 to 1 African-
American, with only 2 Hispanic reports in this time 
period). Seventy-six percent of GHB reports occurred 
among those age 25–44.  There were no ED GHB 
reports for those younger than 18, and there was only 
one report for the 45 and older category. The reported 
preferred route of administration was almost exclu-
sively oral.   
 
The NDIC reports that the primary distributors and 
abusers of GHB are White young adults. The DEA 
Atlanta Division reports that in 2003, liquid GHB 
sold for $500 to $1,000 per gallon and $15 to $20 per 
dose (one dose is usually the equivalent of a capful 
from a small water bottle). 
 
In 2004, there were five unweighted ED ketamine 
reports among males and none among females.  
 
INFECTIOUS DISEASES RELATED TO SUBSTANCE 
ABUSE 
 
At the end of 2003, Georgia ranked eighth in the Na-
tion for cumulative AIDS cases. At the end of 2001, 
the State was ninth. The number of overall AIDS 
cases was significantly higher in 2003 (22 per 
100,000 population) than in 2002 (17.2 per 100,000 
population). Approximately 1,907 new AIDS cases 
were reported in the State in 2003, for a cumulative 
total of 14,023 persons living with AIDS. HIV sur-
veillance nationwide indicates a consistent increase 
in new infections.  
 
In 2003, nearly 73 percent of all new AIDS diagnoses 
were male, while African- Americans accounted for 
74 percent of these total cases. In Georgia, nearly 73 
percent of the new HIV/AIDS cases were older than 
25, with the highest prevalence occurring among 35–
44 year-olds. The majority of new AIDS cases in 
Georgia continue to come from Atlanta’s Fulton and 
DeKalb Counties. 
 
New cases of sexually transmitted diseases identified 
in Georgia in 2003 included chlamydia (n=35,686), 
gonorrhea (n=17,686), and syphilis (n=585). In 2003, 
there were 484 statewide total cases of hepatitis B 
and 64 statewide reports of hepatitis C; the majority 
of cases originated in the Atlanta metropolitan area. 
 
For inquiries concerning this report, please contact Brian J. Dew, 
Ph.D., LPC, Assistant Professor, Georgia State University, De-
partment of Counseling and Psychological Services, P.O. Box 
3980, Atlanta, GA  30302-3980, Phone: (404)651-3409, Email: 
<bdew@gsu.edu>. 
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Exhibit 1. Data Completeness for Atlanta Metropolitan Area DAWN Live! Emergency Departments  
 (n=30),1 by Month:  2004 
 
No. of EDs Reporting per Month: 
Completeness of Data (%)  Total Eligible 
Hospitals1 
No. of Hospi-
tals in DAWN 
Sample 
Total EDs in 
DAWN Sam-
ple2 90–100% 50–89% <50% 
No. of EDs Not 
Reporting 
39 30 33 16–18 0–2 0–1 14–16 
 
1Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital 
Association Annual Survey. 
2Some hospitals have more than one emergency department. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/13–4/14, 2005 
 
 
 
Exhibit 2. Number of Drug Reports in Drug-Related ED Visits, by Drug Category (Unweighted):  20041 
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1The unweighted data are from 16–18  EDs reporting to Atlanta hospitals reporting to DAWN in 2004.  All DAWN cases are re-
viewed for quality control.  Based on this review, cases may be corrected or deleted, and, therefore, are subject to change. 
SOURCE:  DAWN Live!, OAS, SAMHSA; updated 4/13–4/14/2005 
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Exhibit 4. Percentages of Primary Treatment Admissions in Atlanta: FYs 2000–2004 
 
Drug FY 2000 FY 2001 FY 2002 FY 2003 FY 2004 
Cocaine/Crack 58.3 58.5 43.1 42.8 39.5 
Heroin 6.6 6.7 7.6 6.3 5.6 
Marijuana 16.0 15.5 18.7 20.0 21.7 
Methamphetamine 1.5 1.6 3.1 5.1 8.5 
Other Drugs1 17.6 26.1 21.3 25.8 24.6 
Total Admissions (N=) (6,990) (7,996) (7,909) (7,178) 7,996 
 
1Includes “alcohol-in-combination.” 
SOURCE: Georgia Department of Human Resources 
 
 
 
Exhibit 5. Metropolitan Atlanta Public Substance Abuse Treatment Admissions, Selected Drugs by Race:      
2004  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Other Category includes Asian, American Indian, multicultural, or other race. 
SOURCE: Georgia Department of Human Resources 
 
 
 
Exhibit 6. Number of Analyzed Items and Percentage of All Items Tested in Atlanta: 2004 
 
Drug Number Percent 
Cocaine 7,923 44.2 
Methamphetamine 5,434 30.3 
Cannabis 2,578 14.4 
Alprazolam 380 2.1 
MDMA/MDA 424 2.4 
Hydrocodone 315 1.8 
Heroin 194 1.1 
Oxycodone 159 0.9 
Methadone 83 0.5 
Diazepam 65 0.4 
Other1 301 1.9 
Total 17,922 100.0 
 
1Includes carisoprodol, amphetamine, clonazepam, morphine, codeine, psilocin, non-controlled non-narcotic drug, methylphenidate, 
ketamine, gamma hydroxybutyrate, hydromorphone, 1-(3-trifluoromethylphenyl)-piperazine, lorazepam, and lysergic acid diethyla-
mide. 
SOURCE:  NFLIS, DEA 
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Exhibit 7. Number of Prescription Drug Misuse Reports in Drug-Related ED Visits,    
 by Case Type (Unweighted1): 2004 
 
 
 
 
 
 
 
 
 
 
 
 
1The unweighted data are from 16–18 EDs reporting to Atlanta hospitals reporting to DAWN in 2004.  All DAWN cases are reviewed 
for quality control.  Based on this review, cases may be corrected or deleted, and, therefore, are subject to change. 
SOURCE:  DAWN Live!, OAS, SAMHSA; updated 06/04/205 
 
 
212
268
814
Oxycodone
Hydrocodone
Benzodiazepines
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Baltimore 
 
 
Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005 18 
Drug Use in the Baltimore 
Metropolitan Area: Epidemi-
ology and Trends, 2000–2004 
 
Leigh A. Henderson, Ph.D., and Doren H. 
Walker, M.S.1  
 
ABSTRACT 
 
Heroin indicators for the Baltimore metropolitan 
area as a whole have generally indicated an in-
crease over 2001 levels. In 2004, heroin was respon-
sible for 52 percent of drug-related treatment ad-
missions. Heroin use in the Baltimore metropolitan 
area is complex. There are several groups of heroin 
users differing by urbanicity, route of administra-
tion, age, and race. Baltimore has a core of older 
African-American heroin users, both intranasal 
users (37 percent of all 2004 heroin treatment ad-
missions) and injectors (19 percent all 2004 heroin 
treatment admissions). White users entering treat-
ment for heroin were younger and were predomi-
nantly injectors (29 percent of all 2004 heroin 
treatment admissions) rather than intranasal users 
(10 percent of all heroin treatment admissions). 
Cocaine indicators also began to increase in 2001. 
In 2004, cocaine use was reported by 50 percent of 
drug-related treatment admissions in the Baltimore 
PMSA, with 14 percent reporting primary use and 
36 percent reporting use secondary to use of alcohol 
or another drug. Cocaine smoking was the most 
prevalent route of administration among both pri-
mary and secondary users, followed by injection 
and intranasal use. Cocaine use was associated with 
heroin use, but the preferred route of administra-
tion of heroin differed with the preferred route of 
administration of cocaine. More than one-third (37 
percent) of cocaine smokers used intranasal heroin. 
Almost all cocaine injectors (90 percent) injected 
heroin. More than one-third (35 percent) of intra-
nasal cocaine users used heroin intranasally. Indi-
cators of marijuana use have tended to increase 
since 2000. Like cocaine, marijuana was reported 
more frequently as a secondary substance than as a 
primary substance—34 percent of drug-related 
treatment admissions used marijuana, 15 percent as 
a primary substance and 19 percent as a secondary 
substance. More often than not, marijuana use in 
the indicator data sets was associated with the use of 
alcohol or other drugs—in 2004, 61 percent of 
marijuana treatment admissions reported use of  
 
                                                           
1 The authors are affiliated with Synectics for Management Deci-
sions, Inc., Arlington, Virginia. 
additional substances. Persons entering treatment 
for primary marijuana use were young—44 percent 
were less than age 18. A large proportion of 2004 
marijuana treatment admissions (62 percent) repre-
sented referrals through the criminal justice system. 
Indicators for opiates and narcotics other than her-
oin have increased over the past several years. 
Stimulants other than cocaine are rarely mentioned 
as the primary substance of abuse by treatment ad-
missions. 
 
INTRODUCTION 
 
Area Description 
 
The Baltimore primary metropolitan statistical area 
(PMSA) was home to some 2.6 million persons in 
2004. It comprises Baltimore City and the suburban 
counties of Anne Arundel, Baltimore, Carroll, Har-
ford, Howard, and Queen Anne’s. Baltimore City is 
the largest independent city in the United States. The 
city’s population declined from 735,000 in 1990 to 
629,000 in 2003. The population of the surrounding 
counties has grown from approximately 1.7 million 
in 1990 to 2.0 million in 2004.  
 
The city and the suburban counties represent dis-
tinctly different socioeconomic groups. In 2000, me-
dian household income in the city was $30,000, and 
23 percent of the population lived in poverty. In the 
suburban counties, however, median household in-
come ranged from $51,000 to $74,000, and the pov-
erty rate averaged 5 percent. In 2000, the median 
value of a single-family home was $69,100 in the city 
and averaged $152,000 in the suburban counties. The 
2000 population composition of the city differed 
markedly from that of the surrounding counties: 32 
percent White and 64 percent African-American, 
versus 80 percent White and 15 percent African-
American, respectively. Two percent of the popula-
tion in the city and 3 percent of the population in the 
suburban counties was Asian. Two percent of the 
population in both the city and the suburban counties 
was Hispanic.  
 
The Baltimore area is a major node on the north-south 
drug trafficking route. It has facilities for entry of 
drugs into the country by road, rail, air, and sea. Balti-
more is located on Interstate 95, which continues north 
to Philadelphia, New York, and Boston, and south to 
Washington, DC, Richmond, and Florida. Frequent 
daily train service is available on this route. The area is 
served by three major airports (Baltimore-Washington 
International Airport in Baltimore County and Reagan 
National and Dulles Airports in the vicinity of Wash-
ington, DC, approximately 50 miles from the Balti- 
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more City center). Baltimore is also a significant active 
seaport. The area has numerous colleges and universi-
ties and several military bases.  
 
Data Sources 
 
• Population and demographic data, including 
population estimates for 1990–2003 and income, 
poverty, and housing cost estimates for 2000 for 
Maryland counties, were derived from U.S. Bu-
reau of the Census data (electronic access: 
<http://factfinder.census.gov> last accessed June 
13, 2004). 
 
• Treatment admissions data were provided by 
the Maryland Alcohol and Drug Abuse Admini-
stration, Department of Health and Mental Hy-
giene, for 1992 through 2004. Data are presented 
for the PMSA as a whole, as well as separately 
for Baltimore City and the suburban counties. 
Included are those programs receiving both pub-
lic and private funding. All clients are reported, 
regardless of individual source of funding. Sig-
nificant omissions are the Baltimore City and 
Fort Howard Veterans’ Administration Medical 
Centers, which do not report to the State data 
collection system. Treatment data in this report 
exclude admissions for abuse of alcohol alone 
(about 15 percent of all treatment admissions). 
Admissions with primary abuse of alcohol and 
secondary/tertiary abuse of drugs (about 12 per-
cent of all admissions) are included. 
 
• Emergency department (ED) drug mentions 
data were provided by the Drug Abuse Warning 
Network (DAWN), Office of Applied Studies 
(OAS), Substance Abuse and Mental Health 
Services Administration (SAMHSA), for the 
Baltimore PMSA for 2004. Data reflect cases 
that have been received by DAWN as of: 4/13-
14/2005. All DAWN cases are reviewed for 
quality control. Based on this review, cases may 
be corrected or deleted. Data are unweighted, 
noncomparable across areas, and subject to 
change. DAWN data are reported for the follow-
ing case types: Suicide attempt, Seeking detox, 
Alcohol only (age<21), Adverse reaction, Over-
medication, Malicious poisoning, Accidental in-
gestion, and Other. Data are reported for all case 
types combined (except Seeking detox, which is 
reported for all major substances combined) for 
major substances of abuse (Cocaine, Heroin, 
Marijuana, Amphetamines, Methamphetamine, 
MDMA (Ecstasy), GHB, Ketamine, LSD, PCP, 
Miscellaneous hallucinogens, Inhalants, and 
Combinations NTA). For other substances, only  
 
the case types Seeking detox, Overmedication, 
and Other are included. In the Baltimore PMSA, 
there were 21 hospitals with 24 EDs in the 
DAWN sample, reporting for 182 of a possible 
288 months, a response rate of 63 percent. 
 
• Mortality data were provided by the Drug Abuse 
Warning Network (DAWN), Office of Applied 
Studies (OAS), Substance Abuse and Mental 
Health Services Administration (SAMHSA), for 
the Baltimore PMSA for 2003. Drug Abuse Warn-
ing Network, 2003. Area Profiles of Drug Mortal-
ity. DAWN Series D-27, DHHS Pub. No. (SMA) 
05-4023. Rockville, MD, 2005. 
 
• Illicit drug prices were provided by the Na-
tional Drug Intelligence Center, Narcotics Digest 
Weekly 3(52), December 28, 2004, for July 
2004–December 2004. 
 
• Data on drug seizures were provided by the 
National Forensic Laboratory Information Sys-
tem (NFLIS), for January-December, 2004. 
 
DRUG ABUSE PATTERNS AND TRENDS 
 
Polydrug use in general is the norm in the Baltimore 
PMSA. About three-quarters of drug-related treat-
ment admissions in 2004 reported problems with at 
least one substance other than their primary sub-
stance. In 2003, 87 percent of the 538 drug-related 
deaths reported to the area’s medical examiners in-
volved multiple substances. DAWN emergency de-
partment (ED) data for 2004 (see notes under Data 
Sources above) reported 3,876 DAWN non-detox 
cases, and 10,528 mentions of major substances of 
abuse among these cases, an average of 2.7 sub-
stances per case. 
 
Cocaine/Crack 
 
Cocaine indicators (treatment admission rates, rates 
of ED mentions, and cocaine-involved deaths) all 
began to increase in 2001 (exhibit 1). Cocaine was 
present in 226 (42 percent) of drug-related deaths in 
2003. The cocaine treatment admission rate increased 
from 162 per 100,000 population age 12 and over in 
2000 to 225 per 100,000 in 2003 (exhibit 2). The rate 
declined slightly, to 203 per 100,000, in 2004. 
 
In 2004, cocaine was mentioned by 43 percent of the 
DAWN non-detox ED cases (see notes under Data 
Sources above), a proportion similar to the 43 percent 
of ED cases involving heroin. The cocaine and heroin 
cases were demographically similar—64 percent 
male, 44 percent and 46 percent White, respectively,  
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and twenty-one percent of each aged 45 or older. It is 
likely that many of the ED cases reflect co-use of 
cocaine and heroin (see Exhibit 4, below).  
 
Smoked cocaine (crack) represented 79 percent of the 
treatment admissions for primary cocaine use in the 
Baltimore PMSA in 2004 (exhibit 2). The population 
in treatment for cocaine smoking has aged (exhibit 
3). About three-quarters (72 percent) were age 35 or 
older in 2004, an increase from 59 percent in 2000. 
The median age at admission to treatment was 39 
years, compared with 36 in 2000. Almost one-half 
(45 percent) of those in treatment for smoking co-
caine were women, and about two-thirds (65 percent) 
were African-American. The majority (62 percent) of 
the cocaine smokers had been in treatment before, 
and most (67 percent) were referred through sources 
other than the criminal justice system. Daily use of 
smoked cocaine was reported by 42 percent, and use 
of other drugs in addition to smoked cocaine was 
reported by more than two-thirds (69 percent). Alco-
hol was the most common secondary drug (used by 
47 percent), followed by marijuana (23 percent) and 
heroin used intranasally (14 percent). Only 3 percent 
of crack smokers reported heroin injection. 
 
Primary use of cocaine represented 14 percent of 
drug-related treatment admissions in 2004, well be-
hind the 52 percent of admissions represented by 
primary use of heroin (exhibit 2). Despite the appar-
ent dominance of heroin in the Baltimore PMSA, 
testing of some 40,000 items in FY 2004 by the Na-
tional Forensics Laboratory found that 43 percent 
were cocaine and 26 percent were heroin. This appar-
ent discrepancy may be explained by the use of co-
caine as a secondary substance. Cocaine was reported 
as a secondary substance by 36 percent of treatment 
admissions in 2004 (exhibit 2), meaning that 50 per-
cent of treatment admissions reported cocaine abuse 
as a primary or secondary problem.  
 
Exhibit 4 compares the characteristics of treatment 
admissions for primary and secondary cocaine use 
according to the route of administration of cocaine. 
Cocaine smoking was the most prevalent among both 
primary and secondary users, followed by injection 
and intranasal use. Differences between primary and 
secondary users were generally small, although sec-
ondary users were consistently less likely to be enter-
ing treatment for the first time than primary users. 
User characteristics were more pronounced between 
routes of administration. Cocaine smokers were more 
likely to be female (50 percent of cocaine smokers, 
compared to 39 percent of injectors and 32 percent of 
intranasal users), African-American (67 percent, 51 
percent, and 42 percent, respectively), age 35 and  
 
older (70 percent, 60 percent, and 54 percent, respec-
tively). Cocaine smokers were less likely to be age 25 
and younger (9 percent, compared with 18 percent of 
injectors and 25 percent of intranasal users). Cocaine 
smokers and injectors were more likely to be treated 
in the City (67 percent and 69 percent, respectively, 
compared to 44 percent of the intranasal users).  
 
Cocaine use was associated with heroin use, but the 
preferred route of administration of heroin differed 
with the preferred route of administration of cocaine 
(exhibit 4). More than one-third (37 percent) of co-
caine smokers used intranasal heroin—50 percent as 
their primary substance, and 14 percent as a secon-
dary substance. Almost all cocaine injectors (90 per-
cent) injected heroin—93 percent as their primary, 
and 60 percent of as a secondary substance. More 
than one-third (35 percent) of intranasal cocaine users 
used heroin intranasally—41 percent as their primary 
substance problem, and 10 percent as a secondary 
problem. 
 
Thirty-seven percent of the cocaine smokers reported 
cocaine smoking as their primary problem (exhibit 
4). Secondary cocaine smokers were somewhat more 
likely to be female (53 percent of secondary smokers, 
compared to 45 percent of primary smokers), and 
more likely to be treated in Baltimore City (71 per-
cent and 60 percent, respectively). Other primary 
problems reported by secondary cocaine smokers 
were alcohol (21 percent) and heroin injection (21 
percent). 
 
Only 7 percent of the cocaine injectors reported co-
caine injection as their primary problem (exhibit 4). 
Secondary cocaine injectors were somewhat older 
(49 percent of secondary injectors, compared to 37 
percent of primary injectors). They were less likely to 
be experiencing a first treatment episode (26 percent 
of secondary injectors, compared to 33 percent of 
primary injectors). They were less likely to enter 
treatment through a criminal justice referral (25 per-
cent of secondary injectors, compared to 31 percent 
of primary injectors). Secondary injectors were 
somewhat more likely to be treated in Baltimore City 
(70 percent and 64 percent, respectively).  
 
About one-fifth (22) percent of the cocaine inhalers 
reported cocaine inhalation as their primary problem 
(exhibit 4). Secondary cocaine inhalers were less 
likely to be experiencing a first treatment episode (41 
percent of secondary inhalers, compared to 49 per-
cent of primary inhalers). They were more likely to 
enter treatment through a criminal justice referral (38 
percent of secondary inhalers, compared to 19 per-
cent of primary inhalers). Secondary inhalers were 
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somewhat less likely to be treated in the suburban 
counties (55 percent and 63 percent, respectively).  
 
Exhibit 5 compares the number of cocaine treatment 
admissions (primary, secondary, or tertiary use) in 
2004 by route of administration, age, and race. For all 
three routes of administration, the younger users 
tended to be White rather than African-American.  
 
Prices for powdered cocaine for the second half of 
2004 were reported as $20,000–$32,000 per kilogram 
at the wholesale level; $900–$1,200 per ounce at 
midlevel; and $0–$200 per gram at the retail level. 
Prices for crack cocaine were reported as $20,000–
$26,000 per kilogram at the wholesale level; $600–
$1,200 per ounce at midlevel; and $40–$200 per 
gram at the retail level. For powdered cocaine, the 
price range at the wholesale kilogram level was un-
changed from the second half of 2003, while the 
lower limit for a retail-level gram was less. For crack 
cocaine, the lower limit for a wholesale kilogram was 
unchanged from the second half of 2003, while the 
lower limit for a retail-level gram was less. 
 
Heroin 
 
Heroin indicators for the Baltimore metropolitan area 
as a whole generally indicated an increase over 2001 
levels (exhibit 1). Opiates were present in 469 (87 
percent) of drug-related deaths in 2003. The heroin 
treatment admission rate increased from 652 per 
100,000 population age 12 and over in 2001 to 893 
per 100,000 in 2003 (exhibit 2). However, it declined 
slightly to 770 per 100,000 in 2004. 
 
In 2004, heroin was mentioned by 43 percent of the 
DAWN non-detox ED cases (see notes under Data 
Sources above), a proportion similar to the 43 percent 
of ED cases involving cocaine. The heroin and co-
caine cases were demographically similar—64 per-
cent male, 44 percent and 46 percent White, respec-
tively, and twenty-one percent of each aged 45 or 
older. It is likely that many of the ED cases reflect 
co-use of heroin and cocaine (see Exhibit 4, below).  
 
Heroin use in the Baltimore metropolitan area is 
complex. There are several groups of heroin users 
differing by urbanicity, route of administration, age, 
and race. In 2004, the heroin treatment admission rate 
was about seven times higher in Baltimore City than 
in the suburban counties (exhibit 2).  
 
In Baltimore City, intranasal use was the preferred 
route of administration among treatment admissions 
(exhibit 2), and the admission rate for intranasal use 
was 26 percent higher than for injection. In the sub-
urban counties, however, the rate for heroin injection 
was 86 percent higher than for inhalation. 
 
Exhibit 6 compares the number of treatment admis-
sions in 2004 by route of administration, age, and 
race. Baltimore has a core of older African-American 
heroin users, both injectors and intranasal users. 
White users entering treatment for heroin were 
younger and were predominantly injectors.  
 
African-American heroin intranasal users made up 37 
percent of the heroin-using treatment admissions in 
the Baltimore PMSA in 2004, and most (89 percent) 
were treated in Baltimore City. Among heroin intra-
nasal users in the city (exhibit 7), most admissions 
were African-American (88 percent) and were age 35 
and older (74 percent). Almost half (47 percent) of 
the intranasal heroin users were women. The median 
age at admission was 39, and the median duration of 
use before first entering treatment was 14 years. Sev-
enty percent reported daily heroin use. About one-
third (31 percent) entered treatment through the 
criminal justice system, and about one-third (34 per-
cent) were receiving treatment for the first time. 
Two-thirds (68 percent) reported use of other drugs—
42 percent smoked cocaine, 24 percent used alcohol, 
11 percent used marijuana, and 9 percent used co-
caine intranasally.   
 
White heroin injectors made up 29 percent of the 
heroin-using treatment admissions in the Baltimore 
PMSA in 2004, and more than half were (59 percent) 
were treated in the suburban counties. Among heroin 
injectors in the suburban counties (exhibit 8), most 
admissions were White (86 percent). More than one-
third (38 percent) of suburban injectors were age 25 
and younger. Sixty percent of the suburban heroin 
injectors were male. The median age at admission 
was 28, and the median duration of use before first 
entering treatment was 6 years. About two-thirds (68 
percent) reported daily heroin use. About one in five 
(23 percent) entered treatment through the criminal 
justice system, and one-third (31 percent) were re-
ceiving treatment for the first time. More than two-
thirds (70 percent) reported use of other drugs—, 29 
percent injected cocaine, 28 percent used marijuana, 
21 percent used alcohol, 15 percent smoked cocaine, 
and 8 percent used opiates other than heroin.   
 
African-American heroin injectors made up 19 per-
cent of the heroin-using treatment admissions in the 
Baltimore PMSA in 2004. Most (88 percent) were 
treated in Baltimore City. Among heroin injectors in 
the city (exhibit 8), the majority of admissions (58 
percent) were African-American, and were age 35 
and older (66 percent), although the proportion of  
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injection users age 25 and younger increased from 9 
percent in 2000 to 14 percent in 2004. Some 43 per-
cent of the city’s heroin injectors were women. The 
median age at admission was 40, and the median du-
ration of use before first entering treatment was 14 
years. Most (79 percent) reported daily heroin use. 
Less than one-quarter (20 percent) entered treatment 
through the criminal justice system, and about one-
quarter (27 percent) were receiving treatment for the 
first time. Most (76 percent) reported use of other 
drugs—47 percent injected cocaine, 23 percent used 
alcohol, 15 percent smoked cocaine, and 7 percent 
used marijuana.   
 
White heroin intranasal users made up 10 percent of 
the heroin-using treatment admissions in the Balti-
more PMSA in 2004. Almost two-thirds (63 percent) 
were treated in the suburban counties. Among heroin 
intranasal users in the suburban counties (exhibit 7), 
more than half (59 percent) were White, and 49 per-
cent were age 35 and older, although the proportion 
of intranasal users age 25 and younger was 23 per-
cent in 2004. Some 35 percent of the suburban intra-
nasal users were women. The median age at admis-
sion was 34, and the median duration of use before 
first entering treatment was 7 years. Most (63 per-
cent) reported daily heroin use. About one-quarter 
(27 percent) entered treatment through the criminal 
justice system, and 43 percent were receiving treat-
ment for the first time. A majority (66 percent) re-
ported use of other drugs—21 percent each smoked 
cocaine, used alcohol, and/or used marijuana, 17 per-
cent used cocaine intranasally, and 11 percent used 
opiates other than heroin.  
 
In 2004, there were 4,531 DAWN heroin ED cases, a 
number similar to the 4,511 cases involving cocaine. 
Given the co-use of heroin and cocaine demonstrated 
in Exhibit 4, it is likely that these cases represent use 
of both these drugs by the individual seeking ED 
care. The heroin and cocaine cases were demographi-
cally similar as well—64 percent male, 44 percent 
and 46 percent White, respectively. Twenty-one per-
cent of both heroin and cocaine cases were aged 45 
or older, and 56 percent of heroin cases were 35 or 
older, as were 61 percent of cocaine cases.  
 
Of the 37,000 items from Baltimore tested by the 
National Forensic Laboratory in 2004, 26 percent 
were heroin.  
 
Most of the heroin sold in Baltimore is from South 
America. Its purity for 2003 was reported by the 
DEA’s Domestic Monitor Program as 35 percent 
(based on 24 samples), and the price as $0.31 per mil-
ligram pure. Both priority and price were lower than 
the national average of 42 percent putity and $0.77 per 
milligram pure. One Southeast Asian sample was pur-
chased (purity, 20 percent; price $0.31 per milligram 
pure, and one Southwest Asian sample was purchased 
(purity, 2.8%, price $1.55 per milligram pure).  
 
Other Opiates and Narcotics 
 
For opiates and narcotics other than heroin, indicators 
have increased over the past several years (exhibit 1). 
Treatment admission rates for opiates other than her-
oin more than doubled between 2000 and 2003, from 
23 per 100,000 population age 12 and over to 55 per 
100,000 in 2003 and 2004 (exhibit 2). In 2004, there 
were 1,307 ED cases involving opiates/opioids 
among a subset of the DAWN ED cases (see notes 
under Data Sources above). Forty-one percent of 
these cases specified oxycodone, 7 percent specified 
hydrocodone, 32 percent specified other opiates, and 
the opiate was unspecified in 21 percent of cases  
 
Opiates other than heroin were reported by 4 percent 
of admissions as the primary substance of abuse, and 
were reported by an additional 4 percent as a secon-
dary or tertiary substance (exhibit 2). Exhibit 9 com-
bines all admissions reporting opiates other than her-
oin as primary, secondary, or tertiary substances. 
Treatment admissions involving opiates other than 
heroin were primarily White (88 percent). Just over 
half (57 percent) were male. Almost half (44 percent) 
were ages 35 or older, although the proportion age 25 
and younger increased from 21 percent in 2000 to 34 
percent in 2004. The median age at admission was 
32, and the mediation duration of use of opiates other 
than heroin before first entering treatment was 4 
years. Daily use of opiates other than heroin was re-
ported by 67 percent. Only a small proportion (13 
percent) entered treatment through the criminal jus-
tice system, and 44 percent were entering treatment 
for the first time.   
 
Marijuana 
 
Indicators of marijuana use have tended to increase 
since 2000 (exhibit 1). The rates of marijuana ED 
mentions increased significantly in 2002 over 2001. 
The annual marijuana treatment admission rate in-
creased from 200 per 100,000 population age 12 and 
over in 2000 to 249 per 100,000 in 2003, then de-
clined slightly to 222 in 2004 (exhibit 2). The propor-
tion of marijuana treatment admissions in 2004 was 
higher in the suburban counties (20 percent of county 
admissions) than in Baltimore City (11 percent of 
City admissions), but the admission rate for 2004 was 
higher in the city (380 per 100,000 population age 12 
and over, compared with 173 per 100,000 in the 
counties).  
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In 2004, marijuana was mentioned by 12 percent of 
the DAWN non-detox ED cases (see notes under 
Data Sources above). Two-thirds (65 percent) were 
male and 65 percent were White. Twenty-three per-
cent were less than 18 years of age, and another 30 
percent were aged 18 to 24. 
 
More often than not, marijuana use in the indicator 
data sets was associated with the use of alcohol or 
other drugs. Marijuana was more frequently reported 
as a secondary substance than as a primary substance 
by treatment admissions in the total PMSA in 2004, 
at 15 percent and 19 percent, respectively (exhibit 2). 
Among treatment admissions for primary marijuana 
use in the total PMSA, 61 percent reported using ad-
ditional substances (exhibit 10). More than one-half 
(53 percent) reported alcohol use, 8 percent reported 
cocaine use, 3 percent reported use of heroin, and 3 
percent reported use of opiates other than heroin. 
Some 7 percent of admissions used other secondary 
substances, primarily hallucinogens, stimulants, PCP, 
tranquilizers, and sedatives.  
 
Persons entering treatment for marijuana use were 
young: 44 percent were less than age 18, and the me-
dian age at admission to treatment was 18 (exhibit 
10). Marijuana admissions were primarily male (82 
percent) and increasingly likely to be African-
American (51 percent in 2004, compared with 46 
percent in 2000). A large proportion of marijuana 
treatment admissions (62 percent) represented refer-
rals through the criminal justice system. Admissions 
were likely to be experiencing their first treatment 
episode (66 percent), and more than one-third (35 
percent) reported daily marijuana use. 
 
Of the 37,000 items from Baltimore tested by the 
National Forensic Laboratory in 2004, 30 percent 
were cannabis. 
 
Prices for marijuana for the second half of 2004 were 
reported as $2,390–$4,000 per pound for hydroponic 
marijuana or $1,000–$1,600 per pound for commer-
cial grade marijuana at the wholesale level. Midlevel 
prices were $275 per ounce for hydroponic and $130 
per ounce for commercial grade. At the retail level, 
prices were $35–$60 per one-quarter ounce or $20–
$40 per bag. The price range for hydroponic mari-
juana was slightly more for the wholesale-level kilo-
gram than in the second half of 2003. The lower limit 
for commercial-grade marijuana at the wholesale-
level kilogram was more than in the second half of 
2003, but the upper limit was unchanged. The price 
range was unchanged for a retail-level one-quarter 
ounce or bag. 
 
Stimulants 
 
Stimulants other than cocaine were rarely mentioned 
as the primary substance of abuse by treatment ad-
missions (exhibit 2). Nevertheless, the numbers, al-
though small, increased from 42 admissions in 2000 
to 76 in 2004. The majority (68 percent) of the 2004 
stimulant admissions were for methamphetamine, 
and 24 percent were for amphetamine. The treatment 
admission rate for stimulants increased from 2.0 per 
100,000 population age 12 and over in 2000 to 3.5 
per 100,000 in 2004.  
 
In 2004, all stimulants combined were mentioned by 
1 percent of the DAWN non-detox ED cases (see 
notes under Data Sources above).  
 
Other Drugs 
 
Drugs other than alcohol, cocaine, heroin, opiates 
(other than heroin), marijuana, and stimulants were 
responsible for less than 2 percent of treatment ad-
missions in 2004 (exhibit 2). In 2004, in a subset of 
DAWN ED cases (see notes under Data Sources 
above), there were 59 cases involving methylenedi-
oxymethamphetamine (MDMA), 34 involving phen-
cyclidine (PCP), 19 involving inhalants, 18 involving 
lysergic acid diethylamide (LSD), 7 involving keta-
mine, and 4 involving gamma hydroxylbutyrate 
(GHB).  
 
Treatment admissions for benzodiazepines and other 
tranquilizers increased slightly, from 4.0 per 100,000 
population age 12 and over in 2003 to 4.8 per 
100,000 in 2004. In 2004, there were 888 DAWN ED 
cases involving benzodiazepines. 
 
Treatment admissions for barbiturates and other seda-
tives decreased slightly, from 4.2 per 100,000 popu-
lation age 12 and over in 2003 to 3.7 per 100,000 in 
2004.  
 
Treatment admissions for lysergic acid diethylamide 
(LSD) increased from 2.4 per 100,000 population age 
12 and over in 2003 to 3.1 per 100,000 in 2004. 
Treatment admissions for PCP declined from 4.3 per 
100,000 population age 12 and over in 2003 to 2.0 
per 100,000 in 2004. Between 2003 and 2004, treat-
ment admissions for inhalants were relatively stable, 
at 0.7 per 100,000 population age 12 and over in 
2003 and 0.6 per 100, 000 in 2004. Treatment admis-
sions for over-the-counter drugs were unchanged at 
0.5 per 100,000 population age 12 and over in 2003 
and 2004. 
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INFECTIOUS DISEASES RELATED TO DRUG ABUSE 
 
The annual AIDS case report rate for 2003 for the 
Baltimore PMSA (39 cases per 100,000) ranked fifth 
behind New York City (59 per 100,000), Miami (46 
per 100,000), San Francisco (45 per 100,000) and 
Fort Lauderdale (40 per 100,000) (CDC 2003).  
 
The Baltimore PMSA accounted for 64 percent and 
63 percent, respectively, of Maryland’s incident and 
prevalent human immunodeficiency virus (HIV) 
cases, 59 percent of its incident AIDS case, and 60 
percent of its prevalent AIDS cases (AIDS Admini-
stration 2004). Baltimore City by itself accounted for 
51 percent of Maryland’s 2003 incident and prevalent 
HIV cases, 46 percent of its incident AIDS cases, and 
47 percent of its prevalent AIDS cases. The Balti-
more metropolitan area had an AIDS incidence rate 
of 33 per 100,000 population for 2003, and an HIV 
incidence rate of 49 per 100,000. The AIDS preva-
lence rate in the Baltimore metropolitan area in 2003 
was 298 per 100,000 population, and the HIV preva-
lence rate was 382 per 100,000.  
 
In 2003, Baltimore City’s prevalent HIV/AIDS cases 
were about 62 percent male and 81 percent African-
American (AIDS Administration 2004). Forty-four 
percent were aged 40–49 years, and another 24 per-
cent were aged 30–39 years. Fifty-six percent of the 
prevalent HIV/AIDS cases in Baltimore City in 
which the risk category was determined were injec-
tion drug users (IDUs), 15 percent were non-IDU 
men who had sex with men, and 26 percent involved 
heterosexual transmission. In the suburban counties, 
prevalent HIV/AIDS cases were 66 percent male and 
55 percent African-American. Forty-one percent 
were aged 40–49, and another 29 percent were aged 
30–39. For cases in which the risk category was de-
termined, 36 percent of prevalent HIV/AIDS cases in 
the suburban counties were IDUs, 29 percent were 
non-IDU men who had sex with men, and 31 percent 
involved heterosexual transmission. In Maryland as a 
whole, IDUs represented 47 percent of prevalent 
HIV/AIDS cases in 2003.  
 
In 1999, Baltimore City ranked highest among the 20 
cities most burdened by sexually transmitted diseases 
(STDs) for gonorrhea (949 per 100,000 population), 
fifth for chlamydia (819 per 100,000 population), and 
third for syphilis (38 per 100,000 population) (CDC 
2000). By 2003, STD rates for Baltimore City had 
decreased for gonorrhea (to 617 per 100,000) and for 
syphilis (to 23 per 100,000), but had increased for 
chlamydia (to 1,001 per 100,000) (AIDS Administra-
tion 2004). 
 
Voluntary HIV testing is offered to Maryland prison 
entrants. Among those tested in 2003, 5 percent were 
positive for HIV (AIDS Administration 2004). A 2002 
survey of entrants to Baltimore City detention facilities 
and Maryland State prison entrants found that newly 
incarcerated females had much higher HIV rates than 
newly incarcerated males (13 percent and 4 percent, 
respectively) (AIDS Administration 2004). 
   
The survey of prison entrants also found that 25 per-
cent had been infected by hepatitis B and 30 percent 
had antibodies to hepatitis C (Solomon et al. 2004). 
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Exhibit 1. Annual Rates of Drug-Related Treatment Admissions and ED Mentions per 100,000 Population,  
   and Numbers of Drug-Related Deaths in Baltimore: 1994–2004 
 
Heroin
0
300
600
900
1994 1996 1998 2000 2002 2004
P
er
 1
00
,0
00
ED Treatment Deaths (no.)
Cocaine
0
100
200
300
400
1994 1996 1998 2000 2002 2004
P
er
 1
00
,0
00
ED Treatment Deaths (no.)
 
 
 
 
 
Marijuana
0
50
100
150
200
250
1994 1996 1998 2000 2002 2004
P
er
 1
00
,0
00
ED Treatment
Other Opiates
0
50
100
150
200
250
1994 1996 1998 2000 2002 2004
P
er
 1
00
,0
00
ED Treatment Deaths (no.)
 
 
SOURCES:  DAWN, OAS, SAMHSA, and Alcohol and Drug Abuse Administration, Maryland Department of Health and Mental  
Hygiene 
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Exhibit 5. Numbers of Primary, Secondary, and Tertiary Cocaine Treatment Admissions in Baltimore, by  
   Route of Administration, Age, and Race: 2004 
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SOURCE:  Alcohol and Drug Abuse Administration, Maryland Department of Health and Mental Hygiene 
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Exhibit 6. Numbers of Primary Heroin Treatment Admissions in Baltimore, by Route of Administration,  
   Age, and Race: 2004 
 
Injection
0
50
100
150
200
250
300
350
400
10 20 30 40 50 60
Age
N
um
be
r
White African-American
Intranasal
0
50
100
150
200
250
300
350
400
10 20 30 40 50 60
Age
N
um
be
r
White African-American
 
 
 
SOURCE:  Alcohol and Drug Abuse Administration, Maryland Department of Health and Mental Hygiene 
 
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Baltimore 
 
 
Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005 32 
 
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Baltimore 
 
 
Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005 33
 
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Baltimore 
 
 
Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005 34 
 
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Baltimore 
 
 
Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005 35
 
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Greater Boston 
 
 
Proceedings of the Community Epidemiology Work Group, June 2005 36 
Patterns and Trends in Drug 
Abuse: Greater Boston 
 
Daniel P. Dooley1 
 
ABSTRACT 
 
Heroin and cocaine indicators remain at very high 
and stable, if not increasing, levels of abuse. Mari-
juana indicators show widespread use and stable 
levels of abuse. Prescription drugs, most notably 
narcotic analgesics including oxycodone (OxyCon-
tin) and benzodiazepines, show stable levels of mis-
use and abuse as well. With the exception of 
substance abuse treatment admissions, indicators 
show no signs of overall decreasing misuse and 
abuse. The number of treatment admissions has 
fallen considerably during the past three years, but 
field sources say reductions in funding caused re-
ductions in available services and, consequently, 
fewer admissions. In 2003, there were 269 adult 
HIV/AIDS cases diagnosed in Boston. The primary 
transmission risk factors for these cases included 12 
percent who were IDUs, 5 percent who had sex with 
IDUs, and 35 percent with an unknown/undeter-
mined risk factor.  
 
INTRODUCTION 
 
Area Description 
 
This report presents data from a number of different 
sources with varied Boston-area geographical pa-
rameters. A description of the relevant boundary pa-
rameters is included with each data source 
description. For simplicity, these are all referred to as 
“Boston” throughout the text. 
 
According to the 2000 U.S. census, Massachusetts 
ranks 13th in population (6,349,097 people). The 
746,914 people in the metropolitan Boston area rep-
resent 12 percent of the total Massachusetts popula-
tion. The 2000 census data show that there were 
589,141 residents of the city of Boston. The racial 
composition includes 50 percent White non-Hispanic, 
23 percent Black non-Hispanic, 14 percent Hispanic/ 
Latino, and 8 percent Asian. 
 
Several characteristics influence drug trends in Bos-
ton and throughout Massachusetts: 
 
                                                 
1The author is affiliated with the Boston Public Health Commis-
sion, Boston, Massachusetts. 
• Contiguity with five neighboring States (Rhode 
Island, Connecticut, New York, Vermont, and 
New Hampshire) linked by a network of State and 
interstate highways 
 
• Proximity to Interstate 95, which connects Boston 
to all major cities on the east coast, particularly 
New York 
 
• A well-developed public transportation system 
that provides easy access to communities in east-
ern Massachusetts 
 
• A large population of college students in both the 
greater Boston area and western Massachusetts 
 
• Several seaport cities with major fishing industries 
(now in decline) and harbor areas 
 
• Logan International Airport and several regional 
airports within a 1-hour drive of Boston 
• State budget cutbacks on social services 
• A high number of homeless individuals seeking 
shelter  
 
Data Sources 
 
Data sources for this report include the following: 
 
• Emergency department (ED) drug mentions 
data were provided by the Drug Abuse Warning 
Network (DAWN), Office of Applied Studies 
(OAS), Substance Abuse and Mental Health Ser-
vices Administration (SAMHSA), for a Boston 
metropolitan area consisting of five Massachusetts 
counties: Essex, Middlesex, Norfolk, Plymouth, 
and Suffolk. DAWN weighted estimates for 2002 
are presented in this paper and are the most recent 
final estimates. In 2003, OAS instituted a redes-
igned ED system. The data from the new system 
cannot be compared with those for 2002 and be-
fore. In the Boston metropolitan area, 29 of the 41 
eligible hospitals are in the new DAWN sample 
(exhibit 1). The EDs in the new sample total 34. 
(Some hospitals have more than one ED.) For this 
report, data were accessed from the DAWN Live! 
restricted-access online query system for 2004, 
updated on May 13, 2005. The 2004 data are un-
weighted. They are not estimates for the Boston 
area and cannot be used for comparison with fu-
ture data. Only weighted data released by 
SAMHSA can be used in trend analysis. The data  
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reported here are incomplete. Between 18 and 23 
EDs reported each month during the year. Since 
all DAWN cases are reviewed for quality control, 
and cases may be corrected or deleted based on 
the review, the data are subject to change. Data 
presented in this paper represent drug reports in 
drug-related visits in 2004. Drug reports exceed 
the number of visits, since a patient may report 
use of multiple drugs (up to six drugs plus alco-
hol). A full description of the DAWN system can 
be found at <http://dawninfo.samhsa.gov>. 
 
• Drug-related death data were provided by 
DAWN, OAS, SAMHSA, for 2003 for a Boston 
metropolitan area consisting of five Massachusetts 
counties, including Essex, Middlesex, Norfolk, 
Plymouth, and Suffolk, and two New Hampshire 
counties, including Rockingham and Strafford. 
 
• State-funded substance abuse treatment ad-
missions data for a Boston region comprising the 
cities of Boston, Brookline, Chelsea, Revere, and 
Winthrop (Community Health Network Area 
[CHNA] 19), for fiscal year (FY) 1997 through 
FY 2004 (July 1, 1996, through June 30, 2004) 
and the first half of FY 2005 (July 1, 2004–
December 31, 2004) were provided by the Massa-
chusetts Department of Public Health (DPH), Bu-
reau of Substance Abuse Services.  
 
• Analysis of seized drug samples for a Boston 
region comprising the cities of Boston, Brookline, 
Chelsea, Revere, and Winthrop (CHNA 19) for 
1997 through 2004 was provided by the Massa-
chusetts Department of Public Health Drug 
Analysis Laboratory in Amherst, Massachusetts.  
The Boston area drug sample counts do not in-
clude samples analyzed at the Worcester County 
or State Police laboratories. 
 
• Information on drug mentions in Helpline calls 
for a Boston region comprising the cities of Bos-
ton, Brookline, Chelsea, Revere, and Winthrop 
(CHNA 19) for FY 2000 through FY 2004 were 
provided by the Massachusetts Substance Abuse 
Information and Education Helpline. 
 
• Drug arrests data for the city of Boston for 
1997–2004 were provided by the Boston Police 
Department, Drug Control Unit and Office of Re-
search and Evaluation.  For arrest data only, Black 
and White racial designations include those who 
identify themselves as Hispanic. 
 
• Drug price, purity, and availability data for 
New England were provided by the Drug En-
forcement Administration (DEA), New England 
Field Division Intelligence Group, June 2005. 
 
• Data on Massachusetts pharmacy OxyContin 
thefts for 2001 through 2004 were provided by 
the Massachusetts Pharmacy Board of Registra-
tion. 
 
• Adult acquired immunodeficiency syndrome 
(AIDS) and human immunodeficiency virus 
(HIV) data for 2003, and cumulative data 
through May 1, 2005, were provided by the 
Massachusetts Department of Public Health 
AIDS Surveillance Program. 
 
Cocaine/Crack 
 
Cocaine and crack are among the most heavily 
abused drugs in Boston. Recent cocaine/crack indica-
tors are stable at high levels of use and abuse. 
 
In 2003, cocaine was indicated in 216 of the 486 drug 
misuse deaths in greater Boston (44.4 percent)—
more than any other drug. Seventy-two of those were 
single-drug deaths. 
 
The cocaine/crack ED mentions rate of 156 per 
100,000 population in 2002 was similar to that of the 
2 previous years. Exhibit 2 shows 5,611 cocaine ED 
mentions in 2002. 
The 2002 ED rates by gender show that the co-
caine/crack rate for males was almost 1.8 times the 
rate for females (200 vs. 113 per 100,000 popula-
tion). The highest rate by an age group (358 per 
100,000 population) occurred among those age 26–
34. Within that group, those age 26–29 experienced a 
rate of 403 per 100,000 population. A 2-year rate 
increase of 76 percent was reported among those age 
18–25. Similarly, a 2-year rate increase of 70 percent 
occurred among those age 45–54. 
 
In the unweighted data accessed from DAWN Live! 
for 2004, cocaine reports totaled 3,348. 
 
In the first half of FY 2005, there were 674 treatment 
admissions (8 percent of all admissions) with clients 
reporting cocaine or crack as their primary drug (ex-
hibit 3). Of these, 401 (60 percent) indicated crack as 
the client’s primary drug.  There were 2,230 men-
tions (25 percent of all admissions) of current (past- 
month) cocaine/crack use among those admitted to 
State-funded treatment programs (exhibit 3).  
 
A comparison of the last full year of data (FY 2004) 
to previous years shows the proportion reporting co- 
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caine/crack as their primary drug decreased 10 per-
cent from FY 2003, 16 percent from FY 2002, and 62 
percent from FY 1997. The proportion of mentions of 
current (past-month) cocaine/crack use decreased 6 
percent from FY 2003 and 33 percent from FY 1997. 
Exhibit 4 shows demographic characteristics of all 
treatment admissions, and exhibit 5a shows them for 
cocaine/crack treatment admissions in Boston. For 
further demographic comparisons of annual treatment 
admissions, see “Patterns and Trends in Drug Abuse: 
Greater Boston” in Proceedings of the Community 
Epidemiology Work Group, Volume II, January 2005.  
 
There were 1,650 Class B (mainly cocaine and crack) 
drug arrests in 2004 (exhibit 6). Class B arrests ac-
counted for the largest proportion of drug arrests (43 
percent) in the city of Boston in 2004, similar to 
2003. However, the proportion of Class B arrests 
decreased 9 percent from 1997 to 2004. 
 
The proportion of White Class B arrests (31 percent) 
decreased 20 percent from 1997 to 2004, while the 
proportion of Black Class B arrests (68 percent) in-
creased 13 percent. The proportion of Class B arrests 
represented by those age 40 and older (27 percent) 
increased 66 percent from 1997, while arrests for 
those age 25–39 (44 percent) decreased 19 percent 
and arrests for those younger than 20 decreased 27 
percent during the same period.  
 
In 2004, 2,632 seized samples of cocaine/crack were 
analyzed. The proportion of cocaine/crack samples 
among all drug samples analyzed (30 percent) did not 
change from 2003, but it decreased 14 percent from 
1997. 
 
Cocaine/crack was self-identified as a substance of 
abuse in 1,017 calls to the Helpline in FY 2004. The 
proportion of Helpline calls with mentions of co-
caine/crack (18 percent) decreased 9 percent from FY 
2003 to FY 2004. 
  
The DEA reports that cocaine costs $50–$90 per 
gram and purity is increasing in Boston (exhibit 7). A 
rock of crack costs $10–$20. Cocaine is considered 
“readily available at all levels” throughout Massa-
chusetts. 
 
Heroin 
 
Heroin sits solidly among the most abused drugs in 
Boston.  A few of the most recent indicators show 
heroin abuse possibly stabilizing at very high levels 
after years of continued growth. Heroin was men-
tioned often among drug abuse deaths. Heroin ED  
 
mentions were stable at high levels. The proportion 
of heroin treatment admissions continued to rise, with 
more than one-half of all clients in treatment report-
ing heroin as their primary drug.  
 
In 2003, heroin/morphine was indicated in 109 of the 
486 drug misuse deaths (22.4 percent). Fifty of those 
were single-drug misuse deaths. 
 
In 2002, there were 3,999 heroin ED mentions; her-
oin was a factor in 22.3 percent of all drug episodes 
(exhibit 2). The heroin ED mentions rate of 111 per 
100,000 population was similar to that of the 2 previ-
ous years. 
 
The 2002 ED rates by gender show that the heroin rate 
for males is more than two times the rate for females 
(152 vs. 72 per 100,000 population). The highest rate 
by an age group (311 per 100,000 population) oc-
curred among those age 26–29. A 2-year rate increase 
of 215 percent was seen among those age 18–19. 
 
In the unweighted data accessed from DAWN Live! 
for 2004, heroin reports totaled 3,341. 
 
In the first half of FY 2005, 4,589 treatment admis-
sions (51 percent of all admissions) indicated heroin 
as the primary drug, and there were 4,338 mentions 
(48 percent of all admissions) of current (past-month) 
heroin use among those admitted to State-funded 
treatment programs (exhibit 3).  
 
A comparison of the last full year of data (FY 2004) 
to previous years shows the proportion of admissions 
reporting heroin as the primary drug in FY 2004 was 
stable from FY 2003 but reflected increases of 11 
percent from FY 2002 and 68 percent from FY 1997. 
Similarly, the proportion of mentions of current 
(past-month) heroin use in FY 2004 was stable from 
FY 2003, but this reflected increases of 7 percent 
from FY 2002 and 62 percent from FY 1997 
 
Exhibit 5b shows demographic characteristics of her-
oin or other opiates primary treatment admissions in 
Boston. For further demographic comparisons of 
annual treatment admissions, see “Patterns and 
Trends in Drug Abuse: Greater Boston” in Proceed-
ings of the Community Epidemiology Work Group, 
Volume II, January 2005.  
 
There were 791 Class A (mainly heroin and other 
opiates) drug arrests in 2004 (exhibit 6). The propor-
tion of Class A drug arrests among all drug arrests in 
the city of Boston in 2004 (21 percent) was a de-
crease of 8 percent from 1997. The proportion of 
Class A male arrests in 2004 (82 percent) reflected a  
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6-percent decrease from 2003 but is similar to 2002 
and 1997. The proportion of Class A arrests among 
those age 20–24 in 2004 (18 percent) reflected an 88-
percent increase from 1997.  
 
In 2004, 1,139 seized samples of heroin (13 percent of 
all drug samples) were analyzed. The proportion of 
heroin samples among all drug samples analyzed de-
creased 17 percent from 2003 to 2004.  
 
Heroin was self-identified as a substance of abuse in 
2,230 calls to the Helpline in FY 2004 (40 percent of 
all mentions). The proportion of heroin Helpline call 
mentions in FY 2004 represented increases of 9 per-
cent from FY 2003, 13 percent from FY 2002, and 21 
percent from FY 2001. 
  
The DEA reports that in Boston, street heroin costs 
$6–$20 per bag, with an average purity between 40 
and 60 percent (exhibit 5).  Boston’s heroin is typi-
cally from South America and transported to the area 
from the New York metropolitan area.  Heroin is 
considered “readily available throughout New Eng-
land” and is available in all forms: bag, bundle, gram, 
ounce, kilogram, and cylinder-shaped bullets/eggs. 
 
Narcotic Analgesics 
 
After years of growing narcotic analgesic abuse, a 
couple of indicators suggest that this trend may be 
starting to stabilize. 
 
Narcotic analgesics were mentioned 223 times 
among 486 drug misuse deaths in 2003. Forty-nine of 
those mentions were single-drug deaths, representing 
24 percent of the 206 total single-drug deaths.   
 
Morphine was identified in 85 of the total 486 drug 
misuse deaths.  Of these, 15 were single-drug deaths. 
Oxycodone was identified in 72 drug misuse deaths 
(15 percent of the total). Of these, 13 were single-
drug deaths.  Methadone was identified in 35 drug 
misuse deaths; 8 of these were single-drug deaths. 
Fentanyl was mentioned in 13 drug misuse deaths, of 
which six were single-drug deaths. 
 
There were an estimated 3,479 narcotic analge-
sics/combinations ED mentions in 2002. This number 
represents a 73-percent increase from 2000 and 153-
percent increase from 1995. The 2002 narcotic anal-
gesics/combinations rate of 97 ED mentions per 
100,000 population is twice the national rate of 46 
and fourth highest among all 21 DAWN sites.  
 
In 2002, Boston had the highest oxycodone/combina-
tions ED rate (a subset of the narcotic analge- 
 
sics/combinations category) among all 21 DAWN 
sites. Boston’s rate of 34 was 3.8 times the national 
rate of 9 and an increase of 118 percent from 2000. 
 
Preliminary unweighted data from DAWN Live! show 
2,968 ED reports of opiates/opioids in 2004; there 
were 1,587 oxycodone reports and 355 reports for hy-
drocodone. 
 
In the first half of FY 2005, there were 195 clients (2 
percent of all admissions) admitted to treatment who 
identified other opiates/synthetics as their primary drug, 
and there were 466 mentions (5 percent of all admis-
sions) of current other opiate use among those admitted 
to State-funded treatment programs (exhibit 3). 
 
Though the half-year treatment data suggest de-
creases in the proportion and number of opiate ad-
missions, a comparison of the last full year of data 
(FY 2004) to previous years shows the number of 
clients reporting other opiates as their primary drug 
(n=781) increased 243 percent from FY 2000 to FY 
2004 and 830 percent from FY 1997 to FY 2004. The 
number of mentions of current other opiate use in FY 
2004 (n=1,529) represented increases of 65 percent 
from FY 2000 and 166 percent from FY 1997. 
 
In 2004, 246 seized samples of oxycodone (3 percent 
of all drug samples) were analyzed. The proportion of 
oxycodone samples among all drug samples analyzed 
was stable from 2003 to 2004.  
 
In FY 2004, there were 1,025 calls to the Helpline 
during which opiates were mentioned (18 percent of 
all calls). Oxycodone (including OxyContin) was men-
tioned in 691 calls. Helpline calls with oxycodone 
mentions in FY 2004 (12 percent of total) reflected 
increases of 25 percent from FY 2003, 52 percent from 
FY 2002, and 261 percent from FY 2001. Other nar-
cotic analgesics, including methadone, codeine, mor-
phine, Percocet, Vicodin, and Roxicet, were mentioned 
among 401 calls (7 percent of total calls). 
 
Statewide OxyContin thefts continued to decrease in 
number. There were 33 statewide OxyContin thefts 
from pharmacies reported during 2004, compared 
with 62 in 2003, 93 in 2002, and the peak of 139 
thefts in 2001. Changes in pharmacy supply proce-
dures are believed to have played a major role in pre-
venting thefts.  
 
The DEA reports that OxyContin is “available” on 
the street and typically costs about $1 per milligram 
(exhibit 7). 
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Marijuana 
 
The most recent marijuana indicators for greater Bos-
ton are stable at relatively high levels. 
 
Marijuana was identified in 18 of the 486 drug mis-
use deaths in 2003. 
 
In 2002, there were 4,273 marijuana ED mentions; 
marijuana was a factor in 24 percent of all drug epi-
sodes (exhibit 2). The marijuana ED mentions rate of 
119 per 100,000 population was similar to that of the 
2 previous years. 
 
The 2002 marijuana ED rates by gender show that the 
rate for males was almost two times the rate for fe-
males (156 vs. 83 per 100,000 population). The high-
est rate by an age group (321 per 100,000 population) 
occurred among those age 18–25. Within that group, 
those age 18–19 experienced a rate of 630 per 
100,000 population. 
 
The unweighted data from DAWN Live! indicate 
there were 1,801 ED reports for marijuana in 2004. 
 
In the first half of FY 2005, there were 296 treatment 
admissions (3 percent of all admissions) with clients 
reporting marijuana as their primary drug (exhibit 3), 
and 839 mentions (9 percent of all admissions) of 
current marijuana use among those admitted to State-
funded treatment programs (exhibit 3).  
 
A comparison of the last full year of data to previous 
years shows the proportion of treatment admissions 
reporting marijuana as their primary drug in FY 2004 
was similar to the proportions in FY 2003, FY 2002, 
and FY 1997. The proportion of mentions of current 
marijuana use decreased 10 percent from FY 2003 to 
FY 2004 and 34 percent from FY 1997 to FY 2004. 
 
Exhibit 5c shows demographic characteristics of 
marijuana treatment admissions in Boston. For fur-
ther demographic comparisons of annual treatment 
admissions, see “Patterns and Trends in Drug Abuse: 
Greater Boston” in Proceedings of the Community 
Epidemiology Work Group, Volume II, January 2005.  
 
There were 1,247 Class D (mainly marijuana) drug 
arrests in 2004 (exhibit 6). The proportion of Class D 
arrests among all drug arrests (33 percent) in the city 
of Boston in 2004 remained stable from 2003 and 
2002 but increased 14 percent from 2001.  
 
The proportion of Black (including Hispanics) Class 
D arrests (70 percent) in 2004 increased 6 percent 
from 2003, 13 percent from 2002, and 25 percent 
from 1997. The proportion of White (including His-
panics) Class D arrests (29 percent) decreased 10, 21, 
and 32 percent, respectively, during the same periods.  
 
There were 3,358 seized samples of marijuana, more 
than any other drug, analyzed by the drug lab in 
2004. The proportion of marijuana samples analyzed 
in 2004 (38 percent of all drug samples) was similar 
to 2003 and 2002. 
 
Marijuana was mentioned in 253 calls to the Helpline 
in FY 2004. The proportion of helpline calls with 
marijuana mentions remained stable at 5 percent from 
FY 2003 to FY 2004. 
 
The DEA reports that marijuana is readily available 
in Massachusetts and sells for $800–$1,500 per 
pound for “commercial grade” and $1,000–$1,200 
per pound for “sinsemilla grade.” A marijuana ciga-
rette or “joint” typically costs $5. Commercial grade 
is said to be “readily available,” and high potency 
hydroponic marijuana termed “Hydro” is said to be 
“available” throughout New England. 
 
Benzodiazepines  
 
As a group, benzodiazepines are showing high levels 
of abuse.  
 
Benzodiazepines were mentioned in 88 of 486 drug 
misuse deaths in 2003.  Of these, 16 were single-drug 
deaths. 
 
There were an estimated 3,665 benzodiazepines ED 
mentions in 2002. Boston’s 2002 rate of 102 benzo-
diazepines ED mentions per 100,000 population was 
highest among all 21 DAWN sites and nearly 2½ 
times the national rate of 42.  
 
In the unweighted DAWN Live! data for 2004, there 
were 2,095 benzodiazepine reports. Clonazepam, 
alprazolam, lorazepam, and diazepam were the most 
often indicated benzodiazepines in preliminary ED 
data for 2004. 
 
In FY 2004, there were 98 treatment admissions (less 
than 1 percent of all admissions) with clients report-
ing benzodiazepines as their primary drug, but 1,613 
mentions (8 percent of all admissions) of current 
(past-month) benzodiazepine use among those admit-
ted to State-funded treatment programs. Of treatment 
admissions reporting current benzodiazepine use, 85 
percent were White, 56 percent were younger than 
age 35, and 66 percent were male.  
 
Arrest and drug lab data are currently unavailable for 
benzodiazepines.  
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In FY 2004, there were 175 calls to the Helpline dur-
ing which benzodiazepines (including Ativan, Val-
ium, Xanax, Klonopin, Rohypnol, Halcion, and 
others) were self-identified as substances of abuse (3 
percent of all calls). The number and proportion of 
Helpline call mentions attributable to benzodiazepi-
nes remained fairly stable from 2000 to 2003. 
 
Methylenedioxymethamphetamine (MDMA)  
 
MDMA (ecstasy) indicators show stable and rela-
tively low levels of abuse. 
 
There were an estimated 116 MDMA ED mentions in 
2002 (down slightly from 140 in 2001) (exhibit 2). 
Of these, 59 percent were among males, and 79 per-
cent were among those younger than 26.  
 
The unweighted data from DAWN Live! for 2004 
show 101 MDMA reports. 
 
Drug lab submissions show the number of MDMA 
samples has decreased steadily from a peak of 106 in 
2000 to 24 (fewer than 1 percent of the 8,901 total 
samples) in 2004.  
 
In FY 2004, there were 24 calls to the Helpline dur-
ing which MDMA was self-identified as a substance 
of abuse (fewer than 1 percent of all mentions). The 
number of MDMA Helpline calls has decreased 47 
percent from a peak of 45 calls in FY 2002. 
 
The DEA reports that one MDMA tablet costs be-
tween $20 and $25 retail (exhibit 7). Distributed at 
clubs and on college campuses, MDMA has re-
mained widely available “in spite of law enforcement 
seizures.” 
 
Other Drugs 
 
Amphetamines 
 
There were an estimated 541 amphetamine ED men-
tions in 2002. The 2002 rate of 15 mentions per 
100,000 population was the highest amphetamines 
ED mentions rate that Boston has experienced in 8 
years of DAWN reporting.  
 
Unweighted DAWN Live! data for 2004 show 184 
amphetamine reports. 
 
The number of amphetamine lab samples decreased 
from 47 in 2003 to 14 in 2004. The number of 
Helpline calls with stimulant mentions remained sta-
ble from 60 in FY 2003 to 49 in FY 2004. 
 
Methamphetamine  
 
There were only 13 estimated ED mentions of 
methamphetamine in 2002 (exhibit 2). This number 
is similar to each of the 2 previous years.  
 
In the unweighted DAWN Live! data for 2004, there 
were 39 methamphetamine ED reports. 
Though still relatively small in number, metham-
phetamine treatment admissions increased from 5 in 
FY 2001 to 66 in FY 2003 and 53 in FY 2004. 
 
In FY 2004, there were 14 methamphetamine men-
tions among calls to the Helpline. 
 
The DEA reports that methamphetamine costs $250 
per gram and is available “in limited (user-level) 
quantities” in New England (exhibit 7). The purity 
level is unknown. 
 
Ketamine 
 
There were an estimated 13 ketamine ED mentions in 
2002. This number is similar to each of the 2 previ-
ous years.   
 
Only three ketamine ED reports appear in the un-
weighted DAWN Live! data for 2004.  
 
Ketamine lab samples have decreased in number 
from 43 in 2002 to 11 in 2003 and 8 in 2004. The 
DEA reports that a vial of ketamine costs $55 to 
$100. 
 
Barbiturates 
 
There were an estimated 637 barbiturates ED mentions 
in 2002. Boston’s ED rate of 18 barbiturates mentions 
per 100,000 population was the highest barbiturates 
rate among the 8 years of DAWN reporting and 4½ 
times the national rate of 4. 
 
In the unweighted DAWN Live! data for 2004, there 
were 115 barbiturate ED reports. 
 
Lysergic Acid Diethylamide (LSD), Phencyclidine 
(PCP), and Gamma Hydroxybutyrate (GHB) 
 
There were few estimated LSD, PCP, or GHB ED 
mentions in Boston during 2002 (19, 20, and 27, re-
spectively) (exhibit 2). The DEA reports that LSD 
costs $5 per dose. GHB costs $150 per ounce. 
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INFECTIOUS DISEASES RELATED TO DRUG ABUSE 
 
In 2003, there were 269 adult HIV and AIDS cases 
diagnosed in Boston. The primary risk factor for 
these cases included 12 percent who were injection 
drug users (IDUs), 5 percent who had sex with IDUs, 
and 35 percent with an unknown/undetermined 
transmission status. As of May 1, 2005, cumulative  
 
adult AIDS cases numbered 6,054. By primary risk 
factor, these included 26 percent who were IDUs, 7 
percent who had sex with IDUs, and 13 percent for 
whom the risk behavior was unknown/undetermined. 
 
For inquiries concerning this report, please contact Daniel P. 
Dooley, Boston Public Health Commission, 1010 Massachusetts 
Avenue, Boston, MA  02118, Phone: (617) 534-2360, Fax: (617) 
534-2422, E-mail: Ddooley@bphc.org. 
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Exhibit 1. DAWN ED Sample and Reporting Information:  January–December 2004 
 
No. of EDs Reporting per Month: 
Completeness of Data (%)  CEWG Area Total Eligible Hospitals1 
No. of Hos-
pitals in 
DAWN 
Sample 
Total EDs in 
DAWN 
Sample2 90–100% 50–89% <50% 
No. of 
EDs Not 
Reporting 
Boston 41 29 34 15–23 0–3 0–4 11–16 
 
1Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association An-
nual Survey. 
2Some hospitals have more than one emergency department. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 5/13/2005  
 
 
 
 
 
Exhibit 2. Estimated Emergency Department Mentions for Selected Drugs as a Percentage of  
 Total Drug Episodes1:  1995–2002 
 
1995 1996 1997 1998 1999 2000 2001 2002 
Drug 
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
Alcohol-in-comb. 6,297 (39) 5,351 (40) 4,890 (40) 5,130 (38) 4,438 (38) 4,975 (33) 5,818 (35) 5,916 (33)
Cocaine/ 
Crack 5,267 (33) 4,106 (30) 3,332 (27) 4,526 (33) 3,560 (31) 4,099 (28) 4,933 (29) 5,611 (31)
Marijuana/ 
Hashish 2,401 (15) 2,127 (16) 1,768 (15) 2,907 (21) 1,960 (17) 2,945 (20) 3,423 (20) 4,273 (24)
Heroin/ 
Morphine 2,956 (18) 2,729 (20) 2,500 (21) 2,738 (20) 2,861 (25) 3,867 (26) 4,358 (26) 3,999 (22)
Oxycodone/ 
comb. 276 (2) 241 (2) 231 (2) 247 (2) 294 (3) 598 (4) 948 (6) 1,239 (7)
Hydrocodone/ 
comb. 85 (<1) 74 (<1) 93 (<1) 97 (<1) 106 (<1) 201 (1) 208 (1) 288 (2)
PCP 81 (<1) 18 (<1) 22 (<1) 21 (<1) 7 (<1) 11 (<1) 23 (<1) 20 (<1)
LSD 184 (1) 82 (<1) 37 (<1) 53 (<1) 44 (<1) 41 (<1) 33 (<1) 19 (<1)
Methampheta-
mine 7 (<1) …. —
2 …. —2 6 (<1) 12 (<1) 14 (<1) 14 (<1) 13 (<1)
MDMA 7 (<1) 9 (<1) 16 (<1) 39 (<1) 87 (<1) 125 (<1) 140 (<1) 116 (<1)
Total drug  
Episodes 16,065 13,530 12,224 13,656 11,668 14,901 16,853 17,965 
Total drug  
Mentions 30,026 24,904 22,383 24,875 21,217 25,854 29,795 32,488 
 
1Percentage of episodes for which each drug was mentioned (mentions/total drug episodes) rounded to the nearest whole number, 
except when <1 percent. 
2Estimate does not meet standard of precision. 
SOURCE:  Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (03/2003 update); prepared by the Boston Public 
Health Commission, Research Office 
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Exhibit 3. Percentages of Admissions to State-Funded Substance Abuse Treatment Programs by Primary  
   Drug and Drug Used in the Past Month in Greater Boston1:  FY 1997–1H FY 20052 
 
 FY 1997 FY 1998 FY 1999 FY 2000 FY 2001 FY 2002 FY 2003 FY 2004 1H FY 2005 
Primary Drug          
Alcohol 
Heroin and/or Other 
Opiates 
   Heroin 
   Other Opiates 
Cocaine and/or Crack 
   Cocaine (powder) 
   Crack 
Marijuana 
Other3 
46 
29 
 
29 
0 
19 
9 
10 
4 
1 
45 
35 
 
35 
0 
14 
7 
7 
4 
1 
45 
36 
 
36 
1 
13 
7 
6 
5 
1 
45 
37 
 
36 
1 
12 
5 
6 
5 
1 
44 
42 
 
40 
2 
9 
4 
5 
4 
1 
40 
46 
 
43 
3 
9 
4 
5 
4 
1 
36 
50 
 
47 
3 
8 
3 
5 
4 
1 
35 
52 
 
48 
4 
7 
3 
4 
4 
1 
34 
53 
 
51 
2 
8 
3 
4 
3 
1 
Total (N) 25,470 23,008 24,653 24,478 25,334 25,586 24,440 20,041 8,948 
Drug Used Past Month          
Alcohol 
Heroin and/or Other 
Opiates 
   Heroin 
   Other Opiates 
Cocaine and/or Crack 
   Cocaine (powder) 
   Crack 
Marijuana 
60 
29 
 
28 
2 
34 
22 
19 
16 
59 
34 
 
33 
3 
30 
21 
16 
14 
59 
35 
 
34 
3 
30 
21 
15 
14 
58 
37 
 
35 
4 
28 
20 
13 
13 
56 
42 
 
39 
5 
25 
18 
12 
13 
53 
45 
 
42 
6 
24 
17 
11 
11 
50 
48 
 
45 
7 
24 
18 
11 
11 
47 
49 
 
46 
8 
23 
16 
11 
10 
47 
51 
 
48 
5 
25 
16 
13 
9 
Total (N) 25,470 23,008 24,653 24,478 25,334 25,586 24,440 20,041 8,948 
 
1Excluding prisoners and out-of-State admissions. 
2Fiscal years (FYs) run July 1–June 30, with the year named for the January–June portion of the year. 1H FY 2005 runs July 2004–
December 2004. 
3Includes barbiturates, other sedatives, tranquilizers, hallucinogens, amphetamines, “over-the-counter,” and other drugs. 
SOURCE:  Massachusetts Department of Public Health, Bureau of Substance Abuse Services; prepared by the Boston Public 
Health Commission, Research Office 
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Exhibit 4. Demographic Characteristics of Admissions to Greater Boston State-Funded Substance Abuse  
   Treatment Programs1, by Percent:  FY 1997–FY 20042 
 
Characteristic FY 1997 FY 1998 FY 1999 FY 2000 FY 2001 FY 2002 FY 2003 FY 2004 
Gender 
 Male 
 Female 
 
72 
28 
 
75 
25 
 
74 
26 
 
76 
24 
 
77 
23 
 
77 
23 
 
74 
26 
 
73 
27 
Race 
 White 
 Black 
 Hispanic 
 Other 
 
47 
35 
14 
3 
 
49 
32 
15 
4 
 
48 
33 
16 
4 
 
49 
32 
16 
4 
 
48 
30 
18 
4 
 
49 
29 
18 
4 
 
50 
28 
18 
4 
 
54 
26 
17 
3 
Age at Admission 
 (Average age) 
 18 and younger 
 19–29 
 30–39 
 40–49 
 50 and older 
 
(35.1) 
3 
25 
43 
22 
7 
 
(35.6) 
3 
24 
42 
23 
8 
 
(36.5) 
2 
22 
41 
27 
9 
 
(36.7) 
2 
21 
40 
29 
9 
 
(36.5) 
2 
22 
38 
29 
9 
 
(36.5) 
2 
24 
37 
28 
10 
 
(36.7) 
2 
24 
34 
30 
10 
 
(36.9) 
2 
26 
31 
30 
11 
Marital Status 
 Married 
 Separated/divorced 
 Never married 
 
10 
22 
68 
 
10 
22 
68 
 
10 
21 
69 
 
10 
19 
71 
 
10 
18 
72 
 
10 
18 
72 
 
10 
18 
72 
 
9 
17 
74 
Annual Income 
 None 
 $1–$1,000 
 $1,000–$9,999 
 $10,000 and higher 
 
56 
3 
26 
15 
 
56 
3 
24 
16 
 
54 
4 
26 
16 
 
59 
3 
21 
17 
 
61 
2 
19 
18 
 
69 
2 
14 
16 
 
68 
2 
14 
16 
 
63 
3 
18 
16 
Homeless 32 31 31 30 34 37 37 36 
Criminal Justice System 
Involvement 26 26 28 27 26 27 24 23 
Mental Health 
 No prior treatment 
 Prior treatment  
 (counseling or  
 hospitalization) 
 
82 
 
18 
 
 
 
80 
 
20 
 
 
 
79 
 
21 
 
 
 
80 
 
20 
 
 
 
81 
 
19 
 
 
 
80 
 
20 
 
 
 
80 
 
20 
 
 
 
78 
 
22 
 
 
Needle Use in Past Year 22 25 26 26 27 32 37 38 
Total (N) (25,470) (23,008) (24,653) (24,478) (25,334) (25,586) (24,440) (20,041)
 
1Excludes prisoners and out-of-State admissions. 
2Fiscal years (FYs) run July 1–June 30, with the year named for the January–June portion of the year. 
SOURCE: Massachusetts Department of Public Health, Bureau of Substance Abuse Services; prepared by the Boston Public 
Health Commission, Research Office 
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Greater Boston 
 
 
Proceedings of the Community Epidemiology Work Group, June 2005 46 
Exhibit 5a. Demographic Characteristics of Clients1 in Greater Boston State-Funded Substance Abuse  
    Treatment Programs with a Primary Problem with Cocaine/Crack, by Percent:  FY 1997–FY 20042 
 
Characteristic FY 1997 FY 1998 FY 1999 FY 2000 FY 2001 FY 2002 FY 2003 FY 2004 
Gender 
 Male 
 Female 
 
60 
40 
 
61 
39 
 
59 
41 
 
59 
41 
 
62 
38 
 
63 
37 
 
56 
44 
 
57 
43 
Race 
 White 
 Black 
 Latino 
 Other 
 
25 
63 
10 
2 
 
24 
64 
10 
3 
 
23 
63 
11 
3 
 
23 
65 
10 
3 
 
26 
60 
12 
3 
 
25 
61 
11 
3 
 
27 
58 
11 
4 
 
27 
58 
12 
3 
Age at Admission 
 (Average age) 
 18 and younger 
 19–29 
 30–39 
 40–49 
 50 and older 
 
(32.8) 
1 
31 
53 
13 
2 
 
(33.6) 
1 
28 
53 
16 
2 
 
(35.2) 
1 
19 
56 
21 
4 
 
(35.5) 
<1 
18 
55 
23 
4 
 
(36.0) 
1 
15 
55 
26 
4 
 
(36.7) 
<1 
15 
51 
29 
5 
 
(37.1) 
1 
15 
49 
31 
5 
 
(38.0) 
1 
13 
45 
35 
7 
Marital Status 
 Married 
 Separated/divorced 
 Never married 
 
9 
17 
75 
 
10 
19 
71 
 
11 
19 
71 
 
10 
16 
74 
 
11 
17 
72 
 
12 
19 
69 
 
12 
19 
70 
 
10 
21 
69 
Annual Income 
 $0–$999 
 $1,000–$9,999 
 $10,000 and higher 
 
59 
28 
13 
 
57 
27 
17 
 
56 
29 
16 
 
59 
24 
17 
 
58 
22 
21 
 
60 
23 
18 
 
56 
26 
18 
 
54 
29 
17 
Homeless 28 26 23 21 23 28 24 24 
Criminal Justice System 
Involvement 20 25 30 29 30 33 31 31 
Mental Health Problem 21 22 27 28 29 31 36 36 
Needle Use in Past Year 5 6 6 5 7 7 9 8 
Total (N) (4,920) (3,266) (3,165) (2,837) (2,291) (2,230) (1,985) (1,470) 
 
1Excludes prisoners and out-of-State admissions. 
2Fiscal years (FYs) run July 1–June 30, with the year named for the January–June portion of the year. 
SOURCE:  Massachusetts Department of Public Health, Bureau of Substance Abuse Services; prepared by the Boston Public 
Health Commission, Research Office 
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Exhibit 5b. Demographic Characteristics of Clients1 in Greater Boston State-Funded Substance Abuse  
    Treatment Programs with a Primary Problem with Heroin or Other Opiates, by Percent: 
    FY 1997–FY 20042 
 
Characteristic FY 1997 FY 1998 FY 1999 FY 2000 FY 2001 FY 2002 FY 2003 FY 2004 
Gender 
 Male 
 Female 
 
69 
31 
 
72 
28 
 
72 
28 
 
75 
25 
 
76 
24 
 
77 
23 
 
74 
26 
 
72 
28 
Race 
 White 
 Black 
 Latino 
 Other 
 
49 
26 
21 
4 
 
48 
24 
22 
6 
 
49 
24 
22 
5 
 
51 
22 
23 
5 
 
50 
21 
25 
5 
 
53 
19 
25 
4 
 
56 
18 
22 
5 
 
61 
15 
21 
3 
Age at Admission 
 (Average age) 
 18 and younger 
 19–29 
 30–39 
 40–49 
 50 and older 
 
(34.5) 
1 
28 
45 
24 
3 
 
(34.6) 
1 
29 
42 
24 
4 
 
(35.2) 
1 
27 
42 
25 
6 
 
(35.3) 
1 
27 
40 
27 
5 
 
(35.1) 
1 
29 
39 
26 
6 
 
(34.6) 
1 
32 
37 
24 
6 
 
(35.2) 
1 
31 
35 
26 
7 
 
(35.1) 
1 
33 
32 
26 
8 
Marital Status 
 Married 
 Separated/divorced 
 Never married 
 
11 
22 
68 
 
11 
21 
68 
 
10 
20 
70 
 
11 
19 
71 
 
10 
17 
73 
 
10 
15 
75 
 
9 
16 
75 
 
7 
16 
77 
Annual Income 
 $0–$999 
 $1,000–$9,999 
 $10,000 and higher 
 
67 
23 
10 
 
69 
21 
10 
 
67 
23 
10 
 
72 
16 
12 
 
73 
15 
12 
 
78 
11 
11 
 
78 
12 
10 
 
74 
16 
10 
Homeless 28 25 26 22 29 35 40 39 
Criminal Justice System 
Involvement 16 18 20 19 19 19 16 16 
Mental Health Problem 17 17 18 16 16 16 16 18 
Needle Use in Past Year 64 63 63 63 58 62 68 68 
Total (N) (7,372) (8,145) (8,932) (9,151) (10,613) (11,850) (12,210) (10,402) 
 
1Excludes prisoners and out-of-State admissions. 
2Fiscal years (FYs) run July 1–June 30, with the year named for the January–June portion of the year. 
SOURCE: Massachusetts Department of Public Health, Bureau of Substance Abuse Services; prepared by the Boston Public 
Health Commission, Research Office 
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Exhibit 5c. Demographic Characteristics of Clients1 in Greater Boston State-Funded Substance Abuse  
    Treatment Programs with a Primary Problem with Marijuana, by Percent:  FY 1997–FY 20042 
 
Characteristic FY 1997 FY 1998 FY 1999 FY 2000 FY 2001 FY 2002 FY 2003 FY 2004 
Gender 
 Male 
 Female 
 
76 
24 
 
78 
22 
 
76 
24 
 
73 
27 
 
78 
22 
 
77 
23 
 
77 
23 
 
71 
29 
Race 
 White 
 Black 
 Latino 
 Other 
 
37 
39 
20 
4 
 
32 
42 
22 
4 
 
28 
44 
23 
4 
 
28 
47 
21 
4 
 
29 
47 
22 
3 
 
27 
48 
20 
5 
 
26 
49 
22 
4 
 
29 
47 
20 
3 
Age at Admission 
 (Average age) 
 18 and younger 
 19–29 
 30–39 
 40–49 
 50 and older 
 
(24.0) 
33 
43 
18 
5 
1 
 
(24.2) 
29 
48 
18 
5 
1 
 
(25.1) 
24 
50 
17 
6 
2 
 
(25.4) 
19 
56 
18 
5 
2 
 
(24.3) 
27 
51 
16 
6 
1 
 
(24.8) 
24 
50 
19 
6 
1 
 
(25.2) 
22 
52 
18 
7 
2 
 
(26.3) 
17 
52 
21 
7 
2 
Marital Status 
 Married 
 Separated/divorced 
 Never married 
 
6 
5 
89 
 
6 
6 
89 
 
4 
6 
90 
 
5 
7 
88 
 
5 
6 
90 
 
6 
7 
88 
 
6 
6 
89 
 
6 
6 
88 
Annual Income 
 $0–$999 
 $1,000–$9,999 
 $10,000 and higher 
 
58 
28 
15 
 
50 
31 
19 
 
59 
27 
14 
 
55 
27 
18 
 
57 
22 
21 
 
60 
21 
19 
 
64 
21 
16 
 
53 
28 
19 
Homeless 8 8 9 10 11 12 9 11 
Criminal Justice System 
Involvement 38 47 53 48 48 50 43 44 
Mental Health Problem 25 31 23 27 25 29 31 35 
Needle Use in Past Year 1 2 2 2 2 2 2 2 
Total (N) (1,119) (928) (1,125) (1,109) (1,100) (1,054) (1,046) (857) 
 
1Excludes prisoners and out-of-State admissions. 
2Fiscal years (FYs) run July 1–June 30, with the year named for the January–June portion of the year. 
SOURCE:  Massachusetts Department of Public Health, Bureau of Substance Abuse Services; prepared by the Boston Public 
Health Commission, Research Office 
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Exhibit 6. Boston Police Department Arrests, by Substance,1 Number, and Percent:  1997–2004 
 
1997 1998 1999 2000 2001 2002 2003 2004 
Drug Class Number 
(%) 
Number 
(%) 
Number 
(%) 
Number 
(%) 
Number 
(%) 
Number 
(%) 
Number 
(%) 
Number 
(%) 
A 
(Mostly  
Heroin) 
1,392 
(22.7) 
1,061 
(22.5) 
984 
(24.0) 
1,022 
(27.1) 
905 
(26.4) 
947 
(22.5) 
939 
(22.5) 
791 
(20.8) 
B 
(Mostly  
Cocaine) 
2,918 
(47.5) 
2,225 
(47.1) 
1,847 
(45.1) 
1,532 
(40.6) 
1,428 
(41.7) 
1,762 
(41.9) 
1,736 
(41.6) 
1,650 
(43.3) 
D 
(Mostly  
Marijuana) 
1,617 
(26.3) 
1,211 
(25.6) 
1,133 
(27.7) 
1,093 
(29.0) 
982 
(28.7) 
1,375 
(32.7) 
1,366 
(32.7) 
1,247 
(32.8) 
Other 216 (3.5) 
226 
(4.8) 
133 
(3.3) 
123 
(3.3) 
111 
(3.2) 
125 
(3.0) 
133 
(3.2) 
119 
(3.1) 
Total Drug 
Arrests 6,143 4,723 4,097 3,770 3,426 4,209 4,174 3,807 
Total Arrests 27,843 25,481 23,592 22,216 20,470 21,025 20,686 19,577 
Drug Per-
centage of 
Total Arrests 
(23.7) (18.5) (17.4) (17.0) (16.7) (20.0) (20.2) (19.4) 
 
1Includes all arrests made by the Boston Police Department (i.e., arrests for possession, distribution, manufacturing, trafficking, 
possession of hypodermic needles, conspiracy to violate false substance acts, and forging prescriptions). 
SOURCE:  Boston Police Department, Office of Planning and Research; prepared by the Boston Public Health Commission, Re-
search Office 
 
 
Exhibit 7.  Drug Street Price, Purity, and Availability in Boston:  November 2003–December 2004 
 
Drug Price Purity Availability 
Heroin 
$53–$100 per gram 
$60–$100 per bundle 
$6–$20 per bag 
High (bag-40%-60%) Readily 
Cocaine (powder) $50–$90 per gram retail Increasing Steady, available 
Crack $10–$20 per rock   
Marijuana $5 per joint $200–$250 per ounce Commercial Grade Readily 
Methamphetamine $250 per gram Unknown Limited quantities 
MDMA (Ecstasy) $20–$25 per tablet  High (clubs & colleges) 
OxyContin $1 per milligram   
LSD $5 per dose   
Ketamine $50–$100 per vial   
GHB $5 per capful, $150 per ounce   
 
SOURCES: New England Field Division, Drug Enforcement Administration (DEA) as of June 2005; prepared by the Boston Public 
Health Commission, Research Office 
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Patterns and Trends of Drug 
Abuse in Chicago 
 
Dita Broz, M.P.H., Matthew Magee, Wayne 
Wiebel, Ph.D., and Lawrence Ouellet, Ph.D.1  
 
ABSTRACT 
 
Most indicators suggest that heroin and cocaine 
continue to pose a serious problem for Chicago and 
Illinois. According to preliminary unweighted data 
from DAWN Live!, cocaine and heroin were the top 
two illicit drugs most reported in emergency de-
partments in 2003 and 2004. Heroin-related treat-
ment episodes increased between FYs 2000 and 
2004, indicating continued high levels of use. The 
purity of street-level heroin decreased between 2001 
and 2003 from about 24 percent to 16 percent, 
though ethnographic reports suggest a recent in-
crease. Many cocaine indicators remain the highest 
for all substances except alcohol. Cocaine-related 
treatment episodes increased between FYs 2002 and 
2003 by 20 percent, but they decreased slightly in 
FY 2004. Marijuana remains the most widely avail-
able and used illicit drug. Methamphetamine indi-
cators continued to show low but increasing levels 
of use in some areas of Chicago, especially on the 
north side, where young gay men and clubgoers 
congregate. Methamphetamine use is significantly 
higher in downstate Illinois. MDMA (ecstasy) ED 
mentions decreased 60 percent between 2000 and 
2002, but increases in use have been reported 
among young African-Americans. LSD and PCP 
indicators suggest a downward trend in use. The 
proportion of new AIDS cases attributed to injection 
drug use peaked at 33 percent in 1996 then steadily 
decreased to 24 percent in 2002. Prospective studies 
of young heroin users in Chicago conducted by the 
authors of this report suggest low HIV and HCV 
seroprevalence, but substantial levels of risk prac-
tices that place them at high risk for acquiring these 
infections.  
 
INTRODUCTION 
 
Area Description 
 
Due to its geographic location and multifaceted 
transportation infrastructure, Chicago is a major 
transportation hub and distribution center for illegal 
drugs throughout the Midwest. Located in northeast-
ern Illinois, the city of Chicago stretches for 25 miles 
                                                 
1The authors are affiliated with the University of Illinois at Chi-
cago, School of Public Health, Chicago, Illinois. 
along the southern tip of Lake Michigan's shore. The 
2000 U.S. census estimated the population of Chi-
cago at 2.9 million and Cook County (which includes 
Chicago) at 5.4 million. In June 2003, the U.S. Office 
of Management and Budget (OMB) revised defini-
tions for the Nation’s Metropolitan Statistical Areas 
(MSA). The Chicago-Naperville-Joliet, Illinois, MSA 
includes Cook, DeKalb, DuPage, Grundy, Kane, 
Kendall, McHenry, and Will Counties, and its popu-
lation size was estimated at slightly more than 9 mil-
lion (ranking third in the Nation).  
 
According to the U.S. Census Bureau, the city popu-
lation increased about 4 percent between 1990 and 
2000, but it is estimated to have decreased about 1 
percent in 2003. The number of Hispanics living in 
Chicago increased 38 percent between 1990 and 
2000, while the number of Whites and African-
Americans declined by 14 and 2 percent, respec-
tively.  
 
Based on the 2000 census, the Chicago population is 
36 percent African-American, 31 percent White, 26 
percent Hispanic, and 4 percent Asian-
American/Pacific Islander. In 2000, the median age 
of Chicagoans was 31.5, with 26 percent of the pop-
ulation younger than 18 and 10 percent age 65 or 
older. The unemployment rate is 6.2 percent, and the 
percentage of families living below the poverty level 
with children younger than 18 is 11.4 percent. 
 
Data Sources 
 
This report is based on the most recent data available 
from the various sources detailed below: 
 
• Drug-related mortality data were derived from 
the Drug Abuse Warning Network (DAWN), Of-
fice of Applied Studies (OAS), Substance Abuse 
and Mental Health Services Administration 
(SAMHSA), mortality system for 1998–2003. The 
DAWN system recently restructured its data col-
lection methods; mortality estimates produced as 
of 2003 are not comparable to previous years. In 
2003, 122 jurisdictions in 35 metropolitan areas 
and 6 States reported mortality data to DAWN. Of 
the 14 targeted counties in the Chicago metropoli-
tan area, only 5 (DuPage, Kane, Kendall, Lake, 
McHenry) reported mortality data to DAWN in 
2003, covering about 26 percent of the population. 
A full description of the DAWN system can be 
found on the DAWN Web site: http://dawn 
info.samhsa.gov. Data on pediatric toxicity and 
on deaths related to accidental drug poisonings 
have not been available from the Illinois Depart-
ment of Public Health (IDPH) Adverse Pregnancy 
Outcome Reporting System (APORS) and from 
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the Chicago Department of Public Health, respec-
tively, since 2002. 
 
• Emergency department (ED) data were pro-
vided by DAWN, OAS, SAMHSA, for 1994 
through 2002. The 2000 ED data were unavailable 
for methamphetamine. Also presented in this pa-
per are preliminary unweighted data from the 
DAWN Live! restricted-access online query sys-
tem administered by OAS, beginning in 2003. 
The 2003–2004 data represent a redesign of 
DAWN, and the data are not comparable to those 
from 2002 and before. The redesigned system 
has 74 of the 88 eligible hospitals in the Chicago 
sample, with 76 EDs in the sample. (Some hospi-
tals have more than one ED.) Data completeness 
differs considerably for the 2 years (see exhibit 
1) due, in part, to limitations associated with im-
plementing a new system in 2003. During 2004, 
between 24 and 32 EDs reported data each 
month.  The completeness of data reported by 
participating EDs varied by month. The 2003–
2004 data are incomplete (not all EDs reported 
each month) and unweighted; these data cannot 
be used as estimates, nor can they be used for 
comparison with future data. Only weighted data 
released by SAMHSA can be used for trend 
analysis. All DAWN cases are reviewed for 
quality control; based on the review, cases may 
be corrected or deleted. Therefore, data pre-
sented in this report are subject to change. The 
2003–2004 data were accessed from the DAWN 
Live! update between April 14, 2005, and June 9, 
2005, and represent drug reports. Drug reports 
exceed the number of visits, since a patient may 
report use of multiple drugs (up to six drugs plus 
alcohol). For the purpose of this report, drug-
related reports include all DAWN case types, 
and drug misuse reports include only the follow-
ing three DAWN case types: “seeking detox,” 
“overmedication,” and “other.” The latter is used 
in the “Other Opiates” and “Depressants” sec-
tions of this report. A full description of the 
DAWN system can be found on the DAWN Web 
site: http://dawninfo.samhsa.gov. 
 
• Treatment data for the State of Illinois for fis-
cal years (FYs) 2000–2004 (July 1–June 30) 
were provided by the Illinois Division of Alco-
holism and Substance Abuse (DASA).  National 
and State-specific treatment admissions data for 
1992–2002 were provided by the Treatment Epi-
sode Data Set (TEDS) maintained by SAMHSA.  
 
• Arrestee drug testing data were provided by the 
Arrestee Drug Abuse Monitoring (ADAM) pro-
gram, National Institute of Justice (NIJ), and are 
also described in the June 2004 Chicago CEWG 
report. 
 
• Incidence data on drug-related calls were pro-
vided by the Illinois Poison Center (IPC) in Chi-
cago for Cook County for 2001 through 2003. 
The IPC answered more than 93,000 calls in 
2003 on household products, herbal products, 
medication overdoses, adverse reactions to 
medications, alcohol or drug misuse, occupa-
tional accidents, chemical spills, and other poi-
sonings. 
 
• Price and purity data were provided by the Drug 
Enforcement Administration (DEA), Domestic 
Monitor Program (DMP), for heroin for 1991–
2003. Price and purity data on drug samples ana-
lyzed through April 2005 were provided by the Il-
linois State Police (ISP), Division of Forensic Sci-
ence. National and Illinois data on drug availabil-
ity, demand, production, cultivation, and distribu-
tion were available from the National Drug Threat 
Assessment February 2005 and the Illinois Drug 
Threat Assessment May 2002 reports, National 
Drug Intelligence Center, U.S. Department of Jus-
tice. The Office of National Drug Control Policy 
(ONDCP) report on Profile of Drug Indicators, 
Chicago, Illinois, published in April 2004, as well 
as the National Drug Intelligence Center 2003 Il-
licit Drug Prices: July 2003–December 2003 re-
port, were reviewed. Data from the National Fo-
rensic Laboratory Information System (NFLIS) 
for FY 2003 and FY 2004 were used to report dif-
ferences between different drugs in the relative 
amounts submitted for testing in Illinois and Chi-
cago. Ethnographic data on drug availability, 
prices, and purity are from observations and inter-
views conducted by the Community Outreach 
Intervention Projects (COIP), School of Public 
Health, University of Illinois at Chicago (UIC). 
 
• Criminal justice data were available from the 
Illinois Criminal Justice Information Authority 
(ICJIA), which collects, maintains, and updates a 
variety of criminal justice data to support its re-
search and evaluation efforts. ICJIA regularly 
publishes criminal justice research, evaluation 
reports, and statistical profiles. ICJIA’s drug ar-
rest data for 1990–2002 and the special report on 
methamphetamine trends in Illinois were re-
viewed. 
 
• Survey data on student and household popu-
lations were derived from several sources. Stu-
dent drug use data were provided by the national 
Monitoring the Future (MTF) Study, the Youth 
Risk Behavior Surveillance System (YRBSS) 
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survey, and the Illinois Youth Survey and are de-
scribed in the June 2004 Chicago CEWG report. 
National data on substance use and abuse were 
provided by SAMHSA’s 2002 National Survey 
on Drug Use and Health.  
 
• Most recent drug use estimates were derived 
from two currently ongoing studies of young 
heroin users in metropolitan Chicago conducted 
by COIP at the UIC School of Public Health. 
The Family Process and Risk Reduction Study 
(Family Process), funded by the National Insti-
tute on Drug Abuse (NIDA), assesses a human 
immunodeficiency virus (HIV) prevention inter-
vention that targets young injection drug users 
(IDUs) and their parents. Participants are age 
18–25 and have injected in the last 6 months 
(n=636 as of June 2005). All data from the Fam-
ily Process Study are preliminary. Current non-
injecting heroin users (NIHUs) age 16–30 were 
recruited for the NIDA-funded NIHU Study to 
evaluate the rate of transition to injecting and 
drug and sexual practices associated with HIV, 
hepatitis B (HBV), and hepatitis C (HCV) infec-
tions (n=649 as of June 2005). 
 
• Acquired immunodeficiency syndrome (AIDS) 
and HIV data were derived from both agency 
sources and UIC studies. IDPH and CDPH sur-
veys provided statistics on AIDS and HIV 
through October 2004 and December 2003, re-
spectively. The CDPH Office of HIV/AIDS Sur-
veillance provided data through 2003 (2003 data 
are preliminary). CDC’s “HIV/AIDS Surveil-
lance Report,” December 2001, provided addi-
tional data on HIV and AIDS. The agency data 
are complemented by UIC’s studies of IDUs 
conducted by COIP at UIC’s School of Public 
Health. One is the NIDA-funded “AIDS Inter-
vention Study,” based on a panel of IDUs par-
ticipating from 1988 to 1996. The second is the 
CDC-funded HIV Incidence Study (CIDUS I and 
II). The CIDUS data are from analyses of a 
1994–1996 study of 794 IDUs, age 18–50, in 
Chicago (Ouellet et al. 2000) and a 1997–1999 
study of 700 IDUs, age 18–30, in Chicago and 
its suburbs (Thorpe et al. 2000; Bailey et al. 
2001). Most sources have not been updated since 
the Chicago CEWG December 2002 report. 
 
Several of the sources traditionally used for this re-
port have not been updated by their authors or were 
unavailable at the time this report was generated. 
Because some information has not changed—and to 
avoid redundancy—this report occasionally refers 
readers to a previous Chicago CEWG report for more 
information in a particular area. For a discussion of 
the limitations of survey data, the reader is referred to 
the December 2000 Chicago CEWG report. 
 
DRUG ABUSE PATTERNS AND TRENDS 
 
This report of drug abuse patterns and trends is or-
ganized by major pharmacologic categories. Readers 
are reminded, however, that multidrug consumption 
is the normative pattern among a broad range of sub-
stance abusers in Chicago. Various indicators suggest 
that drug combinations play a substantial role in drug 
use prevalence. Preliminary unweighted DAWN data 
show that 26 percent of all ED drug reports in Chi-
cago in 2004 were alcohol-in-combination mentions. 
During FY 2004, heroin was the most often men-
tioned reason for seeking treatment in Chicago. 
Among these treatment episodes, the most common 
secondary substances reported were cocaine (37 per-
cent) and alcohol (13 percent).  
 
According to DAWN ED data, Chicago was report-
ing the highest ED drug mentions among the 21 
DAWN sites between 2000 and 2002.  Both DAWN 
mortality cases and CDPH death certificates suggest 
that total drug-related deaths remained stable at high 
numbers between 2000 and 2002. According to 
APORS, 718 children in Chicago were exposed to 
some drug at birth in 2002, which corresponds to an 
annual rate of 150 exposures per 10,000 live births. 
In 2003, DAWN reported a rate of 57 drug misuse-
related deaths per 1,000,000 and 14 drug-related sui-
cide deaths per 1,000,000 in the Chicago MSA. 
Drug-related deaths were more common among 
males and those age 35–54. 
 
Cocaine/Crack 
 
The majority of quantitative and qualitative cocaine 
indicators suggest that use remains stable at high lev-
els and that cocaine continues to be a serious drug 
problem for Chicago and Illinois.  
 
In 2002, both the DAWN ME drug-induced or drug-
related death data and CDPH death certificate data 
showed that cocaine remains a factor in more deaths 
in the Chicago area than any other illicit drug. How-
ever, multiple drug use was involved in 65 percent of 
these cases. According to the new 2003 DAWN ME 
report, 77 percent (67 deaths) of all drug-related 
deaths recorded that year were related to cocaine. 
Five of the 67 cocaine-related deaths were ruled as 
suicide.  Multidrug use was involved in the majority 
(64 percent) of cocaine-related deaths. 
 
In 2002, ED mentions for cocaine remained at high 
levels, and they represented a 52-percent increase 
over 10,702 mentions in 1995. Chicago continued to 
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have the most cocaine ED mentions among DAWN 
sites in 2002 (16,227 mentions) and the highest rate 
of mentions (275 per 100,000 population) (exhibit 2).  
 
Preliminary unweighted data accessed from DAWN 
Live! for 2003 and 2004 show that slightly more than 
one-third of total ED reports were cocaine related (33 
and 34 percent, respectively).  ED cocaine reports 
totaled 5,981 in 2004 (exhibit 3).  In 2004, the major-
ity of the cocaine reports involved males (65 per-
cent), African-Americans (56 percent), and those 
between 35 and 54 years of age (64 percent).  
 
According to the Illinois Poison Center, approxi-
mately 120 cocaine-related calls were received annu-
ally in Chicago for 2001–2003. During this period, 
cocaine generated more calls than any other “street 
drug” (approximately 25 percent of all “street 
drugs”). 
 
The FY 2004 Illinois drug treatment report indicates 
that cocaine abuse remains one of the top three rea-
sons for entering treatment (excluding primary alco-
hol-only abuse) (exhibit 4). A total of 31,430 persons 
were treated for cocaine-related problems in Illinois 
during FY 2004, of which 48 percent occurred in 
Chicago. Cocaine was the most commonly mentioned 
secondary drug among persons treated for primary 
heroin-related problems. In FY 2004, African-
Americans remained the largest group among total 
persons treated (60 percent) for cocaine abuse. Males 
accounted for more services rendered (57 percent) 
than females. Smoking continued to be the most 
common route of cocaine administration (85 percent) 
in FY 2004. 
 
According to the 2003 ADAM report, 51 percent of 
adult male arrestees (exhibit 5) and 33 percent of 
adult female arrestees tested cocaine positive. 
 
Cocaine use appears common among heroin users in 
Chicago. In an ongoing study of non-injecting heroin 
users (NIHU Study), 70 percent of participants re-
ported ever using powder cocaine, and 34 percent 
used it in the past 6 months. Crack cocaine use was 
reported by 67 percent of the study participants, and 
52 percent reported using crack in the past 6 months. 
Among injecting drug users (Family Process study), 
84 percent reported ever using powder cocaine, and 
64 percent of them used it in the past 12 months. 
Somewhat fewer participants had ever used crack 
cocaine (75 percent), but 83 percent of lifetime users 
reported using it in the past 12 months. 
 
According to IDPH’s Adverse Pregnancy Outcome 
Reporting System, cocaine exposure among children  
 
at birth in Chicago decreased between 1999 and 2002 
by 29 percent, from 95.2 to 73.8 per 10,000 live 
births. Nonetheless, cocaine continued to be the most 
often cited drug exposure among children in Chicago. 
In 2002, the highest proportion of such births oc-
curred among African-American mothers (approxi-
mately 78 percent) and to mothers between 25 and 34 
years of age. 
 
State (ISP) and Federal (NFLIS) labs reported that 
cocaine was the drug most often received for testing 
after cannabis. Cocaine purity for samples weighing 2–
25 grams tested by the ISP was 81 percent in 2003 and 
77 percent in 2004, but analyses were conducted on 
only a few samples, and reasonable comparison with 
earlier data is not possible.  
 
Cocaine prices have not changed since the June 2003 
report. Ounce prices for powder cocaine were reported 
by street sources to be between $400 and $800, de-
pending on the drug’s quality and the buyer’s relation-
ship to the seller. Gram prices for powder and rock 
cocaine ranged from $50 to $150, with most reports 
around $75. Ounces of crack cocaine (“rock”) sold for 
about the same price as ounces of powder cocaine, 
with reports ranging from $900 to $1,600. The NDIC 
reported the wholesale price of a kilogram of cocaine 
in Chicago was $18,000–$20,000 for powdered co-
caine and $22,000–$24,000 for crack. The June 2003 
report contains more detailed information about drug 
prices in Chicago.  
 
According to the 2003 YRBSS study, the proportion of 
lifetime cocaine/crack use among Chicago-area 9th 
through 12th grade students remained level at about 5 
percent between 1995 and 2003. Male students re-
ported cocaine/crack use nearly twice as often as their 
female counterparts during this period. The 2002 Illi-
nois Youth Survey of Chicago-area 8th through 12th 
grade students reported a similar level of use (about 5 
percent) between 1998 and 2002. The June 2004 Chi-
cago CEWG report provides a more complete discus-
sion of the 2002 Illinois Youth Survey.  
 
Heroin 
 
Similar to cocaine, heroin abuse indicators in this 
reporting period continue to suggest high levels of 
use in the Chicago area. 
 
Of the 711 total drug-induced or drug-related deaths 
reported by the DAWN ME for Cook County in 
2002, 48 percent (339) had a mention of her-
oin/morphine. After reporting 1 death per year in 
2000 and 2001 caused by accidental heroin exposure, 
CDPH reported 18 deaths in 2002.  The new DAWN  
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ME system recorded 27 heroin-related deaths in 2003 
in the Chicago MSA, and 5 of those were single-drug 
deaths. 
 
The rate of heroin ED mentions in Chicago increased 
significantly from 83 per 100,000 population in 1995 
to 220 in 2002 (exhibit 2), an increase of 167 percent. 
This rate was the highest in the contiguous United 
States.   
 
Preliminary unweighted DAWN Live! ED data for 
2003 and 2004 indicate that heroin is the second most 
frequently reported drug, following only cocaine (ex-
hibit 3). In the DAWN Live! 2004 data, the majority 
of heroin ED reports involved males (63 percent), 
African-Americans (52 percent), and those between 
ages 35 and 54 (58 percent).  
 
The number of persons treated for heroin use in State-
supported programs in FY 2004 was 30,531, a 12-
percent decrease from 2003. (exhibit 4). Nonetheless, 
28 percent of treatment services rendered during 2004 
in Illinois were for heroin. Seventy-one percent of the 
total heroin treatment episodes reported in FY 2004 
occurred in Chicago alone, supporting other indicators 
of high levels of heroin use in the city. The majority 
(73 percent) of persons treated for heroin in 2004 re-
ported intranasal “snorting” as the primary route of 
administration. In Chicago, 81 percent reported snort-
ing as their primary route of administration (14 percent 
injected), compared with 52 percent of patients report-
ing snorting (41 percent injected) in the rest of the Illi-
nois. Demographic differences between patients from 
Chicago and the rest of the State may account for some 
of this difference. Patients entering treatment in Chi-
cago were more likely to be African-American (81 
percent), while patients from the rest of Illinois were 
more likely to be White (58 percent). Preliminary 
analysis of data collected for the currently ongoing 
study of young non-injecting heroin users in Chicago 
(NIHU), conducted by COIP at UIC, found that at 
followup, White study participants and those younger 
than 23 were significantly more likely to initiate injec-
tion. African-Americans in the study appeared resistant 
to injection initiation despite a longer duration of use. 
A recent report (Kane-Willis and Schmitz-Bechteler 
2004) examined age and race trends among persons 
treated for heroin use in Illinois and found that Whites 
were far more likely to be age 18–24 (41 percent) than 
were African-Americans (2 percent) and Hispanics (20 
percent).  
 
According to the 2003 ADAM report, 25 percent of 
adult male arrestees tested opiate positive (exhibit 5). 
The proportion of adult female arrestees testing opi-
ate positive decreased significantly between 2000 and 
2003, from 40 to 22 percent, respectively. The June 
2004 Chicago CEWG report provides a more com-
plete discussion of the ADAM data.  
 
According to the 2003 DMP report, availability of 
heroin in Chicago, especially South American and 
Southeast Asian heroin, continued (exhibit 6). Heroin 
from other geographic source areas, including South-
west Asia and Mexico, was also available. The consis-
tent availability of heroin from all four of these source 
areas makes Chicago unique among other U.S. cities. 
The purity of street-level heroin peaked in 1997 at 
about 31 percent and has since declined. In 2003, 
South American heroin exhibits purchased by DMP in 
Chicago averaged 16.6 percent pure, a 19-percent de-
crease from 2002. However, the average price per mil-
ligram pure remained consistent, with a low in 2003 of 
$0.45 for South American heroin. Recent ethnographic 
reports suggest a new source of heroin on the south 
side of Chicago that is said to offer a higher purity 
level. On the street, this heroin has been referred to as 
“tornado” for its strength or “retro-dope,” as it reminds 
older users of higher-purity heroin from years past.  
 
According to ISP, the amount of heroin analyzed in 
Cook County decreased slightly from 21 kilograms in 
2003 to 18 kilograms in 2004. 
 
Participants in a study of young non-injecting heroin 
users reported high availability of heroin on the 
streets of Chicago. Sixty-three percent reported “a 
lot” (the highest rating) of heroin on the street in the 
past 30 days. Use of brand name heroin was reported 
by 29 percent of participants. Most (80 percent) paid 
$10 per bag in the 30 days prior to interview. Regard-
ing heroin quality in the past 30 days, only 10 percent 
gave the highest quality rating (“very good”); 31 per-
cent thought the quality was “good,” and 50 percent 
perceived the heroin quality as “fair.” 
 
Heroin prices have not changed since the June 2003 
report. On the street, heroin is commonly sold in $10 
and $20 units (bags), though bags for as little as $5 are 
available. Prices for larger quantities varied greatly, 
depending on the type and quality of heroin, the buyer, 
and the area of the city where the heroin was sold. At 
outdoor drug markets, purchases of multibag quanti-
ties—versus grams and fractions of ounces—were the 
most common means of buying larger amounts of her-
oin. Data indicated that buyers on the West Side could 
obtain 11–13 $10 bags for $100 (sometimes called a 
“jab”). Recent ethnographic reports suggest that some 
dealers offer regular customers a free piece of crack 
cocaine along with their heroin purchase (typically on 
Fridays) and distribute free samples when they have 
“new product,” practices that indicate a potential in-
crease in competition. 
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Among Illinois high school students, increases in 
heroin use have not yet been evidenced in periodic 
representative surveys. The Illinois Youth Survey 
indicates that heroin use among Chicago-area stu-
dents is still relatively rare. In 2003, 3.7 percent of 
students reported lifetime use of heroin, compared 
with 2.5 percent in 2001 and 3.1 percent in 1999. 
More information is available in the December 2004 
Chicago CEWG report. 
 
APORS data indicated that opioid toxicity was de-
creasing between 2000 and 2002 among infants 
tested for controlled substances, from 22.4 per 10,000 
live births to 16.1 per 10,000 live births, respectively. 
In 2002, and similarly in 2000 and 2001, most infants 
who tested positive to heroin exposure at birth were 
born to African-American mothers (69 percent) and 
to mothers age 25–34.  
 
Other Opiates 
 
In 2003, 50 deaths related to opiate/opioid (other than 
heroin and methadone) misuse were recorded in the 
DAWN ME system. Multidrug use was associated 
with 86 percent of deaths, and 11 were ruled as sui-
cide. Methadone misuse was responsible for 15 
deaths during the same year.  
 
According to unweighted data accessed from DAWN 
Live!, 1,399 opiate/opioid misuse-related ED reports 
were recorded in Chicago in 2004. Hydrocodone ac-
counted for 22 percent of the overall opiate/opioid 
reports. A substantial proportion (46 percent) of hy-
drocodone ED reports were classified as “overmedi-
cation.”  Six percent of the opiate/opioid-related re-
ports were specifically attributed to oxycodone mis-
use. Unlike hydrocodone mentions, the largest pro-
portion of oxycodone mentions (36 percent) were 
classified as “seeking detox.”  
 
Between 2001 and 2003, the Illinois Poison Center 
reported a 55-percent increase in calls involving rec-
reational abuse of Coricidin HBP, which contains 30 
milligrams of dextromethorphan HBr (DXM) per tab-
let. DXM is a synthetically produced substance that is 
chemically related to codeine, though it is not an opi-
ate. The majority of the cases involving DXM (ap-
proximately 90 percent) were among those age 13–19.  
 
The occasional use of other opiates is common 
among young non-injecting heroin users in Chicago. 
Fifty-seven percent of NIHU Study participants re-
ported ever trying codeine, Tylenol 3 and 4, Dilaudid, 
Demerol, morphine, or methadone without a legal 
prescription. Ethnographic reports suggest that co-
deine may be used by heroin users to moderate with-
drawal symptoms or to help kick a drug habit.  
In Illinois, treatment services rendered related to the 
use of other opioids, tranquilizers, or sedatives in FY 
2004 accounted for 2 percent of total treatment epi-
sodes (excluding alcohol). The majority (80 percent) 
of treatment for other opiates occurred outside Chi-
cago and among Whites (75 percent); the majority 
(62 percent) reported administering these drugs 
orally. Readers are referred to the June 2004 and De-
cember 2004 Chicago CEWG reports for more details 
regarding other opioids, tranquilizers, or sedatives 
treatment data.  
 
Marijuana 
 
Marijuana continues to be the most widely available 
and used illicit drug in Chicago and Illinois. 
 
According to the 2003 DAWN ME report, 11 percent 
of total deaths recorded mentioned marijuana. All of 
these deaths were multidrug related. 
 
The rate of marijuana ED mentions per 100,000 
population was 89 for both 2000 and 2001 and de-
creased to 78 per 100,000 in 2002 (exhibit 2), a 
change of nearly 12 percent from 2001. 
 
Preliminary unweighted data accessed from DAWN 
Live! show that ED reports of marijuana in 2003 and 
2004 represented 10 percent and 13 percent of all 
drug-related reports, respectively. In 2004, marijuana 
ED reports totaled 2,222 (exhibit 3).  Marijuana pa-
tients in 2004 most often were African-Americans 
(49 percent), followed by Whites (26 percent); males 
(66 percent); and younger than 30 (52 percent). 
 
Marijuana users represented 20 percent of all treatment 
episodes in Illinois in FY 2004 and 28 percent of epi-
sodes when those for primary alcohol abuse were ex-
cluded. The number of treatment episodes for mari-
juana increased from 20,705 in FY 2000, to 26,371 in 
FY 2003, but fell to 30,650 in FY 2004 (exhibit 4). 
Alcohol was the most commonly reported secondary 
drug among persons receiving treatment for marijuana. 
During FY 2004, treatment episodes for marijuana 
were highest for males (76 percent) and for Whites (48 
percent). Approximately 25 percent of Illinois treat-
ment episodes of marijuana occur in Chicago.  
 
According to 2003 ADAM data, 53 percent of adult 
male arrestees tested positive for marijuana (exhibit 
5), a level close to proportions in 2002 and 2001. The 
proportion of adult female arrestees who tested posi-
tive for marijuana increased from 25 percent in 2000 
to 39 percent in 2003. 
 
Marijuana use was common among the young heroin 
users participating in local studies. Sixty-seven per-
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cent of non-injecting heroin users and 73 percent of 
young injectors smoked marijuana in the 6–12 
months prior to their interview. 
 
The 2003 YRBSS data and the 2002 Illinois Youth 
Survey both reported a recent decrease in lifetime use 
of marijuana among 8th through 12th grade students. 
For more information about results from these youth 
surveys, readers are referred to the December 2004 
CEWG report.   
 
According to DEA, the bulk of marijuana shipments 
are transported by Mexico-based polydrug trafficking 
organizations that conceal marijuana among legiti-
mate goods in tractor-trailers coming into the Chi-
cago areas from the southwest border. The primary 
wholesalers of marijuana are the same Mexico-based 
organizations that supply most of the cocaine, 
methamphetamine, and Mexican heroin in the Mid-
west. Marijuana produced locally (indoor and out-
door) by independent dealers is also available. Ac-
cording to the DEA Domestic Cannabis Eradica-
tion/Suppression Program, 14,409 outdoor and 1,273 
indoor cultivated plants were eradicated in 2000. 
 
In general, currently available marijuana is of vari-
able quality. The abundance and popularity of mari-
juana across the city has led to an increased array of 
varieties and prices. Marijuana prices, which re-
mained level since the June 2003 report, ranged from 
$650 to $4,000 per pound, depending on the type and 
quality. Ounces typically sold for about $80−$250. 
On the street, marijuana was most often sold in bags 
for $5–$20 or as blunts. The NDIC reported the fol-
lowing prices for marijuana in Chicago in 2003: 
$900–$1,200 per pound, $50–$75 per ounce, and $3–
$5 per gram. 
 
Both ISP and NFLIS laboratories analyzed more mari-
juana samples than samples for any other drug. Forty-
nine percent of drug samples analyzed by the NFLIS 
for Chicago in 2004 were identified as cannabis.  
 
Stimulants 
 
Since the mid-1990s, many indicators of metham-
phetamine (“speed”) use in Illinois increased steadily. 
The most significant increases occurred from 1998 to 
2002 in rural areas of Illinois.  
 
Methamphetamine ED mentions in Chicago slowly 
increased during the 1990s but remained stable be-
tween 2001 and 2002, when they totaled 45 and 42, 
respectively.  
During 2004, unweighted DAWN Live! data showed 
47 ED methamphetamine reports for Chicago (ex-
hibit 3). Males (81 percent), persons age 25–45 (74 
percent), and Whites (51 percent) accounted for the 
majority of the 2004 ED methamphetamine reports.  
 
As reported in the January 2005 report, metham-
phetamine calls to the Illinois Poison Center in Chi-
cago are infrequent. From 2001 to 2003, the Poison 
Center received a total of 29 such calls.  
 
Like methamphetamine, amphetamine ED mentions 
increased steadily in Chicago since 1995. By 2002, 
415 amphetamine ED mentions were reported, an in-
crease of 188 percent from 1995. A rate of 7 mentions 
per 100,000 persons was reported for 2002.  
 
According to unweighted data accessed from DAWN 
Live!, there were 81 amphetamine ED reports for 
Chicago in 2004 (exhibit 3). Sixty-five percent of 
reports were among males, 42 percent were White, and 
48 percent were among persons younger than 25.  
 
Since FY 2000, treatment for methamphetamine as a 
proportion of all State treatment episodes (excluding 
primary abuse of alcohol only) increased steadily from 
1 percent to 4 percent in 2004.  Treatment services ren-
dered for amphetamine also increased during this pe-
riod but remained stable between 2003 and 2004 (ex-
hibit 4).  In FY 2003, the number of methamphetamine 
treatment episodes (3,582) greatly outnumbered those 
for amphetamines (476). Methamphetamine treatment 
episodes totaled 4,628 during FY 2004, while those for 
amphetamine remained stable at 485. Only 1 percent of 
treatment episodes for methamphetamine were from 
Chicago. Exhibit 7 illustrates the substantial difference 
between the number of methamphetamine treatment 
episodes recorded in the city of Chicago and those in 
the rest of the State for the period of FYs 2000 to 2004. 
This trend in treatment supports other indicators that 
suggest lower use of methamphetamine in Chicago 
compared to the rural parts of the State. Most treatment 
episodes for methamphetamine during 2004 involved 
Whites (97 percent) and males (53 percent); a similar 
trend was observed for amphetamine patients (89 and 
54 percent, respectively). 
 
According to 2002 ADAM data, only 0.3 percent of 
male arrestees in Chicago tested positive for metham-
phetamine, but 1.0 percent tested positive during the 
first quarter of 2003, suggesting an increase in use.  
 
The 2003 YRBSS data indicated that 3.7 percent of 
high school students in Chicago used methampheta-
mine one or more times during their life. Male students 
were nearly six times more likely to have tried 
methamphetamine than female students. For more in-
formation about methamphetamine use among students 
in Chicago, readers are referred to the December 2004 
Chicago CEWG report. 
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Data from the ISP indicated that more metham-
phetamine continued to be seized than cocaine or her-
oin in nearly 50 percent of Illinois counties in 2004. In 
2004, the amount of methamphetamine received by ISP 
from Cook County was about 8 kilograms, while the 
total methamphetamine received from all Illinois coun-
ties was about 24 kilograms, similar to the previous 
year.  According to the NFLIS 2004 report, 0.41 per-
cent of the items analyzed in Chicago were metham-
phetamine, which is a considerable increase from 0.21 
percent reported the year before. 
 
According to ICJIA, the number of methamphetamine-
related arrests in Illinois increased significantly be-
tween 1997 (3 arrests) and 2003 (1,112 arrests). While 
methamphetamine arrests increased across all regions 
during this period, rural task force units experienced the 
greatest increase in arrests (from 0 to 514 arrests), fol-
lowed by mixed urban/rural units (from 3 to 373 ar-
rests) and by mostly urban units (from 0 to 225 arrests). 
Since 1994, the ICJIA has reported a dramatic increase 
in the quantity of methamphetamine seized, from 3,433 
grams in 1994 to 26,597 grams in 2003, with a peak of 
28,002 in 2002. Similarly, clandestine methampheta-
mine labs seizures increased from 24 in 1997 to 971 in 
2003. Seventy-seven percent of lab seizures in 2003 
were in rural counties.  
 
Within Chicago, a low but stable prevalence of 
methamphetamine use has been reported in some areas 
of the city for a number of years, especially on the 
North Side, where young gay men, homeless youth, 
and White clubgoers congregate. Of note, ethnographic 
data suggest that methamphetamine availability in-
creased substantially since June 2001 among at least 
some networks of gay White men on the North Side, 
who may use the drug to enhance sexual experiences. 
There were also reports from persons who said they 
began to use methamphetamine in order to lose weight 
but became addicted to the drug.  
 
In the NIHU Study, 19 percent of participants reported 
ever trying amphetamine or methamphetamine, and 
only 5 percent reported using it in the 6 months prior to 
the interview. Among injectors in the Family Process 
study, 20 percent of participants reported amphetamine 
use, and 8 percent used it in the previous 12 months.  It 
is likely that participants’ use of the drug often took 
place somewhere other than Chicago or Illinois. 
 
Methylphenidate (Ritalin) remained readily available 
in some South Side neighborhoods, where it could be 
purchased for injection, either alone or in combi-
nation with heroin. Pills, often referred to as “beans” 
in these areas, are sold for $1.50 to $5.00 each, de-
pending on the quantity being purchased. The cost of 
Ritalin on the West Side of Chicago was reported to 
be $10 per pill. Some study participants report that 
Ritalin was readily available in their schools and that 
students knew which students had been prescribed 
Ritalin and often requested the drug from them. 
 
Methamphetamine prices have not changed since June 
2003, when it was reported that bags of metham-
phetamine sold for $20. Most drug users reported that 
the drug remained difficult to obtain. However, police 
and street reports suggest that some Mexico-based drug 
dealers are attempting to introduce methamphetamine 
for local consumption by offering free samples, which 
may eventually change the low and stable trend of 
methamphetamine use in Chicago. Furthermore, one 
street-level report suggested a limited availability of 
methamphetamine on the West Side. There was also 
one report of methamphetamine being sold at a South 
Side street drug market. According to the NDIC 2003 
report, methamphetamine cost $1,000–$1,300 per 
ounce and $80–$100 per gram.  
 
Depressants 
 
Three patterns of depressant-in-combination use have 
been common in Chicago and throughout Illinois: 
 
• Depressants are taken with narcotics to poten-
tiate the effect of opiates. Pharmaceutical depres-
sants are frequently combined with heroin. 
 
• Depressants are taken with stimulants to mod-
erate the undesirable side effects of chronic 
stimulant abuse. Chronic cocaine and speed 
abusers often take depressants along with stimu-
lants, or when concluding “runs,” to help induce 
sleep and to reduce the craving for more stimu-
lants (especially in the case of cocaine). 
 
• Alcohol, also a central nervous system depres-
sant, is taken with pharmaceutical depressants 
(such as hypnotics or tranquilizers). The practice 
of mixing alcohol with other depressants may 
indicate illicit pharmaceutical depressant use. 
 
In 2003, 17 benzodiazepine misuse-related deaths 
were reported to the DAWN ME system from the 
Chicago MSA. Fourteen of these deaths were ruled as 
suicide. 
 
Benzodiazepine ED mentions increased significantly 
between 1995 (n=1,959) and 2002 (2,776), a 42-
percent change. Both ED mentions and ethnographic 
reports indicate that alprazolam appears to be the 
benzodiazepine most readily available on the street, 
closely followed by clonazepam and lorazepam, with 
variations in different areas of the city. 
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Preliminary unweighted data accessed from DAWN 
Live! showed that 907 ED reports were related to the 
misuse of benzodiazepines in 2004. Nearly one-half 
of these mentions were classified as overmedication. 
 
Benzodiazepine-related calls to the Illinois Poison 
Center in Chicago repeatedly represented nearly one-
half of all substance misuse calls between 2001 and 
2003. On average, approximately 500 calls annually 
were reported during this time period. 
 
Treatment data suggest depressants are not the pri-
mary drugs of choice for most users. In FY 2004, 
DASA reported 2,472 treatment episodes for other 
opioids, tranquilizers, and sedatives/hypnotics. The 
majority of treatment episodes for depressants oc-
curred outside of Chicago (80 percent) and among 
Whites (75 percent). Primary opioid, tranquilizer, and 
sedative/hypnotics users represented only about 2 
percent of all treatment episodes, excluding alcohol. 
 
Lifetime use of tranquilizers or barbiturates without a 
prescription (Valium, Elavil, Ativan, Xanax) was 
reported by 31 percent of young non-injecting heroin 
users in the NIHU study. Thirteen percent reported 
use in the past 30 days. In the Family Process study, 
43 percent of young injectors reported ever using 
barbiturates, and 30 percent used them during the 
previous 12 months. 
 
The 2002 APORS data indicate that the rate of in-
fants testing positive for barbiturates has been de-
creasing since 2000. In 2002, the rate of children ex-
posed to barbiturates at birth was 0.4 per 10,000 live 
births, compared with 0.8 per 10,000 in 2001 and 1.4 
per 10,000 in 2000.  
 
No updated prices for depressants were available. As 
stated in past Chicago CEWG reports, alprazolam 
typically sells for $2–$3 for 0.5-milligram tablets and 
$5–$10 for 1-milligram tablets. 
 
Hallucinogens 
 
Recent declines in lysergic acid diethylamide (LSD) 
ED mentions suggest a downward trend in LSD use 
in Chicago. Between 1995 and 2002, LSD ED men-
tions declined by 92 percent. The rate of LSD ED 
mentions per 100,000 population was less than 1 in 
2002 for the first time in the prior 7 years. 
 
As observed with LSD, phencyclidine (PCP) ED data 
showed declines in Chicago. After a peak in 2000, 
when 1,003 ED mentions were reported, PCP ED 
mentions decreased to 874 in 2001 and to 459 in 
2002. Similarly, ED rates declined between 2001 and 
2002 from 15 to 8 (per 100,000), a 48-percent 
change.  
 
According to unweighted data accessed from DAWN 
Live!, there were 17 LSD and 158 PCP ED reports in 
2004.   
 
No deaths related to hallucinogens were reported to 
the DAWN ME system in 2003. 
 
Recent trends in hallucinogen treatment have varied, 
but overall the number of episodes in publicly funded 
treatment programs in Illinois has been relatively 
high, compared with trends in the 1990s. In FY 2003, 
472 treatment episodes were reported, while there 
were 324 in FY 2004. The percentage of Illinois hal-
lucinogen treatment episodes occurring in Chicago 
has increased since 2000, and during 2004, the ma-
jority of episodes occurred in Chicago (57 percent).   
 
According to the 2003 ADAM report, the percentage 
of adult male arrestees testing positive for PCP de-
creased between 2002 and 2003, from 2.2 percent to 
1.3 percent. PCP use appears to be more common 
among adult female arrestees; 5.6 percent of female 
arrestees tested positive for PCP in 2003.  
 
In the study of young non-injecting heroin users, 36 
percent of participants reported ever trying LSD, 
mescaline, mushrooms, or other hallucinogens, but 
only a few (6 percent) reported use in the 6 months 
prior to their interview. Among young injectors, 74 
percent of participants reported ever trying hallucino-
gens, and 32 percent reported use in the 12 months 
prior to their interview. Whites were much more 
likely than African-Americans to report recent use of 
hallucinogens. 
 
Recent reports from young heroin snorters indicate that 
in this population, PCP use is more common than LSD 
use. Fifty-one percent of study participants reported ever 
trying PCP, and 15 percent used in the 6 months prior to 
their interview. 
 
According to the 2002 Illinois Youth Survey, 5 per-
cent of students in grades 8 through 12 reported life-
time use of “any hallucinogen” (including LSD and 
PCP). This is a considerable decrease in use from 
2000 (7 percent) and 1998 (8.5 percent). Further dis-
cussion of the Illinois Youth Survey is provided in 
the December 2003 CEWG report.  
 
The amount of PCP samples received by the ISP labo-
ratory for analysis decreased significantly between 
2002 and 2004, from 4.2 kilograms to 0.59 kilograms. 
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Ethnographic reports on PCP use are available in the 
June 2003 Chicago CEWG report. On the West side, 
2–3 PCP “sticks” about the size of toothpicks were 
reportedly available for $5–$10, according to the 
June 2003 CEWG report. Some “wicky sticks” are 
said to also include embalming fluid, and these cost 
more. Sherm sticks typically are cigarettes or small 
cigars dipped in PCP, drained, and dried. The ciga-
rettes—most often Mores®—are sold for about $20–
$30 each and are mainly available on the far South 
Side. PCP was also said to be sold in sugar cubes for 
$20 each. Liquid PCP (“water”) was said to sell for 
$120 for a vial. 
 
LSD hits typically cost $5–$10. LSD is available in 
the city and suburbs.  
 
According to some accounts by White youth, hallu-
cinogenic mushrooms remain available. Reported 
prices were $20–$40 per mushroom.  
 
Club Drugs 
 
In the Chicago area, methylenedioxymethamphet-
amine (MDMA or ecstasy) continues to be the most 
prominently identified of the club drugs, and its use 
appears to have increased among African-Americans. 
 
Of all the CEWG sites, Chicago had the most MDMA 
ED mentions in 2000 (215), but it ranked 10th in 2002 
(87).  
 
The preliminary unweighted data extracted from 
DAWN Live! show 27 MDMA reports in 2003 and 63 
in 2004. MDMA ED reports in 2004 were more com-
mon among male patients (77 percent) and those 
younger than 30 (84 percent). ED reports by 
race/ethnicity were fairly evenly distributed between 
African-Americans (38 percent) and Whites (29 per-
cent), but race/ethnicity in 23 percent of reports was 
unknown. 
 
Illinois DASA treatment data related to “club drugs” 
has been increasing slightly since FY 2002, when 50 
such episodes were reported. In FY 2003 and 2004, 
79 and 81 episodes were reported, respectively. Dur-
ing FY 2004, 69 percent of “club drug” treatment 
episodes were among males, and 56 percent were 
among Whites. Twenty-nine percent of treatment 
episodes occurred in Chicago during FY 2003; this 
proportion rose to 37 percent in FY 2004. 
 
In 2002, the Illinois Youth Survey for the first time 
included separate questions regarding MDMA use. 
Lifetime and past-year ecstasy use appears to be low 
among 8th through 12th grade students (0.6 percent 
and 0.4 percent, respectively).  
MDMA samples sent to ISP from Cook County had 
been decreasing since 2000, when 6.7 kilograms were 
analyzed in the State laboratory.  The amount of 
MDMA samples then increased from 0.8 kilograms 
in 2003 to 3.1 kilograms in 2004. Similarly, the 
NFLIS reported an increase in the proportion of all 
items analyzed for Chicago that were MDMA, from 
0.16 in FY 2003 to 0.35 percent in FY 2004. 
 
Drugs sold as ecstasy remained available in most 
mainstream dance clubs and at many house parties. 
“Raves” featuring ecstasy use are said to be close to 
nonexistent.  Recent ethnographic reports suggest 
that ecstasy may be purchased in some “open air” 
street markets on the west side of Chicago.  It contin-
ued to be sold in pill or capsule form, and the price 
range remained unchanged from December 2002: 
$20–$40 per pill. Individuals with connections to 
suppliers or producers reported prices as low as $12–
$15 per pill. These prices parallel the 2003 NDIC 
report: wholesale prices ranged between $10 and $12 
per tablet and the retail price was $25–$35 per dosage 
unit. Along with other club drugs, ecstasy may con-
tinue to be used predominantly by White youth, but 
there have been increasing reports of ecstasy use 
from African-Americans in their twenties and thirties 
who have been involved in club scenes. Among par-
ticipants in the NIHU Study, 36 percent reported 
MDMA use.  
 
Gamma hydroxybutyrate (GHB), a central nervous 
system depressant with hallucinogenic effects, is used 
infrequently in Chicago, mainly by young White 
males. ED mentions for GHB decreased 43 percent, 
from 139 in 2000 to 79 in 2002.  
 
According to preliminary unweighted data accessed 
from DAWN Live!, there were only 6 GHB ED re-
ports in 2003 and 45 reports in 2004. 
 
GHB is sold as a liquid (also referred to as “Liquid 
G”), in amounts ranging from drops (from a dropper 
at raves or parties) to capfuls. Prices for a capful have 
been reported at $5–$25. Compared with other club 
drugs, overdoses are more frequent with GHB, espe-
cially when used in combination with alcohol. GHB 
is not tracked in most quantitative indicators, but its 
use is perceived to be low compared with ecstasy. 
 
Ketamine, an animal tranquilizer, is another depres-
sant with hallucinogenic properties and is often re-
ferred to as “Special K.” Ketamine ED mentions to-
taled 10 in 2002, compared with 14 in 2001. The rate 
of ketamine ED mentions per 100,000 population 
(0.1) also remained unchanged. DASA reported only 
five patients served for ketamine use in FY 2004 in 
publicly funded treatment programs in Illinois. As 
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Chicago 
 
 
Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005 60 
reported in the June 2004 Chicago CEWG report, 
street reports indicate that ketamine is usually sold in 
$5–$30 bags of powder or in liquid form. The drug is 
somewhat available at rave parties or in clubs fre-
quented by younger adolescents.  
 
INFECTIOUS DISEASES RELATED TO DRUG ABUSE 
 
Most sources regarding trends in HIV/AIDS and 
other infectious diseases have not been updated by 
their authors or were not available during this report-
ing period. Readers are referred to the December 
2004 Chicago CEWG report for a more detailed re-
view of the available information for Chicago and the 
State. 
 
As reported previously, findings suggest that the rate 
of new HIV infections has declined among IDUs in 
Chicago since peaking in the late 1980s. 
 
Through October 2004, 30,865 diagnosed AIDS 
cases were reported to the State. More than one-
quarter of adult AIDS cases occurred among IDUs, 
while an additional 6.5 percent involved male IDUs 
who had sex with men. Within Illinois, 79 percent of 
the cumulative AIDS cases reported originate in the 
Chicago metropolitan area.  
 
HIV cases may represent more recent trends in risk 
behaviors. From January to October 2004, 2,193 HIV 
cases and 1,095 AIDS cases were reported to the 
State. Of newly reported HIV cases, 82 percent were 
in Cook County. Overall, IDUs accounted for 17 per-
cent of cases in Illinois, while 3.5 percent occurred 
among male IDUs who had sex with other men.  
 
The most recent report on HIV/AIDS cases in Chi-
cago indicated that by the end of 2003, 7,590 HIV 
cases and 21,420 AIDS cases were reported. An es-
timated 17,169 individuals are living with HIV and 
AIDS in Chicago.  
 
In 2002, the number of deaths from AIDS declined 5 
percent in Illinois and 9 percent in Chicago compared 
to 2001, a level approximately equal to the number of 
deaths in 2000. Given the long latency between HIV 
infection and AIDS diagnosis, these figures do not 
reflect the full scope of the epidemic. Data from the 
authors’ studies provide additional information on the 
extent of HIV infection among IDUs. In studies of 
IDUs cited in previous CEWG reports, HIV preva-
lence ranged from 18 to 25 percent at baseline, with 
reported incidence rates of 1 to 2 percent per person-
year. Recent studies of young IDUs indicate high 
levels of HIV risk behaviors but very low levels of 
HIV infection, particularly among those who reside 
in the suburbs. It should be noted, however, that the 
studies are not directly comparable, because each had 
unique sampling and recruitment strategies. Analysis 
of the NIHU Study (n=571) of young noninjecting 
heroin users found an HIV and HCV seroprevalence 
of 4 and 2 percent, respectively. During the 12-month 
followup period, no HIV seroconversions and eight 
HCV seroconversions were observed. 
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Exhibit 1. Range of Emergency Departments (EDs) Reporting to DAWN: Monthly in 2003 and 20043 
 
No. of EDs Reporting per Month: 
Completeness of Data (%)  Year Total Eligible Hospitals1 
No. of Hos-
pitals in 
DAWN 
Sample 
Total EDs in 
DAWN 
Sample2 90–100% 50–89% <50% 
No. of 
EDs Not 
Reporting 
2003 88 74 76 9–15 0–4 0–4 60–66 
2004 88 74 76 19–31 0–6 0–7 44–52 
 
1Short-term, general, non-Federal hospital with 24-hour emergency departments based on the American Hospital Association An-
nual Survey. 
2Some hospitals have more than one emergency department. 
3January through December. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/14-6/9, 2005 
 
 
 
 
Exhibit 2. Estimated Rates of ED Mentions Per 100,000 Population in Chicago for Selected Drugs: 
    1995–20021 
 
Year Cocaine Heroin Marijuana Metham-phetamine Amphetamines 
1995 188 83 51 1 3 
1996 220 109 61 0 3 
1997 247 148 76 0 4 
1998 232 158 85 1 3 
1999 225 162 77 0 3 
2000 246 206 89 …2 6 
2001 277 203 89 1 7 
2002 275 220 78 1 7 
 
1Data collected between 1995 and 2002 are not comparable to estimates produced on or after 2003. 
2Dots (…) indicate that an estimate with a relative standard of error greater than 50 percent has been suppressed. 
SOURCE:  DAWN, OAS, SAMHSA 
 
 
 
 
Exhibit 3. Numbers of Selected Illicit Drug Reports in Chicago EDs (Unweighted1):  2004 
5,981
4,163
2,222
81
47
Cocaine
Heroin
Marijuana
Amphetamine
Methamphetamine
1Unweighted data are from 24–32 Chicago EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control.  
Based on this review, cases may be corrected or deleted and, therefore, are subject to change.  
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/14/2005–6/9/2005 
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Exhibit 4. Numbers of Patients Served in Publicly Funded Treatment Programs in Illinois1 and Chicago, by  
   Primary Drug of Abuse:  FY 2000–FY 2004  
 
FY 2000 FY 2001 FY 2002 FY 2003 FY 2004 Primary 
Drug Chicago Illinois Chicago Illinois Chicago Illinois Chicago Illinois Chicago Illinois 
Cocaine 15,327 15,957 15,734 14,430 13,426 13,238 16,443 17,439 15,034 16,396 
Heroin 14,952 4,822 16,790 6,232 15,136 5,649 24,396 10,219 21,758 8,773 
Marijuana 5,905 14,800 6,512 17,748 6,649 17,526 7,959 18,412 7,539 23,111 
Meth2 33 698 31 1,373 29 1,955 35 3,547 47 4,581 
Amp3 50 217 48 246 45 272 32 444 48 437 
 
1Illinois data exclude Chicago 
2Meth = Methamphetamine 
3Amp = Amphetamine 
SOURCE:  Illinois Department of Human Services, Division of Alcoholism and Substance Abuse 
 
 
 
 
 
Exhibit 5. Percentages of ADAM Adult Male Arrestees Testing Positive in Chicago for Selected Drugs by  
  Year:  2000–20031 
45
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1Data for 2000 are for the first through third quarters; data for 2001 are for the fourth quarter only; and data for 2003 are for the first 
three quarters. 
SOURCE: ADAM, NIJ 
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Exhibit 6. Heroin Price and Purity Trends in Chicago, by Geographic Origin of the Heroin:  2000–2003  
 
2000 2001 2002 20034 Trend SEA1 SWA2 SA3 SEA SWA SA SEA SWA SA SWA SA 
Purity (%) 16.9 20.2 23.8 20.7 20.8 19.5 20.8 19.8 20.4 18.4 16.6 
Price Per Milligram 
Pure $1.16 $0.32 $0.48 $0.45 $0.41 $0.71 $0.71 $0.39 $0.43 $0.52 $0.45 
 
1Southeast Asia. 
2Southwest Asia. 
3South America. 
4SEA data are not available for 2003. 
SOURCE:  DMP, DEA  
 
 
 
 
 
Exhibit 7. Number of Patients Served in Publicly Funded Treatment Programs in Illinois for Methampheta- 
mine: FY 2000–FY 2004 
 
33 31 29 35 47
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1,955
3,547
4,581
0
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2,000
3,000
4,000
5,000
FY 2000 FY 2001 FY 2002 FY 2003 FY 2004
Patients Served
Chicago
Illinois
SOURCE:  Illinois Department of Human Services, Division of Alcoholism and Substance Abuse 
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Patterns and Trends in Drug 
Abuse: Denver and Colorado, 
2004 
 
Nancy E. Brace, R.N., M.A.1 
 
ABSTRACT 
 
Alcohol remained Colorado’s most frequently 
abused substance, and tobacco is responsible for 
4,200 deaths in Colorado annually. Excluding alco-
hol and tobacco, the use and trafficking of illegal 
drugs continues to be an expanding problem for 
Colorado, with much of the transporting, distribu-
tion, and selling of illegal substances supported by 
organized crime entities. Cocaine consistently had 
the highest drug incidence rate per 100,000 popula-
tion for emergency department visits, drug-related 
hospital discharges, and drug-related mortality rates 
for 1996 through 2002. In 2003, opiate-related drug 
misuse mortalities exceeded those that were co-
caine-related. Cocaine accounted for the highest 
number of drug-related calls to the Rocky Mountain 
Poison and Drug Center for 2001–2003 for the 
Denver area. In 2004, amphetamines, metham-
phetamine, and other stimulants combined exceeded 
cocaine in the number of these calls statewide. In 
2003 and 2004, methamphetamine surpassed co-
caine in the number of treatment admissions. Drug 
enforcement officials and treatment providers have 
corroborated this increase in methamphetamine use 
and trafficking in Colorado. Marijuana has ac-
counted for the highest number of treatment admis-
sions annually since 1997 and in the highest per-
centage of users entering treatment within 4 years 
of initial use. Methamphetamine ranks second in 
the latter category, surpassing both cocaine and 
heroin. Most indicators for heroin are decreasing, 
with the exception of mortality data. Experts in the 
field report an increase in opiate prescription diver-
sion, especially among adolescents. Initial use for 
most of these illegal substances seems to be occur-
ring at a younger age. 
 
INTRODUCTION 
 
Area Description 
 
Denver, the capital of Colorado, is located slightly 
northeast of the State's geographic center.  Covering 
only 154.6 square miles, Denver is bordered by sev-
                                                 
1 The author is affiliated with the Alcohol and Drug Abuse Divi-
sion, Colorado department of Human Services, Denver, Colorado. 
eral suburban counties: Arapahoe on the southeast, 
Adams on the northeast, Jefferson on the west, 
Broomfield on the northwest, and Douglas on the 
south. These areas made up the Denver Population 
and Metropolitan Statistical Area (PMSA) through 
2004.  
 
In 2005 the Federal Office of Management and 
Budget (OMB) added four new counties (Elbert, 
Park, Clear Creek, and Gilpin) and renamed the area 
the Denver-Aurora MSA. The Denver-Aurora MSA 
covers 8,390 square miles. These additions should be 
noted in the future when comparing 2005 with previ-
ous years’ data. 
 
Denver and the surrounding counties experienced 
rapid population growth from the 1990s through 
2003. According to the 2004 Colorado census fore-
cast, the Denver-PMSA population was 2,348,764. 
The city of Denver accounts for 12 percent of Colo-
rado's total population. The Denver PMSA accounts 
for 50 percent of the total State population. By the 
end of 2006, the Denver-Aurora MSA population is 
expected to increase by 4.0 percent to 2,415,156.   
 
Colorado was the third fastest growing State in the 
United States until 2004, when the growth rate de-
clined. The population more than doubled from 1960 
to 2000. Recently, however, the population that 
moved from Colorado to the surrounding States ex-
ceeded new arrivals. Colorado now ranks among 
those States with the lowest rates of net domestic 
immigration and is 14th on the list of fastest growing 
States. Statewide, the population is expected to in-
crease from the 2004 census projection of 4,642,589 
to 4,706,754 by the end of 2005, or by 1 percent.  
 
The median age in the Denver area is 33.1. Males 
accounted for 50.5 percent and females represent 
49.5 percent of the population. Ethnic and racial 
characteristics of the area are as follows: 65 percent 
White, 11 percent Black or African-American, 3 per-
cent Native American Indian, 3 percent Asian, and 
0.1 percent Native Hawaiian and Other Pacific Is-
landers. Hispanics or Latinos of any race compose 32 
percent of the area’s population. 
 
The average household size is 2.27, and the average 
family size is 3.14. For the population age 25 and 
older, 79 percent are high school graduates or higher, 
and 35 percent have bachelor’s degrees or higher. 
 
The major industries in Colorado are communica-
tions, utilities, agriculture, and transportation. The 
employment growth rate in the State exceeded the 
Nation’s at the end of 2004, with the United States 
and Colorado employment rates growing at 1.6 and 
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2.1 percent, respectively. The per capita income for 
Denver is $24,101. The median household income is 
$55,883, and the median family income is $47,203. 
Eleven percent of families and 14 percent of indi-
viduals in the area live below the poverty level. The 
unemployment rate as of March 2005 was 5.7; na-
tionally, it was 5.6. 
 
Two major interstate highways, I-25 and I-70, bisect 
Denver. I-25 runs north-south from Wyoming 
through New Mexico, and I-70 runs east-west from 
Maryland through Utah. 
 
The Violent Crime Rate National Ranking for Colo-
rado is 27 out of 50. 
 
Several considerations may influence drug use in 
Denver and Colorado: 
 
• Easy transit across multiple States is possible via 
the interstate highways. 
 
• The area’s major international airport is nearly at 
the midpoint of the continental United States. 
 
• The area is marked by population growth and 
expanding economic opportunities. 
 
• Remote rural areas are ideal for the undetected 
manufacture, cultivation, and transport of illicit 
drugs. 
 
• A young citizenry is drawn to the recreational 
lifestyle available in Colorado. 
 
• The large tourism industry draws millions of 
people to the State each year. 
 
• Several major universities and small colleges are 
in the area. 
 
• The Denver-Aurora MSA unemployment rate 
was 5.0 percent as of November 2004, a decrease 
of 1 percent from a year earlier.  
 
Data Sources 
 
Unless otherwise specified, the data in this report are 
for calendar year (CY) 2004 and were collected and 
analyzed in May 2005. Although these indicators 
reflect trends throughout Colorado, they are domi-
nated by the Denver metropolitan area.  
 
• Qualitative and ethnographic data for this 
report were available mainly from clinicians 
from treatment programs across the State, local 
researchers, and street outreach workers.  
• Emergency department (ED) data were derived 
for 2004 from the Drug Abuse Warning Network 
(DAWN) Live! restricted-access online query sys-
tem administered by the Office of Applied Studies 
(OAS), Substance Abuse and Mental Health Ser-
vices Administration (SAMHSA). Eligible hospi-
tals in the Denver area totaled 14; hospitals in the 
DAWN sample numbered 14, with the number of 
EDs in the sample totaling 14. During this 12-
month period, between 5 and 8 EDs reported data 
each month. The completeness of data reported by 
participating EDs varied by month (see exhibits 1a 
and 1b). Exhibits in this paper reflect cases that 
were received by DAWN as of April 13–14, 2005. 
All DAWN cases are reviewed for quality control. 
Based on this review, cases may be corrected or 
deleted. Therefore, the data presented in this paper 
are subject to change. Data derived from DAWN 
Live! represent drug reports in drug-related ED 
visits. Drug reports exceed the number of ED vis-
its, since a patient may report use of multiple 
drugs (up to six drugs and alcohol). The DAWN 
Live! data are unweighted and, thus, are not esti-
mates for the reporting area. These data cannot be 
compared to DAWN data from 2002 and before, 
nor can preliminary data be used for comparison 
with future data. Only weighted DAWN data re-
leased by SAMHSA can be used for trend analy-
sis. Exhibit 1c shows the number of unweighted 
DAWN ED cases by case type. A full description 
of the DAWN system can be found at the DAWN 
Web site: http://dawninfo.samhsa.gov.  
 
• Drug related mortality data for the Denver 
metropolitan area for 2003 were provided by 
SAMHSA’s Drug Abuse Warning Network, 
2003: Area Profiles of Drug Related Mortalities. 
The Colorado Department of Public Health and 
Environment (CDPHE) provided statewide mor-
tality data for 2003. Data for 2004 were unavail-
able at the time of document completion. Data 
for the Denver metropolitan area for 1996–2002 
are also reported. 
 
• Hospital discharge data statewide for 1997–
2003 were provided by the Colorado Hospital 
Association through the CDPHE Health Statis-
tics Section. Data included diagnoses (ICD-9-
CM codes) for inpatient clients at discharge from 
all acute care hospitals and some rehabilitation 
and psychiatric hospitals. These data did not in-
clude ED care.  
 
• Drug/Alcohol Coordinated Data System 
(DACODS) reports are completed on clients at 
admission and discharge from all Colorado alco-
hol and drug treatment agencies licensed by 
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ADAD, Colorado Department of Human Ser-
vices. Annual figures are given for 1997 through 
2004. DACODS data are collected and analyzed 
by ADAD. 
 
• Data regarding methamphetamine use in men 
who have sex with men (MSM) in Denver were 
provided by Dr. Mark Thrun, Medical Director, 
HIV Prevention, Denver Public Health. 
 
• Availability, price, and distribution data were 
collected from local Drug Enforcement Admini-
stration (DEA) Denver Field Division (DFD) of-
ficials in their fourth quarter fiscal year (FY) 
2004 report, the Office of National Drug Control 
Policy (ONDCP), Drug Policy Information 
Clearinghouse, “Denver, Colorado, Profile of 
Drug Indicators, June 2004” and from the De-
cember 28, 2004 issue of Narcotics Digest 
Weekly, Volume 3, Number 52. 
 
• Communicable disease data were obtained 
from the CDPHE. Data are presented from 1997 
through 2004. 
 
• Rocky Mountain Poison and Drug Center 
(RMPDC) data are presented for the Denver 
area for 2001–2003 and for Colorado for 2004. 
The data represent the number of calls to the cen-
ter regarding "street drugs."  
 
• Arrestee urinalysis results were provided by 
the Arrestee Drug Abuse Monitoring (ADAM) 
program, based on quarterly studies conducted 
under the auspices of the National Institute of 
Justice. ADAM data in Colorado were collected 
and analyzed by the Division of Criminal Justice. 
In 2000, NIJ changed its procedures from a con-
venience to a probability sample. Thus, no 
ADAM data trend analysis is presented. Rather, 
2001, 2002, and 2003 use percentages by drug 
type were included as a historical reference.  
 
• Sentencing data on Federal drug convictions in 
the State of Colorado for Federal fiscal year (FY) 
2002 were compiled by the United States Sen-
tencing Commission, Office of Policy Analysis.  
 
• Information about offenders in the Colorado 
correctional system for substance abuse-related 
crimes was supplied by The Colorado Depart-
ment of Corrections, Overview of Substance 
Abuse Treatment Services, FY 2004.  
 
• Statistics on seized and forensically analyzed 
drug items were provided by the DEA, Office of 
Diversion Control, National Forensic Laboratory 
Information System (NFLIS) for Denver for 
2004; the Rocky Mountain High Intensity Drug 
Trafficking Area (HIDTA) Taskforce; and from 
information reported by the Denver Police De-
partment Crime Laboratory.  
 
• Alcohol data were obtained from the “U.S. Ap-
parent Consumption of Alcoholic Beverages 
Based on State Sales” by the U.S. Department of 
Health and Human Services, June 2004, the 
Rocky Mountain Insurance Information Associa-
tion (RMIIA), the Department of Transportation 
Fatality Analysis Reporting System (FARS), and 
Colorado State Patrol statistics. 
 
• Drug testing index data for 2004 were provided 
by Quest Diagnostics. The positivity rate is the 
number of positive test results compared to the 
total number of drug tests performed by Quest 
Diagnostics (7.2 million workplace drug tests na-
tionally) in 2004. Quest Diagnostics performs 
workplace testing for three major populations: 
federally mandated, safety-sensitive workers 
(such as pilots, bus and truck drivers, and work-
ers in nuclear power plants); the general work-
force, and the combined workforce. (Note: The 
positivity rate may also reflect the availability 
and type of employment opportunities for differ-
ent geographic areas of Colorado.)  
 
• Tobacco statistics for 2004 were excerpted from 
the “State of Tobacco Control 2004” by the 
American Lung Association. Statistics for 2003 
were provided by the CDPHE, “Health Watch 
2003.” 
 
• Crime statistics for Colorado in 2003 were 
taken from the Colorado Bureau of Investigation 
crime reports. 
 
• Cost estimates for untreated substance abuse 
in Colorado were taken from National Estimates 
of Expenditures for Substance Abuse Treatment, 
1997, SAMHSA, February 2001. 
 
• Population statistics were obtained from the 
Colorado Demography Office, Census 2000 in-
cluding estimates and projections, and fact-
finder.census.gov. 
 
DRUG ABUSE PATTERNS AND TRENDS 
 
Cocaine/Crack 
 
Cocaine indicators remained mixed, with some in-
creasing and some decreasing during this period. Co-
caine was the most common illegal drug noted in 
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Denver-area emergency department reports and sec-
ond only to alcohol among all drug reports. Denver 
PMSA ED mentions for cocaine increased steadily 
from 1996 (53 per 100,000) through 2002 (82 per 
100,000).  
 
Unweighted DAWN Live! data showed 1,569 ED 
reports for cocaine in 2004 (exhibit 2). 
 
Males represented 63 percent of all ED cocaine pa-
tients; 47 percent were age 30–44 (exhibits 3 and 4). 
Overall, those age 21–64 accounted for 89 percent of 
all cocaine patients. 
 
Statewide hospital discharges showed that cocaine-
related visits per 100,000 population rose steadily 
from 1997 (56 per 100,000) through 2003 (80 per 
100,000) (exhibit 5). Cocaine was second only to 
alcohol in drug-related hospital discharges in 2003. 
 
The number of cocaine-related calls to the Rocky 
Mountain Poison and Drug Center for the Denver 
area rose from 2001 (59) through 2003 (68); during 
that period, cocaine was the most common drug of 
concern (second only to alcohol) (exhibit 6a). In 
2004, the number (316) of statewide calls about 
stimulants and amphetamines exceeded those for 
cocaine (120). There were 95 methamphetamine calls 
statewide in 2004.  
 
CDPHE cocaine-related mortality data for the Denver 
PMSA showed an increase in such deaths from 1996 
(68) to 2001 (126); they declined slightly in 2002 to 
108 (exhibit 7). Throughout this entire time period, 
cocaine-related deaths were higher than those for any 
other drug (including alcohol) in the area.  
 
Statewide, cocaine deaths climbed from 92 in 1997 
(23.6 per million) to 146 in 1999 (36.1 per million). 
While they declined to 116 in 2000 (27 per million), 
they increased again to 134 in 2001 (30.4 per million) 
and to 153 in 2002 (34.1 per million). CDPHE data 
from 2003 places cocaine deaths at 180 (39.2 per 
million), the highest number and rate in the time pe-
riod indicated. In spite of this increase, cocaine 
ranked behind alcohol (1,141) and the opiates (her-
oin, morphine, other opioids, and narcotics combined 
for a total of 247).  Reports from clinicians, research-
ers, and street outreach workers around the State cor-
roborate the continuing cocaine problems reflected in 
the indicator data. However, qualitative reports indi-
cate a shift to methamphetamine among some stimu-
lant users, especially the younger population. Clini-
cians report cocaine is rarely a primary drug for those 
younger than 18, regardless of urban or rural setting. 
Cocaine use is slightly higher among 18–25-year-
olds, but it is a major drug of abuse for those age 26–
64, especially in urban areas.  
 
Cocaine was the primary drug for 21 percent of all 
treatment admissions (excluding alcohol) in 2004 
(exhibit 8). The proportion of clients admitted to 
treatment with cocaine as their primary drug de-
creased slightly from 1997 (24 percent of all drug 
admissions) to 2004. Since 2001, primary cocaine 
admissions have remained in the 19–21 percent 
range. Since 1997, marijuana as a primary drug has 
exceeded cocaine, and this trend continued in 2004. 
In 2003 and 2004, methamphetamine exceeded co-
caine as a primary drug of abuse.  
 
The majority of cocaine admissions were clients who 
had been using this drug for 4 or more years. The 
proportion of admissions of “new” cocaine users 
(those using less than 4 years) rose from 17 percent 
in 1997 to 19 percent in 2003 and 18 percent in 2004 
(exhibit 9a). It takes an average of 10.7 years after 
first use for the majority of those users with cocaine 
as their primary drug to seek treatment (exhibit 9b).  
  
The percentages of clients who smoke cocaine de-
clined steadily from 65 percent in 1997 to 58 percent 
in 2001, but rebounded in 2003 and 2004 to 63 and 
62 percent, respectively. The proportion of clients 
who inhale cocaine has been steadily increasing, 
from 19 percent in 1997, to 26 percent in 2001, to 30 
percent in 2004. 
 
Whites accounted for the largest percentage of co-
caine admissions in 2003 and 2004 (45 percent for 
both years), showing a small decline from 2000 (48 
percent). Hispanic cocaine admissions increased 
dramatically from 19 percent in 1997 to 29 percent in 
2000 and 33 percent in 2004.  
 
The proportion of African-American cocaine admis-
sions dropped sharply from 33 percent in 1997 to 20 
percent in 2001, with a mild increase in 2003 (24 
percent), followed by a decline in 2004 (to 18 per-
cent). However, crack cocaine is fairly well en-
trenched in the African-American urban communi-
ties. African-American admission percentages for all 
other drugs remain in the single digits, with the ex-
ception of marijuana (13 percent). 
 
In 1997, 56 percent of cocaine treatment admissions 
were younger than 36; this decreased to 50 percent in 
both 2003 and 2004. The majority (68.5 percent) of 
2004 cocaine admissions were between the ages of 
26 and 45. Two percent of cocaine admissions in 
2004 were younger than 18, and only 12 percent were 
older than 45. 
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Cocaine admissions remain predominately male, with 
their proportion growing slightly from 1997 (57 per-
cent male) to 2004 (61 percent). Sixty-nine percent 
were admitted to treatment for cocaine dependence, 
compared with 26 percent for abuse. Thirty-eight 
percent of cocaine users indicated they used alcohol 
as a secondary drug, and 24 percent used marijuana.  
 
Treatment providers indicated that marijuana is 
commonly used with cocaine to lessen the effects of 
withdrawal and to potentiate the effects of the co-
caine. 
 
In Federal FY 2002, 34 percent of those sentenced to 
Federal correctional systems in Colorado had drugs 
as their primary offense category, compared with 41 
percent nationally. Of the 34 percent, powder and 
crack cocaine were each involved. Thirty-one percent 
were sentenced because of drug trafficking. 
 
According to recent ADAM data for a sample of 
Denver arrestees, 35.4 percent of males and 46.5 per-
cent of females had cocaine-positive urine samples in 
2001. These numbers were down slightly in 2002, 
with 32.7 percent of males and 43.6 percent of fe-
males testing positive. However, in 2003, 38.3 per-
cent of males and 52.5 percent of females tested posi-
tive for cocaine (exhibit 10). 
 
According to the National Forensic Laboratory In-
formation System, in Denver, cocaine accounted for 
49 percent of all drugs seized by law enforcement 
and submitted to a forensic laboratory for analysis in 
2004. 
 
When drug testing for employment in Colorado, 
Quest Diagnostics ranked cocaine lowest on the 
Quest Drug Test Index (0-2.54 percent), possibly 
indicating that few individuals undergoing screening 
for employment that requires testing in Colorado 
used cocaine (exhibit 11). 
 
According to the National Drug Intelligence Center 
and the DEA, powder cocaine was readily available 
throughout the State in 2004. Crack cocaine was 
more available in urban population centers. In gen-
eral, Caucasians prefer powder cocaine and African-
Americans prefer crack. Cocaine was the drug most 
often associated with violent crime in Colorado in 
2004. 
 
The majority of cocaine is Mexican; it is imported 
into Colorado by organized Mexican nationals or 
family groups who have connections to gangs on the 
west coast. In the last year, two significant drug or-
ganizations began to compete to control the whole-
sale supply. They transport the cocaine from the 
Mexican border or from western States, such as Cali-
fornia and Arizona, to Denver, using automobiles 
with hidden compartments, commercial and cargo 
airlines, delivery services, and other mail carriers. 
Denver serves as a major distribution center for co-
caine for the entire country, especially the Midwest 
and east coast States. Proceeds from cocaine sales are 
transported to Mexico or the western States via the 
same means. 
 
In Colorado, street distribution is controlled by 
gangs. There are more than 10,000 gang members in 
the Denver area, with an average of 1,500 new mem-
bers added each year. According to the Denver Drug 
Enforcement Agency and treatment providers, gangs 
also control the market for distribution of cocaine in 
the southern, northern, and western slope areas of the 
State. Gangs are ubiquitous throughout Colorado, but 
they are less dominant in the eastern region, where 
the population is much less dense. Cocaine prices 
depend on the purity of the product.  
 
In 2004, powder cocaine sold for $16,000–$20,000 
per kilogram and $600–$700 per ounce in the Denver 
metropolitan area (exhibit 12). These prices are 
slightly lower than in previous years. Crack cocaine 
prices have remained relatively stable at $700–$1,200 
per ounce, while “rock” prices on the street are $20–
$60 in Denver. Prices are slightly higher outside of 
the Denver metropolitan area. Purity ranges from 60 
to 75 percent for crack and 16 to 90 percent for pow-
der. Treatment providers stated that crack is fairly 
rare on the western slope, and its use remains en-
trenched in the African-American communities in 
southern Colorado.  
 
Overall, Colorado has seen a decrease in the whole-
sale price of powder cocaine, because some users 
switched to methamphetamine. Treatment providers 
indicate this switch is due to the cheaper prices and a 
longer lasting “high” of methamphetamine.  
 
Heroin and Other Opiates 
 
Heroin and other opiate use pose a considerable 
threat to Colorado, although indicators for both were 
mixed. The number of heroin-related ED mentions in 
Denver was 22 per 100,000 in 1996, with a gradual 
increase to 43 per 100,000 in 2002.  
 
In 2004, unweighted DAWN Live! data revealed 609 
heroin ED reports (exhibit 2). Males represented 74 
percent of these patients; 40 percent were age 30–44, 
and 99 percent were age 21–64 (exhibits 3 and 4). 
 
Opiates other than heroin include hydrocodone, hy-
dromorphone, codeine, and oxycodone. ED mentions 
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related to narcotic analgesics for Denver rose steadily 
from 18 in 1996 to 41 in 2001, with a drop to 34 in 
2002.  
 
In 2004, unweighted DAWN Live! data show 699 ED 
reports for prescription drug misuse of opiates and 
opioids; 43 percent were classified as overmedication 
case types, 40 percent were “other,” and 17 percent 
were seeking detoxification (exhibit 13). ED reports 
for hydrocodone totaled 174, with 64 percent of case 
types being overmedication. Oxycodone ED reports 
totaled 191, with 48 percent of these classified as 
overmedication. 
 
CDPHE statewide hospital discharge data for 1997–
2003 combined all narcotic analgesics, including her-
oin (exhibit 5). These discharges have been steadily 
increasing, with the rate almost doubling in 7 years, 
from 37 per 100,000 in 1997 to 73 per 100,000 in 
2003. Treatment providers indicated a rapid rise in 
popularity in the abuse of prescription narcotics such 
as OxyContin and hydrocodone, especially among 
youth; these discharge data may reflect that.  
 
CDPHE’s heroin/morphine-related mortality data for 
the Denver PMSA showed that such deaths increased 
from 34 in 1996 to 79 in 1999, declined to 66 in 
2000, rose to 77 in 2001, and declined to 64 in 2002 
(exhibit 7). CDPHE reported that opiate-related 
deaths increased from 53 (3 per 100,000 population) 
in 1997 to 79 (4 per 100,000) in 1999 for the Denver 
PMSA. From this peak, deaths declined back to 3 per 
100,000 in 2002.  
 
CDPHE statewide data for 2003 show there were 247 
opiate-related deaths. 
 
DAWN mortality data for the Denver-Aurora Metro-
politan Area for 2003 identified opiates/opioids as 
having the highest frequency in the top five drugs 
related to drug misuse deaths, with 113 multiple drug 
and 25 single-drug deaths (exhibit 14). 
 
Heroin and other narcotic analgesic-related calls to 
the Rocky Mountain Poison and Drug Center for the 
Denver area have remained fairly steady, with 19 
calls in 2001 and 22 calls in 2003 (exhibit 6a). In 
2004, there were 20 heroin/morphine calls statewide 
(exhibit 6b). 
 
According to recent ADAM data for a sample of 
Denver arrestees, 5.2 percent of males and 2.4 per-
cent of females tested positive for opiates in 2001. 
However, in 2002, 5.3 percent of females and 4 per-
cent of males tested positive for opiates. In 2003, 
male arrestees again showed a slightly higher per-
centage of opiate-positive urines (6.8 percent) than 
female arrestees (6.1 percent) (exhibit 10). 
 
The proportion of Colorado treatment admissions 
(excluding alcohol) for clients with heroin as their 
primary drug has steadily declined. In 1997, 16 per-
cent of all drug treatment admissions identified her-
oin as their primary substance, while in 2004 only 9 
percent did so (exhibit 8) Admissions for primary 
“other opiates” abuse remained steady during this 
period, representing 3 and 4 percent, respectively. 
 
Admissions for “new” heroin and other opiate users 
entering treatment within 4 years of initial use fluctu-
ated since 1997 at 17.9 percent, to 21.6 percent in 
2000 and 16.1 percent in 2004 (exhibit 9a). The ma-
jority of those in treatment for heroin are long-time 
users. According to ADAD’s 2004 data, it takes these 
clients an average of 14 years from first use before 
they enter treatment (exhibit 9b). 
 
Opiates (heroin and other opiates combined) ranked 
low for all four generations of users, from 2 percent for 
the Y generation, to 8 percent for the X generation, and 
13 percent for the Baby Boomers (exhibit 15). 
 
Nearly all (99.6 percent) heroin and other opiate us-
ers were older than 18 at the time of admission to 
treatment. Sixty-one percent were male, and 88 per-
cent lived in urban settings.  
 
Treatment providers reported an increasingly young 
population in their early teens using OxyContin and 
any other drug they can obtain, usually stolen from 
their parents. Providers also stated they are seeing 
more polysubstance abuse in clients. 
 
Sixty-nine percent of treatment admissions for heroin 
and other opiates were White, 20 percent were His-
panic, and 7 percent were Black or African-
American. Forty-two percent had completed the 12th 
grade, and 3 percent completed college. Wages were 
the primary source of income for 46 percent. Twenty-
seven percent had no prior treatment, while 29 per-
cent had three or more treatment episodes before this 
admission.  
 
Fifty-four percent of these clients self-referred into 
treatment. Eighty-six percent were dependent upon 
heroin or other opiates, while 12 percent received the 
diagnostic impression of abuse. Twenty-nine percent 
had no use of heroin or other opiates in the 30 days 
prior to treatment admission, while 44 percent used 
daily. Sixty-two percent injected, and 29 percent re-
ported the oral route of administration.  
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Twenty-eight percent of these clients were younger 
than 18 when they first tried heroin or other opiates, 
and 48 percent were 21 or older. Forty-three percent 
had no secondary drug, while 23 percent used co-
caine as their secondary drug. Fifty-one percent of 
clients indicated they began to use their secondary 
drug before the age of 18, and 28 percent began at or 
after age 21. 
 
Seven percent of those in Colorado who were sen-
tenced to Federal facilities were heroin or other opi-
ate users, and this percentage mirrors the national 
percentage for Federal FY 2002. Heroin represented 
only 5 percent of all items seized by law enforcement 
in Denver and submitted to forensic laboratories for 
analysis in 2004.  
 
Mexican black tar and brown powdered heroin are 
the most common types available in Denver, with 
black tar being slightly more available in Colorado. 
Most new users are young adults who smoke or snort 
it. Mexican drug trafficking organizations transport 
heroin into Colorado and serve as the primary whole-
sale distributors and frequently as retail sellers, con-
trolling the street-level market for heroin. Gang-
related crimes are frequently associated with the sale 
of heroin. It is widely available in both urban and 
rural settings. While typical users are older White 
males living in the lower downtown Denver area, 
new suburban users are emerging.   
 
Prices for illegal drugs vary widely depending on 
source, geographic area, purity, and risk. One ounce 
of Mexican heroin at 40 percent purity costs $2,000–
$3,000. One gram of heroin that is 8–64 percent pure 
costs $100–$150. Costs in Denver are slightly lower 
than in the rest of the State. Heroin can be obtained in 
Denver for $440 per one-quarter ounce or $100–$150 
per gram (exhibit 12).  
 
Pharmaceutical diversions of OxyContin and other 
narcotic analgesics are increasing, as they provide the 
abuser with reliable strength and dosage levels. A $4 
prescription dose of OxyContin sells on the street for 
$40, or $1 per milligram, 10 times the legal prescrip-
tion price. One pill sells for $6.50 in Denver (exhibit 
12). More abusers are using the Internet to obtain 
prescription medications. Drug enforcement officials 
have found a severe, systemic failure in pharmacies 
and physicians’ offices related to keeping proper re-
cords, reporting thefts, and maintaining controlled 
substances in Colorado. In response, Colorado re-
cently passed Prescription Drug Tracking legislation 
to monitor the use of controlled substances. 
 
 
 
Marijuana 
 
Marijuana indicators are mixed. Marijuana is second 
to alcohol in the number of users in Colorado, yet ED 
data fall far below those for cocaine or narcotic anal-
gesics. ED mentions increased steadily from 1996 
(19) through 2001 (50).  
 
In 2004, unweighted DAWN Live! data showed 755 
ED marijuana reports (exhibit 2). Males represented 
61.6 percent of the patients, and smoking was the 
primary route of administration. Marijuana ED pa-
tients involved the widest age groups (exhibit 14).  
 
Marijuana-related hospital discharges increased 
steadily from 53 per 100,000 in 1997 to 71 per 
100,000 in 2003 (exhibit 5). 
 
Marijuana-related calls to the Rocky Mountain Poi-
son and Drug Center remained fairly static from 1996 
through 2003 for the Denver area (exhibit 6a). In 
2004, there were 68 calls related to marijuana for the 
entire State (exhibit 6b). 
 
CDPHE reported that marijuana-related deaths for 
the Denver PMSA have been quite few in number, 
from 1 in 1996 to a peak of 31 in 2001, with a decline 
to 5 in 2002 (exhibit 7). The number of cases in 2003 
and 2004 were too small to report. According to 
DAWN mortality data, marijuana was not one of the 
top five drugs involved in drug misuse deaths for 
2003. 
 
ADAM data indicated that 40 percent of the male 
arrestee sample and 33 percent of the female arrestee 
sample had positive marijuana urine screens in 2001. 
These percentages remained stable in 2002 (with 40.3 
percent of males and 32.6 percent of females testing 
positive), but increased slightly in 2003 (42.3 percent 
positives for males and 34.3 percent positives for 
females) (exhibit 10).  
 
Overall, marijuana is second only to alcohol as an 
entry substance to illegal drug use and abuse. 
 
Excluding alcohol, Colorado has more treatment ad-
missions for marijuana than for any other drug (ex-
hibit 8). The percentage of clients admitted to treat-
ment with marijuana as their primary drug has been 
fairly steady from 1997 (41 percent) to 2004 (38 per-
cent).  
 
More “new” marijuana users seek treatment within 4 
years of first use than for any other drug (exhibit 9a). 
This finding has been consistent since 1997 (42.4  
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percent) through 2004 (30.5 percent). Marijuana us-
ers take an average of 8 years from time of first use 
to first treatment, which is a shorter time frame than 
for any other drug discussed here, except metham-
phetamine (also 8 years) (exhibit 9b). 
 
Males accounted for 74 percent of treatment admis-
sions in 2004, maintaining the historical male-to-
female ratio of approximately 3 to 1 since 1997. 
Thirty-nine percent were younger than 18 at time of 
admission to treatment. This figure has been fluctuat-
ing between 45 and 35 percent since 1997. Sixty-
seven percent of treatment admissions with marijuana 
as their primary drug were living in urban settings.  
 
Race proportions for marijuana admissions remain 
relatively stable. In 2004 53 percent were White, 30 
percent were Hispanic, and 13 percent were African-
American. Whites represented 56 percent in 2003, 
followed by Hispanics (27 percent) and African-
Americans (11 percent). Sixty-five percent used to-
bacco products daily. Fifty-six percent had no prior 
treatment episodes, while 27 percent had one. Sixty-
seven percent were unemployed, and 62 percent were 
living in a dependent setting (the majority with their 
parents). Only 8 percent self-referred to treatment, 
while 21 percent were referred by Social Services and 
52 percent were referred by non-DUI criminal justice. 
 
Forty-six percent of marijuana treatment admissions 
were considered abusers, while 41 percent were de-
pendent on marijuana. Smoking was the route of ad-
ministration for 95 percent of treatment admissions 
with marijuana as primary drug. Ninety percent of all 
clients stated they started to use marijuana before age 
18. Thirty-two percent had no secondary drug, while 
44 percent used alcohol and 12 percent used 
methamphetamine as their secondary drug. Of those 
with a secondary drug, 76 percent started using it 
before the age of 18. 
 
Among persons 18 or older, 28 percent of those who 
first used marijuana before age 12 were assessed at 
treatment admission as having a mental health prob-
lem in addition to a substance abuse problem, com-
pared with 21 percent of those who first used mari-
juana at age 18 or older. In both 2003 and 2004, 79 
percent of treatment clients aged 18 or older reported 
first use before age 18, and 9 percent reported initiat-
ing use before the age of 12. 
 
Quest Diagnostics reported that their employment 
testing showed marijuana with a higher positivity rate 
in Denver than any other drug in 2004 (exhibit 11). 
 
Of those individuals sentenced to Federal facilities in 
Colorado, 17 percent had use of marijuana as their 
primary offense, which was lower than the national 
percentage at 29.  
 
Cannabis represented 19 percent of all items seized in 
Denver and submitted to NFLIS for analysis in 2004. 
Both Mexican imported and locally grown marijuana 
were readily available statewide. 
 
The marijuana used in Colorado was primarily pro-
duced in and imported from Mexico. A small portion 
was grown in Colorado or other western States, par-
ticularly California. It was distributed primarily by 
Mexican drug trafficking organizations and criminal 
groups at the wholesale level and by Hispanic and 
African-American street gangs at the retail level. 
Caucasian criminal groups and local independent 
dealers were the primary distributors of the marijuana 
and sinsemilla produced in Colorado.  
 
BC Bud, a Canadian import with a high level of tet-
rahydrocannabinol (THC), was available only in lim-
ited quantities and relatively hard to obtain in Colo-
rado until 2003. Since then, an increase in availability 
of BC Bud has contributed to an increased THC level 
in both the Denver and Boulder areas. BC Bud sells 
for $700–$1,000 per ounce and $3,200–$4,500 per 
pound. On the street, BC Bud costs $10 per joint.  
 
Locally produced sinsemilla sold for $1,000–$3,000 
per ounce and $50–$200 per gram in 2004 (exhibit 
12). Domestic marijuana grown indoors was preferred 
over Mexican grown marijuana and sold for $1,000–
$3,000 per pound and $200–$300 per ounce. This 
price range remained static from 2003 to 2004. DEA 
officials report “grow” operations are becoming in-
creasingly sophisticated and technical. Outdoor mari-
juana is most likely a product of eastern Colorado.  
 
Prices of marijuana are slightly cheaper in Colorado 
than in surrounding States. Trafficking on the western 
slope is dominated by Hispanics importing it into 
Colorado from Mexico. Officials are noticing more 
individual Mexican nationals independent of the large 
drug organizations trafficking marijuana statewide.  
 
Treatment providers almost uniformly indicated that 
marijuana use is socially accepted in their areas and 
that the perception of risk associated with marijuana 
use is declining. Treatment providers felt this decline 
is related to national media coverage of marijuana as 
a medicinal drug, and to a high frequency of parental 
use of marijuana.  
 
Methamphetamine 
 
Most indicators for methamphetamine increased over 
the past few years, and this drug was and remains a 
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rapidly expanding social problem for Colorado. Vio-
lent crime related to methamphetamine use has been 
increasing, and the social consequences, particularly 
as related to children residing in methamphetamine 
cook houses, are major concerns. 
 
DAWN ED data for methamphetamine was fairly 
static, shifting between 5 and 8 mentions per 100,000 
since 1996, with the exception of 1997, when there 
were inexplicably 19 mentions per 100,000 population. 
 
The unweighted DAWN Live! data show 475 ED 
methamphetamine reports in the Denver PMSA in 
2004 (exhibit 2). Sixty-three percent of all ED stimu-
lant reports for 2004 were related to methampheta-
mine.  Fifty-eight percent of the ED methampheta-
mine patients were male (exhibit 3). Seventy percent 
of methamphetamine ED patients were age 21–44. 
 
Methamphetamine was not broken out from other 
stimulants for hospital discharge data, but overall 
amphetamine-related hospital discharges have in-
creased since 1999 from 16 per 100,000 to 40 per 
100,000 in 2003 (exhibit 5). 
 
There were 39 methamphetamine-related calls to the 
Rocky Mountain Poison and Drug Center for the 
Denver area in 2003 (exhibit 6a). In 2004, there were 
95 such calls statewide (exhibit 6b).  
 
CDPHE reported a small but steady increase in 
methamphetamine-related mortality since 1996 (3 
deaths). In 1999, there were 8 methamphetamine-
related deaths, compared with 10 in 2000, 19 in 2001, 
and 17 in 2002 (exhibit 7). However, deaths related 
to amphetamines increased only slightly from 5 in 
1997 to 13 in 2002. Though amphetamine-related 
deaths in Colorado are far fewer than those for opi-
ates or cocaine, the number increased sharply from 
only 20 between 1996 and 1999 to 37 between 2000 
and 2003 (an 85-percent increase). In 2003, there 
were 47 deaths related to amphetamines statewide. 
 
Colorado treatment providers reported that metham-
phetamine is the most popular illegal drug, and it is 
frequently used in combination with alcohol, mari-
juana, and cocaine. It was readily available, inexpen-
sive, and at times free. Potency was reported to be 
good. Providers noted an increasing problem with 
methamphetamine use statewide, especially in 
younger populations. They indicated this increase 
was in part related to easy access, difficulty obtaining 
other amphetamines, and relatively low prices. Con-
sistent with this trend, providers noted use of other 
amphetamines has dropped in popularity. 
 
According to ADAM data, only a small percentage of 
positive methamphetamine urine screens were re-
ported in 2001: 3.4 percent of the male arrestee sam-
ple and 4.3 percent of the female arrestee sample. 
These figures increased slightly for males in 2002 
(3.8 percent) and slightly more for females (6.6 per-
cent). Again, only small changes were noted in 2003, 
with 4.7 percent of males and 5.0 percent of females 
testing positive for methamphetamine (exhibit 10). 
 
In 2004, staff at the Public Health Sexually Transmit-
ted Disease (STD) Clinic in Denver surveyed clien-
tele (N=981) and noted an increased use of metham-
phetamine among men who have sex with men 
(MSM) (exhibit 16a). They found that MSM 
methamphetamine users are typically younger than 
non-users (exhibit 16b) and more likely to have been 
arrested in the 12 months preceding the survey, use 
erectile dysfunction drugs, be homeless, have more 
sexual partners in the last 12-month period, have 
more unprotected sex, and use the Internet for con-
necting with casual partners. Methamphetamine users 
seen in the STD clinic were twice as likely to have 
gonorrhea or HIV than non-users. At the Denver 
Health Infectious Disease/AIDS Clinic in 2004, 11 
percent of randomly surveyed patients (n=202) re-
ported use of methamphetamine in the 3 months pre-
ceding the survey. 
 
Colorado treatment admissions for clients using 
methamphetamine as their primary drug have risen 
dramatically. Methamphetamine is now second only 
to marijuana in the number of treatment admissions 
(excluding alcohol). Exhibit 8 shows that in 1997 
there were 1,081 admissions for methamphetamine. 
This number has since tripled to 3,209 in 2004.  
 
The proportion of treatment admissions for new users 
(those using less than 4 years at time of treatment) 
does not reflect this steady rise (exhibit 9a), with 34 
percent in 1997, dropping to 22 percent in 2001, and 
rising slightly to 24 percent in 2004. According to 
2004 treatment data, methamphetamine users take an 
average of 8 years from first use to first treatment 
(exhibit 9b). 
 
A comparison of 2004 treatment admissions involv-
ing new (using less than 4 years, n=562) versus more 
longstanding users (using 4 or more years, n=2,647) 
shows some notable differences between these two 
groups. New users were more likely than longstand-
ing users to be female (56 percent vs. 41 percent, 
respectively) and non-White (22 percent vs. 15 per-
cent, respectively). Also, as expected, new users had 
a higher proportion of those age 25 and younger (56 
percent) than longstanding users (31 percent). Ac- 
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cordingly, new users were more likely than long-
standing users to have never married (58 percent vs. 
44 percent, respectively) and to be unemployed (67 
percent vs. 61 percent, respectively).  
 
Looking at “severity” data, new users were less likely 
to inject methamphetamine (10 percent vs. 25 per-
cent) and more likely to ingest the drug by smoking 
(74 percent vs. 60 percent, respectively) than were 
long-standing users. Fewer new users were diagnosed 
as drug dependent (57 percent vs. 73 percent), but 
they had a higher proportion of concurrent mental 
health problems (33 percent) than longstanding users 
(29 percent).  
 
Methamphetamines were combined with all other 
stimulants in the generational snapshot of treatment. 
Both the X generation and the Baby Boomers used 
stimulants (36 percent and 25 percent, respectively) 
more than the Y generation or seniors (18 percent and 
5 percent, respectively) (exhibit 15). 
 
During 2004, 4 percent of treatment admissions with 
methamphetamine as a primary drug were for clients 
younger than 18. The majority of those in treatment 
(69 percent) were between ages 18 and 35. During 
2004, 56 percent of treatment admissions for 
methamphetamines were male. Methamphetamine 
use was found in both urban (60 percent) and rural 
(40 percent) areas of Colorado. Treatment providers 
stated they are seeing an increase in methampheta-
mine use in both rural and urban areas and an in-
crease in the social and community problems related 
to this use. 
 
Whites dominated among methamphetamine admis-
sions (83 percent) in Colorado. Few Hispanics (13 
percent) and even fewer African-Americans (1 per-
cent) used methamphetamine as their primary drug. 
However, treatment providers indicated that Hispan-
ics, who have traditionally been involved in the traf-
ficking of methamphetamine, were beginning to use 
it in greater numbers. Fifty-two percent of all 
methamphetamine users were referred to treatment 
by the non-DUI criminal justice system, and 18 per-
cent were referred by Social Services.  
 
Injecting had been the most common route of ad-
ministration for methamphetamine. However, the 
proportion of those injecting declined from 1997 
(32.6 percent) to 2004 (21 percent), while smoking 
increased in the last 7 years. In 1997, only 29.1 per-
cent smoked methamphetamine; in 2003, 61 percent 
of methamphetamine treatment admissions smoked 
the drug. In 2004, 63 percent smoked it, while 21 
percent injected it. 
 
Forty-one percent of clients began to use metham-
phetamine before the age of 18. Most (72 percent) 
used a secondary drug in addition to methampheta-
mine, usually marijuana (37 percent), alcohol (21 
percent), or cocaine (10 percent). Seventy-nine per-
cent of those using a secondary drug initiated use of 
this secondary drug before the age of 18.  
 
Treatment outcomes for methamphetamine users are 
as good as or better than outcomes for users of other 
drugs. 
 
Federal sentencing data report that methamphetamine 
was the primary substance for 34 percent of the drug 
convictions in Federal FY 2002. This is almost dou-
ble the percentage of offenders sentenced because of 
cocaine (powder and crack) and marijuana and four 
times greater than heroin.  
 
The DEA describes widespread methamphetamine 
availability, with a majority of the drug originating 
from Mexico or from large-scale laboratories in Cali-
fornia. However, methamphetamine lab seizures in 
Colorado increased significantly from around 25 in 
1997 to 464 in 2002. These laboratories, generally 
capable of manufacturing an ounce or less per 
“cook,” varied from being primitive to quite sophisti-
cated. The ephedrine reduction method remains the 
primary means of manufacturing methamphetamine 
in the area. In spite of law enforcement pressure, 
there has been an increase in the number of small, 
local methamphetamine labs, with the occasional use 
of trucks for mobile labs. 
 
Most lab operators are able to get the precursor 
chemicals from legitimate businesses (e.g., discount 
stores, drug stores, chemical supply companies, etc.). 
Treatment providers report that the current practice is 
for separate individuals or groups to each acquire one 
of the key ingredients and then deliver it to the 
“cook,” thereby decreasing the risk involved when 
one party obtains all the ingredients. In 2005, Colo-
rado passed legislation limiting public access to 
methamphetamine precursor drugs. Impact from this 
legislation has yet to be determined. 
 
During 2004, several major cocaine and metham-
phetamine trafficking organizations that had been 
transporting drugs to Denver from Arizona and Cali-
fornia were shut down. Methamphetamine from one 
of these organizations had purity levels of 95 percent. 
An organization on the western slope of Colorado 
employed a number of drivers who transported any-
where from 2 to 10 pounds from Sinaloa, Mexico, or 
California. Federal drug seizures in Colorado in 2004 
included 28.8 kilograms of methamphetamine. 
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Methamphetamine prices fluctuated from 2003 to 
2004, with prices in some geographic areas of the 
State increasing while others decreased. In general, 
methamphetamine could be obtained for $700–
$1,500 per ounce, $4,500–$5,600 per one-half pound, 
and $16,000 per pound in the Denver area (exhibit 
12). In southern Colorado, prices are $600 per ounce 
and $13,000 per pound. On the western slope, it sells 
for $1,000–$1,200 per ounce. Purity varied from 0 to 
100 percent, with most in the 50–95 percent range. In 
Denver “ice,” a smokable form of methamphetamine 
that looks like rock candy or rock salt, is nearly 100 
percent pure and widely available. Street prices for 
methamphetamine in Denver rose from $80–$125 per 
gram in 2003 to $150 per gram in 2004. 
 
Other Amphetamines and Stimulants 
 
Indicators for other amphetamines and stimulants in 
Colorado were mixed, but overall use of other am-
phetamines and stimulants (excluding cocaine and 
methamphetamine) is approximately one-half that of 
cocaine or methamphetamine.  
 
There were 280 unweighted ED reports of ampheta-
mines in 2004 in the Denver PMSA (exhibit 2). The 
age group most represented among patients was 30–
44-year-olds (exhibit 4). 
 
CDPHE hospital discharge data did not differentiate 
between methamphetamine and other amphetamines. 
The statewide number of amphetamine-related hospi-
tal discharges rose steadily from 1997 (959) to 2003 
(1,814) (exhibit 5). 
 
Denver-area amphetamine-related calls (which exclude 
methamphetamine) to the Rocky Mountain Poison and 
Drug Center were the smallest of any of the major 
drug groups: 3 in 2001 and 6 in 2003 (exhibit 6a). In 
2004, there were 316 such calls statewide (excluding 
methamphetamine and cocaine) (exhibit 6b). 
 
In 1997, there were 52 (0.7 percent of the treatment 
admissions) admissions to treatment with some other 
amphetamine or stimulant as primary drug (exhibit 
8). In 2003, there were a total of 78 (0.7 percent of 
the treatment population) admissions. Such admis-
sions declined to 46 (or 0.4 percent) in 2004.  
 
CDPHE mortality data for the Denver PMSA showed 
an increase in amphetamine and other stimulant-
related deaths, from 2 in 1996 to 13 in 2002 (exhibit 
7). In 2003, the number of statewide deaths for other 
stimulants/amphetamines was 47, more than deaths 
for methamphetamine but only one-fourth the amount 
of the deaths related to cocaine.  
 
Quest Diagnostics noted that in 2004, 0.14–0.33 per-
cent of employment drug tests in the Denver area 
were positive for amphetamines (exhibit 11).  
 
Barbiturates, Sedatives, and Tranquilizers 
 
According to DAWN Live! data, there were 409 ED 
prescription drug misuse reports related to benzodi-
azepines in the Denver area in 2004. Fifty-nine per-
cent of these reports were related to overmedication, 
9 percent to those seeking detox, and 32 percent were 
related to “other” (exhibit 13). 
 
CDPHE data on drug-related mortality data for the 
Denver PMSA were not available for 2003 or 2004. 
DAWN mortality data identified benzodiazepines as 
one of the top five drugs involved in drug misuse 
deaths for the Denver-Aurora Metropolitan Area for 
2003, with 30 multidrug deaths (exhibit 14). 
 
During 2004, there were 87 treatment admissions for 
barbiturates, sedatives, or tranquilizers as a primary 
drug. Fifty-one percent were female, and 90 percent 
were older than 18. Seventy-three percent were ur-
ban, and 69 percent were White. When comparing 
this group to all clients who reported other primary 
drugs, this group used daily tobacco the least and had 
the highest percentage of married clients; unemploy-
ment (the category “unemployment” includes those 
out of the workforce, such as students, homemakers, 
persons with disabilities, etc.); mental health prob-
lems; and visits to medical and psychiatric emer-
gency rooms.  They also had the highest percentage 
of slight to moderate socialization issues or concerns. 
 
Sixty-four percent administered their drug orally, 25 
percent smoked it, 7 percent inhaled it, and 1 percent 
injected it. Forty-eight percent were younger than 18 
when they began to use this category of drugs, and 41 
percent were age 21 or older. Sixty-eight percent 
used a secondary drug, such as alcohol (34 percent), 
opiates (13 percent), and marijuana (6 percent); 59 
percent of those with a secondary drug were younger 
than 18 when they first used it. 
 
These drugs are frequently obtained as prescription 
medications and fall into the diverted pharmaceutical 
class as well. Local independent dealers and Internet 
services are the principal distributors of diverted 
pharmaceuticals. 
 
Club Drugs 
 
Club drugs are a group of synthetic drugs commonly 
associated with all-night dance clubs called raves. 
These drugs include methylenedioxymethampheta- 
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mine (MDMA, or ecstasy), gamma hydroxybutyrate 
(GHB), flunitrazepam (Rohypnol or “roofies”), and 
ketamine (Special K).  
 
Information on use of these drugs in Colorado, while 
still limited, is expanding. ADAD added club drugs 
to the enhanced DACODS data set in July 2002. 
Also, there are currently three sources of institutional 
indicator data that include the club drugs (DAWN, 
CDPHE mortality, and the Rocky Mountain Poison 
and Drug Center). In addition, ADAD has worked 
with OMNI Research and Training, a Denver-based 
firm, to add club drug questions to the Colorado 
Youth Survey.  
 
Unweighted DAWN Live! ED data showed 64 
MDMA-related reports in 2004, 5 reports for GHB, 
and 2 reports for ketamine (exhibit 2). 
 
The Rocky Mountain Poison and Drug Center re-
corded 30 calls related to club drugs in 2001, 55 in 
2002, and 40 in 2003 for the Denver area (exhibit 
6a). In 2004, there were 11 calls statewide concern-
ing club drugs (exhibit 6b). 
 
CDPHE club drug-related mortality data for the Den-
ver PMSA showed two deaths in 2000, four in 2001, 
and two in 2002 (exhibit 7). These data were unavail-
able for 2003 and 2004. 
 
MDMA, or ecstasy, originally developed as an appe-
tite suppressant, is chemically similar to the stimulant 
amphetamine and the hallucinogen mescaline and 
thus produces both stimulant and psychedelic effects. 
 
MDMA is readily obtainable at raves, nightclubs, 
strip clubs, or private parties. The traffickers are typi-
cally White and in their twenties or early thirties. 
They obtain their MDMA from Nevada or California, 
with source connections in Europe, and target young 
adults and adolescents as users. Mexican trafficking 
organizations were making inroads in the Colorado 
MDMA market. The DEA reported one tablet or cap-
sule costs $6–$25, with larger quantities selling for 
$8–$16 per tablet (exhibit 12). These price ranges 
have dropped slightly from 2003. 
 
GHB is a central nervous system depressant that can 
sedate the body, and at higher doses, can slow breath-
ing and heart rate dangerously. It can be produced in 
clear liquid, white powder, tablet, and capsule forms 
and is often used in combination with alcohol—
making it even more dangerous. 
 
The DEA reported that the majority of GHB custom-
ers were White and in their twenties or thirties. Past 
DEA reports placed the GHB price at $5–$10 per 
dosage unit (i.e., one bottle cap full). 
 
Rohypnol (roofies) is a benzodiazepine sedative ap-
proved as a treatment for insomnia in more than 60 
countries, but not in the United States. Rohypnol is 
tasteless, odorless, and dissolves easily in carbonated 
beverages, and its effects are aggravated by alcohol 
use. There does not appear to have been widespread 
use of Rohypnol among either the general population 
or those in the rave scene in Colorado. What use 
there was occurred in the adolescent to mid-thirties 
age range. 
 
Ketamine, often called Special K on the street, is an 
injectable anesthetic that has been approved for both 
human and animal use in medical settings. However, 
about 90 percent of the ketamine legally sold today is 
intended for veterinary use. Produced in liquid form 
or white powder, it can be injected, inhaled, or swal-
lowed. Similar to phencyclidine (PCP) in its effects, 
it can bring about dream-like states and hallucina-
tions.  
 
Club drugs were primarily used by young adults and 
adolescents, and either these clients did not enter 
treatment or their small numbers did not draw the 
attention of indicator organizations. Certain club 
drugs are also used as “date rape” drugs and their use 
in this manner may be underreported. 
 
In 2002, there were 12 treatment admissions for club 
drugs statewide, or 0.1 percent of all treatment ad-
missions. In 2003 and 2004, there were 37 (0.3 per-
cent) and 48 (0.4 percent), respectively. 
 
Alcohol  
 
Alcohol continues to be the most abused substance in 
the State. Colorado ranks 19 percent higher than the 
national average and 5th in the Nation in per capita 
consumption of beverage alcohol. Alcohol use disor-
ders are medically based disorders related to abuse of 
or dependence on alcohol. 
 
Alcohol has consistently been the most frequently 
mentioned drug in EDs the Denver PMSA. Prior to 
2003, DAWN data for ED mentions for alcohol in the 
Denver area peaked in 1999 and 2000, with rates of 
107 per 100,000 population and 109 per 100,000, 
respectively.  
 
Unweighted DAWN Live! data show that alcohol was 
involved in 38 percent of all drug-related visits in 
2004. Five-hundred-fifteen (22 percent) adults sought 
detoxification through the emergency department, 
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and 45 percent had other alcohol-related issues (ex-
hibit 17).  
 
Alcohol-related emergency department visits for 
those younger than 21 (n=755) represented 33 per-
cent of all alcohol-related visits and 12 percent of all 
drug-related emergency department visits. Of these 
youth, 61 percent were male; 53 percent irrespective 
of gender were age 12–17; and 46 percent were age 
18–20 (exhibit 18).  
 
Statewide alcohol-related hospital discharges rose 
yearly from 418 per 100,000 in 1998 to 518 per 
100,000 in 2003 (exhibit 5). Discharge data for 2004 
were unavailable for this report. 
 
According to DAWN 2003 mortality data, alcohol 
ranked second in multidrug deaths in 2003 and was 
third among the top five drugs related to drug misuse 
deaths (exhibit 14) for the Denver-Aurora metropoli-
tan area. 
 
During 2004, 41 percent of all clients admitted to 
treatment stated their primary drug of abuse was al-
cohol (exhibit 19). This figure has been steadily in-
creasing since 2001. Six percent of these clients were 
younger than 18. Of those age 18 or older, 72 percent 
began to use alcohol before age 18. Anecdotal infor-
mation from clinicians in the treatment field indicated 
that alcohol was one of two major gateway drugs (the 
other being marijuana) Colorado youth used to enter 
the drug culture. 
 
During 2004, ADAD reported 44,514 detoxification 
discharges and 20,452 discharges from the Drinking 
Driver DUI education and therapy program.  Un-
treated alcoholism accounts for some of Colorado’s 
greatest concerns, such as violent crimes, homeless-
ness, domestic violence, vehicular crashes, over-
crowded jails, poverty, and overcrowded emergency 
and foster care systems.  Each year Colorado spends 
$4.4 billion in costs related to untreated substance 
abuse, adding a substantial financial burden to taxes 
and already stressed governmental resources.  
 
Even though laws exist that prohibit selling alcoholic 
beverages to minors, alcohol is the number one drug 
for adolescents in Colorado. It is readily available 
and inexpensive, and purveyors target younger age 
groups. Recent marketing trends include marijuana 
and alcohol-flavored lollypops and gum, “jello shots” 
(a mixture of alcohol and fruit-flavored gelatin), 
sweet soda-pop-flavored alcoholic beverages, and 
inhaled alcohol.  
 
Colorado’s Youth Risk Behavior Survey noted that 
almost 50 percent of students in grades 9–12 during 
2003 currently were using alcohol, and 80 percent 
had had one or more drinks of alcohol in their life-
time. 
 
Abuse of alcohol at an early age is frequently a pre-
cursor to use and abuse of illegal substances. During 
2004, deaths related to binge drinking on college 
campuses brought national notoriety to Colorado, 
with five confirmed deaths of college-age individuals 
from alcohol poisoning. 
 
Moderate use of alcohol among adults is culturally 
acceptable, and denial of abuse is particularly diffi-
cult to overcome. The average treatment client in 
Colorado with alcohol as a primary drug uses or 
abuses it for 16.5 years before seeking treatment. For 
detoxification clients, that time period expands to 20 
years.  
 
In 2003, the Colorado State Patrol (CSP) investigated 
approximately 30 percent of all vehicular crashes in 
the State, including about 70 percent of all traffic 
crashes involving fatalities. CSP reported that the 
majority of fatal crashes involved inebriated drivers. 
Some 2,161 vehicular crashes were directly caused 
by individuals driving under the influence of alcohol, 
and 116 crashes were caused by individuals driving 
under the influence of drugs. Seven percent of all 
crashes were DUI-related.  
 
In 2004, CSP made 9,509 DUI arrests and investi-
gated 87 fatal crashes and 2,117 non-fatal crashes. 
DUI-caused crashes usually were more severe than 
other types, because of higher speeds, and often the 
occupants were not wearing seat belts.  
 
In 2003, 56.7 percent of DUI-caused crashes resulted 
in fatalities or injuries, compared with 29.6 percent 
when DUI was not the cause of the crash. One-
hundred-eight of these DUI-related crashes were fa-
tality cases, 1,184 were injury cases, and 985 were 
property damage cases. In 39 percent of alcohol-
related crashes, the blood alcohol content (BAC) was 
greater than 0.01; it was greater than 0.08 in 35 per-
cent. CSP reported 8,600 DUI citations for 2003.  
 
In 2003, FARS data indicated that 39 percent (246) 
of the 632 individuals killed in Colorado in vehicular 
crashes involved alcohol.  
 
In 2004, 665 individuals were killed in motor vehicle 
crashes in Colorado.  
 
In 2003, the CDPHE reported 1,141 alcohol-induced 
deaths unrelated to motor vehicular accidents state-
wide. 
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The number of alcohol-related calls statewide to the 
Rocky Mountain Poison and Drug Center increased 
markedly from 110 in 2001 to 150 in 2003 for the 
Denver PMSA (exhibit 6a). In 2004, there were 764 
alcohol calls statewide.  
 
Drug use by “generation” was analyzed for 2004 us-
ing four age groups: Generation Y, Generation X, 
Baby Boomers, and Seniors. Exhibit 15 shows that 
sedatives and tranquilizers, including alcohol, are the 
primary drug types for the X generation, Baby 
Boomers, and Seniors.  
 
Tobacco   
 
Tobacco use is the leading cause of preventable death 
and disability in the State and one of Colorado’s most 
serious public health problems. Tobacco use is re-
sponsible for more than 4,200 deaths and the devel-
opment of 130,000 tobacco-related illnesses in adults 
annually. Smoking tobacco causes 30 percent of all 
cancer deaths, 21 percent of coronary heart disease-
related deaths, and 18 percent of stroke deaths. Re-
ports show that 193,000 children in the State are ex-
posed to secondhand smoke at home, resulting in 
asthma and respiratory illnesses. 
 
Annual health care costs directly related to smoking 
exceed $1 billion (or $259 per capita) in the State. 
Every Colorado household incurs more than $511 per 
year in State and Federal taxes to pay for smoking-
related health care costs. 
 
Approximately 630,000 (19 percent) of all Colorado 
adults use tobacco products, compared with the 23 
percent nationwide average. Sixty-eight percent of 
clients who received substance abuse treatment 
and/or detoxification services in State fiscal year 
2004 used tobacco products daily.  
 
The American Lung Association Tobacco Report 
Card for Colorado indicated a failing (“F”) grade for 
smoke-free air, youth access, and prevention and con-
trol spending. Colorado was mediocre (a “C”) on the 
cigarette tax. 
 
Laws enacted in Colorado prohibit the sale of to-
bacco products to adolescents (those younger than 
18). In spite of that, the Youth Risk Behavior Survey 
identified 27 percent of students in grades 9–12 as 
current cigarette smokers. Adolescents who smoke 
are more likely to smoke as adults and be at risk for 
tobacco-related illnesses. 
 
The sale of tobacco products is monitored by Colo-
rado’s Department of Revenue Tobacco Enforcement 
Division, and tobacco prevention efforts fall primar-
ily under the purview of the Department of Public 
Health and Environment.  
 
In 2004, several cities in Colorado passed legislation 
prohibiting the smoking of tobacco in certain public 
areas, and advocacy groups are initiating a statewide 
awareness campaign. Colorado also increased the 
tobacco tax from $0.20 to $0.84, with monies going 
to health care-related concerns.  
 
INFECTIOUS DISEASES AMONG INJECTING DRUG 
USERS 
 
Of the 8,088 acquired immunodeficiency syndrome 
(AIDS) cases reported in Colorado through Decem-
ber 31, 2004, 9.2 percent were classified as injection 
drug users (IDUs), and 10.7 percent were classified 
as homosexual or bisexual males and IDUs (exhibit 
20). 
 
CORRECTIONS: THE HIDDEN POPULATION 
 
The Colorado Department of Corrections reports an-
nually on new court commitments and parole popula-
tions. Unfortunately, data for substance abusers are 
not broken out by primary drug. However, this popu-
lation is large enough that to exclude it would mean 
giving a skewed picture of Colorado’s substance  
abuse problem. As of December 31, 2004, there were 
20,144 adult offenders incarcerated, 7,383 on parole, 
and 225 youthful offenders.  
 
In State FY 2004, there were 5,240 new court com-
mitments. Eighty-two percent of these individuals 
were identified as substance abusers. Substance abus-
ers were more likely to be female, Caucasian, single, 
and younger. Substance abusers had significantly 
more crimes on their current incarceration and aver-
aged more than six times as many drug crimes as 
non-abusers. Substance abusers were also more likely 
to have prior Department of Corrections (DOC) in-
carcerations. When assessed for measure of criminal 
risk, substance abusers scored substantially higher, 
indicating that they have more serious criminal histo-
ries than non-abusers. Substance abusers were, how-
ever, less likely to be identified as sex offenders or to 
have medical needs. 
 
New court commitment female offenders were more 
likely to have higher substance abuse treatment needs 
overall than males. 
 
Substance abusers accounted for 89 percent of the 
parole returns during State FY 2004. When compared 
with non-abusing parole returns, no significant dif-
ferences were noted in demographic characteristics.  
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Seventy-eight percent of the prison population 
(N=16,191, an increase of 826 individuals from FY 
2003) were identified as substance abusers. These 
individuals were more likely to be Latino, single or 
common-law married, and younger. In the prison 
population, substance abusers were significantly dif-
ferent from non-abusers on several needs areas. Sub-
stance users demonstrated higher needs in the follow-
ing areas: academic, vocation, psychological, seri-
ously mentally ill, and mental retardation. Substance 
abusers demonstrated lower needs than non-abusers 
in the following areas: sex offender, self-destruction, 
assault/anger management, and medical.  
 
Substance abusers represented 85 percent of all 
prison releases. There were no differences between 
abusers and non-abusers on gender, marital status, or 
age. However, releases with substance abuse prob-
lems were more likely to be African-American than 
were non-abusers.  
 
For inquiries concerning this report, please contact Nancy E. 
Brace, R.N., M.A., Evaluation and Information Director, Alcohol 
and Drug Abuse Division, Colorado Department of Human Ser-
vices, 4055 South Lowell Boulevard, Denver, CO 80236-3120, 
Phone: 303-866-7502, Fax: 303-866-7481, E-mail: nancy.brace@ 
state.co.us.
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Exhibit 1a. Denver DAWN ED Sample and Reporting Information: January–December 2004 
 
No. of EDs Reporting per Month: Com-
pleteness of Data (%)  Total Eligible 
Hospitals1 
No. of Hospi-
tals in DAWN 
Sample 
Total EDs in 
DAWN Sam-
ple2 90–100% 50–89% <50% 
No. of EDs 
Not Report-
ing 
14 14 14 5–8 0–1 0–1 6–9 
 
1Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association An-
nual Survey. 
2Some hospitals have more than one emergency department. All DAWN cases are reviewed for quality control. Based on this re-
view, cases may be corrected or deleted. Therefore these data are subject to change. 
SOURCE: DAWN Live! OAS, SAMHSA, updated 4/13–14/05. 
 
 
 
 
Exhibit 1b. Data Completeness for Denver Metropolitan Area DAWN Live! Emergency Departments (n=14)  
 by Month, 2004 
 
Data Com-
pleteness 
Jan. Feb. Mar. Apr. May June July Aug. Sep. Oct. Nov. Dec. 
Basically 
complete1 
5 5 5 5 5 5 5 7 7 8 7 7 
Partially 
Complete2 
0 0 0 0 0 0 1 0 0 0 1 1 
Incomplete3 1 0 0 0 0 0 0 0 0 0 0 0 
No Data 
Reported 
8 9 9 9 9 9 8 7 7 6 6 6 
Total EDs 
in Sample4 
14 14 14 14 14 14 14 14 14 14 14 14 
1Total eligible hospitals in area=14, Hospitals in DAWN sample=14. Tables reflect cases that have been received by DAWN as of 
4/13–14/05. Unweighted data from Denver hospitals reporting to DAWN. 
290%+ Complete; 350–89% Complete; 4Less than 50% Complete. 
Some hospitals in the DAWN sample have more than one emergency department. All DAWN cases are reviewed for quality control. 
Based on this review, cases may be corrected or deleted. Therefore these data are subject to change. 
SOURCE: DAWN Live! OAS, SAMHSA, updated 4/13–14/05 
 
 
 
 
Exhibit 1c. Number of Unweighted DAWN ED Cases, by Case Type (Unweighted1): 2004 
 
Case Type Number 
Suicide attempt 600 
Seeking detox 412 
Alcohol only (age<21) 755 
Adverse reaction 1,370 
Overmedication 1,235 
Malicious poisoning 12 
Accidental ingestion 196 
Other 2,979 
 
1Unweighted data are from 5–8 Denver EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on 
this review, cases may be corrected or deleted. Therefore these data are subject to change. 
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14/05 
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Exhibit 2. Number of Unweighted1 Drug Reports in Drug-Related ED Visits,2 by Drug Category: 2004 
 
Drug Category and Selected Drugs3 Drug Reports 
Major Substances of Abuse 6,186 
Alcohol 2,304 
 Alcohol-in-combination with other drugs 1,549 
 Alcohol only (age<21) 755 
Cocaine 1,569 
Heroin 609 
Marijuana 755 
Stimulants 755 
 Amphetamines 280 
 Methamphetamine 475 
MDMA (ecstasy) 64 
GHB 5 
Ketamine 2 
LSD 9 
PCP 12 
Miscellaneous hallucinogens 32 
Inhalants 62 
Combinations not tabulated above 8 
 
1Unweighted data are from 5–8 Denver EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on 
this review, cases may be corrected or deleted. Therefore these data are subject to change. 
2Drug-related ED visits often involve multiple drugs (e.g., both cocaine and heroin may be reported for the same case). Therefore, 
the number of drug reports will exceed the number of ED visits. 
3This classification of drugs is derived from the Multum Lexicon, Copyright 2003, Multum Infomation Services, Inc. The classification 
has been modified to meet DAWN's unique requirements (2004). The Multum Licensing Agreement governing use of the Lexicon is 
provided in most DAWN publications and can be found on the Internet at http://www.multum.com. 
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14/05 
 
 
 
 
Exhibit 3. Unweighted Gender Percentages by Drug Type for ED Patients (Unweighted1), by Drug Type:  
 2004 
63.1
74.2
61.6 58.1
36.9
25.8
38.4 41.9
0
20
40
60
80
100
Cocaine Heroin Marijuana Methamphetamine
Male Female
 
1Unweighted data are from 5–8 Denver EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on 
this review, cases may be corrected or deleted. Therefore these data are subject to change. 
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14/05 
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Exhibit 4. Unweighted1 ED Patient Age Data, by Selected Drugs: 2004  
 
Age Cocaine Heroin Marijuana Amphetamines Methamphetamine 
5 and younger 4 1 4 2 0 
6–11 1 0 1 1 0 
12–17 61 3 178 26 52 
18–20 94 22 115 33 49 
21–29 399 151 186 84 159 
30–44 736 246 195 108 172 
45–64 268 182 73 26 43 
65 and older 6 4 2 0 0 
 
1Unweighted data are from 5–8 Denver EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on 
this review, cases may be corrected or deleted. Therefore these data are subject to change. 
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14/05 
 
 
 
 
Exhibit 5. Drug-Related Hospital Discharges per 100,000 Population for Selected Drugs in Colorado:  
 1997–2003 
 
Drug/Rate per 
100,000 Population 1997 1998 1999 2000 2001 2002 2003 
Alcohol NA1 17,154 18,577 18,744 20,644 21,433 23,750 
Rate per 100,000  418.0 440.6 432.3 464.3 474.02 518.0 
Amphetamines 959 815 682 942 1161 1463 1814 
Rate per 100,000 24.0 20.0 16.2 21.7 26.1 32.3 39.6 
Cocaine 2,245 2,492 2,517 2,732 2,787 3,305 3,658 
Rate per 100,000 56.1 60.7 59.7 63.0 63.0 73.1 80.3 
Marijuana 2,118 2,227 2,204 2,455 2,755 3,016 3,246 
Rate per 100,000 53.0 54.3 52.3 56.6 62.0 66.7 71.0 
Narcotic Analgesics 1,458 1,566 1,639 2,053 2,237 2,605 3,368 
Rate per 100,000 36.5 38.2 39.0 47.3 50.3 57.6 73.4 
Population 3,995,923 4,102,491 4,215,984 4,335,540 4,446,529 4,521,484 4,586,455 
 
1NA=Not available. 
SOURCE: Colorado Department of Public Health and Environment, Colorado Hospital Association  
 
 
Exhibit 6a. Number of Drug-related Calls to the Rocky Mountain Poison and Drug Center for Denver,  
 Colorado: 2001–2003 
 
Drug 2001 2002 2003 
Alcohol 110 149 150 
Cocaine/crack 59 66 68 
Heroin/morphine 19 16 22 
Marijuana 34 37 36 
Methamphetamine 20 39 39 
Other Stimulants/ Am-
phetamines 3 3 6 
Club Drugs 30 55 40 
Inhalants 4 16 10 
 
SOURCE: Rocky Mountain Poison and Drug Center 
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Exhibit 6b. Number of Drug-Related Calls to the Rocky Mountain Poison and Drug Center for Colorado:  
 2004 
 
Drug 2004 
Alcohol 764 
Cocaine/Crack 120 
Heroin/Morphine 20 
Marijuana 68 
Methamphetamine 95 
Other Stimulants Amphetamines 316 
Club Drugs 11 
Hallucinogens 29 
 
SOURCE: Rocky Mountain Poison and Drug Center 
 
 
 
 
Exhibit 7. Drug-Related Mortality Numbers for the Denver PMSA: 1996–2002 
 
Drug 1996 1997 1998 1999 2000 2001 2002 
Alcohol 47 49 61 74 75 99 86 
Cocaine/Crack 68 56 66 82 80 126 108 
Heroin/Morphine 34 53 51 79 66 77 64 
Marijuana 1 4 3 20 20 31 5 
Methamphetamine 3 6 3 8 10 19 17 
Other Stimulants 
Amphetamines 
2 5 3 5 9 8 13 
Club Drugs -- -- -- -- 2 4 2 
Inhalants -- 1 2 -- 1 -- 1 
 
SOURCE: Colorado Department of Public Health and Environment 
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Exhibit 8. Numbers and Percentages of Treatment Admissions in Colorado (Excluding Alcohol) by Primary  
 Drug Type:  1997–2004 
 
Drug 1997 1998 1999 2000 2001 2002 2003 2004 
Heroin         
N 1,200 1,418 1,585 1,577 1,482 1,415 1,640 1,093 
% 15.7 14.4 16.3 16.3 14.7 13.1 14.0 8.9 
Non-Rx Methadone         
N 4 15 15 16 9 17 15 20 
% 0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.2 
Other Opiates         
N 195 230 274 304 386 394 519 514 
% 2.6 2.3 2.8 3.1 3.8 3.6 4.4 4.2 
Methamphetamine         
N 1,081 1,436 1,214 1,314 1,659 2,070 2,744 3,209 
% 14.2 14.6 12.5 13.6 16.5 19.2 23.3 26.1 
Other Amphetamines/Stimulants        
N 52 61 89 107 91 104 78 46 
% 0.7 0.6 0.9 1.1 0.9 1.0 0.7 0.4 
Cocaine         
N 1,797 2,309 2,099 1,916 1,888 2,193 2,330 2,572 
% 23.6 23.5 21.6 19.8 18.8 20.3 19.8 20.9 
Marijuana         
N 3,152 4,126 4,061 4,135 4,248 4,343 4,159 4,610 
% 41.3 42.0 41.8 42.8 42.3 40.2 35.4 37.5 
Hallucinogens         
N 40 56 68 72 71 38 23 21 
%  0.5 0.6 0.7 0.7 0.7 0.4 0.2 0.2 
PCP         
N 0 0 4 5 2 5 8 5 
% 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 
Barbiturates         
N 7 11 15 5 6 20 14 12 
% 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 
Sedatives         
N 4 17 16 21 13 89 63 29 
% 0.1 0.2 0.2 0.2 0.1 0.8 0.5 0.2 
Tranquilizers         
N 37 40 40 38 44 49 52 46 
% 0.5 0.4 0.4 0.4 0.4 0.5 0.4 0.4 
Inhalants         
N 28 50 28 26 31 21 20 20 
% 0.4 0.5 0.3 0.3 0.3 0.2 0.2 0.2 
Club Drugs         
N NA NA NA NA NA 12 37 48 
% NA NA NA NA NA 0.1 0.3 0.4 
Other         
N 31 51 218 123 119 37 54 54 
% 0.4 0.5 2.2 1.3 1.2 0.3 0.5 0.4 
Total N 7,628 9,820 9,726 9,659 10,049 10,807 11,756 12,299 
 
SOURCE:  Drug/Alcohol Coordinated Data System (DACODS) from the Alcohol and Drug Abuse Division, Colorado Department of  
Human Services 
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Exhibit 9a. New Users of Selected Drugs Among Colorado Treatment Admissions: 1997–2004 
 
Drug2 1997 1998 1999 2000 2001 2002 2003 2004 
Heroin         
 N 214 314 342 340 283 267 255 176 
 %  17.9 22.3 21.7 21.6 19.1 18.9 15.5 16.1 
Methamphetamine         
 N 362 472 308 311 367 475 676 777 
 %  33.6 33.0 25.5 23.7 22.1 23.0 24.6 24.2 
Cocaine         
 N 310 423 390 374 348 394 438 460 
 %  17.3 18.4 18.6 19.5 18.4 18.0 18.8 17.9 
Marijuana         
 N 1,326 1,584 1,434 1,552 1,505 1,403 1,464 1,408 
 %  42.4 39.1 35.9 37.7 35.7 32.3 35.2 30.5 
Total New Users (N) 2,212 2,793 2,474 2,577 2,503 2,539 2,833 2,821 
% of Total Admissions 30.8 30.4 27.9 28.9 27.1 25.3 26.1 24.6 
Total Admissions 7,190 9,188 8,880 8,915 9,241 10,016 10,871 11,484 
 
1New Users are those reporting using for less than 4 years at the time of treatment 
2Reported primary drug of use 
SOURCE: Drug/Alcohol Coordinated Data System (DACODS) from the Alcohol and Drug Abuse Division, Colorado Department of 
Human Services 
 
 
 
 
Exhibit 9b. Average Number of Years Between First Use of Drug and First Treatment1: 2004 
 
Drug2 Years 
Marijuana 7.9 
Methamphetamine 8.1 
Other Opiates 10 
Cocaine/Crack 10.7 
Heroin 14.3 
Alcohol 16.5 
 
1Includes only for those reporting no prior treatment admissions. 
2Reported primary drug of use. 
SOURCE: Drug/Alcohol Coordinated Data System (DACODS) from the Alcohol and Drug Abuse Division, Colorado Department of 
Human Services 
 
 
 
 
Exhibit 10. Percentages of Denver Adult Arrestees Testing Positive for Drugs: 2003 
 
Drug Type Males Females 
Cocaine 38.3 52.5 
Opiates 6.8 6.1 
Marijuana 42.3 34.3 
Methamphetamine 4.7 5.0 
Any Drug 66.4 69.1 
Multiple Drugs 23.3 24.9 
 
SOURCE: ADAM, NIJ, February 2005 
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Exhibit 11. Quest Diagnostics Drug Testing Index Positivity Rate for Colorado1 Combined Workforce and  
 the Combined U.S. Workforce: 2004 
 
Positivity Rate Range for States 
Denver 
Area 
North 
Central 
CO 
North. 
West CO 
South 
Central 
CO 
South 
West CO 
South 
East CO U.S. 
Amphetamines 0–2.63 0.14–0.33 0.14–0.33 0.6–1.01 0–0.14 0.33–0.6 0.14–0.33 10.2 
Cocaine 0–2.54 0.25–0.51 0.25–0.51 0.25–0.51 0.51–0.81 0–0.25 0.81–1.28 14.7 
Marijuana 0–8.4 2.1–2.7 2.1–2.7 2.7–3.7 2.1–2.7 2.1–2.7 2.1–2.7 54.8 
Opiates 0–7.53 0.09–0.24 0.09–0.24 0.24–0.49 0.24–0.49 0.24–0.49 0.24–0.49 6.2 
 
N=7.2 million tests. 
1No statistical data available for North East Colorado. 
SOURCE: Quest Diagnostics Drug Test Index 
 
 
 
 
Exhibit 12. Drug Price and Purity in Denver: 2004 
 
Drug Wholesale Price Retail Price Street Price Purity at Retail 
Powder Cocaine $16,000–$20,000/kg $600–$700/oz $70–$125/gm 16–90% 
Crack Cocaine $14,000–$18,500/kg $700–$1,200/oz $20–$60/rock 60–75% 
Heroin $15,000–$60,000/kg $2,000–$3000/oz $100–$150/gm 8–64% 
Methamphetamine $4,500–$16,000/lb $700–$1,500/oz $80–$150/gm 0–100% 
Marijuana $16,000/lb $1,000–$3,000/oz $50–$200/gm -- 
Ecstasy -- -- $6–$25/pill -- 
OxyContin -- -- $6.50/pill Prescription 
 
SOURCE: DEA, treatment providers, National Drug Intelligence Center, local law enforcement 
 
 
 
 
Exhibit 13. Number of Unweighted1 Prescription Drug Misuse Drug Reports in Denver, by Case Type: 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Unweighted data are from 5–8 Denver EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on 
this review, cases may be corrected or deleted. Therefore these data are subject to change. 
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14/05 
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Exhibit 14. Top Five Drugs Involved in Drug Misuse Deaths in the Denver-Aurora Metropolitan Area: 2003  
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SOURCE: DAWN 2003 Area Profiles of Drug-Related Mortality 
 
 
 
 
Exhibit 15. Numbers and Percentages of Generational Primary Drug Use: FY 2004 
 
Age Ranges Sedatives Tranquilizers1 Stimulants Opiates Marijuana 
Hallucin- 
ogens 
Club 
Drugs 
Other 
Drugs Total 
Y Generation2 1,512 28% 
1,008 
18% 
107 
2% 
2,754 
50% 
12 
<1% 
20 
<1% 
38 
1% 
5,451 
26% 
X Generation3 3,805 40% 
3,397 
36% 
773 
8% 
1,480 
16% 
9 
<1% 
23 
<1% 
21 
<1% 
9,508 
47% 
Baby Boom-
ers4 
3,067 
55% 
1,408 
25% 
719 
13% 
364 
6% 
5 
<1% 
4 
<1% 
13 
<1% 
5,580 
27% 
Seniors5 234 81% 
14 
5% 
28 
10% 
12 
4% 0 
1 
<1% 
1 
<1% 
290 
<1% 
Total 8,618 41% 
5,827 
28% 
1,627 
8% 
4,610 
22% 
26 
<1% 
48 
<1% 
73 
<1% 
20,829 
100% 
 
1Sedatives Tranquilizers include alcohol 
2Y Generation includes anyone born after 1981 
3X Generation includes anyone born between 1965 and 1981 
4Baby Boomers include anyone born between 1946 and 1964 
5Seniors include anyone born before 1946 
SOURCE: Drug/Alcohol Coordinated Data System (DACODS) from the Alcohol and Drug Abuse Division, Colorado Department of 
Human Services 
 
 
 
Exhibit 16a. Methamphetamine Use Among MSM in Denver Community Survey: 2004–2005 
 
 Number Percent 
MSM, N=981 108 11.0 
HIV negative MSM, n=763 69 9.0 
HIV positive MSM, n=153 32 20.9 
 
SOURCE: Dr. Mark Thrun, Denver Public Health 2004–2005 NHBS MSM Survey 
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Exhibit 16b. Sexual Risk and Methamphetamine Use: 2004–2005 
 
 Meth Users N=108 
Non-users 
N=873 Odds Ratio 
Mean age 33.1 39.4  
Mean number of male/female 
partners last 12 months 12.5 / 5.0 7.7 / 2.3  
Any unprotected sex last 12 
months 76 (70.4%) 380 (43.5%) 
3.1 
(2.0-4.8) 
Ever tested for HIV 101 (93.5%) 815 (93.4%)  
Most recent HIV test result was 
positive 32 (31.7%) 121 (14.9%) 
2.7 
(1.7-4.2) 
 
SOURCE: Dr. Mark Thrun, Denver Public Health 2004–2005 NHBS MSM Survey 
 
 
 
 
Exhibit 17. Number of Unweighted1 Alcohol-Related ED Reports, by Case Type: 2004 
 
Case Type Number of Cases Percent of Alcohol 
Cases 
Percent of all Drug-Related 
Cases 
Seeking detox 515 22 8 
Alcohol only, <21 years of age 755 33 12 
Other Alcohol 1,034 45 17 
 
1Unweighted data are from 5–8 Denver EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on 
this review, cases may be corrected or deleted. Therefore these data are subject to change. 
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14/05 
 
 
 
 
Exhibit 18. Gender and Age of Alcohol Only (Age <21) ED Patients (Unweighted1), by Number and Percent:  
 2004 
 
 Number Percent 
Gender   
   Male 461 61 
   Female 293 39 
Age   
   5 and younger 0 0 
   6–11 4 0.5 
   12–17 402 53 
   18–20 349 46 
 
1Unweighted data are from 5–8 Denver EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on 
this review, cases may be corrected or deleted. Therefore these data are subject to change. 
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14/05 
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Exhibit 19. Numbers and Percentages of Treatment Admissions in Colorado (Including Alcohol), by Primary 
Drug Type: 1997–2004 
 
Drug 1997 1998 1999 2000 2001 2002 2003 2004 
Alcohol         
n 6,353 7,833 6,573 6,577 6,311 6,839 7,044 8,531 
% 45.4 44.4 40.3 40.5 38.6 38.8 37.5 40.9 
Heroin         
N 1,200 1,418 1,585 1,577 1,482 1,415 1,640 1,093 
% 8.6 8.0 9.7 9.7 9.1 8.0 8.7 5.2 
Non-Rx Methadone         
N 4 15 15 16 9 17 15 20 
% 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
Other Opiates         
N 195 230 274 304 386 394 519 514 
% 1.4 1.3 1.7 1.9 2.4 2.2 2.8 2.5 
Methamphetamine         
N 1,081 1,436 1,214 1,314 1,659 2,070 2,744 3,209 
% 7.7 8.1 7.4 8.1 10.1 11.7 14.6 15.4 
Other Amphetamines/Stimulants        
N 52 61 89 107 91 104 78 46 
% 0.4 0.3 0.5 0.7 0.6 0.6 0.4 0.2 
Cocaine         
N 1,797 2,309 2,099 1,916 1,888 2,193 2,330 2,572 
% 12.9 13.1 12.9 11.8 11.5 12.4 12.4 12.3 
Marijuana         
N 3,152 4,126 4,061 4,135 4,248 4,343 4,159 4,610 
% 22.5 23.4 24.9 25.5 26.0 24.6 22.1 22.1 
Hallucinogens         
N 40 56 68 72 71 38 23 26 
% 0.3 0.3 0.4 0.4 0.4 0.2 0.1 0.1 
PCP         
N 0 0 4 5 2 5 8 5 
% 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Barbiturates         
N 7 11 15 5 6 20 14 12 
% 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 
Sedatives         
N 4 17 16 21 13 89 63 29 
% 0.0 0.1 0.1 0.1 0.1 0.5 0.3 0.1 
Tranquilizers         
N 37 40 40 38 44 49 52 46 
% 0.3 0.2 0.2 0.2 0.3 0.3 0.3 0.2 
Inhalants         
N 28 50 28 26 31 21 20 20 
% 0.2 0.3 0.2 0.2 0.2 0.1 0.1 0.1 
Club Drugs         
N NA NA NA NA NA 12 37 48 
% NA NA NA NA NA 0.1 0.2 0.2 
Other         
N 31 51 218 123 119 37 54 54 
% 0.2 0.3 1.3 0.8 0.7 0.2 0.3 0.3 
Total N 13,981 17,653 16,299 16,236 16,360 17,646 18,800 20,830 
 
SOURCE: Drug/Alcohol Coordinated Data System (DACODS) from the Alcohol and Drug Abuse Division, Colorado Department of 
Human Services 
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Exhibit 20. Colorado Cumulative AIDS Cases by Gender and Exposure Category Through December 31,  
 2004 
 
 Number of AIDS Casesa 
Percent of AIDS 
Cases 
Number of Indi-
viduals Testing 
Positive for HIV 
Percent of Indi-
viduals Testing 
Positive for HIV 
Gender     
   Male 7,452 92.1% 5,394 89.8% 
   Female 636 7.9% 612 10.2% 
   Total 8,088 100% 6,006 100% 
Exposure Category     
   Men/sex/men (MSM) 5,446 67.3% 3,807 63.4% 
   Injecting drug user (IDU) 747 9.2% 525 8.7% 
   MSM and IDU 866 10.7% 555 9.2% 
   Heterosexual contact 482 6.0% 397 6.6% 
   Other 182 2.2% 64 1.1% 
   Risk not identified 365 4.5% 658 11.0% 
 
1In October 2004, Colorado omitted cases who moved to other States, thereby reducing their HIV/AIDS database by 758 cases. 
Thus reports produced before October 2004 show higher numbers of AIDS cases than reports produced after October, 2004.  
SOURCE: The Colorado Department of Public Health and Environment 
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Drug Abuse in Detroit/Wayne 
County and Michigan 
 
Cynthia L. Arfken1 
 
ABSTRACT 
 
Cocaine and heroin are the two major drugs of abuse 
in the area. Cocaine treatment admissions continued 
to stabilize; a high percentage of ED drug reports 
and a high number of items reviewed by forensic 
laboratories involved cocaine. Heroin treatment ad-
missions, especially as the primary substance of 
abuse, are high and climbing, but there are few her-
oin ED drug reports and few heroin items reviewed 
by forensic laboratories. Indicators for metham-
phetamine point to less involvement than for other 
major drugs of abuse. 
 
INTRODUCTION 
 
Area Description 
 
Detroit and surrounding Wayne County are located in 
the southeast corner of Michigan’s Lower Peninsula. 
In 2000, the Wayne County population totaled 2.1 
million residents (of whom 46 percent live in Detroit) 
and represented 21 percent of Michigan’s 9.9 million 
population.  
 
Currently, Michigan is the eighth most populous 
State in the Nation. In 2000, Detroit ranked 10th in 
population among cities with 951,000 people, but the 
population has since dropped below 900,000. It has 
the highest percentage of African-Americans (82 
percent) of any major city in the country. The follow-
ing factors contribute to probabilities of substance 
abuse in the State: 
 
• Michigan has a major international airport, with a 
new terminal that opened 2002; 10 other large air-
ports that also have international flights; and 235 
public and private small airports. Long-term pro-
jections for the Detroit Metropolitan Airport fore-
cast a 31-percent increase in flights during the 
next 10 years. 
 
• The State has an international border of 700 
miles with Ontario, Canada; land crossings at 
Detroit (bridge and a tunnel), Port Huron, and 
Sault Ste. Marie; and water crossings through 
three Great Lakes and the St. Lawrence Seaway, 
                                                           
1The author is affiliated with Wayne State University, Detroit, 
Michigan. 
which connects to the Atlantic Ocean. Many 
places along the 85 miles of heavily developed 
waterway between Port Huron and Monroe 
County are less than one-half mile from Canada. 
Michigan has more than 1 million registered 
boats. In fiscal year (FY) 2002, three major 
bridge crossings from Canada (Windsor Tunnel, 
Ambassador Bridge, and Port Huron) had 9.7 
million cars, 2.6 million trucks, and 93,000 buses 
cross into Michigan. Southeast Michigan is the 
busiest port on the northern U.S. border with 
Canada. Detroit and Port Huron also have nearly 
10,000 trains entering from Canada each year. 
The Foreign Mail Branch in Detroit processes 
275,000 foreign parcels and about 900,000 letter-
class pieces monthly.  
 
• Additional factors influence substance use in 
Detroit: 
 
• The percentage of individuals living below pov-
erty line (26.1 percent) is more than twice the na-
tional level (12.4 percent). 
 
• The percentage of working age individuals (age 
21–64) with disability is substantially higher than 
the national level (32.1 versus 19.2 percent). 
 
• There are chronic structural unemployment prob-
lems. At the State level, the unemployment rate 
has been among the highest in the country since 
2002. Within the State, Detroit has one of the 
lowest rates of employed adults.  
 
Data Sources 
 
Data for this report were drawn from the sources 
shown below: 
 
• Emergency department (ED) data were de-
rived for 2004 from the Drug Abuse Warning 
Network (DAWN) Live! restricted-access 
online query system administered by the Office 
of Applied Studies (OAS), Substance Abuse 
and Mental Health Services Administration 
(SAMHSA). Eligible hospitals in the Detroit 
area totaled 38; hospitals in the DAWN sample 
numbered 23, with the number of EDs in the 
sample totaling 24. (Some hospitals have more 
than one emergency department.) During this 
12-month period, between 17 and 19 EDs re-
ported data each month. The completeness of 
data reported by participating EDs varied by 
month (see exhibit 1a). Exhibits in this paper 
reflect cases that were received by DAWN as of 
April 13–14, 2005. All DAWN cases are re-
viewed for quality control. Based on this re-
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view, cases may be corrected or deleted. There-
fore, the data presented in this paper are subject 
to change. Data derived from DAWN Live! rep-
resent drug reports in drug-related ED visits. 
Drug reports exceed the number of ED visits, 
since a patient may report use of multiple drugs 
(up to six drugs and alcohol). The DAWN Live! 
data are unweighted and, thus, are not estimates 
for the reporting area. These data cannot be 
compared to DAWN data from 2002 and be-
fore, nor can preliminary data be used for com-
parison with future data. Only weighted DAWN 
data released by SAMHSA can be used for 
trend analysis. A full description of the DAWN 
system can be found at the DAWN Web site: 
http://dawninfo.samhsa.gov. 
 
• Treatment admissions data were provided by 
the Bureau of Substance Abuse and Addiction 
Services, Division of Substance Abuse and 
Gambling Services, Michigan Department of 
Community Health (MDCH), for the State and 
Detroit/Wayne County, as reported by State and 
federally funded programs. MDCH, following 
revised Treatment Episode Data Set (TEDS) 
Federal guidelines, is converting to an episode-
based reporting system in which changes in lev-
els of care that are part of the treatment plan 
(moving from residential treatment to outpatient, 
for example) are not reported as new separate 
admissions but rather as transfers within an epi-
sode. This transition has not been fully imple-
mented by all publicly funded programs. As this 
change is fully implemented, it is expected that 
total admissions will decline, and comparisons of 
admissions trends before and after this change 
are not recommended. In contrast to including 
previously reported ED data in this report, dis-
cussions included regarding treatment data in 
this report will be limited to instances where 
treatment is the only indicator source for a par-
ticular drug or group of drugs. 
 
• Mortality data on drug-related deaths were ob-
tained from DAWN, OAS, SAMHSA for 2003. 
 
• Drug intelligence data were provided by the 
Michigan State Police. 
 
• Data on drug seizures were provided by the 
National Forensic Laboratory Information Sys-
tem (NFLIS) for January–December 2004. 
 
• Information on the number of prescriptions was 
obtained from a special report by the Michigan 
Board of Pharmacists, 2004. 
 
DRUG ABUSE PATTERNS AND TRENDS 
 
Cocaine/Crack 
 
For FY 2004, 24.6 percent of Detroit/Wayne County 
treatment admissions listed cocaine/crack as the pri-
mary drug of abuse (exhibit 2). An additional 20.7 
percent of treatment admission listed cocaine/crack 
as the secondary drug. Between 1994 and 2003, 
statewide treatment admissions for cocaine crept 
from 2.1 percent to 2.8 percent (exhibit 3). In con-
trast, treatment admissions for crack declined from 
17.7 to 13.9 percent during the same period.  
 
Cocaine constituted 42 percent of drug items re-
viewed by forensic laboratories in 2004 (exhibit 4). 
 
According to unweighted DAWN Live! data, cocaine 
was the most frequent major substance of abuse re-
ported in DAWN ED data in the metropolitan Detroit 
area in 2004. The number of metropolitan Detroit ED 
cocaine reports was 3,287, or 33 percent of the total 
reports (including alcohol reports). Patients reporting 
cocaine were most likely to be male (61 percent), 
African-American (75 percent), and age 35–44 (37 
percent).  
 
Cocaine represented 53 percent of drugs involved in 
drug misuse deaths in 2003. 
 
Availability, prices, and purity for powder cocaine 
and crack remained relatively stable during the most 
recent reporting period. Ounce and kilogram prices 
have been stable over the past decade. There are 
some reports of decreases in prices at the kilogram 
quantity level and above. The cost of crack rocks is 
approximately $20 (exhibit 5). Ounce amounts of 
cocaine and crack generally have sold for the same 
price ($750–$1,500) since 2001 in Detroit. 
 
Heroin 
 
In FY 2004, 31.8 percent of Detroit/Wayne County 
treatment admissions listed heroin as the primary 
drug of abuse (exhibit 2). An additional 3.1 percent 
of treatment admissions listed heroin as the secon-
dary drug. Between 1994 and 2003, the proportion of 
statewide treatment admissions for heroin almost 
doubled, from 7.3 to 12.6 percent (exhibit 3).  
 
Only 12 percent of drug items reviewed by forensic 
laboratories were found to be heroin in 2004 (exhibit 
4). 
 
According to DAWN Live! unweighted data, 19 per-
cent of ED reports for major substances of abuse in the 
metropolitan Detroit area were for heroin. Patients re-
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porting heroin were most likely to be male (61 percent), 
African-American (62 percent), and between the ages 
of 45 and 54 (45 percent).  
 
Heroin deaths steadily increased in Detroit/Wayne 
County between 1992 and 2002. In 1996, there were 
240 heroin-present deaths; by 2000, the annual num-
ber had nearly doubled. Deaths with heroin metabo-
lites present in 1999 represented a 24-percent in-
crease from 1998, while in 2000, heroin cases 
increased again, by 23 percent over the 1999 total. 
The 465 heroin-present deaths in 2001 were a slight 
decrease from the 473 deaths in 2000. During 2002, 
496 heroin-present deaths were identified, which 
again exceeded the number of cocaine-involved 
deaths. In 2003, the Wayne County ME identified 
446 heroin deaths, a level slightly below the 2001 
findings. Heroin and prescription opioids, however, 
were the drugs most likely involved in drug misuse 
deaths. In Wayne County, they accounted for 75 per-
cent, while in nearby affluent Oakland County heroin 
and prescription opiates accounted for 78 percent. 
 
Heroin street prices remained stable and relatively 
low in Detroit. Packets or “hits” available in Detroit 
are typically sold in $10 units (exhibit 5).  
 
Other Opiates/Narcotic Analgesics 
 
Other opiates represented 2.8 percent of primary 
treatment admissions in Detroit/Wayne County in FY 
2004 (exhibit 2). The percentage of statewide treat-
ment admissions listing other opiates as the primary 
drug of abuse increased from 1.2 percent in 1994 to 
4.0 percent in 2003 (exhibit 3).  
 
According to the number of prescriptions filled in 
2002 and 2003, oxycodone products were most 
common; they represented 38 percent of all opioids 
prescriptions in 2002 and 34 percent in 2003 (exhibit 
6). Prescriptions for fentanyl products, however, in-
creased by 95 percent between 2002 and 2003 to rep-
resent 25 percent of the opioid prescriptions being 
filled in 2003. 
 
Marijuana 
 
Marijuana indicators remain mostly stable but at highly 
elevated levels. 
 
The proportion of primary marijuana treatment admis-
sions has plateaued since 1997–1998. Marijuana ac-
counted for 9.3 percent of all substance abuse admis-
sions (including alcohol) in FY 2004 in Detroit/Wayne 
County (exhibit 2). Statewide marijuana admissions 
increased from 9.7 percent in 1994 to 15.9 percent in 
2003 (exhibit 3).  
In 2004, marijuana accounted for 45 percent of items 
analyzed by forensic laboratories in Detroit (exhibit 4).  
Mexican marijuana continued to be the dominant form 
available, but there have been reports of increases in 
marijuana from Canada. 
 
According to unweighted DAWN Live! data, metro-
politan Detroit-area ED marijuana reports represented 
15 percent of the total reports for major substances of 
abuse in 2004 (n=1,525). Marijuana ED patients were 
most likely to be male (65 percent), African-American 
(72 percent), and between the ages of 35 and 44 (23 
percent).  
 
Prices for marijuana at the retail level are $20 per 
gram for commercial grade (exhibit 5). 
 
Stimulants 
 
The latest treatment data show that admissions for 
primary drugs of abuse for stimulants other than co-
caine included 0.9 percent for amphetamines and two 
admissions for other stimulants in Detroit/Wayne 
County in FY 2004. Unweighted DAWN Live! ED 
data for 2004 show 115 reports of stimulants (99 for 
amphetamines and 16 for methamphetamine). 
 
Michigan’s border with Canada has been the focus of 
efforts to stop the flow of large amounts of pseu-
doephedrine and ephedrine into the United States. 
These imports are the necessary ingredients for mak-
ing methamphetamine and have been destined for the 
western United States and Mexico. Indictments of 
numerous individuals and seizures of millions of 
pseudoephedrine dosage units have continued.  
 
Club Drugs 
 
The club drugs category includes methylenedioxyme-
thamphetamine (MDMA or ecstasy), gamma hy-
droxybutyrate (GHB), flunitrazepam (Rohypnol), and 
ketamine. Indicators seem to be stabilizing for ec-
stasy and ketamine and declining for GHB.  
 
The drug known as ecstasy is typically MDMA or 
methylenedioxyamphetamine (MDA). Both drugs 
have been identified in past lab testings of ecstasy 
samples, sometimes in combination. There have been 
many anecdotal reports of widespread and increasing 
use since about 1997, but these drugs rarely appear in 
traditional indicators identifying abuse.  
 
For inquiries concerning this report, please contact Cynthia L. 
Arfken PhD, Wayne State University, 2761 E. Jefferson, Detroit, 
Michigan 48207 E-mail: carfken@med.wayne.edu. 
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Exhibit 1. Detroit DAWN ED Sample and Reporting Information:  January–December 2004 
 
No. of EDs Reporting per Month: Com-
pleteness of Data (%)  Total Eligible 
Hospitals1 
No. of Hospi-
tals in DAWN 
Sample 
Total EDs in 
DAWN Sam-
ple2 90–100% 50–89% <50% 
No. of EDs 
Not Report-
ing 
38 23 24 7–21 0–2 0–2 3–15 
 
1Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association An-
nual Survey. 
2Some hospitals have more than one emergency department. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/13-4/14, 2005  
 
 
 
Exhibit 2. Treatment Admissions in Detroit/Wayne County, by Primary and Secondary Drugs of Abuse and  
 Percent:  FY 2004 
 
Drug Primary Drug of Abuse (%) Secondary Drug of Abuse (%) 
Alcohol 30.9 20.8 
Heroin 31.8 3.1 
Cocaine 24.6 20.7 
Other Opiates 2.8 3.1 
Marijuana 9.3 11.0 
Other Drugs 0.5 1.2 
 
N=15,243 
SOURCE:  Michigan Department of Community Health, Division of Substance Abuse and Gambling Services, Bureau of Substance 
Abuse and Addiction Services 
 
 
 
 
Exhibit 3. Treatment Admissions in Michigan, by Primary Drug of Abuse and Percent:  1994–2003 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Michigan Department of Community Health, Division of Substance Abuse and Gambling Services, Bureau of Substance 
Abuse and Addiction Services 
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Exhibit 4. Numbers and Percentages of Seized Drug Items Analyzed in Detroit:  2004 
 
Substance Number of Items Seized Percent of Items Seized 
Cannabis 2,041 45.25 
Cocaine 1,890 41.91 
Heroin 546 12.11 
Codeine 24 0.53 
Propoxyphene 4 0.09 
MDMA 3 0.07 
Methadone 1 0.02 
Methamphetamine 1 0.02 
Total Items Reported 4,510 100.0 
 
SOURCE:  National Forensic Laboratory Information System 
 
 
 
Exhibit 5. Illegal Drug Prices in Detroit:  December 2004 
 
Drug Wholesale Midlevel Retail 
Cocaine (Powder) $17,000–$26,000 per kilogram 
$750–$1,500 
per ounce 
$100 
per gram 
Crack NR1 NR $20 per rock 
Heroin $65,000–$80,000 per kilogram 
$3,300–$6,000 
per ounce 
$10 
per dosage unit 
MDMA $5.25 per dosage unit 
$7.25 
per dosage unit 
$17–$25 
per dosage unit 
Marijuana $4,000–$4,500 per pound 
$150 
per ounce CG2 
$20 
per gram CG 
Methamphetamine $16,000 per pound 
$1,200 
per ounce 
$175 
per gram 
 
1NR=Not reported. 
2CG=Commercial grade 
SOURCE:  Michigan State Police 
 
 
 
Exhibit 6. Number of Drug Prescriptions for Opioids in Michigan:  2003–2004 
 
Drug 2002 2003 
Fentanyl 112,158 218,872 
MS Contin 48,410 59,562 
Dilaudid 14,367 21,393 
Demerol 7,314 7,760 
Morphine 107,302 113,521 
Oxycodone 246,091 296,629 
Methadone 47,846 79,845 
Percodan 58,301 103,687 
Total 641,789 863,100 
 
SOURCE:  Michigan Board of Pharmacists 
 
 
 
 
 
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Honolulu and Hawai'i 
 
 
Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005 96 
Illicit Drug Use in Honolulu 
and the State of Hawai'i 
 
D. William Wood, M.P.H., Ph.D.1 
 
ABSTRACT 
 
Substance use in the State of Hawai'i in 2004 was 
mixed in terms of its indicators, yet consequences of 
substance use remained clear. Little change oc-
curred for cocaine treatment admissions; decedents 
with positive cocaine toxicology results were down, 
while police cases related to cocaine were up. Both 
treatment admissions and positive toxicology reports 
on decedents were down for heroin, but police cases 
increased in number. Marijuana data show de-
creased admissions to treatment, fewer positive toxi-
cology reports for decedents, but more police cases. 
For Hawai'i’s drug of choice, methamphetamine, 
data from treatment providers and the Medical Ex-
aminer are consistently higher than in previous 
reports for previous time periods, while police cases 
are lower. While the ice labs in Hawai'i are not 
large, more were closed and more ice was seized 
than in any previous reporting period.  
 
INTRODUCTION 
 
This report presents current information on illicit 
drug use in Hawai'i, based on the Honolulu Commu-
nity Epidemiology Work Group (CEWG), described 
later in this section. 
 
Area Description 
 
Hawai'i, the Aloha State, had a population of 
1,211,537 as of April 1, 2000, and by July 1, 2004, 
the population was estimated to be 1,262,840.  
 
 
 
                                                 
1The author is affiliated with the Department of Sociology, Univer-
sity of Hawai’i at Manoa, Honolulu, Hawai’i. 
The State’s population is differentially distributed 
across the seven major islands of the Hawaiian chain, 
shown in the figure above. In fact, there are 26 is-
lands within the State’s boundaries, which extend 
from South Point on the Big Island of Hawai'i (the 
most southerly point in the United States) to Kure 
atoll, near Midway Island. The chain spans a total of 
1,200 miles from one end to the other.  
 
Hawai'i is unique within the Nation in that there is no 
one majority race or ethnicity.  
 
Hawai’i has the fourth largest foreign-born population 
in the Nation. Seventeen percent are foreign born, with 
27.8 percent speaking a language other than English as 
the primary language in the home. Using U.S. Census 
categories, the ethnic distribution of the population is 
24.3 percent White, 1.8 percent Black, 0.3 percent 
American Indian and Alaska Native, 9.4 percent Na-
tive Hawaiian and Other Pacific Islanders, 41.6 per-
cent Asian, and 1.3 percent “Others.” Single-race-only 
described 79.6 percent of the population. 
 
In Hawai'i, ethnicity data are collected using many 
more categories than the U.S. Census (for a total of 
28 categories). The distribution of population of the 
larger groups is as follows: 
 
Primary Ethnic Group Percent 
White 24.3 
Japanese 16.7 
Filipino 14.1 
Native Hawaiian 6.6 
Chinese  4.7 
Korean 1.9 
Black or African-American 1.8 
Samoan 1.3 
Vietnamese 0.6 
Tongan 0.3 
Micronesian/Other Pacific Islander 0.8 
American Indian/Native Alaskan 0.3 
Other Asian 0.7 
 
The history of the State of Hawai'i is rooted in a lack 
of intolerance, a collective identity, and a strong 
sense of group problem solving. The population af-
fected by drug use also has strong ties throughout all 
levels of the society; it is common for family mem-
bers to enforce the laws of society on their own ex-
tended family members. The State’s strong multicul-
tural history leaves many frustrated and unable to act, 
for fear of offending the family or bringing shame to 
relatives.  
 
The year 2004 was to be a pivotal year for substance 
abuse prevention, treatment, interdiction, and re-
search in the State of Hawai'i. More monies were 
City and County 
of Honolulu 
Maui County
Kaua’i 
County 
61,929 
City and 
County of 
Honolulu 
899,593 
Maui County 
138,347 
Hawai’i County 
162,971 
State of Hawai’i 
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appropriated for substance abuse prevention and 
treatment by the State legislature than ever before.   
 
Data Sources 
 
Much of the data presented in this report are from the 
Honolulu CEWG, which met on May 6, 2005. The 
meeting was hosted by the Hawai'i High Intensity 
Drug Trafficking Area (HIDTA) program office, 
whose staff facilitated the attendance of the Drug 
Enforcement Administration (DEA) representatives, 
as well as persons knowledgeable about drug data 
from Honolulu and neighbor islands. The State of 
Hawai'i Narcotics Enforcement Division, although 
invited, did not participate in the CEWG meeting. 
The Honolulu Police Department submitted data and 
was able to attend and participate in the CEWG meet-
ing. This report is focused only on drug activities in 
O'ahu for calendar year 2004, with the exception of 
State treatment data, which were available for all of 
the State only. Other specific data sources are listed 
below: 
 
• Treatment admissions and demographic data 
were provided by the Hawai’i State Department 
of Health, Alcohol and Drug Abuse Division 
(ADAD). Previous data from ADAD are updated 
for this report whenever ADAD reviews its re-
cords. These data represent all State-supported 
treatment facilities (90 percent of all facilities). 
About 5–10 percent of these programs and two 
large private treatment facilities do not provide 
data. During this reporting period, approximately 
45 percent of the treatment admissions were paid 
for by ADAD; the remainder was covered by 
State health insurance agencies or by private in-
surance. The rate of uninsurance for the State is 
about 10 percent. 
 
• Drug-related death data were provided by the 
Honolulu City and County Medical Examiner 
(ME) Office. These data are based on toxicology 
screens performed by the ME Office on bodies 
brought to them for examination. The sorts of 
circumstances that would lead to the body being 
examined by the ME include unattended deaths, 
deaths by suspicious cause, and clear drug-
related deaths. In short, while the ME data are 
consistent, they are not comprehensive and ac-
count for only about one-third of all deaths on 
O’ahu. To allow a direct comparison between 
ME data and treatment data, the ME data were 
multiplied by a factor of 10 on the exhibits.  
 
• Law enforcement case data for 2004 were re-
ceived from the Honolulu Police Department 
(HPD), Narcotics/Vice Division only.  
• Drug price data were provided for 2004 by the 
HPD, Narcotics/Vice Division. 
 
• Uniform Crime Reports (UCR) data were ac-
cessed from the State’s Attorney General’s Web 
site for 1975–2003. 
 
Emergency department (ED) drug mentions data 
have not been available in Hawai'i since 1994. Dis-
cussions with the Healthcare Association of Hawai'i 
regarding inclusion in the Drug Abuse Warning Net-
work (DAWN) program have resulted in a briefing of 
all hospital CEOs and the sharing of DAWN infor-
mation. Over the past 2 years, the healthcare industry 
of the State has been hoping for a meeting with this 
program. To date nothing is scheduled. 
 
DRUG ABUSE PATTERNS AND TRENDS 
 
Hawaiians and Whites remain the majority user groups 
among the 17 identified ethnic groups (plus 2 other 
categories: "other" and "unknown/blank") who access 
ADAD facilities for substance abuse treatment. During 
the first half of 2004, 46.6 percent and 22.5 percent of 
the admissions were Hawaiians/Part Hawaiians or 
Whites, respectively. All other groups represented 
significantly lower proportions of admissions.  
 
Methamphetamine remains the leading primary sub-
stance of abuse for those admitted to treatment, ac-
counting for 45.0 percent of admissions. Marijuana 
remained the third most frequently reported primary 
substance for treatment admissions (21.1 percent) 
behind alcohol (22.9 percent). It is important to point 
out, however, that almost all polydrug treatment ad-
missions list alcohol as a substance of abuse. The 25–
44 age group had the highest representation among 
treatment admissions and accounted for 25.0 percent 
of admissions; 35–44-year-olds accounted for 24.3 
percent. While marijuana abuse accounts for the ma-
jority of treatment admissions among those younger 
than 18 (the third most frequently admitted age 
group), the abuse of ice or crystal methamphetamine 
still looms as a major treatment category for this 
group. 
 
During this reporting period, drug prices have been 
stable, except for some minor upward price adjust-
ments for crystal methamphetamine in smaller 
amounts (exhibit 1). The size of the drug supply ap-
pears to make for a relatively stable drug market, 
with only a few market adjustments caused by sei-
zures of specific drugs or oversupply of others. 
 
Ice continues to dominate the Hawaiian drug market. 
Prices have increased slightly during the reporting 
period, and this is likely reflective of several seizures. 
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It is now easier, however, to purchase larger quanti-
ties than in the past. The final police evidence of in-
creased ice availability is that of clandestine labs—
almost exclusively reprocessing labs that continue to 
be closed at a regular pace. 
 
Marijuana has been a drug of choice in the islands for 
decades. All police departments in the State partici-
pate in the joint State-Federal “Operation Green Har-
vest.” However, police are now reporting that “Com-
petition from Mainland marijuana growers and con-
tinuing law enforcement efforts have drastically re-
duced the state's outdoor production from the 1980s.” 
During the latest “Operation Green Harvest,” more 
than 10,400 plants were seized on the Big Island; in 
Maui County, more than 16,800 plants were seized, 
with about 10,000 recovered within a couple miles of 
the Moloka'i airport; on O'ahu, 1,500 plants were 
seized; and on Kaua'i, 250 plants were seized. The 
most recent 10-day statewide sweep recovered about 
39,000 marijuana plants, an indication that marijuana 
cultivation has dropped dramatically from the 1980s. 
Federal officials have said that marijuana cultivation 
was a major problem during that decade; 1.9 million 
plants were recovered in 1987 alone, mostly from the 
Big Island. 
 
The Hawai'i DEA continues its efforts with the 
Honolulu Police Department to deal with crystal 
methamphetamine and, in particular, to break the 
supply route from California for the chemicals neces-
sary to operate Hawai'i’s ice labs. During this period, 
the HPD seized and closed 24 clandestine metham-
phetamine laboratories. In 2000, 8 labs were closed, 
compared with 7 in 2001, 15 in 2002, and 10 in 2003. 
 
The police data used in this report are only for the 
Honolulu Police Department. In previous reports, 
attempts have been made to include whatever data 
were available from Neighbor Island police depart-
ments.  The frequency and consistency of reporting 
made it impossible to continue the practice, and from 
this point forward only HPD data will be reported. 
 
Cocaine/Crack 
 
Powder cocaine and crack treatment admissions were 
relatively stable during the current period. There 
were 363 primary cocaine treatment admissions in 
2004, compared with 355 in 2003, 428 in 2002, and 
433 in 2001 (exhibit 2). This shows that the number 
of clients listing cocaine as the primary drug, after 
being quite stable for several years, began a decline 
in 1999 that has now stabilized with data for 2004. 
Powder cocaine/crack now ranks fourth among pri-
mary drugs of treatment admissions, after metham-
phetamine, alcohol, and marijuana. 
The Honolulu ME reported 22 deaths with cocaine-
positive toxicology screens in 2004, compared with 
26 in 2003 and 22–24 in 1999–2002 (exhibit 2). It 
should be remembered that data on the chart have 
been adjusted to allow for their presentation on the 
same axes by multiplying all death data by a constant 
of 10. 
 
According to the HPD, cocaine prices have remained 
relatively stable over the past several years. One-
quarter gram of crack currently sells for $25–$30, 
and the same amount of cocaine powder costs $25–
$35 (exhibit 1). Police cases for cocaine/crack in-
creased slightly in 2004 to 239 (exhibit 3). Over the 
past several years, the number of HPD cocaine cases 
plummeted from more than 1,200 cases in 1996 to 
202 in 2003.  
 
Heroin and Other Opiates 
 
China white heroin has been uncommon in Hawai’i 
for many years, but it is occasionally available for a 
premium price. The heroin market for Honolulu is 
dominated by black tar heroin, and it is readily avail-
able in all areas of the State. HPD data show 1,251 
grams of black tar and 1.699 grams of China white 
powder were seized in 2004. This is lower than the 
3,502 grams of black tar seized in 2003 but higher 
than the 0.019 grams of powder seized in 2003. For 
2002, 992 grams of black tar and 494 grams of pow-
der were seized. In 2001, 530 grams of powder were 
seized, along with 3,258 grams of black tar heroin. 
According to the HPD, black tar heroin prices re-
mained stable in Honolulu at $50–$75 per one-
quarter gram, $150–$200 per half “teen” (1/6 ounce), 
and $2,500–$3,000 per ounce (exhibit 1). 
 
Heroin treatment admissions continued the decline 
begun in 1999 (exhibit 4). In 1998, record levels of 
treatment admissions were recorded, with more than 
500 individual admissions that year. In 2004, how-
ever, heroin ranked fifth among treatment admissions 
at 2.1 percent (n=175).  
 
The Honolulu ME reported that deaths in which opi-
ates were detected have declined in 2004, however, 
the residuals of heroin versus other opiates could not 
be definitively separated for several cases. For now, 
only 12 heroin deaths are confirmed for 2004 (exhibit 
4). Decedents with a positive toxicological result for 
other opiates were primarily comprised of those in 
whom oxycodone or methadone were detected. The 
exact medication (OxyContin® or another) used was 
not specified. However, the 15 decedents with oxy-
codone in their toxicology screens represent a death 
rate for the city and county of Honolulu of 17.2 per 
1,000,000 persons. An additional concern was ex-
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pressed by the Medical Examiner’s office this year, 
and that was with respect to methadone. Previously, 
the ME had been asked to review its records and to 
monitor the appearance of methadone among dece-
dents. In 2004, there were 25 decedents with a posi-
tive toxicology screen for methadone, compared with 
22 in 2003 and 28 in 2002. 
 
The HPD reported 25 heroin cases in 2001, 44 in 
2002, 30 in 2003, and 34 in 2004 (exhibit 5). In spite 
of the very high number of cases reported in 1998, 
the decade-long trend in heroin cases is a downward 
one from the 54 cases reported in 1995. 
 
According to the Domestic Monitor Program 2003 
Report, “In response to reports of a black tar heroin 
problem in Hawaii, a Geo-Probe was conducted in 
Honolulu in July and August 2003. This probe 
marked the first instance of DMP purchases made 
outside of the continental United States. Black tar 
heroin is popular in the islands because of the price—
approximately $100 to $200 per gram. This price is 
substantially cheaper than that for white powder her-
oin, which is very rarely encountered, but which is 
sold locally for approximately double the price of 
black tar. The Geo-Probe resulted in the purchase of 
five exhibits, three of which were qualified samples 
determined to be MEX heroin averaging approxi-
mately 51.3 percent pure. The samples cost, on aver-
age, $0.95 per milligram pure. Honolulu’s average 
price was comparable to San Francisco’s, but the 
purity levels were more than four times as high as 
San Francisco’s, and higher than other Pacific coast 
DMP cities.” 
 
Marijuana 
 
Statewide, marijuana treatment admissions decreased 
slightly in 2004, with only 1,461 reported for the year 
(exhibit 6). There was an increase in 2003, following 
the slight decline in admissions in 2002. Those ad-
mitted for treatment in 2004 continue to be younger 
persons referred by the courts. In examining these 
treatment data, it is important to remember that the 
number of persons in treatment for marijuana use in 
2004 was triple the number in treatment in 1992. It is 
also important to note that while marijuana is listed 
as the primary drug of use at admission, many users 
of other drugs use marijuana as a secondary or terti-
ary drug of choice. 
 
Between 1994 and 1999, the O'ahu ME reported 12–
21 deaths per year in which marijuana was found in 
the specimens submitted for toxicology screening 
(exhibit 6). Those numbers increased to 25 in 2000, 
36 in 2001, 30 in 2002, 32 in 2003, and 31 in 2004. 
Again, in most instances, marijuana was used with 
other drugs if there was a drug-related death. 
 
The HPD continues to monitor, but to not specifically 
report, case data for marijuana. As mentioned in pre-
vious CEWG reports, possession cases are steady at 
about 650 per year, although distribution cases have 
continued to increase. Law enforcement sources 
speculate that much of the Big Island's marijuana is 
brought to O'ahu for sale.  Exhibit 7 shows Honolulu 
police case data for marijuana. 
 
As shown in exhibit 1, marijuana cost $5–$20 per 
joint, $25 per gram, and $6,000–$9,000 per pound in 
2004. 
 
Methamphetamine 
 
Hawai'i’s drug of choice among the 18–34-year-old 
population group remains crystal methamphetamine. 
The California-based Mexican sources use Hawai'i’s 
cultural diversity to facilitate smuggling and distribu-
tion to and within the islands. Analysis of confiscated 
methamphetamine reveals that the product is still a 
high-quality d-methamphetamine hydrochloride in 
the 90–100-percent purity range, which makes it 
ideal for smoking (the route of admission of choice). 
 
Methamphetamine treatment admissions remained 
extremely high (accounting for 45 percent of admis-
sions in 2004), continuing the increase in admissions 
observed for the past 13 years (exhibit 8). In 2003, 
there were 3,182 such admissions, up from 2,677 in 
2002. The rate of increase in demand for treatment 
space for methamphetamine abusers has been nearly 
2,000 percent since 1991. This situation has so far 
outstripped the treatment system's capacity, that peo-
ple who might want treatment for alcohol or any 
other drug would not likely receive it in a timely 
manner. With court diversion programs in place, the 
available treatment slots for non-judicial treatment 
admissions are extremely tight. 
 
Between 1994 and 2000, the O'ahu ME mentioned 
crystal methamphetamine in 24–38 cases per year 
(exhibit 8). In 2001, that number jumped to 54, and 
methamphetamine-positive decedents increased to 62 
in 2002. In 2003, the number of decedents with ice 
detected in their toxicology reports was 56. For 2004, 
there were 67 deaths with positive toxicology results 
for methamphetamine, representing 76.5 deaths per 
1,000,000 for the island of O'ahu. 
 
Crystal methamphetamine prices remained stable in 
2004. The drug is sold in the islands as "clear" (a 
clear, white form) or "wash" (a brownish, less proc-
essed form). Prices for ice vary widely according to 
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these two categories and availability, as illustrated by 
prices on O'ahu: $50 (wash) or $75 (clear) per 0.25 
gram; $200–$300 (wash) or $600–$900 (clear) per 
gram; $450–$600 (wash) or $1,000–$2,000 (clear) 
per one-quarter ounce; and $2,200–$3,000 (wash) per 
ounce. 
 
HPD methamphetamine case data peaked at 984 in 
1995 (exhibit 9). The annual number of cases subse-
quently declined annually, and they totaled 616 in 
2002 and 964 in 2003. In 2004, a total of 883 cases 
were reported. Minimal data are available from the 
neighbor islands, but they also show an increase in 
cases. 
 
NFLIS data for FY 2003 and FY 2004 show that 
methamphetamine was the most often seized sub-
stance, with 62 percent of the FY 2003 and 57 per-
cent of the FY 2004 samples testing positive for 
methamphetamine.  
 
Depressants 
 
Barbiturates, sedatives, and sedatives/hypnotics are 
combined into this category. Few data were provided 
about these drugs in the islands. 
 
ADAD maintains three categories under this heading: 
benzodiazepines, other tranquilizers, and barbiturates. 
Treatment admissions for these drugs are minimal in 
terms of impact on the system. Annually, the num-
bers admitted to treatment for these drugs total less 
than 10.  
 
The number of ME mentions for depressants has re-
mained stable for several years at five or less. 
 
The HPD has not reported depressant case data since 
1991. Neighbor island police reported fewer than 15 
cases per year since 1996. 
 
Prices remain stable at $3–$20 per unit for barbitu-
rates and $2–$3 per pill for secobarbital (Seconal or 
"reds"). 
 
Hallucinogens 
 
Hallucinogen treatment admissions total less than 
five per year. No hallucinogen ME mentions have 
been reported since the beginning of data collection. 
 
Prices for lysergic acid diethylamide (LSD) were $4–
$6 per "hit" and $225–$275 per 100 dosage unit 
sheets (a "page") in this reporting period. 
 
A Final Point 
 
An examination of Exhibit 10 shows that over the 
past 13 years, Honolulu Police Department drug 
cases have varied considerably. Brief descriptions of 
drug trends, as seen from the interdiction view, were 
very complex in the early 1990s, with similar num-
bers of cases for cocaine, methamphetamine, and 
marijuana. In addition it is important to note that the 
accumulation of drug cases in 1993–1995 was quite 
high (1,752 for marijuana, cocaine, and metham-
phetamine). With no marijuana cases reported by 
HPD in 1996, the accumulated numbers for metham-
phetamine and cocaine was 1,720 cases, with cocaine 
accounting for 70 percent of the cases. 
 
By 2000, cocaine, methamphetamine, and marijuana 
accounted for only 1,097 cases, with methampheta-
mine accounting for more cases than the other two 
drugs combined. In 2004, there were 1,257 cases for 
these three drugs, with methamphetamine represent-
ing 70 percent of the cases. 
 
For inquiries concerning this report, please contact D. William 
Wood, Ph.D., Department of Sociology, University of Hawai’i at 
Manoa, 265 North Kalaheo Avenue, Honolulu, HI  96822, Phone:  
250-384-3748, Fax:  808-965-3707, E-mail:  dwwood@shaw.ca. 
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Exhibit 1. Drug Prices in Honolulu:  2004 
 
Drug Paper (1/4 Gram) 
½ Teen 
(0.88 Grams) 
8 Ball 
(1/8 Ounce) 
Quarter 
(1/4 Ounce) 
“O” 
(1 Ounce) 
“LBs” 
(1 Pound) 
“Kilos” 
(1 Kilogram) 
Heroin (White) $50 $200–$300  $2,000–$3,000 $5,000 $50,000 $100,000 
Heroin (Black 
Tar) $50–$75 $150–$200  $750 
$2,500–
$3,000 N/A
1 N/A 
Cocaine $25–$35 $100–$120 $500–$600 $250–$350  
$1,100–
$1,500 
$13,500–
$25,000 
$26,500–
$52,000 
Rock Cocaine $100  $200–$300    N/A 
Crack Cocaine $25–$30 $100–$250   $1,000–$1,500 $24,000  
Crystal 
Methampheta-
mine (Wash) 
$50 $200–$300 $450–$600  $2,200–$3,000 $30,000 
$50,000–
$70,000 
LSD $4–$6 per hit   $225–$275per 100 hits    
Marijuana   $5–$20 per joint $25 $100–$200  $400–$800 
$6,000–
$9,000 N/A 
Hashish N/A $10 $40–$60  $150–$300  $1,400–$1,800 
Dilaudids $40–$80 per capsule       
MDMA $25–$40 each       
Phencyclidine 
(PCP) $10–$20 $100  $350–$550 $900–$1,200 N/A N/A 
 
1N/A= Not available. 
SOURCE: Honolulu Police Department 
 
 
 
Exhibit 2. Cocaine-Related Death1 and Treatment Data in Hawaii:  1991–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1To allow direct comparison between ME data and treatment data, the ME data have been multiplied by 10. 
SOURCES: Honolulu Medical Examiner and Department of Health, Alcohol and Drug Abuse Division 
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Exhibit 3. Cocaine-Related Police Cases in Honolulu:  1991–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE: Honolulu Police Department 
 
 
 
 
Exhibit 4. Heroin and Opiate Deaths1 and Heroin Treatment Admissions in Hawaii:  1991–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1To allow direct comparison between O’ahu ME data and treatment data, the O’ahu ME data have been multiplied by 10. 
SOURCES:  Honolulu Medical Examiner and Department of Health, Alcohol and Drug Abuse Division 
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Exhibit 5. Heroin-Related Police Case Data in Honolulu:  1991–2004 
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SOURCE: Honolulu Police Department 
 
 
 
 
Exhibit 6. Marijuana-Related Deaths1 and Treatment Admissions in Hawaii:  1991–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1To allow direct comparison between O’ahu ME data and treatment data, the O’ahu ME data have been multiplied by 10. 
SOURCES: Honolulu Medical Examiner and Department of Health, Alcohol and Drug Abuse Division 
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Exhibit 7. Marijuana-Related Police Case Data in Honolulu:  1991–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE: Honolulu Police Department 
 
 
 
 
Exhibit 8. Methamphetamine-Related Deaths1 and Treatment Admissions in Hawaii:  1991–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1To allow direct comparison between O’ahu ME data and treatment data, the O’ahu ME data have been multiplied by 10. 
SOURCES: Honolulu Medical Examiner and Department of Health, Alcohol and Drug Abuse Division 
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Exhibit 9. Methamphetamine-Related Police Case Data in Honolulu:  1991–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE: Honolulu Police Department 
  
 
 
 
 
Exhibit 10. Honolulu Police Department Cases, by Drug and Year:  1991–2004 
 
0
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Cases
Cocaine 316 648 613 901 1056 1218 1045 874 385 225 153 122 202 239
Heroin 43 35 54 49 39 87 71 53 25 44 30 34
Marijuana 608 670 237 492 569 92 136 173 115 146 98 135
Methamphetamine 260 434 915 589 984 502 742 602 583 699 631 616 964 883
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
 
SOURCE: Honolulu Police Department 
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A Semiannual Update of 
Drug Abuse Patterns and 
Trends in Los Angeles 
County, California 
 
Beth Finnerty, M.P.H.1 
 
ABSTRACT 
 
Two main themes dominate Los Angeles County-
level substance abuse indicator data in the current 
reporting period (through December 2004): (1) a 
relatively stable or mixed pattern for many drugs 
and (2) increasing patterns for methamphetamine. 
Los Angeles is the only city that is a primary drug 
market (i.e., distribution hub, transshipment area, 
and final destination) for all five major drugs (i.e., 
heroin, cocaine/crack, marijuana, methampheta-
mine, and MDMA). With regards to treatment admis-
sions, for the first time, a higher proportion of Los 
Angeles County treatment admissions were for pri-
mary methamphetamine abuse (5,395 admissions; 
23.4 percent of the total) than for primary heroin 
abuse (5,341 admissions; 23.2 percent of the total). 
The proportion of cocaine/crack admissions re-
mained stable at 18 percent, and primary marijuana 
admissions continued to creep to 14.4 percent of the 
total. Once again, the Los Angeles HIDTA led all 
California HIDTAs in terms of clandestine metham-
phetamine laboratory seizures, accounting for more 
than one-half of the 449 seizures made in California 
in 2004. Even though four States had more labora-
tory seizures than California, and despite the steady 
decline in the number of methamphetamine labora-
tories throughout the State, California remains the 
home of the domestic methamphetamine ‘superlab.’ 
Seventy-five percent of the 48 superlabs seized 
throughout the United States were located in Cali-
fornia; 64 percent of those were located in four 
southern California counties: Los Angeles, San Ber-
nardino, Orange, and Riverside. Drug prices and 
purities were relatively stable in the second half of 
2004, with small changes occurring at the midlevel 
and retail level for certain drugs. Los Angeles 
County-level California Poison Control System major 
drug exposure calls in the first half of 2004 were 
dominated by cocaine/crack, methampheta-
mine/amphetamine, ecstasy, and heroin. Further-
more, among prescription and over-the-counter 
medication-related exposure calls, benzodiazepines 
were the most frequently mentioned category, fol-
                                                 
1 The author is affiliated with UCLA Integrated Substance Abuse 
Programs, Los Angeles, California. 
lowed by opiates/analgesics and Coricidin HBP. Ado-
lescent substance use data gathered from the Cali-
fornia Healthy Kids Survey for the 2003–2004 school 
year illustrated that lifetime and past-month usage 
percentages among Los Angeles County secondary 
school students in grades 7, 9, and 11 were either the 
same or lower than percentages reported in previous 
school years. Aside from alcohol, students were most 
likely to report lifetime marijuana use (20 percent), 
followed by inhalants (13 percent), cocaine or 
methamphetamine (each at 7 percent), and LSD/ 
other psychedelics or ecstasy (each at 6 percent). In-
dicator data for prescription drugs, PCP, LSD, 
MDMA (ecstasy), and GHB remained limited, but 
use and abuse are reported among some of the non-
traditional indicators.  
 
INTRODUCTION 
 
Area Description 
 
Los Angeles County has the largest population 
(9,937,739, 2004 estimate) of any county in the Na-
tion. If Los Angeles County were a State, it would 
rank ninth in population behind California, New 
York, Texas, Florida, Pennsylvania, Illinois, Ohio, 
and Michigan. Approximately 29 percent of Califor-
nia’s residents live in Los Angeles County. The 
population of Los Angeles County has increased 3.7 
percent since the 2000 Census. Nearly 90 percent of 
all Los Angeles County residents live within 88 in-
corporated cities; the remaining 10 percent reside in 
unincorporated areas of the county. The five most 
populated cities are, in descending order of population, 
Los Angeles (3,694,820), Long Beach (461,522), 
Glendale (194,973), Santa Clarita (151,088), and 
Pomona (149,473).  
 
Just over one-half of all Los Angeles County resi-
dents are female (50.6 percent) (exhibit 1). More than 
one-quarter (28.0 percent) are younger than 18; 9.7 
percent are older than 65. The racial and ethnic com-
position of Los Angeles County residents is quite 
diverse. Of those residents who report being of one 
race, just under one-half identify as White (48.7 per-
cent), followed by Asians (11.9 percent), Blacks/Afri-
can-Americans (9.8 percent), American Indians/Alaska 
Natives (0.8 percent), and Native Hawaiians/Other 
Pacific Islanders (0.3 percent). About one-quarter of 
residents (23.5 percent) identify with another race (not 
specified). Furthermore, 5 percent report two or more 
races. Residents of Hispanic/Latino origin may be of 
any race. Therefore, they are included in the appropri-
ate racial categories above. Nearly 45 percent of Los 
Angeles County residents are of Hispanic/Latino 
origin; approximately 31 percent of Whites are not of 
Hispanic/Latino origin.  
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According to an April 2004 Policy Brief from United 
American Indian Involvement and the UCLA Ralph 
and Goldy Lewis Center for Regional Policy Studies, 
3 percent of the Nation’s 3.7 million American Indi-
ans/Alaska Natives (AIs/ANs) reside in the Los An-
geles area. The largest concentration of urbanized 
AIs/ANs is located in the county. Furthermore, the 
local AI/AN population grew 35 percent from the 
1990 to the 2000 U.S. census, compared to the over-
all county growth of 7 percent.   
 
Los Angeles County encompasses approximately 
4,080 square miles and includes the islands of San 
Clemente and Santa Catalina. The county is bordered 
on the east by Orange and San Bernardino Counties, 
on the north by Kern County, on the west by Ventura 
County, and on the south by the Pacific Ocean. Los 
Angeles County’s coastline is 81 miles long.  
 
Two of the busiest maritime ports in the world—
Long Beach and Los Angeles—are located in Los 
Angeles County. The Port of Long Beach is the Na-
tion’s busiest maritime cargo container facility, while 
the Port of Los Angeles ranks second, according to a 
report by the National Drug Intelligence Center 
(NDIC) in 2001. Los Angeles County is also home to 
the world’s third busiest airport—Los Angeles Inter-
national Airport. The airport handles more than 1,000 
cargo flights each day; 50 percent of this activity is 
international in origin or destination (NDIC 2001).  
 
Residents of Los Angeles County primarily rely on 
automobiles for transportation, and the Los Angeles 
area has one of the most intricate highway systems in 
the world. Of these, Interstates 5, 10, and 15 connect 
the area to the rest of the Nation. Interstate 5 runs 
from the U.S.-Canada border to the U.S.-Mexico 
border and links Los Angeles to other key west coast 
cities, such as San Diego, Oakland, San Francisco, 
Sacramento, Portland, and Seattle. Interstate 10 
originates in Santa Monica, California, and runs 
across the United States to I-95 in Jacksonville, Flor-
ida; Interstate 15 originates in the area and runs 
northeast through Las Vegas, Nevada, to the U.S.-
Canada border in Montana. In addition, State high-
ways 1 and 101 are extensively traveled roadways.  
 
The National Drug Threat Assessment 2005 identi-
fied 12 primary drug market areas throughout the 
United States that serve as major consumption and 
distribution centers of cocaine, marijuana, metham-
phetamine, heroin, and methylenedioxymetham-
phetamine (MDMA or ecstasy). California is one of 
the most active drug smuggling and production areas 
in the United States and contains three market ar-
eas—Los Angeles, San Diego, and San Francisco. 
This is caused, in part, by the State’s proximity to the 
Pacific Ocean and Mexico. Los Angeles is a national-
level transportation hub and distribution center, and it 
is the only primary market for all five of the major 
drugs of abuse listed above (NDIC 2005).  
 
Data Sources 
 
This report describes drug abuse trends in Los Ange-
les County from January 1998 to December 2004. 
Information was collected from the following 
sources: 
 
• Drug treatment data were derived from the 
California Department of Alcohol and Drug Pro-
grams (ADP), California Alcohol and Drug Data 
System (CADDS), and correspond to Los Ange-
les County alcohol and other drug treatment and 
recovery program admissions for July 2001 to 
December 2004. This is the first semiannual re-
port for which user demographic data are pre-
sented by route of administration for the major 
drugs of abuse (including cocaine/crack, heroin, 
and methamphetamine). It should be noted that 
admissions for heroin treatment are dispropor-
tionately represented because of reporting re-
quirements for facilities that use narcotic re-
placement therapy to treat heroin users. Both pri-
vate and publicly funded narcotic treatment 
providers must report their admissions to the 
State, while for other drug types, only publicly 
funded providers must report.  
 
• DAWN emergency department (ED) data for 
the Los Angeles division (i.e., Los Angeles 
County only) of the Los Angeles metropolitan 
area were accessed from the Office of Applied 
Studies (OAS), Substance Abuse and Mental 
Health Services Administration (SAMHSA)’s 
restricted-access database—DAWN Live!—for 
calendar year 2004 (based on updates from April 
13–14, 2005, and June 10, 2005). Thirty-four of 
the 79 eligible hospitals in the Los Angeles area 
are in the DAWN sample. The sample includes 
37 emergency departments (some hospitals have 
more than 1 ED). The data are incomplete and 
are based on 9 to 14 EDs reporting each month 
over the 12-month period (exhibit 2). The data 
are unweighted and, thus, are not estimates for 
the Los Angeles area. The data cannot be com-
pared to DAWN data for 2002 and before, nor 
can the preliminary data be used for comparison 
with future data. Only weighted DAWN data re-
leased by SAMHSA can be used for trend analy-
sis. The preliminary unweighted data for calen-
dar year 2004 represent drug reports in drug-
related visits; reports exceed the number of vis-
its, since a patient may report use of multiple 
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drugs (up to six drugs and alcohol). The analysis 
for this paper includes the “major substances of 
abuse,” as well as prescription drug misuse. For 
major substances of abuse, all case types are in-
cluded (i.e., suicide attempt, seeking detoxifica-
tion, alcohol only [<21], adverse reaction, over-
medication, malicious poisoning, accidental in-
gestion, and other) (exhibit 3). For pharmaceuti-
cals (nonmedical use), only overmedication, ma-
licious poisoning, and other case types are in-
cluded. As noted earlier, the data included in this 
report are preliminary. All DAWN cases are re-
viewed for quality control. Based on this review, 
cases may be corrected or deleted. Therefore, 
preliminary data are subject to change. A full de-
scription of DAWN can be found at 
<http://www.dawninfo.samhsa.gov>. 
 
• Poison control center call data were accessed 
from the California Poison Control System 
(CPCS) for 2000 through June 2004. The CPCS 
provides poison information and telephone man-
agement advice and consultation about toxic ex-
posures; hazard surveillance to achieve hazard 
elimination; and professional and public educa-
tion on poison prevention, diagnosis, and treat-
ment. The information obtained from the CPCS 
includes calls in which there was a confirmed 
exposure to an illicit substance (e.g., cocaine, 
heroin, marijuana, ecstasy, etc.), a prescription 
drug or substance with common household uses, 
or a combination of both. The statistical analysis 
contained in this report is preliminary and fo-
cuses mostly on illicit substances; more indepth 
analyses of the prescription and household sub-
stance categories will be conducted for future 
area reports.   
 
• Drug availability, price, purity, seizure, and 
distribution data were derived from the Los An-
geles Police Department (LAPD), the Los Ange-
les High Intensity Drug Trafficking Area 
(HIDTA), the Los Angeles County Regional 
Criminal Information Clearinghouse (LA 
CLEAR), the National Drug Intelligence Center, 
and the Drug Enforcement Administration (DEA).  
 
• Drug analysis results from local forensic labo-
ratories were derived from the Drug Enforce-
ment Administration, National Forensic Labora-
tory Information System (NFLIS). The statistics 
correspond to items analyzed between January 1, 
2004, and December 31, 2004. It is important to 
note that data from the Los Angeles County 
Sheriff’s Department laboratory are complete, 
but data from the LAPD laboratory are not com-
plete for some months.  
• Demographic and geographic data were pro-
vided by the United Way of Greater Los Ange-
les, Los Angeles County Online, United Ameri-
can Indian Involvement, the UCLA Ralph and 
Goldy Lewis Center for Regional Policy Studies, 
and the U.S. Census Bureau (State and County 
QuickFacts).  
 
• Adolescent substance use statistics were ac-
cessed from the Los Angeles County-level Cali-
fornia Healthy Kids Survey (CHKS) data for the 
1997–1998, 1998–1999, 1999–2000, 2000–2001, 
2001–2002, 2002–2003, and 2003–2004 school 
years from WestEd. The CHKS is a modular 
survey that assesses the overall health of secon-
dary school students (in grades 7, 9, 11, and a 
small sample of nontraditional school students). 
In California, Local Education Agencies (LEAs) 
and County Offices of Education (COEs) that 
accept funds under the Federal Title IV Safe and 
Drug Free Schools and Communities (SDFSC) 
program or the State Tobacco Use Prevention 
Education (TUPE) program must administer the 
CHKS at least once every 2 years. Individual 
school districts are given the opportunity to ad-
minister the survey in every school year, how-
ever, if the resources exist to do so. Section A 
(Core Module) includes questions on lifetime 
and past-30-day use of alcohol, drugs, and to-
bacco. Another module (Section C) is comprised 
of additional questions related to alcohol and 
drug use, violence, and safety.  
 
• Acquired immunodeficiency syndrome (AIDS) 
and human immunodeficiency virus (HIV) 
data (cumulative through December 2004) were 
provided by the Los Angeles County Department 
of Health Services, HIV Epidemiology Program, 
Advanced HIV (AIDS) Quarterly Surveillance 
Summary, January 2005. 
 
DRUG ABUSE PATTERNS AND TRENDS 
 
Cocaine/Crack 
 
Approximately 18 percent of all Los Angeles County 
treatment and recovery program admissions in July–
December 2004 reported a primary crack or powder 
cocaine problem (exhibit 4). The total number of 
primary cocaine/crack admissions decreased 20 per-
cent from the first to the second half of 2004. But as a 
percentage of the total, cocaine admissions have re-
mained quite stable at 18–20 percent for several 
CEWG reporting periods (exhibit 5). Alcohol was the 
most commonly reported secondary drug problem 
among primary cocaine admissions (37 percent) (ex-
hibit 6), followed by marijuana (18 percent). Smok-
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ing is the reported route of administration for 86 per-
cent of all cocaine admissions, followed by inhalation 
(10 percent). When asked whether they had used any 
drug intravenously in the year prior to admission, 
approximately 4 percent of all primary cocaine ad-
missions reported that they had used needles to ad-
minister one or more drugs intravenously at least 
once during the specified time period (exhibit 6a).   
 
Sixty-six percent of the primary cocaine admissions 
reported in the second half of 2004 were male, simi-
lar to the gender breakdown seen in the first half of 
the year. Black non-Hispanics continued to dominate 
cocaine admissions (at 56 percent), followed by His-
panics (22 percent) and White non-Hispanics (16 
percent). In terms of age at admission, nearly 40 per-
cent were concentrated in the 36–45 year age group; 
an additional 23 percent of all primary cocaine ad-
missions were between the ages of 26 and 35.  
 
Primary cocaine treatment admissions are more likely 
than treatment admissions for any other substance 
(alcohol, prescription medications, or illicit drugs) to 
report being homeless at admission (28 percent). The 
proportion of cocaine admissions referred to treat-
ment through the criminal justice system in the sec-
ond half of 2004 continued to decrease to 16 percent 
of all admissions (down from 20 percent in the first 
half of the year). More frequently mentioned referral 
sources included self-referral (33 percent) or referral 
through Proposition 36 (a.k.a., SACPA) 
court/probation (31 percent). Although slightly more 
than one-third of primary cocaine admissions had 
never been admitted to treatment for a primary co-
caine problem, 44 percent had one or two prior 
treatment episodes. Forty-three percent had earned a 
high school diploma or GED. At the time of admis-
sion, approximately 15 percent were employed either 
full- or part-time.   
 
Cocaine injectors were more likely than cocaine in-
halers or crack smokers to be White non-Hispanic 
(70 percent), 36 or older (70 percent), homeless (53 
percent), or to have been through four or more prior 
treatment episodes (21 percent). Crack smokers were 
more likely than cocaine inhalers or injectors to be 
male (64 percent), Black non-Hispanic (63 percent), 
or have a high school diploma/GED (43 percent). 
Lastly, cocaine inhalers were more likely than their 
counterparts to be Hispanic (56 percent) or employed 
full- or part-time (40 percent). 
 
Preliminary unweighted data accessed from DAWN 
Live! for calendar year 2004 indicate that of the 8,982 
major substances of abuse reported in the Los Ange- 
 
 
les division, 2,348 (26 percent) were cocaine/crack 
(exhibit 7). Cocaine was the second most likely major 
substance to be reported, following alcohol. Sixty-
eight percent of the patients reporting cocaine use 
were male; 44 percent were Black (followed by 28 
percent Hispanic and 23 percent White); 33 percent 
were age 35–44; and 54 percent reported smoking 
crack. A total of 5,067 chief complaints were logged 
for patients reporting cocaine. The top three specific 
complaints were intoxication (973 complaints), psy-
chiatric condition (943 complaints), and altered men-
tal status (868 complaints). Cocaine-using patients 
were most likely to be discharged home (44 percent) 
or admitted to a psychiatric unit (25 percent).  
 
California Poison Control System calls involving the 
use of cocaine/crack by Los Angeles County resi-
dents increased from 69 in 2000 to a high of 97 in 
2003. In the first 6 months of 2004 alone, 41 calls 
involving cocaine/crack were received (exhibit 8a). 
Between January 2003 and June 2004, 68 percent of 
the cocaine-exposed callers were male, and 51 per-
cent were between the ages of 26 and 44 (exhibit 9). 
An additional 21 percent were between the ages of 18 
and 25.   
 
According to CHKS data for the 2003–2004 school 
year (exhibit 10), 7.4 percent of all Los Angeles 
County secondary school students (including 7th, 9th, 
and 11th graders, and a small sample of nontradi-
tional students) who responded to the survey had ever 
used cocaine (crack or powder), and 3.8 percent were 
current cocaine users (defined as any use in the past 
30 days). A breakdown of the data by grade level 
illustrated that among responding ninth graders, 5.4 
percent had ever used cocaine and 3.0 percent were 
current cocaine users. A higher percentage of 11th 
graders than 9th graders reported current co-
caine/crack use in the past 30 days. Of the lifetime 
cocaine users, 55 percent were male and 45 percent 
were female. The gender distribution was slightly 
wider for past-30-day use of cocaine (63 percent 
male vs. 37 percent female). Frequent cocaine use is 
defined as 20 or more days of use in the previous 30 
days. Twenty-four percent of the current cocaine us-
ers reported frequent use. Among the frequent users, 
74 percent were male. When asked about past-6-
month use of cocaine (any form), methamphetamine, 
or other stimulants, 7.1 percent of 9th graders and 6.5 
percent of 11th graders responded in the affirmative 
(exhibit 11).    
 
According to long-term trends calculated from CHKS 
data spanning over the most recent 5 school years 
(exhibit 12), the pattern of past-30-day cocaine 
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(powder or crack) use among responding secondary 
school students was similar to usage patterns for 
some of the other licit and illicit drugs, such as lyser-
gic acid diethylamide (LSD)/other psychedelics and 
methamphetamine. Past-30-day cocaine/crack use 
decreased consistently from the peak level seen in 
1999–2000 (4.9 percent) to 3.8 percent in 2002–
2003. In 2003–2004, current cocaine use remained 
stable at 3.8 percent of all respondents.   
 
A total of 10,717 cocaine arrests were made within the 
city of Los Angeles in calendar year 2004. This repre-
sented a 3-percent deficit from the number of cocaine 
arrests made during the same time period in 2003. Co-
caine arrests accounted for 30 percent of all narcotics 
arrests made between January 1 and December 31, 
2004.  
 
Citywide cocaine (including crack and powder) sei-
zures increased 31 percent, from 1,835 pounds seized 
in the first half of 2003 to 2,404 pounds seized in 
2004. The street value of the seized cocaine accounted 
for 29 percent of the total street value of all drugs 
seized in 2004. 
 
Data from NFLIS for calendar year 2004 showed that 
out of 54,916 analyzed items reported by participating 
laboratories within Los Angeles County, 38.3 percent 
(21,037) of all items analyzed were found to be co-
caine/crack. Cocaine/crack was the most likely illicit 
drug to be found among items tested in the county, 
followed closely by methamphetamine and more dis-
tantly by cannabis.  
 
Los Angeles remains one of the primary markets for 
cocaine (in addition to Houston, Chicago, New York, 
Atlanta, and Miami; NDIC 2004). Mexican and Co-
lombian traffickers control the wholesale distribution 
of cocaine and crack in Los Angeles; African-
American and Hispanic street gangs control distribu-
tion at the retail level. All substance use and abuse 
indicators are higher for crack than for powder co-
caine. Despite this, powder cocaine availability and 
use is reported in the area. Current midlevel prices of 
crack cocaine remained level (as compared to the 
January 2005 report) at $500–$1,200 per ounce (ex-
hibit 13), as did the retail price range ($10–$40 per 
rock). The current wholesale price for 1 kilogram of 
powder cocaine ranges from $14,000 to $17,000, 
which is identical to the wholesale price cited in the 
past few CEWG reports. The current midlevel and 
retail prices of powder cocaine remained stable, as 
well, at $500–$600 per ounce and $80 per gram. The 
purity of powder cocaine is approximately 78 percent, 
similar to the purity cited in the last few CEWG re-
ports.  
 
Heroin 
 
From July to December 2004, 5,341 Los Angeles 
County treatment and recovery program admissions 
were attributable to primary heroin abuse, compared 
with 6,942 admissions reported in the county in the 
first half of 2004 (exhibit 4). In 2003, it was thought 
that heroin admissions were leveling off at roughly 
25.4 percent of all admissions, after several half-year 
decreases. In the first half of 2004, however, the pro-
portion of primary heroin admissions among all Los 
Angeles County treatment and recovery programs 
decreased slightly to 24.5 percent of all admissions. 
And in the second half of 2004, the percentage of 
primary heroin admissions continued to fall to 23.2 
percent of all admissions. For the first time ever, 
methamphetamine surpassed heroin as the most fre-
quently mentioned primary drug among treatment 
admissions (by a very small margin).  
 
Demographics of heroin admissions have remained 
stable over recent reporting periods. In the second 
half of 2004, primary heroin admissions were 
predominantly male (72 percent), most likely to be 
age 45–50 (22 percent), and somewhat more likely to 
be Hispanic (42 percent) than White non-Hispanic 
(39 percent) or Black non-Hispanic (11 percent) 
(exhibit 6). Compared with other major types of illicit 
drug admissions, primary heroin admissions in the 
first half of 2004 had the largest proportion of users 
age 36 and older (74 percent). Just over one-third (36 
percent) of all primary heroin admissions initiated 
their heroin use prior to age 18, which is quite low 
compared to other primary substances, such as alco-
hol, marijuana, methamphetamine, and phencyclidine 
(PCP). If primary heroin admissions abused another 
drug secondarily to heroin, it was most likely to be 
cocaine/crack (24 percent), followed by alcohol (11 
percent).  
 
Heroin administration patterns remained relatively 
stable in the second half of 2004, with injectors ac-
counting for 85 percent, smokers accounting for 8 
percent, and inhalers (snorters) accounting for 5 per-
cent (exhibit 6). When asked whether they had used 
any drug intravenously in the year prior to admission, 
88 percent of all primary heroin admissions reported 
that they had used needles to administer one or more 
drugs intravenously at least once during the specified 
time period.  
 
Sixteen percent of all primary heroin admissions 
were homeless at time of admission, and only 4 per-
cent were referred by the court or criminal justice 
system. Primary heroin users were most likely to  
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have self-referred for the current treatment episode 
(77 percent of all heroin admissions, up from 72 per-
cent in the first half of 2004). In a measure of current 
legal status, the majority (77 percent) were not in-
volved at all with the criminal justice system. This 
corroborates with the very low proportion of criminal 
justice referrals among primary heroin users. Seven-
teen percent indicated that they had never received 
treatment for their heroin problem, whereas 51 per-
cent reported three or more primary heroin treatment 
episodes. Forty-five percent of all primary heroin 
admissions graduated from high school (down from 
49 percent), and, at the time of admission, 24 percent 
were employed full- or part-time (an increase from 
20 percent in the first half of 2004). 
 
Heroin injectors were more likely than their inhaler 
or smoker counterparts to be Black non-Hispanic (22 
percent), homeless (16 percent), or to have been 
through four or more prior treatment episodes (42 
percent). Heroin smokers were more likely than her-
oin inhalers or injectors to be White non-Hispanic 
(65 percent), employed full- or part-time (39 per-
cent), or have a high school diploma/GED (53 per-
cent). Lastly, heroin inhalers were more likely than 
their counterparts to be male (76 percent), Hispanic 
(61 percent), and 36 and older (89 percent). 
 
Preliminary unweighted data accessed from DAWN 
Live! for calendar year 2004 indicate that of the 8,982 
major substances of abuse reported in the Los Ange-
les division, 712 (8 percent) were heroin (exhibit 7). 
Heroin was the fifth most likely major substance to 
be reported, following alcohol, cocaine, stimulants 
(amphetamines and methamphetamine), and mari-
juana. Seventy-three percent of the patients reporting 
heroin use were male; 43 percent were Hispanic (fol-
lowed by 35 percent White and 20 percent Black); 35 
percent were age 45–54; and 82 percent reported in-
jecting heroin. A total of 1,438 chief complaints were 
logged for individuals reporting heroin. The top three 
complaints were altered mental status (235 com-
plaints), abscess/cellulitis/skin/tissue (231 com-
plaints), and intoxication (213 complaints). Heroin-
using patients were most likely to be discharged 
home (45 percent) or admitted to a psychiatric unit 
(17 percent).  
 
Los Angeles County-based California Poison Control 
System calls involving exposure to heroin fluctuated 
between 15 and 20 from 2000 to 2003 (exhibit 8a). In 
the first half of 2004 alone, 11 heroin exposure calls 
were reported, which may indicate a shifting upward 
trend. Between January 2003 and June 2004, 79 per-
cent of the heroin-exposed callers were male, and 67 
percent were between the ages of 26 and 54. An addi-
tional 11 percent of the callers were between the ages 
of 18 and 25.   
 
According to CHKS data for the 2003–2004 school 
year (exhibit 10), 3.3 percent of all Los Angeles 
County secondary school students (including 7th, 9th, 
and 11th graders, and a small sample of nontradi-
tional students) who responded to the survey had ever 
used heroin. A breakdown of the data by grade level 
illustrated that lifetime heroin use was nearly identi-
cal among responding 9th graders (3.1 percent) and 
11th graders (3.0 percent). When asked about past-6-
month use of other drugs, heroin, or sedatives, 6.3 
percent of 9th graders and 5.2 percent of 11th graders 
responded in the affirmative (exhibit 11).    
 
A total of 934 heroin arrests were made within the 
city of Los Angeles during calendar year 2004. This 
represented a 24-percent increase from the number of 
heroin arrests made in 2003. Heroin arrests accounted 
for approximately 2.6 percent of all narcotics arrests 
made from January 1 to December 31, 2004.  
 
Twenty pounds of black tar heroin were seized within 
the city of Los Angeles in 2004, a slight decrease of 7 
percent compared with the amount seized during the 
same time in 2003. Seizures of other types of heroin 
remained stable at approximately 16 pounds seized in 
2004. The street value of all seized heroin accounted 
for approximately 1 percent of the total street value of 
all drugs seized in 2004. 
 
According to NFLIS data based on 54,916 analyzed 
items reported by participating laboratories within Los 
Angeles County between January 1 and December 31, 
2004, only 4.1 percent (2,236) of all items analyzed 
were found to be heroin. This small proportion corre-
sponds to the small proportion of heroin (black tar and 
other forms) reported among Los Angeles City sei-
zures.  
 
As in the past, Los Angeles is the primary market for 
Mexican black tar heroin, and to a lesser extent, 
brown powder heroin distributed to other Western 
States (NDIC 2004). In addition, Mexican black tar 
heroin remains the predominant type of heroin used 
by Los Angeles County users. Mexican criminal 
groups control the transportation and wholesale, mid-
level, and retail activity (NDIC 2004). According to 
LA CLEAR, the wholesale price per kilogram of 
Mexican black tar heroin is approximately $20,000 
(the same price reported in the last few CEWG re-
ports) (exhibit 13). The current mid-level and retail 
prices are $500–$800 per “pedazo” (Mexican ounce) 
and $90–$100 per gram, which are stable since the 
last report. A regular ounce is 28.5 grams, whereas a 
pedazo is 25.0 grams.  
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Mexican brown powder heroin sells for a wholesale 
price of $25,000 per kilogram, when available in the 
area. Retail distribution of Southeast Asian heroin 
remains limited, but it is associated with a wholesale 
price range of $70,000–$80,000 per kilogram. The 
lack of China white on the streets is related, in part, 
to local users’ preference for black tar.  
 
The LA HIDTA and NDIC continue to report that Co-
lombian drug trafficking organizations may be estab-
lishing networks within the Los Angeles area to dis-
tribute South American heroin. The wholesale price 
for a kilogram of Colombian heroin is $86,000–
$100,000. This type of heroin has a purity level of 94 
percent. The LA HIDTA also reports that because the 
Los Angeles metropolitan area has one of the largest 
Middle Eastern populations in the United States, 
Southwest Asian opium trafficking activities have in-
creased in the area. Southwest Asian opium is associ-
ated with a cost of $650–$800 for an 18-gram stick.  
 
Other Opiates/Narcotics 
 
Other opiates/synthetics continue to constitute a mar-
ginal proportion of all Los Angeles County treatment 
admissions. Recently, their representation as a pri-
mary drug of abuse increased slightly in the local 
treatment data, rising from 1.5 percent of all admis-
sions in 1999 to 2.1 percent (583 admissions) in the 
first half of 2004. In the second half of 2004, how-
ever, the proportion of other opiates/synthetics 
dipped down to 1.6 percent of all admissions (373 
admissions). Despite the small overall numbers of 
admissions, it will be important to carefully monitor 
future treatment admissions data, given the increase 
in prescription opiate abuse/misuse in other major 
CEWG areas. Other opiates/synthetics admissions 
were typically male (64 percent), White non-Hispanic 
(76 percent), and age 36–50 (54 percent). None of the 
primary other opiate/synthetic admissions were 
younger than 18. Interestingly, 82 percent adminis-
tered other opiates/synthetics orally, but an additional 
15 percent reported smoking. Fifty-nine percent of 
primary other opiate/synthetic admissions reported no 
secondary or tertiary substance use. An additional 11 
percent reported secondary alcohol use, and 4 percent 
reported secondary cocaine/crack use. Reports of 
primary non-prescription methadone admissions con-
tinued to be minimal among Los Angeles County 
treatment admissions (23 admissions, 0.1 percent of 
all admissions).  
 
According to reports from many CEWG representa-
tives, non-heroin opiate users across the Nation have 
a definite preference of hydrocodone (i.e., Vicodin) 
over oxycodone (i.e., OxyContin) or vice versa. In 
Los Angeles, hydrocodone is much more likely to 
show up in the indicator data than oxycodone. This is 
evidenced by the fact that among NFLIS exhibits, 25 
percent of the analgesic samples were found to be 
hydrocodone (vs. 6 percent oxycodone); among 
DAWN opiate/opioid drug reports, 33 percent were 
hydrocodone (vs. 2 percent oxycodone); and among 
poison control calls for opiate/analgesic exposure, 60 
percent were for hydrocodone (vs. 11 percent for 
oxycodone). 
 
In addition to encompassing major substances of 
abuse, unweighted data accessed from DAWN Live! 
cover pharmaceutical drug categories, such as psy-
chotherapeutic agents (antidepressants, antipsychot-
ics, anxiolytics, sedatives and hypnotics, and central 
nervous system [CNS] stimulants), CNS agents (an-
algesics, anticonvulsants, antiparkinson agents, and 
muscle relaxants), respiratory agents, cardiovascular 
agents, and anti-infectives. The case types that are of 
interest for pharmaceuticals include seeking detoxifi-
cation, overmedication, and other. Of the 2,255 
pharmaceuticals falling within these three case types 
in calendar year 2004 in the Los Angeles division, 
387 (17 percent) were opiates/opioids (exhibit 14), 
and an additional 296 were other analgesics. For the 
opiates/opioids, “other” was the most frequently 
stated case type (56 percent of opiates/opioids), fol-
lowed by overmedication (35 percent) and more dis-
tantly by seeking detoxification (9 percent). Among 
other analgesics, 73 percent (215) of the drugs were 
reported as overmedication cases.   
 
Los Angeles County-based California Poison Control 
System calls involving exposure to opiates/analgesics 
increased from a low of 25 in 2000 to a high of 67 in 
2003 (exhibit 8b). In the first half of 2004 alone, 31 
opiate/analgesic exposure calls were reported, which 
may indicate a stabilizing of the trend line. Between 
January 2003 and June 2004, calls involving an expo-
sure to hydrocodone were more likely than calls in-
volving an exposure to oxycodone (58 calls vs. 11 
calls, respectively).  
 
Approximately 950 of the 54,916 items analyzed and 
reported to NFLIS between January 1 and December 
31, 2004, were identified as pharmaceuticals/prescrip-
tion/non-controlled non-narcotic medications (as op-
posed to illicit substances). Of those, a large proportion 
(401 items; 43 percent) were found to be narcotic/other 
analgesics. The most frequently cited analgesics were 
hydrocodone (224 items; 56 percent) and codeine (64 
items; 16 percent). Other analgesics identified included 
methadone (33 items), oxycodone (23 items), and pro-
poxyphene (11 items). To put these numbers/per-
centages into perspective, analgesics accounted for 0.7 
percent of all items analyzed by participating Los An-
geles County laboratories.  
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Efforts are underway throughout Los Angeles to quan-
tify the extent of pharmaceutical diversion to the street. 
One result of this effort is the availability of expanded 
prices for diverted opiates/analgesics. According to LA 
CLEAR, Vicodin, a member of the hydrocodone fam-
ily of opiate pain relievers, retails for $1 per 10-
milligram tablet in Los Angeles County (down from 
$5 per 5-milligram tablet reported in January 2005; 
exhibit 13). OxyContin, the trade name for the power-
ful analgesic oxycodone hydrochloride, sells on the 
streets for $50 to $80 per 80-milligram tablet. Percocet 
sells for $1–$5 per 5-milligram tablet (down from $5–
$10); MS Contin sells for $20 per 60-milligram tablet; 
codeine sells for $1–$2.50 per tablet (and $80–$200 
for a pint of liquid codeine); Dilaudid (hydromor-
phone) sells for $20–$60 per 4-milligram tablet (down 
from $100); fentanyl patches sell for $25–$100 each; 
and methadone sells for $10 per tablet.  
 
Marijuana 
 
The number of primary marijuana treatment admis-
sions has fluctuated over several semi-annual reporting 
periods (exhibit 4), but the proportion of the total has 
remained somewhat fixed between 11 and 13 percent. 
In the second half of 2004, 3,318 primary marijuana 
admissions were reported in Los Angeles County. As a 
percentage of the total, marijuana accounted for 14.4 
percent of all admissions (up 1 percentage point from 
the proportion reported in January–June 2004). Like 
many of the other major drugs of abuse, the user 
demographics of primary marijuana admissions were 
relatively stable in the second half of 2004. Three out 
of four primary marijuana admissions were male, and 
individuals younger than 18 constituted 48 percent of 
these admissions (exhibit 6). Primary marijuana ad-
missions were most likely to be Hispanic (49 percent), 
followed by Black non-Hispanics (29 percent) and 
White non-Hispanics (15 percent).  
 
Alcohol was identified as a secondary drug problem 
for 39 percent of the primary marijuana admissions in 
the second half of 2004. An additional 16 percent re-
ported methamphetamine, and 9 percent reported co-
caine/crack as their secondary drug problem. Com-
pared with other major illicit drug admissions, primary 
marijuana admissions had the largest proportion of 
males (75 percent) and users age 17 and younger (48 
percent). When asked whether they had used any drug 
intravenously in the year prior to admission, only 1 
percent of all primary marijuana admissions answered 
affirmatively. 
 
Approximately 7 percent of the primary marijuana 
treatment admissions in the second half of 2004 were 
homeless at the time of admission, and 30 percent  
 
were referred to treatment by the court or criminal 
justice system (most likely by the juvenile justice 
system, given the large proportion of adolescents 
represented among primary marijuana admissions). 
Sixty-nine percent were entering treatment for the 
first time. Twenty-five percent had graduated from 
high school, and, at the time of admission, 14 percent 
were employed full- or part-time. Such characteristics 
reflect the fact that just under one-half of all primary 
marijuana admissions were younger than 18 at the 
time of admission.  
 
Preliminary unweighted data accessed from DAWN 
Live! for calendar year 2004 indicate that of the 8,982 
major substances of abuse reported in the Los Ange-
les division, 1,067 (12 percent) were marijuana re-
ports (exhibit 7). Marijuana was the fourth most 
likely major substance to be reported, following al-
cohol, cocaine, and stimulants. Seventy-two percent 
of the patients reporting marijuana use were male; 37 
percent were Hispanic (followed by 30 percent Black 
and 24 percent White); and 57 percent were age 12–
29. A total of 2,148 chief complaints were logged for 
individuals reporting marijuana. The top three com-
plaints were intoxication (544 complaints), psychiat-
ric condition (334 complaints), and altered mental 
status (316 complaints). Marijuana-using patients 
were most likely to be discharged home (54 percent) 
or admitted to a psychiatric unit (17 percent).  
 
California Poison Control System calls involving 
exposure to marijuana among Los Angeles County 
residents were stable at 35–39 calls between 2000 
and 2003 (exhibit 8a). In the first half of 2004, mari-
juana-related exposure calls plummeted to eight calls. 
Between January 2003 and June 2004, 74 percent of 
the marijuana-exposed callers were male, and 81 per-
cent were age 25 or younger.  
 
According to CHKS data for the 2003–2004 school 
year (exhibit 10), 19.8 percent of all Los Angeles 
County secondary school students (including 7th, 9th, 
and 11th graders, and a small sample of nontradi-
tional students) who responded to the survey had ever 
used marijuana, and 10.3 percent were current mari-
juana users (defined as any use in the past 30 days). 
A breakdown of the data by grade level illustrated 
that among responding seventh graders, 7.3 percent 
had ever used marijuana and 4.3 percent were current 
marijuana users. A higher percentage of 9th graders 
than 7th graders and a higher percentage of 11th 
graders than 9th graders reported marijuana use in the 
past 30 days. When asked about past-6-month use of 
marijuana, 9.2 percent of 7th graders, 15.9 percent of 
9th graders, and 22.7 percent of 11th graders re-
sponded in the affirmative (exhibit 11). 
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According to long-term trends calculated from CHKS 
data spanning over the 5 most recent school years 
(exhibit 12), the pattern of past-30-day marijuana use 
among responding secondary school students was 
more likely than the use of many other drugs, but 
slightly less likely than binge drinking. Past-30-day 
marijuana use has decreased consistently from the 
peak level of 13.2 percent seen in 1999–2000 to 10.3 
percent in 2003–2004.  
 
According to NFLIS data based on 54,916 analyzed 
items reported by participating laboratories within Los 
Angeles County between January and December 2004, 
22 percent (12,327) of all items analyzed were found 
to be cannabis. Cannabis was the third most frequently 
identified substance in Los Angeles County.  
 
A total of 6,139 marijuana arrests were made within 
the city of Los Angeles in 2004; this represents a 14-
percent increase over the number of marijuana arrests 
made during the same time period in 2003 (5,369). 
Marijuana arrests accounted for approximately 17 per-
cent of all narcotics arrests made between January 1 
and December 31, 2004. 
 
Marijuana continues to dominate drug seizures in the 
city of Los Angeles. The amount of marijuana seized 
increased nearly 115 percent, from 14,823 pounds in 
2003 to 31,758 pounds in 2004. Between January and 
December 2004, the amount of marijuana seized ac-
counted for 92 percent of the total weight of drugs (in 
pounds) seized. Cocaine was a very distant second, 
accounting for an additional 7 percent of the total 
weight. The street value of the seized marijuana ac-
counted for approximately 59 percent of the total 
street value of all drugs seized in calendar year 2004. 
 
According to NDIC, California and Mexico appear to 
supply most of the marijuana available throughout 
the United States. In addition, cultivation of mari-
juana on U.S. public lands is widespread, especially 
in California. This is evidenced by the fact that more 
than two-thirds of all cannabis plants eradicated from 
National Forest System lands were located in Cali-
fornia (NDIC 2004). Caucasian, Mexican, and Jamai-
can trafficking groups are responsible for the whole-
sale distribution of marijuana to Los Angeles. Street 
gangs and independent dealers distribute domestic 
and Mexican-grown marijuana in both Los Angeles 
and San Diego (NDIC 2004). The wholesale price of 
Mexican-grade marijuana ranges from $300 to $400 
per pound (exhibit 13). The midlevel and retail prices 
of commercial grade marijuana are $60–$80 per 
ounce and $10 per gram. All prices have been stable 
since early 2003. The wholesale price of domestic 
mid-grade marijuana ranges from $1,000 to $1,200 
per pound. Midlevel and retail prices are $200–$250 
per ounce and $25 per gram. The wholesale price of 
high-grade sinsemilla is $2,500–$6,000 per pound. 
An ounce of sinsemilla sells for $300–$600, and one-
eighth ounce sells for $60–$80.  
 
Indications regarding the local availability of “BC 
Bud,” a hybrid type of cannabis bud grown in Cana-
dian British Columbia, continue to circulate. A pound 
of BC Bud, which would cost approximately $1,500 
in Vancouver, has a wholesale per pound value of 
$6,000 in Los Angeles. Supposedly, a pound of BC 
Bud can be swapped straight across for a pound of 
cocaine. Demand for hashish, the compressed form of 
tetrahydrocannabinol (THC)-rich resinous cannabis 
material, remained limited throughout the Los Ange-
les HIDTA. When it is available, it has a wholesale 
price of $8,000 per pound. 
 
Stimulants 
 
The proportion of primary methamphetamine admis-
sions to Los Angeles County treatment and recovery 
programs increased further from the first to second 
half of 2004, surpassing heroin for the first time ever 
(exhibit 4). The 5,395 primary methamphetamine 
admissions reported in July–December 2004 ac-
counted for 23.4 percent of all admissions. Meth-
amphetamine is the one illicit drug that has con-
tinually increased among treatment admissions over 
the past 4 years (exhibit 5). Compared with other 
major illicit drug admissions, primary methampheta-
mine admissions had the largest proportion of fe-
males (40.1 percent), White Non-Hispanics (39.2 
percent), Asian/Pacific Islanders (2.6 percent), 18–
25-year-olds (30.4 percent), and 26–35-year-olds 
(33.7 percent) (exhibit 6).  
 
For the past few years, the proportion of Hispanics 
among primary methamphetamine admissions has 
been growing, as the proportion of Whites has been 
shrinking. In the first half of 2004, the proportion of 
White non-Hispanics was 41.4 percent, whereas the 
proportion of Hispanics was 41.9 percent among all 
primary methamphetamine admissions. In the second 
half of 2004, the racial/ethnic gap once again wid-
ened, with Hispanics accounting for 47 percent of all 
primary methamphetamine admissions vs. 39 percent 
for Whites. 
 
At one time, females accounted for 49 percent of 
both primary methamphetamine and other ampheta-
mine admissions. This practically equal distribution 
of males and females was unique to metham-
phetamine and other amphetamines. The shifting 
gender distribution with methamphetamine treatment 
admissions has been discussed in detail in recent re-
ports. In the second half of 2003, the percentage of 
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females among primary other amphetamine admis-
sions plummeted to 36.8 percent. In early 2004, how-
ever, the proportion of females climbed back up a bit 
to 40 percent of all admissions. But in the second half 
of 2004, the proportion of females decreased once 
again, this time to 32.1 percent of all amphetamine 
admissions. It is important to monitor this drug cate-
gory to see if the gender distribution will return to 
equitable proportions.  
 
In the second half of 2003, primary amphetamine 
admissions were most likely to fall within the 31–35 
age group (23.6 percent), which was the modal age 
group in the second half of 2002. Between January 
and June 2004, however, primary amphetamine ad-
missions were most likely to fall within the 26–30 
age group (20.6 percent). In the second half of 2004, 
18–25-year-olds and 26–30-year-olds each accounted 
for 17 percent of all primary amphetamine admis-
sions. Primary amphetamine admissions were mar-
ginally more likely to be Hispanic (36.9 percent) than 
White non-Hispanic (34.5 percent). Primary metham-
phetamine and other amphetamine admissions tended 
to most frequently report secondary abuse of alcohol 
or marijuana. 
 
As shown in exhibit 6, smoking continued as the 
most frequently mentioned way for primary meth-
amphetamine admissions to administer the drug. In 
1999, one-half of all primary methamphetamine 
admissions smoked the drug. By the second half of 
2004, 66.7 percent reported this mode of administra-
tion. Conversely, the proportions of injectors and 
inhalers continued to decline, from 15.2 and 29.5 
percent, respectively, in 1999, to 6.7 and 22.6 per-
cent, respectively, in the second half of 2004.  
 
Like primary methamphetamine admissions, the mode 
of other amphetamine administration has shifted in 
recent years, as well. Two-thirds of all other ampheta-
mine admissions in the second half of 2004 smoked 
amphetamines, followed by 22.6 percent who inhaled, 
8.3 percent who ingested orally, and 1.2 percent who 
injected. In 1999, a lower percentage smoked, and 
higher percentages injected, inhaled, and used other 
amphetamines orally.  
 
Eleven percent of all primary methamphetamine ad-
missions reported past-year intravenous use of one or 
more drugs. Approximately one-fifth of the primary 
methamphetamine treatment admissions were home-
less (21.6 percent) and referred by the court or crimi-
nal justice system (18.1 percent). Forty-eight percent 
were entering treatment for the first time. Forty-three 
percent had graduated from high school, and, at the 
time of admission, 19.2 percent were employed full- 
or part-time. 
Methamphetamine injectors were more likely than 
their inhaler or smoker counterparts to be male (67 
percent), White non-Hispanic (75 percent), 36 or 
older (41 percent), homeless (41 percent), or to have 
been through four or more prior treatment episodes 
(12 percent). They were, by far, the most impaired of 
all primary methamphetamine abusers. Metham-
phetamine smokers were more likely than metham-
phetamine inhalers or injectors to be referred by the 
criminal justice system (19 percent). Lastly, metham-
phetamine inhalers were more likely than their coun-
terparts to be Hispanic (56 percent) or employed (25 
percent). No differences existed among the three 
modes of administration with regards to the percent-
age of Black non-Hispanics or the percentage of ad-
missions with a high school diploma/GED.  
 
Preliminary unweighted data accessed from DAWN 
Live! for calendar year 2004 indicate that of the 8,982 
major substances reported in the Los Angeles divi-
sion, 1,235 (14 percent) were stimulants (exhibit 7). 
The stimulant category encompasses amphetamines 
(326 reports, 26 percent of stimulant reports) and 
methamphetamine (909 reports, 74 percent of stimu-
lant reports). Stimulants were the third most likely 
major substance to be reported, following alcohol and 
cocaine. For the remainder of the DAWN discussion, 
stimulant user demographics will be broken out for 
methamphetamine and amphetamines. 
 
Seventy-five percent of the patients reporting 
methamphetamine use to the DAWN Live! system 
were male, and 48 percent were Hispanic (followed 
by 35 percent White and 6 percent Black). More than 
one-half (55 percent) were age 25–44, and an addi-
tional 33 percent were 18–24. The three most fre-
quently reported complaints were intoxication (412 
complaints), psychiatric condition (392 complaints), 
and altered mental status (350 complaints). Metham-
phetamine-using patients were most likely to be dis-
charged home (47 percent) or admitted to a psychiat-
ric unit (30 percent). Nearly 50 percent of the patients 
reporting methamphetamine use indicated that they 
smoked the drug, followed by 13 percent reporting 
inhalation.  
 
Sixty percent of the patients reporting amphetamine 
use to DAWN were male, and 47 percent were His-
panic (followed by 34 percent White and 9 percent 
Black). More than one-half (53 percent) were age 25–
44, and an additional 25 percent were 18–24.  
 
California Poison Control System calls involving ex-
posure to methamphetamine/amphetamine among Los 
Angeles County residents have fluctuated over the 
years, with 48 calls logged for 2000, a high of 63 calls 
in 2001, and approximately 55 calls in 2002 and 2003 
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(exhibit 8a). In the first half of 2004 alone, 33 metham-
phetamine/amphetamine-related exposure calls were 
made to the system. If an equal number of calls are 
made in the second half of 2004, the overall number 
will exceed the peak level seen in 2001. Between 
January 2003 and June 2004, slightly more callers 
reporting exposure to methamphetamine or other am-
phetamines were male (53 percent) than female (44 
percent), and 64 percent were between the ages of 18 
and 34 (exhibit 9). In addition to calls relating to 
methamphetamine and amphetamine exposure, a total 
of 37 Ritalin/Adderall exposure calls were recorded 
between January 2000 and June 2004.  
 
According to CHKS data for the 2003–2004 school 
year (exhibit 10), 7.3 percent of all Los Angeles 
County secondary school students (including 7th, 9th, 
and 11th graders, and a small sample of nontradi-
tional students) who responded to the survey had ever 
used methamphetamine, and 3.7 percent were current 
methamphetamine users (defined as any use in the 
past 30 days). A breakdown of the data by grade level 
illustrated that among responding ninth graders, 5.4 
percent had ever used methamphetamine and 2.9 per-
cent were current users. A higher percentage of 11th 
than 9th graders reported methamphetamine use in 
the past 30 days. A nearly equal proportion of males 
and females identified as lifetime methamphetamine 
users (51 percent were male and 49 percent were fe-
male). The gender gap widened with past-30-day use 
of methamphetamine (63 percent male vs. 37 percent 
female). Frequent methamphetamine use is defined as 
20 or more days of use in the previous 30 days. 
Twenty-three percent of the current methampheta-
mine users reported frequent use. Among the fre-
quent users, 68 percent were male and the remaining 
32 percent were female. When asked about past-6-
month use of cocaine, methamphetamine, or other 
stimulants, 7.1 percent of 9th graders and 6.5 percent 
of 11th graders responded in the affirmative (exhibit 
11).    
 
According to long-term trends calculated from CHKS 
data spanning over the most recent 5 school years (ex-
hibit 12), the pattern of past-30-day methamphetamine 
use among responding secondary school students was 
similar to patterns seen for cocaine and LSD/other 
psychedelics. From 1999–2000 to 2001–2002, past-30-
day methamphetamine use decreased consistently from 
the peak level of 4.6 percent in 1999–2000 to 4.1 per-
cent in 2001–2002. In 2002–2003, the percentage of 
current methamphetamine users increased slightly to 
4.3 percent, but it decreased to 3.7 percent (the lowest 
level yet) in 2003–2004.  
 
According to NFLIS data based on 54,916 analyzed 
items reported by participating laboratories within Los 
Angeles County between January and December 2004, 
32 percent (17,789) of all items analyzed were found 
to be methamphetamine/amphetamine. Methampheta-
mine accounted for the second largest proportion of 
samples positively identified by NFLIS. An additional 
18 items were identified as amphetamine, and 15 items 
were identified as pseudoephedrine (each accounting 
for less than one-tenth of a percent).  
 
Throughout calendar year 2004, 458 amphetamine 
arrests were made within the city of Los Angeles, 
exceeding the number of arrests made during the 
same period in 2003 (274 arrests) by 67 percent. De-
spite this large increase in the overall number of am-
phetamine arrests, as a class, such arrests continued 
to account for slightly less than 1 percent of the total. 
Arrests for methamphetamine are included in the 
category “other narcotics.” In early 2004, 17,825 
arrests for other narcotics were made (many of which 
could be attributable to methamphetamine, but there 
is no way of knowing from the LAPD report), ac-
counting for 49 percent of all arrests.  
 
While methamphetamine is not reported separately in 
citywide drug arrests, it is broken out in citywide 
seizures. Citywide methamphetamine seizures actu-
ally decreased 33 percent, from 535 pounds seized in 
2003 to 356 pounds seized in 2004. The street value 
of the seized methamphetamine accounted for ap-
proximately 10 percent of the total street value of all 
drugs seized in 2004. 
 
Los Angeles is considered by NDIC to be one of the 
largest methamphetamine markets in the United 
States. Mexican criminal groups based in both Mex-
ico and California control the wholesale and midlevel 
distribution of methamphetamine and distribute the 
drug via private vehicles and commercial trucks. Not 
only does a large quantity of the drug stay in the 
southern California region, but methamphetamine is 
transported to other major cities and regions, includ-
ing San Francisco and Phoenix, and the West Central, 
Southwest, and Southeast areas of the United States. 
Hispanic gangs, independent dealers, outlaw motor-
cycle gangs (OMGs), and Asian gangs control the 
retail distribution of methamphetamine within and 
beyond California.  
 
The wholesale price per pound of methamphetamine 
ranged from $5,000 to $7,000 (exhibit 13), which is 
similar to the range reported in January 2005, but 
higher than the wholesale price reported in 2002–
2003 ($3,700 to $5,000).  The midlevel and retail 
prices are $500–$800 per ounce (up from $450–$550 
reported in January 2005), $50 per gram, $60–$75 
per one-sixteenth ounce (“teener”), and $100–$120 
per one-eighth ounce. According to one intelligence 
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source, the purity of finished methamphetamine 
available in the Los Angeles area remains at ap-
proximately 30–35 percent. Given the many different 
production “recipes” and the multiple types of 
methamphetamine entering into and staying in the 
Los Angeles area (locally produced and Mexican 
produced), however, it is very possible that there is a 
wide range of purity (especially since such a high 
percentage of users report smoking methampheta-
mine).  
 
Crystal methamphetamine has a wholesale price of 
$8,000–$11,000 per pound in Los Angeles. The mid-
level price for an ounce of crystal methamphetamine is 
$600–$900, which represents a slight widening of the 
range reported in January 2005. A double case of 
pseudoephedrine (17,000 60-milligram tablets per 
case) sells for $3,250–$4,000.  
 
In parts of the United States, the number of metham-
phetamine clandestine laboratory seizures has consis-
tently increased. According to Rudy Lovio, Criminal 
Intelligence Specialist in the LA CLEAR Research 
and Analysis Unit, this increase is due to the prolif-
eration of “Nazi” methamphetamine labs (small-scale 
labs capable of producing gram to ounce quantities of 
finished product) in the Midwest and rural South. 
Since calendar year 1999, however, the number of 
clandestine laboratory incidents has decreased consis-
tently in both the LA HIDTA and in California over-
all.  In 1999, 2,090 labs were seized in California 
(1,187 of which occurred in the 4-county LA HIDTA 
region). By 2004, only 449 labs were seized state-
wide (263 in the LA HIDTA). Possible explanations 
for the decrease in seizures include precursor chemi-
cal restrictions, chemical control laws, increased 
methamphetamine production in Mexico, and the 
downsizing of clandestine laboratory enforcement 
teams. Despite the decrease in the number of sei-
zures, the wholesale and retail prices for metham-
phetamine have remained relatively stable over the 
same time period, which is a barometer for metham-
phetamine availability in Los Angeles County.  
 
According to EPIC’s National Clandestine Labora-
tory Seizure System, California had the fifth highest 
number of laboratory-only seizures in 2004 (449), 
following Missouri (906), Tennessee (798), Arkansas 
(563), and Indiana (517). Within California, the Los 
Angeles HIDTA once again led the State in the over-
all number of methamphetamine seizures (including 
laboratories, dumpsites, and chemicals/glass/equip-
ment) made in 2004, accounting for 59 percent of all 
seizures made in California (236 of 449 total inci-
dents). Of the 4 counties in the LA HIDTA, Los An-
geles County had the third highest number of inci-
dents during that time period (60), lagging behind 
San Bernardino County (115) and Riverside County 
(70). Orange County rounded out the HIDTA with 18 
incidents.  
 
Even though four States exceed California in terms of 
laboratory seizures, California leads the country in 
the number of domestic “superlabs.” Thirty-six of 48 
U.S. superlabs (75 percent) seized in 2004 were in 
California. In the past, these large-scale labs were 
capable of producing 10 or more pounds of finished 
methamphetamine in a single production cycle, but 
superlabs have stepped up the pace and are now ca-
pable of producing 20 or more pounds of finished 
drug in a single production cycle (NDIC 2004). The 
LA HIDTA reported the highest proportion of super-
labs seized throughout California (23 out of 36 super-
labs seized between January 1 and December 31, 
2004, or 64 percent). Within the LA HIDTA, Los 
Angeles County led with 13 superlab seizures, fol-
lowed by Riverside County (5), San Bernardino 
County (4), and Orange County (1). Furthermore, 
totals reported in the LA HIDTA exceeded totals 
reported by all States outside of California.  
 
The cost to clean up labs located in the LA HIDTA in 
2004 totaled $759,672. Thirty percent of this total 
corresponds to the cost of cleaning up Los Angeles 
County laboratories, second only to Riverside County 
(38 percent of the cleanup costs). It is important to 
note that these cleanup figures do not encompass 
building and environment remediation, which each 
cost taxpayers even more money. 
 
A negative consequence of clandestine metham-
phetamine laboratory activity is the effect on children 
living in or around the makeshift, often home- or 
apartment-based, laboratories. Local, statewide, and 
national efforts, known as Drug Endangered Children 
Programs, have been launched to address the issue of 
what happens to children who are found at a 
methamphetamine laboratory when it is seized. Na-
tionally, in 2004, 2,900 children were “affected” by 
methamphetamine laboratories. Seven percent of the 
affected children resided in California. Within Cali-
fornia, 98 of the 200 affected children resided in the 4 
LA HIDTA counties. The highest proportion was 
reported in Riverside County (77 of the 98 children), 
followed by San Bernardino County (26), Los Ange-
les County (9), and Orange County (8). It is impor-
tant to note that these numbers are underreported, due 
to differences in county- and State-level reporting 
procedures.   
 
Depressants  
 
In the second half of 2004, treatment and recovery 
program admissions associated with primary barbitu-
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rate, benzodiazepine, or other sedative/hypnotic abuse 
continued to account for less than 1 percent of all 
admissions in Los Angeles County. 
 
Of the 2,255 pharmaceuticals reported among those 
seeking detoxification, overmedication, and other 
cases accessed from DAWN Live! for calendar year 
2004 in the Los Angeles division, 249 (11 percent) 
were antidepressants, 249 were antipsychotics (11 
percent), 51 were barbiturates (2 percent), and 450 
were benzodiazepines (20 percent) (exhibit 14). For 
all of the above categories except for barbiturates, 
overmedication was the most frequently stated reason 
for visiting the emergency department. The propor-
tion of overmedication cases ranged from a low of 51 
percent (for antipsychotics) to a high of 73 percent 
(antidepressants).  
 
Los Angeles County-based California Poison Control 
System calls involving exposure to benzodiazepines 
fluctuated. From 2000 to 2001, benzodiazepine-
related exposure calls increased from 64 to 83 (ex-
hibit 8b). In 2002, the number of calls decreased to 
52, and such calls then increased to 70 in 2003. In the 
first half of 2004 alone, 52 benzodiazepine exposure 
calls were reported, which may indicate a further 
increase from the number of calls seen in 2003. Be-
tween January 2003 and June 2004, 19 of the benzo-
diazepine-related exposure calls were for alprazolam, 
29 were for clonazepam, and 20 were for diazepam. 
In addition to calls for benzodiazepine exposures, a 
total of 52 antidepressant exposure calls and 25 an-
tipsychotic calls were reported between January 2000 
and June 2004.  
 
Approximately 944 of the 54,916 items analyzed and 
reported to the NFLIS system in calendar year 2004 
were identified as pharmaceuticals/prescription/non-
controlled non-narcotic medications (as opposed to 
illicit substances). Of those, roughly 21 percent (195 
items) were found to be benzodiazepines. The most 
frequently cited benzodiazepines were diazepam (65 
items; 33 percent) and clonazepam (58 items; 30 per-
cent).  
 
According to LA CLEAR, Valium retails for $1 per 
5-milligram tablet (exhibit 13), which is one-half the 
cost reported in the January 2004 report. Xanax re-
tails for $1 per 4-milligram tablet.  
 
Phencyclidine and Hallucinogens  
 
Primary PCP treatment admissions accounted for 0.6 
percent of all admissions in the second half of 2004 
(exhibit 4). The proportion of PCP admissions among 
all admissions has been stable for several years, but 
the overall number of PCP admissions increased 89 
percent from 1999 to the first half of 2003. In the 
second half of 2003, however, the number of PCP 
admissions decreased slightly (16 percent) to 262 
admissions, and they continued to decrease further 
(12 percent) in the first half of 2004 to 230 admissions, 
and in the second half of 2004 to 135 admissions (41 
percent decrease from the first half of the year). Alco-
hol (20 percent), marijuana (22 percent), and co-
caine/crack (15 percent) were the three most frequently 
reported secondary drugs among primary PCP admis-
sions. The majority (88 percent) of the primary PCP 
admissions smoked the drug. Interestingly, 6 percent 
reported taking PCP orally, and 4 percent reported 
injecting PCP. This is the first time that such high per-
centages reported modes other than smoking. There 
were no notable changes from the previous reporting 
period in terms of user demographics. Other hallu-
cinogens, such as LSD, peyote, and mescaline, contin-
ued to account for approximately 0.1 percent of the 
total treatment admissions. 
 
Preliminary unweighted data accessed from DAWN 
Live! for calendar year 2004 indicate that of the 8,982 
major substances of abuse reported in the Los Ange-
les County division, 164 (2 percent) were PCP (ex-
hibit 7). Seventy-nine percent of the patients report-
ing PCP use were male and 46 percent were White 
(followed by 29 percent Black and 22 percent His-
panic). Sixty-seven percent were age 30–54, and an 
additional 11 percent were between 18 and 24. A 
total of 398 chief complaints were logged for patients 
reporting PCP. The top three complaints were 
intoxication (95 complaints), altered mental status 
(87 complaints), and psychiatric condition (65 com-
plaints). Patients were more likely to smoke PCP (62 
percent) than inject (10 percent). PCP-using patients 
were most likely to be either be discharged home or 
admitted to a psychiatric ward (each at 31 percent).  
 
California Poison Control System calls involving 
exposure to PCP among Los Angeles County resi-
dents fluctuated between 10 and 20 calls from 2000 
to 2003 (exhibit 8a). In the first half of 2004, there 
were five PCP-related exposure calls.  
 
According to CHKS data for the 2003–2004 school 
year, 5.8 percent of all Los Angeles County secon-
dary school students (including 7th, 9th, and 11th 
graders, and a small sample of nontraditional stu-
dents) who responded to the survey had ever used 
LSD or another psychedelic, and 2.9 percent had 
used LSD/other psychedelics in the past 30 days (ex-
hibit 10). A breakdown of the data by grade level 
illustrated that among responding ninth graders, 4.4 
percent had ever used LSD/other psychedelics, and 
2.5 percent were current users. Among 11th graders, 
5.9 percent had ever used LSD/other psychedelics, 
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and 2.5 percent used a psychedelic at least once 
within the past 30 days.  
 
According to long-term trends calculated from CHKS 
data spanning over the last 5 school years (exhibit 
12), the pattern of past-30-day LSD/other psychedel-
ics use among responding secondary school students 
(in grades 7, 9, and 11) was similar to usage patterns 
seen with other licit and illicit drugs. Current use of 
LSD/other psychedelics has been trending downward 
since the late 1990s, to a low of 2.8 percent in 2002–
2003. In 2003–2004, the percentage was slightly 
higher at 2.9 percent of all respondents.   
 
According to NFLIS data based on 54,916 analyzed 
items reported by participating laboratories within Los 
Angeles County between January and December 2004, 
0.5 percent (n=280) of all items analyzed were found 
to be PCP.  
 
One hundred and forty-eight PCP arrests were made 
within the city of Los Angeles in calendar year 2004, 
which represented a 12-percent decline from 2003 
(169 arrests). Like amphetamine arrests, PCP arrests 
accounted for a very low proportion (less than 1 per-
cent). 
 
The street value of the PCP seized between January 
and December 2004 represented approximately 3.2 
percent of the total street value of all drugs seized 
during that period. The total amount of PCP seized 
throughout 2004 (26.5 pounds) was 15 percent lower 
than the amount seized during the same period in 
2003 (31 pounds).  
 
The wholesale price for a gallon of PCP remains at the 
high level reported in January 2005, ranging from 
$15,000 to $20,000 (exhibit 13). The ounce price, 
however, decreased recently, from $600 to $300–$350. 
A sherm cigarette dipped in liquid PCP continues to 
sell for $20–$30. A tight-knit group of Los Angeles-
based African-American street gang members contin-
ues to produce, supply, and distribute PCP in the Los 
Angeles area.   
 
A sheet of approximately 100 doses of LSD has a 
wholesale price range of $150–$200. Typically, a 
single dose sells for $5–$10. At the retail level, psilo-
cybin mushrooms cost about $20 per one-eighth 
ounce.  
 
Club Drugs 
 
Comprehensive indicator data relating to the use and 
abuse of club drugs is still lacking for Los Angeles 
County. Therefore, it is difficult to accurately and com-
prehensively describe the use and abuse patterns of club 
drugs in Los Angeles County. Despite this lack of tradi-
tional indicator information, anecdotal evidence from a 
variety of sources continues to circulate with regard to 
the availability of club drugs in Los Angeles County, 
particularly MDMA (ecstasy) and gamma hydroxybu-
tyrate (GHB).  
 
Collectively, club drugs played a limited role in pre-
liminary unweighted data accessed from DAWN Live! 
in 2004. Sixty-five of the 8,982 major substances of 
abuse reported in the Los Angeles division were 
MDMA (ecstasy), 5 were GHB, and 1 was ketamine 
(exhibit 7). Rohypnol did not have a presence at all.  
 
The demographics of patients reporting MDMA use 
were interesting, when compared to the demographics 
for many other drug users in Los Angeles. Fifty-four 
percent of the patients reporting MDMA use were fe-
male, and 35 percent were Hispanic (followed by 26 
percent White and 22 percent Black). More than one-
half of the MDMA users (55 percent) were between 12 
and 24 years of age. Of the 148 complaints, the three 
most frequently reported complaints were altered men-
tal status (47 complaints), intoxication (40 complaints), 
and psychiatric condition (35 complaints). Metham-
phetamine-using patients were most likely to be admit-
ted to a psychiatric unit (43 percent) or discharged 
home (26 percent).  
 
California Poison Control System calls involving 
exposure to ecstasy among Los Angeles County resi-
dents have decreased consistently over recent years, 
from a high of 56 in 2000 to a low of 16 in 2003 (ex-
hibit 8a). In the first half of 2004 alone, however, 12 
calls relating to ecstasy exposure were reported. If an 
equal number of calls are made in the second half of 
2004, the overall number will exceed the 2003 level. 
Between January 2003 and June 2004, more callers 
reporting exposure to ecstasy were male (57 percent) 
than female (43 percent), and 64 percent were be-
tween the ages of 13 and 25 (exhibit 9). In addition to 
calls relating to ecstasy exposure, a total of 14 GHB 
exposure calls, 4 ketamine calls, and 3 Rohypnol 
calls were recorded between January 2003 and June 
2004.  
 
The California Poison Control System also kept track 
of calls relating to Coricidin HBP and dextromethor-
phan (DXM) exposures. Between January 2003 and 
June 2004, 50 Coricidin HBP calls and 17 DXM calls 
were logged in the system (exhibit 8a). Fifty-two 
percent of Coricidin HBP calls and 59 percent of 
DXM calls were male. Furthermore, 84 percent of the 
Coricidin HBP calls and 65 percent of the DXM calls 
were made because of exposure to individuals 
younger than 18. Those age 18–25 represented an 
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additional 16 percent of the Coricidin HBP calls and 
23 percent of the DXM calls (exhibit 9).  
 
According to CHKS data for the 2003–2004 school 
year (exhibit 10), 5.5 percent of all Los Angeles 
County secondary school students (including 7th, 9th, 
and 11th graders, and a small sample of nontradi-
tional students) who responded to the survey had ever 
used ecstasy. Current use of ecstasy was not assessed, 
although a question regarding past-6-month use of 
psychedelics, ecstasy, or other club drugs was in-
cluded in the survey. Overall, 6.2 percent of all re-
spondents reported use of these drugs (exhibit 11). 
By grade, 6 percent of 9th graders and 5 percent of 
11th graders answered in the affirmative.    
 
According to NFLIS data based on 54,916 analyzed 
items reported by participating laboratories within Los 
Angeles County between January and December 2004, 
less than 1 percent (277) of all items analyzed were 
found to be MDMA, GHB, or ketamine. Of those three 
club drugs, MDMA was most likely to be detected; it 
represented 81 percent of the club drug samples ana-
lyzed by NFLIS. GHB represented an additional 10 
percent of the samples, and ketamine accounted for 8 
percent. 
 
According to NDIC, the majority of MDMA avail-
able in Los Angeles is transported directly from 
Western Europe. Los Angeles is a source of both 
wholesale and midlevel amounts of MDMA, which 
are destined for markets around the United States, 
including Pacific, Southwest, and West Central States 
(NDIC 2004). Israeli and Russian criminal groups 
control the wholesale distribution, and independent 
dealers (usually White males) are responsible for 
retail marketing and distribution. Mail service and air 
travel are the two most likely ways to transport the 
product into Los Angeles. Within Los Angeles, Is-
raeli and Russian traffickers control the distribution 
at the wholesale level.  
 
Wholesale and retail prices for club drugs remained 
stable since the January 2005 report. In multiple 
quantities, MDMA has a wholesale price of $12 per 
pill or capsule (exhibit 13). At the retail level, ecstasy 
usually sells for $20–$40 per pill. A standard dose of 
ecstasy is 60–150 milligrams, which is equivalent to 
one or two pills. In Los Angeles, ecstasy “boats” con-
tinue to be mentioned. A boat contains 1,000 MDMA 
pills and sells for $8,000. Flunitrazepam (Rohypnol), 
when available, has a retail value of $6–$10 for a 1-
milligram pill. On the street, ketamine sells for $100–
$200 per 10-milliliter vial. In addition, ketamine re-
tails for $20 for two-tenths of a gram of powder. The 
wholesale price for GHB is $275–$350 per gallon,  
 
and a liter sells for $80–$100. A 16-ounce bottle of 
GHB, which once ranged from $65 to $100, now 
sells for $120. Capfuls can still be purchased for $5–
$20 each. The vast majority of GHB users ingested 
the drug as a liquid, either in straight shots or mixed 
with a drink. When available, gamma butyrolactone 
(GBL) sells for $600 per liter. 
 
INFECTIOUS DISEASES RELATED TO DRUG ABUSE 
 
A cumulative total of 49,116 adult/adolescent AIDS 
cases were reported in Los Angeles County through 
December 31, 2004. Of those cases, 1,384 were re-
ported between July 1, 2004, and December 31, 
2004. Currently, approximately 20,316 Los Angeles 
County residents are living with advanced HIV dis-
ease. Los Angeles County cumulative cases represent 
approximately 36 percent of the 135,975 cumulative 
cases in California and approximately 5 percent of 
the 929,985 cumulative cases nationwide. Of the cu-
mulative cases reported in Los Angeles County, 47 
percent were White, 30 percent were Hispanic, 20 
percent were African-American, 44 percent were age 
30–39, and 92 percent were male. 
 
The proportion of newly diagnosed males solely ex-
posed through injection drug use has ranged between 
4 and 6 percent from 1998 to 2004 (exhibit 15). The 
proportions for other exposure categories, such as the 
combination of male-to-male sexual contact and in-
jection drug use, heterosexual contact, blood transfu-
sion, and hemophilia/coagulation disorder, have re-
mained relatively stable since 1998. The proportion 
of men exposed to AIDS through male-to-male sex-
ual contact has decreased slowly but steadily, from 
65 percent in 1998 to 61 percent in 2004. The propor-
tion of male cases with an “other” or “undetermined” 
exposure category accounted for 28 percent of all 
male cases diagnosed in 2004. Since the 2004 data 
are preliminary, it is possible that some of the cases 
in the “other/undetermined” category will be trans-
ferred into the other exposure categories.   
 
The modal exposure category for females diagnosed 
with AIDS in 1998 was heterosexual contact (46 per-
cent). This exposure category has been associated 
with a lower proportion of female AIDS cases since 
1999; in 2004, it was associated with 34 percent of all 
newly diagnosed female AIDS cases. Female cases 
attributable to injection drug use, which were stable at 
17–19 percent of all female cases from 2000 to 2002, 
decreased to 13 percent in 2003 and remained there in 
2004. The proportion of female cases with an “other” 
or “undetermined” exposure category continued to 
increase, accounting for 49 percent of all female cases 
diagnosed in 2004.  
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In Los Angeles County in 2004, approximately 7 
percent of all AIDS cases involved injection drug use 
(alone) as the primary route of exposure. Among the 
3,387 cumulative cases primarily attributable to in-
jection drug use, 72 percent occurred among males. 
African-Americans are the modal group of male in-
jection drug users (IDUs) (accounting for 37 per-
cent), followed by Hispanics (32 percent) and Whites 
(30 percent). A similar pattern was seen with female 
IDU AIDS cases. African-Americans continued to 
constitute the greatest proportion (44 percent), fol-
lowed by Whites (31 percent) and Hispanics (22 per-
cent).  
 
An additional 7 percent of the total cumulative cases 
were attributable to a combination of male-to-male 
sexual contact and injection drug use. Fifty-one per-
cent of the male-to-male sexual contact and injection 
drug use cases were White.  
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Exhibit 1. Population Characteristics, Los Angeles County and the State of California, by Percent:  
  2000 U.S. Census 
 
Population Characteristics Los Angeles County California 
Population, 2003 estimate (N) (9,871,506) (35,484, 453) 
Population, percent change, April 1, 2000, 
to July 1, 2003 
3.7 4.8 
Population, year 2000 (N) (9,519,338) (33,871,648) 
Persons younger than 5  7.7 7.3 
Persons younger than 18  28.0 27.3 
Persons age 65 and older 9.7 10.6 
Female 50.6 50.2 
White 48.7 59.5 
Black or African-American 9.8 6.7 
American Indian or Alaska Native 0.8 1.0 
Asian persons 11.9 10.9 
Native Hawaiian or Other Pacific Islander 0.3 0.3 
Persons reporting some other race 23.5 16.8 
Persons reporting two or more races 4.9 4.7 
White, not Hispanic/Latino origin 31.1 46.7 
Persons of Hispanic/Latino origin 44.6 32.4 
 
SOURCE: U.S. Census Bureau, State and County QuickFacts 
 
 
Exhibit 2.  Data Completeness for Los Angeles County DAWN Live! Emergency Departments (n=37)1,  
 by Month: 2004 
 
Number of EDs by Month Data 
Completeness Jan- 04 
Feb- 
04 
Mar- 
04 
Apr- 
04 
May- 
04 
Jun- 
04 
Jul- 
04 
Aug- 
04 
Sep- 
04 
Oct- 
04 
Nov- 
04 
Dec- 
04 
Basically 
Complete2 12 12 12 10 9 7 7 7 8 7 7 9 
Partially 
Complete3 0 0 0 1 1 1 2 1 1 2 3 2 
Incomplete4 1 2 2 2 1 3 0 1 2 3 2 1 
No Data 
Reported 24 23 23 24 26 26 28 28 26 25 25 25 
Total EDs in  
Sample5 37 37 37 37 37 37 37 37 37 37 37 37 
 
1Total eligible hospitals in area=79; Hospitals in DAWN sample=34; Hospitals not in DAWN Sample = 45. Tables reflect cases that have 
been received by DAWN as of either 4/13–14/2005 or of 6/10/05; the exact date will be indicated in future tables. 
290% Complete; 350% to 89% Complete; 4Less than 50% Complete; 5Some hospitals in the DAWN sample have more than one 
emergency department. All DAWN cases are reviewed for quality control. Based on this review, cases may be corrected or deleted. 
Therefore, these data are subject to change. 
SOURCE: DAWN Live!, OAS, SAMHSA, update 4/13–14/05 and 6/10/05 
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Exhibit 3. Number of ED Visits, by Case Type, in the Los Angeles County Division (Unweighted1) and Percent 
of All ED Visits: January–December 2004 
 
Case Type Number of ED Visits1 (%) 
Suicide Attempt 516 (6) 
Seeking Detoxification 190 (2) 
Alcohol Only (age <21) 531 (6) 
Adverse Reaction  1,467 (17) 
Overmedication 894 (11) 
Malicious Poisoning 28 (<1) 
Accidental Ingestion 119 (1) 
Other 4,739 (57) 
Total 8,484 (100) 
 
1The unweighted data are from 9 to 14 EDs reporting to Los Angeles area hospitals. All DAWN cases are reviewed for quality con-
trol. Based on this review, cases may be corrected or deleted. Therefore, these data are subject to change.  
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/13–14/05 
 
 
 
Exhibit 4. Number and Proportion of Semiannual Treatment Admissions in Los Angeles County, by Primary 
Illicit Drug of Abuse:  January 2002–December 2004 
 
Primary Drug 
01/02–06/02 
Number  
(%) 
07/02–12/02 
Number 
(%) 
01/03–06/03 
Number 
(%)  
07/03–12/03 
Number 
(%) 
01/04–06/04 
Number 
(%) 
07/04–12/04 
Number 
(%)  
Cocaine/Crack 4,655 
(19.6) 
4,354 
(19.0) 
5,242 
(19.3) 
4,815 
(18.2) 
5,137 
(18.1) 
4,124 
(17.8) 
Heroin 7,767 
(32.8) 
7,096 
(30.9) 
6,891 
(25.4) 
6,704 
(25.4) 
6,942 
(24.5) 
5,341 
(23.2) 
Marijuana 2,686 
(11.3) 
2,816 
(12.3) 
3,669 
(13.5) 
3,452 
(13.1) 
3,812 
(13.4) 
3,318 
(14.4) 
Methamphetamine 3,453 
(14.6) 
3,692 
(16.1) 
4,961 
(18.3) 
5,095 
(19.3) 
5,840 
(20.6) 
5,395 
(23.4) 
PCP 196 
(0.8) 
219 
(0.9) 
314 
(1.2) 
262 
(1.0) 
230 
(0.8) 
135 
(0.6) 
Total Admissions 23,695 22,934 27,110 26,393 28,371 23,059 
 
SOURCE:  California Alcohol and Drug Data System (CADDS) 
 
 
 
Exhibit 5. Number and Proportion of Annual/Semiannual Treatment Admissions in Los Angeles County, by 
Primary Illicit Drug of Abuse:  2001–2004 
 
2001 2002 2003 2004 
Primary Drug 
Number (%) Number (%) Number (%) Number (%) 
Cocaine/Crack 8,703 (18.9) 9,009 (19.3) 10,057 (18.8) 9,261 (18.0) 
Heroin 17,560 (38.1) 14,863 (31.9) 13,595 (25.4) 12,283 (23.9) 
Marijuana 4,286 (9.3) 5,502 (11.8) 7,121 (13.3) 7,130 (13.9) 
Methamphetamine 5,418 (11.7) 7,145 (15.3) 10,056 (18.8) 11,235 (21.8) 
PCP 405 (0.9) 415 (0.9) 576 (1.1) 365 (0.7) 
Total Admissions 46,127  46,629  53,503  51,430  
 
SOURCE:  California Alcohol and Drug Data System (CADDS) 
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Exhibit 6. Characteristics of Treatment Admissions in Los Angeles County, by Primary Illicit Drug of Abuse  
  and Percent:  July–December 2004 
 
Characteristics Cocaine/Crack Heroin Marijuana Metham- phetamine 
All 
Admissions 
Gender      
 Male 65.7 71.5 75.2 59.9 67.2 
 Female 34.3 28.5 24.8 40.1 32.8 
Race/Ethnicity      
 White, non-Hispanic 15.6 38.7 14.7 39.2 30.7 
 Black, non-Hispanic 56.4 11.4 29.1 3.2 22.7 
 Hispanic  21.5 42.2 48.5 47.3 38.4 
 American Indian 0.6 0.8 0.8 0.9 0.8 
 Asian/Pacific Islander 1.4 1.0 1.6 2.6 1.8 
 Other 4.5 5.9 5.3 6.8 5.6 
Age      
 17 and younger 1.3 0.2 48.1 8.2 12.2 
 18–25 9.3 7.7 23.4 30.4 16.4 
 26–35 22.8 18.4 15.6 33.7 22.2 
 36 and older 66.6 73.7 12.9 27.7 49.2 
Route of Administration      
 Oral 2.2 1.4 2.5 3.1 21.5 
 Smoking 86.0 8.3 96.8 66.7 48.8 
 Inhalation 10.4 4.5 0.6 22.6 7.7 
 Injection 1.1 85.3 0.1 6.7 21.6 
 Unknown/other 0.3 0.5 0.1 0.7 0.4 
Secondary Drug Alcohol Cocaine/ Crack Alcohol Marijuana Alcohol 
Positive for Intravenous 
Drug Use in Past Year 4.4 87.9 1.1 10.9 24.9 
Homeless 27.8 15.7 7.1 21.6 18.8 
Employed Full- or Part-
Time 14.8 24.0 13.5 19.2 18.3 
Graduated from High 
School 42.5 44.8 24.9 42.6 39.9 
Referred by 
Court/Criminal Justice 
System (Not Including 
SACPA1 Referrals) 
16.4 3.6 30.1 18.1 15.3 
First Treatment Episode 36.0 17.0 68.5 47.8 42.7 
Total Admissions (N) (4,124) (5,341) (3,318) (5,395) (23,059) 
 
1SACPA = Substance Abuse and Crime Prevention Act of 2000 (a.k.a., Proposition 36) 
SOURCE:  California Alcohol and Drug Data System (CADDS) 
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Exhibit 7. Number of ED Reports, by Drug and Drug Category (Major Substances of Abuse), in the Los  
 Angeles County Division (Unweighted1): January–December 2004 
 
Major Substance of Abuse Number of ED Reports1 
Alcohol 
     Alcohol only (age <21) 
3,307 
531 
Cocaine 2,348 
Heroin 712 
Marijuana 1,067 
Stimulants 
     Amphetamines 
     Methamphetamine 
1,235 
326 
909 
MDMA (Ecstasy) 65 
GHB 5 
Ketamine 1 
LSD 5 
PCP 164 
Miscellaneous hallucinogens 3 
Inhalants 44 
Combinations NTA 26 
Total 8,982 
 
1The unweighted data are from 9 to 14 EDs reporting to the Los Angeles area hospitals. All DAWN cases are reviewed for quality 
control. Based on this review, cases may be corrected or deleted. Therefore, these data are subject to change.  
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14/05 
 
Exhibit 8a. Los Angeles County Poison Control Center Exposure Calls for Major Substances of Abuse: 
January 2000–June 2004  
 
Major Substance 2000 Number  
2001 
Number  
2002 
Number 
2003 
Number 
1H2004 
Number 
Total 
Number 
Cocaine/Crack1 69 66 77 97 41 350 
Heroin1 20 15 20 17 11 83 
Marijuana1 35 35 39 39 8 156 
Ecstasy (MDMA)1 56 50 33 16 12 167 
Rohypnol/flunitrazepam1 7 4 4 1 2 18 
GHB1 57 35 25 10 4 131 
PCP1 10 17 13 16 5 61 
LSD1  
   Mushrooms 
   Other hallucinogens 
18 
2 
2 
2 
1 
0 
6 
0 
2 
1 
2 
2 
1 
0 
1 
28 
5 
7 
Other Illicit1 2 1 2 0 0 5 
Inhalants2 1 0 3 2 2 8 
Methamphetamine/  
Amphetamine2 48 63 51 54 33 249 
Ketamine2 3 2 3 1 3 12 
 
1Includes calls for all exposure reasons. 
2Includes calls for the following exposure reasons: intentional misuse, intentional abuse, intentional unknown, contamina-
tion/tampering, and other malicious.  
SOURCE:  California Poison Control System
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Exhibit 8b. Los Angeles County Poison Control Center Exposure Calls for Prescription and Over-the- 
  Counter Medications and Common Household Substances:  January 2000–June 2004  
 
Substance1 2000 Number  
2001 
Number  
2002 
Number 
2003 
Number 
1H2004 
Number 
Total 
Number 
Antidepressants  10 8 12 15 7 52 
Antipsychotics 4 5 5 4 7 25 
Benzodiazepines      
   Alprazolam 
   Clonazepam 
   Diazepam 
   Other   
 
10 
14 
16 
24 
 
14 
23 
17 
29 
 
8 
10 
8 
26 
 
12 
15 
16 
27 
 
7 
14 
4 
27 
 
51 
76 
61 
133 
Barbiturates 0 1 0 2 1 4 
Opiates/Analgesics 
   Codeine 
   Hydrocodone 
   Methadone 
   Oxycodone 
   Narcotic analgesics 
   Other (non-narcotic) 
 
2 
5 
3 
1 
5 
9 
 
6 
10 
4 
4 
6 
14 
 
2 
32 
5 
7 
6 
10 
 
4 
39 
3 
9 
8 
4 
 
1 
19 
1 
2 
3 
5 
 
15 
105 
16 
23 
28 
42 
Fentanyl 1 1 2 0 1 5 
Dextromethorphan 8 10 10 12 5 45 
Coricidin HBP 4 13 26 28 22 93 
Miscellaneous 
Anxiolytics 1 4 2 8 1 16 
Muscle Relaxants 7 6 8 13 8 42 
Ritalin/Adderall 5 10 11 9 2 37 
Other Stimulants 2 4 2 1 0 9 
Other 13 20 23 16 12 84 
Unknown 2 2 3 4 2 13 
 
1Includes calls for the following exposure reasons: intentional misuse, intentional abuse, intentional unknown, contamina-
tion/tampering, and other malicious.  
SOURCE:  California Poison Control System 
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Exhibit 9. Los Angeles County Poison Control Center Exposure Calls for Select Substances, by Gender, 
Age, and Percent: January 2003–June 2004  
 
 Cocaine/ Crack 
Meth/ 
Ampheta-
mine 
Ritalin/ 
Adderall Ecstasy 
Coricidin 
HBP 
Dextro- 
methorphan 
Gender 
   Male 
   Female 
   Unknown 
 
68 
32 
0 
 
53 
44 
3 
 
64 
36 
0 
 
57 
43 
0 
 
52 
48 
0 
 
59 
35 
6 
Age Group 
   Younger than 13 
   13–17 
   18–25 
   26–34 
   35–44 
   45–54 
   55 and older 
 
9 
7 
21 
25 
26 
12 
<1 
 
14 
10 
39 
25 
7 
4 
1 
 
18 
36 
28 
18 
0 
0 
0 
 
7 
14 
50 
18 
11 
0 
0 
 
6 
78 
16 
0 
0 
0 
0 
 
12 
53 
23 
6 
6 
0 
0 
Total Number of 
Calls 
 
138 
 
87 
 
11 
 
28 
 
50 
 
17 
 
SOURCE:  California Poison Control System  
 
 
 
 
Exhibit 10. Reported Drug Use Among Los Angeles County Secondary School Students, by Percent: 2003–
2004 School Year 
 
Usage Patterns Among  
Survey Respondents 7th Grade
1 9th Grade 11th Grade All Respondents2 
Cocaine (any form) 
   Lifetime 
   Past 30 days 
 
*** 
*** 
 
5.4 
3.0 
 
7.5 
3.5 
 
7.4 
3.8 
Ecstasy 
   Lifetime 
   Past 30 days 
 
*** 
N/A3 
 
4.3 
N/A 
 
5.7 
N/A 
 
5.5 
N/A 
Heroin 
   Lifetime 
   Past 30 days 
 
*** 
*** 
 
3.1 
N/A 
 
3.0 
N/A 
 
3.3 
N/A 
Inhalants 
   Lifetime 
   Past 30 days 
 
12.5 
5.5 
 
13.7 
5.3 
 
12.6 
4.1 
 
13.4 
5.3 
LSD/Other Psychedelics  
   Lifetime 
   Past 30 days 
 
 
*** 
*** 
 
 
4.4 
2.5 
 
 
5.9 
2.5 
 
 
5.8 
2.9 
Marijuana 
   Lifetime 
   Past 30 days 
 
7.3 
4.3 
 
20.4 
10.9 
 
32.8 
15.1 
 
19.8 
10.3 
Methamphetamine 
   Lifetime 
   Past 30 days 
 
*** 
*** 
 
5.4 
2.9 
 
7.2 
3.4 
 
7.3 
3.7 
 
1The 7th grade data for several drugs (i.e., cocaine/crack, ecstasy, heroin, LSD/other psychedelics, and methamphetamine) were 
based on responses from a very small subset of 7th graders. Therefore, these results have been suppressed (***). 
2All respondents include responding 7th graders (when applicable), 9th graders, 11th graders, and a small sample of nontraditional 
students (enrolled in continuation or alternative schooling programs).  
3 N/A=Not applicable. 
SOURCE:  California Healthy Kids Survey, Los Angeles County Sample, WestEd 
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Exhibit 11. Past-6-Month Substance Use Among Los Angeles County Secondary School Students, by  
 Percent: 2003–2004 School Year 
 
Usage Patterns Among  
Survey Respondents 7th Grade
1 9th Grade 11th Grade All Respondents2 
Any Alcohol 22.1 36.7 52.5 34.7 
Inhalants 10.4 9.2 6.2 9.2 
Marijuana 9.2 15.9 22.7 15.4 
Cocaine (any form), Metham-
phetamine, or Other 
Stimulants 
*** 7.1 6.5 7.5 
Psychedelics, Ecstasy, or 
Other Club Drugs *** 6.2 5.0 6.2 
Other Drugs, Heroin, or 
Sedatives *** 6.3 5.2 6.2 
Two or More Drugs at the 
Same Time  9.9 9.4 12.4 11.4 
 
1The 7th grade data for several drug categories were based on responses from a very small subset of 7th graders. Therefore, these 
results have been suppressed (***). 
2All respondents include responding 7th graders (when applicable), 9th graders, 11th graders, and a small sample of nontraditional 
students (enrolled in continuation or alternative schooling programs).  
 
SOURCE:  California Healthy Kids Survey, Los Angeles County Sample, WestEd 
 
Exhibit 12. Long-Term Trends in the Percentage of Current Substance Users Among a Sample of Los  
 Angeles County Secondary School Students, by Percent: 1999–2004 
 
School Year Respondents1 Reporting Past 30-Day 
Use of… 1999–2000 2000–2001 2001–2002 2002–2003 2003–2004 
At Least One Drink of Alcohol  29.2 28.4 25.4 24.8 24.6 
5+ Alcoholic Drinks/Occasion (a.k.a., Binge 
Drinking)  
 
14.4 
 
13.4 
 
12.4 
 
12.4 
 
12.3 
Cocaine (any form)  4.9 4.3 3.9 3.8 3.8 
Inhalants  5.7 5.1 5.0 5.3 5.3 
LSD/Other Psychedelics  5.0 4.4 3.3 2.8 2.9 
Marijuana  13.2 13.0 12.0 10.9 10.3 
Methamphetamine   4.6 4.3 4.1 4.3 3.7 
 
1All respondents include responding 7th graders (when applicable), 9th graders, 11th graders, and a small sample of nontraditional 
students (enrolled in continuation or alternative schooling programs).  
SOURCE: California Healthy Kids Survey, Los Angeles County Sample, WestEd 
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Exhibit 13.  Illicit and Prescription Drug Prices in Los Angeles:  July–December 2004 
 
Price Type of Drug Wholesale Midlevel Retail 
Cocaine 
     Powder 
     Crack Cocaine  
 
$14,000–$17,000 per kilogram 
N/R1 
 
$500–$600 per ounce 
$500–$1,200 per ounce 
 
$80 per gram 
$10–$40 per rock 
Heroin 
     Mexican Black Tar 
     Mexican Brown   
          Powder 
     Southeast Asian 
     Southwest Asian  
          Opium 
     South American 
 
$20,000 per kilogram 
$25,000 per kilogram 
 
$70,000–$80,000 per kilogram 
$30,000 per kilogram 
 
$86,000–$100,000 per kilogram 
 
$500–$800 per 25 grams 
N/R 
 
N/R 
N/R 
 
N/R 
 
$90–$100 per gram 
N/R 
 
N/R 
$650–$800 per 18-gram 
stick 
N/R 
Marijuana 
     Mexico-produced 
     Domestic 
     Sinsemilla 
     BC Bud 
 
$300–$400 per pound 
$1,000–$1,200 per pound 
$2,500–6,000 per pound 
$6,000 per pound 
 
$60–$80 per ounce 
$200–$250 per ounce 
$300–$600 per ounce 
N/R 
 
$10 per gram 
$25 per gram 
$60–$80 per 1/8 ounce 
N/R 
Hashish $8,000 per pound N/R N/R 
Methamphetamine 
 
 
 
Crystal Methamphetamine 
$5,000–$7,000 per pound 
 
 
 
$8,000–$11,000 per pound 
$500–$800 per ounce 
 
 
 
$600–$900 per ounce 
$50 per gram 
$60–75 per 1/16 ounce 
$100–$120 per 1/8 ounce 
 
$100–125 per gram 
Pseudoephedrine 
$3,250–$4,000 double case        
     (1 case=17,000 60-mg  
     tablets) 
N/R N/R 
PCP $15,000–$20,000 per gallon $300–$350 per ounce $20–$30 per sherm ciga-rette 
LSD $150–$200 per sheet (100 
doses) 
N/R $5–$10 per dose 
Psilocybin Mushrooms N/R N/R $20 per 1/8 ounce 
MDMA (ecstasy) $8,000 per boat (1,000 tablets) $12 per tablet (multiple quanti-ties) $20–$40 per tablet 
GHB 
$275–$350 per gallon 
$80–$100 per liter 
$120 per 16 ounce bottle 
N/R $5–$20 per capful 
GBL $600 per liter NR N/R 
Ketamine N/R $100–$200 per 10 milliliter vial $20 per two-tenths gram 
Rohypnol (flunitrazepam) N/R N/R $6–$10 per 1-mg pill 
Steroids N/R N/R $10 per dose 
Valium (diazepam) N/R N/R $1 per 5-mg tablet 
Vicodin ES (hydrocodone) N/R N/R $1 per 10-mg tablet 
OxyContin (oxycodone) N/R N/R $50–$80 per 80-mg tablet 
MS Contin  N/R N/R $20 per 60-mg tablet 
Percocet/Percodan N/R N/R $1–$5 per 5-mg tablet 
Dilaudid (hydromorphone) N/R N/R $20–$60 per 4-mg tablet 
Methadone N/R N/R $10 per tablet 
Codeine N/R $80–200 per liquid pint $1–$2.5 per tablet 
Duragesic Patch (fentanyl) N/R N/R $25–$100 per patch 
Xanax (alprazolam) N/R N/R $1 per 4-mg tablet 
 
1N/R=Not reported. 
SOURCE:  National Drug Intelligence Center and LA County Regional Criminal Information Clearinghouse 
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Exhibit 14. Number of ED Reports, by Drug Category and Case Type (Selected Drugs) in the Los  
  Angeles County Division (Unweighted1): January–December 2004 
 
Selected Drug Categories, by Case Type Number of ED Reports1 
Antidepressants 
     Seeking detoxification 
     Overmedication 
     Other 
249 
2 
181 
66 
Antipsychotics 
     Seeking detoxification 
     Overmedication 
     Other 
249 
0 
204 
45 
Benzodiazepines 
     Seeking detoxification 
     Overmedication 
     Other 
450 
25 
251 
174 
Barbiturates 
     Seeking detoxification 
     Overmedication 
     Other 
51 
2 
6 
43 
Opiates/Opioids 
     Seeking detoxification 
     Overmedication 
     Other 
387 
35 
134 
218 
Muscle Relaxants 
     Seeking detoxification 
     Overmedication 
     Other 
81 
3 
72 
6 
Total of Other Substances 2,255 
 
1The unweighted data are from 9 to 14 EDs reporting to Los Angeles area hospitals. All DAWN cases are reviewed for quality con-
trol. Based on this review, cases may be corrected or deleted. Therefore, these data are subject to change.  
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14/05 
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Exhibit 15. Annual Adult/Adolescent AIDS Cases by Gender, Year of Diagnosis, and Exposure Category:  
  1998–2004 
 
Adult/Adolescent  
Exposure Category1 
1998 
Number 
(%) 
1999 
Number
(%) 
2000 
Number
(%) 
2001 
Number
(%) 
2002 
Number 
(%) 
20032 
Number 
(%) 
20042 
Number
(%) 
Males 
Male-to-Male Sexual  
Contact 
1,117 
(65) 
1,039 
(66) 
943 
(64) 
914 
(64) 
1,001 
(65) 
871 
(68) 
451 
(61) 
Injection Drug Use  102 
(6) 
76 
(5) 
92 
(6) 
92 
(6) 
83 
(5) 
56 
(4) 
41 
(6) 
Male-to-Male Sexual  
Contact/Injection Drug Use 
115 
(7) 
97 
(6) 
110 
(7) 
100 
(7) 
101 
(7) 
81 
(6) 
22 
(3) 
Hemophilia or Coagulation 
Disorder 
<5 
(-) 
<5 
(-) 
<5 
(-) 
5 
(<1) 
<5 
(-) 
<5 
(-) 
<5 
(-) 
Heterosexual Contact 61 
(4) 
57 
(4) 
53 
(4) 
72 
(5) 
60 
(4) 
56 
(4) 
18 
(2) 
Transfusion Recipient 5 
(<1) 
<5 
(-) 
<5 
(-) 
5 
(<1) 
6 
(<1) 
<5 
(-) 
<5 
(-) 
Mother with/at Risk for HIV <5 
(-) 
<5 
(-) 
<5 
(-) 
<5 
(-) 
<5 
(-) 
<5 
(-) 
<5 
(-) 
Other/Undetermined 304 
(18) 
300 
(19) 
273 
(18) 
249 
(17) 
291 
(19) 
221 
(17) 
206 
(28) 
Male Subtotal 1,706 1,573 1,481 1,437 1,543 1,290 738 
Females 
Injection Drug Use 47 
(22) 
42 
(20) 
39 
(17) 
42 
(19) 
43 
(19) 
22 
(13) 
14 
(13) 
Hemophilia or Coagulation 
Disorder 
<5 
(-) 
<5 
(-) 
<5 
(-) 
<5 
(-) 
<5 
(-) 
<5 
(-) 
<5 
(-) 
Heterosexual Contact 99 
(46) 
101 
(47) 
103 
(46) 
85 
(37) 
79 
(36) 
71 
(41) 
35  
(34) 
Transfusion Recipient <5 
(-) 
<5 
(-) 
<5 
(-) 
7 
(3) 
8 
(4) 
<5 
(-) 
<5 
(-) 
Mother with/at Risk for HIV <5 
(-) 
<5 
(-) 
<5 
(-) 
<5 
(-) 
<5 
(-) 
<5 
(-) 
<5 
(-) 
Other/Undetermined 64 
(30) 
67 
(31) 
82 
(36) 
92 
(41) 
90 
(41) 
79 
(46) 
51 
(49) 
Female Subtotal 215 214 226 227 221 173 104 
Total 1,921 1,787 1,707 1,664 1,764 1,463 842 
 
1Exposure categories are ordered hierarchically. Cases with multiple exposure categories are included in the category listed first.  
2Data are provisional due to reporting delay. 
SOURCE:  Los Angeles County Department of Health Services, HIV Epidemiology Program 
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Drug Abuse in South Florida:  
January–December 2004 
 
James N. Hall1 and Madeline Camejo, 
Pharm.D.2 
 
ABSTRACT 
 
Cocaine continues to dominate the consequences of 
drug abuse across South Florida as the epidemic 
enters its fourth decade. Its steady flow into the re-
gion fuels consequences with widely available, 
cheap cocaine. The majority of morbidity and mor-
tality cocaine indicators are among those older than 
35. Cocaine’s prevalence among selected popula-
tions is linked to poly-substance abuse patterns that 
are reflected in rising consequences of intentional 
medication abuse and the introduction of metham-
phetamine. Miami was ranked second to Jackson-
ville in the number of cocaine-related deaths in 
2004. Broward and Palm Beach Counties led the 
State in the number of heroin deaths in 2004. Over-
all, however, heroin deaths are down statewide, as 
narcotic analgesic fatalities are steadily increasing. 
Methadone-related deaths rose 40 percent between 
2003 and 2004 statewide, as deaths caused by 
methadone increased 51 percent. Problems linked to 
the club drugs, GHB and MDMA, continue the de-
cline observed since 2001. Five vectors of metham-
phetamine trafficking are spreading its abuse to 
new populations. Benzodiazepine deaths are second 
only to alcohol deaths in the State. Medication 
abuse appears to be a significantly greater problem 
in Broward County than in Miami-Dade. 
 
INTRODUCTION 
 
This report addresses drug abuse in Miami-Dade and 
Broward Counties, Florida, during 2004. It includes 
data on drug-related deaths, medical emergencies, 
addiction treatment admissions, and law enforcement 
intelligence. Information is presented by primary 
substance of abuse, with topics including cocaine, 
heroin, other opiates, marijuana, gamma hydroxybu-
tyrate (GHB), methylendioxymethamphetamine 
(MDMA or “ecstasy”), methamphetamine, and ben-
zodiazepines. While the information is classified by a 
single drug or category, the reader should note an 
underlying problem of polysubstance abuse as men-
                                                           
1Mr. Hall is the director of the Center for the Study and Prevention 
of Substance Abuse at Nova Southeastern University and is execu-
tive director of Up Front Drug Information Center in Miami, Florida. 
2Dr. Camejo is affiliated with the Memorial Regional Hospital, 
Hollywood, Florida, and the United Way of Broward County Com-
mission on Substance Abuse, Ft. Lauderdale, Florida. 
tioned throughout this report. Exhibits for the report 
follow the narrative text. 
 
Area Description 
 
Located in the extreme southern portion of the Florida 
peninsula, Miami-Dade County has a population of 
nearly 2.6 million; 56 percent are Hispanic, 21 percent 
are Black, 21 percent are White, and 2 percent are 
Asian/Pacific Islander. Miami is Dade County’s largest 
city, with 360,000 residents. More than 100,000 immi-
grants arrive in Florida each year; one-half establish 
residency in Miami-Dade County. 
 
Broward County, situated due north of Miami-Dade, is 
composed of Ft. Lauderdale plus 28 other municipali-
ties and an unincorporated area. The county covers 
1,197 square miles, including 25 miles of coastline. 
According to the 2000 census, the population was 
1,649,925. The population is roughly 63 percent White 
non-Hispanic, 21 percent Black non-Hispanic, and 17 
percent Hispanic.  
 
Broward County is the second most populated county 
in Florida and accounts for approximately 10 percent of 
Florida’s population. Broward was the top growth 
county in Florida in the 1990s and added 367,000 more 
people during that decade. Palm Beach County (popu-
lation 1,154,464) is located due north of Broward 
County and is the third most populated county in the 
State. Together, the 5.4 million people of these 3 coun-
ties constitute one-third of the State’s 16.3 million 
population.  
 
Starting in 2003, these three counties constitute the new 
federally designated Metropolitan Statistical Area 
(MSA) for South Florida, making it the sixth largest in 
the Nation. Previously, the MSA included only Miami-
Dade County. This means that Broward County will 
now be included in more national data sets tracking 
health-related conditions and criminal justice informa-
tion. One change is that more local hospitals will be-
come a part of the national Drug Abuse Warning Net-
work (DAWN) that monitors emergency department 
(ED) reports of drug-related episodes. 
 
Approximately 25 million tourists visit South Florida 
annually. The region is a hub of international transpor-
tation and the gateway to commerce between the 
Americas, accounting for sizable proportions of the 
Nation’s trade: 40 percent with Central America, 37 
percent with the Caribbean region, and 17 percent with 
South America. South Florida’s airports and seaports 
remain among the busiest in the Nation for both cargo 
and international passenger traffic. These ports of entry 
make this region a major gateway for illicit drugs. 
Smuggling by cruise ship passengers is an important 
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Miami-Ft. Lauderdale, Florida 
 
 
Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005 133
trend in South Florida drug trafficking and has appar-
ently been growing because of airline security increases 
after September 11, 2001. 
 
Several factors impact the potential for drug abuse 
problems in South Florida, including the following: 
 
• Proximity to the Caribbean and Latin America 
exposes South Florida to the entry and distrib-
ution of illicit foreign drugs destined for all re-
gions of the United States. Haiti remains a link 
with Colombian traffickers. 
 
• South Florida is a designated High Intensity Drug 
Trafficking Area and one of the Nation’s leading 
cocaine importation centers. It also became a 
gateway for Colombian heroin in the 1990s. Mil-
lions of MDMA (“ecstasy,” or “XTC”) tablets 
originate in the Benelux countries and often—
more recently—are flown to the Caribbean before 
entering the United States in South Florida. 
 
• Extensive coastline and numerous private air and 
sea vessels make it difficult to pinpoint drug im-
portation routes into Florida and throughout the 
Caribbean region. 
 
• Lack of a prescription monitoring system in 
Florida now makes the State a source for di-
verted medications throughout the southeastern 
United States. 
 
Data Sources 
 
This report describes current drug abuse trends in 
South Florida, using the data sources summarized 
below: 
 
• Drug-related mortality data were provided by 
the Florida Department of Law Enforcement 
(FDLE), Medical Examiners Commission’s 2004 
Report of Drugs Identified in Deceased Persons 
by the Florida Medical Examiners’ Commission. 
 
• Emergency department data were derived for 
calendar year 2004 from the DAWN Live! re-
stricted-access online query system administered 
by the Office of Applied Studies (OAS), Sub-
stance Abuse and Mental Health Services Ad-
ministration (SAMHSA). Eligible hospitals in 
only the Miami-Dade County Division totaled 
21; hospitals in the DAWN sample numbered 17, 
with the number of emergency departments in 
the sample also totaling 17. (Some hospitals have 
more than one emergency department.) During 
this 12-month period, 8 to 10 EDs reported data 
each month. The completeness of data reported 
by participating EDs varied by month (see ex-
hibit 1). Exhibits in this paper for Miami-Dade 
County reflect cases that were received by 
DAWN as of April 13–14, 2005. Eligible hospi-
tals in the Ft. Lauderdale Division only (that in-
cludes Broward and Palm Beach Counties) to-
taled 27; there were 22 hospitals in the DAWN 
sample, and the number of emergency depart-
ments in the sample also totaled 22. During this 
12-month period, 4 to 7 EDs reported data each 
month. The completeness of data reported by 
participating EDs varied by month (see exhibit 
2). Exhibits in this paper for Broward and Palm 
Beach Counties reflect cases that were received 
by DAWN as of the dates described below. Data 
from the two Broward County EDs for the first 
half of 2004 were accessed by the CEWG repre-
sentative directly on December 7, 2004, from the 
two participating hospitals, since at least four EDs 
in an area must report before the data are accessi-
ble through DAWN Live!. Data for the second 
half of 2004 for the Ft. Lauderdale Division were 
accessed from DAWN Live! on April 22, 2005, 
for cocaine, heroin, marijuana, and MDMA (ec-
stasy). Data for the second half of 2004 for the Ft. 
Lauderdale Division were accessed from DAWN 
Live! for oxycodone, hydrocodone, and benzodi-
azepines on May 10, 2005. Data for the second 
half of 2004 for the Ft. Lauderdale Division were 
accessed from DAWN Live! for amphetamine, 
methamphetamine, GHB, lysergic acid diethyla-
mide (LSD), and phencyclidine (PCP) on June 10, 
2005. All DAWN cases are reviewed for quality 
control. Based on this review, cases may be cor-
rected or deleted. Therefore, the data presented 
in this paper are subject to change. Data derived 
from DAWN Live! represent drug reports in 
drug-related ED visits. Drug reports exceed the 
number of ED visits, since a patient may report 
use of multiple drugs (up to six drugs and alco-
hol). The DAWN Live! data are unweighted and, 
thus, are not estimates for the reporting area. 
These data cannot be compared to DAWN data 
from 2002 and before, nor can preliminary data 
be used for comparison with future data. Only 
weighted DAWN data released by SAMHSA can 
be used for trend analysis. A full description of 
the DAWN system can be found at DAWN Web 
site http://dawninfo.samhsa.gov/. 
 
• Drug treatment data for 2004 were provided by 
the Broward Addiction Recovery Centers 
(BARC) of the Broward County Department of 
Human Services. 
 
• Crime lab drug analyses data were derived 
from the Drug Enforcement Administration’s 
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(DEA) National Forensic Laboratory Information 
System (NFLIS) 2004 Annual Report for Miami-
Dade County (January 2004 through December 
2004) and by the Broward Sheriff’s Office 
(BSO) Crime Lab for 2004 in Broward County.  
 
• Drug pricing data for South Florida were de-
rived from the National Drug Intelligence Center 
(NDIC), Narcotics Digest Weekly, December 28, 
2004. 
 
• Heroin price and purity information is from 
the U.S. DEA Domestic Monitoring Program 
2003 Report. 
 
• Survey data on prevalence of drug use among 
middle and high school students are from the 
2004 Florida Youth Substance Abuse Survey.  
 
Other information on drug use patterns was derived 
from ethnographic research and callers to local drug 
information hotlines. 
 
DRUG ABUSE PATTERNS AND TRENDS 
 
Beginning in 2003, SAMHSA’s national DAWN 
Live! increased the number of hospitals reporting to 
the national system and enhanced the surveillance of 
drug-related hospital ED mentions to provide ex-
panded and more rapid local reporting on such activ-
ity. In South Florida, DAWN is growing, with new 
emergency departments for the system in Broward 
and Palm Beach Counties to complete coverage for 
the region’s newly expanded national MSA. The new 
area is named the Miami/Ft. Lauderdale MSA. 
DAWN will also expand to the Tampa/St. Petersburg 
MSA in Florida, as well. 
 
Cocaine/Crack 
 
Now entering its fourth decade, South Florida’s co-
caine epidemic is characterized by morbidity and 
mortality rates that rank among the highest in the 
Nation. The steady flow of cocaine into the region 
fuels the epidemic with widely available cheap co-
caine. Cocaine abuse indicators dominate conse-
quences of drug abuse at high, yet stable rates. The 
majority of cocaine deaths, medical emergencies, and 
addiction treatment reports are among those older 
than 35. Many of the indicators reflect cocaine use in 
combination with other drugs, including opiates and 
benzodiazepines. 
 
Throughout Florida, the number of cocaine-related 
deaths increased in 2004, continuing a rising trend 
since 2000. There were 1,702 cocaine-related fatali-
ties during 2004 across Florida (exhibit 3), a 5-
percent increase from the 1,614 deaths in 2003. Co-
caine-related deaths in 2004 were at their highest 
peak statewide since the drug has been tracked in the 
late 1980s. Among the 2004 cases, 75 percent in-
volved the use of another drug, thus reflecting preva-
lent polydrug abuse patterns with cocaine. A large 
proportion of cocaine ED episodes also involved at 
least one other substance. 
 
In Florida, a drug is considered to be the cause of 
death if it can be detected in an amount considered to 
be a lethal dose by the local medical examiner (ME). 
Statewide, the number of lethal cocaine-induced death 
cases increased 9 percent from 541 in 2003 to 591 in 
2004. 
 
There were 160 deaths related to cocaine abuse in 
Miami-Dade County during 2004 (exhibit 4), repre-
senting a 15-percent decrease over the total from 
2003. Cocaine was detected at a lethal level in 35 
percent of the 2004 cases, up from 25 percent of the 
2003 cases and 21 percent of the 2002 cocaine-related 
deaths. Cocaine was found in combination with an-
other drug in 62 percent of the 2004 cases. Three of 
the 2004 cocaine-related fatalities were younger than 
18; 16 percent were age 18–25, 17 percent were 26–
34, 40 percent were 35–50, and 26 percent were older 
than 50. Cocaine-related deaths in Miami-Dade 
County totaled 189 in 2003, 151 in 2002, 149 in 
2001, 144 in 2000, 226 in 1999, and 273 in 1998.  
 
There were 120 deaths related to cocaine abuse in 
Broward County during 2004 (exhibit 5), represent-
ing a 13-percent decrease over the 138 cases from 
2003. Cocaine was detected at a lethal level in 37 
percent of the 2004 cases in Broward County, a pro-
portion that is down from 45 percent of 2003 cases and 
53 percent of the 2002 cases. Cocaine was found in 
combination with another drug in 85 percent of the 
2004 cases. None of the 2004 cocaine-related fatali-
ties was younger than 18; 12.5 percent were age 18–
25, 12.5 percent were 26–34, 50 percent were 35–50, 
and 25 percent were older than 50. Cocaine-related 
deaths in Broward County totaled 138 in 2003, 121 in 
2002, 94 in 2001, 80 in 2000, and a record high 139 
in 1999.  
 
The Jacksonville area had the highest number of co-
caine-related deaths in the State during 2004, with 205 
cases, followed by Miami with 160, West Palm Beach 
with 151, St. Petersburg with 150, Orlando with 136, 
and Broward County with 120. Jacksonville reported 
the highest number of cocaine deaths with 74, fol-
lowed by Palm Beach County with 68. 
 
Unweighted data on ED cocaine reports in Miami-
Dade County were accessed from DAWN Live! for 
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2004. Cocaine was the most commonly involved il-
licit drug in local emergency department visits, ac-
counting for 59 percent of the 9,225 Miami-Dade 
major substances of abuse reports (not including al-
cohol-in-combination with another drug, any alcohol 
below the age of 21, and medications) in 2004 (ex-
hibit 6).  
 
Most (71 percent) of the 5,420 Miami-Dade cocaine-
involved ED patients were male. Non-Hispanic 
Blacks accounted for 46 percent of the cocaine pa-
tients; 30 percent were non-Hispanic Whites; and 17 
percent were Hispanics. Race/ethnicity was not 
documented or unknown for 6 percent of the patients. 
Cocaine-involved ED patients were age 35 or older in 
61 percent of the reports, which continues a pattern 
of older cocaine ED patients. The patients’ ages were 
as follows: less than 1 percent (25) were age 12–17, 
12 percent were 18–24, 26 percent were 25–34, 37 
percent were age 35-44, and 24 percent were 45 or 
older.  
 
Broward County drug-related ED episodes are based 
on a record review of two Broward County hospitals 
participating in DAWN during the first 6 months of 
2004 and from 4 to 6 hospitals through DAWN Live! 
in the second half of the year. The network is expand-
ing, and data from more hospitals will be included in 
future reports. Cocaine was clearly the most com-
monly reported illicit drug in local emergency de-
partment visits, accounting for 58 percent of the 
3,383 Broward major substances of abuse reports 
(not including alcohol-in-combination with another 
drug, any alcohol below the age of 21, and medica-
tions) in 2004 (exhibit 7).  
 
Most (69 percent) of the 1,953 Broward cocaine ED 
patients were male. Fifty-seven percent were non-
Hispanic Whites, 32 percent were non-Hispanic 
Blacks, and 10 percent were Hispanic/other. Cocaine-
involved ED patients were age 35 or older in 48 per-
cent of these cases. The patients’ ages were as fol-
lows: 1 percent were in their teens, 15 percent were 
age 18–24, and 37 percent were 25–34.  
 
Cocaine accounted for 2,924 (or 41 percent) of pri-
mary, secondary, and tertiary treatment drug men-
tions (excluding alcohol) among the 3,609 BARC 
patients who cited as least 1 drug of abuse at time of 
admission during 2004. Of the cocaine mentions, 51 
percent were as the primary drug of abuse, 39 percent 
were as secondary drug, and 9 percent were as the 
tertiary drug problem. One-half of the cocaine treat-
ment mentions were from White, non-Hispanic cli-
ents, 37 percent were from Black, non-Hispanic pa-
tients, and 13 were from Hispanics. BARC client data 
are for clients age 18 and older. Those age 18–24 
accounted for 7 percent of the cocaine treatment 
mentions; 20 percent were age 25–34 years; and 73 
percent were older than 34. If alcohol clients were 
included, the number of total patients citing at least 1 
substance of abuse rises to 6,114, of whom 37 per-
cent cited alcohol as a primary, secondary, or tertiary 
problem. The inclusion of alcohol lowers the propor-
tion of cocaine mentions to 26 percent of all BARC 
mentions including alcohol. 
 
Powder cocaine and crack are still described as 
“widely available” throughout Florida. Cocaine is 
still the most commonly analyzed substance by the 
Miami-Dade and Broward Sheriff’s Office crime 
labs. It accounted for 10,972 cases (or 69 percent of 
all items tested) in Miami-Dade for 2004 and for 
5,458 cases or 68 percent of all items analyzed in 
Broward County in 2004. The second most com-
monly analyzed substance was marijuana in both 
counties.  
 
According to the National Drug Intelligence Center, 
in South Florida powder cocaine sells for $18,000–
$26,000 per kilogram wholesale, $700–$800 per 
ounce, and $40–$110 per gram retail. Crack cocaine 
sells for $700–$800 per ounce, $100 per gram, and 
$10–$20 per “rock” in South Florida.  
 
In 2004, current (past-30-day) cocaine use was re-
ported in results of the Florida Youth Substance 
Abuse Survey by 0.9 percent of Broward County 
middle and high school students (down from 1.4 per-
cent in 2000) (exhibit 8a). Current crack cocaine use 
was reported by 0.6 percent of Broward students in 
2004 (down from 0.9 percent in 2000). Among Mi-
ami-Dade County middle and high school students, 
1.2 percent reported current cocaine use in 2004 
(down from 1.5 percent in 2000). Current crack co-
caine use was reported by 0.6 percent of Miami-Dade 
students in 2004 (down from 0.8 percent in 2000). 
Current cocaine use was reported by 1.6 percent of 
Palm Beach County middle and high school students 
in 2004 (up from 0.9 percent in 2000 and 2002). Cur-
rent crack cocaine use was reported by 0.6 percent of 
Palm Beach students in 2004 (up from 0.4 percent in 
2000 and 0.3 in 2002). The proportion for the middle 
and high school students in all of Florida reporting 
current cocaine use was 1.5 percent in 2004, and 0.6 
percent reported crack use.  
 
Heroin 
 
The wholesale and retail prices of heroin have de-
clined locally recently, as the area has experienced a 
diversification of opioid abuse to include oxycodone, 
methadone, hydrocodone, heroin, and other opioids. 
Frequently, benzodiazepines are involved as well. 
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Most deaths, ED visits, and addiction treatment ad-
missions continue to be among older, White males. 
South American heroin has been entering the area 
over the past decade. Abuse of narcotic pain medica-
tion has fueled opioid consequences. Polydrug abuse 
patterns have facilitated first-time use of opiate 
drugs, including heroin.  
 
Throughout Florida, there were 180 heroin-related 
deaths in 2004, representing a 31-percent decline from 
261 such deaths in 2003; heroin-related deaths totaled 
326 in 2002 and 328 in 2001. Yet, heroin was found to 
be the most lethal drug, with 83 percent (n=150) of 
heroin-related deaths being caused by the drug in 
2004, a 35-perent decline from 2003. Heroin deaths 
continued a 4-year decline, but deaths from prescrip-
tion narcotic opiates have increased over the same 
period. Polysubstance abuse was noted in 83 percent 
of the heroin-related deaths statewide (exhibit 3).  
 
In 2004, Broward County (n=35) and Palm Beach 
County (n=29) had the greatest number of heroin-
related deaths in the State. They were followed by 
Orlando (22 cases), Miami-Dade County (18), Sara-
sota (15), and Tampa and St. Petersburg (each with 
14 cases). 
In Miami-Dade County, heroin was found at a lethal 
dose level in all of the 18 deaths in which heroin was 
detected. Other drugs were detected in 14 (78 per-
cent) of the cases (exhibit 4). None of the heroin-
related fatalities was younger than 26; 33 percent 
were age 26–34, 56 percent were 35–50, and 11 per-
cent were older than 50.  
 
The 18 heroin-related deaths in Miami-Dade during 
2004 reflected a 44-percent decrease over the 32 in 
2003. Heroin deaths peaked in Miami-Dade County in 
2000 with 61 fatalities.  
In Broward County, the 35 deaths in which heroin 
was detected included 22 cases (63 percent) in which 
the drug was found at a lethal dose level. Other drugs 
were detected in 33 (94 percent) of the cases (exhibit 
5). None of the heroin-related fatalities was younger 
than 18; 11 percent were age 18–25, 20 percent were 
26–34, 49 percent were 35–50, and 20 percent were 
older than 50.  
The 35 heroin-related deaths during 2004 in Broward 
County reflected a 29-percent decrease over the 49 in 
2003. There were 50 heroin-related deaths in 2002 
and 41 in 2001. The relatively low number of 24 her-
oin-related deaths in 2000 was attributed to a sharp 
rise in other opioid deaths linked to prescription nar-
cotics. Heroin-related deaths rose from 9 in 1995 to 
49 in 2003. 
 
Based on unweighted data accessed from DAWN 
Live! from Miami-Dade County emergency depart-
ments during 2004, there were a total of 1,387 heroin 
reports, representing 15 percent of major substances 
of abuse reports (not including alcohol-in-
combination with another drug, any alcohol below 
the age of 21, and medications) (exhibit 6). Males 
accounted for 79 percent of these patients, and 47 
percent were non-Hispanic Whites. Blacks repre-
sented 22 percent of the heroin ED patients, and His-
panics accounted for 21 percent of the patients. There 
were two patients younger than 5 and three age 12–
17, while 12 percent were age 18–24, 37 percent 
were 25–34, and 51 percent were older than 34.  
 
Unweighted data for 2004 from the Broward emer-
gency departments identified a total of 399 heroin 
reports, representing 12 percent of major substances 
of abuse reports (not including alcohol-in-
combination with another drug, any alcohol below 
the age of 21, and medications) (exhibit 7). The her-
oin ED patients were predominantly older White 
males seeking detoxification. Males accounted for 66 
percent of the patients, and 77 percent were non-
Hispanic Whites. Hispanics accounted for 12 percent 
of the heroin ED patients, and Blacks also repre-
sented 12 percent of the patients. There were no pa-
tients younger than 18, while 12 percent were age 
18–24, 33 percent were age 25–34, and 54 percent 
were older than 34. The most common reason for a 
heroin patient to visit the ED was dependence and 
withdrawal or seeking detoxification in 64 percent of 
the cases. 
 
Heroin accounted for 956 (or 13 percent) of primary, 
secondary, and tertiary treatment drug mentions (ex-
cluding alcohol) among the 3,609 BARC patients 
who cited as least 1 drug of abuse at time of admis-
sion during 2004. Of the heroin mentions, 80 percent 
were as the primary drug of abuse, 12 percent were as 
secondary drug, and 7 percent were as the tertiary 
drug problem. Two-thirds (66 percent) of the heroin 
treatment mentions were from White, non-Hispanic 
clients, 23 percent were from Hispanics, and 11 per-
cent were from Black, non-Hispanic patients. BARC 
client data are for clients age 18 and older. Those age 
18–24 accounted for 9 percent of the heroin treatment 
mentions; 30 percent were age 25–34, and 61 percent 
were older than 34. 
 
Heroin accounted for 658 crime lab cases in Miami-
Dade for 2004 according to the NFLIS, representing 
4 percent of all drugs tested. There were 153 heroin 
cases worked by the Broward Sheriff’s Office Crime 
Lab in 2004, a 40-percent decrease from the 254 her-
oin cases in 2003. The U.S. DEA Domestic Monitor-
ing Program analyzed 40 street-level samples of her-
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oin in South Florida in 2003. All of the samples were 
South American heroin, and they averaged 25.8 per-
cent pure heroin. The average price per milligram 
pure was $0.90. Compared with 2002 purities, the 
average purity of samples declined modestly, while 
the price per milligram pure rose by 50 percent 
($0.29) and thus returned to levels recorded in 2001. 
Nationally, there were 470 South American heroin 
samples tested by the program in 2003. The average 
purity was 41.8 percent heroin, and the average price 
was $0.77 per milligram pure. 
 
Colombian heroin is widely available in South Flor-
ida as described by law enforcement officials and 
epidemiologists/ethnographers. According to NDIC, 
1 kilogram of heroin sells for $45,000–$65,000 in the 
region and for $2,500 per ounce; retail prices are 
roughly $100–$150 per gram. The top price for her-
oin has dropped 19 percent at the kilogram level and 
25 percent at the gram level in the past 12 months. 
The most common street unit of heroin is a bag of 
heroin (roughly 20 percent purity) weighing about 
one-tenth of a gram that sells for $10.  
 
In 2004, current (past-30-day) heroin use was re-
ported in results of the Florida Youth Substance 
Abuse Survey by 0.3 percent of Broward County 
middle and high school students, down from 0.5 per-
cent in 2000 and equal to the proportion in 2002. 
Among Miami-Dade County middle and high school 
students, 0.6 percent reported current heroin use in 
2004, up from 0.5 percent in 2000 and 0.3 percent in 
2002. Current heroin use was also reported by 0.6 
percent of Palm Beach County middle and high 
school students, in 2004, up from 0.5 percent in 2000 
and 0.3 percent in 2002. The proportion for the mid-
dle and high school students in all of Florida report-
ing current heroin use was 0.3 percent in 2004. 
 
Other Opiates 
 
Following inhalants, the group of drugs mostly likely 
to be cited across Florida at lethal levels as the cause 
of death in cases where the drug was detected was 
opiates. As mentioned above, in 2004 heroin was 
considered the cause of death in 83 percent of the 
cases where it was detected, followed by 66 percent 
of the methadone deaths, 63 percent of fentanyl 
cases, and 50 percent of oxycodone deaths. Deaths 
from opiates other than heroin (including hydro-
codone, oxycodone, and methadone) have been 
tracked in Florida since 2000. Beginning in 2003, 
morphine, propoxyphene, fentanyl, hydromorphone, 
meperidine, and other opioids were included in the 
Florida Medical Examiners Commission’s surveil-
lance monitoring program. Deaths for all opiates 
tracked, including heroin, totaled 279 in Broward 
County and 140 in Miami-Dade in 2004. 
 
Methadone-related deaths statewide increased sig-
nificantly in 2004, rising by 40 percent when com-
pared to 2003, and deaths caused by methadone rose 
51 percent over the same period. This continues a 
steady increase of methadone-related deaths since 
2001. Methadone was considered the cause of death 
in 66 percent of the 849 deaths related to the drug in 
2004.  
 
The number of oxycodone-related deaths increased 7 
percent statewide between 2003 and 2004, when they 
totaled 674. Oxycodone was the cause of death in 50 
percent of the deaths related to it in 2004, causing a 
14-percent increase in oxycodone-induced deaths 
compared to 2003. 
 
The number of hydrocodone deaths increased 10 per-
cent statewide between 2003 and 2004, when they 
reached 572. Hydrocodone was the cause of death in 
36 percent of the hydrocodone-related deaths during 
2004, representing a 27-percent increase in hydro-
codone-induced deaths compared to 2003. 
 
Additional opiate-related analgesic deaths statewide in 
2004 included morphine (597), propoxyphene (347), 
fentanyl (182), hydromorphone (98), meperidine (42), 
and other opioids (194). When the ME mentions for all 
opiate analgesics are added to those for heroin, these 
opioid-related ME mentions in Florida during 2004 
total 3,915 cases. This total is even greater than the 
3,575 alcohol-related deaths during the same year. 
Most of the statewide opioid cases were polydrug epi-
sodes, including 88 percent of the oxycodone ME 
cases, 87 percent of the methadone ME cases, 87 per-
cent of the hydrocodone ME cases, 83 percent of the 
heroin deaths, 78 percent of propoxyphene deaths, and 
74 percent of morphine ME cases (exhibit 3). 
 
Miami-Dade County recorded 30 oxycodone-related 
deaths during 2004, of which 11 (37 percent) were 
oxycodone induced. Fourteen of these deaths (88 per-
cent) involved oxycodone found in combination with 
at least one other drug (exhibit 4). Miami-Dade 
County recorded 19 hydrocodone-related deaths dur-
ing 2004, and 5 (26 percent) were hydrocodone in-
duced. Miami-Dade County recorded 17 methadone-
related deaths in 2004, with 7 (41 percent) considered 
methadone induced. Miami-Dade recorded 41 mor-
phine-related deaths during 2004, of which 8 (20 per-
cent) were morphine induced. There were 15 pro-
poxyphene-related deaths in Miami-Dade County in 
2004, of which 4 (27 percent) were propoxyphene 
induced.  
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Broward County recorded 71 oxycodone-related 
deaths during 2004, of which 48 (68 percent) were 
oxycodone induced. All but two of these deaths in-
volved oxycodone found in combination with at least 
one other drug (exhibit 5). Broward County recorded 
38 hydrocodone-related deaths in 2004, and 18 (47 
percent) were hydrocodone induced. Broward County 
recorded 73 methadone-related deaths during 2004, 
with 45 (62 percent) considered methadone induced. 
Broward County recorded 44 morphine-related deaths 
during 2004, of which 12 (27 percent) were morphine 
induced. Broward County recorded 18 propoxyphene-
related deaths in 2004, of which 4 (22 percent) were 
propoxyphene induced.  
 
Unweighted data accessed from DAWN Live! for 
Miami-Dade County EDs for 2004 show 158 oxy-
codone ED reports. There were also 45 hydrocodone 
ED reports and 215 ED reports for other narcotic 
analgesics. Of the total 418 narcotic analgesic ED 
reports, 40 percent of the patients were seeking de-
toxification, 17 percent were considered overmedica-
tion cases, and 44 percent were considered drug 
abuse cases. 
 
Unweighted data from the Broward County EDs for 
2004 show 329 oxycodone ED reports. Males ac-
counted for 58 percent of these patients. White, non-
Hispanics represented 74 percent of the patients; 14 
percent were Black, non-Hispanics; and 12 percent 
were Hispanic/other. There were no patients younger 
than 18, while 24 percent of the oxycodone ED pa-
tients were age 18–24, 29 percent were 25–34, and 46 
percent were older than 34. The most common rea-
sons or chief complaints for the oxycodone ED pa-
tients to visit the ED were seeking detoxification (35 
percent) and overdose (14 percent). 
 
Unweighted data from the Broward County EDs for 
2004 show 151 hydrocodone ED reports. Males ac-
counted for 51 percent of these patients. White, non-
Hispanics represented 62 percent of the patients; 14 
percent were Black, non-Hispanics; and 24 percent 
were Hispanic/other. There were no patients younger 
than 18, while 21 percent of the hydrocodone ED 
patients were age 18–24, 35 percent were 25–34, and 
44 percent were older than 34. The most common 
reasons or chief complaints for the hydrocodone ED 
patients to visit the ED were overdose (27 percent) 
and seeking detoxification (24 percent), while 21 
percent had adverse reactions.  
 
Prescription opiates accounted for 714 (or 10 percent) 
of primary, secondary, and tertiary treatment drug 
mentions (excluding alcohol) among the 3,609 
BARC patients who cited as least 1 drug of abuse at 
time of admission during 2004. Of the prescription 
opiate mentions, 67 percent were as the primary drug 
of abuse, 14 percent were as secondary drug, and 18 
percent were as the tertiary drug problem.  
 
The NFLIS reported 59 oxycodone crime lab cases, 
26 hydrocodone cases, and 9 methadone cases in 
2004 in Miami-Dade County. The Broward Sheriff’s 
Office Crime Lab worked 250 oxycodone cases in 
2004. There were also 173 hydrocodone cases, 15 
hydromorphone cases, and 2 buprenorphine cases in 
2004. 
 
In 2004, current (past-30-day) use of oxycodone was 
reported in results of the Florida Youth Substance 
Abuse Survey by 0.4 percent of Miami-Dade County 
middle and high school students, up from 0.2 percent 
in 2002. Among Miami-Dade County middle and 
high school students, 1.7 percent reported use of 
other prescription pain medications in 2004 (exhibit 
8a), up from 1.4 percent in 2002. Current (past-30-
day) use of oxycodone was reported in results of the 
2004 Florida Youth Substance Abuse Survey by 0.3 
percent of Broward County middle and high school 
students, down from 0.6 percent in 2002. Among 
Broward middle and high school students, 1.8 percent 
reported use of other prescription pain medications in 
2004, just above the 1.7 percent reported in 2002. In 
Palm Beach County, current (past-30-day) use of 
oxycodone was reported by 0.9 percent of middle and 
high school students, up from 0.7 percent in 2002. 
Among Palm Beach County middle and high school 
students, 2.3 percent reported use of other prescrip-
tion pain medications in 2004, down from 3.5 percent 
in 2002. The proportion for the middle and high 
school students in all of Florida reporting current 
oxycodone use was 0.8 percent in 2004, and 3 per-
cent reported current use of other prescription pain 
medication. 
 
Marijuana 
 
Marijuana is abused by more Americans, particularly 
youth, than any other illicit drug. Consequences of its 
abuse and addiction continue, even as rates of its use 
are declining among youth. 
 
Cannabinoids were detected in 871 deaths statewide 
in Florida during 2004, representing an increase of 21 
percent from the 722 such cases during the year. 
 
Unweighted data from DAWN Live! for 2004 show 
that marijuana accounted for 2,098, or 23 percent, of 
the 9,225 Miami-Dade major substances of abuse 
reports (not including alcohol-in-combination with 
another drug, any alcohol below the age of 21, and 
medications) in 2004 (exhibit 6). Seventy-six percent 
of the marijuana ED patients were male. Non-
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Miami-Ft. Lauderdale, Florida 
 
 
Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005 139
Hispanic Blacks accounted for 44 percent of these 
patients; non-Hispanic Whites accounted for 29 per-
cent; and Hispanic/others accounted for 21 percent. 
Race/ethnicity was not documented or was unknown 
for 6 percent of the patients. There were 79 patients 
(4 percent) younger than 18, while 29 percent of the 
patients were age 18–24, 30 percent were 25–34, and 
36 percent were older than 34. 
 
Unweighted ED data from Broward County show 
that marijuana was involved in 25 percent, or 849, of 
the 3,383 drug abuse ED reports (not including alco-
hol-in-combination with another drug, any alcohol 
below the age of 21, and medications) in 2004 (ex-
hibit 7). Sixty-eight percent of the marijuana ED pa-
tients were male. Non-Hispanic Whites accounted for 
61 percent of these patients, non-Hispanic Blacks for 
25 percent, and Hispanics/other for 13 percent. Mari-
juana is still the most commonly abused illicit drug 
among young people visiting the emergency depart-
ment. Two-thirds of marijuana ED reports were 
among the 12–34 age group. There were 68 patients 
(8 percent) younger than 18, while 27 percent of pa-
tients were age 18–24, 32 percent were 25–34, and 33 
percent were older than 34.  
 
Marijuana accounted for 1,949 (or 27 percent) of 
primary, secondary, and tertiary treatment drug men-
tions (excluding alcohol) among the 3,609 BARC 
patients who cited as least 1 drug of abuse at time of 
admission during 2004. Of the marijuana mentions, 
37 percent were as the primary drug of abuse, 34 
percent were as secondary drug, and 29 percent were 
as the tertiary drug problem. One-half (49 percent) of 
the marijuana treatment mentions were from White, 
non-Hispanic clients, 37 percent were from Black, 
non-Hispanic patients, and 14 percent were from 
Hispanics. BARC client data are for clients age 18 
and older. Those age 18–24 accounted for 20 percent 
of the marijuana treatment mentions; 32 percent were 
age 25–34; and 48 percent were older than 34. 
 
The NFLIS reported 3,250 marijuana crime lab cases 
in Miami-Dade County in 2004, representing 20 per-
cent of all exhibits analyzed. There were 979 mari-
juana cases worked by the BSO Crime Lab during 
2004 (12 percent of all cases). Statewide, marijuana 
was seized more frequently than any other illicit drug 
in Florida. Marijuana is still described as widely 
available throughout Florida, with local commercial, 
sinsemilla, and hydroponic grades available. A pound 
of commercial grade marijuana sells for $450–$1,000 
per pound. Hydroponic grades sell for $2,500–$4,000 
per pound. Commerical grade prices range from $100 
to $150 per ounce, while hydroponic grade marijuana 
sells for $350–$450 per ounce. Depending on its po-
tency, marijuana may sell for $5–$18 per gram. 
 
In 2004, current (past-30-day) marijuana use was 
reported in results of the Florida Youth Substance 
Abuse Survey by 10.2 percent of Broward County 
middle and high school students (exhibit 8b), up 
slightly from 10.0 percent in 2002 but down from 
11.5 percent in 2000. Among Miami-Dade County 
middle and high school students, 8.6 percent reported 
current marijuana use in 2004, up from 6.5 percent in 
2002. In 2000, 8.9 percent of Miami-Dade middle 
and high school students reported current marijuana 
use. Current marijuana use was also reported by 11.4 
percent of Palm Beach County middle and high 
school students in 2004, down from 13.5 percent in 
2000 and 14.1 percent in 2002. The proportion for the 
middle and high school students in all of Florida re-
porting current marijuana use was 11.5 percent in 
2004. 
 
Gamma Hydroxybutyrate  
 
GHB, an anesthetic, has been a commonly abused 
substance in South Florida for the past 8 years. There 
are several compounds that are converted by the body 
to GHB, including gamma butyrolactone (GBL) and 
1,4 butanediol (1,4 BD). Most recently, GHB abuse 
involves the abuse of 1,4 BD. Indicators of abuse of 
these drugs continue to decline. Commonly used with 
alcohol, they have been implicated in drug-facilitated 
rapes and other crimes. They have a short duration of 
action and are not easily detectable on routine hospi-
tal toxicology screens. GHB was declared a federally 
controlled Schedule I drug in March 2000, and indi-
cators of its abuse have declined since that time. 
More recently, GHB and its related substances are 
reported to be used by those seeking to come down 
from stimulant effects of methamphetamine. 
 
There were 11 GHB-related deaths statewide during 
2004. The drug was considered the cause of death in 
six (55 percent) of these cases. There were also 11 
GHB-related deaths reported statewide during 2003, 
of which 27 percent were considered to have been 
caused by the drug. In all of Florida, GHB-related 
deaths increased from 23 in 2000 to 28 in 2001 and 
then declined to 19 in 2002 before declining to 11 in 
2003 and again in 2004.  
 
Unweighted data accessed from DAWN Live! for 
Miami-Dade County show 21 GHB-related ED re-
ports in 2004. There were six such DAWN Live! re-
ports in Broward County during 2004. 
 
From the previous tracking system for drug-related 
hospital ED episodes in Broward County, there had 
been a dramatic decrease in the number of GHB 
emergency department cases treated in emergency 
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departments from 2000 to 2003. The Broward Gen-
eral Medical Center (BGMC) Emergency Department 
treated three people with GHB or GHB precursor 
overdose in 1996. The number of these cases in-
creased to 48 in 1999 and peaked at 77 in 2000. 
There were 71 GHB cases in 2001 and 34 cases in 
2002. In 2003, there were 30 GHB ED cases at 
BGMC. This downward trend reflects the national 
pattern with GHB since 2000, when the drug was 
banned by Federal legislation.  
 
The NFLIS reported 23 crime lab cases of 1,4 BD in 
Miami-Dade County during 2004, along with 2 GHB 
cases and 2 GBL cases. The Broward Sheriff’s Office 
crime lab reported six cases of 1,4 BD, two cases of 
GHB, and one case of GBL in 2004. 
 
Methylenedioxymethamphetamine (MDMA, or 
“Ecstasy”) 
 
Measures of MDMA abuse suggest problems may 
have peaked in 2001, declined thereafter, and then 
stabilized between 2003 and 2004. 
 
Ecstasy pills generally contain 75–125 milligrams of 
MDMA, although pills are often adulterated and may 
contain other drugs being sold as “ecstasy.” The ma-
jor sources of the designer logo-emblazoned pills 
seem to be clandestine labs in Western Europe, espe-
cially the Netherlands and Belgium (and more re-
cently Spain). The pills enter South Florida from the 
Caribbean and are brought in by cruise ship passen-
gers because of post 9-11 airline security.  
 
There were 41 MDMA-related deaths statewide in 
Florida during 2004, with the drug being cited as the 
cause of death in 8 of these cases. There were also 27 
methylenedioxyamphetamine (MDA)-related deaths 
statewide in Florida in 2004, with that drug being 
cited as the cause of death in 5 of the cases. An addi-
tional six deaths were related to other unidentified 
methylated amphetamines in 2004, with those sub-
stances being the cause of two of the deaths. In 2003, 
there were 34 MDMA-related deaths, 20 MDA-
related deaths, and 1 other death from an unidentified 
methylated amphetamine in Florida. 
 
Unweighted DAWN data show 106 MDMA ED re-
ports from Miami-Dade County during 2004, repre-
senting only 1 percent of major substances of abuse 
ED reports.  
 
In the unweighted DAWN data for Broward County 
during 2004, there were 24 MDMA-related ED re-
ports. Males accounted for 58 percent of these pa-
tients; 79 percent were non-Hispanic Whites, 13 per-
cent were Hispanics, and 8 percent were non-
Hispanic Blacks. Thirteen percent were younger than 
18, 38 percent were age 18–24, 46 percent were age 
25–34, and one patient was older than 35.  
 
The NFLIS reported the Miami-Dade Crime Lab ana-
lyzed 250 MDMA exhibits and 42 MDA exhibits 
during 2004, representing 2 percent of all substances 
analyzed. In 2004, MDMA was the ninth most com-
mon case worked at the Broward Sheriff’s Office 
Crime Lab, with 89 MDMA cases analyzed, and 
there were also 22 MDA cases. In the last half of 
2003, the Crime Lab analyzed 58 MDMA cases and 
10 MDA cases. The number of MDMA cases peaked 
in the first half of 2001, with 132 cases; such cases 
declined to 42 in the second half of 2004. 
 
In South Florida, ecstasy tablets sell for $5–$7 per 
tablet wholesale (in bulk), $10–$20 retail for a single 
pill, or up to $50 per pill at expensive nightclubs. 
These prices have remained the same since 2002. 
 
In 2004, current (past-30-day) MDMA use was re-
ported in results of the Florida Youth Substance 
Abuse Survey by 0.6 percent of Broward County 
middle and high school students (exhibit 8a), down 
from 1.3 percent in 2002. Among Miami-Dade 
County middle and high school students, 1.0 percent 
reported current MDMA use in 2004, down from 1.4 
percent in 2002. Current MDMA use was also re-
ported by 1.3 percent of Palm Beach County middle 
and high school students in 2004, down from 1.9 
percent in 2002. The proportion of middle and high 
school students in all of Florida reporting current 
MDMA use was 1.1 percent in 2004. 
 
Methamphetamine 
 
Methamphetamine abuse continues to be a local 
problem, as new supply sources have been identified. 
“Crystal,” or smokable, methamphetamine has been 
shipped by overnight delivery from California for sev-
eral years. Law enforcement sources confirm in-
creased trafficking from Atlanta and North Carolina of 
high-grade Mexican-manufactured methamphetamine 
in the last year. There have also been several seizures 
of local methamphetamine labs. Mexican drug traf-
ficking organizations are supplying powered metham-
phetamine directly to local Latino populations of Cen-
tral and South American nationalities. Outlaw motor-
cycle gang activity involved with local lab production 
and distribution has also been noted in the past year. 
Signs of methamphetamine abuse spreading to new 
populations indicate the local epidemic has progressed 
from the incubation period of the past 3 years to an 
expansion phase with growing numbers of users. 
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Methamphetamine-related deaths totaled 93 during 
2004 statewide in Florida, representing a 21-percent 
increase from the 77 such deaths in the previous year. 
Methamphetamine was considered the cause of death 
in 19 of the 93 cases in 2004. There were also 95 am-
phetamine-related deaths in 2004 across Florida, a 28-
percent increase over 2003. Amphetamine was consid-
ered the cause of death in 7 of the 95 cases in 2004. 
 
Unweighted data accessed from DAWN Live! show 
38 methamphetamine-related ED reports during 2004 
in Miami-Dade County. Among those patients, 92 
percent were males, 55 percent were non-Hispanic 
Whites, 26 percent were Hispanics, and 8 percent 
were non-Hispanic Blacks. No methamphetamine ED 
patients were younger than 18; 26 percent were age 
18–24, 50 percent were age 25–34, and 24 percent 
were older than 34. 
 
Unweighted data accessed from DAWN Live! show 
18 methamphetamine-related ED reports during 2004 
in Broward County. Among those patients, 61 per-
cent were males, 67 percent were non-Hispanic 
Whites, 17 percent were Hispanics, and 11 percent 
were non-Hispanic Blacks. One methamphetamine 
ED patient was between 12 and 18 years of age; 28 
percent were age 18–24, 44 percent were age 25–34, 
and 22 percent were older than 34.  
 
Methamphetamine and other amphetamines accounted 
for 81 or (1 percent) of primary, secondary, and terti-
ary treatment drug mentions (excluding alcohol) 
among the 3,609 BARC patients who cited as least 1 
drug of abuse at time of admission during 2004. Of 
these mentions, 46 percent were as the primary drug of 
abuse, 22 percent were as secondary drug, and 32 per-
cent were as the tertiary drug problem.  
 
The NFLIS reported the Miami-Dade Crime Lab ana-
lyzed 153 methamphetamine exhibits during 2004, 
representing 1 percent of all substances analyzed. In 
2004, there were 96 Broward Sheriff’s Office Crime 
Lab methamphetamine cases analyzed. In 2003, there 
were 90 such cases. The number of these cases has 
more than doubled since 2001.  
 
Statewide, the number of clandestine methampheta-
mine labs or equipment seizures has risen from 30 
cases in fiscal year (FY) 2000 (October 1999 to Sep-
tember 2000) to 332 in the FY ending September 30, 
2004. 
 
In South Florida, methamphetamine has some of the 
highest prices in the Nation: $15,000–$20,000 per 
pound and $900–$1,200 per ounce. Higher potency 
“crystal” methamphetamine sells for $1,800–$2,000 
per ounce and $50 per quarter gram. 
 
In 2004, current (past-30-day) methamphetamine use 
was reported in results of the Florida Youth Sub-
stance Abuse Survey by 0.6 percent of Broward 
County middle and high school students (exhibit 8a), 
down from 0.9 percent in 2000. Among Miami-Dade 
County middle and high school students, 1.3 percent 
reported current methamphetamine use in 2004, up 
from 1.0 percent in 2000. Current methamphetamine 
use was also reported by 0.7 percent of Palm Beach 
County middle and high school students in 2004, 
down from 1.1 percent in 2000. The proportion for 
the middle and high school students in all of Florida 
reporting current methamphetamine use was 0.9 per-
cent in 2004. 
 
Hallucinogens 
 
Unweighted data accessed from DAWN Live! show 
35 LSD ED reports in Miami-Dade County in 2004 
and 6 in Broward County. There were 13 miscellane-
ous hallucinogen-related ED reports in Miami-Dade 
and 2 in Broward in 2004. There were 10 PCP ED 
reports in Miami-Dade during 2004 and 1 in Broward 
County. 
 
The NFLIS reported the Miami-Dade Crime Lab ana-
lyzed four LSD exhibits during 2004, and the Bro-
ward Sheriff’s Office crime lab analyzed three LSD 
samples. 
 
Benzodiazepines 
 
Benzodiazepines in general and alprazolam (Xanax) 
in particular are a substantial problem. Benzodiazepi-
nes were second only to alcohol in their involvement 
in drug-related deaths throughout Florida for the past 
several years. There were 2,011 benzodiazepine-
related deaths across Florida in 2004, representing a 
12-percent increase over the 1,794 such deaths in the 
previous year. Of the benzodiazepine-related deaths in 
2004, a benzodiazepine was identified as the cause of 
death in 460 cases (or 23 percent). 
 
In Miami-Dade County, there were 64 alprazolam-
related deaths during 2004, of which 13 (20 percent) 
were alprazolam induced. Seventy-eight percent of the 
deaths involved at least one other drug (exhibit 4). 
There were also 25 diazepam-related deaths in Miami-
Dade County, of which 2 (8 percent) were caused by 
the drug; 64 percent of these deaths involved at least 1 
other drug.  
 
Broward County recorded 115 alprazolam-related 
deaths during 2004, of which 38 (33 percent) were 
induced by the drug. Only 10 (9 percent) of the deaths 
involved alprazolam alone (exhibit 5). In the same 
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year, Broward County recorded 101 diazepam-related 
(Valium) deaths, of which 17 (17 percent) were di-
azepam induced. All but six of these cases involved 
at least one other drug. 
 
Unweighted data on ED benzodiazepine reports in 
Miami-Dade County show 917 such reports for 2004. 
Overmedication accounted for 33 percent of the re-
ports, while seeking detoxification was the reason for 
27 percent of the benzodiazepine reports. 
 
Unweighted ED data from Broward County show 
that there were 1,171 benzodiazepine ED cases in 
2004, ranking third behind alcohol and cocaine in the 
number of ED reports. Fifty-four of the benzodi-
azepine ED patients were male. Non-Hispanic Whites 
accounted for 77 percent of these patients, non-
Hispanic Blacks for 10 percent, and Hispanics/other 
for 14 percent. Nearly one-fifth of these patients were 
younger than 25, including 4 percent of total users 
younger than 18. Fifteen percent of patients were age 
18–24, 21 percent were 25–34, and 61 percent were 
older than 34. 
Benzodiazepines accounted for 616 (or 9 percent) of 
primary, secondary, and tertiary drug treatment men-
tions (excluding alcohol) among the 3,609 BARC 
patients who cited as least 1 drug of abuse at the time 
of admission during 2004. Of these mentions, 17 per-
cent were as the primary drug, 46 percent were as 
secondary drug, and 37 percent were as the tertiary 
problem.  
 
The NFLIS reported that the Miami-Dade Crime lab 
analyzed 265 alprazolam exhibits in 2004, as well as 
18 diazepam exhibits and 11 clonazepam cases. In 
Broward, the BSO crime lab analyzed 553 alprazolam 
cases, 67 unnamed benzodiazepine cases, and 29 
clonazepam samples. 
 
In 2004, current (past-30-day) depressant use (nam-
ing “Xanax” as an example) was reported in results 
of the Florida Youth Substance Abuse Survey by 1.6 
percent of Broward County middle and high school 
students (exhibit 8a), down from 2.7 percent in 2002 
but equal to the proportion in 2000. Among Miami-
Dade County middle and high school students, the 
proportion doubled between 2000 and 2004, rising 
from 0.6 to 1.2 percent. Current depressant use was 
also reported by 2.9 percent of Palm Beach County 
middle and high school students in 2004, down from 
3.6 percent in 2002 but nearly double the 2000 pro-
portion of 1.5 percent. The proportion for the middle 
and high school students in all of Florida reporting 
current depressant use was 2.8 percent in 2004.  
 
For inquiries regarding this report, please contact James N. Hall, 
Center for the Study and Prevention of Substance Abuse, Up Front 
Drug Information Center, Nova Southeastern University, Suite 
215, 12360 Southwest 132nd Court, Miami, FL 33186, Phone: 
(786) 242-8222, E-mail: upfrontin@aol.com.  
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Exhibit 1. DAWN ED Miami-Dade County Sample and Reporting Information:  January–December 2004 
 
No. of EDs Reporting per Month: 
Completeness of Data (%)  Total Eligible 
Hospitals1 
No. of Hospitals 
in DAWN Sample 
Total EDs in 
DAWN Sample2 90–100% 50–89% <50% 
No. of EDs Not 
Reporting 
21 17 17 5–9 1–3 0–1 7–9 
 
1Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association An-
nual Survey. 
2Some hospitals have more than one emergency department. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/13-4/14, 2005  
 
 
 
 
Exhibit 2. DAWN ED Ft. Lauderdale Sample and Reporting Information:  January–December 2004 
 
No. of EDs Reporting per Month: 
Completeness of Data (%)  Total Eligible 
Hospitals1 
No. of Hospitals 
in DAWN Sample 
Total EDs in 
DAWN Sample2 90–100% 50–89% <50% 
No. of EDs Not 
Reporting3 
27 22 22 0–6 0–2 0–1 15–20 
 
1Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association An-
nual Survey. 
2Some hospitals have more than one emergency department. 
3Note that only 2 EDs participated in the first half of 2004. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/22, 2005  
 
 
 
 
Exhibit 3. Numbers of Drug-Related Deaths in Florida, by Single Drug or In Combination:  2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Florida Department of Law Enforcement, Florida Medical Examiners Commission Report 2004 
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Exhibit 4. Numbers of Drug-Related Deaths in Miami-Dade County, by Single Drug or In Combination:   
 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Florida Department of Law Enforcement, Florida Medical Examiners Commission Report 2004 
 
 
 
 
Exhibit 5. Numbers of Drug-Related Deaths in Broward County, by Single Drug or In Combination:  2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Florida Department of Law Enforcement, Florida Medical Examiners Commission Report 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exhibit 6. Numbers of Selected Drug Reports in Miami-Dade County DAWN ED Data (Unweighted1), by  
 Drug Category: 2004 
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1The unweighted data are from 8–10 Miami-Dade EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. 
Based on this review, cases may be corrected or deleted, and, therefore, are subject to change. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/13–4/14, 2005 
 
 
 
 
Exhibit 7. Numbers of Selected Drug Reports in Broward County DAWN ED Data (Unweighted1), by Drug 
Category:  2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1The unweighted data are from 4–7 Ft. Lauderdale Division EDs reporting to DAWN in 2004. All DAWN cases are reviewed for qual-
ity control. Based on this review, cases may be corrected or deleted, and, therefore, are subject to change. 
SOURCE:  Broward EDs, first half of 2004; DAWN Live!, OAS, SAMHSA, updated 4/22, 2005 
 
 
 
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Miami-Ft. Lauderdale, Florida 
 
 
Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005 146 
1.6
1.8
0.9
0.6 0.6
1.2
1.7
1.2
1.0
1.3
2.9
2.3
1.6
1.3
0.7
2.8
3.0
1.5
1.1
0.9
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Depressants Narcotic Pain Rx Cocaine Ecstasy Methamphetamine
Broward
Miami-Dade
Palm Beach
All Florida
Percent
30.3
13.3
7.8
4.6
30.9
14.6
8.6 8.1
3.7
35.1
15.6
11.4
9.6
4.4
32.3
16
11.5 11.4
4.2
0
5
10
15
20
25
30
35
40
Alcohol Binge Alcohol Marijuana Cigarettes Inhalants
Broward
Miami-Dade
Palm Beach
All Florida
Percent
10.2
Exhibit 8a. Percentages of Middle and High School Students Reporting Past-30-Day Substance Abuse:   
 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Florida Youth Substance Abuse Survey 2004 
 
 
 
 
Exhibit 8b. Percentages of Middle and High School Students Reporting Past-30-Day Substance Abuse:   
 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Florida Youth Substance Abuse Survey 2004 
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Drug Abuse Trends in  
Minneapolis/St. Paul 
 
Carol Falkowski1 
 
ABSTRACT 
 
The far-reaching consequences and public expense 
related to the abuse and manufacture of metham-
phetamine remained apparent in the Twin Cities 
and throughout the State in 2004, placing increased 
demands on law enforcement, the corrections sys-
tem, environmental health officials, child protection 
workers, hospital emergency rooms, and treatment 
centers. Ten percent of admissions to addiction 
treatment programs were for methamphetamine in 
2004—a record high. The number of overdose 
deaths, methamphetamine labs, and children af-
fected by methamphetamine labs declined slightly. 
Cocaine abuse resulted in more hospital emergency 
department reports than any other drug of abuse, 
with 3,046 in 2004 (compared with 874 for metham-
phetamine and 779 for heroin), and accounted for 
13.3 percent of treatment admissions. Opiate-related 
accidental overdose deaths outnumbered those for 
any other illicit drug, with 72 in 2004 (compared 
with 49 for cocaine, 20 for methamphetamine, and 
8 for MDMA, ‘ecstasy’). The accidental OxyContin 
overdose death of a suburban high school student 
brought heightened public attention to the non-
medical, recreational abuse of prescription painkill-
ers by young people. Marijuana accounted for 19.9 
percent of treatment admissions, and there were 
2,556 emergency department reports of marijuana 
in 2004. Nearly one-half of those receiving addic-
tion treatment services were younger than 18, as 
were 26 percent of the marijuana-involved patients 
at hospital emergency departments. 
 
INTRODUCTION 
 
This report is produced twice annually for participa-
tion in the Community Epidemiology Work Group of 
the National Institute on Drug Abuse, an epidemiol-
ogical surveillance network comprised of researchers 
from 21 U.S. areas who monitor emerging patterns 
and trends in drug abuse. It is compiled using the 
most recent data and information obtained from mul-
tiple sources. This report is also available online at 
www.hazelden.org/research. 
 
                                                 
1The author is affiliated with Hazelden Foundation, Butler Center 
for Research, Center City, Minnesota. 
Area Description 
 
The Minneapolis/St. Paul, “Twin Cities,” metropoli-
tan area includes Minnesota’s largest city, Minneapo-
lis (Hennepin County), the capital city of St. Paul 
(Ramsey County), and the surrounding counties of 
Anoka, Dakota, and Washington. Recent estimates of 
the population of each county are as follows: Anoka, 
313,197; Dakota, 375,462; Hennepin, 1,239,837; 
Ramsey, 515,274; and Washington, 213,395. The 
population of these counties totals 2,557,165, or 
roughly one-half of the Minnesota State population. 
In the five-county metropolitan area, 84 percent of the 
population is White. African-Americans constitute the 
largest minority group in Hennepin County, while 
Asians are the largest minority group in Ramsey, 
Anoka, Dakota, and Washington Counties. St. Paul 
has the largest Hmong population of any U.S. city. 
The Hmong were Laotian residents who were re-
cruited by the CIA to fight in the “secret war” for the 
United States during the Vietnam War. Later, after 
their communist opponents won a long civil war, 
many fled to Thailand and eventually resettled in the 
United States and other countries. 
 
The remainder of the State is less densely populated 
and more rural in character than the “Twin Cities” 
area. Minnesota shares an international border with 
Canada, a southern border with Iowa, an eastern bor-
der with Wisconsin, and a western border with North 
Dakota and South Dakota, two of the country’s most 
sparsely populated States. Illicit drugs are sold and 
distributed within Minnesota by Mexican drug traf-
ficking organizations, street gangs, independent en-
trepreneurs, and other criminal groups. Drugs are 
typically shipped or transported into the Minneapo-
lis/St. Paul area for further distribution across the 
State. 
 
Data Sources 
 
Data for this report were drawn from the following 
sources: 
 
• Mortality data on drug-related deaths are from 
the Hennepin County Medical Examiner and the 
Ramsey County Medical Examiner (through 
March 2005). Hennepin County cases include 
those in which drug toxicity was the immediate 
cause of death and those in which the recent use 
of a drug was listed as a significant condition 
contributing to the death. Ramsey County cases 
include those in which drug toxicity was the 
immediate cause of death and those in which 
drugs were present at the time of death. 
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• Hospital emergency department (ED) data 
were derived from the Drug Abuse Warning 
Network (DAWN) Live!, a restricted-access 
online query system administered by the Office 
of Applied Studies (OAS) of the Substance 
Abuse and Mental Health Services Administra-
tion (SAMHSA). These unweighted data are 
from participating hospital emergency depart-
ments in the Minneapolis and St. Paul Standard 
Metropolitan Statistical Area from January 1, 
2004, through December 31, 2004, as accessed 
on April 14, 2005. The DAWN sample includes 
26 of the 28 eligible hospitals in the area, with 26 
emergency departments (exhibit 1). The data re-
ported in this paper are incomplete. Over the ap-
proximately 12-month period, between 7 and 13 
EDs reported data each month, with almost all 
reporting basically complete data (90 percent or 
greater). All DAWN cases are reviewed for qual-
ity control and based on the review, they may be 
corrected or deleted. Therefore, the data reported 
in this paper are subject to change. Data accessed 
from DAWN Live! represent drug reports in 
drug-related visits. Reports exceed the number of 
visits, because a patient may report use of multi-
ple drugs (up to six drugs plus alcohol). The un-
weighted data are not estimates for the Minnea-
polis/St. Paul area and cannot be compared with 
data from 2002 and before, nor can these pre-
liminary data be used for comparison with future 
DAWN data. Only weighted DAWN data re-
leased by SAMHSA can be used for trend analy-
sis. See a full description of DAWN online at 
http://dawninfo.samhsa.gov. 
 
• Addiction treatment data are from addiction 
treatment programs (residential, outpatient, and 
extended care) in the five-county metropolitan 
area as reported on the Drug and Alcohol Abuse 
Normative Evaluation System (DAANES) of 
the Performance Measurement and Quality Im-
provement Division, Minnesota Department of 
Human Services, from 1993 through 2004. Data 
on methadone treatment programs are from the 
Chemical Health Division, Minnesota Depart-
ment of Human Services (as of May 23, 2005). 
 
• Law enforcement data and information are 
from various county, city, State, and Federal 
agencies.  
 
• Crime lab data for St. Paul are from the National 
Forensic Laboratory Information System 
(NFLIS). This system, which began in 1997, is 
sponsored by the U.S. Drug Enforcement Ad-
ministration and collects solid dosage drug 
analyses conducted by State and local forensic 
laboratories across the country on drugs seized 
by law enforcement. Minnesota data on 
methamphetamine labs are from the El Paso In-
telligence Center (EPIC), U.S. Drug Enforce-
ment Administration.  
 
• Human immunodeficiency virus (HIV) infec-
tion data for cases diagnosed in 2004 are from 
the Minnesota Department of Health. 
 
• Additional information is from interviews with 
treatment program staff, poison control special-
ists, narcotics agents, and school-based drug and 
alcohol specialists conducted in May 2005. 
 
DRUG ABUSE PATTERNS AND TRENDS 
 
Cocaine/Crack 
 
Accidental overdose deaths involving cocaine de-
creased from 2003 to 2004 in Hennepin County 
(from 44 to 39) and remained stable in Ramsey 
County (10), as shown in exhibit 2.  
 
Unweighted DAWN Live! data show cocaine reports 
at Twin Cities emergency departments outnumbered 
those for any other illegal drug in 2004 (see exhibit 
3). Of the 3,046 cocaine-related ED reports in 2004, 
65.2 percent of the patients were male and 34.8 per-
cent were female. More than one-half of the patients 
(62.3 percent) were older than 35, 27.0 percent were 
age 25–34, 8.4 percent were age 18–24, and 2.2 per-
cent were younger than 18. Of those with known 
race/ethnicity, 41.7 percent were White, 55.0 percent 
were African-American, and 3.2 percent were His-
panic. 
 
Admissions to addiction treatment programs with 
cocaine as the primary substance problem declined 
very slightly in recent years (see exhibit 4). In 2004, 
treatment admissions involving cocaine as the pri-
mary substance problem accounted for 13.3 percent 
of all admissions, compared with 14.9 percent in 
1998. Most cocaine admissions in 2004 were for 
crack cocaine; 31.6 percent were female and 47.4 
percent were African-American (exhibit 5). The av-
erage age of first crack use was 25.8. Most (86.9 per-
cent) patients receiving treatment for cocaine were 
age 25 or older; 62.1 percent were older than 35. 
More than four out of five patients (81.5 percent) had 
prior treatment episodes. 
 
Cocaine accounted for 21.4 percent of the drug sei-
zures reported to NFLIS in St. Paul in 2004 (exhibit 6).  
 
Gangs continued to play a considerable role in the 
street-level, retail distribution of crack cocaine. A 
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recent sweep of drug dealers in Minneapolis in April 
resulted in 31 warrants for felony sales of crack co-
caine and 7 for misdemeanor marijuana sales. The 
suspects came from 8 different gangs and all but one, 
a juvenile female, had prior criminal records. 
 
Cocaine generally sold for $100 per gram, $200 per 
“eightball” (one-eighth ounce), $700–$800 per 
ounce, and up to $22,000 per kilogram. The price of a 
rock of crack was $10–$20. 
 
Heroin/Opiates/Other Narcotics 
 
Opiate-related deaths, mostly accidental heroin over-
doses, outnumbered cocaine-related deaths in 2004. 
In Hennepin and Ramsey Counties combined, there 
were 72 opiate-related deaths in 2004, compared with 
69 in 2003 and 77 in 2002 (exhibit 2). Eleven of the 
47 accidental opiate-related deaths in Hennepin 
County in 2004 involved methadone, as did 3 of the 
25 deaths in Ramsey County.  
 
According to unweighted DAWN Live! data, there 
were 779 heroin ED reports in 2004 (exhibit 3). Of 
these patients, two-thirds were male. More than one-
half of these heroin patients (54.7 percent) were older 
than 35; 31.8 percent were age 25–34, 13.0 percent 
were age 18–24, and 0.5 percent were younger than 
18. Of those with known race/ethnicity, 61.8 percent 
were White, 35.3 percent were African-American, 
and 2.8 percent were Hispanic.  
 
Prescription narcotic analgesics, used medically in 
the treatment of pain, were increasingly used non-
medically as drugs of abuse for the heroin-like high 
they produce. Of particular concern within this cate-
gory were drugs containing oxycodone: Percodan, 
Percocet (oxycodone combined with aspirin or aceta-
minophen), and the long-acting OxyContin. 
 
The recent (May 2005) accidental death of a 17-year-
old suburban boy from apparent overdose of Oxy-
Contin brought heightened public awareness of the 
growing abuse of prescription painkillers and other 
prescription drugs among Twin Cities-area high 
school students. In 2004, there were 1,361 hospital 
ED reports involving narcotic analgesics in the un-
weighted DAWN Live! data; 475 of these involved 
oxycodone.  
 
Of the patients receiving treatment for heroin in 2004 
at programs that reported on the DAANES system, 
78.7 percent were older than 25 (exhibit 5). Whites 
accounted for 55.2 percent and African-Americans 
represented 36.1 percent; 31.3 percent were women. 
The most common route of administration was injec-
tion (64.2 percent), followed by sniffing (31.8 per-
cent) and smoking, also known as “foiling” (4.0 per-
cent). The average age of first heroin use was 22.5. 
Most heroin admissions (88.4 percent) reported prior 
treatment episodes. 
 
Five methadone maintenance programs serve 1,636 
patients in the metropolitan area. Because the private, 
for-profit methadone programs do not report to 
DAANES, exhibits 4 and 5 do not reflect the total 
number of patients receiving treatment for her-
oin/opiate addiction in the Twin Cities. However, 
effective July 1, 2005, all methadone maintenance 
programs will report on DAANES.  
 
The newest innovation in methadone service delivery 
is the Mobile Medication Unit operated in Minneapo-
lis by Hennepin Faculty Associates. This service-
based (versus program-based) delivery system in-
creases treatment access while reducing the burden 
and inconvenience often associated with methadone 
treatment. It is a mobile methadone van that operates 
in two locations. Since it began operations in October 
2004, 66 patients who would otherwise have been 
remanded to a waiting list received treatment. Similar 
mobile units have been established in the Netherlands 
(1979), Boston (1987), Baltimore (1993), Seattle 
(1999), and Vermont (2004).  
 
Heroin seized by law enforcement officers included 
white, off-white, or tan powder, in addition to dark-
colored Mexican “black tar” heroin. Four Nigerians 
apprehended in April 2004 at the Minneapolis/St. 
Paul International Airport were on a flight from Am-
sterdam carrying suitcases filled with 25 pounds of 
heroin valued at $25 million. Retail and mid-level 
heroin prices remained at $20–$40 per dosage unit or 
“paper,” $300–$400 per gram, and $900–$2,000 per 
ounce. Law enforcement seizures of oxycodone in-
creased, as did pharmacy robberies involving Oxy-
Contin. 
 
A very small segment of Minnesota’s Hmong immi-
grant population regularly smokes opium. Packages 
concealing opium continued to be shipped from Asia 
to residents of that Twin Cities community. One case 
involved 30 pounds of seized opium, with a reported 
street value of $1.3 million, which was delivered to a 
suburban Woodbury couple in January. Luggage with 
opium-soaked fabric was delivered to their house 
after arriving in the country on a Korean Airlines 
flight from Laos to Atlanta and being driven to Min-
nesota by car. 
 
Marijuana 
 
Marijuana remained the overwhelmingly popular 
drug of abuse among adolescents and young adults. 
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According to unweighted DAWN Live! data, there 
were 2,556 marijuana reports at Twin Cities-area 
hospital emergency departments in 2004 (exhibit 3). 
Of these patients, two-thirds were male. Roughly 
one-half were younger than 25, and one-half were 
older than 25. Specifically, 26 percent were younger 
than 18, 26 percent were age 18–24, 23 percent were 
age 25–34, and 25 percent were age 35 and older. Of 
those with known race/ethnicity, 65.7 percent were 
White, 31.7 percent were African-American, and 2.6 
percent were Hispanic.  
 
Marijuana accounted for more admissions into addic-
tion treatment programs than any other illicit drug in 
the Twin Cities, with 3,856 admissions in 2004 (ex-
hibit 4). One out of five (19.9 percent) patients enter-
ing addiction treatment programs reported marijuana 
as the primary substance problem, compared with 
only 8 percent in 1991. Most (76 percent) were 
males; 65.8 percent were White, 22.0 percent were 
African-American, 5.3 percent were Hispanic, 2.9 
percent were American Indian, and 1.1 percent were 
Asian (exhibit 5). For many, it was the first treatment 
experience (45.2 percent). The average age of first 
marijuana use was 13.9.  
 
Marijuana was easily accessible, according to multi-
ple sources, and sold for $5 per joint. Standard, 
commercial-grade marijuana sold for $50 per quarter 
ounce, $150–$175 per ounce, and $600–$900 per 
pound. Higher potency “BC Bud” from British Co-
lumbia was increasingly available and sold for $100 
per quarter ounce, up to $600 per ounce, and $3,200 
per pound. One international marijuana smuggling 
case involved the seizure of 827 pounds of BC Bud 
near the U.S.-Canadian border in northern Minnesota 
in April 2005. According to Border Patrol officials, it 
was one of the largest cases of its kind to date. The 
marijuana was valued at more than $4 million. 
 
Marijuana joints that are dipped in formaldehyde, 
which is often mixed with phencyclidine (PCP), are 
known as “wets,” “wet sticks,” “water,” or “wet dad-
dies.” Marijuana joints containing crack cocaine are 
known as “primos.” 
 
Methamphetamine/Other Stimulants 
 
Aside from cocaine, methamphetamine, also known as 
“meth,” “crystal,” “speed,” or “crank,” is the major 
stimulant of abuse in the area. Prolonged abuse can 
result in addiction, which is characterized by long pe-
riods (up to 2 weeks) of continual drug use, sleep and 
food deprivation, weight loss, and extreme paranoid 
delusions. 
 
In Ramsey County in 2004, there were 9 accidental 
deaths related to methamphetamine abuse, compared 
with 10 in 2003 and 3 in 2002 (exhibit 2). Excluding 
methylenedioxymethamphetamine (MDMA)- related 
deaths, there were 8 methamphetamine-related deaths 
in Hennepin County in 2002, 14 in 2003, and 11 in 
2004 (exhibit 1).  
 
Hospital ED reports of methamphetamine totaled 874 
in 2004 according to unweighted DAWN Live! data 
(exhibit 3). Women accounted for 41.8 percent. Of 
these methamphetamine patients, roughly one-half 
were younger than 25, and one-half were older than 
25. Specifically, 18.8 were younger than 18, 28.0 
percent were 18–24, 32.4 percent were 25–34, and 
20.7 percent were age 35 and older. Of those with 
known race/ethnicity, almost all (93.4 percent) were 
White; 4.6 percent were African-American and 1.9 
percent were Hispanic.  
 
Patients addicted to methamphetamine accounted for 
10.0 percent of total treatment admissions in the 
Twin Cities in 2004 (exhibit 4), compared with 2.9 
percent in 1998 and less than 1 percent in 1991. 
Women accounted for 38.4 percent of methampheta-
mine admissions, the highest percentage within any 
drug category (exhibit 5). Almost all were White 
(91.0 percent), and the average age of first use was 
20.4. One-third (32.5 percent) were in treatment for 
the first time. 
 
Methamphetamine abuse took hold among a younger 
population in 2004. All onsite, school-based drug 
abuse counselors reported growing methampheta-
mine abuse by students who attend metropolitan-area 
high schools. Smoking was the most common route 
of first methamphetamine use. The use of light bulbs 
as pipes for smoking methamphetamine was com-
monplace, especially among youth. The appetite sup-
pressant effects, in particular, attracted young girls. 
 
More than one-half (52.5 percent) of those receiving 
treatment for methamphetamine were age 25 or 
younger: 16.2 percent were younger than 18 and 36.3 
percent were age 18–25 (exhibit 5). Among treatment 
admissions, smoking was the most common route of 
administration (63.6 percent), followed by sniffing 
(18.2 percent) and injection (13.0 percent). 
 
Methamphetamine dominated law enforcement ef-
forts and criminal justice actions in the metropolitan 
and non-metropolitan areas of the State. For example, 
in Ramsey County, the number of methamphetamine 
prosecutions rose from 20 cases in 1999 (2.7 percent 
of drug cases) to 301 in 2004 (29 percent of drug  
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cases). Statewide, methamphetamine was involved in 
14 percent of all felony cases in 2004. According to 
the Minnesota Department of Corrections, there were 
139 methamphetamine offenders in Minnesota pris-
ons in 2001, compared with 1,100 inmates in April 
2005. 
 
Seizures of methamphetamine by law enforcement 
continued upward trends and accounted 60.8 percent 
of the samples reported to the National Forensic 
Laboratory Information System (exhibit 6), which are 
cases from the State crime lab. Seizures by metro-
politan-area law enforcement agencies increased as 
well in 2004.  
 
Methamphetamine prices were as low as $70 per 
gram, $200 for a “teener,” (one-sixteenth ounce), 
$240–$280 for an “eightball” (one-eighth ounce), and 
$1,800 per ounce. Pound prices ranged from $6,000 
to $14,000. “Glass,” or “ice,” the high-purity form 
that is smoked, typically sold for twice as much. 
Methamphetamine came in the form of crystals, 
powder, or chunks that were white, off-white, tan, 
orange, reddish, greenish, or light purple-colored.  
 
The number of clandestine, makeshift methampheta-
mine labs dismantled with the assistance of the U.S. 
Drug Enforcement Administration in the State de-
creased dramatically between 2003 and 2004 (from 
182 to 96), but dismantled labs decreased only 
slightly in the Twin Cities area (from 23 in 2003 and 
21 in 2004) (exhibit 7). One rural county reported 
more than $1 million in costs associated with 
methamphetamine lab cleanup in 2004. The bulk of 
methamphetamine consumed in the State is still im-
ported from Mexico, however, not manufactured in 
small labs.  
 
The presence of minor children in locations where 
methamphetamine was being made also declined 
statewide and in the Twin Cities in 2004. Statewide, 
there were 54 affected children in 2003 and 14 in 
2004 (exhibit 8). However, child protection workers 
all over the State reported larger caseloads attribut-
able to drug abuse; they reported that most, up to 90 
percent in some counties, involved methampheta-
mine-abusing or addicted caregivers. 
 
Legislative efforts focused on restricting the sale of 
over-the-counter cold preparations containing pseu-
doephedrine, a nasal decongestant used in the manu-
facture of methamphetamine. In April 2005, four 
people were arrested in New Ulm, a small town less 
than an hour south of the Twin Cities, after police 
discovered nearly 7,000 pseudoephedrine pills in 
their possession. Even though many stores voluntar-
ily limit sales to two packages per customer, the 
group was traveling across Iowa, Minnesota, North 
Dakota, and South Dakota purchasing the two-box 
limit. They had amassed 6,738 pills in less than 2 
days. If convicted of acquiring the pills to manufac-
ture methamphetamine, they could face up to 8 years 
in prison. 
 
The abuse of MDMA, a stimulant with mild hallu-
cinogenic properties known as “ecstasy,” “X,” or “e,” 
by young people continued and contributed to the death 
of seven African-American males in their twenties in 
Hennepin County in 2004. All were homicide victims 
with “recent MDMA use” listed as an “other significant 
condition.”  
 
Effects of MDMA include tactile sensitivity, hallucina-
tions, and, at high doses, nausea, jaw clenching, hyper-
thermia, and muscle tension. According to unweighted 
DAWN Live! data, there were 102 MDMA ED reports 
in 2004. 
 
Khat, a plant that is chewed or brewed in tea for its 
stimulant effects in East Africa and the Middle East, 
remained within the Somali refugee community in 
the Twin Cities and Rochester, Minnesota. Its active 
ingredients, cathinone and catheine, are controlled 
substances in the United States.  
 
Methylphenidate (Ritalin), a prescription drug used in 
the treatment of attention deficit hyperactive disorder, 
is also used nonmedically as a drug of abuse to in-
crease alertness and suppress appetite by some ado-
lescents and young adults. The pills are crushed and 
snorted or ingested orally. Each pill is sold for $5 or 
simply shared with fellow middle school or high 
school students at no cost. Ritalin is sometimes 
known as a “hyper pill” or “the study drug.” 
 
Hallucinogens 
 
Products that contain dextromethorphan, a cough 
suppressant common in most over-the-counter cough 
syrups, are ingested by adolescents in doses many 
times in excess of the recommended amount for the 
long-acting, hallucinogenic effects. Dextromethor-
phan (also known as “DXM”) is also the active in-
gredient in some over-the-counter cold preparations 
in pill form, such as Coricidin HBP Cough and Cold 
(known as “Triple Cs”). People intoxicated on dex-
tromethorphan experience profound hallucinations and 
altered time perception, slurred speech, sweating, un-
coordinated movements, and high blood pressure. 
Recent growth in the abuse of these products by 
younger teenagers prompted many pharmacies, dis-
count stores, and grocery stores to place these prod-
ucts behind the counter to prevent shoplifting. Being 
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Minneapolis/St. Paul 
 
 
Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005 152 
under the influence of these products is known as 
“Robo-tripping” or “Skittle-ing.” 
 
Lysergic acid diethylamide (LSD or “acid”) is a 
strong, synthetically produced hallucinogen, typically 
sold as saturated, tiny pieces of paper known as 
“blotter acid,” for $5–$10 per dosage unit. There 
were 20 hospital ED reports of LSD in 2004 accord-
ing to unweighted DAWN Live! data. 
 
PCP, a dissociative anesthetic, is most often used in 
combination with marijuana, but it can also be in-
jected or snorted. In 2004, there were 20 ED reports 
for PCP according to unweighted DAWN Live! data. 
In May 2004, a 28-year-old African-American male 
died as the result of drug-induced excited delirium 
involving PCP and MDMA. 
 
Sedative/Hypnotics 
 
Gamma hydroxybutyrate (GHB), known as "G,” 
“Gamma,” “Liquid E,” or “Liquid X,” is a concen-
trated liquid abused for its stupor-like, depressant 
effects. It is also used as a predatory knockout, drug-
induced rape drug and sells for $10 by the capful. 
There were 22 hospital ED reports of GHB in 2004 
according to unweighted DAWN Live! data. 
 
Other Drugs 
 
Alcohol remained the most widely used mood-
altering substance. There were 760 ED reports in-
volving underage drinking in 2004 according to un-
weighted DAWN Live! data (exhibit 3). 
 
Overall, one-half of all admissions to Twin Cities 
addiction treatment programs (49.1 percent) were 
attributable to alcohol in 2004, compared with 57.2 
percent in 1998 (exhibit 4). Of the 9,490 treatment  
admissions for alcohol in 2004, 28.3 percent were 
women, 77.9 percent were White, and 71.0 percent 
had prior treatment experience (exhibit 5). The aver-
age age of first intoxication was 15.8. 
 
Roughly 80 percent of alcohol-related treatment ad-
missions were age 26 and older, with 61.5 percent 
being age 35 or older. Among patients reporting al-
cohol as the primary substance of abuse, only 3.1 
percent were younger than 18. 
 
Daily nicotine use remained widespread among pa-
tients in addiction treatment programs (exhibit 5). 
Adolescents who smoke tobacco are many times 
more likely to use alcohol and other drugs than ado-
lescents who do not use tobacco. 
 
INFECTIOUS DISEASES RELATED TO SUBSTANCE 
ABUSE 
 
Most cases of HIV infection and acquired immunode-
ficiency syndrome (AIDS) in Minnesota are in the 
Minneapolis/St. Paul area. Of the 307 cases of new 
HIV infection in 2004, the exposure categories were 
as follows: men who have sex with men (39 percent), 
injection drug use (4 percent), men who have sex 
with men and injection drug use (4 percent), hetero-
sexual contact (11 percent), unspecified (19 percent), 
and no interview (21 percent) (exhibit 9). 
 
The level of hepatitis C virus (HCV), a blood-borne 
liver disease, among injection drug abusers remained 
high, with estimated rates as high as 90 percent 
among patients in methadone treatment programs. 
 
For inquiries concerning this report, please contact Carol 
Falkowski, Director of Research Communications, Hazelden 
Foundation, Butler Center for Research, 15245 Pleasant Valley 
Road, Box 11, Center City, MN 55012-0011, Phone: 651-213-
4566, Fax: 651-213-4344, E-mail: cfalkowski@hazelden.org. 
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Exhibit 1. Minneapolis/St. Paul DAWN ED Sample and Reporting Information: 2004 
 
No. of EDs Reporting per Month: 
Completeness of Data (%)  CEWG Area Total Eligible Hospitals1 
No. of Hos-
pitals in 
DAWN 
Sample 
Total EDs in 
DAWN 
Sample2 90–100% 50–89% <50% 
No. of 
EDs Not 
Reporting 
Minneapolis/ 
St. Paul 28 26 26 6–13 0–1 0–1 13–19 
 
1Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association An-
nual Survey. 
2Some hospitals have more than one emergency department. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/13-4/14, 2005  
 
 
Exhibit 2. Number of Drug-Related Deaths in Hennepin and Ramsey Counties:  2000–2004 
 
County 2000 2001 2002 2003 2004 
Hennepin County      
Cocaine 43 37 34 44 39 
Opiates 41 58 59 50 47 
Methamphetamine 6 
(includes 3 
MDMA) 
8 
(includes 1 
MDMA) 
11 
(includes 3 
MDMA) 
15 
(includes 1 
MDMA) 
19 
(includes 8 
MDMA) 
Ramsey County      
Cocaine 17 11 11 10 10 
Opiates 17 19 18 19 25 
Methamphetamine 11 
(includes 3 
MDMA) 
2 3 10 9 
 
SOURCE:  Hennepin County Medical Examiner and Ramsey County Medical Examiner, 2005 
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Exhibit 3. Number of Drug Reports (Unweighted)1 in Drug-Related Emergency Department Visits in  
 Minneapolis/St. Paul, by Drug Category:  2004 
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1Unweighted data are from 7–13 Minneapolis/St. Paul EDs reporting to DAWN.  All DAWN cases are reviewed for quality control. 
Based on this review, cases may be corrected or deleted, and, therefore, are subject to change. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/14/2005 
 
 
 
 
Exhibit 4. Admissions to Twin Cities-Area Addiction Treatment Programs, by Primary Substance  
 Problem and Percent:  1998–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Drug and Alcohol Abuse Normative Evaluation System, Minnesota Department of Human Services, 2005 
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Exhibit 5. Characteristics of Persons Admitted to Twin Cities Area Addiction Treatment Programs, by  
 Primary Substance of Abuse and Percent:  2004 
 
Total Admissions 
(N=19,340) 
Alcohol 
(n=9,490) 
49.1 
Marijuana 
(n=3,856) 
19.9 
Cocaine 
(n=2,570) 
13.3 
Methamphetamine 
(n=1,928) 
10.0 
Heroin 
(n=640) 
3.3 
Gender 
 Male 
 Female 
 
71.7 
29.3 
 
76.0 
24.0 
 
68.4 
31.6 
 
61.6 
38.4 
 
68.8 
31.3 
Race/Ethnicity 
 White 
 African-American 
 Hispanic 
 American Indian 
 Asian 
 
77.9 
11.3 
6.1 
3.2 
0.6 
 
65.8 
22.0 
5.3 
2.9 
1.1 
 
43.6 
47.4 
4.5 
2.3 
0.9 
 
91.0 
1.2 
3.4 
1.6 
1.6 
 
55.2 
36.1 
4.9 
2.9 
0.2 
Age Group 
 17 and younger 
 18–25 
 26–34 
 35 and older 
 
3.1 
15.3 
20.0 
61.5 
 
47.6 
29.0 
13.2 
10.2 
 
2.6 
10.5 
24.8 
62.1 
 
16.2 
36.3 
25.2 
22.3 
 
0.9 
20.3 
24.4 
54.3 
Route of Administra-
tion 
 Smoking 
 Sniffing 
 Injecting 
 Oral 
  
 
 
78.4 
19.7 
1.9 
 
 
 
63.6 
18.2 
13.0 
5.2 
 
 
4.0 
31.8 
64.2 
 
Secondary Drug Marijuana 57.0 
Alcohol 
71.4 
Alcohol 
52.2 
Marijuana 
53.4 
Cocaine 
43.2 
Tertiary Drug Cocaine 33.1 
Alcohol 
33.9 
Marijuana 
41.7 
Alcohol 
48.8 
Cocaine 
29.6 
First Treatment Epi-
sode 29.0 45.2 18.5 32.5 11.6 
Average Age First 
Use (in Years) (15.8) (13.9) (25.8) (20.4) (22.5) 
Daily Nicotine Use 59.8 59.7 68.6 74.5 70.5 
 
SOURCE:  Drug and Alcohol Abuse Normative Evaluation System, Minnesota Department of Human Services, 2005 
 
 
 
 
Exhibit 6. Number of Items Analyzed in St. Paul, Minnesota, and Percentage of Total Items:  January– 
 December 2004 
 
Substance Number of Items Percent of Total Items 
Methamphetamine 2,256 60.8 
Cocaine 794 21.4 
Cannabis 208 5.6 
MDMA 62 1.7 
Psilocyn 56 1.5 
Acetaminophen 55 1.5 
Oxycodone 38 1.0 
Hydrocodone 34 0.9 
Heroin 32 0.9 
Amphetamine 30 0.8 
All Other 146 3.9 
Total Items Reported 3,711 100.0 
 
SOURCE:  NFLIS, DEA 
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Exhibit 7. Number of Methamphetamine Lab Seizures in Minnesota and Twin Cities:  2000–2004 
 
Twin Cities1 
Year Minnesota (Number) (Number) (Percent of State Total) 
2000 105 23 21.9 
2001 103 30 29.1 
2002 174 40 22.9 
2003 182 23 12.6 
2004 96 21 21.8 
 
1Includes the counties of Anoka, Dakota, Hennepin, Ramsey, and Washington. 
SOURCE:  El Paso Intelligence Center (EPIC), National Clandestine Laboratory Seizure System, 2005 
 
 
 
 
Exhibit 8. Number of Children Affected1 by Methamphetamine Labs in Minnesota and Twin Cities:   
 2000–2004 
 
Twin Cities2 
Year Minnesota (Number) (Number) (Percent of State Total) 
2000 17 1 5.8 
2001 20 3 15.0 
2002 48 14 29.2 
2003 54 10 18.5 
2004 14 2 14.2 
 
1Children affected includes children exposed to chemicals, children present, children in protective custody, and children residing in a 
methamphetamine lab. 
2Includes the counties of Anoka, Dakota, Hennepin, Ramsey, and Washington. 
SOURCE:  El Paso Intelligence Center (EPIC), National Clandestine Laboratory Seizure System, 2005 
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Exhibit 9. Number of Cases and Rates per 100,000 Population of HIV Infection, by Mode of Exposure1 in  
 Minnesota:  2004 
 
Males Females Total Exposure Category Cases Percent Rate2 Cases Percent Rate2 Cases Percent Rate3 
MSM4 121 56 X -- -- X 121 39 X 
IDU5 8 4 X 5 6 X 13 4 X 
MSM/IDU 13 6 X -- -- X 13 4 X 
Heterosexual6 (Total) (9) 4 X (25) 28 X (34) 11 X 
with IDU  3 -- X 1 -- X 4 -- X 
with Bisexual Male  -- -- X 3 -- X 3 -- X 
with Hemophiliac/other 0 -- X 0 -- X 0 -- X 
with HIV-positive, un-
known risk 6 -- X 21 -- X 27 -- X 
Perinatal7 0 0 X 0 1 X 1 0 X 
Other 0 0 X 1 1 X 1 0 X 
Unspecified8 31 14 X 27 30 X 58 19 X 
No Interview 9 35 16 X 31 34 X 66 21 X 
Total 217 100 8.9 90 100 3.6 307 100 6.2 
 
1HIV infection includes all new cases of HIV infection (both HIV [non-AIDS] and AIDS at first diagnosis) among Minnesota residents  
in 2004. 
2U.S. Census 2000 data necessary to calculate race-specific rates (specifically a breakdown of the State population by "Race alone  
or in Combination with one or more races" by gender) have not yet been released for Minnesota. When these data become avail-
able, this table will be updated. Numbers exclude Federal and private prisoners and refugees in the HIV-Positive Refugee Reset-
tlement Program.   
3Rates calculated using U.S. Census 2000 data. Accurate population estimates for Black, African-born persons living in Minnesota  
are unavailable – anecdotal (50,000) and 2000 U.S. Census data (35,188)) were used to create the range of rates reported for Afri-
can-born persons. The population estimate for Black, African-American persons (167,784) was calculated by subtracting the U.S. 
Census estimate for African-born persons (35,188) from the total Black population (202,972). Note that this assumes that all Afri-
can-born persons are Black (as opposed to another race). 
4MSM = Men who have sex with men. 
5IDU = Injection drug user.  
6Heterosexual = For males: heterosexual contact with a female known to be HIV-positive, an injecting drug user, or a  
hemophiliac/blood product or organ transplant recipient. For females: heterosexual contact with a male known to be HIV-positive, 
bisexual, an injecting drug user, or a hemophiliac/blood product or organ transplant recipient.  
7Perinatal = Mother-to-child HIV transmission; birth may have occurred in a previous year.  
8Unspecified = Cases who did not acknowledge any of the risks listed above. 
9No Interview = Cases who refused to be, could not be, or have not yet been interviewed. 
SOURCE: Minnesota Department of Health 
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Drug Abuse in the Newark 
Primary Metropolitan  
Statistical Area 
 
Allison S. Gertel-Rosenberg, M.S.1 
 
ABSTRACT 
 
In this report, drug abuse indicators in the Newark 
primary metropolitan statistical area (Newark 
PMSA) are presented using substance abuse treat-
ment data, emergency department data, medical 
examiner cases, and other information. Most pri-
mary treatment admissions (72.4 percent) in 2004 
were for illicit drugs. Heroin accounted for 72.7 
percent of all primary admissions for illicit drugs in 
the Newark PMSA, compared with 11.3 percent of 
admissions for primary crack/cocaine, and 11.8 
percent of admissions for primary marijuana use. 
Consistent with the treatment data, emergency de-
partment reports of heroin in the Newark PMSA 
accounted for the largest proportion of drug reports. 
Heroin purity remains high, at 61.3 percent in 2003. 
Between January and December 2004, cocaine ac-
counted for 45.5 percent of items analyzed by 
NFLIS, followed by heroin (34.3 percent) and mari-
juana (9.0 percent).  
 
INTRODUCTION 
 
Area Description 
 
The Newark primary metropolitan statistical area 
(PMSA) consists of five counties (Essex, Morris, 
Sussex, Union, and Warren). In 2003, there were an 
estimated 2,069,188 residents in the PMSA, with 38 
percent living in Essex County (which contains New-
ark City), 26 percent in Union County, 23 percent in 
Morris County, and the rest residing in the remaining 
counties. According to the 2000 Census, the popula-
tion of the Newark PMSA is diverse with respect to 
race: 66 percent are White, 22 percent are Black, and 
4 percent are Asian. Hispanics accounted for 13 per-
cent of the PMSA population in 2000. There is also a 
wide variation in racial/ethnic breakdowns for each 
county. In Essex County, 45 percent of the popula-
tion is White and 41 percent are Black. Union County 
is 65 percent White and 21 percent Black. By com-
parison, Morris County is 87 percent White and 3 
percent Black; Sussex County is 96 percent White  
 
                                                 
1The author is affiliated with the Division of Addiction Services, 
New Jersey Department of Human Services, Trenton, New Jersey. 
and 1 percent Black; and Warren County is 95 per-
cent White and 2 percent Black. Hispanics accounted 
for 15 percent of the population in Essex, 8 percent in 
Morris, 3 percent in Sussex, 20 percent in Union, and 
4 percent in Warren. The counties are also very di-
verse by socioeconomic status. In the Newark PMSA 
as a whole, 5.8 percent of families with children 
younger than 18 live below the poverty level. For 
counties within the PMSA, the poverty status for 
families with children younger than 18 is 18 percent 
in Essex, 3 percent in Morris, 4 percent in Sussex, 9 
percent in Union, and 5 percent in Warren. These 
social, demographic, and economic variations suggest 
substantial differences in drug use behaviors of resi-
dents by county. 
 
New Jersey is situated between major industrial mar-
kets in New York and Pennsylvania and has been 
referred to as the “crossroads of the east.” It is a 
gateway State, with major interstate highways, road-
ways, airports, seaports, and other infrastructures 
capable of accommodating large amounts of passen-
ger and cargo traffic from both the eastern and west-
ern parts of the United States. New Jersey can there-
fore be considered an ideal strategic, as well as vul-
nerable, corridor for the transportation of drug con-
traband and illicit currency.2  
 
New Jersey has one of the highest concentrations of 
pharmaceutical and biochemical manufacturing firms 
in the country. According to the Drug Enforcement 
Administration (DEA), the most prevalent sources of 
diverted pharmaceutical drugs in New Jersey include 
doctor shopping, prescription forgery, and organized 
prescription rings. The forging of prescriptions is a 
continuing problem among employees in the medical 
field who use their positions to gain access to blank 
prescription pads. The most commonly diverted 
pharmaceuticals are the benzodiazepines and opiates, 
especially the hydrocodone products, with Percocet, 
Percodan, Xanax, Dilaudid, Valium, and Vicodin 
representing the most common brand-name drugs 
diverted. The DEA is also reporting an increase in the 
diversion of OxyContin, both in Newark and South 
Jersey, where it has become a particular problem 
among teenagers and young adults.  
 
Illicit Substances in the News 
 
In January and February 2005, the New Jersey Poison 
Information and Education System (NJPIES) re-
ported eight cases of probable cyanide intoxication in 
heroin users. The heroin users were hospitalized in 
three different healthcare facilities in New Jersey.  
 
                                                 
2 DEA Briefs and Background State Fact Sheets.  New Jersey 
2004.  http://www.usdoj.gov/dea/pubs/states/newjersey.html. 
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The source of the heroin was reported as dealers in 
Easton, Pennsylvania, Plainfield, New Jersey, and 
Asbury Park, New Jersey.3 
 
In March 2005, the New Jersey State Police and the 
DEA combined forces to break up a nationwide crys-
tal methamphetamine operation, arresting four indi-
viduals and seizing cash, narcotics, and weapons 
from locations in New Jersey and California. The 
investigation targeted the crystal methamphetamine 
distribution activities of a member and past president 
of the Bandanas Motorcycle Club, headquartered in 
Monmouth County. As a result of the New Jersey 
investigation, a total of 4.5 kilograms of metham-
phetamine was seized, with a street value of ap-
proximately $350,000.4 
 
Data Sources 
 
This report uses data from various sources, as indi-
cated below: 
 
• Drug treatment data were obtained from the 
New Jersey Substance Abuse Monitoring System 
(NJSAMS) and the Alcohol and Drug Abuse Data 
System (ADADS), statewide, episode-based data 
systems operated by the Division of Addiction 
Services of the Department of Human Services. 
The preliminary data for calendar year 2004 in-
clude profiles by primary drug of abuse in Newark 
City, the Newark PMSA, and the State. The 2003 
Treatment Episode Data Set (TEDS), Office of 
Applied Studies (OAS), was used to depict demo-
graphic characteristics of statewide admissions 
and was accessed May 27, 2005.  
 
• Emergency department (ED) drug reports data 
were derived for calendar year 2004 from the 
Drug Abuse Warning Network (DAWN) Live! re-
stricted-access online query system administered 
by the OAS, Substance Abuse and Mental Health 
Services Administration (SAMHSA). Eligible 
hospitals in the Newark metropolitan area totaled 
47; hospitals in the DAWN sampled numbered 
39, with the number of emergency departments in 
the sample totaling 43. (Some hospitals may have 
more than one emergency department.) During 
this 12-month period, between 10 and 12 EDs re-
ported data each month. The completeness of data 
reported by participating EDs varied by month 
(exhibit 1). Exhibits in this paper reflect cases that 
were received by DAWN as of April 13–14, 2005. 
All DAWN cases are reviewed for quality control. 
Based on this review, cases may be corrected or 
                                                 
3 Perspectives:  A journal on addiction research and public policy.  
NCADD New Jersey, February 2005. 
4 NJ State Police Press Release. March 21, 2005. 
deleted. Therefore, the data presented in this paper 
are subject to change. Data derived from DAWN 
Live! represent drug reports in drug-related ED 
visits. Drug reports exceed the number of ED vis-
its, since a patient may report use of multiple 
drugs (up to six drugs and alcohol). The DAWN 
Live! data are unweighted and, thus, are not esti-
mates for the reporting area. These data cannot be 
compared to DAWN data from 2002 and before, 
nor can preliminary data be used for comparison 
with future data. Only weighted DAWN data re-
leased by SAMHSA can be used for trend analy-
sis. A full description of the DAWN system can 
be found at http://dawn info.samhsa.gov. 
 
• Drug seizure and law enforcement data were 
provided by the National Drug Intelligence Cen-
ter’s “New Jersey Drug Threat Assessment Up-
date” released in April 2004. Updated data on 
Federal drug-related sentences were gathered 
from the United States Sentencing Commission, 
Office of Policy Analysis, for fiscal year (FY) 
2002. 
 
• Forensic analysis data on specific drugs were 
provided by the Drug Enforcement Administra-
tion’s National Forensic Laboratory Information 
System (NFLIS) for January through December 
2004. 
 
• Mortality data were obtained from the 
SAMHSA January 2004 report entitled “Mortal-
ity Data From the Drug Abuse Warning Network 
2002.” The DAWN system compiled data for 
counties in the Newark PMSA. The DAWN sys-
tem covered 88 percent of the metropolitan sta-
tistical area (MSA) population in 2002. Addi-
tional mortality data were analyzed from the 
New Jersey Department of Health and Senior 
Services, Center for Health Statistics. The addi-
tional mortality data are for calendar year 2002. 
 
• Illicit drug price and purity data were ob-
tained from the Current Intelligence Unit at the 
National Drug Intelligence Center. The data for 
July through December 2004 were reported in 
the December 28, 2004, edition of Narcotics Di-
gest Weekly. Additional information on heroin 
purity was provided by the Domestic Monitor 
Program (DMP) and represents the time period 
of January through December 2003. 
 
• Human immunodeficiency virus (HIV) and 
acquired immunodeficiency syndrome (AIDS) 
data were obtained from the statewide AIDS 
Registry maintained by the New Jersey Depart-
ment of Health and Senior Services, Division of 
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Newark PMSA 
 
 
Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005 160 
AIDS Prevention and Control, HIV/AIDS Sur-
veillance Program. Data on the State, Newark 
PMSA, and Newark City compiled as of Decem-
ber 31, 2004, are used in this report. 
 
SPECIAL CONSIDERATIONS: DAWN LIVE!  
EMERGENCY DEPARTMENT REPORTS DATA 
 
Preliminary analysis of ED visit data indicate 5,785 
drug-related visits for major substances of abuse (in-
cluding alcohol) in the Newark metropolitan area 
between January and December 2004. Visits are 
identified as belonging to one of eight categories. 
These categories are related to ED visits associated 
with substance abuse and drug misuse, both inten-
tional and accidental. The case types are suicide at-
tempt, seeking detoxification, alcohol only in patients 
under 21, adverse reaction, overmedication, mali-
cious poisoning, accidental ingestion, and other. The 
“other” category is designed to capture all of the 
drug-related ED visits that could not be classified in 
any of the other categories—this category captures 
most of the drug abuse cases. 
 
In the Newark metropolitan area, the majority (44.7 
percent) of DAWN visits are classified as “other,” a 
category that includes most illicit drugs. This is to be 
expected, given the protocol for assigning visits to 
categories. “Overmedication” plus “other” plus 
“seeking detoxification” accounted for 62.3 percent 
of all visits. For a breakdown of all visits by type, see 
exhibit 2. 
 
DRUG ABUSE PATTERNS AND TRENDS 
 
Cocaine/Crack 
 
In preliminary data for January through December 
2004, primary cocaine/crack treatment admissions 
accounted for 7.2 percent of all admissions in New-
ark City (compared to 6.2 percent in 2003) and for 
7.9 percent of admissions for illicit drugs (i.e., ex-
cluding alcohol, compared to 6.8 percent in 2003) 
(exhibits 3 and 4).  
 
In the Newark PMSA, the proportion of primary 
crack/cocaine admissions (excluding alcohol) was 
somewhat higher than in the city—11.3 percent in 
2004, up slightly from 9.8 percent in 2003. The pro-
portion of crack/cocaine admissions among all ad-
missions was higher in the PMSA as well: 9.0 per-
cent in 2004 and 7.8 percent in 2003.  
 
The proportion of primary cocaine/crack admissions 
(excluding alcohol) statewide increased slightly from 
14.0 percent in 2003 to 15.1 percent in 2004. In 2004, 
the proportion of statewide primary crack/cocaine 
admissions was much higher than reported in Newark 
City (7 percentage points higher) and almost 4 per-
centage points higher than in the PMSA (exhibit 3).  
 
TEDS data for the State for 2003 show crack admis-
sions were somewhat more likely to be Black than 
White (53 versus 43 percent) and male rather than 
female (58 versus 42 percent). Admissions for pri-
mary abuse of powder cocaine, however, were sub-
stantially more likely to be White than Black (65 
versus 30 percent) and male rather than female (70 
versus 30 percent) (exhibit 5). 
 
According to unweighted data accessed from DAWN 
Live!, cocaine ranked second to heroin in the number 
of ED reports for major substances of abuse in the 
Newark PMSA in 2004 (exhibit 6). The data for 2004 
collected from the DAWN Live! system on April 13–
14, 2005, indicate 1,505 cocaine ED reports for all 
causes. Approximately 68 percent of the cocaine ED 
patients were Black (exhibit 7), and 83 percent were 
age 30 and older.  
 
The most recently available mortality data from 2002 
indicated 127 cocaine/crack-related deaths. 
 
Between January and December 2004, cocaine/crack 
accounted for 45.5 percent of the 2,858 items ana-
lyzed by NFLIS, the highest proportion for any drug 
(exhibit 8). 
 
According to the National Drug Intelligence Center 
(NDIC) National Drug Threat Survey (NDTS) 2003, 
80.1 percent of law enforcement agency respondents 
in New Jersey reported that powder cocaine was 
readily available (availability described as either high 
or moderate), while 73.0 percent reported that crack 
cocaine was readily available. Additionally, 29.2 per-
cent of law enforcement officials throughout New 
Jersey identified cocaine, either powder (12.1 per-
cent) or crack (17.1 percent), as their greatest drug 
threat. 
 
More cocaine is seized in the State than any other 
illicit drug except marijuana. According to Federal-
wide Drug Seizure System (FDSS) data, Federal law 
enforcement officials seized 480 kilograms of co-
caine in 2002. Data from the United States Sentenc-
ing Commission (USSC) indicate that the percentage 
of drug-related Federal sentences in New Jersey that 
were related to cocaine in FY 2001 (45.1 percent) 
surpassed the percentage nationwide (42.5 percent) 
for the first time in the previous 5 years. In FY 2002, 
the percentage of drug-related Federal sentences at-
tributable to cocaine rose to 56 percent (exhibit 9), 
once again surpassing the national average (42.7 per-
cent) (exhibit 9). 
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Cocaine, particularly crack, is the drug most often 
associated with violent crime in New Jersey. Federal, 
State, and local law enforcement in New Jersey re-
port that dealers frequently carry firearms and com-
mit drive-by shootings, assaults, and murders. Ac-
cording to the NDTS, 49.5 percent of New Jersey law 
enforcement agencies identified cocaine, either pow-
der (15 percent) or crack (34.5 percent), as the drug 
that most contributes to violent crime. The Essex 
County Narcotics Task Force reported major in-
creases in the number of cocaine-related homicides in 
2003. As of June 5, 2003, there were 60 drug-related 
homicides in Essex County; most were attributable to 
powder or crack cocaine distribution. 
 
Between July and December 2004, the retail price for 
powder cocaine in Newark was $9–$100 per gram; 
crack sold for $20–$100 per gram (exhibit 10). 
 
Heroin 
 
As a proportion of illicit drug treatment admissions, 
primary heroin accounted for 81.8 percent in Newark 
City in 2004, which was slightly lower than the 85.4 
percent in 2003 (exhibits 3 and 4). In the Newark 
PMSA, primary heroin admissions accounted for 
72.7 percent of illicit drug admissions in 2004, 
slightly lower than the 77.3 percent in 2003, and for 
58.2 percent of all treatment admissions (including 
alcohol). 
 
Primary heroin admissions predominated across the 
State in 2004, accounting for 59.2 percent of all ad-
missions for drugs other than alcohol (exhibit 3). This 
is down from 64.2 percent in 2003 (exhibit 4) and 
represents the second annual decrease in the propor-
tion of primary heroin admissions statewide since 
1996.  
 
TEDS data for 2003 indicate that, statewide, 56.4 
percent of primary heroin admissions were White and 
37.6 percent were Black (exhibit 5). Sixteen percent 
were Hispanic. Primary heroin users were also pre-
dominately male (65.5 percent) (exhibit 5). 
 
The unweighted data accessed from DAWN Live! 
show that the number of ED reports for heroin in 
2004 was higher than the number of reports for other 
single illicit drugs, at 1,764 reports between January 
and December 2004 (as of April 13–14, 2005). Of the 
1,764 heroin ED reports, 55.2 percent were for male 
patients, 62.5 percent were for patients who were 
Black (exhibit 7), and 82.5 percent were for patients 
age 30 and older.  
 
Although heroin is the leading drug among treat-
ment admissions and ED reports in Newark, it ac-
counted for only 34.3 percent of the 2,858 items 
analyzed by NFLIS between January and December 
2004 (exhibit 8). 
 
The most recently available mortality data from 2002 
indicate 149 heroin death mentions. The number of 
death mentions was down from 177 reported in 2001, 
however, and 179 reported in 2000. The slight 
downward trend in death mentions in 2002 is consis-
tent with recent patterns in both treatment and ED 
data. 
 
According to the NDTS 2003, 73.4 percent of New 
Jersey law enforcement agencies reported that heroin 
was readily available, while 31.6 percent of agencies 
identified heroin as the greatest drug threat. 
 
According to FDSS data, Federal law enforcement 
officials in New Jersey seized 91 kilograms of heroin 
in 2000, 169 kilograms in 2001, and 188 kilograms in 
2002. USCC data indicate that in FY 2001, heroin-
related Federal sentences accounted for a signifi-
cantly higher percentage of all drug-related Federal 
sentences in New Jersey (31.5 percent) than nation-
wide (7.2 percent). This trend continued in FY 2002, 
when heroin-related Federal sentences accounted for 
25.6 percent of New Jersey’s drug-related Federal 
sentences, compared with 7.1 percent nationally (ex-
hibit 9). 
 
Heroin purity is still very high, but it decreased 
somewhat in 2003 in the Newark PMSA. In 2001, 
heroin was 70.5 percent pure, and in 2002, it was 
71.4 percent pure. In 2003, however, heroin purity 
dropped to 61.3 percent pure. The price per gram 
between July and December 2004 was $25–$320 
(exhibit 10). In 2003, despite the drop in heroin pu-
rity, the Newark PMSA had the highest heroin purity 
coupled with the lowest price among the 21 DAWN 
cities. According to the DMP, almost all of the heroin 
sold in the Newark PMSA is South American. 
 
Marijuana 
 
Primary marijuana treatment admissions represented 
7.1 percent of all treatment admissions in Newark 
City in 2004, compared with 9.4 percent in the New-
ark PMSA and 12.0 percent in the State as a whole. 
As a proportion of illicit drug treatment admissions, 
marijuana accounted for 7.8 percent in Newark City 
and 11.8 percent in the Newark PMSA (exhibit 3) in 
2004, both approximately 1 percentage point higher 
than in 2003 (exhibit 4). 
 
Statewide primary marijuana admissions (excluding 
alcohol) were more than twice the proportion of those 
in Newark City (16.6 vs. 7.8 percent) and about 5 
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percentage points higher than those in the Newark 
PMSA (16.6 percent vs. 11.8 percent)(exhibit 3).  
 
Statewide TEDS data for 2003 indicate that 81.7 per-
cent of primary marijuana admissions were male, 
51.3 percent were White, and 42.5 percent were 
Black. About 17.2 percent of primary marijuana ad-
missions statewide were Hispanic. Across the State, 
30.9 percent of primary marijuana admissions were 
younger than 18, and 72.2 percent were younger than 
26 (exhibit 5). 
 
According to unweighted data accessed from DAWN 
Live!, the number of marijuana ED reports between 
January and December 2004 was 505 (exhibit 6). 
Individuals younger than 30 represented approxi-
mately 60 percent of the marijuana patients.  
 
Among the 2,858 items analyzed by NFLIS between 
January and December 2004, marijuana accounted 
for 9.0 percent (258 items) (exhibit 8). 
 
Marijuana is the most widely available and most fre-
quently seized illicit drug in New Jersey. According 
to the NDTS 2003, 96.9 percent of New Jersey law 
enforcement agencies report that marijuana is readily 
available, although only 30.6 percent of New Jersey 
law enforcement agencies identified marijuana as 
their greatest drug threat. 
 
According to FDSS data, marijuana accounted for 
57.0 percent (1,626 kilograms) of illicit drugs seized 
by law enforcement officials in New Jersey in 2002. 
Data from the DEA Domestic Cannabis Eradica-
tion/Suppression Program indicate that law enforce-
ment officials eradicated 831 plants from outdoor 
grows in New Jersey in 2001 and 957 in 2002. In 
addition, law enforcement officials eradicated 182 
plants from indoor grows in the State in 2001 and 
1,345 in 2002. USSC data indicate that the percent-
age of drug-related Federal sentences related to mari-
juana in New Jersey in FY 2001 (8.4 percent) was 
significantly lower than the percentage nationwide 
(32.8 percent). The percentage of drug-related Fed-
eral sentences related to marijuana in New Jersey 
decreased in FY 2002 to 4.9 percent, compared with 
28.9 percent nationally (exhibit 9). 
 
Between July and December 2004, locally produced 
marijuana sold in Newark for $5–$30 per bag (ex-
hibit 10). 
 
Pharmaceuticals 
 
The distribution and abuse of pharmaceuticals is 
growing at an increasing rate in New Jersey. Accord-
ing to the NDTS 2003, 60.4 percent of New Jersey 
law enforcement agencies reported that pharmaceuti-
cals were readily available. NDTS 2003 data further 
indicate that New Jersey law enforcement agencies 
reported OxyContin, Percocet, and Xanax as the most 
commonly diverted or illicitly used pharmaceuticals 
in the State. Diverted pharmaceuticals often are sold 
behind closed doors and occasionally at open-air drug 
markets, primarily in Essex (Newark and Irvington), 
Camden, and Salem Counties. According to the DEA 
Newark Division, diverted OxyContin sold for $15 
per 20-milligram tablet and $30 per 40-milligram 
tablet during the second quarter of FY 2003. Diverted 
Percocet sold for $1 to $10 per tablet, and diverted 
Xanax sold for $1 to $2 per tablet during that same 
period. 
 
Opiates Other Than Heroin 
 
In 2004, primary treatment admissions for “other 
opiates or synthetics” in Newark City totaled nine (or 
0.2 percent of the admissions, excluding alcohol ad-
missions). The number was higher in the PMSA—
137 (1.2 percent of the admissions, excluding alco-
hol). This is unchanged from 2003, when figures for 
the city and PMSA, respectively, were 0.2 and 1.3 
percent. In the State as a whole, primary admissions 
for other opiates in 2004 totaled 1,142, or 2.9 percent 
of all admissions, excluding alcohol. In 2003, the 
number of primary admissions for other opiates to-
taled 1,112, representing more than double the ad-
missions reported in 1997 (513). The biggest increase 
in numbers of other opiate admissions occurred be-
tween 2000 (592) and 2002 (1,124). In 2003, admis-
sions reporting other opiates as primary, secondary, 
or tertiary drug of abuse numbered 2,303 and ac-
counted for nearly 6 percent of all drug admissions 
statewide. In the TEDS data for 2003, 91 percent of 
the primary “other opiate” admissions were White 
and 6 percent were Black (exhibit 5). Only 5 percent 
of the primary “other opiate” admissions were His-
panic; about 62 percent were male. 
 
In an analysis run April 13–14, 2005, the DAWN 
Live! system recorded 469 opiates/opioids ED reports 
related to seeking detoxification, overmedication, and 
“other” between January and December 2004. Of 
those reports in the ED, 10.4 percent were patients 
seeking detoxification, 26.0 percent had overmedi-
cated, and 63.5 percent were classified in the “other” 
category (exhibit 11).  
 
In 2002, there were 151 ME death mentions for nar-
cotic analgesic/combinations, representing the largest 
number of death mentions for any drug. Although the 
number of mentions was down from 190 in 2001, the 
number of mentions was more than twice that re-
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ported in 2000 (75) and more than 3 times the num-
ber in 1999 (44). 
 
Benzodiazepines  
 
In an analysis run April 13–14, 2005, the DAWN 
Live! system recorded 383 benzodiazepine ED re-
ports related to seeking detoxification, overmedica-
tion, and “other” between January and December 
2004. Of those, 6.3 percent were patients seeking 
detoxification, 39.4 percent had overmedicated, and 
54.3 percent were classified in the “other” category 
(exhibit 11). The proportion of ED benzodiazepine 
reports to opiates/opioids reports is 0.8. 
 
The 2002 DAWN mortality data show only 54 ben-
zodiazepine mentions in the Newark PMSA. How-
ever, this represents an increase from 33 mentions in 
2001 and 35 mentions in 2000. Benzodiazepines ac-
counted for approximately 7.8 percent of all ME 
death mentions in 2002, up from 4.2 percent in 2001. 
 
Methamphetamine and Amphetamines 
 
In 2004, only 31 primary amphetamine treatment ad-
missions, including 5 primary methamphetamine ad-
missions, were reported in the Newark PMSA. As a 
primary drug of abuse, amphetamines were also rare in 
the State. There were 149 primary amphetamine ad-
missions in 2004, including 47 admissions for 
methamphetamine. The number of total admissions for 
primary amphetamine abuse demonstrated an increase 
from the 112 admissions reported in 2003. According 
to the 2003 TEDS data, amphetamine users are much 
more likely to be male than female (68 percent versus 
32 percent, respectively). Amphetamine users are also 
significantly more likely to be White (81 percent) than 
Black (10 percent) or Hispanic (11 percent). Approxi-
mately one-third of amphetamine users are age 25 or 
younger (37 percent); one-third are between the ages 
of 26 and 35 (34 percent); and one-third are older than 
35 (29 percent). 
 
Preliminary unweighted data accessed through 
DAWN Live! for January through December 2004 
show only four methamphetamine ED reports. ED 
reports for amphetamines, however, were higher, at 
42 (exhibit 6). Patients younger than 25 accounted for 
approximately 50 percent of amphetamine reports.  
Methamphetamine availability is limited in New Jer-
sey. According to the NDTS 2003, 17.1 percent of 
New Jersey law enforcement agencies reported that 
methamphetamine was readily available, and 1.3 per-
cent of agencies identified methamphetamine as their 
greatest drug threat. According to FDSS data, Federal 
law enforcement officials in New Jersey seized 0.8 
kilograms of methamphetamine in 2002.  
USSC data indicate that the percentage of drug-
related Federal sentences related to methampheta-
mine in New Jersey in FY 2001 (5.2 percent) was 
lower than the percentage nationwide (14.2 percent). 
Sentencing data from FY 2002 indicate that metham-
phetamine-related sentences in New Jersey repre-
sented 3.4 percent of all drug-related sentences (ex-
hibit 9). This continues to be significantly lower than 
the nationwide average of 15.5 percent in FY 2002. 
Methamphetamine prices at the wholesale and mid-
level have fluctuated in New Jersey. These price 
variations resulted primarily from increased costs 
associated with obtaining methamphetamine (particu-
larly crystal methamphetamine) from other regions of 
the country and other countries and transporting the 
drug to New Jersey.  
 
Methamphetamine previously sold for $8,500 to 
$20,000 per kilogram and $800 to $1,000 per ounce; 
between July and December 2004, methamphetamine 
sold for $15,000–$25,000 per kilogram and $800–
$1,500 per ounce (exhibit 10). On the retail level, 
methamphetamine sold for between $20 and $180 per 
gram.  
 
Methylenedioxymethamphetamine (MDMA or 
Ecstasy) 
 
The number of unweighted MDMA ED reports in 
2004 in the DAWN Live! system was 21.  
 
Between July and December 2004, MDMA sold for 
between $20 and $30 per tablet (exhibit 10). 
 
Phencyclidine (PCP) 
 
The unweighted number of PCP ED reports in 2004 
accessed from the DAWN Live! system was 22 (ex-
hibit 6).  
 
Alcohol 
 
In the Newark PMSA, alcohol-only treatment admis-
sions as a proportion of all admissions decreased 
from 12.3 percent in 2003 to 10.2 percent in 2004, 
while alcohol-in-combination admissions increased 
slightly from 8.0 percent to 9.8 percent during the 
same time period. 
 
Alcohol-in-combination with other drugs or alcohol 
alone for those younger than 21 accounted for 1,273 
ED reports in the DAWN system for the Newark 
PMSA in 2004 (exhibit 6). 
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INFECTIOUS DISEASES RELATED TO DRUG ABUSE 
 
In 2003, New Jersey ranked fifth nationally in cumula-
tive AIDS cases, third in cumulative pediatric AIDS 
cases, and ninth in cases reported in 2003. As of De-
cember 31, 2004, there were 65,404 cumulative 
HIV/AIDS cases reported in New Jersey, about 1,182 
of which were reported in 2004. Of the cumulative 
cases, 25,880 (39.6 percent of the State total) were in 
the Newark PMSA, and 12,527 (19.2 percent of the 
State total) were in Newark City. A total of 64,167 
cumulative HIV/AIDS cases statewide, and 12,244 in 
Newark City, were adults/adolescents age 13 or older. 
 
Statewide, the proportion of HIV/AIDS cases involv-
ing injection drug use has declined substantially. 
Thus, approximately 41 percent of cumulative 
HIV/AIDS cases statewide historically involved in-
jection drug use alone, compared with 14 percent of 
the cases diagnosed between January and December 
2004. In Newark City, 49 percent of cumulative cases 
involved injection drug use alone (only cumulative 
transmission mode data are available for Newark). 
 
The proportion of cases linked to heterosexual trans-
mission in New Jersey has increased dramatically. 
Approximately 29 percent of cumulative cases and 46 
percent of cases reported between January and De-
cember 2004 can be attributable to heterosexual 
transmission. The majority of this difference can be 
found in the “partners of unknown HIV risk” cate-
gory. There has been a slight increase in the propor-
tion of transmission cases among men having sex 
with men (MSM). The cumulative proportion is 19 
percent, while the proportion for this mode of trans-
mission between January and December 2004 is 22 
percent. Additionally, 15 percent of cases reported 
between January and December 2004 are still re-
corded in the “other or unknown” transmission mode 
category. 
 
In Newark City, 10 percent of cumulative HIV/AIDS 
cases involved MSM, 20 percent involved heterosex-
ual contact, and 19 percent involved “other or un-
known” transmission. A larger proportion of females 
(34 percent of cumulative cases in Newark and 53 
percent in the State) were infected through hetero-
sexual contact than males (11 percent and 19 percent 
in Newark and the State, respectively). 
 
There has been a steady increase in the number of 
persons living with HIV/AIDS in Newark and in the 
State as a whole. The total number statewide has in-
creased from 25,343 in 1997 to 32,746 as of Decem-
ber 31, 2004.  
 
Among people living with HIV/AIDS as of Decem-
ber 31, 2004, about 35 percent statewide and 41 per-
cent in Newark City are female (exhibits 12 and 13). 
Compared to the State as a whole, a substantially 
higher proportion of people living with HIV/AIDS in 
Newark are non-Hispanic Black (79 vs. 56 percent) 
(exhibits 12 and 14). About 17 percent among those 
living with HIV/AIDS in Newark and 21 percent 
statewide are Hispanic, and about 3 percent in New-
ark and 22 percent statewide are non-Hispanic White. 
 
With respect to transmission mode among people 
living with HIV/AIDS, injection drug use alone ac-
counted for 31 percent of cases statewide and 38 per-
cent in Newark. Heterosexual contact accounted for 
21 percent of cases statewide and 25 percent in New-
ark. Male-to-male sexual contact alone accounted for 
19 percent statewide and 10 percent in Newark, while 
such behavior and injection drug use combined were 
involved in 3 percent of cases statewide and 3 percent 
of cases in Newark. The continued increase in heroin 
injection by the young (age 18–25) and the very high 
levels of heroin abuse and heroin-related deaths con-
tinue to pose a serious risk for an increase in the 
prevalence of infectious diseases. However, no data 
are yet available to document any rise in the preva-
lence of HIV/AIDS in New Jersey. 
 
For inquiries concerning this report, please contact Allison Gertel-
Rosenberg, M.S., Program Manager, Division of Addition Ser-
vices, Office of Policy Management, New Jersey Department of 
Human Services, 120 South Stockton Street, 3rd Floor, P.O. Box 
362, Trenton, NJ 08625, Phone: 609-984-4050, Fax: 609-292-
1045, E-mail: Allison.gertel@dhs.state.nj.us. 
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Exhibit 1. Newark DAWN ED Sample and Reporting Information:  January–December 2004 
 
No. of EDs Reporting per Month: 
Completeness of Data (%)  Total Eligible 
Hospitals1 
No. of Hospitals 
in DAWN Sample 
Total EDs in 
DAWN Sample2 90–100% 50–89% <50% 
No. of EDs Not 
Reporting 
47 39 43 7–10 0–2 0–3 31–33 
 
1Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association An-
nual Survey. 
2Some hospitals have more than one emergency department. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/13-4/14, 2005  
 
 
 
 
Exhibit 2: Distribution of DAWN ED Visits, by Visit Type (Unweighted1):  2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
1The unweighted data are from the 10–12 Newark EDs reporting to DAWN in 2004.  All DAWN cases are reviewed for quality con-
trol.  Based on this review, cases may be corrected or deleted.  Therefore, these data are subject to change.   
SOURCE:  Dawn Live!, OAS, SAMHSA, updated April 13–14, 2005 
 
 
 
 
Exhibit 3. Percentages of Primary Treatment Admissions (Excluding Alcohol) for Selected Drugs in Newark  
 City, Newark PMSA, and New Jersey:  January–December 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Alcohol and Drug Abuse Data System, New Jersey Substance Abuse Monitoring System, Division of Addiction Services, 
NJ Department of Human Services 
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Exhibit 4. Percentages of Primary Treatment Admissions (Excluding Alcohol) for Selected Drugs in Newark  
 City, Newark PMSA, and New Jersey:  2003 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Alcohol and Drug Abuse Data System, New Jersey Substance Abuse Monitoring System, Division of Addiction Services, 
NJ Department of Human Services 
 
 
 
 
Exhibit 5. Characteristics of Primary Substance Abuse Treatment Admissions in the State, by Percent:   
 20031 
 
Characteristic Alcohol Only 
Alcohol-in-
Combination Crack Cocaine Marijuana Heroin 
Other 
Opiates 
Gender        
Male 73.7 74.7 58.0 69.4 81.7 65.5 61.9 
Female 26.1 25.2 41.9 30.4 18.2 34.4 37.9 
Race/Ethnicity        
White 81.8 67.4 42.6 64.8 51.3 56.4 91.4 
Black 13.1 28.1 53.2 29.5 42.5 37.6 6.0 
Hispanic 11.2 10.1 8.8 17.6 17.2 16.0 5.2 
Age at Admission        
17 and younger 1.1 5.1 0.7 2.4 30.9 0.4 1.7 
18–25 9.0 20.4 11.1 19.3 41.3 19.0 17.4 
26–35 17.5 25.8 33.2 32.6 19.1 31.5 30.5 
36 and older 72.4 48.7 55.0 45.7 8.7 49.1 50.4 
 
1Percentages may not add to 100 due to rounding or missing values. 
SOURCE: TEDS, OAS, SAMHSA, accessed May 27, 2005 
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Exhibit 6. Number of Drug Reports in Drug-Related ED Visits in the Newark PMSA, by Drug Category  
 (Unweighted1):  2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1The unweighted data are from the 10–12 Newark EDs reporting to DAWN in 2004.  All DAWN cases are reviewed for quality con-
trol.  Based on this review, cases may be corrected or deleted.  Therefore, these data are subject to change.   
SOURCE:  Dawn Live!, OAS, SAMHSA, updated April 13–14, 2005 
 
 
 
 
Exhibit 7. Race/Ethnicity of ED Reports for Selected Drugs (Unweighted1):  2004 
 
Cocaine Heroin 
Race/Ethnicity 
N (%) N (%) 
White 251 16.7 354 20.1 
Black 1,024 68.0 1,102 62.5 
Hispanic 128 8.5 186 10.5 
Race/Ethnicity NTA 3 0.2 3 0.2 
Not Documented 99 6.6 119 6.7 
TOTAL 1,505 100 1,764 100 
 
1The unweighted data are from the 10–12 Newark EDs reporting to DAWN in 2004.  All DAWN cases are reviewed for quality con-
trol.  Based on this review, cases may be corrected or deleted.  Therefore, these data are subject to change.   
SOURCE:  Dawn Live!, OAS, SAMHSA, updated April 13–14, 2005 
 
 
 
Exhibit 8. Number of Items Analyzed for Specific Drugs in Newark and Percentage of Total Items:  20041 
 
Substance Count Percent (%) 
Cocaine 1301 45.52 
Heroin 980 34.29 
Marijuana 258 9.03 
 
1N = 2,858 
SOURCE:  NFLIS, DEA 
 
 
 
(250 are alcohol only for patients younger than 21)
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Exhibit 9. Drug-Related Federal Sentences in New Jersey, by Drug and Percent:  FY 2002 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N=266 
SOURCE:  United States Sentencing Commission, Office of Policy Analysis, 2002 Datafile 
 
 
 
 
Exhibit 10.  Illicit Drug Prices for Newark City:  July 2004–December 2004 
 
Price in Dollars ($) 
Drug 
Wholesale Midlevel Retail 
Powder Cocaine $15,000–$34,000 per kilogram $600–$1,800 per ounce $9–$100 per gram 
Crack Cocaine $20,000–$35,000 per kilogram $644–$2,000 per ounce $20–$100 per gram $150–$200 per 1/8 ounce 
Heroin $52,000–$120,000 per kilogram $1,600–$3,360 per ounce $25–$320/g 
Marijuana 
$500–$1,700 per pound (boogie) 
$3,500–$6,500 per pound (hydro-
ponic) 
$6,000–$7,000 per pound (purple 
haze) 
$50–$600 per ounce 
$100–$400 per ounce (hydro-
ponic) 
$400–$1,100 per 1/4 pound 
$250–$1,750 per 1/4 pound 
(hydroponic) 
$400–$2,000 per 1/2 pound 
$500–$2,500 per 1/2 pound 
(hydroponic) 
$2–$5 per joint 
$5–$20 per blunt 
$5–$30 per bag 
$10–$30 per bag (hydroponic) 
$20–$50 per gram 
Methamphetamine $8,000–$20,000 per pound $15,000–$25,000 per kilogram $800–$1,500 per ounce 
$20–$180 per gram 
$9–$180 per gram (crystal meth) 
$140–$300 per 1/8 ounce 
$400–$1,200 per 1/2 ounce 
MDMA $7–$12 per tablet NA $20–$30 per tablet 
 
SOURCE:  Narcotics Digest Weekly Dec. 28, 2004, National Drug Intelligence Center 
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Exhibit 11. Prescription Drug Misuse – Number of Drug Reports in Drug-Related ED Visits, Selected Drugs,  
 by Case Type (Unweighted1):  2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1The unweighted data are from the 10–12 Newark EDs reporting to DAWN in 2004.  All DAWN cases are reviewed for quality con-
trol.  Based on this review, cases may be corrected or deleted.  Therefore, these data are subject to change.   
2Hydrocodone:  4 seeking detox. 
3Muscle relaxants:  10 overmedication, 0 seeking detox, 4 other. 
SOURCE:  Dawn Live!, OAS, SAMHSA, updated April 13–14, 2005 
 
 
 
 
Exhibit 12. Numbers and Percentages of Adult/Adolescent Cases Living with HIV/AIDS in New Jersey by  
 Exposure Category, Race/Ethnicity and Gender as of December 31, 2004 
 
Males Females Total  
N (%) N (%) N (%) 
Exposure Category       
Men/sex/men (MSM) 6,100 29 0 0 6,100 19 
Injection drug user (IDU) 6,484 31 3,555 31 10,039 31 
IDU/MSM 860 4 0 0 860 3 
Heterosexual Contact 2,350 11 4,468 39 6,818 21 
Other/Unknown 4,891 24 3,319 29 8,210 26 
TOTAL1 20,685 100 11,342 100 32,027 100 
Race/Ethnicity       
White 5,216 25 1,951 17 7,167 22 
Black 10,724 51 7,457 64 18,181 56 
Hispanic 4,710 22 2,085 18 6,795 21 
Asian/Pacific Islander 157 1 67 1 224 1 
Other/Unknown 236 1 143 1 379 1 
TOTAL2 21,043 100 11,703 100 32,746 100 
 
1Does not include pediatric cases. 
2Includes pediatric cases. 
SOURCE:  NJ Department of Health and Senior Services, Division of AIDS Prevention and Control 
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Exhibit 13. Adult/Adolescent Cases Living with HIV/AIDS in Newark City by Exposure Category and Gender  
 as of December 31, 2004 
 
Males Females Total Exposure Category N (%) N (%) N (%) 
Men/sex/men (MSM) 565 17 0 0 565 10 
Injection drug user (IDU) 1,292 39 852 36 2,144 38 
IDU/MSM 159 5 0 0 159 3 
Heterosexual Contact 506 15 908 39 1,414 25 
Other/Unknown 822 25 596 25 1,418 25 
TOTAL 3,344 100 2,356 100 5,700 100 
 
SOURCE:  NJ Department of Health and Senior Services, Division of AIDS Prevention and Control 
 
 
 
 
Exhibit 14.  Race/Ethnicity of Cases Living with HIV/AIDS in Newark City:  Through December 31, 2004 
 
Adult/Adolescent Pediatric Total Race/Ethnicity N (%) N (%) N (%) 
White, Non-Hispanic 198 3 0 0 198 3 
Black, Non-Hispanic 4,546 79 82 92 4,628 79 
Hispanic 980 17 7 8 987 17 
Other 52 1 0 0 52 1 
TOTAL 5,776 100 89 100 5,865 100 
 
SOURCE:  NJ Department of Health and Senior Services, Division of AIDS Prevention and Control 
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Drug Abuse Indicators in 
New Orleans 
 
Gail Thornton-Collins1 
 
ABSTRACT 
 
Although indicators continue to show a decline in 
cocaine abuse, they remain high. In 2004, cocaine 
accounted for 38 percent of drug items analyzed by 
forensic laboratories, nearly 32 percent of treatment 
admissions in Orleans Parish, and more than 49 
percent of the (unweighted) ED illicit drug reports. 
Marijuana abuse indicators are also high, account-
ing for nearly 53 percent of items analyzed by fo-
rensic labs, 32 percent of treatment admissions, and 
25 percent of the (unweighted) illicit drug reports. 
Heroin abuse indicators continue to be relatively 
low. A growing problem is the abuse of narcotic 
analgesics, especially hydrocodone. While not a 
problem in Orleans Parish, methamphetamine ac-
counts for around 4 to 6 percent of primary treat-
ment admissions in four other large parishes, and 
small clandestine methamphetamine labs are re-
portedly increasing in some rural areas. 
 
INTRODUCTION 
 
Area Description 
 
Located in southern Louisiana, the city of New Or-
leans covers 366 square miles, of which 164 are wa-
ter. Nearly one-half of the metropolitan area’s 1.3 
million inhabitants live in Orleans Parish, the largest 
of Louisiana’s 64 parishes. The total State population 
is about 4.5 million people, based on 2003 census 
projections (exhibit 1). As shown in exhibit 1, New 
Orleans has a much higher percentage of African-
Americans than the State overall (67.2 vs. 32.1 per-
cent) and a much lower percentage of Whites (28.1 
vs. 64.0 percent). Nearly 21 percent of individuals in 
New Orleans live below the poverty level, a propor-
tion similar to the State overall. 
 
Serviced by several deep-water ports, New Orleans is 
located at the connection of two principal waterways: 
the Gulf Intracoastal Waterway and the Mississippi 
River. Barge lines, ocean carriers, and truck lines 
serve the Port of New Orleans.  
 
                                                           
1The author is affiliated with the New Orleans Health Department, 
New Orleans, Louisiana. 
Data Sources 
 
Information for this report was collected from the 
sources described below: 
 
• Forensic laboratory testing data were provided 
by the Drug Enforcement Administration (DEA) 
for 2004, as reported to the National Forensic 
Laboratory Information System (NFLIS). Data 
for 2003 are also included in this paper. 
 
• Drug treatment data were provided by the Lou-
isiana State Office for Addictive Disorders and 
by not-for-profit treatment facilities for Orleans 
Parish for fiscal year (FY) 1995 through FY 
2004, when 2,306 persons were treated in New 
Orleans Parish. (Fiscal years run July through 
June.) Data for FY 2004 in another eight of the 
largest parishes in the State are also reported. 
 
• Emergency department (ED) data for calendar 
year 2004 were accessed through the Drug 
Abuse Warning Network (DAWN) Live! re-
stricted-access online query system, which is 
administered by the Office of Applied Studies 
(OAS), Substance Abuse and Mental Health 
Services Administration (SAMHSA). Nineteen 
of the 21 eligible hospitals in the New Orleans 
metropolitan area are in the DAWN sample, with 
a total of 21 EDs in the sample. (Some hospitals 
have more than one ED.) The data reported in 
this paper were not complete. During the 12-
month period, between 8 and 11 EDs reported 
data to DAWN each month (exhibit 2). Com-
pleteness of the data is summarized in exhibit 2. 
The data in this paper were updated by OAS on 
January 13–14, 2005; they are unweighted and 
are not estimates for the New Orleans area. Since 
all DAWN cases are reviewed for quality con-
trol, and may be corrected or deleted, the data 
reported here are subject to change. The informa-
tion derived from DAWN Live! represent drug 
reports in drug-related visits; reports exceed the 
number of ED visits because a patient may report 
use of multiple drugs (up to six drugs and alco-
hol may be represented in DAWN). This paper 
presents data on “Illicit Drugs of Abuse” (ex-
cluding “Alcohol Only” for patients younger 
than 21), reports for prescription-type drugs, and 
reports on visits involving alcohol. These data 
cannot be compared with DAWN data from 2002 
and before, nor can these preliminary data be 
used for comparison with future data. Only 
weighted ED data released by SAMHSA can be 
used for trend analysis. A full description of the 
DAWN system can be found at the DAWN Web 
site: <http://dawninfo.samhssa.gov>. 
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• Drug arrest data were provided by the New 
Orleans Police Department (NOPD) for 2003–
2004. Anecdotal information on arrests in 2004 
was also provided by NOPD. 
 
• Drug price, purity, and seizure information 
was extracted from Narcotics Digest Weekly, 
Volume 3, Number 52, December 28, 2004, Na-
tional Drug Intelligence Center (NDIC), and the 
DEA for the last quarter of 2004. Data for heroin 
purity were derived from the DEA’s Domestic 
Monitor Program (DMP) for 2003. 
 
• Acquired immunodeficiency syndrome (AIDS) 
and human immunodeficiency virus (HIV) 
data were provided by the Louisiana HIV/AIDS 
Surveillance System and represent cases reported 
in the third quarter of 2004.  
 
No recent drug-related mortality or survey data were 
available for this reporting period. Trends in drug-
related mortality data (DAWN) and trends in data from 
the Youth Risk Behavior Surveillance (YRBS) survey, 
Centers for Disease Control and Prevention, can be 
found in “Overview of Drug Abuse Indicators in New 
Orleans,” Epidemiologic Trends in Drug Abuse, Pro-
ceedings Vol. II, published by NIDA, June 2004. 
 
DRUG ABUSE PATTERNS AND TRENDS 
 
Cocaine/Crack 
 
Crack has been and continues to be the most serious 
drug problem in New Orleans; it is associated with 
high rates of violence and crime in the city. In 2004, 
the DEA reported that crack and cocaine hydrochlo-
ride (HCl) were widely available in New Orleans in 
quantities ranging from kilograms to grams. 
 
Approximately 41.0 percent of all items analyzed by 
NFLIS laboratories in New Orleans in 2004 were co-
caine (exhibit 3), compared with 38.4 percent in 2003. 
 
The proportion of primary cocaine/crack treatment 
admissions in Orleans Parish has been declining since 
1993. Cocaine/crack treatment admissions in the par-
ish decreased from 40.4 percent of all admissions in 
FY 1995 to 31.6 percent in FY 2004 (exhibit 4). A 
possible reason for the decrease in the proportion of 
cocaine admissions includes increases in court refer-
rals of marijuana abusers to treatment. 
 
A relatively high proportion (39.8 percent) of pri-
mary cocaine/crack treatment admissions in Orleans 
Parish in 2004 was female. Most (80.3 percent) of the 
male and female primary cocaine/crack admissions 
were African-American. A relatively large percentage 
(41.4 percent) of the African-American female co-
caine/crack admissions was age 35–44.  
 
Across eight other Louisiana parishes in 2004, pri-
mary cocaine admissions were highest in East Baton 
Rouge Parish (45.5 percent) and lowest in Calcasieu 
Parish (15.8 percent) (exhibit 5). 
 
Preliminary unweighted data accessed from DAWN 
Live! show that cocaine ED reports totaled 1,607 in 
2004, accounting for 49.5 percent of the illicit drug 
reports (exhibit 6a), another indicator of the cocaine 
problem in New Orleans. Patients involved in these 
visits were most likely to be male (69.2 percent), 35 
or older (56.0 percent), and African-American (59.1 
percent) (exhibit 6b). 
 
In 2004, there were fewer arrests for cocaine posses-
sion (n=2,249) than in 2003 (2,941) (exhibit 7), con-
tinuing the pattern from 2002. 
 
In New Orleans, Mexican and Caribbean drug traf-
ficking organizations (DTOs) are the primary dis-
tributors of cocaine HCl at the wholesale level. DTOs 
usually do not sell cocaine in the crack form because 
of the more severe Federal sentencing guidelines for 
the distribution of cocaine in this form. Street dealers 
generally assume responsibility for converting co-
caine HCl to crack. The dominant street-level crack 
dealers in New Orleans are African-Americans. 
 
At the retail level, crack is commonly sold in the 
form of rocks and cookies in small plastic bags, clear 
plastic vials, and 35-millimeter film canisters. In the 
last half of 2004, the DEA reported that purity levels 
for crack ranged from 40 to 90 percent, while purity 
levels for HCl were more variable in the 17–90 per-
cent range. 
 
Powder cocaine is commonly sold in quarter, one-
half, and 1 ounce quantities. Prices range from $800 
to $1,200 per ounce at the midlevel and approxi-
mately $18,000 to $25,000 per kilogram at the 
wholesale level (see exhibit 8). When cut/mixed with 
adulterants, and less potent, powder cocaine can be 
purchased at low prices at the street level. Crack has 
been available at $5 to $25 per rock and can be pur-
chased on the street for $900 to $1,200 per ounce. 
 
Heroin 
 
Heroin indicators remained relatively stable in New 
Orleans from 2001 to 2004.  
 
In 2004, 5.3 percent of all drug items (n=651) ana-
lyzed by forensic labs in New Orleans were heroin 
(exhibit 3). 
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After increasing from 12.2 percent of all treatment 
admissions in 1999 to 14.8 percent in 2001, heroin 
treatment admissions remained level, at about 11 
percent, from 2002 to 2004 (exhibit 4). As in the 
prior 3 years, most of the heroin admissions in 2004 
were male (74.5 percent). Of the males, 80.5 percent 
were African-American and 52.6 percent were in the 
25–34 age category. More than one-half (53.8 per-
cent) of the female heroin admissions were African-
American. St. Tammany (3.3 percent) was the only 
other parish in which more than 1 percent of admis-
sions were primary heroin abusers (exhibit 5). 
 
The 2004 preliminary unweighted DAWN Live! data 
show 490 ED reports involved heroin, accounting for 
15.1 percent of illicit drug reports (exhibit 6a). More 
than 76 percent of these patients were male (exhibit 
6b). The patients were slightly more likely to be age 
25–34 (37.1 percent), but 28.0 percent were younger 
than 25. Most were African-American (59 percent) or 
White (37 percent). 
 
The DEA reported that the primary heroin traffickers 
for the heroin that is marketed in New Orleans are 
Colombian, Nigerian, and African-American. Much 
of the heroin is transported into the area from Texas 
in privately owned vehicles. Some of the heroin is 
also brought into the ports near New Orleans via ves-
sels. 
 
Like crack cocaine, heroin distribution and abuse has 
a major impact on the homicide and robbery rates in 
New Orleans. In 2004, the NOPD reported that a 
relatively high percentage of individuals arrested for 
robbery in 2004 were African-Americans in the 25–
36 age category. The 2004 arrest data show that Afri-
can-American males predominated in arrests involv-
ing heroin (exhibit 7). In 2004, there were 309 arrests 
for heroin possession and 87 for heroin distribution. 
Arrests for heroin distribution in 2004 were 50 per-
cent lower than in 2003. 
 
African-American trafficking organizations distribute 
heroin in government-supported housing projects and 
in other low-income neighborhoods. Heroin is most 
commonly sold on the streets of New Orleans in 
“bags” or “papers.”  Mixtures containing 0.3–0.5 
grams are wrapped in small foil packages which are 
placed in plastic sandwich bags for multiple sales. 
Bags or papers are sold for $20 to $25 each at the 
retail level (exhibit 8), but it is possible to buy a bun-
dle (25) of bags for about $300. 
 
In 2003, most of the DMP heroin street buys in New 
Orleans were of South American origin. The purity of 
the heroin averaged 31.8 percent and sold for $1.62 
per milligram pure. 
Other Opiates/Narcotics 
 
Indicators for opiates other than heroin remained low. 
Hydromorphone (Dilaudid) is being replaced by 
OxyContin as the most popular opiate of abuse in the 
New Orleans area, but hydrocodone (Vicodin), pro-
poxyphene (Darvon), alprazolam (Xanax), oxyco-
done (Percodan), and hydromorphone are the most 
widely diverted opiates. 
 
Of the 12,290 items analyzed by NFLIS in 2004, 152 
(1.2 percent) were “other opiates/narcotics” (exhibit 
3); 91 (60 percent) of these other opiate items were 
hydrocodone. The percentage of other opiates/narcot-
ics in 2004 was the same as in 2003. 
 
Among treatment admissions in Orleans Parish in FY 
2004, 82 (3.6 percent) were for primary abuse of 
“other opiates or synthetic opioids” or non-
prescription methadone. All but seven were White: 
57 percent were White females and 35 percent were 
White males. Whites also dominated among these 
other opiate admissions in other parishes. The pro-
portions of these admissions in East Baton Rouge and 
Ouachita Parishes (ranging from 4.7 to 5.0 percent) 
were similar to that in Orleans Parish, while those in 
the other parishes were higher, ranging from ap-
proximately 7 to 21 percent (exhibit 5). In St. Tam-
many Parish, 21 of the 216 other opiate admissions 
were for nonprescribed methadone, the highest num-
ber in any of the 9 parishes represented in exhibit 5. 
Across the other seven parishes (excluding Orleans 
Parish), other opiates admissions were highest in St. 
Tammany Parish (21.1 percent) and Lafayette Parish 
(11.5 percent). 
 
According to news reports, a large number of persons 
abusing methadone were from pain management clin-
ics. Because of the large number of deaths, many of 
which involved methadone and other opiates, the State 
of Louisiana asked for an investigation of pain clinics 
in the New Orleans area. The legislative branch has 
closed down many of these clinics and placed stricter 
guidelines on others. 
 
The unweighted DAWN ED data for 2004 show 1,221 
reports of opiates/opioids. Of the opiate/opioid reports, 
46.7 percent were hydrocodone reports and 8.7 percent 
were oxycodone reports. Fifty-four percent of the hy-
drocodone-involved visits were for overmedication, as 
were 46 percent of the oxycodone-involved visits. 
 
In 2004, there were 1,087 arrests for possession of 
Schedule II narcotic drugs and 366 for distribution of 
Schedule II narcotics. Of the possession arrests, 55.6 
percent were African-American males and 26.0 per-
cent were White males (exhibit 9). More than 46 per-
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cent of these arrestees for possession were between the 
ages of 21 and 33, nearly 41 percent were 36 or older, 
and nearly 13 percent were younger than 21. Of the 
366 arrests for distribution of Schedule II narcotics, 
241 (65.8 percent) were African-American males. 
Nearly 30 percent of those arrested for distribution of 
Schedule II narcotics were younger than 21, with 34 
percent being age 21–35, and 36 percent being 36 and 
older. 
 
Marijuana 
 
Marijuana indicators were stable in 2004, but mari-
juana is still the most readily available illicit drug in 
New Orleans and the State of Louisiana. The price of 
marijuana decreased in recent years as the supply 
from Mexico increased. Mexican DTOs dominate the 
wholesale distribution of marijuana, which flows up 
through the Southwest border and through such 
Texas hub sites as Houston, Dallas, San Antonio, 
Brownsville, and El Paso. African-American and 
Mexican criminal groups transport large quantities of 
the drug and make it available to local dealers. Local 
independent dealers, street gangs, and other small 
groups are the local distributors. 
 
One-half of the items analyzed in NFLIS labs in 2004 
contained cannabis (exhibit 3), down from 52.2 per-
cent in 2003. 
 
In FY 2004, primary marijuana admissions in Or-
leans Parish exceeded those for other substances for 
the first time, accounting for nearly one-third (32.1 
percent, n=740) of the 2,306 treatment admissions 
(exhibit 4). Most (80.5 percent) were male. Mari-
juana treatment admissions increased sharply from 
11.5 percent in 1993 to 16.5 percent in 1994 to 28.2 
percent in 1995. However, from 1995 to 2004, the 
percentage of marijuana treatment admissions re-
mained relatively stable. 
 
In the other eight parishes in FY 2004, primary mari-
juana admissions were proportionately highest in 
Terrebonne (37.3 percent), Calcasieu (30.0 percent), 
and Ouachita (26.6 percent) (exhibit 5). 
 
There were 821 DAWN marijuana ED reports identi-
fied through DAWN Live! in 2004, accounting for 
25.3 percent of unweighted illicit drug reports (ex-
hibit 6a). Nearly two-thirds of the patients involved 
in these visits were male, and 57 percent were White 
(exhibit 6b). Nearly 41 percent were younger than 25.  
 
In 2004, there were 5,967 arrests for marijuana pos-
session and 1,048 arrests for marijuana distribution, 
reflecting little change from 2003 (exhibit 7). 
 
According to NDIC, the price of marijuana was sta-
ble in 2004. Joints sold for as low as $2, and grams 
could be purchased for $10 (exhibit 8). Marijuana 
was sold by the ounce at the retail level for $125–
$160 and by the pound wholesale for $800–$1,000. 
 
Methamphetamine/Amphetamines 
 
Methamphetamine indicators remained at low levels 
in New Orleans in 2003–2004. However, metham-
phetamine may be gaining popularity in some small 
towns and communities in the State, according to the 
DEA New Orleans Field Division (NOFD). Small 
clandestine methamphetamine labs have reportedly 
increased in some rural areas. Most methampheta-
mine seized in Louisiana came from Mexico and was 
transported from California or Texas in private and 
commercial vehicles.  
 
Of the items analyzed by NFLIS labs in 2004, 58 (0.5 
percent of all items analyzed) were methampheta-
mine or amphetamines (exhibit 3). 
 
In FY 2004, only five primary methamphetamine 
abusers entered treatment programs in Orleans Par-
ish, representing only 0.2 percent of all admissions. 
Primary methamphetamine admissions were higher in 
eight other parishes, based on the assessment of the 
Louisiana State Epidemiology Work Group. As 
shown in exhibit 5, the parishes with the highest 
numbers and percentages of primary methampheta-
mine admissions in 2004 included Rapides (6.7 per-
cent), Bossier (6.2 percent), Calcasieu (4.2 percent), 
and Ouachita (3.8 percent). Rapides is located near 
the Texas border, through which most of the 
methamphetamine in Louisiana was transported. 
 
Of the preliminary unweighted DAWN emergency 
department reports for illicit drugs in New Orleans in 
2004, 112 involved amphetamines and 25 involved 
methamphetamine (exhibit 6a).  
 
Club Drugs  
 
Use of club drugs continues to be reported in clubs 
and bars around the city’s French Quarter. Drugs 
such as methylenedioxymethamphetamine (MDMA 
or ecstasy) and gamma hydroxybutyrate (GHB) are 
most likely to be abused near metropolitan areas of 
the State where there are large college populations. 
Use of drugs such as ecstasy and flunitrazepam (Ro-
hyphnol) and similar “date rape” drugs are on the rise 
among youth in the city. Youth continue to be lured 
to these drugs because of their “hipness” and the 
myth that club drugs are safe. Ketamine abuse ap-
pears to have declined in the city, with little mention  
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of the drug other than among teenagers experiment-
ing with it. 
 
Of the 12,290 items analyzed by NFLIS in 2004, 126 (1 
percent) were MDMA (exhibit 3). Another five were 
ketamine, and one was lysergic acid diethylamide 
(LSD).  
 
The unweighted DAWN Live! ED data for 2004 show 
98 MDMA reports, representing 3.0 percent of illicit 
drug reports (exhibit 6a). ED reports for other drugs 
sometimes used in the “club scene” were few in num-
ber: 19 phencyclidine (PCP) reports, 13 GHB reports, 5 
LSD reports, and 2 ketamine reports.  
 
The retail cost of MDMA in the second half of 2004 
was $15–$20 per tablet (exhibit 8). 
 
Benzodiazepines 
 
Benzodiazepines accounted for 0.7 percent of the 
items analyzed by NFLIS in 2004 (exhibit 3). Of the 
88 benzodiazepine-type items, 49 (56 percent) were 
alprazolam, and 35 percent were diazepam. In 2003, 
1.0 percent of all drug items analyzed were a benzo-
diazepine. Of these 120 items, 62 percent were alpra-
zolam. 
 
Preliminary unweighted data accessed from DAWN 
Live! show that ED reports of benzodiazepines to-
taled 1,134 in 2004; 36 percent of the benzodi-
azepine-involved visits were for overmedication. 
 
Alcohol 
 
Alcohol abuse is a serious problem in New Orleans, 
as it is in many cities and towns in the United States. 
Alcohol and drugs are often used together, also a 
common pattern across the Nation. 
 
In Orleans Parish, primary alcohol admissions ac-
counted for nearly 19 percent of all admissions in FY 
2004 (exhibit 4). Primary alcohol admissions in eight 
other parishes in 2004 ranged from a low of 25 per-
cent in St. Tammany Parish to a high of 41 percent in 
Bossier Parish (exhibit 5). 
 
In the unweighted data accessed from DAWN Live! 
for 2004, there were 1,217 reports involving alcohol-
in-combination with other drugs and another 133 
“alcohol only” reports involving patients younger 
than 21. Sixty-two percent of the alcohol-only reports 
involved patients who were male; 74 percent in-
volved patients who were White, and 19 percent rep-
resented Black patients. In this patient group, 69 per-
cent were age 18–20, with the remainder being age 
12–17. 
INFECTIOUS DISEASES RELATED TO DRUG ABUSE  
 
In the first quarter of 2005, there were 7,545 persons 
living with HIV (n=3,702) or AIDS (3,843) in metro-
politan New Orleans. Of the 4,866 for whom expo-
sure risk was known, 16 percent (489 men and 275 
women) were exposed through injection drug use. 
Another 8 percent of the exposed cases were men 
who have sex with men and inject drugs. In addition, 
approximately 18 percent of the cases (650 women 
and 240 men) were exposed through heterosexual 
contact. Of the total 7,545 cases, 60 percent were 
Black non-Hispanic and 35 percent were White non-
Hispanic. More than three-quarters (77.2 percent) 
were older than 34. 
 
For inquiries concerning this report, please contact Gail Thorn-
ton-Collins, New Orleans Health Department, 2025 Canal Street, 
Suite 200, New Orleans, LA 70112, Phone:(504) 528-1912, E-mail 
<gailc@new-orleans.la.us>. 
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Exhibit 1. Population Demographics for the City of New Orleans vs. the State of Louisiana, by Percent:   
 2000 and 2003 (Estimates) 
 
2000 2003 (Estimates) Population Demographic New Orleans Louisiana New Orleans Louisiana 
Total Population (N) (484,674) (4,468,976) (451,316) (4,361,271) 
Male 46.9 48.4 46.1 48.1 
Female 53.1 51.6 53.9 51.9 
Median Age (Years) (33.1) (34.0) (34.3) (34.7) 
One Race 98.7 98.9 99.3 98.9 
White 28.1 63.9 28.1 64.0 
Black or African-American 67.3 32.5 67.2 32.1 
Asian 2.3 1.2 2.6 1.5 
Other 1.1 1.3 1.4 1.2 
Two or More Races 1.3 1.1 0.7 1.1 
Hispanic or Latino (of any race) 3.1 2.4 3.1 2.5 
Average Household Size (n) (2.48) (2.62) (2.49) (2.61) 
Median Household Income ($) ($27,133) ($32,566) ($35,677) ($34,141) 
Individuals Living Below Poverty Level 27.9 19.6 20.8 20.3 
 
SOURCE:  U.S. Census Bureau 
 
 
 
 
Exhibit 2. New Orleans DAWN ED Sample and Reporting Information:  2004 
 
Total Eligible 
Hospitals1 
No. of Hospitals 
in DAWN Sample 
Total EDs in 
DAWN Sample2 
No. of EDs Reporting per Month:  
Completeness of Data (%) 
No. of EDs 
Not Reporting 
90–100% 50–89% <50% 21 19 21 9–11 0–2 0–2 10–13 
 
1Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association An-
nual Survey. 
2Some hospitals have more than one emergency department. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/13–4/14, 2005 
 
 
 
 
Exhibit 3. Number of Analyzed Items and Percentage of All Items Tested1 in New Orleans, by Drug:  2004 
 
Drug Number Percent 
Cannabis 6,174 50.2 
Cocaine 5,013 40.8 
Heroin 651 5.3 
Other Opiates 152 1.2 
Benzodiazepines 88 0.7 
MDMA/MDA 126 1.0 
Methamphetamine/Amphetamines 58 0.5 
 
1A total of 12,290 items were reported. 
SOURCE:  NFLIS, DEA 
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Exhibit 4. Percentages of Treatment Admissions in Orleans Parish, by Selected Drug:  FY 1995–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Louisiana State Office of Alcohol and Drug Abuse 
 
 
 
 
Exhibit 5. Treatment Admissions for Selected Drugs in Eight Parishes Outside Orleans Parish, by Percent:    
      2004 
 
Parish 
Drug 
Bossier Calcasieu East Baton Rouge 
Lafay-
ette Ouachita Rapides 
St. Tam-
many 
Terre-
bonne 
Cocaine 26.7 15.8 45.5 32.3 24.8 26.5 28.4 17.3 
Heroin 0.0 0.3 0.8 0.9 0.3 0.7 3.3 0.3 
Other Opiates 8.9 11.4 5.0 11.5 4.7 11.4 21.1 7.5 
Marijuana 15.4 30.0 13.2 13.3 26.6 17.5 17.3 37.3 
Methampheta-
mine 6.2 4.2 2.1 1.0 3.8 6.7 1.6 1.0 
Alcohol 40.8 30.7 32.6 37.8 36.1 32.9 24.7 34.2 
Other Drugs 2.0 7.6 0.8 3.2 3.7 4.3 3.6 2.4 
Total (N=)1 (292) (983) (3,432) (885) (914) (1,295) (1,026) (986) 
 
 1Excludes a few admissions for whom a primary drug was not reported. 
SOURCE:  Louisiana State Office of Alcohol and Drug Abuse 
 
 
 
 
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
45.0
Cocaine 40.4 41.1 36.2 38.1 35.5 34.4 32.5 34.5 34.0 31.6
Heroin 3.5 3.6 6.2 8.4 12.2 11.2 14.8 11.8 10.6 11.1
Marijuana 28.2 31.3 30.9 30.2 33.0 29.2 30.5 29.8 28.9 32.1
Alcohol 25.5 22.3 24.9 21.4 17.8 20.5 18.6 19.3 21.2 18.7
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
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Exhibit 6a. Number and Percent of Selected Illicit1 Drug Reports in DAWN ED (Unweighted2):  20042 
 
Drug Number Percent 
Cocaine 1,607 49.5 
Heroin 490 15.1 
Marijuana 821 25.3 
Amphetamines 112 3.4 
Methamphetamine 25 0.8 
MDMA 98 3.0 
Other Illicit Drugs 94 2.9 
 
1Excludes “Alcohol Only” reports for persons younger than 21. 
2Unweighted data are from 8–11 New Orleans EDs reporting to DAWN in 2004.  All DAWN cases are reviewed for quality control.  
Based on this review, cases may be corrected or deleted and, therefore, are subject to change. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 1/13–1/14, 2005 
 
 
 
Exhibit 6b. Demographic Characteristics of Patients Reporting Abuse of Illicit Drugs in New Orleans DAWN  
       EDs, by Percent (Unweighted1):  2004 
 
Characteristic Cocaine Heroin Marijuana 
Gender    
 Male 69.2 76.3 66.4 
 Female 30.7 23.32 33.6 
Age Group    
 Younger than 25 16.6 28.0 40.6 
 25–34 27.4 37.1 28.0 
 35 and older 56.0 34.9 31.4 
Race/Ethnicity    
 White 36.8 36.9 57.4 
 Black 59.1 59.0 35.8 
 Hispanic 1.0 1.2 2.1 
 Other 0.1 0.2 0.1 
 Not documented 3.0 2.7 4.6 
 
1Unweighted data are from 8–11 New Orleans EDs reporting to DAWN.  All DAWN cases are reviewed for quality control.  Based on 
this review, cases may be corrected or deleted and, therefore, are subject to change. 
2Gender was not documented for 2 heroin-involved visits. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 1/13–1/14, 2005 
 
 
 
Exhibit 7. Drug Arrests in Orleans Parish by Race/Ethnicity, Gender, and Offense:  2003–2004 
 
Males Females 
Black White Other Black White Other Total Drug/ Of-fense 
2003 2004 2003 2004 2003 2004 2003 2004 2003 2004 2003 2004 2003 2004 
Cocaine 
 Possession 
 Distribution 
 
2,134 
1,086 
 
1,662 
1,106 
 
306 
38 
 
140 
11 
 
14 
6 
 
7 
6 
 
385 
120 
 
367 
156 
 
101 
11 
 
72 
7 
 
1 
1 
 
1 
0 
 
2,941 
1,262 
 
2,249 
1,286 
Heroin 
 Possession 
 Distribution 
 
230 
155 
 
220 
76 
 
66 
5 
 
42 
3 
 
0 
0 
 
0 
0 
 
24 
16 
 
22 
6 
 
38 
0 
 
25 
2 
 
0 
0 
 
0 
0 
 
358 
176 
 
309 
87 
Marijuana 
 Possession 
 Distribution 
 
4,389 
832 
 
4,468 
860 
 
1,034 
80 
 
925 
67 
 
18 
1 
 
9 
10 
 
447 
119 
 
412 
94 
 
182 
23 
 
152 
16 
 
0 
2 
 
1 
1 
 
6,070 
1,057 
 
5,967 
1,048 
Other Drugs 197 198 51 58 1 1 24 239 25 17 0 0 298 513 
Drug Para-
phernalia 1,404 1,435 631 524 18 12 402 541 195 188 2 2 2,652 2,702 
 
SOURCE: New Orleans Police Department 
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Exhibit 8.  Illicit Drug Prices in New Orleans:  July–December 2004 
 
Price in Dollars 
Drug 
Wholesale Midlevel Retail 
Powder Cocaine $18,000–$25,000 per kilogram $9,000–$10,000 per pound $800–$1,200 per ounce 
$250 per ¼ ounce 
$80–$150 per gram 
Crack $20,000–$28,000 per kilogram $8,000 per pound $900–$1,200 per ounce 
$5–$25 per rock 
$80–$125 per gram 
Heroin $80,000–$100,000 per kilo-gram $4,000–$9,000 per ounce 
$20–$25 per paper 
$300–$600 per gram 
Marijuana $2,000 per kilogram $800–$1,000 per pound $125–$160 per ounce 
$10 per gram 
$2 per joint 
Methamphetamine $20,000 per pound $1,400–$1,600 per ounce $400–$500 per ¼ ounce $100 per gram 
MDMA $8–$12 per tablet $12–$15 per tablet $15–$20 per tablet 
 
SOURCE: DEA and Narcotics Digest Weekly, NDIC 
 
 
 
 
Exhibit 9. Arrests for Possession and Distribution of Schedule II Narcotics in New Orleans, by Age Group  
      and Race/Ethnicity:  2004 
 
Possession 
Males Females Age Group 
Black White Other Black White Other Total 
<17 56 0 0 2 0 0 58 
17–20 43 24 2 7 7 0 83 
21–25 96 50 2 19 15 0 182 
26–30 76 53 0 16 18 0 163 
31–35 72 60 0 16 12 0 160 
36–40 80 31 0 21 10 0 143 
>41 181 65 0 36 16 0 298 
Distribution 
Males Females Age Group 
Black White Other Black White Other Total 
<17 57 1 1 2 0 0 61 
17–20 37 5 1 4 1 0 48 
21–25 49 16 0 5 4 0 74 
26–35 39 4 0 5 4 0 52 
≥36 59 37 1 20 14 0 131 
 
SOURCE:  New Orleans Police Department 
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Drug Use Trends in New York 
City 
 
Rozanne Marel, Ph.D., John Galea, M.A., 
Robinson B. Smith, M.A., and Gregory  
Rainone, Ph.D.1 
 
ABSTRACT 
Drug use trends were again mixed for this reporting 
period. Admissions to treatment with cocaine as a 
primary drug rose again this reporting period. Al-
though both cocaine powder and crack remain of 
good quality, many crack locations are seeing a de-
cline in buyers and sellers. Heroin indicators 
remained stable. Heroin remains widely available, 
although the purity levels have fallen recently. Mari-
juana indicators, which had been reaching new peaks, 
seem to have stabilized. Marijuana continues to be 
available in a wide variety of flavors and colors. Al-
though the numbers remain small, there is concern 
about methamphetamine. Many kinds of prescription 
drugs continue to be available on the street, and they 
seem to be growing in popularity, based on indicator 
data and street observations. Of the 92,021 New York-
ers living with HIV or AIDS, men having sex with 
men and injection drug use history remain the two 
major transmission risk factors.  
INTRODUCTION 
 
Area Description 
 
New York City, with 8 million people, is by far the 
largest city in the United States. It is situated in the 
southeastern corner of the State on the Atlantic coast 
and encompasses an area of 320 square miles. It has 
nearly 600 miles of waterfront and one of the world’s 
largest harbors. 
 
Historically, New York City has been home to a large 
multiracial, multiethnic population. New York City is 
the largest and most racially/ethnically diverse city in 
the country. As has been true throughout its history, 
immigration continues to shape the character of New 
York City. It has contributed to a substantial shift in the 
race/ethnic composition of New York. Findings from 
the 2000 census show that the population diversity con-
tinues: 35 percent are White; 27 percent are Black; 27 
percent are Hispanic of any race; and 10 percent are 
Asian and Pacific Islander. The five largest Asian 
groups in the city are Chinese, Asian Indian, Korean, 
                                                 
1The authors are affiliated with the New York State Office of Alco-
holism and Substance Abuse Services, New York, New York. 
Filipino, and Pakistani, and the five largest groups of 
Hispanic origin are Dominican, Mexican, Puerto Rican, 
Colombian, and Ecuadorian. Moreover, New York City 
includes people who identify with races/ethnicities from 
all over the world. It is estimated, for example, that in 
Queens alone more than 120 languages are spoken. 
Nearly 3 million New York City residents are foreign 
born (2,871,032), which represents 36 percent of the 
resident population, and about 1.2 million legal immi-
grants became New York City residents between 1990 
and 2000. The Dominican Republic remains the city’s 
largest source of immigrants. 
 
The city remains the economic hub of the Northeast. Its 
main industries include services and wholesale and re-
tail trade. Of the more than 3.7 million people em-
ployed in the city, 22 percent commute from 
surrounding areas. Overall, the unemployment rate in 
New York City for April 2005 was 5.7 percent, com-
pared with 4.9 percent in New York State and 5.2 
percent in the Nation. According to the Bureau of Labor 
Statistics, the New York City rate is dramatically lower 
than it was in October 2003, when it was 8.3, but it is 
higher than the unemployment rate for October 2000, 
when the rate was 5.4. New York City is still experi-
encing the economic aftereffects of the September 11, 
2001, attacks on the World Trade Center. Many jobs in 
New York City were lost as a result of decreased busi-
ness activity and the relocation of business firms. 
 
Census 2000 data showed that the median household 
income for New York City residents was $38,323, as 
compared to $43,393 for State residents and $41,994 
for U.S. residents as a whole.  The percentages of per-
sons living below the poverty level for New York City 
and the State as a whole were 21.2 percent and 14.6 
percent, respectively. The comparable figure for U.S. 
residents as a whole in 2000 was 12.4 percent. 
 
Data Sources 
 
This report describes current drug abuse trends in New 
York City from 1995 to 2004, using the data sources 
summarized below: 
 
• Emergency department (ED) data were derived 
for calendar year 2004 from the Drug Abuse Warn-
ing Network (DAWN) Live! restricted-access 
online query system administered by the Office of 
Applied Studies (OAS), Substance Abuse and Men-
tal Health Services Administration (SAMHSA).  
Eligible hospitals in the New York 5 Boroughs Di-
vision totaled 52; hospitals in the DAWN sample 
numbered 39, with the number of emergency de-
partments in the sample totaling 60. (Some 
hospitals have more than one emergency depart-
ment.) During this 12-month period, between 29 
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and 37 EDs reported data each month. The com-
pleteness of data reported by participating EDs 
varied by month (see exhibit 1). Exhibits in this 
paper reflect cases that were received by DAWN 
as of May 31, 2005–June 2, 2005. All DAWN 
cases are reviewed for quality control. Based on 
this review, cases may be corrected or deleted. 
Therefore, the data presented in this paper are sub-
ject to change. Data derived from DAWN Live! 
represent drug reports in drug-related ED visits. 
Drug reports exceed the number of ED visits, since 
a patient may report use of multiple drugs (up to 
six drugs and alcohol). The DAWN Live! data are 
unweighted and, thus, are not estimates for the re-
porting area. These data cannot be compared to 
DAWN data from 2002 and before, nor can pre-
liminary data be used for comparison with future 
data. Only weighted DAWN data released by 
SAMHSA can be used for trend analysis. A full 
description of the DAWN system can be found at 
http://dawninfo.samhsa.gov/. ED drug mentions 
data before 2003 were derived from the DAWN, 
OAS, SAMHSA, for 1995 through 2002. The 
weighted data are based on a representative sample 
of hospitals in New York City and Westchester, 
Rockland, and Putnam Counties.  
 
• Drug abuse-related death data are from the 
DAWN mortality system. Data from 2003 covered 
New York, New York, Newark, New Jersey, and 
Edison, Pennsylvania. For 2003, the following nine 
counties participated: Morris, New Jersey; Union, 
New Jersey; Bronx, New York; Kings, New York; 
New York, New York; Putnam, New York; Queens, 
New York, Richmond, New York; and Suffolk, New 
York. Data from 1995 covered New York City, 
Long Island, and Putnam County and included her-
oin/morphine and unspecified types of opiates. 
Between 1996 and 2002, DAWN covered only New 
York City, and the category for heroin/morphine no 
longer included other opiates. According to Mortal-
ity Data From the Drug Abuse Warning Network, 
2001, incomplete data were received for the New 
York metropolitan area, so data for New York are 
not presented for 2001.  
 
• Treatment admissions data were provided by the 
New York State Office of Alcoholism and Sub-
stance Abuse Services (OASAS) for 1995 through 
2004 and included both State-funded and nonfunded 
admissions. Demographic data are for 2004. 
 
• Drug-related arrest data were provided by the 
New York City Police Department (NYPD) for 
1994–2002. 
 
• Forensic laboratory testing data for New York 
City were provided by the Drug Enforcement Ad-
ministration (DEA)’s National Forensic Laboratory 
Information System (NFLIS) for January through 
December 2004. 
 
• Drug price, purity, and trafficking data were pro-
vided by the DEA’s Domestic Monitor Program 
(DMP) for heroin. These data are supplemented by 
information from the OASAS Street Studies Unit 
(SSU) reports.  
 
• Cocaine use during pregnancy data were provided 
by the New York City Department of Health for 
1995–2003. 
 
• Acquired immunodeficiency syndrome (AIDS) 
and human immunodeficiency virus (HIV) data 
were provided by the New York City Department of 
Health and Mental Hygiene, HIV Epidemiology 
Program, for 1984 through June 30, 2004. 
 
DRUG ABUSE PATTERNS AND TRENDS 
 
Cocaine/Crack 
 
In general, many cocaine indicators, which had been 
declining, are beginning to show increases, and the 
drug still accounts for major problems in New York 
City (exhibit 2). 
 
For the five boroughs of New York City, there were 
10,134 unweighted DAWN Live! reports for cocaine in 
January–December 2004. Of these reports for cocaine, 
39 percent of the patients were seeking detoxification. 
 
While primary cocaine treatment admissions to State-
funded and nonfunded programs in New York City had 
declined from 17,572 in 1998 to 14,059 in 2000, they 
increased to 16,642 in 2004—the highest total in 6 
years. It should be noted that even when the cocaine 
treatment admissions were in decline, they did not show 
the same type of dramatic long-term decline that was 
seen in the other indicators. In 2004, cocaine admis-
sions constituted 24 percent of all New York City’s 
69,065 drug and alcohol treatment admissions (exclud-
ing alcohol-only). 
 
Exhibit 3 shows demographic characteristics of cocaine 
treatment admissions for 2004 by the two primary  
 
 
modes of use: smoking crack (representing 62 percent 
of cocaine admissions) and using cocaine intranasally 
(representing 35 percent). Those who smoke crack are 
more likely than intranasal users to be female (36 vs. 25 
percent), Black (69 vs. 42 percent), readmissions to 
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treatment (83 vs. 71 percent), and without income (34 
vs. 25 percent), although for both groups, there were 
fewer clients with no source of income than in the pre-
vious reporting period. Those using intranasally are 
more likely to be Hispanic or White and to have some 
criminal justice status. The two groups are similar in 
secondary drugs of abuse, primarily alcohol and mari-
juana. It should be noted that all admissions for primary 
cocaine abuse represent an aging population, and those 
smoking crack tend to be older than those using cocaine 
intranasally.  
 
Another data source, the DEA’s National Forensic 
Laboratory Information System, showed that of the 
45,514 items reported for New York City in 2004, 
22,264 (49 percent) were cocaine. 
 
According to the Street Studies Unit, cocaine hydro-
chloride (HCl) buying and use continues at a stable 
pace. Although cocaine has traditionally been sold from 
indoor locations, field observers report that there has 
been a steady increase in the number of street sellers 
offering powder cocaine in various parts of New York 
City, and they expect the trend to continue during the 
summer. Cocaine prices can fluctuate, as sellers vary 
the purity of the product and offer several different-
sized packages. Cocaine is sold in $20, $25, $30, and 
$60 packages. The most common price on the street is 
the $20 packet, which contains approximately 0.25 
ounces of cocaine powder.  
 
A number of different methods are used in the packag-
ing of cocaine in New York City, including vials, nail-
sized plastic bags, aluminum foil glassine bags, light 
plastic wrap knotted at both ends, cellophane, folded 
paper, magazine pages, and balloons. Of these, the tra-
ditional method of aluminum foil continues to the most 
frequently used method, followed by plastic wrap and 
cellophane. Although users prefer the malleability of 
aluminum, they dislike the fact that the cocaine can 
“cook-up” (melt) in the foil from simple body heat. The 
use of brand names in association with the sale of co-
caine is becoming increasingly rare, since brand names 
may attract attention from law enforcement and may be 
easily duplicated by competitors. 
 
According to the DEA, the majority of the cocaine in 
New York City is supplied by Colombians. Dominican 
drug gangs continue to dominate the distribution of 
cocaine in New York City. Many cocaine sellers appear 
to be part of an extended organization composed of 
family, relatives, and long-term friendships. At the 
street level, most sellers are of the same ethnic identity 
as the largest ethnic group in the community. There are 
three basic methods used to sell cocaine HCl. The 
techno-method or virtual connection method, in which 
the buyer contacts the seller (via beeper, cell-phone, or 
Internet), places an order, and arranges a meeting and 
location, seems to be enjoying great popularity. In the 
second method, sellers work out of their own apart-
ments. The third method is selling cocaine on the street. 
These sellers deal solely with the “personal use” buyer 
who may want to buy less than $50 of cocaine. 
 
Cocaine selling is typically found in Black and His-
panic low-income communities, and the majority of the 
cocaine HCl street buyers are Hispanic and Black. 
Compared with heroin and crack, however, cocaine also 
has a large number of White street buyers. Cocaine 
users as a whole tend to have a higher social-economic 
status (SES). This is probably the result of cocaine’s 
popularity among young, white-collar professionals. 
According to field observations, cocaine users appear to 
be almost evenly split in terms of gender, but the major-
ity of the individuals actually making the buys continue 
to be males. Cocaine users appear to be younger on 
average than either heroin or crack users. Observations 
of large clusters of young buyers age 18–25 may sug-
gest a new generation of cocaine HCl users. 
 
According to street interviews, most cocaine HCl users 
report that they “only” snort the drug. Some recent re-
ports from the street, however, suggest that because of 
“speedballing” cocaine and heroin, injecting may be 
increasing. Most users report that they use cocaine 
solely for recreational purposes, typically in group set-
tings, at special events (such as parties or at clubs), and 
only on weekends. Field workers have also reported 
names of combinations involving cocaine and other 
drugs. “Russian” refers to a combination of cocaine 
HCl, crack, and Viagra; “Honey Devil” is a combina-
tion of cocaine, Viagra, and marijuana, or just Viagra 
and marijuana. 
 
Crack users report that crack cocaine continues to be 
highly available; however, because of police pressure, 
crack selling is less overt. Although there has been a 
decline in “open-air” markets, the Street Studies Unit 
expects that as the weather continues to get warmer, 
there will be a gradual shift to outdoor selling. 
 
Field researchers report that street-level crack in New 
York City is being sold in $5, $10, and $20 packages. 
The most common price/package combination is the 
$10 packet. During the summer, the $5 amount be-
comes more popular. 
 
There are three basic packaging methods associated 
with crack in New York City. They are thumb-nail size 
plastic bags, plastic vials, and glassine bags. Of these, 
the thumbnail-size bag continues to be the most popular 
packaging method. The field staff, however, reports an 
increase in the appearance of thin, 1-inch plastic vials 
with tops of various colors. Street contacts indicate that 
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—New York City 
 
 
Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005 183
these containers serve to protect the product from body 
heat and humidity, an issue of obvious importance dur-
ing the summer. The downside, according to some 
street contacts, is that the vials tend to be easier to find 
and more difficult to get rid of when one is trying to 
avoid arrest.  
 
What currently serves as a brand name in the selling of 
crack on the street is the color of the package or top—
(“blue bag” or “green tops,” etc.). The use of brand 
names, in general, is becoming increasingly rare.   
 
Street crack sellers are typically African-American or 
Hispanic males, between 17 and 35 years old. Although 
the sellers usually reflect the racial composition of the 
community, there appear to be slightly more Hispanic 
sellers than Black sellers. According to street contacts, 
Dominican drug gangs are the midlevel suppliers of the 
street sellers. The street-level sellers tend to be inde-
pendent entrepreneurs with no direct connection with 
the midlevel dealer.   
 
Based on field observations of both high and medium 
volume selling sites, there seems to be a trend away 
from the large extended organizations controlling mul-
tiple sites.  Most crack sellers are part of a two- or 
three-person partnership that serves a specific location. 
This street-level cooperative reduces overhead, extends 
selling hours, enables larger and cheaper inventory 
buys, provides mutual security for the sellers from rip-
offs, and decreases challenges to the selling site by rival 
sellers.  The truly independent single seller may best be 
described as a floater, who serves a small general area 
but does not claim a specific location. The single seller 
usually has a smaller client list and is more likely to 
extend credit or other allowances to keep his clients.  
 
Although midlevel dealers offer ready-made crack, 
most street sellers would prefer to buy cocaine HCl and 
cook their own crack. Preparing their own crack allows 
them to control the purity or quality of their product, 
thereby increasing profit margins.  
 
Field researchers report that many of the heavy crack 
selling locations around the city continue to be found in 
or around public housing developments. While police 
presence has pressured many “open-air” street locations 
to move indoors, the SSU expects an increase in outside 
selling locations during the summer. Operating in the 
open is also becoming more difficult, because the po-
lice are installing more special surveillance cameras, 
suspended from buildings and street lights, to monitor 
heavy selling locations.  
 
As a rule, street crack sellers do not sell other drugs. 
Other drug sellers, however, may operate from the same 
street corner. Crack sellers operating from indoor loca-
tions, on the other hand, have the room, time, and op-
portunity to offer a secondary product line. The most 
common secondary drug is marijuana, which many us-
ers smoke in conjunction with crack or use to reduce 
the “crash-effect” after the prolonged use of crack.  
  
The majority of the crack users are African-American 
or Hispanic males with low socio-economic status. 
Field researchers report that most observed buyers ap-
pear to be in their thirties. The SSU has not observed 
young or new users; most buyers observed appear to be 
veteran users.  
 
Every crack user interviewed reported smoking crack, 
typically using an old broken glass stem or tobacco 
leaves.  Field workers also report the use of the phrase 
“Chasing the Dragon” again to refer to the use of crack 
and heroin in a pipe together, with the crack first at the 
bottom on a bed of ashes. Reportedly, this method helps 
the drugs burn more slowly. There continues to be talk 
on the street about some individuals injecting crack, 
and there have been reports of users injecting crack 
with alcohol. 
  
The DEA reports that prices for cocaine powder for 
July to December 2003 were $22,000–$26,000 per 
kilogram and $800–$1,600 per ounce. The DEA reports 
that crack sells for about $28,000–$30,000 per kilo-
gram, $800–$1,600 per ounce, $27–$45 per gram, and 
$7–$10 per rock. 
 
DAWN figures for cocaine-involved deaths showed 
520 cocaine-involved drug misuse deaths in 2003 (ex-
hibit 2). For the cocaine drug-related deaths in 2003, 18 
percent involved one drug. 
 
The NYPD reports a decline in cocaine arrests since 
1995 (n=40,846) (exhibit 2). The number of cocaine 
arrests in 2002 was 13,574, a 67-percent decrease since 
1995. Of the cocaine arrests in 2002, 79 percent in-
volved crack. 
 
Another important indirect indicator of cocaine in-
volvement is the number of births in New York City to 
women who admit using cocaine during pregnancy. 
This not only indicates use among women, but it under-
scores a serious aspect of the cocaine problem. For 
several years, the number of women using cocaine dur-
ing pregnancy increased. In 1989, the number of births 
to women who used cocaine peaked at 3,168. After 
1989, the number steadily declined to 354 in 2003—an 
89-percent decline over 14 years (exhibit 2). It should 
be noted, however, that the change between 2002 and 
2003, 2 percent, was the smallest decline in recent 
years. 
 
Heroin 
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Heroin indicators remained stable during this reporting 
period (exhibit 4). For the five boroughs of New York 
City, there were 6,374 preliminary unweighted DAWN 
Live! heroin ED reports for January through December 
2004. Of these heroin reports, 52 percent of the patients 
were seeking detoxification. 
 
Primary heroin admissions to treatment programs in 
New York City gradually increased between 1995 and 
2004, from 18,287 to 23,687, an increase of almost 30 
percent (exhibit 4). Primary heroin admissions in 2004 
constituted 34 percent of New York City’s 69,065 drug 
and alcohol treatment admissions (excluding alcohol-
only). 
 
Intranasal heroin use may have peaked in the second 
half of 1998, with 62 percent of heroin admissions to all 
New York City drug treatment programs reporting this 
as their primary route of administration. Since then, the 
proportions reporting intranasal use declined slightly, to 
60 percent in 1999 through 2002, 59 percent in 2003, 
and 60 percent in 2004.  Meanwhile, heroin injection 
increased among heroin admissions, from 32 percent in 
the second half of 1998 to 37 percent in 2004. 
 
Exhibit 5 highlights general demographic characteris-
tics of heroin abusers admitted to all New York City 
treatment programs in 2004 by mode of use. In general, 
primary heroin admissions were overwhelmingly male 
(75 percent), older than 35 (71 percent), more likely to 
be Hispanic (53 percent) than Black (27 percent) or 
White (18 percent), usually readmissions to treatment 
(89 percent), and likely to report cocaine as a secondary 
drug of abuse (40 percent). Compared with heroin in-
jectors, intranasal users were more likely to be Black 
(32 vs. 16 percent) and have some criminal justice 
status (37 vs. 25 percent). In contrast, primary heroin 
injectors were more likely than intranasal users to be 
White (30 vs. 11 percent), to report cocaine as a secon-
dary drug of abuse (46 vs. 36 percent), and to have 
started use before reaching age 20 (56 vs. 41 percent). 
 
In addition to heroin admissions to traditional treatment 
programs, heroin admissions for detoxification or crisis 
services in New York City have become sizable in 
number. These special services are usually short term, 
provided in a hospital or community-based setting, and 
medically supervised. In 1995, 4,503 such admissions 
were reported for heroin abuse; by 2004 that figure in-
creased to 15,913, slightly less than in 2003 (16,067). 
 
DAWN medical examiner (ME) figures for heroin-
involved deaths in the New York metropolitan area 
show 104 drug misuse deaths in 2003 (exhibit 4). Of 
these, 13 percent were single-drug deaths. The category 
of opiates/opioids, which includes heroin (specified), 
methadone, and all other opiates/opioids, accounted for 
more drug misuse deaths than any other category in 
2003. 
 
NFLIS data show that 12 percent of the 45,514 cases 
for New York City in 2004 (5,313) were related to 
heroin. 
 
From 1992 to 2000, the DMP found average heroin 
purities to be generally above 60.0 percent. Findings for 
2003, however, show an average purity of 53.5 percent, 
down from 61.4 percent in 2002. The associated price is 
$0.48 per milligram pure, an increase from $0.36 per 
milligram pure in 2002. According to the DEA, kilo-
gram prices for January to June 2004 were $60,000–
$70,000 for South American heroin and $60,000–
$90,000 for Southwest Asian heroin. 
 
According to the SSU field staff, heroin in New York 
City continues to be highly available and accessible, 
with no shortage of selling locations. The “count” or 
amount sold in a $10 bag appears unchanged, and 
comments from buyers appear to suggest that dealers do 
not appear to be trying to stretch their supply. The ma-
jority of heroin copping locations are inside or off-the-
street operations. With the advent of warmer weather, 
however, the SSU predicts a substantial increase in 
heroin street dealing. Field staff members continue to 
report seeing nodding behavior by heroin users. 
 
While the quality of the heroin can vary by location and 
seller, most street contacts indicate that the current 
quality on the street is still fairly high, although the 
quality has been higher in recent years. The source of 
most of the heroin sold and used in New York City is 
South America. According to the DEA, Colombians are 
the principal importers and smugglers. Street sources 
indicate that the high and middle level distribution of 
heroin in New York City is done by Dominican drug 
gangs. The majority of the low-level distributors and 
street sellers continue to be Hispanics in some sections 
of New York and Blacks in other sections. 
 
The most common price for heroin bought on the street 
is $10 per packet. Each package contains approximately 
0.10 grams of powder. Regular heroin users report that 
they spend approximately $40 per day. Many of these 
individuals pay for their habit through panhandling or 
selling cigarettes or other articles on the street. Many of 
the females often exchange sexual favors for money or 
drugs.  
 
There are five basic packaging methods associated with 
heroin in New York. These methods include the glass-
ine bag, plastic wrap, and cellophane. The color of the 
bag usually identifies a given dealer’s product without 
identifying the dealer to the police. 
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The heroin user is typically older (thirties to fifties). 
While the majority of the heroin users are Black or His-
panic males, most street contacts report that heroin 
sellers, regardless of where they operate, have frequent 
White buyers. Although, at one time, heroin sellers did 
not sell other drugs, the SSU reports that more heroin 
dealers are selling crack in addition to heroin. There is an 
increasing trend for heroin users to use both drugs in or-
der to produce a speedball effect. Until very recently, 
most heroin users would have described themselves as 
snorters. There are reports, however, of greater use of 
needles, particularly among users younger than 30.  
 
There is less use of brand names in the marketing of 
heroin on the street because these names or symbols 
either attract too much police attention or they can be 
easily duplicated by competitors.  
 
Much like cocaine arrests, heroin arrests reached a high 
of 28,083 in 1989, declined for a few years, and then 
peaked in 1995 (n=38,131) (exhibit 4). Heroin arrests 
decreased from 33,665 in 2000 to 27,863 in 2001, but 
they increased again in 2002 to 34,098, an increase of 
22 percent in the year. 
 
Other Opiates/Narcotics 
 
According to preliminary unweighted DAWN Live! 
data for the five boroughs of New York City for Janu-
ary through December 2004, there were 3,732 ED 
reports of opiates/opioids. Of these reports for opi-
ates/opioids, 35 percent were for detoxification. 
 
Street researchers are reporting more use and diversion 
of OxyContin. Some users are using it by itself, while 
others are injecting it with cocaine for a speedball ef-
fect. Reports indicate that to remove the special coating 
on OxyContin in order to inject, some users are soaking 
the tablet in hot water. Although street researchers have 
not observed people hawking OxyContin, they have 
encountered a number of street buyers asking for Oxy-
Contin and claiming that the tablets are selling for $10 
per pill.  
 
Among ME deaths for the New York metropolitan area 
reported by DAWN, the category of opiates/opioids, 
which includes all legal and illegal narcotic analgesics 
and combinations, accounted for more drug misuse 
deaths than any other category. For specific narcotic-
type drugs in DAWN ME reports, methadone ac-
counted for 250 deaths in the New York metropolitan 
area in 2003, while all other opiates, excluding heroin, 
accounted for 532 deaths. 
 
Marijuana 
 
In New York City, marijuana indicators, which had 
recently increased steadily and dramatically, appear to 
be stabilizing (exhibit 6). For the five boroughs of New 
York City, there were 3,118 preliminary unweighted 
DAWN Live! ED reports for marijuana for January 
through December 2004.  
 
Primary marijuana admissions to all treatment programs 
had been increasing steadily over the past several years. 
The number increased more than ninefold between 
1991 and 2002, from 1,374 to 14,310, the highest an-
nual number (exhibit 6). Although the number fell again 
to 13,247 in 2004, that is still among the highest yearly 
totals for primary marijuana admissions. In 1991, pri-
mary marijuana admissions represented less than 5 
percent of all treatment admissions; by 2004, these ad-
missions represented 17 percent of admissions 
(excluding alcohol-only) to all New York City treat-
ment programs. 
 
Exhibit 7 shows demographic characteristics of primary 
marijuana admissions to all New York City treatment 
programs in 2004. The vast majority were male (79 
percent), and 28 percent were younger than 21. More 
than one-half (57 percent) were Black, about one-third 
(32 percent) were Hispanic, and 8 percent were White. 
Alcohol was the secondary drug of abuse for 38 percent 
of the marijuana admissions, and almost two-thirds had 
some criminal justice status (65 percent). 
 
Marijuana continues to be the most widely abused illicit 
drug in New York City. According to street contacts, 
marijuana is readily available at levels similar to those 
reported in the previous study period.  Street contacts 
also report that most of the marijuana currently avail-
able in New York City is of good to very good quality, 
the same assessment as the last reporting period.   
 
Field researchers report that street-level marijuana is 
associated with three basic prices: $10, $20–$25 (half-
ounce), and $50–$60 (ounce) amounts. During the pre-
sent study period, field researchers were unable to find 
any location offering marijuana for $5 or in loose joints.  
 
The most common street selling price continues to be 
$10. Unlike most other drug users, marijuana users 
commonly pool their money and share the drug. The 
$50 amounts of marijuana are rarely sold on the street; 
they are usually made through house connections. The 
pricing pattern has not changed since the last reporting 
period. 
 
There are several packaging methods associated with 
marijuana street sales in New York City: the thumbnail-
size plastic bags, glassine bags, aluminum foil, and ma-
nila envelopes.  The thumb-nail-size plastic bag is 
currently the most popular packaging method. Since 
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buyers prefer to examine the marijuana before buying, 
the manila envelopes and aluminum foil have fallen out 
of favor with sellers. 
 
Marijuana sellers are on average the youngest group of 
drug sellers. Most are adolescents and young adults 
(16–30 years old). As is true for most drug sellers, the 
marijuana sellers tend to reflect the ethnic make-up of 
the community, and most sellers operate in the area 
where they live. Most street-level sellers tend to be very 
young, African-American or Hispanic males. In more 
affluent communities, however, the seller is usually 
White and operates out of his parents’ home. Most of 
those selling marijuana are independent sellers, and 
their customers tend to be from their circle of acquaint-
ances. Most sellers initially start selling marijuana in 
order to support their own habit. The general availabil-
ity of marijuana, its low-price, and the perception of 
minor legal consequences tend to attract sellers, who 
with a small amount of money to invest can start their 
own business. In cases in which marijuana sellers are 
associated with large organizations, marijuana is typi-
cally a secondary product, and the organization’s 
principal interest is another drug (i.e., heroin, crack, or 
cocaine).  
  
As with other drugs, there are three basic selling meth-
ods associated with marijuana. The techno/virtual 
method remains very popular. A buyer makes a connec-
tion with a seller through the use of a beeper, cell-
phone, or Internet. An order is made, and a meeting is 
arranged or a delivery is scheduled. Another method is 
the use of a private residence. Marijuana sellers typi-
cally work out of their own apartments, and for many 
sellers, this constitutes a part-time avocation that helps 
supplement their income and habit. Many of these indi-
viduals develop a client list and require an introduction 
before they sell to a stranger. The third method, street 
sales, is associated with the highest risk but is still quite 
common in some communities. 
 
Although the majority of marijuana selling is done from 
indoor locations because of police pressure, marijuana 
selling is also found in outside locations. Sellers, par-
ticularly during the summer, tend to gravitate toward 
outside venues that attract crowds of young people (i.e., 
the park, beach, concerts). As a rule, street marijuana 
sellers do not sell other drugs; however, on occasion, 
phencyclidine (PCP) and methylenedioxymetham-
phetamine (MDMA or ecstasy) have been known to be 
sold from the same location. 
  
The use of marijuana cuts across all social demarcations 
(age, race, ethnicity, social class). Nevertheless, this 
drug seems to be most popular among adolescent and 
young adult users. In general, from any given location, 
the buyer and the seller tend to be from the same ethnic 
group. According to street observations, the majority of 
marijuana buyers are Hispanics and African-Americans. 
   
 
Marijuana users appear to be the youngest of any of the 
buyers of the main drug categories. Many of the buyers 
are currently in college or high school. Most users re-
ported having tried marijuana for the first time in high 
school or junior high school at the urging of a friend. 
According to observations by field staff, the majority of 
buyers are male, although there are a substantial num-
ber of lone female buyers. As a group, marijuana users 
are somewhat higher than other drug users in terms of 
socio-economic status. 
 
Most of the buyers interviewed on the street indicate 
that they use marijuana for purely recreational pur-
poses. The younger users indicate that most of their 
friends smoke the drug, and the most frequently offered 
reason for using marijuana is to “wind-down,” “loosen-
up,” or “chill” (relax). Almost all use some form of 
alcohol in conjunction with smoking marijuana. Most 
users indicated that they saw nothing wrong with mari-
juana use and felt that the legal penalties for using 
marijuana were less severe than those associated with 
other illicit drugs.  
  
Traditionally, marijuana was smoked in a joint. This 
method is no longer very popular, and many stores no 
longer even stock rolling paper.  Currently, the most 
popular method involves the use of blunts: hollowed-
out cigars or marijuana wrapped in cigar leaves. Very 
often, the leaves are dipped in brandy or some other 
aromatic liquor. The tobacco industry has responded to 
this by developing a large and varied selection of cigars 
for the adolescent marijuana user, featuring such selec-
tions as grape or vanilla cigars. A popular type of 
marijuana is called “Haze,” and it comes in a variety of 
flavors, including strawberry and bubblegum. Another 
street term is “Combo,” referring to a mixture of two or 
three different flavors of “Haze” mixed with cocaine 
and smoked in a blunt. Marijuana users seem to be 
equally comfortable using the drug in a group setting or 
in private. In private, the drug serves to reduce tension; 
in social gatherings, it serves to lower social inhibi-
tions.  
 
DAWN ME mentions for marijuana-involved drug mis-
use deaths in the New York City metropolitan area 
numbered 53 in 2003. None of these was a single-drug 
death. 
 
According to National Forensic Laboratory Information 
System data, 25 percent of the cases for New York City 
in 2004 (11,523) were related to cannabis. 
 
According to the DEA, marijuana prices can range from 
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$1,000 to $2,000 per pound wholesale and from $3,000 
to $5,000 per pound for hydroponic marijuana. 
 
In spite of decriminalizing possession of small amounts 
of marijuana, the NYPD continues to make a large 
number of marijuana-related arrests in New York City. 
The number of arrests has stabilized, however (exhibit 
6). Cannabis-involved arrests had reached a low of 
4,762 in 1991, but they increased more than 12 times in 
the next 9 years to 60,455 in 2000. Arrests for 2002 
(47,250) were at the same level as in 2001, which was 
the second largest yearly total. For arrests in 2002, ap-
proximately 98 percent were for misdemeanors, and 32 
percent involved persons age 20 or younger. Moreover, 
cannabis arrests accounted for 48 percent of all drug 
arrests in New York City in 2002, a dramatic change 
from earlier years and a continuation of the trend seen 
in the last 5 years. 
 
Stimulants 
 
Although methamphetamine is popular in other parts of 
the Nation, there were relatively few arrests, ED reports, 
deaths, or treatment admissions related to the drug in 
New York City. For example, in 2003, only seven stimu-
lant deaths were reported in the New York metropolitan 
area. In the five boroughs of New York City, there were 
154 DAWN Live! ED reports for stimulants for January 
through December 2004, according to preliminary un-
weighted data. 
 
According to the SSU, numerous sources in the gay 
community talk of the growing concern about the use of 
methamphetamine among young gay males and the 
relationship between the use of this drug and the spread 
of HIV. A number of gay male users have reported ex-
periencing crystal methamphetamine binges during 
which they have engaged in unsafe sexual activity. 
There are also indications that the use of metham-
phetamine has spread and is increasing among the “non 
gay” club-going crowd and college students. Metham-
phetamine is also known as crystal, Tina, Christina, 
crank, ice, speed, and chalk. 
 
Since the use of methamphetamine continues to appeal 
to a small segment of the general population, most sales 
involve mutual acquaintances making the initial interac-
tions. The closest thing to street sales is found at raves 
or other public events.  
 
Methamphetamine use appears to be especially on the 
rise among young males in the gay community. The 
recent growth in Crystal Meth Anonymous (CMA) 
meetings in New York City is one indicator of this. In 
1999, CMA had one meeting per week with six atten-
dees. By 2002, CMA had 4 meetings per week with an 
average of 20–30 attendees per meeting, and in 2005, 
CMA has 22 meetings per week with an average of 30–
50 attendees per meeting. Many experts worry about 
the implications methamphetamine has for the spread of 
HIV and other sexually transmitted diseases (STDs). 
 
Depressants 
 
While some indicators of the nonmedical use of psy-
choactive prescription drugs (e.g., hospital 
emergencies, deaths, and treatment admissions) have 
not been increasing, the SSU continues to report a vari-
ety of drugs readily available on the street for $1 or 
more per pill. 
 
For the five boroughs of New York City, there were 
1,751 benzodiazepine ED reports from January through 
December 2004 according to preliminary unweighted 
DAWN Live! data. Of these benzodiazepine reports, 25 
percent were for patients seeking detoxification. 
 
According to the SSU, pill selling, the street diversion 
of legitimately manufactured pharmaceuticals, seems to 
be increasing. The three most frequently sold pills on 
the street are Xanax, Elavil, and Catapres. The prices of 
these three medications range from $1 to $5 per pill. 
Although some pill buyers attributed their use of these 
and other drugs to some physical or emotional medical 
condition, most users indicated that their primary rea-
son for buying these medications was to get “high.” 
Very few respondents indicated that they used these 
medications or others to reduce withdrawal symptoms. 
 
Most street pill sellers appear to obtain their inventory 
from their physician through Medicaid at no cost to them-
selves. Although there are exceptions, most pills are sold 
individually and not in bottles. Most buyers seem to pre-
fer or are only able to afford to buy 1 day’s supply. In 
contrast to medication associated with pain, the diversion 
of HIV medication has less to do with getting high and 
more to do with making money. HIV medications are not  
 
usually sold individually; rather they are sold in sealed 
(unopened) bottles. In many cases, the price of a bottle 
(or 30-day supply) of the medication may sell for as 
much as $700. The buyers of the HIV medication do not 
seem to be interested in buying the medication for their 
own use or the use of a loved one. Instead, these medica-
tions appear to be bought in an effort to stockpile a 
supply of the medication which is eventually either sold 
back to a pharmacy for “re-sale” to another customer or 
shipped out of the country to a less developed nation with 
an AIDS problem. 
 
There continue to be few (about 1 percent) treatment 
admissions with a psychoactive prescription drug as a 
primary drug of abuse. 
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Among ME deaths reported by DAWN, benzodi-
azepine-involved drug misuse deaths numbered 201 in 
2003—among the top five categories of drug misuse 
deaths. Antidepressants were also in the top five cate-
gories of drug misuse deaths, accounting for 210 such 
deaths in 2003. Moreover, antidepressants were the 
number one category in suicide deaths in the New York 
metropolitan area in 2003, with 29 such deaths. 
 
Since these drugs are manufactured by legitimate phar-
maceutical companies, purity is not an issue. Most of 
these medications come in a variety of strengths, how-
ever, and not all strengths are found on the street. 
Observations indicate that the following pills are sold 
on the street: 1-milligram ($3) and 2-milligram ($5) 
Xanax tablets; 1-milligram ($1) Elavil tablets; and 2-
milligram ($1) and 3-milligram ($2) Catapres tablets. 
 
Hallucinogens 
 
For the five boroughs of New York City, there were 
294 preliminary unweighted DAWN Live! ED reports 
for PCP for January through December 2004. 
 
According to DAWN ME data for the New York met-
ropolitan area for 2003, hallucinogens (including PCP, 
lysergic acid diethylamide [LSD], and other hallucino-
gens) accounted for 12 drug misuse deaths. 
 
Street sources continue to report that PCP is becoming 
more readily available in the city. One method of use is 
to pour liquid PCP on marijuana by placing the mari-
juana in a glass jar with a rubber cap. The PCP is 
“injected” through the rubber top onto the marijuana. 
Hydroponic marijuana is especially popular in this 
method. Reports are that the caps on these PCP jars are 
usually red or orange with a picture of a butterfly. Some 
street sources say the butterfly symbolizes an angel, as 
in angel dust, another name for PCP, while others say 
the butterfly stands for “how high you can get.”  
Club Drugs 
 
Club drugs are a collection of various synthetic chemi-
cal compounds that are often abused by young people 
in festive social settings, such as dance clubs, after-hour 
clubs, “raves,” and other special events. Club drugs 
include MDMA, methamphetamine, gamma hydroxy-
butyrate (GHB), and ketamine. Raves and other all-
night parties are about endurance and sensory over-
stimulation, and, not surprisingly, many of the club 
drugs have stimulant or hallucinogenic properties. 
Since many of club drugs are synthetic and manufac-
tured, purity is not a real issue, but the quality of these 
products poses a serious concern. The chemical exper-
tise of the producers, the ingredients used, and 
laboratory conditions used to manufacture these sub-
stances are uncertain and potentially dangerous. 
 
According to preliminary unweighted DAWN Live! ED 
data for the five boroughs of New York City, there 
were 157 reports for MDMA for January through De-
cember 2004. 
 
Although the club drugs are, in fact, part of the New 
York drug scene at some level, street research suggests 
that their use is limited to a small segment of the New 
York City drug-using population. Of these drugs, ec-
stasy seems to be the most popular and frequently used 
club drug in the city. Lagging somewhat behind are 
GHB and ketamine.  LSD is a strong hallucinogen that 
has not been a major problem in New York City since 
the late 1960s and early 1970s. It is also known as acid, 
boomer, and yellow sunshine. Most contacts indicated 
that they never used LSD, nor did they know where it 
could be obtained.  
 
The price for a single pill of ecstasy ranges between $5 
and $30. The prices tend to run at the high end if these 
substances are purchased inside a club or rave. The 
most common sales unit for ecstasy is the single white 
pill or tablet. No additional packaging is required.  
 
Club drug sellers are usually young (early twenties or 
younger) White males, and many are attending college. 
Many of the sellers are middle-class or higher. This 
profile, however, is beginning to expand across racial, 
ethnic, and social class boundaries. In a club setting, a 
seller may also have marijuana, cocaine HCl, and other 
club drugs for sale.  
 
Club drug users tend to be White and young (ranging 
between 15 and 30). According to street contacts, ec-
stasy is almost as popular among females as males. 
Many of the users are older high school students, col-
lege students, or young working professionals. The 
latter group tends to be of a mid-to-high socio-
economic status. The socio-economic status of the 
younger users, who appear to be the fastest growing 
group of users, seems to be more widely spread. Ac-
cording to some informants, the appeal for these drugs 
is strongest among suburban White youth, who regu-
larly venture into the city for entertainment, fun, and 
excitement. There are, however, indications that club 
drugs, particularly ecstasy, are making greater inroads 
among New York residents, especially non-White us-
ers. There are reports that some Hispanic groups are 
becoming involved in the distribution of ecstasy, which 
may suggest that more Hispanics and other inner-city 
residents are beginning to use this drug. 
 
The route of administration varies with the drug. Club 
drug use typically involves the ingestion of multiple 
substances. Typically, a club drug user will also use 
alcohol, marijuana, cocaine, or other club drugs.  
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These club drugs continue to be used primarily for rec-
reational purposes, with use largely limited to weekends 
and special events. Except for clubs and other special 
events, most connections are made through a network 
of acquaintances that very often revolve around the 
user’s high school or college.  
 
The number of DAWN deaths involving the category of 
club drugs (including MDMA, ketamine, GHB, and 
Rohypnol) totaled 10 in 2003 for the New York metro-
politan area. 
 
INFECTIOUS DISEASES RELATED TO DRUG ABUSE 
 
The AIDS epidemic, with its impact on injection drug 
users (IDUs), has played a crucial role in shaping the 
New York City drug scene over the last two decades. 
HIV first entered New York City in the mid- to late-
1970s. AIDS reporting was mandated in 1983, but re-
porting of HIV infection began in June 2000.  
 
According to the New York City Department of Health, 
as of June 30, 2004, 92,021 New Yorkers were diagnosed 
with HIV or AIDS; 32,688 were living with HIV (non-
AIDS), and 59,333 were living with AIDS. The true 
number of persons living with HIV/AIDS (PLWHA) is 
actually higher, since the New York City Department of 
Health and Mental Hygiene estimates that 25 percent of 
persons living with HIV have never been tested and do 
not know that they are infected. AIDS incidence in New 
York City peaked in 1993, with 12,649 cases. Mortality 
dropped sharply beginning in 1996, but New York City 
residents continue to die of HIV. Between January 1, 
2004, and June 30, 2004, 1,051 people with HIV or  
 
AIDS died of all causes. In 2002, HIV/AIDS was the 
leading cause of death among New Yorkers age 35–44 
and the third leading cause among those age 25–34. In 
2003, the age-adjusted HIV-mortality rate in adults with 
AIDS declined by 12 percent. 
 
Of the 92,021 PLWHA in New York City as of June 
30, 2004, 64 percent were diagnosed with AIDS, and 
36 percent were diagnosed with non-AIDS HIV. Sev-
enty percent were male, and 30 percent were female. In 
terms of race/ethnicity, 44 percent were Black, 32 per-
cent were Hispanic, and 21 percent were White. For 
transmission risk factors, 27 percent (25,066) were men 
who have sex with men, 24 percent (21,881) had an 
injection drug use history, 18 percent reported a hetero-
sexual transmission factor, 3 percent had a perinatal 
transmission risk factor, 1 percent had another risk fac-
tor, and 28 percent had an unknown risk factor or were 
under investigation. Men and women showed different 
patterns of HIV transmission in 2003. Among women 
with known risk, heterosexual sex was the predominant 
risk for HIV, accounting for 75 percent of new HIV 
(non-AIDS) diagnoses. Among men with known risk, 
sex with men accounted for 71 percent of new HIV 
(non-AIDS) diagnoses. 
 
In 2003, 4,205 New Yorkers were diagnosed with HIV; 
1,050 (25 percent) first learned they were HIV-positive 
at the time they learned they had already progressed to 
AIDS. Also in 2003, 5,056 AIDS cases were diagnosed. 
New AIDS diagnoses increased by 13 percent from the 
previous year, with the largest increases occurring 
among Hispanic women (26 percent) and White men 
(29 percent). The majority (81 percent) of new HIV 
(non-AIDS) diagnoses and 80 percent of new AIDS 
diagnoses were among Blacks and Hispanics in 2003. 
Black women accounted for 61 percent of AIDS cases 
of women. Among Black men, the prevalence of 
HIV/AIDS was 2.8, significantly higher than the city-
wide average of 1.1 percent. HIV/AIDS is concentrated 
in the poorest neighborhoods of New York City. 
The New York City Department of Health and Mental 
Hygiene, Bureau of Communicable Diseases, also has a 
surveillance of hepatitis C data. As of December 2004, 
there were 15,129 newly reported individuals with a 
diagnosis date (or specimen collection date) in 2003. 
For 2002, that figure was 13,940. 
 
For inquiries concerning this report, please contact Rozanne Marel, 
Ph.D., Chief of Epidemiology, New York State Office of Alcoholism 
and Substance Abuse Services, 501 7th Avenue, 9th Floor, New York, 
New York 10018, Phone: (646) 728-4605, Fax: (646) 728-4685, or E-
mail: RozanneMarel@oasas.state.ny.us. 
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Exhibit 1: New York City DAWN ED Sample and Reporting Information: January–December 2004 
 
No. of EDs Reporting per 
Month: Completeness of Data 
(%) 
Total 
Eligible 
Hospitals1 
No. of 
hospitals in 
DAWN 
Sample 
Total EDs 
in DAWN 
Sample2 90–100% 50–89% <50% 
No. of EDs 
Not 
Reporting 
52 39 60 20–31 2–11 1–5 23–31 
 
1Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association Annual 
Survey. 
2Some hospitals have more than one emergency department 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 5/31/2005–6/2/2005 
 
 
 
Exhibit 2.   Semiannual Cocaine Trends for Selected Indicator Data in New York City: 1995–2004 
 
Year 
Semiannual/ 
Annual 
Periods 
Deaths Involv-
ing Cocaine1 
Cocaine ED 
Mentions/ 
Reports2 
Treatment 
Admissions: 
Cocaine as 
Primary Drug 
of Abuse3 
Cocaine 
Arrests4 
Births to 
Women 
Using  
Cocaine5 
1995 
1H 
2H 
Total 
 
 
908 
  9,915 
  9,808 
   19,715 
  8,371 
  7,836 
16,207 
 
 
40,846 
 
 
1,059 
1996 
1H 
2H 
Total 
 
 
659 
11,070 
10,522 
21,592 
  8,561 
  8,817 
17,378 
 
 
38,813 
 
 
1,005 
1997 
1H 
2H 
Total 
 
 
501 
10,233 
  9,969 
20,202 
  9,048 
  8,401 
17,449 
 
 
35,431 
 
 
   864 
1998 
1H 
2H 
Total 
 
 
438 
  9,989 
  9,560 
19,549 
  8,999 
  8,573 
17,572 
 
 
35,577 
 
 
   742 
1999 
1H 
2H 
Total 
 
 
394 
7,386 
7,413 
14,799 
8,346 
7,567 
15,913 
 
 
31,781 
 
 
626 
2000 
1H 
2H 
Total 
 
 
492 
6,883 
7,367 
14,250 
7,337 
6,722 
14,059 
 
 
31,919 
 
 
490 
2001 
1H 
2H 
Total 
– 
7,449 
6,450 
13,898 
7,343 
7,032 
14,375 
 
 
23,498 
 
 
438 
2002 
1H 
2H 
Total 421 
6,679 
7,282 
13,961 
7,736 
7,872 
15,608 13,574 
 
363 
2003 
1H 
2H 
Total         520  
8,203 
7,911 
16,114 
 
354 
2004 
1H 
2H 
Total 
  
10,134 
8,395 
8,247 
16,642 
 
 
 
 
 
 
SOURCES:  1DAWN, OAS, SAMHSA, including New York City, Long Island, and Putnam County through 1995; starting with 1996 
the  
 data include New York City only.  In 2003, data are for the 5 boroughs of New York City plus Suffolk and Putnam  
 Counties in New York, and Union and Morris Counties in New Jersey.   
2DAWN, OAS, SAMHSA, updated 5/31/2005-6/02/2005.  The 2004 number of reports are unweighted data and are 
from 60 EDs in the 5 boroughs of New York City reporting to DAWN in 2004.  During this 12-month period, however, 
between 29 and 37 EDs reported data each month.  All DAWN cases are reviewed for quality control.  Based on this 
review, cases may be corrected or deleted, and, therefore, are subject to change.   Prior to 2003, DAWN, OAS, 
SAMHSA, weighted data, based on a representative sample of hospitals for New York City and Westchester, Rock-
land, and Putnam Counties  
 3New York State Office of Alcoholism and Substance Abuse Services (OASAS)-funded and nonfunded treatment ad-
missions 
  4New York City Police Department 
  5New York City Department of Health 
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Exhibit 3. Characteristics of Primary Cocaine Admissions1 to State-Funded2 and Nonfunded3 Treatment 
   Programs in New York City, by Route of Administration and Percent:  2004 
 
Demographic  
Characteristic 
Percent Total 
(N=16,642) 
Percent Smoking 
Crack 
(n=10,262) 
Percent Using 
Cocaine Intranasally 
(n=5,754) 
Gender 
     Male 
     Female 
 
68 
32 
 
64 
36 
 
75 
25 
Age at Admission 
     25 and younger 
     26–35 
     36 and older 
     (Average age) 
 
6 
23 
71 
(39.2 years) 
 
4 
21 
75 
(39.9 years) 
 
11 
27 
62 
(38.0 years) 
Race 
     Black 
     Hispanic 
     White 
59 
25 
14 
 
69 
18 
11 
 
42 
36 
19 
No Source of Income4 30 34 25 
Some Criminal Justice Status 41 38 48 
Readmissions 79 83 71 
Age of First Use 
     14 and younger 
     15–19 
     20–29 
     30 and older 
 
 6 
29 
43 
22 
 
  5 
25 
46 
24 
 
  8 
36 
39 
18 
Secondary Drug of Abuse 
     Alcohol 
     Marijuana 
     Heroin 
 
43 
23 
  6 
 
45 
21 
  6 
 
39 
26 
5 
 
1Figures on this table may differ somewhat from figures cited on other tables, because computer runs may have been executed at 
different times and files are being updated continuously. 
2State-funded programs receive some or all funding through the New York State Office of Alcoholism and Substance Abuse Ser-
vices (OASAS). 
3Nonfunded programs receive funding through sources other than OASAS. 
4Defined as not earning income, not receiving support from family or significant others, and not receiving any public assistance. 
SOURCE: New York State Office of Alcoholism and Substance Abuse Services 
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Exhibit 4. Semiannual Heroin Trends for Selected Indicator Data in New York City: 1995–2004 
 
Year 
Semiannual/ 
Annual 
Period 
Deaths 
Involving Her-
oin1 
Heroin/ 
Morphine 
ED Mentions/ 
Reports2 
Treatment Admis-
sions: Heroin as 
Primary Drug of 
Abuse3 
Heroin 
Arrests4 
Average 
Purity of 
Street Heroin 
(%)5 
1995 
1H 
2H 
Total 
 
 
751 
5,288 
5,440 
10,706 
  9,286 
  9,001 
18,287 
 
 
38,131 
 
 
(69.4) 
1996 
1H 
2H 
Total 
 
 
192 
5,654 
5,478 
11,132 
  9,161 
  9,617 
18,778 
 
 
37,901 
 
 
(56.3) 
1997 
1H 
2H 
Total 
 
 
272 
4,900 
4,581 
9,481 
10,276 
10,431 
20,707 
 
 
35,325 
 
 
(62.5) 
1998 
1H 
2H 
Total 
 
 
230 
4,613 
4,605 
9,218 
10,793 
10,203 
20,996 
 
 
37,483 
 
 
(63.6) 
1999 
1H 
2H 
Total 
 
 
174 
4,153 
5,150 
9,302 
10,690 
10,189 
20,879 
 
 
32,949 
 
 
(61.8) 
2000 
1H 
2H 
Total 194 
5,378 
5,630 
11,009 
10,944 
10,672 
21,616 
 
 
33,665 
 
 
(62.9)  
2001 
1H 
2H 
Total 
– 
5,428 
5,216 
10,644 
11,324 
11,455 
22,779 
   
   
27,863 
 
 
(56.0) 
2002 
1H 
2H 
Total 224 
4,954 
5,443 
10,397 
11,357 
11,157 
22,514 34,098 (61.4) 
2003 
1H 
2H 
Total           104 
 
11,540 
12,023 
23,563 
 
(53.5) 
2004 
1H 
2H 
Total  6,374 
12,029 
11,658 
23,687 
 
 
 
SOURCES: 1DAWN, OAS, SAMHSA,  including New York City, Long Island, and Putnam County through 1995.  (Between 1996 
and  
   2002, the data include New York City only.  Prior to 1996, the data include heroin/morphine deaths as well as opiates 
not  
   specified by type.  Between 1996 and 2002, the data include only heroin/morphine deaths.)  In 2003, data are for the 5 
   boroughs of New York City plus Suffolk and Putnam Counties in New York, and Union and Morris Counties in New  
   Jersey.   
2DAWN, OAS, SAMHSA, updated 5/31/2005-6/02/2005.  The 2004 number of reports are unweighted data and are  
from 60 EDs in the 5 boroughs of New York City reporting to DAWN in 2004.  During this 12-month period, however, 
between 29 and 37 EDs reported data each month.  All DAWN cases are reviewed for quality control. Based on this re-
view, cases may be corrected or deleted, and, therefore, are subject to change.  Prior to 2003, DAWN, OAS, SAMHSA, 
weighted data, based on a representative sample of hospitals for New York City and Westchester, Rockland, and Put-
nam Counties.  
3New York State Office of Alcoholism and Substance Abuse Services (OASAS)-funded and nonfunded treatment ad-
mis-sions 
4New York City Police Department 
5U.S. Drug Enforcement Administration  
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Exhibit 5. Characteristics of Primary Heroin Admissions1 to State-Funded2 and Nonfunded3 Treatment 
   Programs in New York City, by Route of Administration and Percent:  2004 
 
Demographic  
Characteristic 
Percent Total 
(N=23,687) 
Percent Using Heroin 
Intranasally 
(n=14,146) 
Percent Injecting 
Heroin 
(n=8,775) 
Gender 
   Male 
   Female 
 
75 
25 
 
75 
25 
 
75 
25 
Age at Admission 
25 and younger 
26–35 
36 and older 
(Average age) 
 
7 
22 
71 
(40.2 years) 
 
5 
20 
75 
(40.8 years) 
 
  10 
25 
65 
(39.3 years) 
Race 
Black 
Hispanic 
White 
 
27 
53 
18 
 
32 
55 
11 
 
16 
52 
30 
No Source of Income4 27 28 25 
Some Criminal Justice Status 33 37 25 
Readmissions 89 88 92 
Age of First Use 
14 and younger 
15–19 
20–29 
30 and older 
 
12 
34 
35 
19 
 
10 
31 
36 
23 
 
16 
40 
32 
12 
Secondary Drug of Abuse 
Alcohol 
Marijuana 
Cocaine 
 
13 
8 
40 
 
13 
  9 
36 
 
12 
  6 
46 
 
1Figures on this table may differ somewhat from figures cited on other tables, because computer runs may have been executed at 
different times and files are being updated continuously. 
2State-funded programs receive some or all funding through the New York State Office of Alcoholism and Substance Abuse Ser-
vices (OASAS). 
3Nonfunded programs receive funding through sources other than OASAS. 
4Defined as not earning income, not receiving support from family or significant others, and not receiving any public assistance. 
SOURCE: New York State Office of Alcoholism and Substance Abuse Services 
 
 
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—New York City 
 
 
Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005 194 
Exhibit 6. Semiannual Marijuana Trends for Selected Indicator Data in New York City: 1995–2004 
 
Year Semiannual/ Annual Period 
Marijuana 
ED 
Mentions/ 
Reports1 
Treatment Admissions: Mari-
juana as Primary Drug of Abuse2 
Cannabis 
Arrests3 
1995 
1H 
2H 
Total 
1,516 
1,460 
2,974 
  2,171 
  2,159 
  4,330 
 
 
12,357 
1996 
1H 
2H 
Total 
1,723 
1,848 
3,571 
  2,845 
  3,185 
  6,030 
 
 
18,991 
1997 
1H 
2H 
Total 
1,939 
1,900 
3,839 
  3,794 
  3,657 
  7,451 
 
 
27,531 
1998 
1H 
2H 
Total 
1,986 
1,696 
3,682 
  4,554 
  4,473 
  9,027 
 
 
42,030 
1999 
1H 
2H 
Total 
1,799 
1,692 
3,491 
  5,119 
  5,100 
10,219 
 
 
43,122 
2000 
1H 
2H 
Total 
1,856 
1,688 
3,544 
  5,664 
  5,487 
11,151 
 
 
60,455 
2001 
1H 
2H 
Total 
1,904 
1,598 
3,502 
6,677 
6,593 
13,270 
 
 
47,651 
2002 
1H 
2H 
Total 
1,827 
2,097 
3,924 
7,512 
6,798 
14,310 47,250 
2003 
1H 
2H 
Total 
 
6,844 
6,627 
13,471 
 
2004 
1H 
2H 
Total 
 
 
3,118 
6,832 
6,415 
13,247 
 
 
SOURCES:  1DAWN, OAS, SAMHSA, updated 5/31/2005-6/02/2005.  The 2004 number of reports are unweighted data and are 
from 60 EDs in the 5 boroughs of New York City reporting to DAWN in 2004.  During this 12-month period, however, 
between 29 and 37 EDs reported data each month.  All DAWN cases are reviewed for quality control.  Based on this 
review, cases may be corrected or deleted, and, therefore, are subject to change.  Prior to 2003, DAWN, OAS, 
SAMHSA, weighted data, based on a representative sample of hospitals for New York City and Westchester, Rockland, 
and Putnam Counties  
       2New York State Office of Alcoholism and Substance Abuse Services (OASAS)-funded and nonfunded treatment 
   admissions 
       3New York City Police Department 
 
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—New York City 
 
 
Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005 195
Exhibit 7. Characteristics of Primary Marijuana Admissions1 to State-Funded2 and Nonfunded3 Treatment  
   Programs in New York City, by Percent: 2004 
 
Demographic Characteristic Percent of Total (N=13,247) 
Gender 
     Male 
     Female 
 
79 
21 
Age at Admission 
     20 and younger 
     21–25 
     26–35 
     36 and older 
     (Average Age) 
 
28 
26 
28 
18 
(26.8 years) 
Race 
     Black 
     Hispanic 
     White 
 
57 
32 
8 
No Source of Income4 22 
Some Criminal Justice Status 65 
Readmissions 56 
Age of First Use 
     14 and younger 
     15–19 
     20–29 
     30 and older 
 
49 
41 
8 
2 
Secondary Drug of Abuse 
     Alcohol 
     Cocaine 
 
38 
13 
 
1Figures on this table may differ somewhat from figures cited on other tables, because computer runs may have been executed at 
different times and files are being updated continuously. 
2State-funded programs receive some or all funding through the New York State Office of Alcoholism and Substance Abuse Ser-
vices (OASAS). 
3Nonfunded programs receive funding through sources other than OASAS. 
4Defined as not earning income, not receiving support from family or significant others, and not receiving any public assistance. 
SOURCE: New York State Office of Alcoholism and Substance Abuse Services 
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Drug Use in Philadelphia, 
Pennsylvania 
 
Samuel J. Cutler and Marvin F. Levine, 
M.S.W.1 
 
ABSTRACT 
 
Indicators in Philadelphia remain highest for co-
caine, heroin, alcohol, and marijuana. There has 
been an increase in the number of drugs used in 
combination and an expansion in the number of dif-
ferent drugs being used. During 2002, 2003, and 
2004, the average number of drugs detected in dece-
dents increased from 2.68 to 3.18 to 3.75 per case. In 
2004, 47 percent of decedents testing positive for her-
oin/morphine also tested positive for cocaine. In 
2004, 73 percent of male cocaine treatment admis-
sions and 84 percent of female cocaine treatment 
admissions were crack smokers. There are indica-
tions that PCP use is declining. Negative conse-
quences associated with the use of benzodiazepines 
are increasing.  
 
INTRODUCTION 
 
Area Description 
 
Philadelphia, the largest city in the State, is located in 
the southeastern corner of Pennsylvania. The 2000 
U.S. census count of 1,517,550 Philadelphia residents 
represents 12.4 percent of the State’s population and a 
7-percent increase from the 1990 census count. The 
2000 Philadelphia population was 45.0 percent White, 
43.2 percent African-American, 4.5 percent Asian, 0.3 
percent American Indian and Alaska Native, 4.8 per-
cent other race, and 2.2 percent two or more races. 
Hispanics (of various races) accounted for an estimated 
8.5 percent of the population, and persons age 18 and 
older accounted for 74.7 percent. The unemployment 
rate was 6.1 percent for persons age 16 and older, and 
49.8 percent of the population was employed. 
 
Data Sources 
 
This report focuses primarily on the city/county of 
Philadelphia and includes data from the sources 
shown below. For the purposes of this report, fiscal 
                                                   
1The authors are affiliated with the City of Philadelphia, Office of 
Behavioral Health/Mental Retardation Services, Coordinating Office 
for Drug and Alcohol Abuse Programs (CODAAP), Philadelphia, 
Pennsylvania. John H. Gossard, Richard C. Jones, and Nelson E. Mar-
tin provided assistance in preparing this paper. 
year (FY) refers to a year starting July 1 and ending 
the following June 30. 
 
• Treatment admissions data for programs in 
Philadelphia County were provided by the Penn-
sylvania Department of Health, Client Information 
System, for January 1, 1998, through December 
31, 2004. Data for 2004 are preliminary and sub-
ject to revision because of the treatment reporting 
schedule, which results in frequent delays between 
a treatment admission and the reporting of that 
event. 
 
• Mortality data were provided by the Philadel-
phia Medical Examiner’s (ME) Office. These 
data cover mortality cases with toxicology re-
ports indicating the detection of drugs among 
decedents in Philadelphia. The time period is 
1994 through 2004. (The cases include persons 
who died from the adverse affects of one or mul-
tiple drugs, as well as persons who exhibited 
some substance presence but died from other 
causes. The Philadelphia ME also distinguishes 
between persons who appeared to have a lethal 
reaction to what might be considered a light or 
moderate amount of drugs and persons whose 
toxicology reports showed a high level of drugs 
in their systems.) Mortality cases with positive 
toxicology reports for alcohol are only reported 
if the alcohol was to be found in combination 
with one or more other drugs. 
 
• Arrestee urinalysis data for booked adults were 
derived from reports from the First Judicial Dis-
trict of Pennsylvania, Adult Probation/Parole 
Department (APPD), for the period June 15, 2004, 
through December 15, 2004. 
 
• Drug price information was provided by the 
National Drug Intelligence Center for the period 
January 1, 2004, through June 30, 2004, and fo-
cus group participants in the spring of 2005. 
 
• Heroin purity data were provided by the Drug 
Enforcement Administration (DEA), Domestic 
Monitor Program (DMP), through the first half of 
2004.  
• Information on the identification of drug sam-
ples seized and analyzed by local law enforce-
ment as reported to the DEA’s National Forensic 
Laboratory Information System (NFLIS) during 
2004 were provided for this report. 
 
• Acquired immunodeficiency syndrome (AIDS) 
data were provided by the Philadelphia Depart-
ment of Public Health’s AIDS Activities Coor-
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dinating Office on AIDS cases reported from No-
vember 1, 1981, to December 31, 2004.  
 
• Population and demographic data describing 
the city of Philadelphia emanated from the U.S. 
Census Bureau. 
 
In addition to these sources, this report draws on fo-
cus group and key informant discussions with former 
drug users currently enrolled in treatment programs, 
as well as outreach workers assigned to homeless 
populations, substance abusers, persons with human 
immunodeficiency virus (HIV) infection, and law 
enforcement officials. 
 
A note to those accustomed to reading past editions 
of this report: Due to the levels of incomplete and 
inaccurate data from the Drug Abuse Warning Net-
work (DAWN) Live! hospital emergency department 
data set, the Office of Applied Studies (OAS) of the 
Substance Abuse and Mental Health Services Ad-
ministration (SAMHSA) suspended reporting from 
Philadelphia metropolitan statistical area emergency 
departments, and no such data will appear in the 
Philadelphia paper until problems have been rectified 
to the satisfaction of SAMHSA and DAWN.  
 
DRUG ABUSE PATTERNS AND TRENDS 
 
The four major drugs of abuse in Philadelphia con-
tinue to be cocaine, heroin, marijuana, and alcohol. 
These are frequently used in combination with each 
other and with other supplemental drugs. In 2003 and 
2004, 91.7 percent of people entering treatment iden-
tified one of these drugs as their primary drug of 
abuse.   
 
In 2004, the average number of drugs detected in de-
cedents by the ME (3.75) was the highest on record. 
The average over the previous 10-year period (1994 to 
2003) was 2.43 drugs per case (exhibit 1). The number 
of mortality cases with positive toxicology reports 
(n=888) in 2004 exceeded the previous record high of 
841 in 2003. Of the 888 deaths in 2004, adverse reac-
tion to drugs accounted for 31.0 percent, overdose 
represented 10.1 percent, violence accounted for 24.7 
percent, and “other causes” constituted 34.2 percent 
(exhibit 2).  
 
In 2004, African-American male decedents (n=292) 
and White male decedents (n=292) exceeded all other 
race/ethnicity and gender totals. White females 
(n=121) outnumbered African-American females 
(n=109). The remaining 74 deaths were among His-
panics, Asians, and American Indians. Overall,  
 
Whites accounted for 46.5 percent of the deaths; Af-
rican-Americans accounted for 45.2 percent of the 
deaths; Hispanics represented 7.5 percent; and Asians 
and American Indians accounted for 0.8 percent. 
 
Urinalysis data of booked arrestees from Philadel-
phia’s APPD in the second half of 2004 showed that 
39 percent (n=9,330) of the 23,913 tested arrestees in 
the sample were positive for at least 1 drug.   
  
The Pennsylvania Client Information System is limited 
to the identification of a maximum of three substances 
as drugs of abuse at treatment intake. The highest av-
erage number of drugs of abuse identified at admission 
to treatment occurred in the first half of 1999 (2.06). In 
2002, the average was 1.45 drugs of abuse, in 2003, 
the average was 1.74 drugs of abuse, and in 2004, the 
average was 1.73 drugs of abuse at admission to treat-
ment.  
 
Cocaine/Crack  
 
Cocaine/crack remains the major drug of abuse in 
Philadelphia. ME data show that the proportion of 
cases with cocaine present was 46 percent in 2002, 
39 percent in 2003, and 45 percent in 2004 (exhibit 
1). Cocaine was detected in 3,357 decedents from 
January 1994 through December 2004, a total higher 
than that for any other drug appearing in the toxicol-
ogy reports. In 2004, the average age of mortality 
cases with positive toxicology reports for cocaine was 
40. At least one other drug was detected in 83 percent 
of cocaine-positive cases in 2001and 2002, 85 per-
cent in 2003, and 87 percent in 2004. 
 
The treatment data for 2003 show that cocaine, as a 
primary drug, accounted for 25.8 percent of all 
treatment admissions, the same as in 2001 (exhibit 3). 
In 2003, cocaine was mentioned by an additional 
15.9 percent of clients as a secondary drug and by 2.8 
percent as a tertiary drug. In 2004, cocaine accounted 
for 26.4 percent of all primary drug mentions and 
was mentioned by an additional 14.7 percent of cli-
ents as a secondary drug and by 3.1 percent as a 
tertiary drug. The proportion of cocaine treatment 
admissions peaked in 1991, at 63 percent of all pri-
mary drugs mentioned at admission to treatment.  
 
In 2003 and 2004, males accounted for 59 and 60 
percent of primary cocaine drug treatment admis-
sions, respectively (exhibit 4). During these time 
periods, African-Americans accounted for 79 and 80 
percent of primary cocaine treatment admissions, 
respectively, followed by Whites (16 and 15 per-
cent), Hispanics (4 and 4 percent), and Asians and 
“others” (1 and 1 percent). Among primary cocaine 
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treatment admissions in 2003, the average number of 
drugs of abuse noted upon entering treatment was 
1.85; in 2004, the average was 1.68. 
 
Since 2000, an average of 81.5 percent of the pri-
mary cocaine admissions reported smoking the drug, 
15.5 percent reported intranasal use, 1.6 percent re-
ported injecting, and 1.4 percent reported 
administering the drug through other/unknown routes 
(exhibit 4). Since the first half of 1990, at least 77 per-
cent of cocaine treatment admissions have reported 
smoking the drug. Of all male cocaine admissions in 
2003 and 2004, 77 and 73 percent, respectively, re-
ported smoking the drug; the comparable figures for 
females were 86 and 84 percent. 
 
Urinalysis data of booked arrestees from Philadel-
phia’s APPD in 2004 showed that 13.8 percent 
(n=6,808) of the 49,200 tested arrestees in the sample 
were positive for cocaine or cocaine metabolites. Co-
caine was the second most frequently detected drug; 
marijuana ranked first. 
 
According to the 2004 NFLIS report, 42 percent of 
samples analyzed were positive for cocaine. 
 
The predominant form of crack sold in Philadelphia is 
the “rock,” which costs $5. The $5 rock ranged in size 
from 6 to 9 millimeters from 1996 until 2002. Since 
then, the size of the $5 rock was reduced to 5–6 milli-
meters. Treys ($3 rocks) ranged in size from 3 to 5 
millimeters since 1996. They were reduced to 3 to 4 
millimeters from the latter half of 2002 through the 
spring of 2005, when it was reported that treys are not 
as commonly available as in the past. Shapes of crack 
range from circular, to bumpy-circular, to pieces cut 
into the shape of a parallelogram. Powder cocaine is 
not as readily available in small ($5) quantities; as of 
the spring of 2005, $10 bags became scarcer, with the 
$20 bag becoming the standard retail unit on the street. 
According to the National Drug Intelligence Center, 
the retail/street-level price per ounce of crack ranged 
from $3 to $20 per rock and from $28 to $125 per 
gram of powdered cocaine in the first half of 2004.  
 
Focus group participants from the spring of 2002 
through the spring of 2005 estimated that about 55–
65 percent of powder cocaine buys are for intranasal 
use, 20–25 percent is injected straight, and 15–20 
percent is injected in a “speedball.” 
 
In the spring of 2005, crack users continued to report 
frequent use in combination with 40-ounce bottles of 
malt liquor, beer, wine, or other drugs, including alpra- 
 
 
zolam (Xanax), marijuana, or heroin. Powder cocaine, 
oxycodone, cigarettes, and methamphetamine were 
less frequently mentioned as drugs used with crack.  
 
Heroin/Morphine 
 
According to the DEA’s DMP, the average street-
level purity of heroin in Philadelphia was 71 percent 
in 2001, 66.3 percent in 2002, 59.6 percent in 2003, 
and 53 percent in the first half of 2004 (based on 
only 70 percent of the samples analyzed). The au-
thors pose that declining purity at the retail/street 
level might have a causal relationship for the afore-
mentioned increase in the average number of drugs in 
mortality cases since 2001. With lower heroin purity, 
users may perceive a need for more drugs to achieve 
the desired effect.  
 
Heroin was detected in 3,036 decedents from 1994 
through 2004, making it the second most commonly 
detected drug in decedents (exhibit 1). For the 4-year 
period 1999 through 2002, positive heroin toxicology 
reports occurred in 47 percent of all deaths with the 
presence of drugs. In 2003, heroin was detected in 
only 25 percent of all decedents with drug-positive 
toxicology reports; the proportion was 24 percent in 
2004. 
  
From 2000 through 2003, heroin alone was identified 
in 14, 11, 10, and 7 percent, respectively, of the re-
spective heroin toxicology reports. In 2004, heroin 
alone was identified in only 3 percent of the heroin-
positive toxicology reports. The combination of her-
oin and cocaine was detected in 20, 19, 17, 10, and 
11 percent of all decedents, respectively, from 2000 
through 2004. Cocaine was detected in 47 percent of 
heroin toxicology reports in 2004.  
 
In 2004, heroin treatment admissions ranked second 
highest after ranking first in 2003 (exhibit 3). Heroin 
admissions accounted for 22 percent of all admissions 
in 2002, 27 percent in 2003, and 26 percent in 2004. 
During 2003 and 2004, 65 percent of all treatment 
admissions for heroin, illegal methadone, and other 
opiates were male (exhibit 5). In 2004, 60 percent were 
White, 26 percent were African-American, 12 percent 
were Hispanic, and 2 percent were Asian/other. Indi-
viduals who identified heroin as the primary drug of 
abuse in 2003 used an average of 1.63 drugs; in 2004, 
the average was 1.67. 
 
As depicted in exhibit 5, the preferred routes of ad-
ministration for heroin, illegal methadone, and other 
opiates have been relatively stable among treatment 
admissions.  
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Heroin treatment admissions data from the second 
half of 1997 through 2004 revealed that there was a 
slow, but steady decline in the proportion of heroin 
injectors entering treatment. It was determined that 
the injection percentages were influenced by an in-
flux of relatively new users who entered treatment 
for the first time prior to converting to injection from 
intranasal use, which is characteristic of new users. 
However, most heroin users make the conversion to 
injecting before entering treatment for the first time.  
 
Urinalysis data of booked arrestees from Philadel-
phia’s APPD in 2004 showed that 6.2 percent 
(n=3,035) of the 49,200 tested arrestees in the sample 
were positive for opiates. Opiates were the third most 
frequently detected drugs behind marijuana and co-
caine. 
 
According to the 2004 NFLIS report, 9 percent of 
samples analyzed were positive for heroin. 
 
Key informants in the spring of 2005 continued to re-
port that the $10 bag of heroin remained the standard 
unit of purchase. The $10 bag usually yields one hit; 
$5 and $20 bags reportedly remain available. Accord-
ing to the National Drug Intelligence Center, the 
retail/street-level prices for heroin were $10–$20 per 
bag, $180–$250 per bundle, and $65–$300 per gram 
of heroin in the first half of 2004.  
 
Focus group participants in 2004 reported that the av-
erage age of new users is 20. In the spring of 2005, the 
average age of new users was reported as the late 
teens. All groups since autumn 2000 reported that the 
average heroin user injects the drug four or five times 
per day.  
 
Narcotic Analgesics 
 
Oxycodone 
 
The use of oxycodone products, including OxyCon-
tin, Percocet/Percodan, Roxicet, and Tylox, continues 
to appear problematic in Philadelphia.  
 
Oxycodone was detected in 421 decedents from 1994 
through 2004 (the ninth most frequently detected 
drug during that time period) (exhibit 1). Detections 
of oxycodone have been rapidly increasing since 
2000. In 2003, oxycodone was present in 9.6 percent 
of all drug-positive deaths; in 2004, oxycodone was 
present in 11.6 percent of drug-positive mortality 
cases.  
 
Focus group participants since spring 2002 reported 
the use of oxycodone by all racial/ethnic groups, with 
an age range of mid-teens to 40, with the largest user 
group being people in their twenties. 
 
Hydrocodone 
 
The presence of hydrocodone in mortality cases has 
also increased. There were 40 positive toxicology 
ME reports for hydrocodone in 2003, 51 reports in 
2004, and a total of 239 cases in the 11-year period 
from 1994 through 2004. Hydrocodone detections 
now rank 14th among all deaths with positive toxi-
cology reports.  
 
Opioid Analgesics 
 
Fentanyl 
 
In the spring of 2004, the Pennsylvania State Attor-
ney General’s Office issued information about the 
diversion and nonmedical use of fentanyl citrate. In 
particular, Actiq lozenges were cited as being sold on 
the streets of Philadelphia for $20 each. Actiq con-
tains fentanyl citrate and is indicated for patients who 
continue to experience pain while being treated with 
synthetic opiates. Actiq resembles a lollipop, as the 
medication lozenge is at the end of a small stick and 
it is used by rubbing against the inside soft tissue of 
the mouth. Locally, users call it “Perca-pop” or 
“Narco-pop.” From 1994 through 2004, the ME re-
corded 70 deaths with the presence of fentanyl. Of 
these, 16 occurred in 2003 and 35 occurred in 2004. 
 
Marijuana 
 
Marijuana continued to be readily available and widely 
used in Philadelphia in the second half of 2004. The 
proportion of clients who cited marijuana as the pri-
mary drug of abuse upon entering treatment was 17 
percent in 2003 and 2004 (exhibit 3). Among all ad-
missions in 2003 and 2004, an additional 10 and 11 
percent, respectively, mentioned marijuana as a sec-
ondary drug. During the same time periods, 
marijuana was mentioned as a tertiary drug by 7 per-
cent and 6 percent, respectively. In 2003, among 
primary marijuana admissions, males accounted for 
78 percent; African-Americans accounted for 63 per-
cent, Whites accounted for 21 percent, Hispanics 
accounted for 13 percent, and Asians and others ac-
counted for 3 percent. In 2004, the comparable 
figures were 77 percent male, 62 percent African-
American, 24 percent White, 11 percent Hispanic, 
and 3 percent Asians and others. Among primary 
marijuana treatment admissions in 2003, the average 
number of drugs of abuse noted upon entering treat-
ment was 1.63. The average in 2004 was 1.71. 
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Urinalysis data of booked arrestees from Philadel-
phia’s APPD in 2004 showed that 17.9 percent 
(n=8,786) of the 49,200 tested arrestees in the sample 
were positive for marijuana or marijuana metabolites. 
Marijuana was the most frequently detected drug by 
APPD.  
  
According to the 2004 NFLIS report, 32 percent of 
samples analyzed were positive for cannabis/tetra-
hydrocannabinol (THC). 
 
Key informants continue to report the widespread 
and increasing use of blunts, especially utilizing fla-
vored cigars. The combination of marijuana and 
phencyclidine (PCP) continues to be frequently re-
ported. Blunts laced with crack (called “Turbo”) are 
still common, but less so than the marijuana/PCP 
combination. Blunt users commonly ingest beer, 
wine coolers, whiskey, alprazolam, or diazepam 
along with the blunt. Less commonly, blunt smokers 
use powder cocaine, vodka, barbiturates, clonaze-
pam, oxycodone, cough syrup, and/or methampheta-
mine. These comments by users continue to 
underscore the common practice of multiple drug 
use, either simultaneously or sequentially. 
 
According to the National Drug Intelligence Center, 
the retail/street-level prices per bag of marijuana 
ranged from $5 to $35 in the first half of 2004.  
 
Phencyclidine (PCP) 
 
PCP began to gain popularity as an additive to blunts 
in 1994, and its use increased from 2000 to 2003. 
Users describe its effects as making them hallucinate 
and feel “invincible,” “crazy,” “numb,” or “violent.”  
 
PCP was detected in 449 decedents from 1994 through 
2004, making it the seventh most frequently detected 
drug during that period. In 2004, deaths with the pres-
ence of PCP declined to the second lowest annual total 
in the past 11 years (exhibit 1).  
 
In 2003, PCP was mentioned as a primary, secondary, 
or tertiary drug by 4.3 percent of all treatment admis-
sions. The average number of drugs of abuse men-
tioned by primary PCP treatment admissions was 1.92. 
In the first half of 2004, PCP was mentioned as a pri-
mary, secondary, or tertiary drug in 4.6 percent of all 
admissions, and the average number of drugs of abuse 
mentioned by primary PCP treatment admissions was 
1.89. 
 
Urinalysis data of booked arrestees from Philadel-
phia’s APPD in 2004 showed that 3.5 percent 
(n=1,731) of the 49,200 tested arrestees in the sample 
were positive for PCP, making this drug the sixth 
most frequently detected drug by APPD.   
 
PCP remains readily available. It is more commonly 
found on mint leaves for use in lacing blunts or for 
rolling and smoking. Additionally, some users prefer 
PCP in liquid form that is used by applying the drug 
to cigarettes. This method is referred to as “sherms” 
or “dip sticks.” Focus group participants in the spring 
of 2005 reported the application of PCP oil to the 
outside of blunts before smoking. 
 
Benzodiazepines 
 
Benzodiazepines, particularly alprazolam (Xanax) 
and diazepam (Valium), continue to be used in com-
bination with other drugs. Diazepam, having been 
detected by the ME in 585 decedents from 1994 
through 2004, ranks fourth among drugs present in 
mortality cases in Philadelphia. While users new to 
treatment report that diazepam has become less popu-
lar in recent years, alprazolam use has increased. 
Alprazolam was the 11th most frequently detected 
drug among decedents by the Philadelphia ME 
(n=285) from 1994 through 2004, including 72 cases 
in 2004 (exhibit 1).  
 
Treatment admission reports for 2003 show benzodi-
azepines as primary drugs of abuse in 67 cases, 
compared with 31 in 2004 (exhibit 3); however, these 
drugs were reported as secondary or tertiary drugs of 
abuse in 382 additional cases in 2003 and 311 addi-
tional cases in 2004. Fifty-seven percent of the 
mentions of benzodiazepines as secondary or tertiary 
drugs of abuse in 2004 occurred with heroin as the 
primary drug. Those who reported using benzodi-
azepines as their primary drugs of abuse used an 
average of two drugs in 2003 and 2004. Benzodi-
azepine abuse was reported by focus group 
participants as common among users of heroin, oxy-
codone, cocaine, marijuana, and cough syrup. Since 
spring 2000, all focus groups have reported that al-
prazolam has overtaken diazepam as the “most 
popular pill” on the street.  
 
Alprazolam represented 3 percent of the drugs ana-
lyzed by the Philadelphia Police Department and 
reported to the NFLIS. 
 
Deaths with the presence of oxazepam (Serax) have 
been increasing. In 2003, there were 16 positive toxi-
cology reports for oxazepam, and there were 38 in 
2004. In the 11-year period 1994 through 2004, there 
were 167 mortality cases testing positive for this drug, 
making oxazepam the 20th most frequently detected 
drug (exhibit 2).  
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Deaths with the presence of olanzapine (Zyprexa) 
have been increasing. There were 43 positive toxi-
cology reports for olanzapine in 2003 and 34 in 2004. 
In the 11-year period, 1994 through 2004, there were 
153 mortality cases testing positive for this drug, 
making olanzapine the 23rd most frequently detected 
drug.  
 
Urinalysis data of booked arrestees from Philadel-
phia’s APPD in 2004 showed that 5.7 percent 
(n=2,794) of the 49,200 tested arrestees in the sample 
were positive for benzodiazepines, making this class of 
drugs the fourth most frequently detected drug by 
APPD.  
 
Other Prescription Drugs of Note  
 
Prescription drugs are most frequently detected 
among decedents in combination with other drugs of 
the same type and/or in combination with cocaine, 
heroin, or alcohol. ME mentions for the most fre-
quently detected prescription drugs among decedents 
in 2004 (not already discussed) included methadone 
(n=132), diphenhydramine (n=129), and codeine 
(n=120). With 493 detections from 1994 through 
2004, codeine ranks as the fifth most frequently de-
tected drug. Methadone ranks sixth (n=479), and 
diphenhydramine ranks eighth (n=447). Regarding 
codeine and diphenhydramine, each of which is an 
ingredient in numerous over-the-counter medications 
that are abused in Philadelphia, negative conse-
quences appear most markedly among decedents in 
combination with other drugs.  
 
Deaths with the presence of fluoxetine (Prozac) began 
to increase in the late 1990s. With 176 positive toxi-
cology reports for fluoxetine from 1994 through 2004, 
fluoxetine ranks as the 18th most frequently detected 
drug.  
 
Dextromethorphan is a common ingredient in numer-
ous cough and cold medications. Key informants 
indicated that its use is increasing among people age 
30–40, particularly in combination with alprazolam 
and diazepam. The Philadelphia ME detected dex-
tromethorphan in 40 cases in 2003 and in an 
additional 53 cases in 2004. There were 140 dextro-
methorphan-positive cases from 1994 through 2004, 
ranking it as the 26th most frequently detected drug. 
 
Quetiapine (Seroquel), an antipsychotic, has only 
been on the market for 3–4 years. Twenty of the total 
56 quetiapine detections by the ME occurred in 2003, 
and an additional 23 detections were in 2004. 
 
Methamphetamine/Amphetamines  
 
Methamphetamine and amphetamines remain a rela-
tively minor problem in Philadelphia. There were 98 
deaths with the presence of methamphetamine (ranked 
31st) from 1994 through 2004 and 90 deaths with the 
presence of amphetamine (ranked 35th) during that 
same period.  
 
Annual treatment admissions for methamphetamine/ 
amphetamines as the primary drug of abuse from 1998 
to 2003 totaled 31, 33, 27, 83, 67, and 33, respectively 
(exhibit 3). There were 37 such admissions in 2004. 
Methamphetamine/amphetamines are rarely identified 
as a secondary or tertiary drug of choice among treat-
ment admissions in Philadelphia.  
 
Urinalysis data of booked arrestees from Philadel-
phia’s APPD in 2004 showed that 0.2 percent (n=97) 
of the 49,200 tested arrestees in the sample were 
positive for methamphetamine or amphetamines. 
This was the lowest result in the APPD data.  
 
According to the National Drug Intelligence Center, 
the retail/street-level price of methamphetamine was 
$100 per gram in the first half of 2004. 
 
For the second consecutive half-year, key informants 
indicated a growing popularity of methamphetamine 
among men who have sex with men. Methampheta-
mine continues to be reported as difficult to obtain, not 
usually sold outdoors, and requiring a connection, but 
it is reported that use has increased since 2001. 
 
Club Drugs 
 
There has been relatively little consequence data for 
methylenedioxymethamphetamine (MDMA). MDMA 
was present in 6 mortality cases in 1999 (the first year 
this drug was detected by the ME) and in a total of 42 
from 1999 through 2004, including none in the latter-
most 6-month period.  
 
MDMA is reportedly used in combination with mari-
juana and lysergic acid diethylamide (LSD), which, 
along with its users generally ranging in age from teens 
to early twenties, helps describe its use among club-
goers. 
 
According to the National Drug Intelligence Center, 
the retail/street-level price per MDMA tablet ranged 
from $9 to $35 in the first half of 2004. 
 
The Philadelphia ME first detected methylenedioxy-
amphetamine (MDA) in the second half of 1999. There 
were 30 positive toxicology reports for MDA through 
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2004, including 6 cases in the first half of 2004 and 
zero in the second half.  
 
Ketamine was first detected in decedents in Philadel-
phia in 1996; it was detected in four decedents in 
2000, four in 2001, two in 2002, three in 2003, and 
in only one in 2004. It is not reported to be widely 
available, and it is difficult to obtain. 
 
There is almost no familiarity of gamma hydroxybu-
tyrate (GHB) reported by treatment clients. The 
Philadelphia ME does not test for GHB. 
 
INFECTIOUS DISEASES RELATED TO DRUG ABUSE 
 
As of December 31, 2004, Philadelphia recorded 
17,084 cumulative AIDS cases among adults (exhibit 
6). Among those cases, 6,019 involved injection drug 
users (IDUs) (needle-sharers). Another 859 were in 
the dual exposure category of IDUs who were also 
men who had (unprotected) sex with other men 
(MSM). 
 
Cases reported with (unprotected) heterosexual con-
tact as a risk factor continued to exceed the historical 
average. Heterosexual contact was the identified ex-
posure category in 19.6 percent of all AIDS cases 
reported through December 31, 2004.  
 
For inquiries concerning this report, please contact Samuel Cutler, 
City of Philadelphia, Office of Behavioral Health/Mental Retardation 
Services, Coordinating Office for Drug and Alcohol Abuse Programs 
(CODAAP), 1101 Market Street, Suite 800, Philadelphia, Pennsylvania 
19107-2908, Phone: (215) 685-5414, Fax: (215) 685-4977, E-mail: 
<sam.cutler@phila.gov>. 
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Exhibit 1. Annual Mortality Cases in Philadelphia with the Presence of the 20 Most Frequently Detected  
   Drugs by the Medical Examiner:  1994–2004 
 
Year 
ME-Identified Drugs 
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 
TOTAL
1. Cocaine 368 336 277 304 218 238 321 300 270 326 399 3,357 
2. Heroin/Morphine 262 318 290 336 249 236 332 316 275 208 214 3,036 
3. Alcohol-in-Combination 253 254 182 214 157 179 197 185 153 290 219 2,283 
4. Diazepam 69 44 35 58 39 67 46 56 28 66 88 585 
5. Codeine 34 39 19 20 3 15 19 45 57 120 120 493 
6. Methadone 23 12 26 24 10 36 36 46 55 79 132 479 
7. Phencyclidine (PCP) 46 44 29 46 19 35 48 45 51 58 20 449 
8. Diphenhydramine 19 13 5 4 9 25 33 53 42 116 129 447 
9. Oxycodone 4 2 1 14 29 17 49 53 68 81 103 421 
10. Propoxyphene 30 30 27 32 21 22 40 43 31 41 48  365 
11. Alprazolam 24 8 17 18 19 8 16 31 27 45 72 285 
12. Nortriptylene 14 11 15 18 24 29 20 32 32 50 35 277 
13. Amitriptylene 11 14 13 16 21 23 20 24 35 48 35 263 
14. Hydrocodone 6 1 9 8 15 13 27 38 31 40 51 239 
15. Temazepam 10 4 21 30 20 18 18 23 11 30 41 226 
16. Doxepin 23 8 16 6 16 29 19 18 19 21 28 219 
17. Ibuprofen 2 1 0 2 1 7 8 18 10 53 85 189 
18. Fluoxetine 4 7 9 10 24 14 23 27 13 28 28 176 
19. Phenobarbital 18 17 15 4 10 10 18 26 5 18 27 171 
20. Oxazepam 5 3 9 26 19 11 12 17 11 16 38 167 
Total Drugs Mentioned 1,346 1,245 1,121 1,282 1,039 1,232 1,637 1,857 1,589 2,672 3,334 18,354 
Total Mortality Cases 617 632 565 592 484 533 675 660 593 841 888 7,080 
Average Number of 
Drugs Per Death 2.18 1.97 1.98 2.17 2.15 2.31 2.43 2.81 2.68 3.18 3.75 2.59 
 
SOURCE: Philadelphia Medical Examiner’s Office 
 
 
 
Exhibit 2. Causes of Annual Mortality Cases in Philadelphia, as Determined by the Medical Examiner, by  
   Percent:  1998–2004 
 
ME-Identified Cause 1998 1999 2000 2001 2002 2003 2004 
Adverse Effect of Drugs 60.6 55.7 56.6 56.4 57.7 30.4 31.0 
Overdose 3.7 3.8 2.1 3.8 2.5 6.3 10.1 
Violence by Another Person 10.7 9.6 13.0 10.0 11.6 17.2 16.3 
Violence to Oneself 7.2 6.6 5.6 6.2 5.6 10.5 8.3 
Other Causes1 17.8 24.3 22.7 23.6 22.6 35.6 34.2 
 
1Other Causes include deaths with the presence of drugs caused by accident, injury, drowning, fire, or a health or physical malady. 
SOURCE: Philadelphia Medical Examiner’s Office 
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Exhibit 3. Treatment Admissions by Primary Drug of Abuse in Philadelphia:  1998–2004 
 
Primary Drug 1998 1999 2000 2001 2002 2003 20041 
Cocaine 1,942 2,232 2,497 2,996 3,649 2,225 1,961 
Alcohol 1,477 1,943 1,826 2,366 3,425 1,896 1,640 
Heroin 872 2,272 2,041 4,279 2,679 2,352 1,939 
Other Opiates 48 46 73 92 187 174 162 
Marijuana 791 862 910 1,428 2,025 1,448 1,276 
PCP 32 49 43 74 188 142 116 
Other Hallucinogens 9 9 7 12 12 7 9 
Methamphetamine/ 
Amphetamines 31 33 27 83 67 33 37 
Benzodiazepines 32 46 37 89 66 67 31 
Other Tranquilizers 6 4 8 1 3 3 5 
Barbiturates 13 8 3 8 23 13 17 
Other Sedatives/Hypnotics 13 18 16 36 19 20 19 
Inhalants 2 0 4 1 0 0 1 
Over-the-Counter 7 24 5 2 2 4 8 
Other (Not Listed) 17 1 60 154 111 253 215 
Total 5,292 7,547 7,557 11,621 12,456 8,637 7,436 
 
1Data for this period are preliminary and subject to revision. 
SOURCE:  Pennsylvania Department of Health, Client Information System 
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Exhibit 4. Cocaine Treatment Admissions in Philadelphia by Route of Administration and Gender: 
2000–2004 
  
2000 2001 2002 2003 20041 Route of Administra-
tion and Gender No. (%) No. (%) No. (%) No. (%) No. (%) 
Smoked           
Male 1,112 (44.5) 1,377 (46.0) 1,802 (49.4) 1,014 (45.6) 857 (43.7) 
Female 1,002 (40.1) 1,039 (34.7) 1,212 (33.2) 786 (35.3) 657 (33.5) 
Intranasal           
Male 198 (7.9) 371 (12.4) 384 (10.5) 256 (11.5) 274 (14.0) 
Female 104 (4.2) 140 (4.7) 139 (3.8) 105 (4.7) 98 (5.0) 
Injected           
Male 38 (1.5) 30 (1.0) 28 (0.8) 37 (1.7) 26 (1.3) 
Female 12 (0.5) 14 (0.5) 8 (0.2) 8 (0.4) 8 (0.4) 
Other/Unknown           
Male 16 (0.6) 18 (0.6) 71 (1.9) 9 (0.4) 19 (1.0) 
Female 15 (0.6) 7 (0.2) 5 (0.1) 10 (0.4) 22 (1.1) 
Total Male 1,364 (54.6) 1,796 (59.9) 2,285 (62.6) 1,316 (59.1) 1,176 (60.0) 
Total Female 1,133 (45.4) 1,200 (40.1) 1,364 (37.4) 909 (40.9) 785 (40.0) 
Total 2,497 2,996 3,649 2,225 1,961 
 
1Data for this period are preliminary and subject to revision. 
SOURCE: Pennsylvania Department of Health, Client Information System 
 
 
 
 
Exhibit 5. Heroin, Illegal Methadone, and Other Opiate Treatment Admissions in Philadelphia by Route of  
   Administration and Gender:  2000–2004 
 
2000 2001 2002 2003 20041 Route of Administration 
and Gender No. (%) No. (%) No. No. No. (%) No. (%) 
Injected  
 Male 
 Female 
 
870 
408 
 
(41.2) 
(19.3) 
 
1,917 
805 
 
(43.9) 
(18.4) 
 
1,219 
541 
 
(42.5) 
(18.9) 
 
978 
522 
 
(38.7) 
(20.7) 
 
741 
391 
 
(35.3) 
(18.6) 
Intranasal 
 Male 
 Female 
 
411 
266 
 
(19.4) 
(12.6) 
 
733 
577 
 
(16.8) 
(13.2) 
 
564 
260 
 
(19.7) 
(9.1) 
 
479 
247 
 
(19.0) 
(9.9) 
399 
207 
(19.0) 
(9.9) 
Swallowed 
 Male 
 Female 
 
45 
42 
 
(2.1) 
(2.0) 
 
99 
55 
 
(2.3) 
(1.3) 
 
114 
66 
 
(4.0) 
(2.3) 
 
113 
64 
 
(4.5) 
(2.5) 
82 
66 
(3.9) 
(3.1) 
 
Smoked 
 Male 
 Female 
 
37 
11 
 
(1.8) 
(0.5) 
 
63 
40 
 
(1.4) 
(0.9) 
 
44 
17 
 
(1.5) 
(0.6) 
 
35 
15 
 
(1.4) 
(0.6) 
19 
9 
(0.9) 
(0.4) 
Other/Unknown 
 Male 
 Female 
 
13 
11 
 
(0.6) 
(0.5) 
 
49 
33 
 
(1.1) 
(0.8) 
 
32 
9 
 
(1.1) 
(0.3) 
 
48 
25 
 
(1.9) 
(1.0) 
126 
61 
(6.0) 
(2.9) 
Total Male 
Total Female 
1,376 
738 
(65.1) 
(34.9) 
2,861 
1,510 
(65.5) 
(34.5) 
1,973 
893 
(68.8) 
(31.2) 
1,653 
873 
(65.4) 
(34.6) 
1,367 
734 
(65.1) 
(34.9) 
Total 2,114 4,371 2,866 2,526 2,101 
 
1Data for this period are preliminary and subject to revision. 
SOURCE: Pennsylvania Department of Health, Client Information System 
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Exhibit 6. Cumulative AIDS Cases in Philadelphia by Exposure Category:  November 1, 1981, through 2004 
 
November 1, 1981, to December 31, 2004 Exposure 
Category Number Percent 
Injection Drug Use 6,019 (35.2) 
Male-to-Male Sex and Injection Drug 
Use 859 (5.0) 
Male-to-Male Sex 6,341 (37.1) 
Heterosexual Contact 3,352 (19.6) 
Blood Products 92 (0.5) 
No Identified Risk Factor 421 (2.5) 
Total Adult Cases 17,084 (99.9) 
 
SOURCE:  Philadelphia Department of Public Health, AIDS Activities Coordinating Office 
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Drug Abuse Trends in  
Phoenix and Arizona 
 
Ilene L. Dode, Ph.D.1 
 
ABSTRACT 
 
During FY 2004, 36,375 adults and children in Ari-
zona received treatment through the Arizona De-
partment of Health Services behavioral health sys-
tem for substance use, abuse, or dependence. Ex-
cluding alcohol admissions, 37.5 percent were for 
methamphetamine abuse, 21.4 percent were for 
marijuana abuse, 19.6 percent were for heroin 
abuse, 16.1 percent were for cocaine abuse, and 5.4 
percent were for abuse of all other illicit drugs. In 
2004, there were 8,116 (unweighted) drug reports in 
drug-related ED visits; of these, 2,165 were am-
phetamine and methamphetamine combined, which 
was slightly less than drug reports for alcohol. In 
the last quarter of 2004, NFLIS forensic lab analy-
sis of 2,009 drug items revealed that 32.3 percent 
contained methamphetamine, followed by 32.2 per-
cent for cocaine, 26.8 percent for cannabis, and 6 
percent for heroin. A report based on 2002–2003 
Arrestee Drug Abuse Monitoring program data 
from Maricopa and Pima Counties concluded that 
community prevention efforts based on the assump-
tion that social disorganization and methampheta-
mine use go hand in hand may be ineffective and 
not the best use of scarce resources. Methampheta-
mine was the primary drug of adolescents entering 
intensive treatment. 
 
INTRODUCTION 
 
Area Description 
 
The population of the State is 64 percent White, 25 
percent Hispanic, 3 percent African-American, 5 per-
cent Native American, 2 percent Asian American, 
and 2 percent other groups. Since 1990, the Hispanic 
population has increased by 88 percent statewide. 
The population of Maricopa County (Phoenix) is 
3,389,260 (60.7 percent of State population); 66 per-
cent are White, followed by 25 percent Hispanic, 4 
percent African-American, 2 percent Native Ameri-
can, 2 percent Asian American, and 2 percent other 
groups. 
 
                                                 
1The author is affiliated with Emergency Mobile Pediatric and 
Adult Crisis Team (EMPACT) – Suicide Prevention Center, Phoe-
nix, Arizona. 
Nearly one in four (23 percent) of Arizona’s residents 
live in a county that borders Mexico. While border 
residents are similar to other Arizonans, there are 
notable differences. Despite a high percentage of 
working families, and the fact that border residents 
are more likely to be in school, families along the 
border are poorer than other Arizonans; the median 
income ($35,421) is 13 percent lower than the State 
average of $40,558. Non-Hispanic White children are 
37 percent more likely to live in poverty.  
 
Data Sources 
 
This report is based on the most recent available data 
obtained from sources shown below: 
 
• Drug-related death data are from the 2003 Drug 
Abuse Warning Network (DAWN) medical/ 
coroner (ME/C) system, maintained by the Office 
of Applied Studies (OAS), Substance Abuse and 
Mental Health Services Administration 
(SAMHSA), updated in September 2004. The 
DAWN system covered 94 percent of the Phoe-
nix-Mesa-Scottsdale area population in 2003. The 
redesigned DAWN ME/C system covers any 
death, accidental or intentional, related to recent 
drug use among decedents age 6–97. The deaths 
may be caused/induced by the drug, deemed to 
have contributed to the death, or simply impli-
cated in the death. A DAWN case may involve 
multiple drugs; thus, the number of cases across 
drug categories exceeds the number of deaths. 
Rates for the area were provided for (combined) 
“drugs of misuse,” estimated at 114.8 per 100,000 
population; rates for males (177.5) exceeded those 
for females (52.4). Data on specific drugs, as pre-
sented in this paper, were reported only by un-
weighted numbers. The 2003 data are not compa-
rable to data for 2002 and before because of 
changes in the ME/C system. 
• Drug treatment data are from four sources. 
Statewide admissions data were provided by the 
Arizona Department of Health Services (ADHS), 
Division of Behavioral Health Services (DBHS), 
Bureau of Substance Abuse Treatment and Pre-
vention Services, through fiscal year (FY) 2004. 
Treatment admissions data for adults and juve-
niles in the Treatment and Assessment Screening 
Center (TASC) programs in Phoenix were de-
rived from the Maricopa County Juvenile Proba-
tion Program’s report, March 2004, and the 
Adult Deferred Prosecution Program’s Cumula-
tive Statistical Report, March 1989–March 2004. 
Data on detoxification admissions to Community 
Bridges in Phoenix cover the period from July 
2004 to April 2005, and data on persons treated 
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for methadone and nonmedical use of nonpre-
scription drugs at Phoenix’s Valle del Sol Opioid 
Treatment Program cover FY 2004–2005. 
• Emergency department (ED) drug data for 
2004 were accessed from the DAWN Live! re-
stricted-access online system, maintained by 
OAS, SAMHSA, on April 13–14, 2005. All 25 
eligible hospitals in the Phoenix area are in the 
DAWN sample, with the number of EDs in the 
sample totaling 26. (Some hospitals have more 
than one ED.) The data were incomplete (see ex-
hibit 1). During this 12-month period, between 
11 and 13 EDs reported data each month. 
DAWN covers eight case types; case data for 
Phoenix appear in exhibit 2. All DAWN cases 
are reviewed for quality control. Based on this 
review, cases may be corrected or deleted. 
Therefore, the data presented in this paper are 
subject to change. Data derived from DAWN 
Live! represent drug reports in drug-related ED 
visits. Drug reports exceed the number of ED 
visits, since a patient may report use of multiple 
drugs (up to six drugs and alcohol). The DAWN 
Live! data are unweighted and, thus, are not es-
timates for the reporting area. These data cannot 
be compared to DAWN data from 2002 and be-
fore, nor can preliminary data be used for com-
parison with future data. Only weighted DAWN 
data released by SAMHSA can be used for trend 
analysis. A full description of the DAWN system 
can be found at DAWN Web site: 
http://dawninfo.samhsa.gov. 
• Drug arrest data are from the Arizona Depart-
ment of Public Safety (ADPS), “Crime in Ari-
zona Annual Report 2003.” The data show 
statewide trends for trafficking/manufactur-
ing/sale arrests and arrests for possession of opi-
ates/cocaine, synthetic narcotics, marijuana, and 
other nonnarcotic drugs from 1993 through 
2003.  
• Forensic drug data are from the National Fo-
rensic Laboratory Information System (NFLIS), 
Drug Enforcement Agency (DEA), for the last 
quarter of 2004. 
• Drug seizure data are from the DEA for 2003 
and 2004. 
• Data on drug prices are from the DEA, Phoenix 
Office, in its “Trends in Traffic” First Quarter 
FY 2005 report, and the U.S. Customs Service, 
the ADPS, Phoenix Police Department, and the 
Maricopa County Sheriff’s Department.  Data on  
 
heroin price and purity are from DEA’s Domes-
tic Monitor Program for 2003. Price data on me-
thylenedioxymethamphetamine (MDMA) are 
from the National Drug Intelligence Center Col-
lection Unit for the State overall from January 
through June 2004. 
• Employee drug screening data on heroin were 
provided by laboratories for 1998–2003 and re-
ported by the DEA.  
• Student drug use data are from the Arizona 
Youth Survey supported by the Arizona Criminal 
Justice Commission. The survey covered stu-
dents, statewide, in grades 8, 10, and 12 in 2004 
and prior years. The survey is designed to assess 
school safety, adolescent substance use, antiso-
cial behavior, and risk and protective factors that 
predict adolescent problem behaviors.  
• Data on drug-endangered children were ob-
tained from the Arizona Office of the Attorney 
General, “Multidisciplinary/Integrated Protocol,” 
September 2003. 
• Human immunodeficiency virus (HIV) and 
acquired immunodeficiency syndrome (AIDS) 
data are from the Arizona Department of Health 
Services (DHS), Division of Public Health Ser-
vices, Bureau of Epidemiology and Disease Con-
trol, Office of HIV/STD Services “HIV/AIDS 
Annual Report,” March 2004, and represent new 
and total cases for the State overall from 1998–
2002. 
 
• Chronic hepatitis C data for the State overall 
from 1998 through 2003 are from the Arizona 
Department of Health Services (DHS), Division 
of Public Health Services, Office of Infectious 
Disease Services, Chronic Hepatitis Infection, 
Surveillance Report, 2003. 
 
DRUG ABUSE PATTERNS AND TRENDS 
 
Cocaine/Crack 
 
According to 2003 DAWN mortality data, there were 
130 cocaine-related deaths in the Phoenix area in 
2003, with 30 being single-drug deaths (exhibit 3). 
 
The ADHS, DBHS, Bureau for Substance Abuse 
Treatment and Prevention, reported that 9 percent of 
all clients admitted to State treatment programs (in-
cluding alcohol admissions) in FY 2004 were for 
primary cocaine abuse (exhibit 4). This reflects a 44-
percent decline in cocaine admissions from 2003.  
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For the past 7 reporting periods, cocaine treatment 
admissions (4,703) to the TASC Adult Deferred 
Prosecution Program remained unchanged, at 29 per-
cent of cumulative treatment admissions (10,238) 
(exhibit 5a). Six percent of juveniles tested positive 
for cocaine during the first quarter of 2005 (exhibit 
5b). 
 
The number of unweighted cocaine drug reports in 
DAWN Live! was 1,591 in 2004 (exhibit 6). Cocaine 
represented 27.5 percent of major substances of 
abuse drug reports (excluding alcohol). 
 
Between 2002 and 2003, the ADPS reported a 6-
percent decline in arrests for trafficking/manufac-
ture/sale of opiates and cocaine. Arrests decreased by 
1 percent for possession of opiates/cocaine in 2003 
(exhibit 7). 
 
The DEA reported numerous seizures at the Ari-
zona/Mexico border that involved mixed loads of 
cocaine and methamphetamine. A comparison of FY 
2003 and FY 2004 seizure statistics revealed a 47-
percent increase in the amount of cocaine seized. In 
FY 2004, 3,459 kilograms of cocaine were seized, 
compared with 2,159 kilograms in 2003. 
 
Cocaine remains readily available in Phoenix, Tuc-
son, and Nogales. An ounce of crack cocaine that 
sold for $400–$480 in Phoenix in 2002 sold for 
$540–$600 in 2004 (exhibit 8). 
 
Demand for crack cocaine remains consistently high. 
Crack is available in ounce and pound quantities. In 
the Phoenix African-American community, half-
ounce quantities of crack are called “half birds,” and 
ounce quantities are referred to as “full birds.” 
 
Heroin  
 
According to DAWN mortality data for 2003, 227 
drug misuse deaths involved opiates/opioids; 37 were 
single-drug deaths (exhibit 3). Of these illicit drug 
deaths, 13 involved heroin, with heroin being the 
only drug found in 4 cases. 
 
The ADHS, DBHS, Bureau of Substance Abuse 
Treatment and Prevention, identified heroin as the 
primary substance of abuse for 11 percent of treat-
ment admissions (including alcohol) in FY 2004 (ex-
hibit 4). 
 
Among the 10,653 clients treated at Community 
Bridges detoxification services from July 1, 2004, 
through April 30, 2005, 10 percent identified heroin 
as their drug of choice (exhibit 9). 
 
At the Valle del Sol Opioid Treatment Program, 
which served an average of 350 clients per month in 
FY 2004/2005, individuals seeking methadone treat-
ment reported heroin as the first drug of choice, and 
prescription opiates/opioids and benzodiazepines as 
the second and third drugs of choice, respectively. 
 
The number of unweighted heroin ED reports in 
Phoenix in 2004 was 755 (exhibit 6). Excluding alco-
hol, heroin represented 13 percent of DAWN Live! 
major illicit drug reports.  
 
The DEA reported increased availability of black tar 
heroin in the Phoenix area. There were continued 
reports of the presence of South American white her-
oin. Heroin abuse was reportedly increasing because 
of higher purity levels, lower cost, and the increase in 
noninjecting heroin users. Kilogram quantities of 
black tar heroin are readily available with 1–2 days 
notice when the purchase is 1 kilogram or larger.  
 
In 2003, the retail purity of heroin, before cutting 
agents were added, averaged 58 percent pure heroin. 
A review of the DEA’s Domestic Monitoring Pro-
gram for the recent 5-year period revealed that the 
average retail purity fluctuated between 41.3 and 48.9 
percent pure heroin. In Phoenix, the price of heroin in 
2004 was $60–$110 per gram (exhibit 8).  
 
Drug screening laboratories in Arizona reported a 
steady increase in the number of employees testing 
positive for heroin. In 1999, 8 percent of all drug 
screenings were positive for heroin, compared with 
17 percent in 2003.  
 
Other Opiates 
 
The unweighted number of ED drug reports for 
“other drugs” in DAWN Live! in 2004 included 1,226 
for opiates/opioids, 232 for hydrocodone, and 291 for 
oxycodone (exhibit 6). Case types included over-
medication, seeking detox, and other. 
 
The most commonly abused pharmaceutical con-
trolled substances in Phoenix in 2004 included Vi-
codin ($5 per tablet), Lortab ($5–$6 per 10-milligram 
tablet), and other hydrocodone products: Percocet ($5 
per tablet), OxyContin ($20–$80 per 80-milligram 
tablet and $20–$25 per 40-milligram tablet), and 
other oxycodone products (exhibit 8). Also com-
monly abused are methadone, hydromorphone, mor-
phine, Demerol, codeine products, and anabolic ster-
oids. Soma ($2–$5 per tablet) in combination with 
other analgesic controlled substances, Ultram and 
Nubain, continue to be highly abused prescription-
only substances. 
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The ADPS 2003 arrest data on trafficking/manu-
facture/sale of synthetic narcotics revealed a 21.3-
percent increase from 2001. Arrests for possession of 
synthetic narcotics continued a steady upward trend, 
increasing 38.3 percent from 2001 to 2003 (exhibit 7). 
 
Marijuana 
 
The seeding of marijuana fields in Mexico takes 
place in March or April, and the drug is harvested 
from June through August. Availability of marijuana 
increased between July and September 2004. South-
ern Arizona law enforcement reported an increase in 
the number of vehicles being driven by Hispanic 
males between the ages of 15 and 17. The young 
males are recruited from the border communities of 
Douglas, Nogales, and Naco. It was speculated that 
the vehicle driving was a “summer job” for some 
young males. 
 
Marijuana remains readily available in quantities up 
to hundreds of kilograms packaged for delivery, de-
spite large quantities of seizures by the U.S. Customs 
Service and the U.S. Border Patrol at the Ports of 
Entry and at remote sites along the international bor-
der. In 2004, the Phoenix Police Department seized 
large quantities of “BC bud” also known as 
“chronic.” In 2004, 1 pound bricks of BC bud sold 
for $4,500 each, compared with $500 to $750 for a 
pound of ordinary marijuana.  
 
ADHS/DBHS Bureau for Substance Abuse and Pre-
vention data revealed that 12 percent of treatment 
admissions (including alcohol) in FY 2004 were for 
marijuana (exhibit 4). 
 
Marijuana was reported as the primary drug of choice 
by 23.6 percent of clients in the TASC Adult De-
ferred Prosecution Program from March 1989 
through March 2005 (exhibit 5a). Seventy-three per-
cent (4,194) of juvenile admissions to the TASC Ju-
venile Probation Program were for marijuana treat-
ment during the first quarter of FY 2005 (exhibit 5b). 
 
The unweighted number of marijuana ED drug re-
ports in DAWN Live! in 2004 was 1,122 (exhibit 6). 
Excluding alcohol, marijuana represented 19.4 per-
cent of major substances of abuse drug reports in 
Phoenix.  
 
The DPS data show an 8.4-percent increase in arrests 
for trafficking/manufacture/sale of marijuana and a 
13.9-percent increase in arrests for marijuana posses-
sion from 2002 to 2003 (exhibit 7). 
 
In the 2004 Arizona Youth Survey, the percentage of 
students reporting ever using marijuana was nearly 
46 percent (exhibit 10), down from the nearly 51 per-
cent in 2002. Past-30-day use also declined, from 
approximately 25 percent in 2002 to 19 percent in 
2004. Nevertheless, marijuana continued to be the 
most frequently reported illicit drug among Arizona 
students in grades 8, 10, and 12. 
 
Stimulants 
 
In 2003, there were 104 deaths involving misuse of 
stimulants (amphethamine and methamphetamine) 
reported to DAWN; 23 were single-drug deaths (ex-
hibit 3). 
 
The ADHS/DBHS, Bureau for Substance Abuse 
Treatment and Prevention, reported that 21 percent of 
all clients admitted to State substance abuse treatment 
programs during FY 2004 were for primary metham-
phetamine abuse (exhibit 4). 
 
TASC Adult Deferred Prosecution Program data re-
vealed that 26.9 percent (4,436) of the March 1989 
through March 2005 treatment admissions (10,238) 
were for methamphetamine abuse (exhibit 5a). Eight-
een percent of the juveniles (1,034) in first quarter of 
2005 (who submitted urine samples) tested positive 
for methamphetamine/amphetamine (exhibit 5b).  
 
Slightly more than 11 percent of the admissions to 
Community Bridges detoxification programs from 
July 2004 through April 2005 were for metham-
phetamine abuse. Methamphamine (11 percent) was 
the second drug of choice after alcohol (61 percent), 
followed by heroin (10 percent), crack (6 percent), 
and cocaine (3 percent) (exhibit 9). 
 
The unweighted number of stimulant ED drug reports 
in DAWN Live! in 2004 was 2,165 (exhibit 6). Ex-
cluding alcohol, stimulants (methamphetamine/am-
phetamines) represented 37.4 percent of major sub-
stances of abuse drug reports in Phoenix. 
 
The NFLIS report for the last quarter of 2004 re-
vealed that 32.3 percent of drug items tested by fo-
rensic labs in Phoenix contained methamphetamine. 
Methamphetamine, cocaine, and cannabis together 
accounted for 97.2 percent of all drug samples. 
 
Methamphetamine is the number one drug threat in 
the State of Arizona, according to the National Drug 
Intelligence Center 2005 report. It has been a public 
health crisis that crosses all socioeconomic levels and 
all racial and ethnic groups. It is a statewide epi-
demic, not just a rural or just an urban problem. 
Methamphetmine is the number one illegal drug con-
tributing to violent crime in Arizona.  
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Other Drugs 
 
DAWN ME/C cases in 2003 included 54 deaths in-
volving benzodiazepine misuse (exhibit 3). 
 
The unweighted number of benzodiazepine drug re-
ports in DAWN Live! totaled 963 in 2004 (exhibit 6). 
 
The National Drug Intelligence Center Collection 
Unit reported street-level prices for MDMA in Ari-
zona from January through June 2004. The wholesale 
price was $7–$12 per tablet per 1,000 tablets, and the 
retail price was $20–$30 per tablet. 
 
The DEA reported substantial seizures of gamma 
hydroxybutyrate (GHB) and gamma butyrolactone 
(GBL). 
 
INFECTIOUS DISEASES RELATED TO DRUG ABUSE  
 
HIV/AIDS 
 
In 2002, there were 9,710 persons in Arizona known to 
be living with HIV Disease (HIV or AIDS): 4,402 with 
a diagnosis of AIDS, and 5,250 with a diagnosis of 
HIV. In the State as a whole, the known HIV disease 
prevalence rate was 184.1 per 100,000 persons. Based 
on these prevalence estimates, at least 1 of every 543 
persons in Arizona carries HIV. Maricopa County, the 
State’s most populous urban county, had the second 
highest prevalence rate of reported HIV Disease (207 
per 100,000 population). With 60 percent of the State’s 
population, it has 67.8 percent of known AIDS cases 
and 66.7 percent of known HIV cases. 
 
The rate for new AIDS diagnoses in Arizona has 
shown a steady decline and was 5.31 per 100,000 
population in 2002 (exhibit 10). The rate for new 
HIV diagnoses appeared to be increasing, from 1999 
to 2002 from 7.0 to nearly 8.0 per 100,000 popula-
tion, respectively.  
 
The predominant reported mode of transmission of 
HIV/AIDS in Phoenix continues to be contact among 
men who have sex with men (MSM), which ac-
counted for 57.5 percent of all reported new cases of 
HIV in 2002 (exhibit 10). Injection drug use (with 
and without male-to-male sex) accounted for 22.2 
percent, and heterosexual exposure accounted for 9.6 
percent of reported new cases of HIV/AIDS in Phoe-
nix during 2002 (exhibit 10).  
 
Chronic Hepatitis Infection 
 
From 1998 through 2003, there were 40,427 cases of 
chronic hepatitis C infection (HCV) reported in Ari-
zona. Of the reported cases, 41.37 percent were con-
firmed by recombinant immunoblot assay (RIBA) or 
polymerase chain reaction (PCR) test. Based on the 
Center for Disease Control and Prevention (CDC) 
estimates for the Nation, 92,000 individuals are living 
with HCV in Arizona.  
 
During 2003, there were 9,516 newly reported 
chronic cases of HCV in Phoenix, of which 37 per-
cent were confirmed. Most HCV-infected Arizonans 
are between the ages of 31 and 50. 
 
For inquiries concerning this report, please contact Ilene Dode, 
EMPACT-Suicide Prevention Center, Inc., 1232 East Broadway, 
#120, Tempe, AZ 85282, Phone: 480-784-1514, ext. 1116, Fax: 
480-967-3528, E-mail <idode@aol.com>.  
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20.9%
Overmedication
20.9%
Other
41.8%
Seeking detox
4.6%
Suicide attempt
5.8%
Alcohol only (age <21)
3.7%
Malicious poisoning
0.4%
Accidental ingestion
2.0%
Exhibit 1. DAWN ED Sample and Reporting Information in Phoenix:  2004 
 
 
1Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association An-
nual Survey. 
2One hospital has more than one emergency department. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/13–14, 2005 
 
 
 
Exhibit 2.  Drug-Related ED Visits in Phoenix, by Case Type (Unweighted1):2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1The unweighted data are from 11–13 EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on 
this review, cases may be corrected or deleted, and, therefore, are subject to change. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/13–14, 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No. of EDs Reporting per Month:  Com-
pleteness of Data (%) Total Eligible 
Hospitals1 
No. of Hospi-
tals in DAWN 
Sample2 
Total EDs in 
DAWN 
Sample 90-100% 50-89% <50% 
No. of EDs Not 
Reporting 
25 25 26 9-13 1-2 0-1 13-15 
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All Other accidental
67%
Exhibit 3. Drug-Related Mortality Cases in Phoenix, by Case Type and Drug:  2003 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  DAWN, OAS, SAMHSA, updated 9/24, 2004 
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Exhibit 4. Treatment Admissions in Arizona, by Primary Substance of Abuse and Percent:  FY 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Arizona Department of Health Services, Division of Behavioral Health Services, Bureau for Substance Abuse Treatment 
and Prevention 
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Exhibit 5a. Adult Deferred Prosecution Program Admissions in Phoenix, by Primary Drug:   
  March 1, 1989–March 31, 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Adult Treatment and Assessment Screening Center (TASC) – Deferred Prosecution Program 
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Exhibit 5b. Positive Tests Among Phoenix TASC Juvenile Clients, by Drug and Percent:   
  January–March 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N=5,709 
SOURCE:  Treatment and Assessment Screening Center (TASC), Maricopa County Juvenile Probation 
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Exhibit 6. Number of Drug Reports in Drug-Related ED Visits in Phoenix (Unweighted1):  2004 
 
Selected Drugs Case Type Total 
Major Substances of Abuse  All 8,116 
 Seeking Detox Seeking Detox 671 
Alcohol  All 2,333 
 Alcohol only (age <21) Alcohol-only 409 
Cocaine  All 1,591 
Heroin  All 755 
Marijuana  All 1,122 
Stimulants  All 2,165 
 Amphetamines  All 819 
 Methamphetamine  All 1,346 
MDMA (Ecstasy)  All 20 
GHB  All 4 
Ketamine  All 1 
LSD  All 16 
PCP  All 39 
Miscellaneous Hallucinogens  All 28 
Inhalants  All 30 
Combinations NTA  All 12 
Other Substances  All 5,805 
 Seeking Detox 288 
 Overmedication 3,686 
 Other 1,831 
Benzodiazepines  All 963 
 Seeking Detox 45 
 Overmedication 562 
 Other 356 
Opiates/Opioids  All 1,226 
 Seeking Detox 155 
 Overmedication 496 
 Other 575 
Opiates/Opioids, Unspecified  All 229 
 Seeking Detox 19 
 Overmedication 18 
 Other 192 
Hydrocodone  All 232 
 Seeking Detox 24 
 Overmedication 155 
 Other 53 
Oxycodone  All 291 
 Seeking Detox 63 
 Overmedication 162 
 Other 66 
Muscle Relaxants  All 281 
 Seeking Detox 8 
 Overmedication 214 
 Other 59 
 
1The unweighted data are from 11–13 EDs reporting to Phoenix hospitals reporting to DAWN in 2004. All DAWN cases are reviewed 
for quality control. Based on this review, cases may be corrected or deleted, and, therefore, are subject to change. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/13–14, 2005 
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Exhibit 7. Arrests in Arizona for Trafficking/Manufacture/Sale and Possession of Drugs, by Drug Category:   
 1993–2003 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Data for 1995 are unavailable. 
SOURCE:  Arizona Department of Public Safety 
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Trafficking/Manufacture/ Sale
Opiates/Cocaine 1,048 27.6% 1,030 21.5% 1,606 33.0% 564 12.9% 1,776 33.3% 1,788 35.4%
Syn. Narcotics 507 13.4% 629 13.1% 596 12.3% 641 14.6% 760 14.2% 578 11.4%
Marijuana 1,376 36.2% 1,456 30.4% 1,343 27.6% 1,404 32.0% 1,084 20.3% 1,150 22.7%
Other Drugs-Non Narcotics 866 22.8% 1,675 35.0% 1,320 27.1% 1,778 40.5% 1,716 32.2% 1,540 30.5%
Total 3,797 4,790 4,865 4,387 5,336 5,056
Possession
Opiates/Cocaine 1,917 16.1% 1,842 11.0% 2,752 13.5% 3,263 14.5% 4,088 17.3% 4,081 17.1%
Syn. Narcotics 1,225 10.3% 1,812 10.8% 1,803 8.8% 2,107 9.4% 2,223 9.4% 2,316 9.7%
Marijuana 7,326 61.7% 10,356 61.8% 12,939 63.2% 13,970 62.2% 13,576 57.6% 13,519 56.6%
Other Drugs-Non Narcotics 1,403 11.8% 2,743 16.4% 2,965 14.5% 3,127 13.9% 3,678 15.6% 3,975 16.6%
Total 11,871 16,753 20,459 22,467 23,565 23,891
Trafficking/Manufacture/ Sale 
and Possession Grand Total 15,668 21,543 25,324 26,854 28,901 28,947
No. (%) No. (%) No. (%) No. (%)
Trafficking/Manufacture/ Sale
Opiates/Cocaine 1,635 32.4% 1,602 31.6% 1,489 29.4% 1,405 25.5% -5.6%
Syn. Narcotics 542 10.7% 573 11.3% 607 12.0% 695 12.6% 14.5%
Marijuana 1,283 25.4% 1,310 25.8% 1,132 22.3% 1,227 22.2% 8.4%
Other Drugs-Non Narcotics 1,587 31.4% 1,588 31.3% 1,840 36.3% 2,193 39.7% 19.2%
Total 5,047 5,073 5,068 5,520
Possession
Opiates/Cocaine 3,770 14.7% 3,056 12.1% 2,972 11.9% 2,938 10.5% -1.1%
Syn. Narcotics 2,581 10.1% 2,613 10.4% 3,196 12.8% 3,615 13.0% 13.1%
Marijuana 14,947 58.3% 15,097 59.9% 13,936 56.0% 15,867 56.9% 13.9%
Other Drugs-Non Narcotics 4,334 16.9% 4,436 17.6% 4,779 19.2% 5,446 19.5% 14.0%
Total 25,632 25,202 24,883 27,866
Trafficking/Manufacture/ Sale 
and Possession Grand Total 30,679 30,275 29,951 33,386
2002 2003
Arrests
% Change: 
2002–2003Arrests
1998 1999
2000 2001
   1993 1994 1996 1997
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Exhibit 8. Drug Prices in Phoenix and Tucson:  2001 and 2004 
 
2001 2004 Drug Phoenix Tucson Phoenix Tucson 
Marijuana     
Grams   $10–$25 $5–$10 
Ounce $75–$150 $65–$105 $75–$150 $65–$105 
Pound $500–$750 $400–$600 $500–$750 $400–$600 
Methamphetamine     
1/8 Ounce     $150 (ice) 
$120–$150 
$100–$120 
1/2 Teener N/A N/A $40  $80–$135 
1/4 Ounce $125  $275  $250 (ice) $120–$300 
Ounce $300–$600 $500–$900  $500–$600 $650–$1000 
Pound $3,500–$12,000 
(higher for ice) 
$3,800–$6,000 $5,000–8,600 $6,500–$7,500  
Cocaine     
Rock–1/3 gram crack N/A N/A $20  $20  
Eightball $100–$140 $80–$130 $80–$100 $80–$130 
Ounce $500–$600 $500–$650 $400–$600 $500–$650 
Ounce Crack N/A N/A $540–$600 $550–$700 
Kilogram $15,000–$17,000 $15,000–$18,000 $13,500–$16,000 $14,000–$16,000 
Heroin     
A "20" "BB"  
(80–100 milligrams) 
$20  $20–$25 $20  $20–$25 
A "paper" (.25 gram) $20–30 $20–$25 $10–$15 $20–$25 
Gram $70–$100 $60–$110 $40–$47 $60–$110 
Ounce ("piece", 28 grams) $1,100–$1,500 $1,075–$1,300 $750–$950 $1,075–$1,300 
Kilogram $32,000–$40,000 N/A $28,000–$35,000 $43,000  
     
     
 Dosage Price   
MDMA 1 Tablet $20–$30   
OxyContin 80 mg Tablet $20–$80   
Percocet 1 Tablet $5    
Vicodin ES 1 Tablet $5    
Valium 10 mg Tablet $4    
Lortab 10 mg Tablet $5–$6   
Soma 1 Tablet $2–$5   
 
SOURCES:  DEA Phoenix Division Offices, U.S. Customs, Arizona Department of Public Safety, Phoenix Police Department, Mari-
copa County Sheriff Department 
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Exhibit 9. Drug of Choice and Characteristics of Detoxification Admissions in Community Bridges:   
 July 2004–April 2005 
 
Drug of Choice Number Percent 
Alcohol 6,559 61.57 
Atavan 4 0.04 
Benzodiazepines - Other 7 0.07 
Cocaine 298 2.80 
Crack 649 6.09 
Heroin 1,073 10.07 
Klonopin 10 0.09 
Marijuana 16 0.15 
Methnadone 55 0.52 
Methamphetamine 1,195 11.22 
Not Reported 423 3.97 
Opiates–Other 213 2.00 
Other–Benzodiazepines 11 0.10 
Other–Sedative 14 0.13 
Other–Stimulant 26 0.24 
Oxycontin 59 0.55 
Valium 13 0.12 
Xanax 28 0.26 
Total 10,653 100.00 
 
Age Range Number Percent 
18–30 1,761 16.53 
31–59 8,393 78.79 
60–64 255 2.39 
65–74 201 1.89 
75–Up 43 0.40 
Total 10,653 100.00 
 
Ethnic Background Number Percent 
Asian 114 1.07 
Black 931 8.74 
Hispanic 1,501 14.09 
Native American 1,419 13.32 
Not Reported 9 0.08 
White 6,679 62.70 
Total 10,653 100.00 
 
Gender Number Percent 
Female 2,137 20.06 
Male 8,516 79.94 
Total 10,653 100.00 
 
SOURCE:  Community Bridges 
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 Exhibit 10. HIV/AIDS Annual Report—Arizona Incidence:  1998–2002 
 
 NEW HIV NEW AIDS TOTAL NEW HIV/AIDS 
Characteristics 
 
 
Cases 
% 
State 
Total 
Rate 
Per 
100,000 
Cases 
% 
State 
Total 
Rate 
Per 
100,000 
Cases 
% 
State 
Total 
Rate 
Per 
100,000 
Gender                   
 Male 1,738 84.4% 13.48 1,204 87.7% 9.34 2,942 85.7% 22.82 
 Female 321 15.6% 2.48 169 12.3% 1.31 490 14.3% 3.79 
Total 2,059 100.0% 7.97 1,373 100.0% 5.31 3,432 100.0% 13.28 
Age Group                   
 12 and younger 14 0.7% 0.27 7 0.5% 0.14 21 0.6% 0.41 
 13–19 45 2.2% 1.73 7 0.5% 0.27 52 1.5% 2 
 20–24 212 10.3% 11.67 41 3.0% 2.26 253 7.4% 13.93 
 25–29 338 16.4% 18.11 128 9.3% 6.86 466 13.6% 24.97 
 30–34 415 20.2% 22.06 255 18.6% 13.56 670 19.5% 35.62 
 34–39 420 20.4% 21.57 314 22.9% 16.13 734 21.4% 37.69 
 40–44 288 14.0% 15.26 264 19.2% 13.98 552 16.1% 29.24 
 45–49 170 8.3% 10.16 163 11.9% 9.75 333 9.7% 16.91 
 50–54 86 4.2% 5.81 104 7.6% 7.03 190 5.5% 12.84 
 55–59 37 1.8% 3.07 55 4.0% 4.57 92 2.7% 7.64 
 60 and older 34 1.7% 0.77 35 2.5% 0.8 69 2.0% 1.57 
Total 2,059 100% 7.97 1,373 100% 5.31 3,432 100% 13.28 
Race/Ethnicity                   
 White non-Hispanic 1,204 58.5% 7.23 735 53.5% 4.41 1,939 56.5% 11.64 
 Black non-Hispanic 236 11.5% 28.64 150 10.9% 18.2 386 11.2% 46.84 
 Hispanic 514 25.0% 7.8 399 29.1% 6.06 913 26.6% 13.86 
 A/PI/H1 non-Hispanic 18 0.9% 3.39 11 0.8% 2.07 29 0.8% 5.46 
 AI/AN2 non-Hispanic 81 3.9% 6.5 77 5.6% 6.18 158 4.6% 12.69 
 Multiple race/other non-Hispanic 6 0.3% N/A 1 0.1% N/A 7 0.2% N/A 
Total 2,059 100.0% 7.97 1,373 100.0% 5.31 3,432 100.0% 13.28 
Mode of Transmission                   
 Men having sex with men (MSM) 1,151 55.9% N/A 827 60.2% N/A 1,978 57.6% N/A 
 Injection drug use (IDU) 291 14.1% N/A 209 15.2% N/A 500 14.6% N/A 
 MSM/IDU 172 8.4% N/A 87 6.3% N/A 259 7.5% N/A 
 Heterosexual contact 275 13.4% N/A 171 12.5% N/A 446 13.0% N/A 
 O/H/TF/TPR3 28 1.4% N/A 29 2.1% N/A 57 1.7% N/A 
 No reported risk/unknown risk 142 6.9% N/A 50 3.6% N/A 192 5.6% N/A 
Total 2,059 100.0% 7.97 1,373 100.0% 5.31 3,432 100% 13.28 
 
1Asian/Pacific Islander/Hawaiian. 
2American Indian/Alaskan Native. 
3Other/hemophilia/transfusion and blood products/transplant recipient. 
SOURCE:  Arizona Department of Health Services, Division of Public Health Services, Bureau of Epidemiology and Disease Con-
trol, Office of HIV/STD Services 
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Patterns and Trends in Drug 
Abuse in St. Louis 
 
Heidi Israel, Ph.D., R.N., L.C.S.W.,1 and Jim 
Topolski, Ph.D.2  
 
ABSTRACT 
 
Heroin and cocaine indicators remained mixed, 
while methamphetamine has increased in St. Louis 
indicators. St. Louis and St. Louis County law en-
forcement personnel continued to devote many re-
sources to methamphetamine, and labs in rural ar-
eas continued to be a problem. Club drug use/abuse 
continued to be sparse and decreasing. Marijuana 
indicators have stabilized during this reporting pe-
riod. Primary marijuana treatment admissions more 
than doubled between 1997 and 2001 and remained 
at this elevated level in 2003 and 2004. State budget 
cuts may distort the actual degree of treatment need 
in the future because of a reduction of available 
treatment. In the St. Louis area, 5 percent of HIV 
cases had a risk factor of injection drug use, and 
another 5 percent were among men who have sex 
with men and also inject drugs. 
 
INTRODUCTION 
 
Area Description 
 
The St. Louis metropolitan statistical area (MSA) 
includes approximately 2.6 million people living in 
the city of St. Louis; St. Louis County; the surround-
ing rural Missouri counties of Franklin, Jefferson, 
Lincoln, St. Charles, and Warren; in Illinois, East St. 
Louis; and St. Clair County. St. Louis City’s popula-
tion has continued to decrease to approximately 
350,000, many of whom are indigent and minorities. 
Violent crime increased in 2004, and it remains high 
in drug-trafficking areas. St. Louis County, which 
surrounds St. Louis City, has more than 1 million 
residents, many of whom fled the inner city. The 
county is a mix of established affluent neighborhoods 
and middle and lower class housing areas on the 
north and south sides of the city. The most rapidly 
expanding population areas are in St. Charles and 
Jefferson Counties in Missouri and St. Clair and 
Madison Counties in southern Illinois, which have a 
mixture of classes and both small towns and farming 
areas. The populations in these rural counties total 
                                                 
1Dr. Israel is affiliated with the Division of Infectious Diseases, 
Saint Louis University School of Medicine, St. Louis, Missouri. 
2Dr. Topolski is affiliated with the Division of Evaluation, Policy, 
and Ethics, Missouri Institute of Mental Health, St. Louis, Mis-
souri. 
more than 800,000. The living conditions and cultural 
differences have resulted in contrasting drug use pat-
terns. 
 
Much of the information included in this report is 
specific to St. Louis City and County, with caveats 
that apply to the total MSA. Anecdotal information 
and some treatment data are provided for rural areas 
and for the State. Limited data are also available for 
other parts of Missouri and offer a contrast to the St. 
Louis drug use picture. 
 
Policy Issues 
 
Methamphetamine production and use is a major 
concern for both law enforcement and the legislature. 
Small labs continue to place a hardship on law en-
forcement in terms of personnel and resources. The 
legislature has taken bold moves to require precursor 
drugs, such as pseudoephedrine, that are sold in local 
retail stores to be locked up or placed behind phar-
macy counters. While this policy may now slow 
down local producers, it does not address the major 
source of methamphetamine in the Midwest—
Mexico, a fact that gets lost in the local problem of 
small “mom and pop” lab seizures. 
 
Missouri has been in a budget crisis for years, result-
ing in cuts in services, particularly in health services 
including drug treatment and mental health. Limited 
treatment continues to be available for drug abusers. 
The addiction model as understood through experi-
ence and research has shown that treatment services 
are cost effective to both society and the individual, 
yet the trend is to offer these services on a limited 
outpatient basis. The result is that some of these indi-
cators cannot fully reflect the degree of use or abuse 
of the substances tracked.  
 
Data Sources 
 
The sources used in this report are indicated below:  
 
• Emergency department (ED) drug reports 
data were derived for 2004 from the Drug Abuse 
Warning Network (DAWN) Live! restricted-
access online query system administered by the 
Office of Applied Studies (OAS), Substance 
Abuse and Mental Health Services Administra-
tion (SAMHSA). Eligible hospitals in the St. 
Louis area totaled 37; hospitals in the DAWN 
sample numbered 38, with the number of emer-
gency departments in the sample totaling 38 (ex-
hibit 1). (Some hospitals have more than one 
emergency department.) During this 12-month 
period, between 15 and 18 EDs reported data 
each month. The completeness of data reported 
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by participating EDs varied by month. Exhibits 
in this paper reflect cases that were received by 
DAWN as of June 3, 2005. All DAWN cases are 
reviewed for quality control. Based on this re-
view, cases may be corrected or deleted. There-
fore, the data presented in this paper are subject 
to change. Data derived from DAWN Live! rep-
resent drug reports in drug-related ED visits. 
Drug reports exceed the number of ED visits, 
since a patient may report use of multiple drugs 
(up to six drugs and alcohol). The DAWN Live! 
data are unweighted and, thus, are not estimates 
for the reporting area. These data cannot be com-
pared to DAWN data from 2002 and before, nor 
can preliminary data be used for comparison 
with future data. Only weighted DAWN data re-
leased by SAMHSA can be used for trend analy-
sis. A full description of the DAWN system can 
be found at the DAWN Web site: 
http://dawninfo.samhsa.gov. 
 
• Drug treatment data were derived from the 
Treatment Episode Data Set (TEDS) database 
through 2004. Private treatment programs in St. 
Louis County provided anecdotal information. 
 
• Heroin price and purity information was pro-
vided by the Drug Enforcement Administration 
(DEA), Domestic Monitor Program (DMP), 
through 2004. 
 
• Drug-related mortality data were provided by 
the St. Louis City Medical Examiner’s Office 
through 2004. 
 
• Intelligence data were provided by the Missouri 
Highway Patrol and the DEA. 
 
• Data on drug seizures were provided by the 
National Forensic Laboratory Information Sys-
tem (NFLIS) for 2004. 
 
• Human immunodeficiency virus (HIV), ac-
quired immunodeficiency syndrome (AIDS), 
and sexually transmitted disease (STD) data 
were derived from the HIV Vaccine Trials Unit 
at Saint Louis University and the St. Louis Met-
ropolitan Health Department and AIDS Program. 
 
Linda Cottler, Ph.D., of Washington University, who 
has multiple behavioral research grants, provided 
additional data. 
 
DRUG ABUSE PATTERNS AND TRENDS 
 
Cocaine indicators are stable in St. Louis. While 
methamphetamine has become a prominent drug of 
abuse in other cities and in the rural areas of Missouri, 
cocaine has retained its dominance in the St. Louis 
urban area. Possible reasons for this situation include 
racial differences, with Caucasians using metham-
phetamine and African-Americans using cocaine, and 
the strong influence of the distribution networks. The 
distribution of cocaine and heroin is primarily con-
ducted by African-Americans. Methamphetamine is 
imported into St. Louis from Mexico or produced lo-
cally in the rural areas of the county and State.  
 
Two types of heroin have continued to be available in 
the area, but the heroin is not as pure and is more ex-
pensive when compared with other cities. This Mid-
western city is a destination market, with small entre-
preneurial groups marketing the drug. Heroin is avail-
able in the suburbs and in some of the surrounding 
rural areas on a limited basis, thus illustrating that this 
drug is not confined to the lower socioeconomic strata 
in the city. 
 
Drug education and prevention activities have con-
tinued at the community level. The National Council 
on Alcoholism and Drug Abuse (NCADA) and other 
local education programs target prevention of drug 
use in the area. Faith-based initiatives are being im-
plemented. These groups are particularly active in the 
surrounding counties of St. Louis. The poor city 
economy continues to foster drug abuse and distri-
bution. Marijuana continues to be a very popular drug 
of abuse among younger adults. Gangs continue to be 
involved in the drug trade and related violence, with 
Latino, African-American, and Asian youth and 
young adults involved in these groups. Interdiction 
programs include Operation Jetway and Operation 
Pipeline.  
 
While not reported separately, alcohol abuse and un-
derage use of alcohol are community concerns. Many 
traffic accidents and violence against persons include 
alcohol use in the situation. In St. Louis, 15 percent 
of treatment admissions are for alcohol alone, with 
alcohol used in combination with drugs in another 
12.5 percent of the treatment admissions. In the un-
weighted DAWN ED data, underage alcohol use 
represents 6.5 percent of the reports in 2004. 
 
With the severe cuts in services in this State over the 
next year, the treatment admissions data, an important 
indicator of longer term use of drugs, may not accu-
rately reflect the severity of the drug abuse problem. 
 
Cocaine/Crack 
 
The St. Louis City/County Medical Examiner (ME) 
reported that cocaine-related deaths trended down-
ward from 128 in 1994 to 38 in 2004 (exhibit 2a). 
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Many of the recent deaths involved alcohol and other 
drugs.  
 
According to DAWN, the number of cocaine men-
tions increased significantly between 2000 (n=2,403) 
and 2002 (3,536). The numbers of mentions among 
those age 45–54 and 55 and older increased signifi-
cantly. For 2004, the unweighted DAWN Live! data 
indicate that ED reports for cocaine had the following 
characteristics: more than one-half (51.8 percent) of 
the patients were White, and 58.6 percent of the pa-
tients were older than 34. The top two reasons for the 
ED visit were seeking detox or overmedication. The 
dispositions for most of these patient visits included 
referral to treatment, admission to the psychiatric 
unit, or discharge to home; only three resulted in im-
mediate death.  
 
Among treatment admissions for illicit drug abuse in 
2004, the proportion for primary cocaine abuse re-
flected a slight decrease compared with all of 2003 
(exhibit 2a). Cocaine remained the most common 
primary drug of abuse among all admissions (29.1 
percent), followed by marijuana (25.0 percent) and 
heroin (10.4 percent). The typical cocaine admission 
was an African-American male age 35 or older who 
smoked the drug. 
 
Although the DEA’s emphasis has shifted from co-
caine to methamphetamine and heroin, law enforce-
ment sources, the DEA, and street informants contin-
ued to report high quality, wide availability, and low 
prices for cocaine. Cocaine is used and most avail-
able in the urban areas. Powder cocaine grams sold 
for $100–$125; purity averaged 70 percent (exhibit 
2b). Crack prices remain at $20 per rock on the street 
corner. All cocaine in St. Louis is initially in the 
powder form and is converted to crack for distribu-
tion. Cocaine was readily available on the street cor-
ner in rocks or grams. The price of a gram of crack in 
Kansas City was lower than in St. Louis (at $100–
$120). The “rock” price is the same in smaller cities 
outside St. Louis when it is available, but the gram 
price is higher. 
 
NFLIS data indicated 2,389 (41.5 percent) of items 
analyzed in 2004 were cocaine. 
 
The continued use of cocaine has potentially severe 
long-term consequences by contributing to the spread 
of STDs through multiple partners. Crack cocaine is 
considered to be a primary risk for HIV in many re-
search trials. 
 
Most cocaine users smoke crack cocaine, though 
some use powder cocaine. Only injection drug users 
(IDUs) who combine cocaine and heroin (“speed-
ball”) use cocaine intravenously. Younger users tend 
to smoke cocaine. Polydrug use is also evident in the 
treatment data. The reported use of marijuana, heroin, 
and alcohol in addition to cocaine suggests this trend 
will likely continue.  
 
Heroin 
 
Heroin-related deaths reported by the St. Louis 
City/County ME leveled off in recent years. In 2004, 
there were 64 heroin-related deaths (exhibit 2a). 
Statewide heroin deaths caused by overdose alone 
were not much higher, because heroin purity is higher 
in the St. Louis area than in other cities in Missouri. 
While available primarily in the St. Louis and Kansas 
City areas, heroin is found among small pockets of 
IDUs who reside in small university towns through-
out the State. More heroin deaths occurred in St. 
Louis County than in the inner city in 2004 (32 ver-
sus 20); these deaths support other reports that heroin 
use is increasing in the suburbs.  
 
Heroin consistently appears in all indicators. Un-
weighted data accessed from DAWN Live! show that 
heroin ED reports for 2004 had patient demographics 
of 60.1 percent White and 28.8 percent age 18–24. 
Heroin ED mentions had risen steadily from 1995 to 
2002, when mentions totaled 1,167. The increase in 
heroin mentions among many age groups over this 
earlier 7-year period (1995–2002) indicates the wide 
availability of this drug in this MSA.  
 
While heroin treatment admissions increased dra-
matically as a proportion of all admissions between 
1996 and 2000, they leveled off in 2001–2003. In 
2004, this trend appeared to continue. There are lim-
ited slots for admissions to State-funded methadone 
or modified medical detoxification in Missouri, 
which may influence these data. While heroin avail-
ability increased throughout the region, the decrease 
in admissions may in fact be a result of lack of ade-
quate treatment resources; alternatively, the decrease 
could be related to new users of heroin not yet seek-
ing treatment. When queried, private treatment pro-
grams stated that 25 percent of their admission 
screens were for heroin abuse, but admission de-
pended on “ability to pay.” Some heroin abusers in 
need of treatment utilize “private pay” methadone 
programs. Rapid detoxification, using naltrexone, is 
still a treatment option at private hospitals, but it is 
expensive. About 35 percent of heroin admissions 
were younger than 25 in 2004. Of all heroin admis-
sions, intravenous use was the primary method of 
administration in St. Louis County, but inhalation 
was more popular among admissions in St. Louis 
City. The increased availability of higher purity her-
oin has led to a wider acceptance of the drug in social 
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circles. One of the reasons for its acceptance is that it 
does not have to be injected to get the desired effects.  
 
A steady supply of Mexican heroin remains available. 
The DEA has made buys of heroin in the region in 
addition to buys through the DMP. Mexican black tar 
heroin showed a peak of 24.0 percent purity in 1998; 
purity dropped to 15.1 percent in 2004. South Ameri-
can (Colombian) heroin, which is also white, is of 
poorer quality, averaging around 10 percent. Most 
heroin is purchased in aluminum foil or the number-5 
gel capsule (one-tenth-gram packages of heroin in 
plastic wrap and aluminum foil) for $10 (exhibit 2b). 
 
Heroin costs were about $1.89 per milligram for 
Mexican heroin in the 2003 DMP analysis. The city 
is an end-user market and is dependent on transporta-
tion of the heroin from points of entry into the Mid-
west. The wholesale price remains at $250–$600 per 
gram. On street corners, heroin sells for $250 per 
gram or $10 per “button.” Most business is handled 
by cellular phone, which has decreased the seller’s 
need to have a regular location. Runners continue to 
be used as “middlemen” between users and sellers to 
deliver small quantities of drug. In St. Louis and 
other smaller urban areas, small distribution networks 
sell heroin.  
 
NFLIS reported that 10 percent of the items analyzed 
in 2004 were heroin. 
 
Kansas City’s heroin supply differs from that of St. 
Louis. Most heroin in Kansas City is black tar and is 
typically of poorer quality. The supply is consistent, 
and a $10 bag of heroin is available. Heroin has also 
become available in the smaller, more rural cities of 
Springfield and Joplin, each of which has a small IDU 
population that uses heroin and methamphetamine. 
 
Other Opiates/Narcotics 
 
Other opiates continue to represent less than 1 percent 
of all treatment admissions. Methadone remains avail-
able, which is probably a result of prescription abuse 
as well as patient diversion.  
 
The unweighted DAWN data for 2004 accessed from 
DAWN Live! indicate 797 reports for other opiates; 40 
percent were for overmedication and only 18 percent 
were for patients seeking detoxification. Reasons for 
the ED visit were not delineated for 40 percent of the 
reports.  
 
OxyContin (a long-lasting, time-release version of 
oxycodone) abuse remained a concern for treatment 
providers and law enforcement officials. Prescription 
practices are closely monitored for abuse, and iso-
lated deaths have been reported, but no consistent 
reports are available on the magnitude of this poten-
tial problem. OxyContin costs $40 for an 80-milli-
gram tablet on the street (exhibit 2b). The DAWN 
data indicate 247 oxycodone reports in 2004, with 38 
percent of these patients coming to the ED for over-
medication.  
 
The use of hydromorphone (Dilaudid) remained 
common among a small population of White chronic 
addicts. The drug costs $30–$75 per 4-milligram pill.  
 
Marijuana 
 
According to unweighted data accessed from DAWN 
Live!, marijuana ED reports in 2004 (n=1,230) repre-
sented 20 percent of the total ED reports for major 
substances of abuse. More than 45 percent of the pa-
tients who reported cocaine in 2004 were younger 
than 25. 
  
Marijuana treatment admissions more than doubled 
from 1997 (1,573 admissions) to 2001 (3,210 admis-
sions) and remained stable in 2003 and 2004, when 
they represented 27.2 percent and 25.0 percent of all 
admissions, respectively (exhibit 2a). Marijuana, 
viewed by young adults as acceptable to use, is often 
combined with alcohol. The 25-and-younger age 
group accounted for 65.6 percent of primary mari-
juana treatment admissions in 2004. Some of the pre-
vention organizations report a resurgence in mari-
juana popularity and a belief by users that it is not 
harmful. Prevention programs are targeting this belief 
through education. 
 
Because of the heroin, cocaine, and methamphet-
amine abuse problems and the recent “club drug” 
scare in St. Louis, law enforcement officials have 
focused less attention on marijuana abuse. Limited 
resources require establishing enforcement priorities. 
Often, probation for marijuana offenders requires 
participation in treatment for younger users who do 
not identify themselves as drug dependent. In focus 
groups with African-American adults from various 
social groups, more than one-half identified regular 
use of marijuana but did not identify this use as prob-
lematic. This ethnographic information supports the 
idea of cultural acceptance of marijuana use. A col-
lege town made possession of small quantities of 
marijuana a misdemeanor, further supporting these 
beliefs.  
 
Marijuana is available from Mexico or domestic in-
door growing operations. Indoor production makes it 
possible to produce marijuana throughout the year. In 
addition to the Highway Patrol Pipeline program, 
which monitors the transportation of all types of 
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drugs on interstate highways, Operations Green Mer-
chant and Cash Crop identify and eradicate crops. 
Much of the marijuana grown in Missouri is shipped 
out of the State. NFLIS reported that 40 percent of 
the items analyzed in 2004 were marijuana. 
 
Stimulants 
 
Methamphetamine, along with alcohol, remained a 
primary drug of abuse in both the outlying rural areas 
and statewide. (Most of Missouri, outside of St. Louis 
and Kansas City, is rural.) Methamphetamine contin-
ued to be identified as a huge problem in rural com-
munities, with a focus on “mom and pop” box labs 
and intergenerational use of the drug. 
 
In 2004, unweighted DAWN Live! data show 
methamphetamine ED reports totaled 286 (exhibit 
2a). Ninety-two percent were White, with no pre-
dominant age group. ED methamphetamine mentions 
in St. Louis increased in the late 1990s and totaled 
150 in 2002.  
 
Methamphetamine (“crystal” or “speed”) was found at 
very low levels in city indicators in 1995, but reported 
use has slowly increased over the last 8 years. In rural 
areas, methamphetamine appeared regularly in the 
treatment data, but methamphetamine has been identi-
fied as a problem in all parts of the State. The urban, 
street-level distributors in St. Louis deal in cocaine, so 
amphetamine use is not as widespread in the St. Louis 
area; this could indicate differences in dealing networks 
and access to locally produced drugs (“mom and pop” 
local production). However, an increase in availability 
and purity of Mexican methamphetamine and a growth 
in Hispanic groups in the St. Louis metropolitan area 
may change this trend. Methamphetamine use is re-
ported in the gay male and club communities in the 
city. An increase in treatment admissions may signal 
this change. Traditionally, cocaine and meth-
amphetamine use have been split along racial lines in 
the State. The number of methamphetamine treatment 
admissions in St. Louis was 544 in 2004. In rural 
treatment programs, methamphetamine was the drug of 
choice after alcohol. 
 
The Midwest Field Division of the DEA decreased its 
cleanup of clandestine methamphetamine labs after 
training local enforcement groups; 2,788 labs were 
reported for 2004. The intensity of these law en-
forcement efforts is based on the availability of funds 
for local police departments to clean up box labs un-
der Community Oriented Policing Service (COPS) 
funding. Thefts of anhydrous ammonia continued to 
be identified as an issue in rural areas.  
 
In the current methamphetamine scene, Hispanic traf-
fickers, rather than the old network of motorcycle 
gangs, are the predominant distributors. Shipments 
from “super labs” in the Southwest are trucked in via 
the interstate highway system. This network is in 
contrast to the local “mom and pop” labs that produce 
personal quantities for family and friends. These lo-
cal labs tend to use the Nazi method of production, 
with an output of 60 percent of the quantity of the 
starting products, although the red phosphorus 
method has been seen more frequently. Purity of the 
drugs produced by these labs and the amount of fin-
ished product depends on the experi-
ence/attentiveness of the “cooker” but tends to be 
higher (greater than 80 percent). Most of the avail-
able methamphetamine is produced in Mexico and 
trafficked through the Hispanic traffickers, with less 
pure methamphetamine obtained through this source. 
While much of the law enforcement resources and 
personnel are directed at the local production, the 
majority of methamphetamine that is available in the 
area comes through these Hispanic organizations. As 
the purity increases among the methamphetamine 
obtained from these groups and precursor drugs are 
less available, less local production may be seen. 
Some crystallized methamphetamine has been noted 
in the local market, usually indicating increased pu-
rity in the product.  
 
The term “ice” has been applied to all methampheta-
mine with a crystalline appearance. Methamphetamine 
sold for $700–$1,300 per ounce in St. Louis and for as 
little as $100–$120 per gram in some areas. Metham-
phetamine was represented in only 1.5 percent of the 
NFLIS analysis.  
 
Use of methamphetamine and its derivatives has be-
come more widespread among high school and col-
lege students, who do not consider these drugs as 
dangerous as others. Because methamphetamine is so 
inexpensive and appeals to a wide audience, it is 
likely that its use will continue to spread.  
 
Depressants  
 
Benzodiazepine abuse by prescription continues. In 
2004, unweighted DAWN Live! data showed 808 
benzodiazepine ED reports, with slightly more than 
one-half of the patients indicating overmedication. In 
the ED data, the ratio of benzodiazepines to opi-
ates/opioid drugs is 1.0, indicating a significant de-
gree of usage of this class of drug. 
 
The remaining few private treatment programs often 
provide treatment for benzodiazepine, antidepressant,  
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and alcohol abusers. Social setting detoxification has 
become the treatment of choice for individuals who 
abuse these substances. Since many of the private 
treatment admissions are polysubstance abusers, par-
ticular drug problems are not clearly identified.  
 
Hallucinogens 
 
Over the years, lysergic acid diethylamide (LSD) has 
sporadically reappeared in local high schools and 
rural areas. Blotters sell for $5–$7 per 35-microgram 
dose (exhibit 2b). Unweighted DAWN Live! data for 
2004 showed a small number of LSD ED reports: 9. 
 
Phencyclidine (PCP) has been available in limited 
quantities in the inner city and has generally been 
used as a dip on marijuana joints. While PCP is not 
seen in quantity, it remains in most indicator data, 
including ED reports (29 in unweighted 2004 DAWN 
Live! data), police exhibits, and as a secondary drug 
in ME data. Most of the users of this drug in the inner 
city are African-American.  
 
Club Drugs 
 
Unweighted DAWN Live! ED data show few reports 
of methylenedioxymethamphetamine (MDMA)—
only 27 in 2004. Reports of other club drugs were 
almost non-existent; one ketamine and three gamma 
hydroxybutyrate (GHB) ED reports occurred in 2004. 
MDMA is less available at dance parties and costs 
$20–$30 per tablet. Most of the reports about MDMA 
abuse are anecdotal or are part of a polydrug user’s 
history. Public treatment programs reported no ad-
missions for MDMA 
 
INFECTIOUS DISEASES RELATED TO DRUG ABUSE 
 
HIV 
 
HIV seropositivity among IDUs remained low in St. 
Louis. While the predominant number of cases occur 
among men who have sex with men (MSM), the larg-
est increase was found among young African-
American females, who were infected through hetero-
sexual or bisexual contact, and young homosexual Af-
rican-American males. As a result, increased special-
ized minority prevention efforts have been initiated.  
Of the total 6,672 persons living with HIV disease 
identified through June 2004, 5 percent were IDUs 
and 5 percent involved men who have sex with men 
and are also IDUs (MSM/IDUs) (exhibit 3). The 
number of infected African-Americans was increas-
ing disproportionately among males and females.  
 
HIV Research 
 
Saint Louis University has continued research on 
HIV prevention vaccines. Most of the prevention 
vaccine trials have been Phase I trials in low-risk 
individuals, and MSM and high-risk women in the 
United States and high-risk heterosexuals in the Car-
ibbean are being recruited for a new expanded Phase 
II trial. Another Phase II trial is slated to begin later 
this year. 
 
STDs and Hepatitis C  
 
A resurgence of syphilis among MSM has led to in-
creased surveillance and targeted prevention pro-
grams to this population. Rates of gonorrhea and 
chlamydia remain stable and high in the urban STD 
clinics. St. Louis ranks third in the country for gonor-
rhea, with cases remaining at approximately 1,000 
per year, and second for chlamydia. HIV and syphi-
lis/gonorrhea rates are high in neighborhoods known 
to have high levels of drug abuse, underscoring the 
concept of assortative mixing in cohorts. Inconsistent 
reporting of hepatitis C has made estimation of the 
problem and tracking of hepatitis C cases difficult 
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Exhibit 1. St. Louis DAWN ED Sample and Reporting Information:  2004 
 
No. of EDs Reporting per Month: Com-
pleteness of Data (%)  Total Eligible 
Hospitals1 
No. of Hospitals 
in DAWN 
Sample 
Total EDs 
in DAWN 
Sample2 90–100% 50–89% <50% 
No. of EDs 
Not Reporting 
37 36 38 15–18 0–2 0–2 20–23 
 
1Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association An-
nual Survey. 
2Some hospitals have more than one emergency department. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/13-4/14, 2005  
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Exhibit 2a. Indicators for Cocaine, Heroin, Marijuana, and Methamphetamine in St. Louis:  1996−2004 
 
Indicator Cocaine Heroin Marijuana Metham-phetamine 
Number of Deaths by Year     
 1996 93 51 NA1 9 
 1997 43 67 NA 11 
 1998 47 56 NA 9 
 1999 51 44 NA 4 
 2000 66 47 NA 9 
 2001 75 20 NA 3 
 2002 76 50 NA – 
 2003 78 61 NA -- 
 2004 38 64 NA -- 
DAWN ED Data—Weighted Data4     
 Number of Mentions (2002) 3,536 1,167 2,866 150 
 Number of Mentions (2001) 3,080 1,309 2,311 115 
 Rate per 100,000 Population (2002) 153 51 124 7 
 Gender of Mentions (%) (2002) 
 Male 
 Female 
 
63.3 
36.1 
 
63.8 
36.2 
 
63.4 
35.8 
 
63.3 
36.0 
 Age (%) (2002) 
 12–17 
 18–34 
 35 and older 
 
1.5 
36.9 
61.5 
 
1.4 
56.0 
42.4 
 
8.4 
52.2 
39.5 
 
15.3 
53.3 
31.3 
Race (%) (2002) 
 White 
 African-American 
 Hispanic 
 Other/unknown 
 
39.1 
56.3 
0.6 
2.9 
 
55.6 
39.9 
…2 
3.1 
 
54.9 
40.7 
0.4 
2.7 
 
91.0 
---3 
0.7 
4.7 
Route of Administration (%) (2000) 
Smoking 
Intranasal 
Injection 
Unknown/other 
 
62.3 
25.9 
7.0 
4.8 
 
6.4 
22.2 
71.5 
– 
 
NA 
 
 
 
 
18.8 
15.6 
46.9 
18.8 
DAWN Live! ED Data—Unweighted Data4     
 Number of Reports (2004) 1,702 601 1,230 286 
 Gender of Reports (%) (2004) 
 Male 
 Female 
 
63.3 
36.7 
 
69.2 
30.8 
 
63.3 
36.7 
 
56.6 
43.4 
 Age (%) (2004) 
 12–17 
        18-24 
 25–34 
 35 and older 
 
<1 
14.0 
27.4 
            58.6 
 
<1 
30.3 
30.9 
38.8 
 
--- 
45.0 
23.5 
31.5 
 
0 
38.1 
30.8 
31.1 
Race (%) (2004) 
 White 
 African-American 
 Hispanic 
 Other/unknown 
 
51.8 
49.2 
0.0 
0.0 
 
60.1 
34.4 
…2 
5.5 
 
            68.6 
27.8 
<.1 
<3 
 
91.6 
<1 
<1 
<1 
Route of Administration (%) ( 2004) 
Smoking 
Intranasal 
Injection 
Unknown/other 
21.4 
-- 
2.4 
9.0 
            67.8 
 
0 
9 
35.2 
52 
34.9 
 
 
62.3 
7.9 
8.6 
7.5 
73.6 
 
1NA=Not applicable. 
2Dots (…) indicate that an estimate with a relative standard error greater than 50 percent has been suppressed. 
3Dashes (---) indicate than an estimate has been suppressed because of incomplete data. 
4Unweighted data are from 15–18 St. Louis EDs reporting to DAWN.  All DAWN cases are reviewed for quality control.  Based on 
this review, cases may be corrected or deleted and, therefore, are subject to change. 
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Exhibit 2a. Indicators for Cocaine, Heroin, Marijuana, and Methamphetamine in St. Louis:  1996−2004  
   (Cont’d) 
 
Indicator Cocaine Heroin Marijuana Metham-phetamine 
Treatment Admissions Data     
 Percent of All Admissions (2003) 34.6 10.1 27.2 4.7 
 Percent of All Admissions (2004) 29.1 10.4 25.0 4.6 
 Gender (%) (2004) 
  Male 
  Female 
 
54.9 
45.1 
 
62.5 
37.5 
 
74.0 
26.0 
 
54.2 
45.8 
 Age (%) (2004) 
  12–17 
  18–25 
  26–34 
  35 and older 
 
0.6 
8.0 
24.0 
67.4 
 
0.8 
34.9 
25.6 
38.6 
 
25.5 
40.1 
20.3 
14.1 
4.4 
32.6 
36.5 
26.5 
 Race/Ethnicity (%)  (2004) 
  White 
  African-American 
  Hispanic 
 
26.1 
73.3 
1.1 
 
40.1 
59.0 
0.9 
 
41.1 
57.9 
1.0 
 
98.9 
0.2 
0.0 
 Route of Administration (%) (2004) 
  Smoking 
  Intranasal 
  Injecting 
  Oral 
             other 
 
90.5 
5.1 
1.7 
1.6 
 
1.7 
46.7 
50.4 
1.0 
4.9 
 
96.7 
0.3 
0.1 
1.6 
 
48.9 
15.1 
32.5 
4.0 
 
SOURCES:  DAWN, OAS, SAMHSA; DAWN Live!, OAS, SAMHSA, updated 6/03/2005; TEDS database 
 
 
 
 
Exhibit 2b. Other Combined Indicators for Cocaine, Heroin, Marijuana, and Methamphetamine in St. Louis:  
2002–2004 
 
Indicator Cocaine Heroin Marijuana Methamphetamine and Other Drugs 
Multisubstance  
Combinations 
Older users com-
bine with heroin, 
alcohol 
Older users com-
bine with cocaine, 
alcohol 
Alcohol Marijuana commonly 
used in combination 
Market Data (2004) Powder $100–
$125/g, 70% pure; 
Crack $20/rock, 
50–90% pure;  
eightball $300 
$20/cap or foil; 
$10 per number-5 
gel capsule; 
$3.17/mg pure—
depending if MBT, 
SA, SWA, $250–
$600/g, 13.9–
23.2% pure 
Sinsemilla $700–
$1,800/lb, 20% THC; 
Imported 
$2,000−$4,000/lb 
Methamphetamine 
$100–$120/g, Mexican 
(20–30%) and local 
(70–80% pure); hy-
dromorphone $30–
$50/4-mg pill; LSD 
blotters $5–$7/35 mi-
crogram, OxyContin 
$40 mg 
Qualitative Data Readily available, 
urban choice 
Younger users, 1/3 
younger than 25 
Readily available, 
younger users in 
treatment 
Rural/suburban users 
of amphetamine 
Other Data of Note N/R1 Primarily Mexican 
black tar; young 
users smoke/snort 
N/R Methamphetamine lab 
seizures plateaued; 
producers  are super-
labs–controlled by 
Hispanic groups; mom 
and pop labs 
 
1N/R=Not reported. 
SOURCES:  DEA; client ethnographic information 
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Exhibit 3. Persons Living with HIV Disease in St. Louis Metropolitan Area by Exposure Category, Gender, 
 Race/Ethnicity, and Age: Year-to-Date and Cumulative Totals Reported Through June 2004 
 
HIV-Positive Test Results 
Jan 2004–June 2004 Cumulative Through June 2004 Category 
Number Percent Number Percent 
Exposure Category     
MSM 61 50.0 4,583 70.0 
IDU 6 5.0 301 5.0 
IDU/MSM 3 2.0 319 5.0 
Hemophilia 0 0.0 58 1.0 
Heterosexual 12 10.0 920 14.0 
Blood transfusion 0 0.0 34 0.2 
Perinatal 0 0.0 41 1.0 
Unknown 41 33.0 416 6.0 
Total 123  6,672  
Gender and Race/Ethnicity     
Male     
 White 40 33.0 2,914 45.0 
 African-American 62 51.0 2,582 40.0 
 Hispanic 1 0.0 79 1.0 
 Other 1 0.0 19 0.0 
 Unknown 0 0 208 3.0 
Female     
 White 4 3.0 170 2.0 
 African-American 14 12.0 671 10.0 
 Hispanic 2 0.0 15 0.0 
 Other 0 0.0 13 0.0 
Age     
12 and younger 0 0.0 53 1.0 
13−19 5 4.0 160 2.4 
20−29 39 32.0 1,644 25.2 
30−39 30 24.0 2,799 43.0 
40−49 41 33.0 1332 20.4 
50 and older 8 7.0 522 8.0 
Unknown 0 0 162 2.0 
Total 123  6,672  
 
SOURCE: St. Louis Metropolitan AIDS Program 
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Drug Abuse Patterns and 
Trends in San Diego County, 
California 
 
Steffanie Strathdee, Ph.D.1 
 
ABSTRACT 
 
Methamphetamine abuse indicators continue to be 
high in San Diego. Forty-five percent of the 2004 
treatment admissions (excluding alcohol) in San 
Diego County were for primary methamphetamine 
abuse; approximately 27 percent of all items ana-
lyzed by forensic laboratories and nearly 27 percent 
of the (unweighted) illicit drug reports accessed 
through the DAWN Live! ED system involved 
methamphetamine. Cocaine/crack indicators re-
mained relatively low and stable in 2004. Marijuana 
continued to be a serious problem, accounting for 
50 percent of drug items analyzed by forensic labs 
in 2004, nearly 18 percent of the county’s primary 
illicit drug admissions, and more than 21 percent of 
the (unweighted) illicit drug ED reports. Heroin 
accounted for one-quarter of primary treatment 
admissions (excluding alcohol) and for 16 percent 
of ED reports for illicit drugs, but it represented less 
than 2 percent of all drug items reported by forensic 
laboratories. 
 
INTRODUCTION 
 
Area Description 
 
According to the 2000 census, more than 2.8 million 
persons resided in San Diego County (exhibit 1); 55 
percent were White and 27 percent were Hispanic. In 
2004, the county population was projected to increase 
to slightly more than 3.0 million, with a decrease in 
the White population (to 52 percent) and a slight in-
crease (1 percent) in the Asian and Hispanic/Latino 
populations. The median household income was 
nearly $46,000 in 2000 and was projected at $50,543 
in 2004. 
 
Methamphetamine is a major drug problem in the 
area. Several geographic and social factors foster the 
manufacture, trafficking, and abuse of the drug in 
San Diego County. The county is isolated from the 
rest of California. There are 80 miles of border to the 
south, 70 miles of ocean to the west, mountain ranges 
to the east and northeast, and a military base to the 
                                                 
1The author is affiliated with the University of California San 
Diego, School of Medicine, San Diego, California, and The Johns 
Hopkins University Bloomberg School of Public Health. 
north. The three border crossings to Mexico include 
the Tijuana crossing, which is the busiest in the 
world. Mexico contributes 90 percent of all metham-
phetamine entering the United States and 98 percent 
of all heroin west of the Mississippi river. The border 
and the coastline represent a particular challenge in 
attempts to control the import of illicit drugs. Isolated 
rural areas provide an ideal setting for the establish-
ment of small methamphetamine clandestine labs. In 
addition, there was a 78-percent increase in opium 
poppy cultivation in Mexico, from 2,700 hectares in 
2002 to 4,800 in 2003, suggesting that heroin traf-
ficking from Mexico will continue to be an important 
problem for U.S.-Mexico border States.  
 
Before 1989, there were many small methampheta-
mine labs in San Diego; these were operated by local 
“cookers” and outlaw motorcycle clubs. Over the 
years, the production and abuse of methamphetamine 
“waxed and waned.” The Chemical Diversion and 
Trafficking Act of 1988 and the Chemical Control 
Diversion Act of 1993 helped curtail access to the 
precursors used in making methamphetamine. A 
DEA sting effort, Operation Triple Neck, resulted in 
arrests and the closing of stores that supplied equip-
ment and chemicals to methamphetamine cookers. 
Most methamphetamine indicators declined for a 
time, but new sources and distribution networks 
emerged. Mexican nationals and Mexican-
Americans, operating on both sides of the border, 
began to produce large quantities of high-purity 
methamphetamine. Already established networks that 
distribute other illicit drugs are used to distribute 
methamphetamine. The profits from these operations 
have been large. 
 
Data Sources 
 
Data for this paper were provided by the sources 
shown below: 
 
• Forensic laboratory data were provided by the 
National Forensic Laboratory Information Sys-
tem (NFLIS), Drug Enforcement Administration 
(DEA), for 2004, when 15,773 drug items were 
analyzed by county laboratories. Percentages of 
drug items analyzed in 2003 are also reported. 
• Treatment data for San Diego County were 
provided by the California Alcohol and Drug 
Data System (CADDS) on 14,105 admissions in 
2004, of which 2,877 were primary alcohol ad-
missions. The 2004 data from the State system 
are not totally consistent with CADDS data ac-
cessed from San Diego County in prior years. 
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• Emergency department (ED) data for calendar 
year 2004 were accessed through the Drug 
Abuse Warning Network (DAWN) Live!, which 
is a restricted-access online query system 
administered by the Office of Applied Studies 
(OAS), Substance Abuse and Mental Health 
Services Administration (SAMHSA). Sixteen of 
the 17 eligible hospitals in the San Diego 
metropolitan area are in the DAWN sample, with 
a total of 16 EDs in the sample. The data 
reported in this paper were not complete. During 
the 12-month period, between 6 and 10 EDs 
reported data to DAWN each month (exhibit 2). 
The data in this paper were updated by OAS on 
January 13–14, 2005; they are unweighted and 
are not estimates for the San Diego area. All 
DAWN cases are reviewed for quality control. 
Based on the review, cases may be corrected or 
deleted; therefore, the data reported in this paper 
are subject to change. The information derived 
from DAWN Live! for San Diego in 2004 
represents 6,214 cases, 2,999 reports of illicit 
drugs (excluding alcohol), reports on nonmedical 
use of selected prescription-type drugs, and 
reports on alcohol-related visits. The number of 
drug reports in drug-related visits exceeds the 
number of ED visits, since a patient may report 
use of multiple drugs (up to six drugs and 
alcohol may be represented in DAWN). These 
data cannot be compared with DAWN data from 
2002 and before, nor can these preliminary data 
be used for comparison with future data. Only 
weighted ED data released by SAMHSA can be 
used for trend analysis. A full description of the 
DAWN system can be found on the DAWN Web 
site: <http://dawninfo.samhsa.gov>. 
• Drug-related mortality data were provided by 
the San Diego Medical Examiner for 2003. 
• Drug price information is from the National 
Drug Intelligence Center (NDIC) for July 
through December 2004. 
• Heroin price and purity data are from the Do-
mestic Monitor Program (DMP), DEA, for 2003. 
The data are based on 38 qualified samples. 
• Acquired immunodeficiency syndrome (AIDS) 
data were taken from the San Diego County 
Health and Human Services Agency (HHSA), 
“Acquired Immunodeficiency Syndrome (AIDS) 
Surveillance Report,” April 30, 2005. Data on the 
human immunodeficiency virus (HIV) are from 
the HHSA “Human Immunodeficiency Virus 
(HIV) Surveillance Report,” 2004. 
DRUG ABUSE PATTERNS AND TRENDS 
 
Cocaine/Crack 
 
Cocaine indicators remained relatively stable over the 
past decade, although this stimulant is still a problem 
in San Diego and cocaine hydrochloride (HCl) and 
crack remain readily available. 
 
More than 14 percent of the drug items analyzed by 
forensic labs in 2004 were cocaine items (exhibit 3), 
up slightly from the 13 percent reported in 2003. 
 
Treatment admissions for primary cocaine abuse, 
excluding alcohol, accounted for 8.7 percent of ad-
missions in 2004, according to State data; the county 
CADDS data for prior years suggest a decline in co-
caine admissions from 2001 to 2003 (exhibit 4). 
Eighty percent of the cocaine admissions in 2004 
smoked the drug, indicating most cocaine admissions 
were for crack abuse (exhibit 5). Nearly 70 percent of 
the primary cocaine admissions in 2004 were male. 
Nearly 71.0 percent were age 35 or older, and 58.5 
percent were Black non-Hispanic. More than 30 per-
cent of the primary cocaine abusers reportedly used 
only cocaine; alcohol and marijuana were the sub-
stances most likely to be used as a secondary drug 
(32.1 and 22.0 percent, respectively). 
 
Preliminary unweighted data accessed through 
DAWN Live! show that cocaine was the most promi-
nent drug in visits involving illicit drugs (excluding 
alcohol). ED reports of cocaine totaled 558 in 2004 
and accounted for 18.6 percent of the illicit drug re-
ports (exhibit 6). Nearly two-thirds of the patients in 
the cocaine-involved reports were male, 60 percent 
were 35 or older, 48 percent were White, and 30 per-
cent were Black (exhibit 7). 
 
In 2003, there were 56 deaths involving cocaine, as 
reported by the county medical examiner (exhibit 8). 
 
In the last half of 2004, a gram of powder cocaine, 
retail, sold for $60–$80, and one-quarter gram sold 
for $25–$35 (exhibit 9). A “rock” of crack sold for 
$10–$20. 
 
Heroin 
 
In 2004, 1.5 percent of the 15,773 drug items ana-
lyzed by forensic labs were heroin items (exhibit 3), 
approximately the same percentage as in 2003 (1.7 
percent). 
 
Treatment admissions for primary heroin abuse (ex-
cluding alcohol) represented 25 percent of the illicit 
drug admissions in 2004, based on the State CADDS 
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data (exhibit 4). Of the 2,810 primary heroin admis-
sions in 2004, the majority were male (70.6 percent), 
age 35 or older (57.9 percent), and White (52.0 per-
cent) (exhibit 5). Hispanics represented 38.4 percent 
of these admissions. Eighty-seven percent injected 
the drug. More than 61 percent reported using only 
heroin. Cocaine/crack (12.9 percent) and metham-
phetamine (11.7 percent) were the most frequently 
reported secondary drugs used by primary heroin 
admissions. 
 
Unweighted data accessed from the DAWN Live! 
system for 2004 show 492 heroin reports, represent-
ing16.4 percent of illicit drug reports from participat-
ing San Diego emergency departments (exhibit 6). 
Nearly 70.0 percent of patients involved in these vis-
its were male, 70.5 percent were 35 or older, 54.5 
percent were White, and 30.7 percent were Hispanic 
(exhibit 7). 
 
In 2003, the county medical examiner reported 62 
heroin-involved deaths (exhibit 8). 
 
In 2003, DMP reported that most heroin in San Diego 
was black tar heroin, which was 44.9 percent pure 
and sold for $0.25 per milligram pure. This heroin 
was the cheapest of any recorded across the Nation. 
Most of this heroin originates in Mexico.  
 
NDIC reports that Mexican brown powder heroin 
costs $60–$100 per gram, while Mexican black tar 
heroin costs $50–$100 per gram (exhibit 9). 
 
Other Opiates 
 
Opiates other than heroin accounted for 2.2 percent 
(n=344) of the drug items analyzed by forensic labs 
in 2004 (exhibit 3). Of the other opiate items, 173 
(50.3 percent) were hydrocodone items, 45 (13.1 per-
cent) were oxycodone, 30 (8.7 percent) were codeine, 
and 20 (5.8 percent) were methadone. 
 
In 2004, there were 221 admissions for primary abuse 
of opiates/synthetics other than heroin. These ac-
counted for 2 percent of all illicit drug admissions.  
 
The preliminary unweighted DAWN data for 2004 
show 643 ED reports of opiates/opioids. Of the 643 
reports, 208 (32.3 percent) were hydrocodone reports 
and 94 (14.6 percent) were oxycodone reports. 
 
In 2003, the county medical examiner reported a siz-
able number of deaths involving opiates/narcotic anal-
gesics. The highest number involved morphine/com-
binations (67), followed by hydrocodone/combinations 
(44) (exhibit 8). Codeine/combinations, methadone, 
and oxycodone/combinations were involved in 22–24 
deaths, propoxyphene/combinations were involved in 
19, and fentanyl/combinations were involved in 12. 
 
Marijuana 
 
Marijuana continues to be a serious problem in San 
Diego. Fifty percent of the items analyzed by forensic 
labs in 2004 were cannabis (exhibit 3), down slightly 
from 2003 (52.7 percent). 
 
Primary marijuana abuse accounted for nearly one-
fifth (17.6 percent) of treatment admissions (exclud-
ing alcohol) in 2004 (exhibit 4). Three-quarters were 
male, 41 percent were White, and 34 percent were 
Hispanic (exhibit 5). Seventy-two percent of the pri-
mary marijuana admissions were 25 or younger. 
Slightly more than 26 percent reported using only 
marijuana; 39.2 percent used alcohol as a secondary 
drug, and 26.2 percent used methamphetamine. 
 
Unweighted data accessed from DAWN Live! show 
641 marijuana reports in 2004; these represented 21.4 
percent of the illicit drug reports (exhibit 6). Male 
patients accounted for nearly two-thirds of the visits 
involving marijuana (exhibit 7). These patients were 
most likely to be younger than 25 (46.8 percent) and 
White (52.7 percent). 
 
One death involving marijuana was reported by the 
medical examiner in 2003 (exhibit 8). 
 
In the last 6 months of 2004, an ounce of marijuana 
cost $60–$100 retail (exhibit 9). 
 
Methamphetamine 
 
In 2004, methamphetamine accounted for 26.9 per-
cent of all drug items reported by NFLIS; ampheta-
mines accounted for less than 1.0 percent (exhibit 3). 
 
In 2004, 45.2 percent of illicit drug admissions in the 
county were for primary abuse of methamphetamine 
(exhibit 4). Nearly 61 percent of these patients were 
male, 56 percent were White, and 27 percent were 
Hispanic (exhibit 5). Approximately 72 percent were 
26 or older, with 38.5 percent being 35 or older. 
Smoking was the most frequently reported route of 
administration for methamphetamine, characterizing 
68.6 percent of this admissions group. Slightly more 
than 37 percent reportedly used only methampheta-
mine prior to treatment entry; marijuana (29 percent) 
and alcohol (24 percent) were the most frequently 
used secondary drugs. 
 
Unweighted DAWN data show 797 ED reports of 
methamphetamine in 2004, representing nearly 27 
percent of illicit drug reports. There were also 388 
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amphetamine reports; these represented nearly 13 
percent of illicit drug reports (exhibit 6). Demo-
graphic data on methamphetamine-involved ED visits 
show that approximately 69 percent were male, 45 
percent were age 35 or older, 63 percent were White, 
and 20 percent were Hispanic (exhibit 7). 
 
In 2003, the county medical examiner reported 118 
methamphetamine-involved deaths and 41 ampheta-
mine-involved deaths (exhibit 8). 
 
Price data from NDIC show that methamphetamine 
cost $60 per gram in the last half of 2004 (exhibit 9). 
 
San Diego County has had considerable experience 
over many years in assessing and addressing prob-
lems associated with methamphetamine production 
and abuse. The Methamphetamine Strike Force 
(MSF), established in March 1996 as a collaborative 
“assessment and action” effort involving more than 
60 members and 10 data sources, continues to assess 
the methamphetamine problem at the community 
level, determine appropriate actions to take, and 
evaluate results. The MSF has developed effective 
plans and policies, controlled the availability of pre-
cursor chemicals, taken steps to protect endangered 
children, made effective use of the media, and devel-
oped and used training at all levels. The two newest 
initiatives include a focus on women and the border. 
The MSF Web site is <www.no2meth.org>. 
 
Club Drugs 
 
There were few indicators of club drugs in recent data 
sources. In 2004, 61 methylenedioxymethampheta-
mine (MDMA) and methylenedioxyamphetamine 
(MDA) items were reported by forensic labs. These 
MDMA/MDA items accounted for 0.4 percent of all 
drug items analyzed (exhibit 3). Twenty-seven phen-
cyclidine (PCP) items were also reported by forensic 
labs, representing 0.2 percent of the total items.  
 
The retail price of MDMA per tablet was $15–$30 in 
the last half of 2004 (exhibit 9).  
 
Treatment admissions for primary PCP abuse totaled 
39 in 2004, or nearly 0.3 percent of illicit drug ad-
missions. 
 
In the 2004 unweighted DAWN data, small percent-
ages of the illicit drug reports involved MDMA (0.8 
percent, n=23), PCP (0.8 percent, n=23), and gamma 
hydroxybutyrate (GHB) (0.4 percent, n=11) (exhibit 
6). There were also three reports each for ketamine 
and lysergic acid diethylamide (LSD), drugs that are 
sometimes included in the “club drug” category. 
Benzodiazepines 
 
Benzodiazepine-type drugs accounted for 1.5 percent 
(n=241) of the drug items analyzed by forensic labs 
in 2004 (exhibit 3). Of the 241 items, 38.2 percent 
were diazepam items, 30.3 percent were clonazepam, 
25.7 percent were alprazolam, and 9.1 percent were 
lorazepam. 
 
Unweighted data accessed from DAWN Live! for 
2004 show 545 benzodiazepine ED reports. 
 
Alcohol 
 
As in other areas of the Nation, alcohol abuse is a 
serious problem in San Diego. 
 
In 2004, primary alcohol abuse accounted for one-
fifth of all treatment admissions (n=2,877). 
 
Across San Diego EDs participating in DAWN, the 
preliminary unweighted data show 975 reports for 
alcohol-in-combination with other drugs; another 184 
visits involved “alcohol only” among patients 
younger than 21. Of these alcohol-only involved vis-
its, 48 percent were male, 58 percent were White, 38 
percent were Black, and 14 percent were Hispanic. 
(Race/ethnicity was not documented for 15 patients, 
and 3 other patients were in an “other” category.) 
Fifty-one percent of alcohol-only reports represented 
patients age 18–20, with the remaining patients being 
between the ages of 12 and 17. 
 
INFECTIOUS DISEASES RELATED TO DRUG ABUSE 
 
AIDS 
 
From 1981, when the first AIDS cases in San Diego 
County were diagnosed, through April 2004, there 
were 12,273 adult/adolescent AIDS cases reported in 
the county. The State has the second highest number 
of AIDS cases in the Nation, and San Diego has the 
third highest number of cases in the State. Since 
1999, the number of annual AIDS cases reported in 
San Diego has been in the mid-400 range. The 2004 
report shows that, of the adult/adolescent AIDS 
cases, 63 percent were White, 12 percent were Afri-
can-American, and 22 percent were Hispanic (all 
races). Eighty percent of male San Diego AIDS cases 
have been attributed to male-to-male sex, 10 percent 
to male-to-male sex and injection drug use, and 7 
percent to injection drug use alone. For San Diego 
females, heterosexual contact was the most common 
mode of transmission (53 percent), followed by injec-
tion drug use. 
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HIV 
 
From July 1, 2002, to December 31, 2003, a total of 
4,155 HIV cases were reported for San Diego 
County. Of these, 89 percent were male, 62 percent 
were White, 43 percent were age 30–39, and 72 per-
cent were infected by male-to-male sex. 
 
For inquiries concerning this report, please contact Steffanie 
Strathdee, Ph.D., Professor and Harold Simon Chair, Chief, Divi-
sion of International Health and Cross Cultural Medicine, De-
partment of Family and Preventive Medicine, Adjunct Professor, 
Department of Epidemiology, Johns Hopkins Bloomberg School of 
Public Health, University of California San Diego, School of 
Medicine, 9500 Gilman Drive, Mailstop 0622, San Diego, CA 
92093, Phone: 858-822-1952, Fax: 858-534-4642, E-mail: 
sstrathdee@ucsd.edu. 
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Exhibit 1. Total Population and Population by Race/Ethnicity for San Diego County, by Percent: 
 2000, 2004 
 
Race/Ethnicity 2000 (N=2,813,833) 
2004 
(N=3,017,204) 
White 55 52 
Black or African-American 5 5 
Asian 9 10 
Other Race 4 4 
Hispanic/Latino (of Any Race) 27 28 
Median Household Income $45,871 $50,543 
Single Family Home Median Price  $525,000 
 
SOURCE:  San Diego Association of Governments Census Publications 
 
 
 
 
Exhibit 2. San Diego DAWN ED Sample and Reporting Information:  2004 
 
Number of EDs Reporting per 
Month: Completeness of Data (%)  Total Eligible 
Hospitals1 
Number of Hospitals 
in DAWN Sample 
Total EDs in 
DAWN Sample2 90–100% 50–89% <50% 
Number of EDs 
Not Reporting 
17 16 16 6–9 0–1 0–1 6–10 
 
1Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association An-
nual Survey. 
2Some hospitals have more than one emergency department. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/13-4/14, 2005  
 
 
 
 
Exhibit 3. Number and Percentage of Selected Items Analyzed by Forensic Laboratories in San Diego: 
 2004 
 
Drug Number Percent 
Cocaine 2,259 14.3 
Heroin 239 1.5 
Other Opiates 344 2.2 
Cannabis 7,888 50.0 
Methamphetamine 4,248 26.9 
Amphetamine 15 0.1 
Benzodiazepines 241 1.5 
MDMA/MDA 61 0.4 
PCP 27 0.2 
 
N=15,773 items analyzed. 
SOURCE:  NFLIS, DEA 
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Exhibit 4. Percentages of Primary Treatment Admissions (Excluding Alcohol) for Selected Drugs in San  
 Diego County:  2001–2004 
 
Drug 2001 2002 2003 20041 
Cocaine 12.1 10.2 9.6 8.7 
Heroin 12.3 11.7 10.9 25.0 
Marijuana 25.9 25.3 24.5 17.6 
Methamphetamine 46.7 49.7 52.8 45.2 
Amphetamines 0.6 0.6 0.5 0.4 
 
1Data for 2004 are not totally compatible with data from prior years (see Data Sources). 
SOURCES:  San Diego County Alcohol and Drug Data System for the years 2001–2003 and the California Alcohol and Drug Data 
System for 2004 
 
 
 
 
Exhibit 5. Sociodemographic Characteristics and Drug Use Behaviors of San Diego County Treatment  
 Admissions for 4 Primary Drugs of Abuse, by Percent:  2004 
 
Characteristic Cocaine/ Crack Heroin Marijuana Methamphetamine 
Number 976 2,810 1,979 5,079 
Gender 
 Male 
 Female 
 
69.5 
30.5 
 
70.6 
29.4 
 
75.3 
24.7 
 
60.8 
39.2 
Age Group 
 25 and younger 
 26–34 
 35 and older 
 
10.2 
19.0 
70.9 
 
18.1 
24.0 
57.9 
 
72.0 
15.0 
13.0 
 
27.6 
33.7 
38.5 
Race/Ethnicity 
 White non-Hispanic 
 Black non-Hispanic 
 Hispanic 
 Other 
 
26.6 
58.5 
11.6 
3.2 
 
52.0 
5.1 
38.4 
4.5 
 
40.7 
18.1 
33.8 
7.4 
 
55.8 
7.0 
27.0 
10.2 
Route of Administration 
 Oral 
 Smoking 
 Inhalation 
 Injection 
 Other 
 
0.8 
80.1 
13.9 
4.9 
0.2 
 
1.0 
7.6 
4.0 
87.1 
0.4 
 
1.6 
98.0 
0.3 
0.2 
0.0 
 
1.6 
68.6 
13.3 
16.2 
0.3 
Most Frequently Used Sec-
ondary Drugs 
 Cocaine/crack 
 Methamphetamine 
 Heroin 
 Marijuana 
 Alcohol 
 None 
 
 
– 
10.7 
3.0 
22.0 
32.1 
30.3 
 
 
12.9 
11.7 
– 
3.7 
6.6 
61.5 
 
 
4.9 
26.2 
0.9 
– 
39.2 
26.2 
 
 
5.0 
– 
2.8 
29.0 
24.0 
37.3 
 
SOURCE:  California Alcohol and Drug Data System 
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Exhibit 6. Number and Percentage1 of ED Reports for Selected Illicit Drugs of Abuse (Unweighted2):  2004 
 
Drug Number Percent 
Cocaine 558 18.6 
Heroin 492 16.4 
Marijuana 641 21.4 
Methamphetamine 797 26.6 
Amphetamines 388 12.9 
MDMA 23 0.8 
PCP 23 0.8 
GHB 11 0.4 
 
1Represents the percentage of all illicit drugs, excluding Alcohol Only cases for persons younger than 21. 
2The unweighted data are from 6–10 EDs reporting to San Diego hospitals in 2004.  All DAWN cases are reviewed for quality con-
trol.  Based on this review, cases may be corrected or deleted and, therefore, are subject to change. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 1/13–1/14, 2005 
 
 
 
Exhibit 7. Demographic Characteristics of Patients Reporting Abuse of 4 Illicit Drugs in San Diego DAWN  
 EDs, by Percent (Unweighted1):  2004 
 
Characteristic Cocaine Heroin Marijuana Methamphetamine 
Gender 
 Male 
 Female 
 
66.5 
33.5 
 
69.7 
30.3 
 
65.7 
34.3 
 
69.4 
30.6 
Age Group 
 25 and younger 
 26–34 
 35 and older 
 
19.5 
20.1 
60.4 
 
11.2 
18.3 
70.5 
 
46.8 
21.8 
31.4 
 
27.5 
27.7 
44.8 
Racer/Ethnicity 
 White 
 Black 
 Hispanic 
 Other 
 Not documented 
 
48.4 
30.1 
13.1 
1.3 
7.2 
 
54.5 
10.1 
30.7 
1.2 
3.5 
 
52.7 
20.3 
15.9 
2.7 
8.4 
 
63.0 
6.8 
20.1 
2.5 
7.7 
 
1The unweighted data are from 6–10 EDs reporting to San Diego hospitals in 2004.  All DAWN cases are reviewed for quality con-
trol.  Based on this review, cases may be corrected or deleted and, therefore, are subject to change. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 1/13–1/14, 2005 
 
 
 
Exhibit 8. Number of Drug-Related Deaths1 in San Diego, by Drug:  2003 
 
Drug Number Drug Number 
Alcohol 115 Benzodiazepines 121 
Illicit Drugs  Opiates/Narcotic Analgesics  
 Stimulants 120  Morphine/Combinations 67 
 –  (Amphetamines) (41)  Hydrocodone/Combinations 44 
 –  (Methamphetamine) (118)  Codeine/Combinations 24 
Heroin 62  Methadone 23 
Cocaine 56  Oxycodone/Combinations 22 
Marijuana 1  Propoxyphene/Combinations 19 
   Fentanyl/Combinations 12 
 
1More than one drug may be detected in a decedent. 
SOURCE:  San Diego Medical Examiner 
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Exhibit 9. Retail Prices for Selected Drugs in San Diego:  July–December 2004 
 
Drug Price Unit and Type 
Powder Cocaine $60–$80 Gram 
 $25–$35 One-quarter gram 
Crack $10–$20 Rock 
Heroin $60–$100 Gram (Mexican brown powder) 
 $10–$15 One-tenth gram (Mexican brown powder) 
 $50–$100 Gram (Mexican black tar) 
Marijuana $60–$100 Ounce 
Methamphetamine $60 Gram 
 $20–$25 One-quarter gram 
 $150–$300 One-quarter ounce 
MDMA $15–$30 Tablet 
 
SOURCE:  National Drug Information Center 
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Patterns and Trends of Drug 
Use in the San Francisco Bay 
Area 
 
John A. Newmeyer, Ph.D.1 
 
ABSTRACT 
 
Cocaine use in the bay area remains low compared 
with the rest of the United States. For the 2002–
2005 period, no consistent upward or downward 
trend is evident. The cocaine user population is pre-
dominantly older than 30. Heroin indicators point 
to a significant decline in use between 2000 and 
2005; users remain predominantly White. The me-
dian age of heroin users remains high, perhaps as 
high as 40. Local observers report that Internet traf-
ficking in pharmaceutical opiates, such as Vicodin, 
hydrocodone, and oxycodone, is ‘mushrooming.’ 
Indicators of marijuana use peaked in 2001 and 
have declined significantly since then. Metham-
phetamine use is high compared with other metro-
politan areas of the United States, though it may 
now be leveling off after significant increases dur-
ing 2001–2004. Among some vulnerable popula-
tions (youths, arrestees, gay men), ‘speed’ is far 
more prevalent than heroin. Indicators of use of 
‘club drugs’ reached peaks in 2001 and then de-
clined in 2002; ED and medical examiner reports 
remain few compared to those for cocaine, heroin, 
or ‘speed.’ The prevalence of HIV among hetero-
sexual drug injectors appears to have stabilized at a 
low level (6 to 10 percent), but hepatitis C appears to 
be close to full saturation of that population. 
 
INTRODUCTION 
 
Area Description 
 
The San Francisco Bay area consists of the following 
counties: San Francisco, San Mateo, Alameda, Con-
tra Costa, and Marin. The population was 4,154,000 
as of July 2004. The population is among the most 
multicultural of any urban region of the United 
States, with a particularly large, varied, and long-
established Asian-American representation (19 per-
cent of the total). The Hispanic population represents 
a wide cross-section of persons of Latin American 
origin. Blacks account for some 11 percent of bay 
area residents. San Francisco County has long been a 
                                                 
1The author is affiliated with Haight-Ashbury Free Clinics, Inc., 
San Francisco, California. 
mecca for gays: gay men constitute more than 15 
percent of the adult male population. 
 
The bay area experienced its initial growth during the 
California gold rush. In the succeeding century and a 
half, it expanded greatly as a center for shipping, 
manufacturing, finance, and tourism. In recent years, 
Pacific Basin trade and high technology such as 
software and biotechnology development have led to 
further expansion and to a highly diversified econ-
omy.  
 
From 1994 to 2001, there was a steep rise in the cost 
of rental housing in the bay area, especially in San 
Francisco, Marin, and San Mateo Counties. This 
caused significant out-migration of lower income 
people, which may be exerting downward pressure 
on local drug-use prevalence. However, rental rates 
declined significantly from 2001 to 2003, which may 
have blunted these out-migration pressures. Unem-
ployment rose from 2 to 6 percent during these 2 
years, but it eased back to 5 percent in 2004 and early 
2005. 
 
Data Sources 
 
The sources of data for the drug abuse indicators 
within this report are described below: 
 
• Emergency department (ED) data were ac-
cessed from the Drug Abuse Warning Network 
(DAWN) Live!, a restricted-access online query 
system administered by the Office of Applied 
Studies (OAS), Substance Abuse and Mental 
Health Services Administration (SAMHSA). The 
unweighted data are for three counties of the San 
Francisco Bay area (San Francisco, Marin, and 
San Mateo) for 2004. Seventeen of the 18 eligi-
ble hospitals in the area are in the DAWN sam-
ple. There are 19 emergency departments in the 
sample (some hospitals have more than 1 ED). 
The data for 2004 were incomplete. Over the 12-
month period, between 8 and 11 EDs reported 
data each month, with most reporting data that 
were basically complete (90 percent or greater) 
(exhibit 1). Data are preliminary and are not es-
timates for the San Francisco area. The DAWN 
Live! data were accessed on April 13–14, 2005. 
Since all DAWN cases are reviewed for quality 
control, and may be corrected or deleted, the data 
reported here are subject to change. The informa-
tion derived from DAWN Live! represents drug 
reports in drug-related visits; reports exceed the 
number of ED visits because a patient may report 
use of multiple drugs (up to six drugs and alco-
hol may be presented in DAWN). This paper fo-
cuses on demographic characteristics of different 
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drugs in drug-related visits. Race/ethnicity data 
were absent in 11 to 18 percent of the total cases 
within a drug category; percentages are shown 
for those whose race/ethnicity is known. These 
data cannot be compared with DAWN data from 
2002 and before, nor can these preliminary data 
be used for comparison with future data. Only 
weighted ED data released by SAMHSA can be 
used for trend analysis. A full description of the 
DAWN system can be found at the DAWN Web 
site http://dawninfo.samhsa.gov. 
 
• Treatment admissions data were available for 
all five bay area counties for 1999 through 2004. 
These data were compiled by the California De-
partment of Alcohol and Drug Programs 
(DADP). In addition, admissions data for San 
Francisco County were provided by the San 
Francisco Department of Public Health for fiscal 
years (FYs) 2000 through 2004. 
 
• Medical examiner (ME) data on drug men-
tions in decedents in three counties (San Fran-
cisco, Marin, and San Mateo) were provided by 
the DAWN mortality system for 2002, along 
with comparable data for 1997–2001. The 
DAWN system covered 100 percent of the met-
ropolitan statistical area (MSA) jurisdiction and 
100 percent of the MSA population in 2002. 
Data were also available from the San Francisco 
County Medical Examiner for that county for 
FYs 2000 and 2003. 
 
• Reports of arrests for drug law violations and 
counts of reported burglaries were provided by 
the San Francisco Police Department (SFPD) for 
2001 through the first 4 months of 2005. 
 
• Arrestee drug testing data are from the Ar-
restee Drug Abuse Monitoring (ADAM) pro-
gram, National Institute of Justice, for San Jose 
and Sacramento for 2003 for adult males and for 
San Jose for adult females. 
 
• Price and purity data came from the Drug En-
forcement Administration (DEA), Domestic 
Monitor Program (DMP), and referenced heroin 
“buys,” mostly made in San Francisco County. 
Data for 2003 were compared with those for 
1994–2002. Data on trafficking in heroin and 
other drugs were available from the National 
Drug Intelligence Center’s (NDIC) report, Nar-
cotics Digest Weekly, December 28, 2004. Addi-
tional data on trafficking and production were 
provided by the National Drug Threat Assess-
ment 2005 publication of the NDIC. 
 
• Ethnographic information was obtained through 
interviews with treatment program staff and out-
reach workers in June 2005. Their observations 
were compared with those they made in May 
2004 and January 2005 and pertained mostly to 
San Francisco County. 
 
• Acquired immunodeficiency syndrome (AIDS) 
surveillance data were provided by the San Fran-
cisco Department of Public Health (SFDPH) and 
covered the period through March 31, 2005. Be-
ginning in 2005, the SFDPH provided counts only 
of AIDS cases who were San Francisco residents; 
this resulted in surveillance counts about one-
eighth less than previous counts, which had in-
cluded all persons, resident or non-resident, diag-
nosed in San Francisco.  
 
• A survey of younger gay men was conducted by 
the San Francisco AIDS Office during 2004. Sixty 
percent of this sample were younger than 35.  
 
• Hepatitis B (HBV) data for San Francisco 
County were available for 1996 through 2004 and 
were provided by the SFDPH.  
 
• Hepatitis C (HBC) virus prevalence estimates 
were provided by the Urban Health Study for 
2003. 
 
DRUG ABUSE PATTERNS AND TRENDS   
 
Cocaine/Crack 
 
Local observers note an upsurge in crack use among 
young (under 30) San Franciscans. Some of these 
young people prefer to dissolve this cocaine for injec-
tion, instead of smoking it. 
 
During 2004, there were almost twice as many un-
weighted DAWN Live! reports of cocaine as of her-
oin (2,456 vs. 1,278). The patient characteristics for 
cocaine reports in 2004 were predominantly Black 
(49 percent) and 65 percent male. There were twice 
as many older than 45 (35 percent) as younger than 
30 (17 percent). Smoking was the preferred route of 
use for three-fifths of these patients. 
 
In the five-county bay area, the overall number of 
admissions for drug treatment, other than alcohol, 
declined steadily between 1999 and 2004 (exhibit 2). 
The proportion of cocaine/crack admissions among 
these admissions rose from 24 percent to 26 percent 
between 2001 and 2004, although the actual number 
declined from 7,428 to 6,814. Among these admis-
sions, more than 87 percent cited smoking—
presumably of crack—as the preferred route of use. 
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During FYs 2000 to 2004, San Francisco County co-
caine admissions fluctuated narrowly, with no particu-
lar trend, in the range of 2,250 to 2,600 (exhibit 3). 
 
According to DAWN data, ME death mentions in-
volving cocaine in three bay area counties fluctuated 
within a narrow range, with no particular trend, be-
tween 1997 and 2000 (exhibit 4). In 2002, however, 
total mentions were 39 percent below the 1997–2000 
average. In San Francisco County, cocaine-related 
deaths declined by 28 percent (95 to 68) between FY 
2000 and FY 2003. In FY 2003, these decedents were 
79 percent male, 49 percent White, and 33 percent 
Black; they had a mean age of 40. 
 
Cocaine-positive tests among arrestees in San Jose 
and Sacramento, nearby metropolises which are 
ADAM sites, may give some indication of cocaine 
use prevalence in San Francisco. During 2003, 13 
percent of adult male arrestees in San Jose and 22 
percent of those in Sacramento tested positive for 
cocaine. The two areas had, respectively, the fourth 
and ninth lowest proportions of cocaine-positive ar-
restees among all 39 ADAM sites. For adult female 
arrestees in San Jose, 10 percent tested positive—the 
second lowest proportion among 25 ADAM sites. 
 
A 2004 survey of young San Francisco gay men 
showed 17 percent reported use of cocaine in the past 
year, and 4 percent reported use of crack. 
 
There were nearly 3,800 arrests on cocaine-related 
charges in San Francisco in 2004. The rate of arrests 
in the first 4 months of 2005 was about 12 percent 
less than during a similar period of 2004. 
 
According to the NDIC, local prices for powder co-
caine in 2004 were $16,000–$21,000 per kilogram, 
$530–$800 per ounce, and as low as $10 per quarter 
gram. Crack prices were around $600 per ounce and 
$20–$50 per “rock.” These prices were up slightly 
from 2002. 
 
In summary, cocaine use in the bay area remains low 
compared with the rest of the United States. For the 
2002–2005 period, no consistent upward or down-
ward trend is evident from the indicators. The user 
population is predominantly older than 30. 
 
Heroin 
 
Ethnographic observers note that young people seem 
to represent a larger portion of heroin users, although 
most users are well past age 35. Whites still pre-
dominate over all other ethnicities. 
 
ME death mentions involving heroin in 2002 were at 
their lowest level in 6 years (exhibit 4). The count for 
2002 was 43 percent below the average for 1997–
2000. Males accounted for 87 percent of the heroin-
related death mentions in 2000. The median age of 
the decedents was 40. Heroin-related deaths in San 
Francisco County declined by 37 percent (122 to 77) 
between FY 2000 and FY 2003. In FY 2003, dece-
dents were 79 percent male, 67 percent White, and 22 
percent Black; they had a median age of 40. 
 
According to preliminary unweighted DAWN Live! 
data, reports of heroin during 2004 were two-thirds 
male and 59 percent White. Thirty-nine percent were 
older than 45 and only 18 percent were younger than 
30. For some 93 percent, injection was the preferred 
route of use.  
 
The number of treatment admissions for primary her-
oin problems in the five-county bay area fell by more 
than one-half between 1999 and 2004 (exhibit 1). As 
a proportion of all primary drug admissions exclud-
ing alcohol, heroin constituted 64 percent in 1994, 55 
percent in 1999, and only 34 percent in 2004. Injec-
tion remains by far the predominant route of use: 80 
percent reported that route, compared with 14 percent 
who reported inhalation as the preferred route. San 
Francisco County heroin admissions fell by 9 percent 
between FYs 2002 and 2004 (exhibit 3). 
 
In the ADAM program in 2003, 3.1 percent of adult 
male arrestees in San Jose and 6.9 percent of those in 
Sacramento tested opiate positive; the median across 
the 39 ADAM sites was 5.8 percent. Among female 
arrestees in San Jose, 3.4 percent tested positive, well 
below the 25-city median of 6.6 percent.  
 
A 2004 survey of young San Francisco gay men 
showed only 0.4 percent reported use of heroin in the 
past year. 
 
Arrests for heroin-related offenses totaled 6,136 in 
2002, 16 percent higher than in 2001 and 3 percent 
higher than in 2000. However, in 2003, such arrests 
were about 30 percent below, and in 2004 about 55 
percent below, the 2002 level. The rate of arrests in 
the first 4 months of 2005 showed a significant fur-
ther decline. 
 
Because many heroin users support their habits 
through property crimes, reported burglaries may be 
a good indicator of use. The number of such reports 
in San Francisco fell by 49 percent between 1993 and 
1999 (11,164 to 5,704). After that low point, the 
count rose to 6,706 in 2001, fell to 5,507 in 2003, and 
rose again to nearly the 2001 level in 2004. The rate  
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for the first 4 months of 2005 was higher by 10 per-
cent than that for a similar period of 2004. These 
changes may reflect the price of heroin more than the 
prevalence of users; it is noteworthy that reported 
burglaries and the local price of heroin are both 
barely one-quarter of what they were 20 years ago. 
 
The DEA’s DMP tested heroin street buys in the San 
Francisco area during 2003. The 27 buys were all of 
Mexican origin. The 2003 samples averaged 11 per-
cent pure and $0.98 per pure milligram (exhibit 5). 
Of the last 10 years, 2001, 2002, and 2003 were the 3 
with the highest average price and lowest average 
purity. 
 
Prices of Mexican black tar heroin ranged from 
$9,200 to $30,000 per kilogram and from $230 to 
$850 per ounce in 2004. Gram prices ranged from 
$50 to $75. In 2002, prices were $16,000–$30,000 
per kilogram, $450–$850 per ounce, and around $60 
per gram. 
 
To summarize, most indicators point to a significant 
decline in heroin use in the period from 2000 to 2005. 
Users remain predominantly White. There are indica-
tions of more younger users, but the median age of 
users remains high, perhaps as high as 40. 
 
Other Opiates 
 
Local observers state that Internet trafficking in 
pharmaceutical opiates is “mushrooming.” Vicodin is 
the most frequently cited in this regard; Tylenol-with-
codeine is also prominent. Sources appear to be “all 
over” the world—mostly outside of the United States. 
ME death mentions in the overall “narcotic analge-
sics” category fluctuated within a narrow range in 
1997–2000, but then they dropped in 2001 and 2002 
to a level 29 percent below the 1997–2000 average 
(exhibit 4). The combined count of hydrocodone and 
oxycodone DAWN ED reports during 2004 was 14 
percent that of heroin. The hydrocodone count was 
nearly twice that of oxycodone. 
 
Marijuana 
 
Arrests for marijuana-related offenses in San Fran-
cisco County numbered 1,736 in 2000. The count of 
arrests ranged between 1,300 and 1,450 in the next 3 
years before returning to the 2000 level in 2004. The 
count of arrests for 2005 will be about one-quarter 
lower than that for 2004, if the trend from the Janu-
ary–April period is sustained. 
 
Among adult male arrestees in the ADAM program 
in 2003, 35 percent of those in San Jose and 49 per-
cent of those in Sacramento tested positive for mari-
juana. The median across the 39 ADAM sites was 44 
percent. Among female arrestees in San Jose, 29 per-
cent tested positive, near the 25-site median of 32 
percent.  
 
Marijuana treatment admissions in San Francisco 
County reached a peak in FY 2003, then dropped by 
14 percent in FY 2004 (exhibit 3). 
 
In 2004, sinsemilla marijuana sold for $3,000–$6,000 
per pound, and domestic marijuana sold for $4,000–
$5,000 per pound. Domestic marijuana sold for about 
$200 per ounce. A large, and increasing, quantity of 
marijuana is sold legally from medical marijuana 
outlets to certified purchasers. There appears to be 
effective regulation of price and quality in that new 
“market.”  
 
In November 2004, Oakland voters passed Measure 
Z by a margin of 65 percent to 35 percent. This may 
portend an important development in American pol-
icy on marijuana, in that Measure Z explicitly in-
structs the city of Oakland to create systems for the 
regulation and taxation of adult use of marijuana. 
 
The overall indications are that marijuana use peaked 
in 2001 and has declined significantly since then.  
 
Stimulants 
 
Local observers report that the “speed” scene has 
leveled off after the increases of recent years. White 
users predominate, though there has been a recent 
surge in use among Filipinos. Gay males remain a 
very prominent portion of the user population, but not 
so much as in the past.  
 
In the three-county bay area, ME death mentions in-
volving methamphetamine fell from 58 in 1999 to 32 
in 2001 and 38 in 2002 (exhibit 4). Of the metham-
phetamine-related death mentions in 2000, males 
accounted for 93 percent, and the median age was 40. 
Amphetamine-related deaths in San Francisco 
County increased by 87 percent (15 to 28) between 
FY 2000 and FY 2003. In FY 2003, decedents were 
83 percent male and 70 percent White; they had a 
median age of 38. 
 
Nearly as many preliminary unweighted metham-
phetamine reports as heroin reports (1,092 vs. 1,278) 
were recorded in the DAWN Live! system during 
2004. Four-fifths of the patients involved in metham-
phetamine ED reports in 2004 were male, two-thirds 
were White, and fully 68 percent were older than 30. 
 
The number of treatment admissions for primary 
speed problems in the five-county bay area increased 
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steadily between 1999 and 2004 (exhibit 2). The pro-
portion of primary speed users among all nonalcohol 
drug admissions rose from 13 percent in 1999 to 25 
percent in 2004. It was noteworthy that fully 64 per-
cent of speed users claimed smoking as the preferred 
route; the proportions reporting injection or inhala-
tion as preferred routes were each about one in six. 
Amphetamine treatment admissions in San Francisco 
County rose steadily from FY 2001 to FY 2004, with 
the later year’s count 25 percent higher than the ear-
lier year’s. 
 
Two nearby metropolises that are ADAM sites may 
give some indication of the methamphetamine situa-
tion in San Francisco. In Sacramento and San Jose, 
respectively, 38 and 37 percent of male adult arrest-
ees tested positive for methamphetamine in 2003. 
These were the third and fourth highest proportions 
of methamphetamine-positives among male adults in 
all the 39 ADAM sites. Among the female arrestees, 
45 percent tested positive, the fourth highest among 
25 ADAM sites. 
 
A 2004 survey of young San Francisco gay men 
showed 21 percent reported use of methamphetamine 
in the past year. 
 
According to the NDIC, in 2004 pounds of “crystal” 
methamphetamine sold in the $10,000–$13,000 
range, ounces in the $600–$1,500 range, and grams 
in the $80–$100 range. In 1999, comparable price 
ranges were $3,500 to $10,000 for pounds and $500 
to $1,000 for ounces. The DEA San Francisco Field 
Division reports that Mexican criminal groups con-
trol the local wholesale and midlevel distribution. 
Several counties near the bay area (Alameda, San 
Mateo, Santa Clara, Sacramento, San Joaquin, and 
Stanislaus) have been sites of “superlabs,” capable of 
producing 10 pounds or more of methamphetamine 
per production cycle. The National Drug Threat As-
sessment surveys indicate that Mexican criminal 
gangs control most wholesale and midlevel distribu-
tion, though Hawaiian, Filipino, and other Asian drug 
trafficking organizations produce and distribute sig-
nificant quantities of “ice.” 
 
Methamphetamine use in the bay area is high com-
pared with other metropolitan areas of the United 
States. Among some vulnerable populations (youths, 
arrestees, gay men) “speed” is far more prevalent than 
heroin. There are indications of a leveling off after 
significant increases during the 2001–2004 period. 
 
Depressants 
 
According to preliminary unweighted data accessed 
from DAWN Live!, ED reports of benzodiazepines in 
2003–2004 were mostly White (77 percent), male (63 
percent), and older than 35 (69 percent). ME men-
tions dropped from a 1999–2001 average of 54 to 34 
in 2002 (exhibit 4). 
 
Hallucinogens 
 
Lysergic acid diethylamide (LSD) ED reports among 
the preliminary unweighted DAWN Live! data were 
rare during 2004. Reports of phencyclidine (PCP) 
were about five times more common.  
 
Club Drugs 
 
The NDIC reports that in 2004, street prices of me-
thylenedioxymethamphetamine (MDMA or “X”) 
were in the range of $15–$40 per “tab.” The prelimi-
nary unweighted Dawn Live! ED reports of this drug 
were predominantly (69 percent) among people 
younger than 30. A 2004 survey of young San Fran-
cisco gay men showed 20 percent reported use of 
MDMA in the past year. ED reports of gamma hy-
droxybutyrate (GHB) were on average older, with 64 
percent older than 30. Ketamine reports were very 
rare. The actual number of club drug ED mentions 
remains small compared with mentions for cocaine or 
methamphetamine. The same is the case for club drug 
ME mentions (exhibit 4). 
 
INFECTIOUS DISEASES RELATED TO DRUG ABUSE  
 
AIDS 
 
San Francisco County had a cumulative total of 
26,117 AIDS cases among city residents through 
March 31, 2005. Of these cases, 1,911 (7.3 percent) 
were heterosexual injection drug users (IDUs). An-
other 3,572 AIDS cases (13.7 percent) were among 
men who have sex with other men (MSM) and also 
injected drugs. There were just 42 reported cases 
among lesbian IDUs, barely one-hundredth the num-
ber among MSM/IDUs. A total of 321 AIDS cases 
have been reported for transgender San Franciscans. 
 
Among San Franciscans diagnosed in 2003 through 
2005, heterosexual IDUs accounted for 15 percent, 
up from 10 percent among those diagnosed in 1994–
1996, 14 percent of those diagnosed in 1997–1999, 
and 14 percent of those diagnosed in 2000–2002. 
However, the overall case numbers in 2003–2004 
were far lower than those of the late 1980s and early 
1990s. As a result, the percentage of heterosexual 
IDUs among the cumulative AIDS caseload will 
probably not increase significantly from the current 
level of 7 percent. 
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The demography of the cumulative heterosexual IDU 
caseload with AIDS has changed very little in the 
past 14 years. This caseload is 68 percent male, 51 
percent Black, 35 percent White, 11 percent His-
panic, and 2 percent Asian/Pacific Islander. By con-
trast, the gay/bisexual IDU caseload is 71 percent 
White, 16 percent Black, 10 percent Hispanic, and 
1.5 percent Asian/Pacific Islander. 
 
The heterosexual IDU demography is like that of 
heroin users except for over-representation of Blacks, 
while the gay male IDU demography is similar to that 
for male speed users. 
 
Data from the Urban Health Study (UHS), which 
conducts semiannual surveys, indicate that in 2004, 
seroprevalence of heterosexual IDUs in San Fran-
cisco remained within the same 6–10 percent range 
that has prevailed for the past 16 years. By contrast, 
HIV prevalence among MSM/IDUs had ranged 
around 40 percent in the late 1980s, dropped to 
around 25 percent in the late 1990s, and rose again to 
the 30–35 percent range in 2004. Recent UHS data 
show extensive self-reported past-month injection of 
cocaine (21 percent) and amphetamines (30 percent) 
as well as heroin (68 percent). A surprisingly low 
proportion (c. 15 percent) of heterosexual HIV-
positive IDUs reported being on drug treatment for 
their condition. 
 
Passage of SB1159, which enables California phar-
macies to sell hypodermic equipment without pre-
scriptions, has the potential for significant effects 
upon disease transmission. Many large pharmacies 
have decided to opt into this activity. 
 
Hepatitis B Virus 
 
From 1997 through 2001, reported cases of HBV in 
San Francisco County rarely deviated from a pace of 
a bit more than one per week. The pace dropped in 
2002 and 2003 to about one every 10 days, then 
dropped further in 2004 to about one every 14 days. 
 
Hepatitis C Virus 
 
UHS data from 2003 disclosed that fully two-thirds 
of all IDUs in the sample self-reported HCV sero-
positivity. UHS staff believe, on the basis of earlier 
HCV antibody testing, that true prevalence is be-
tween 90 and 95 percent. This has enormous implica-
tions for the long-term health of San Francisco’s IDU 
population—not only the current user population 
estimated at 18,700, but also the possibly much larger 
number with past (or future) injection drug use. 
“Coinfection” is also a serious problem; a 2003 study 
by the University of California at San Francisco 
found that 73 percent of homeless and marginally 
housed people with HIV were also infected with 
hepatitis C. 
 
For inquiries concerning this report, please contact John A. 
Newmeyer, Ph.D., Haight-Ashbury Free Clinics, Inc., 612 Clayton 
Street, 2nd Floor, San Francisco, CA  94117, Phone: (415) 931-
5420, Fax: (415) 864-6162, E-mail: jnewmeyer@aol.com. 
 
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—San Francisco Bay Area 
 
 
Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005 247
Exhibit 1. San Francisco DAWN ED Sample and Reporting Information:  January–December 2004 
 
No. of EDs Reporting per Month: 
Completeness of Data (%)  CEWG Area Total Eligible Hospitals1 
No. of 
Hospitals in 
DAWN 
Sample 
Total EDs in 
DAWN 
Sample2 90–100% 50–89% <50% 
No. of 
EDs Not 
Reporting 
San Francisco 18 17 19 7–10 0–1 0–3 8–11 
 
1Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association An-
nual Survey. 
2Some hospitals have more than one emergency department. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/13-4/14, 2005  
 
 
 
Exhibit 2. Admissions to Drug Treatment Programs in the San Francisco Bay Area, by Primary Drug of  
 Abuse:  1999–2004 
  
Drug 1999 2000 2001 2002 2003 2004 
Cocaine 8,727 7,718 7,428 6,746 7,114 6,814 
Heroin 19,763 17,416 14,673 11,461 9,898 9,089 
Amphetamine 4,595 4,469 5,073 5,636 6,438 6,701 
All Drugs 36,069 32,034 30,920 28,329 27,626 26,381 
 
SOURCE:  California Department of Alcohol and Drug Programs (DADP)   
 
 
 
Exhibit 3. Admissions to Drug Treatment Programs in San Francisco County, by Primary Drug of Abuse:  
 FYs 2000–2004 
 
Drug FY 2000 FY 2001 FY 2002 FY 2003 FY 2004 
Cocaine 2,600  2,306   2,440   2,274   2,527 
Heroin 4,030  3,867   4,002   3,700   3,646 
Amphetamine 1,008     991  1,053   1,144   1,235 
Marijuana 915     867   1,067   1,110  950 
All Drugs   8,690  8,191   8,764   8,406   8,520 
 
SOURCE:  San Francisco Department of Public Health 
 
 
 
Exhibit 4. Medical Examiner Drug Mentions in Three Counties (Including San Francisco):  1997–2002 
 
Drug 1997 1998 1999 2000 2001 2002 
Cocaine 127 158 158 146 106   90 
Heroin/Morphine 159 164 192 148 117   95 
Methamphetamine   49   45   58   45   32   38 
Narcotic Analgesics 156 185 198 164 124 125 
Benzodiazepines   71   62   50   55   56 34 
Club Drugs1       6     6     5     4 
 
1Includes MDMA, ketamine, GHB, GBL, and Rohypnol 
SOURCE:  DAWN, OAS, SAMHSA 
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Exhibit 5. Price and Purity of Heroin Samples, 1994-2003 
 
Year Price Per Pure Milligram Purity (Percent) 
1994 $0.95 29 
1995 $0.83 35 
1996 $0.83 24 
1997 $0.63 26 
1998 $0.33 26 
1999 $0.47 20 
2000 $0.70 15 
2001 $1.40 10 
2002 $0.99 12 
2003 $0.98 11 
 
SOURCE:  Drug Enforcement Agency, Domestic Monitor Program 
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ABSTRACT 
 
The total number of drug-involved deaths increased 
36 percent in 2004, due primarily to cocaine, pre-
scription-type opiates, and prescription and over-the-
counter depressants/anxiolytics/sedatives. Cocaine-
involved deaths are at their highest level in at least 
10 years, with 92 cocaine-involved deaths in 2004. 
Cocaine is the most common illegal drug among ED 
reports. Treatment admissions for heroin are begin-
ning to increase, along with the increased treatment 
capacity. Heroin-involved deaths totaled 75 in 2004, 
up a bit from 2003 but well below the peak of 144 in 
1998. Deaths and treatment admissions involving 
prescription-type opiates continue to rise steadily. 
Methamphetamine mortality indicators have leveled 
off in King County, while treatment admissions have 
begun to increase again. Negative consequences re-
lated to prescription stimulants appear low, but the 
number of prescriptions has increased substantially, 
and anecdotal reports of youth and young adult mis-
use are common. Marijuana is widely used, particu-
larly by youth. Prescription depressant-involved 
deaths increased substantially. In 2004, 1 in 5 drug-
related deaths involved the combination of prescrip-
tion-type opiates and depressants (and usually other 
drugs as well). Hepatitis B and C infect the majority 
of IDUs. HIV among IDUs is generally low, with the 
exception of methamphetamine-injecting men who 
have sex with men. 
 
INTRODUCTION 
 
Area Description 
 
Located on Puget Sound in western Washington, King 
County spans 2,130 square miles, of which the city of 
Seattle occupies 84 square miles. The combined ports of 
                                                 
The authors affiliations are as follows: 
1Alcohol and Drug Abuse Institute, University of Washington 
2Evergreen Treatment Services 
3HIV/AIDS Program, Public Health – Seattle & King County 
4Division of Alcohol and Substance Abuse, Washington State De-
partment of Social and Health Services 
5Northwest High Intensity Drug Trafficking Area  
6Washington State Alcohol and Drug Help Line 
7Medical Examiner’s Office, Public Health – Seattle & King County 
8HIV/AIDS Epidemiology, Public Health – Seattle & King County 
Seattle and nearby Tacoma make Puget Sound the 
second largest combined loading center in the United 
States. Seattle-Tacoma International Airport, located 
in King County, is the largest airport in the Pacific 
Northwest. The Interstate 5 corridor runs from Ti-
juana, Mexico, in the south, passes through King 
County, and continues northward to Canada. Inter-
state 90’s western terminus is in Seattle; it runs east 
over the Cascade Mountain range, through Spokane, 
and across Idaho and Montana. 
 
According to the 2000 census, the population of 
King County is 1,737,034. King County’s popula-
tion is the 12th largest in the United States. Of 
Washington’s 5.9 million residents, 29 percent live 
in King County. The city of Seattle’s population is 
563,374; the suburban population of King County is 
growing at a faster rate than Seattle itself. 
 
The county’s population is 75.7 percent White, 10.8 
percent Asian/Pacific Islander, 5.5 percent Hispanic, 
5.4 percent African-American, 0.9 percent Native 
American or Alaska Native, 0.5 percent Native Ha-
waiian and Other Pacific Islander, and 2.6 percent 
“some other race.” Those reporting two or more 
races constitute 4.1 percent of the population. In-
come statistics show that 8.0 percent of adults and 
12.3 percent of children in the county live below the 
Federal poverty level, lower than the State averages 
of 10.2 percent and 15.2 percent, respectively. 
 
Data Sources 
 
Information for this report was obtained from the 
sources described below:  
 
• Emergency department (ED) drug data were 
obtained from the DAWN Live! restricted-
access online query system administered by the 
Drug Abuse Warning Network (DAWN), Of-
fice of Applied Studies (OAS), Substance 
Abuse and Mental Health Services Administra-
tion (SAMHSA). Preliminary unweighted data 
for 2004 are presented. Eligible hospitals in the 
Seattle area total 22; hospitals in the DAWN 
sample number 22, with the number of emer-
gency departments in this sample totaling 23. 
(Some hospitals have more than one ED.) Dur-
ing this 12-month period, between 10 and 13 
EDs reported data each month. The complete-
ness of data reported by participating EDs var-
ied by month (see exhibit 1). Exhibits in this 
paper reflect cases that were received by 
DAWN as of April 13–14, 2005, unless other-
wise noted. All DAWN cases are reviewed for 
quality control. Based on this review, cases may 
be corrected or deleted. Therefore, the data in 
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this paper are subject to change. Data derived from 
DAWN Live! represent drug reports in drug-related 
ED visits. Drug reports exceed the number of ED 
visits, since a patient may report use of multiple 
drugs (up to six drugs plus alcohol). These data are 
preliminary, meaning that they may change. Data 
represent unweighted drug reports and are not es-
timates or rates for the reporting area. Data are util-
ized for descriptive purposes only. Data cannot be 
compared to DAWN data from 2002 and before, 
nor can preliminary data be used for comparison 
with future data. Only weighted data released by 
OAS may be used for trend analyses. Available 
data are for King and neighboring Snohomish 
Counties combined, Pierce County is part of the 
statistical sample, but no EDs in Pierce were re-
porting during 2004. There are new case types in 
DAWN, with the primary one presented here being 
the “other” case type, which includes “all ED visits 
related to recreational use, drug abuse, drug de-
pendence, withdrawal, and any misuse” not classi-
fied in other categories such as over-medication 
and seeking detox/treatment. For the sake of clarity 
“other” will be referred to as “drug abuse/other” in 
this report. Unless specifically stated, data pre-
sented are for the drug abuse/other case type. A full 
description of the DAWN system can be found 
online at http://dawninfo.samhsa.gov. 
 
• Treatment data were extracted from the Wash-
ington State Department of Social and Health 
Services, Division of Alcohol and Substance 
Abuse’s Treatment and Assessment Report Gen-
eration Tool (TARGET) via the Treatment Ana-
lyzer system. TARGET is the department’s state-
wide alcohol/drug treatment activity database sys-
tem. Data were compiled for King County resi-
dents from January 1, 1999, through December 
31, 2004. Data are included for all treatment ad-
missions that had any public funding. Department 
of Corrections (only a few cases) and private pay 
clients (at methadone treatment programs) are 
also included. Methadone waiting list data for 
those seen at syringe exchanges are administered 
and provided by Public Health—Seattle & King 
County (PHSKC). 
 
• Drug-related mortality data were provided by the 
King County Medical Examiner (ME). Data for 
2004 are preliminary. The data include deaths di-
rectly caused by licit or illicit drug overdose and 
exclude deaths caused by antidepressants in isola-
tion and by poisons. Totals may differ slightly from 
drug death reports published by the King County 
ME’s office, which include fatal poisonings. Test-
ing is not done for marijuana. Because more than  
 
one drug is often identified per individual drug 
overdose death, the total number of drugs identi-
fied exceeds the number of actual deaths. A cor-
rection to the coding for alcohol-involved deaths 
was made in August 2005. Data from 1997–2000 
previously under-reported the number of deaths 
in which alcohol was identified. 
 
• Toxicology and driving under the influence 
(DUI) data were provided by the Washington 
State Patrol’s Forensic Toxicology Laboratory 
for methamphetamine-involved cases. Note that 
the laboratory’s identification of a substance in 
a death is not equivalent to the medical exam-
iner’s ruling that a drug was causative in the 
death. The toxicology lab is reporting on 
chemical analysis for cases, whereas the ME’s 
office utilizes these data along with their own 
investigation to make a ruling as to the cause of 
death. The number of positive toxicology cases 
for a substance will invariably surpass the num-
ber of deaths ruled to be caused by a substance. 
 
• School drug use survey data are available from 
the Seattle Public School’s Communities That 
Care survey for 2002 and 2004. Response rates 
were 50 percent in 2002 and 60 percent in 2004. 
Trends cannot be determined from these data. 
 
• Prescription drug sales data are extracted from 
the Drug Enforcement Administration’s Auto-
mation of Reports and Consolidated Orders 
System (ARCOS) reports. The data provide re-
tail drug distribution data by ZIP Code, cover-
ing primarily sales to hospitals and pharmacies. 
ARCOS data presented here are for the 3-digit 
ZIP Code areas of 980 and 981, which roughly 
correspond with King County boundaries. The 
population in these two ZIP Code areas is 
1,969,348, compared with 1,737,034 for King 
County in 2000. Available data report the 
“grams of active ingredient” by year; this is 
complicated to translate into the number of pre-
scriptions or users, so data are reported in terms 
of proportional change over time. 
 
• Methamphetamine production data are from 
the Washington State Department of Ecology 
(DOE), which is mandated to respond to and 
document all “Methamphetamine Incidents,” 
including operating labs, dump sites, and other 
sites associated with the manufacture of 
methamphetamine. 
 
• Forensic drug analysis data are from the Na-
tional Forensic Laboratory Information System  
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(NFLIS), which distributes data from the Wash-
ington State Patrol’s Toxicology Laboratory on 
drug test results on local law enforcement sei-
zures. These data include the top 25 drugs identi-
fied in fiscal year (FY) 2003 and FY 2004. Data 
are presented for the Seattle-area lab in compari-
son to the rest of the State. 
 
• Data on infectious diseases related to drug use 
and injection drug use, including the human im-
munodeficiency virus (HIV), acquired immunode-
ficiency syndrome (AIDS), and hepatitis, were 
provided by three sources. One source is “HIV/ 
AIDS Epidemiology Report.” Data on HIV and 
AIDS cases (including exposure related to injection 
drug use) in Seattle-King County, other Wash-
ington counties, and Washington State (2001 
through 2004) are provided by PHSKC, the Wash-
ington State Department of Health. HIV cases were 
reported to PHSKC or the Washington State De-
partment of Health between 2000 and 2004. The 
third source of information, on 18–30-year-old in-
jecting drug users’ preferred drugs over time, was 
provided by the HIV epidemiology unit of PHSKC. 
These data are based upon four studies conducted 
from 1994 to 2003; they included the RAVEN 
(1994–1997), RAVEN II (1998), Kiwi (1998–
2002) and DUIT (2002–2003) studies.  
 
• Syringe exchange data on the number of sy-
ringes exchanged and the number of encounters 
with clients are provided by PHSKC’s HIV/AIDS 
program. 
 
• Drug-related helpline data are from the Washing-
ton State Alcohol/Drug Help Line (ADHL), which 
provides confidential 24-hour telephone-based 
treatment referral and assistance for Washington 
State. Data are presented for January 2001 to De-
cember 2004 for calls originating within King 
County. Data presented are for drugs mentioned. A 
caller may refer to multiple drugs; therefore, there 
are more drug mentions than there are calls. The 
data exclude information on alcohol and nicotine, 
which account for more than one-half of the calls. 
Data are presented primarily for illicit drugs only, 
prescription drugs have not been coded consistently 
over time, therefore limiting trend analyses. The 
large number of unknown drugs in 2001 and 2002 
may obscure some trends as well. 
 
• Key informant interview data are obtained from 
discussions with treatment center staff, street out-
reach workers, and drug users. 
 
DRUG ABUSE PATTERNS AND TRENDS 
 
Cocaine/Crack 
 
The proportion of treatment admissions involving 
cocaine (i.e., cocaine was mentioned as the primary, 
secondary, or tertiary drug of abuse at the time of en-
try into treatment) increased for the first time in sev-
eral years from 38.7 percent in 2003 to 40.1 percent in 
2004 (exhibit 2a). Those entering treatment were older 
in 2004 than those entering in 1999, with 22.6 percent 
age 45–54 in 2004, compared with 10.4 percent in 
1999 (exhibit 2b). Use is quite low among those 
younger than 18: less than 3 percent in both years. The 
largest group remained those age 30–44, representing 
60 percent of admissions in 2004. 
 
Unweighted cocaine ED drug reports for all case types 
totaled 2,725 in 2004, more than those for heroin, 
marijuana, and methamphetamine (exhibits 3a and 
3b). For cocaine, drug abuse/other represented the 
largest proportion of case types (89 percent), followed 
by those seeking detox/treatment (10 percent). Almost 
two-thirds were male, with almost as many Blacks as 
Whites (note substantial missing data). They were an 
older group, with 38 percent age 35–44 and 22 percent 
age 45–54. Psychiatric conditions (24 percent) were 
the predominant complaint, followed by altered men-
tal status (16 percent). Route of administration data 
were missing for 73 percent of reports, with 13 per-
cent smoking, 10 percent injecting, and 2 percent in-
haling/sniffing/snorting.  
 
Cocaine was the most common drug mentioned by 
adults calling the ADHL, representing 32 percent of 
calls in 2004 (exhibit 4). For youth, 12 percent of calls 
were for cocaine in 2004. 
 
Cocaine was not commonly used by high school 
seniors in the past 30 days (exhibit 5). Use levels 
were 1.7 percent in 2002 and 2.5 percent in 2004 
(not significantly different). 
 
Cocaine was the most common substance identified 
in the Seattle area according to NFLIS data on local 
law enforcement drug seizure testing (exhibit 6). 
Cocaine was the second most common drug de-
tected in the laboratories for the rest of the State, 
with about one-half of the level found in the Seattle-
area lab. Minimal change occurred in the proportion 
of cocaine-positive tests from FY 2003 to FY 2004. 
 
Cocaine-involved deaths are at their highest level in 
at least 10 years, with 92 cocaine-involved deaths in 
2004 (exhibit 7a). The most common drugs com- 
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bined with cocaine included heroin, representing 14 
percent of all drug-involved deaths, prescription-type 
opiates (10 percent), and depressants/sedatives/ anxio-
lytics (9 percent) (exhibit 7e). Twenty-one deaths in-
volved only cocaine in 2004, accounting for 23 per-
cent of all cocaine-involved deaths. The number and 
proportion of cocaine-only deaths is second only to 
2000, when 31 of 89 (35 percent) cocaine-involved 
deaths were from cocaine only. 
 
More than three-quarters of cocaine-involved decedents 
were male, a higher proportion than for all drug deaths 
(exhibit 7d). The average age for cocaine decedents 
(41.2) was similar to the age for all drug decedents and 
increased from 39.7 to 43.3 from 1997 to 2004. A dis-
proportionate number of decedents were African-
American, 21 percent, higher than 11 percent for all 
drugs and much higher than the county’s overall Afri-
can-American population. Almost all deaths were ruled 
accidental (94 percent). 
 
The level of cocaine indicators is disproportionately high 
for African-Americans relative to their representation in 
King County. Though African- Americans represent 
approximately 5 percent of the county’s population, they 
represent 21 percent of cocaine-involved deaths, 47 per-
cent of cocaine treatment admissions (exhibit 2c), and 42 
percent of cocaine ED reports. Note that even though 
African-Americans are overrepresented in the ED (26 
percent of reports with race documented) and in treat-
ment (22 percent of admits), their levels of cocaine use 
are still disproportionately high. 
 
The Seattle DEA field division reports that powder 
cocaine availability is increasing. They also have no-
ticed increasing availability of crack in smaller com-
munities in Washington State.  
 
Heroin 
 
The proportion of treatment admissions involving any 
use of heroin increased after several years of decline, 
from 19.8 percent in 2003 to 21.6 percent in 2004 (ex-
hibit 2a). Opiate treatment program capacity was sub-
stantially increased in the later part of 2004; there 
were 673 admissions in the first half of 2004 and 997 
in the second half. The caseload increased by ap-
proximately 200 from January to December of 2004 to 
a total of 2,536 in public and private pay programs 
governed by King County. Heroin users are older than 
other drug users entering treatment on average and 
they continued to get older during the timeframe from 
1999 to 2004; the proportion of those age 45–54 in-
creased from 27 to 34 percent (exhibit 2b). An in-
crease was also seen among those age 55–64, from 3 
to 6 percent of admissions involving heroin. 
 
Among those entering opiate substitution treatment, 
the proportion reporting heroin as their primary drug 
decreased from 95 to 87 percent from 1999 to 2004 
(exhibit 8). 
 
Heroin/opiate/morphine-involved deaths increased 
in 2004 to 75; only 2 years had lower numbers since 
1997 (exhibit 7a). (The category of heroin/opiate/ 
morphine is the best approximation of heroin deaths; 
it excludes all deaths known to involve specific pre-
scription-type opiates.) Heroin/opiate/morphine 
combination deaths most commonly involved co-
caine (14 percent of all drug- involved deaths), al-
cohol (8 percent), a depressant/anxiolytic/sedative 
(8 percent), and prescription-type opiates (6 percent) 
(exhibit 7e). In 2004, 17 percent of heroin/opi-
ate/morphine-involved deaths had no other drug 
present, slightly lower than the 20 percent average 
for all years. 
 
Heroin/opiate/morphine-involved decedents were 
male 81 percent of the time, the highest proportion 
for any substance (exhibit 7d). The average age of 
40.6 was slightly lower than for all drugs, and that 
average increased substantially from 38.0 to 43.8 
from 1997 to 2004. Eighty-four percent of decedents 
were White, and 10 percent were African-American. 
The vast majority of deaths were ruled accidental: 92 
percent. The average number of drugs involved was 
2.4, similar to the average for all drugs (2.3). (Note 
that heroin/opiate/morphine-involved deaths consti-
tuted almost one-half of all deaths, so the averages for 
all deaths are heavily influenced by these data.) 
 
The waiting list for methadone treatment programs 
(which primarily use methadone) was at 487 at the 
end of 2004 and 156 by June 2005 (exhibit 9). Re-
cent increases in treatment capacity have resulted in 
this decreased number on the waiting list. 
 
The predominant form of heroin on the streets is 
Mexican black tar. All DEA DMP buys of heroin 
that have been positively identified were found to be 
Mexican in origin. China white, a common form in 
Vancouver, British Columbia, and on the east coast 
of the United States, is uncommon in the local area 
according to regional HIDTA and DEA information.  
 
Historically, DMP data were reported for the Seattle 
area, which included buys in Seattle and Tacoma, 
and just the average purity was reported. Prelimi-
nary data for the Seattle area showed a spike in the 
average purity of heroin for the Seattle area. The 
Seattle DEA Field Division provided additional de-
tailed data that included the city of purchase as well 
the purity for each buy. This allowed the computa-
tion of medians in addition to averages. These de-
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tailed data revealed that the median heroin purity of 
DMP buys in the city of Seattle was 14 percent in FY 
2004, similar to the prior year, higher than in FY 
2001–2002, and below the 17 percent seen in FY 2000 
(exhibit 10). Most important are the four purchases in 
FY 2004 that ranged from 37 to 46 percent pure; this 
is a much larger range and higher purity than seen in 
the prior 3 years. Followup discussions with local 
DEA indicated that these buys were not different than 
any others (i.e., high purity heroin was not being 
sought). This large of a range is potentially dangerous, 
because users may be getting much more potent heroin 
than they are used to, which, particularly when used in 
combination with other depressants, could prove 
deadly. This is a very small number of samples, but it 
does raise concerns about another potential cause of 
heroin overdoses. 
 
Unweighted data show heroin drug reports in the 
DAWN Live! system were second only to cocaine 
among illegal drug reports (exhibits 3a and 3b). Ninety 
percent of heroin reports were of the drug/abuse other 
case type, with almost all of the remaining reports for 
seeking detox/treatment. Sixty percent were male, with 
five times as many Whites as Blacks. However, 60 
percent of reports did not have race/ethnicity docu-
mented. The group was relatively old, with one-third 
age 35–44 and almost one-quarter age 45–54. By far 
the most common chief complaint was abscess/cellu-
litis/skin/tissue at 39 percent, far higher than for any 
other substance. Overdose was second, with 10 per-
cent of documented complaints. Injection was noted in 
almost all reports for which the route of administration 
was documented. 
 
Heroin mentions in calls to the Help Line represented 15 
percent of adult calls and 4 percent of youth calls in 
2004 (exhibit 4).  
 
NFLIS results show similar levels of law enforcement 
seizures for heroin in the Seattle area (5 percent) and 
the rest of the State (5–7 percent) in FYs 2003 and 
2004. Heroin was the fourth most common substance 
detected in each of these regions (exhibit 6). 
 
Price data for King County from the Northwest HIDTA 
for 2003 for Mexican black tar heroin include $30–$150 
per gram, $400–$900 per ounce, $8,000–$10,000 per 
pound, and $16,000–$25,000 per kilogram. 
 
Other Opiates/Prescription-Type opiates 
 
For the purposes of this report, “other opiates/pre-
scripttion-type opiates” include codeine, dihydroco-
deine, fentanyl, hydrocodone (e.g., Vicodin), metha-
done (source, whether pain medication or opiate treat-
ment program is rarely available), oxycodone (e.g., Per-
cocet and OxyContin), propoxyphene (e.g., Darvon), 
sufentanil, tramadol (e.g., Ultram), hydromorphone 
(e.g., Dilaudid, Palladone), meperidine (e.g., Deme-
rol) pharmaceutical morphine, acetylmethadol, and 
the “narcotic analgesics/combinations” reported in the 
DAWN ED data. 
 
Treatment admissions to any treatment modality 
increased from 81 to 264 for other opiates as the 
primary drug from 1999 to 2004. A substantial in-
crease was seen for the 18–29 age group, rising 
from 16 to 40 percent of other opiate admissions 
from 1999 to 2004. These numbers are an underes-
timate, as prescription-type opiate use is often noted 
as secondary or tertiary to other substances. 
 
Among those entering opiate substitution treatment, 
the proportion reporting prescription-type opiates as 
their primary drug increased from 3 percent in 1999 
to 12 percent in 2004 (exhibit 8). 
 
The number of deaths involving prescription-type 
opiates continues to increase and has surpassed all 
other drugs; prescription-type opiates were identi-
fied in 118 deaths in 2004, up from 84 in 2003 and 
28 in 1997 (exhibit 7a). Thirteen deaths in 2004 (11 
percent) involved just a prescription-type opiate, a 
proportion similar to the prior 3 years, but about 
one-half the level seen from 1998 to 2000. 
 
Demographics for prescription-type opioid deaths 
point to a relatively high proportion of females and a 
group older than all drugs users on average (exhibit 
7d). This group was also disproportionately White 
and had a larger average number of total drugs pre-
sent, 3.0, than among all drug decedents, 2.1. 
 
Three specific prescription-type opiates make up the 
majority of all cases, with methadone present in 57 
percent of prescription-type opiate-involved deaths 
in 2004 (exhibit 7b). Oxycodone was the next most 
common, present in more than one-quarter of such 
deaths in 2004. Hydrocodone was present in 14 
deaths in 2004, with all of the remaining prescrip-
tion-type opiates totaling 33 cases in 2004. 
 
Demographics of oxycodone and methadone dece-
dents are similar in terms of gender and the average 
numbers of drugs present (exhibit 7d). Oxycodone 
users were older on average, 44.7, compared with 
41.4 for methadone, and the manner of death was 
much more often suicide for oxycodone users (22 
percent versus 1 percent for methadone cases). 
 
The most common class of drugs found in combina-
tion with prescription-type opiates in deaths was 
depressants (exhibit 7e). This combination was 
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found in 20 percent of all deaths, the highest propor-
tion of any drug combination deaths in 2004. 
 
Fifteen percent of deaths involving a combination of 
prescription-type opiates and depressants were deter-
mined to be suicides, slightly higher than 11 percent 
for all drug-involved deaths and much lower than the 
24 percent for all depressant-involved deaths. These 
differences indicate that this combination is not just 
part of the commonly seen multiple drug-involved 
suicides, but appear to be also involved in accidental 
deaths from those seeking to get high from this com-
bination. These two classes of drugs are CNS depres-
sants and their effects combine, or potentiate, to create 
a dangerous physiological state. In 2004, 62 percent of 
depressant-involved deaths also involved a prescrip-
tion-type opiate, while 43 percent of all prescription-
type opiate-involved deaths also involved a depressant 
(exhibit 7c). This drug combination has been common 
in the past as well. 
 
Single-drug deaths were infrequent for prescription-
type opiates (13 percent), compared with all drug-
involved deaths (29 percent) (exhibit 7f). Thus, the 
vast majority of prescription-type opiate-involved 
deaths involved multiple substances. Illegal drugs 
were present in two-thirds of all drug-involved deaths 
(exhibit 7g), but in only a minority of prescription-
type opiate-involved deaths (35 percent). It is likely 
that most people using prescription-type opiates in 
combination with illegal drugs were attempting to get 
“high.” The proportion of accidental over-medications 
versus those seeking a high is not known. 
 
What constitutes a prescription-type opiate-related 
death is unclear, however, particularly among opiate-
tolerant individuals. Issues of tolerance, potentiation 
with other drugs, and overlapping therapeutic and le-
thal dose levels complicate assigning causation in pre-
scription-type opiate-involved fatalities. The source 
and form of prescription-type opiates involved in 
deaths are sometimes undetermined. 
 
According to unweighted data accessed from DAWN 
Live!, ED drug reports for prescription-type opiates 
totaled 1,956 in 2004, with the drug abuse/other case 
type representing the largest proportion (41 percent), 
followed by overmedication (25 percent) and adverse 
reaction (21 percent) (exhibit 3a). Some misclassifica-
tion of case type may remain, however it is believed 
that the other/drug abuse case type is likely the most 
accurate category, given that all other case types must 
be ruled out prior to assigning this case type. To ex-
plain more about those who are intentionally misusing 
prescription-type opiates, the drug abuse/other case 
type is discussed further below. 
ED drug reports for the drug abuse/other case type 
indicate that prescription-type opiate patients were 
mostly age 35–54 (58 percent); about one-half were 
male; most used orally, though some injected; and 
withdrawal (23 percent) was the most common pre-
senting complaint (exhibit 3c). 
 
A comparison of drug abuse/other ED reports for 
the two most common prescription-type opiates, 
oxycodone (n=171, 21 percent) and methadone 
(n=234, 29 percent) revealed a few differences. The 
most notable difference was the age distribution, 
with oxycodone patients being younger; 27 percent 
were 18–29, compared with 16 percent for metha-
done patients. Methadone-involved patients tended 
to be on the older end of the scale, with 44 percent 
being age 45 and older, compared with 26 percent of 
oxycodone patients. This is the inverse of the pattern 
seen in deaths with regards to age. Route of inges-
tion information was missing for a substantial pro-
portion reporting each drug. The most common 
route was oral for both. Two people reported in-
haled/snorted/sniffed for oxycodone (compared with 
0 for methadone), and six people reported they in-
jected methadone, compared with none for oxy-
codone.  
 
In 2004, 198 calls about adults to the Help Line in-
volved OxyContin, compared with 9 for youth (ex-
hibit 4). There were 397 calls for “prescription pain 
pills” for adults in 2004 and 6 for youth. As a point 
of comparison, there were 589 calls about adult use 
of heroin in 2004. Categorization of calls to the 
Help Line for other opiates and prescription pain 
pills has changed over time, and categories are not 
mutually exclusive. 
 
Three types of prescription-type opiates are among 
the top 25 substances reported in the NFLIS data: 
oxycodone, hydrocodone, and methadone (exhibit 
6). For the Seattle area, these three substances to-
taled 2 percent in FY 2003 and 3 percent in FY 
2004. For the rest of the State, about 3 percent of 
seizures tested positive for these substances in both 
years. 
 
DEA data on sales of prescription-type opiates to 
hospitals and pharmacies in the King County area 
indicate that methadone sales have steadily in-
creased each year, with a total increase of 359 per-
cent from 1997 to 2003 (exhibit 11). Note that these 
data for methadone only include prescriptions for 
pain written by physicians; they do not include 
methadone provided in opiate treatment programs. 
Oxycodone prescriptions have continued to increase 
in recent years. Prescriptions for hydromorphone 
(80 percent), hydrocodone (93 percent), morphine 
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(88 percent), and fentanyl (174 percent) have all in-
creased as well. Codeine and meperidine prescriptions 
have both steadily declined, decreasing 27 percent and 
30 percent, respectively, between 1997 and 2003. 
 
Several diverse factors may impact these prescribing 
patterns: 1) increased advertising and promotion of 
pharmaceuticals generally, 2) guidelines promoting 
adequate use of opiates for management of pain re-
leased in 1996 by the Washington State Medical Qual-
ity Assurance Commission, and 3) recent efforts to 
shift to methadone and morphine as less expensive 
alternatives to other opiates by Washington State 
agencies administering publicly financed health care 
services. 
 
Marijuana 
 
Nearly one-half (47.8 percent) of those admitted to 
treatment in 2004 reported current marijuana use (ex-
hibit 2a). This represented a slight decline, but mari-
juana is still the most commonly reported illegal drug. 
Those reporting marijuana as their primary drug are 
much younger than other drug users overall: 45 per-
cent of users were younger than 18 in 2004 (exhibit 
2b). However, primary marijuana users are aging, as 
those younger than 18 represented 63 percent of users 
in 1999. 
 
Unweighted DAWN Live! data show marijuana ED 
reports totaled 1,160 in 2004, with 92 percent being 
drug abuse/other case type, followed by 6 percent 
seeking detox/treatment (exhibit 3a). More than two-
thirds were male, and patients were much younger 
than for other illegal drugs. Eleven percent were age 
12–17, and 42 percent were 18–29. Psychiatric condi-
tion was reported most commonly (27 percent), fol-
lowed by altered mental status (20 percent). 
 
Calls to the Help Line for marijuana constituted 51 
percent of youth-related calls and 21 percent of adult 
calls in 2004, similar to prior years (exhibit 4). 
 
Marijuana was the most commonly identified illegal 
drug used by high school seniors in Seattle’s school 
survey. Use in the prior 30 days was reported by 27.0 
percent in 2002 and 25.4 percent in 2004 (exhibit 5). 
 
Cannabis was the third most commonly identified sub-
stance in NFLIS data for both the Seattle area and the 
rest of Washington State in FYs 2003 and 2004 (ex-
hibit 6). In the Seattle area, 17 percent and 15 percent 
of seizures tested positive for cannabis in FYs 2003 
and 2004, respectively. Similar levels were seen in the 
rest of the State: almost 16 percent for both years. 
 
HIDTA data collected from King County law en-
forcement in 2003 show the following prices for 
marijuana: $10–$40 per gram, $250–$500 per ounce, 
and $2,200–$4,000 per pound. Price depends on the 
quality and a variety of other factors, but “BC Bud” 
from British Columbia, Canada, is widely available 
and the most expensive of the marijuana varieties 
available in King County. 
 
Stimulants 
 
Stimulants encompass a range of drugs, including 
methamphetamine, which is available almost exclu-
sively as an illicit drug. Amphetamines are primarily 
prescription drugs, d amphetamine (e.g., Dexedrine) 
for weight control, and dl amphetamine (e.g., Ad-
derall) for attention deficit disorder/ attention defi-
cit-hyperactivity disorder (ADD/ADHD). Another 
prescription medication for ADD/ADHD is methyl-
phenidate (e.g., Ritalin). 
 
Prescriptions for stimulant medications are up sub-
stantially. DL amphetamine (e.g., Adderall) sales 
increased 1,108 percent in the King County area 
from 1997 to 2003 (exhibit 12). D amphetamine 
(e.g., Dexedrine) sales increased 134 percent, and 
methylphenidate sales increased 66 percent over this 
same period. Note that Adderall was approved by 
the U.S. Food and Drug Administration (FDA) in 
1996 (i.e., fairly recently), while methylphenidate 
was approved in 1956 and Dexedrine was approved 
in 1948. 
 
The proportion of ADHL calls related to metham-
phetamine represented 18 percent of both adult and 
youth calls in 2004 (exhibit 4). Methamphetamine is 
the only substance for which youth and adults call in 
the same proportion. It is the second most common 
substance for youth and third most common for 
adult calls, similar to previous years. 
 
The proportion of treatment admissions for King 
County residents involving methamphetamine (ex-
hibit 2a) increased in 2004 after several years of 
stability. Approximately 14 percent of all people 
entering treatment mentioned methamphetamine as 
one of the drugs they used between 2001 and 2003; 
this increased to 16 percent in 2004. 
 
Treatment data indicate that primary methampheta-
mine users are much younger than heroin and cocaine 
users and older than marijuana users overall (exhibit 
2b). Only 5 percent of methamphetamine users were 
older than 45 in 2004, compared with 25 percent of 
cocaine, 40 percent of heroin, and 3 percent of mari- 
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juana users. Methamphetamine users showed the small-
est shift in age distribution from 1999 to 2004, with the 
only group showing any change being those age 45–54; 
their proportion increased from 3 to 5 percent. 
 
Deaths involving methamphetamine were level in 
2003 and 2004 at a new high of 18 per year, up from 3 
in 1997 (exhibit 7a). Since 1997, the average age of 
decedents with methamphetamine involved was 37.9, 
lower than the average for all drugs (exhibit 7d). How-
ever, the average age in 2004 was 42.8, higher than 
any previous year. 
 
Deaths involving the category of prescription stimu-
lants totaled 12 for the 8 years of detailed data (exhibit 
7a). This is a small number, but it appears to have in-
creased slightly; given the increase in prescriptions for 
these substances, as well as national survey data show-
ing increasing use and misuse, these cases were exam-
ined. The fact that these data are based on tiny num-
bers should be kept in mind.  
 
Overall, prescription stimulant-involved deaths had the 
lowest average age for all substances: 33.8, compared 
with 41.6 for all drugs (exhibit 7d). Whites represented 
92 percent of deaths—the highest of any drug. Cause 
of death was accident 92 percent of the time, among 
the highest for all drugs, and the average number of 
drugs was much higher than for any other substance: 
4.2 compared with 2.3 on average for all drugs. The 
use patterns of the two prescription stimulants are 
characterized below. 
 
Amphetamine deaths totaled six from 1997 to 2004, 
with a roughly even distribution over that time. The 
average age of decedents was 31 (range=22–41). One 
death involved only amphetamine. The average num-
ber of drugs involved was 3.3 All combination deaths 
included an opiate plus at least one other drug. 
 
Methylphenidate-involved deaths also totaled six from 
1997 to 2004. However, three were in 2004 and one 
was in 2003. Decedents were age 36.7 on average 
(range=28–53), and the average number of drugs de-
tected was 5.0. All but one death also involved an opi-
ate of some kind. 
 
According to unweighted data accessed from DAWN 
Live!, 89 percent of methamphetamine ED reports in 
2004 were because of drug abuse/other, and 10 percent 
were seeking detox/treatment (exhibit 3a). Seventy 
percent were male, and most patients were White. 
Methamphetamine patients were younger than heroin 
and cocaine patients, but older than marijuana patients 
overall. Similar proportions, just under one- quarter, of 
complaints were for psychiatric condition and altered 
mental status. The next most common complaint was 
abscess/cellulitis/skin/tissue (8 percent). Fifteen per-
cent of methamphetamine-involved patients were 
referred to detox/treatment, a larger proportion than 
for the other common illegal drugs. 
 
Use of methamphetamine in the past 30 days was 
relatively low among Seattle high school seniors: 1.1 
percent in 2002 and 2.0 percent in 2004 (exhibit 5). 
 
A category of amphetamine was added to the Help 
Line data in 2003 (exhibit 4). There were 18 adult 
calls and 0 youth calls about amphetamine in 2004, 
though there may be underreporting because of an 
overlapping category of “prescription drugs.” 
 
Federal law enforcement sources report that less 
methamphetamine is being manufactured in Wash-
ington, but that demand is being met by an increase 
in supply from Mexico and Mexican groups in Cali-
fornia.  
 
Anecdotal information from both users and law en-
forcement indicates that “ice” (crystal metham-
phetamine) distribution has increased in Seattle and 
that in some areas of Seattle, “ice” has supplanted 
powder methamphetamine in terms of availability. 
 
The DEA reports that crystal methamphetamine is 
increasingly available and that prices are slowly 
declining. Regarding purity, the DEA reports: “The 
overall purity of exhibits collected in Washington 
for the first six months of FY 2004 has averaged 50 
percent, up from the average purity of 45 percent 
seen during FY03 and surpassing the 30 percent 
seen during FY01 and FY02. Of the DEA offices in 
Washington, Seattle exhibits have currently yielded 
the highest purity at nearly 66 percent.” 
 
Methamphetamine incidents, a combination of ac-
tive labs used for manufacturing and dump sites of 
lab equipment or inactive labs, decreased for Wash-
ington State as a whole in 2004 (exhibit 13). The 
peak in incidents for the State and the two most 
populated counties was in 2001. In King County, the 
number of incidents remained flat in 2003 and 2004, 
while Pierce County to the south experienced in-
creases, Snohomish County to the north had a slight 
increase, and Kitsap County to the west experienced 
a small decline. The rate of methamphetamine inci-
dents per 100,000 population was 11 in King 
County, 77 in Pierce County, 17 in Snohomish 
County, 19 in Kitsap County, and 23 for Washing-
ton State in 2004.  
 
It is important to note that these data do not indicate 
the manufacturing methods or the quantities manu-
factured at the site of individual incidents. Reports 
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from law enforcement indicate that “super” labs, those 
capable of producing large amounts of methampheta-
mine quickly, represent a small minority of manufac-
turing labs in the State. 
 
NFLIS data indicate that methamphetamine is found in 
law enforcement seizures at a much lower level in the 
Seattle area compared with the rest of the State (ex-
hibit 6). In FY 2004, 29 percent of Seattle-area drug 
tests and 52 percent of drug tests for the rest of Wash-
ington were positive for methamphetamine. These data 
represent slight proportional increases from FY 2003. 
 
Data from the Washington State Patrol’s Toxicology 
laboratory show a more than fivefold increase, from 
less than 100 to more than 500, in the number of driv-
ers testing positive for methamphetamine in DUI cases 
from 1997 to 2004. At the same time, the number of 
deaths in which methamphetamine was identified 
more than doubled to slightly more than 200 (note that 
methamphetamine may or may not have been causa-
tive in the death). 
 
Depressants 
 
Barbiturates, benzodiazepines, and other sedative/ 
depressant drugs in this analysis include alprazolam 
(Xanax), diazepam (Valium), lorazepam (Ativan), 
clonazepam (Klonopin), temazepam (Restoril), tria-
zolam (Halcion), oxazepam (Serax), butalbital 
(Fioricet), chlordiazepoxide (Librium), diphenhy-
dramine (Benadryl), hydroxyzine pamoate (Vistaril), 
meprobamate (Equanil), phenobarbital, promethazine 
(Phenergan), secobarbital (Seconal), and zolpidem 
(Ambien). 
 
Depressants are rarely mentioned as a primary drug at 
intake to drug treatment. Less than 1 percent of admis-
sions were for benzodiazepines, barbiturates, major 
tranquilizers, and other sedatives. A slight increase 
appears to have occurred, with 20 admissions for these 
4 drug categories as the primary drug at treatment en-
try in 1999 and 51 in 2004. Key informants report that 
these drugs are commonly used to enhance the effects 
of other drugs and are rarely taken as the primary drug 
recreationally. 
 
Deaths involving depressants were at the highest level 
since at least 1997 with 82 in 2004, up from 71 in 2003 
(exhibit 7a). A steady increase has occurred since 1999. 
As discussed in the other opiate section in detail, the 
most common co-ingestent was a prescription-type opi-
ate, representing 20 percent of deaths in 2004 (exhibit 
7e). Other co-ingestents included cocaine (9 percent) and 
alcohol and heroin/opiate/morphine (both 8 percent). 
The oldest group of decedents was those with de-
pressants identified: 43.8 on average (exhibit 7d). 
An increase from 41.9 to 45.9 years of age was seen 
over the span of available data. A relatively large 
proportion were female: 43 percent. The manner of 
death was ruled accidental 63 percent of the time 
and suicide 24 percent of the time. Suicides were 
more than twice as common for depressants than for 
any other drug. The average number of drugs identi-
fied was 3.5, more than the 2.3 seen on average. 
 
The two most prevalent depressants in 2004 and for 
the prior 7 years were diazepam and diphenhy-
dramine (exhibit 7b). Diazepam-involved deaths 
totaled 142 from 1997 to 2004, with 23 in 2004, a 
bit below the peak of 27 in 2003 and at the higher 
end of levels seen during this time. Diphenhy-
dramine-involved deaths totaled 111 over this same 
time frame, but showed a clear increase over the 
years, with a peak of 29 in 2004. 
 
Single-drug deaths were infrequent for depressants 
(6 percent), compared with all drug-involved deaths 
(29 percent) from 1997 to 2004 (exhibit 7f), mean-
ing that the vast majority of depressant-involved 
deaths involved multiple substances. Illegal drugs 
were present in two-thirds of all drug-involved 
deaths (exhibit 7g), but only in a minority of depres-
sant-involved deaths (44 percent). It is likely that 
most people using depressants in combination with 
illegal drugs were attempting to get “high.” The 
proportion of accidental over-medications versus 
those seeking a high is not known. 
 
Unweighted DAWN ED drug reports for depres-
sants (barbiturates, benzodiazepines, and anxio-
lytics/ sedatives/hypnotics) totaled 1,218 for all case 
types in 2004 (exhibit 3a). The most common case 
type was overmedication (40 percent), followed by 
drug abuse/other (28 percent), suicide attempt (16 
percent), and adverse reaction (11 percent).  
 
The most common substances in ED drug 
abuse/other reports were benzodiazepines (350 of 
420 reports, 83 percent), with type-not-specified the 
most common, followed by alprazolam (n=83), 
clonazepam (n=58), lorazepam (n=43), and diaze-
pam (n=38). Miscellaneous anxiolytics totaled just 
41 reports; diphenhydramine was the most common 
(n=12). Barbiturates totaled 29 cases, the majority 
with the type not specified. 
 
NFLIS data showed that approximately 1 percent of 
exhibits from the Seattle-area lab and the rest of the 
State were benzodiazepines (i.e., diazepam, and 
clonazepam), with no change between FY 2003 and 
FY 2004 (exhibit 6). 
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A benzodiazepine category was added to the Help 
Line data in 2003; there were 81 adult calls and 1 
youth call in 2004 (exhibit 4). 
 
Hallucinogens, Club Drugs, and  
Dextromethorphan 
 
Hallucinogens include lysergic acid diethylamide 
(LSD), mescaline, peyote, psilocybin (mushrooms), 
phencyclidine (PCP), and inhalants. “Club drugs” is a 
general term used for drugs that are popular at night-
clubs and raves, including the hallucinogens, methyl-
enedioxymethamphetamine (MDMA) (ecstasy), gamma 
hydroxybutyrate (GHB), gamma butyrolactone (GBL), 
ketamine, and nitrous oxide. Dextromethorphan, com-
monly found in over-the-counter cough medicines, can 
have dissociative effects at high dosages.  
 
Research chemicals are another important class of 
drugs used locally, however few indicator data are 
currently able to monitor these substances. Limitations 
in tracking these substances include a lack of aware-
ness of these substances by many providers, the con-
tinually fluctuating substances utilized locally, and the 
multiple, often confusing, names of these substances 
(e.g., foxy methoxy, 2CB, 2CT7). A community-based 
survey conducted in the summer of 2003 found that 21 
percent of subjects surveyed at rave venues in King 
County had ever used research chemicals. 
 
An important new development involving dextro-
methorphan occurred in April 2005 in Whatcom 
County, Washington, north of Seattle. Two teenage 
boys, ages 17 and 19, died after consuming dextro-
methorphan obtained in “wholesale quantities” from a 
chemical company on the Internet, based in Indiana. 
Three other deaths in the United States were also 
linked to this company; as of this writing, the FDA has 
shut down the Web page. These local boys mixed the 
dextromethorphan in an energy drink, and high levels 
of taurine and caffeine from the drink were detected 
along with marijuana. 
 
Treatment admissions in which hallucinogens are 
mentioned as primary drug are infrequent, with just 44 
in 2004, up from 16 in 1999. 
 
Unweighted ED reports in DAWN Live! for all case 
types totaled 85 for PCP, 91 for ecstasy, 17 for GHB, 
23 for LSD, and 53 for psilocybin. 
 
Help Line calls regarding PCP and LSD were infre-
quent, representing less than 1 percent of both youth 
and adult calls in recent years (exhibit 4). Calls involv-
ing MDMA have declined in terms of number and 
proportion since 2001 for both adults and youth,  
 
though the large number of calls for unknown sub-
stances limits trend analysis. In 2001, MDMA rep-
resented 2.5 percent of adult calls; this proportion 
declined to 1.2 percent in 2004. A similar decline 
was seen for youth calls, from 8.7 percent in 2001 to 
4.4 percent of calls in 2004. Calls mentioning the 
more general term “hallucinogens” have remained 
small, but consistent, for adults (about 1 percent of 
calls over time). For youth, hallucinogen-related 
calls appear to have declined from 4 percent to 2 
percent of calls from 2001 to 2004. 
 
School survey data indicate that hallucinogens and 
MDMA are the second most common illicit sub-
stances used in the past month following marijuana 
(exhibit 5). Hallucinogens, broadly defined, were 
reported by 2.5 percent of seniors and MDMA was 
reported by 2.8 percent in 2004. 
 
The combined category of dextromethorphan, 
MDMA, GHB, and PCP was identified in 37 deaths 
since 1997. This group was younger, 36.3, than for 
all drugs on average and had the largest proportion 
of females (43 percent).  
 
There were two MDMA-involved deaths in 2004. 
There have been between one and two MDMA-
involved deaths since 1999, with none in 1997 or 
1998. GHB/GBL-involved deaths totaled three in 
2002; none have been reported since, and none were 
noted prior. There were 5 dextromethorphan-
involved deaths in 2004, a decrease from the 10 in 
2003 (which was by far the highest level since at 
least 1997). PCP deaths totaled two in 2004 and one 
in 2002. 
 
According to the NFLIS, MDMA was detected at 
slightly higher levels in the Seattle-area lab than the 
rest of the State (exhibit 6). The Seattle-area lab 
reported 1.4 and 1.0 percent of evidence tested posi-
tive for MDMA in FY 2003 and FY 2004, while for 
the rest of the State the levels were 0.5 percent in 
each year. Psilocin, the active ingredient in psyche-
delic mushrooms, was seen at similar levels for each 
region and in each year, between 0.5 and 0.7 per-
cent. PCP was not among the top 25 drugs detected 
in Washington, not including Seattle, while in Seat-
tle it represented a bit less than 1 percent of evi-
dence in each year. 
 
Pill presses, necessary for tableting ecstasy, are still 
occasionally seized locally according to Federal law 
enforcement sources. Past customs seizure data in-
dicated that much of the MDMA entering Washing-
ton was in powder form, suggesting that it was to be 
used in creating ecstasy tablets. 
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Federal law enforcement reports that “…crime related 
to MDMA distribution has increased in areas such as 
Seattle because of the introduction of polydrug traf-
fickers distributing MDMA.” Additionally, the U.S. 
Postal Inspection Service reported that Seattle had the 
third highest amount of MDMA dosages seized in 
2003. 
 
Limited availability of LSD was reported by Federal 
law enforcement sources. However, in February 2004, 
DEA and the Seattle Police Department arrested an 
individual who had chemicals, glassware, and instruc-
tions for making LSD. 
 
INFECTIOUS DISEASES RELATED TO DRUG ABUSE AND 
INJECTION DRUG USE TRENDS 
 
Available data for people diagnosed with HIV infec-
tion between 1996 and 2004 are presented in exhibit 
14. In King County, injection drug users (IDUs) and 
men who have sex with men and also inject drugs 
(MSM/IDUs) both represent 7 percent of recent HIV 
cases. For Washington State as a whole, IDUs repre-
sent 10 percent and MSM/IDUs represent 6 percent. 
 
Excepting male drug injectors who also have sex with 
men, the rate of HIV infection among the 15,000–
18,000 IDUs who reside in King County has remained 
low and stable over the past 14 years. Various serosur-
veys conducted in methadone treatment centers and 
correctional facilities and through street and commu-
nity-targeted sampling strategies over this period indi-
cate that 4 percent or less of IDUs who are not MSM 
in King County are infected with HIV. Data from a 
CDC-funded HIV Incidence Study (HIVIS 1996–
2001) suggest that the rate of new infections among 
non-MSM/non-IDUs in King County is less than 0.1 
percent per year. 
 
Syringes exchanged and numbers of encounters have 
remained high in King County, with more than 2 mil-
lion syringes exchanged and more than 60,000 en-
counters in 2004 (exhibit 15). 
 
Hepatitis B and C are endemic among Seattle-area 
injectors. Epidemiologic studies conducted among 
more than 4,000 IDUs by Public Health’s HIV-
AIDS Epidemiology Program between 1994 and 
1998 reveal that 85 percent of King County IDUs 
may be infected with hepatitis C (HCV), and 70 
percent show markers of prior infection with hepati-
tis B (HBV). Local incidence studies indicate that 
21 percent of non-infected IDUs acquire HCV each 
year, and 10 percent of IDUs who have not had 
hepatitis B acquire HBV. 
 
Trends In Primary Injection Drug Use In Seattle-
Area Idus Age 18–30 Participating In 4 Studies, 
1994–2003 (Authored by Richard Burt and Hanne 
Thiede, Public Health-Seattle & King County) 
 
Four different studies of Seattle-area IDUs were 
conducted by Public Health – Seattle & King 
County from 1994 to 2003. They are the RAVEN 
(1994–1997), RAVEN II (1998), Kiwi (1998–2002), 
and DUIT (2002–2003) studies. The four study 
populations were each recruited by different strate-
gies, and there are statistically significant differ-
ences among the study populations in age, race, sex, 
and primary injection drug. The data show trends in 
primary injection drug by year of study enrollment 
among 18–30-year-old IDUs who had injected in the 
6 months prior to enrollment (exhibit 16). 
 
Heroin was the most common primary injection 
drug in all study populations and in all years. There 
was a clear increase in the proportion of participants 
reporting amphetamine as their primary injection 
drug, from 7 percent in 1994 to 32 percent in 2003. 
The proportion reporting cocaine as their primary 
drug declined from 19 percent in 1994 to 5 percent 
in 2004. There does not appear to be a single consis-
tent trend in heroin or speedball use.  
 
For inquiries concerning this report, please contact Caleb Banta-
Green, MPH, MSW, Alcohol and Drug Abuse Institute, Univer-
sity of Washington, 1107 NE 45th St, Suite 120; Seattle, WA 
98105, Phone: (206) 685-3919, Fax: (206) 543-5473, E-mail: 
<calebbg@ u.washington.edu>, Web: http://adai.washington.edu 
or Ron Jackson, MSW, Evergreen Treatment Services, Phone 
(206) 223-3644, E-mail: ronjack@u.washington.edu. 
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Exhibit 1. King and Snohomish Counties
1
 DAWN ED Sample and Reporting Information:   
 January–December 2004 
 
No. of EDs Reporting per Month: Com-
pleteness of Data (%)  Total Eligible 
Hospitals
2
 
No. of Hospi-
tals in DAWN 
Sample 
Total EDs in 
DAWN Sam-
ple
3
 90–100% 50–89% <50% 
No. of EDs 
Not Report-
ing 
22 22 23 8–12 0–2 0–4 10–13 
 
1
Note that the 23 hospitals in the Seattle-area sample are in King, Snohomish, and Pierce Counties. As of June 2005, none of the 
four counties in the sample from Pierce County are participating. Therefore, available data are presently just from Snohomish and 
King Counties. 
2
Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association An-
nual Survey. 
3
Some hospitals have more than one emergency department. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/13–4/14, 2005  
 
 
 
 
Exhibit 2a. Treatment Admissions for Primary, Secondary, or Tertiary Use of Selected Drugs Among  
 Residents of King County, Washington, by Percent:  1999–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary, Secondary, or 
Tertiary Drug 
1999 2000 2001 2002 2003 2004 
Alcohol 79.9 78.1 77.4 75.7 74.4 70.3 
Methamphetamine 9.1 11.4 14.0 13.9 13.9 16.3 
Cocaine 44.5 44.6 42.0 39.9 38.7 40.1 
Marijuana 50.6 51.3 52.4 49.5 50.3 47.8 
Heroin 25.7 26.0 22.5 22.0 19.8 21.6 
Total Admissions 9,845 10,479 9,761 8,871 8,879 11,223 
 
Data include all ages, all treatment modalities, Department of Corrections, and private pay clients at opiate substitution treatment 
clinics. 
SOURCE:  Washington State Treatment and Assessment Report Generation Tool (TARGET) data system—Structured Ad Hoc 
Reporting System 
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Exhibit 2b. Age at Treatment Entry by Primary Drug, for King County, Washington, Admissions:  
1999 and 2004 
 
Cocaine Alcohol Marijuana Heroin Methamphetamine Age at  
Treatment Entry 1999 2004 1999 2004 1999 2004 1999 2004 1999 2004 
17 and younger 2.7 2.5 7.7 7.3 62.8 44.9 0.5 0.5 7.4 6.8 
18–29 15.6 12.4 20.5 22.6 23.8 33.2 16.6 16.8 41.5 39.6 
30–44 69.9 60.4 51.9 44.5 11.5 18.6 53.0 42.3 48.2 48.4 
45–54 10.4 22.6 15.9 20.6 1.8 2.8 27.2 34.0 2.8 5.0 
55–64 1.1 2.1 3.6 4.6 0.1 0.5 2.5 5.8 0.0 0.3 
65 and older 0.2 0.1 0.5 0.4 0.0 0.1 0.3 0.7 0.0 0.0 
 
SOURCE:  Washington State Treatment and Assessment Report Generation Tool (TARGET) data system—Structured Ad Hoc 
Reporting System 
 
 
 
Exhibit 2c. Racial Categories of Treatment Admissions
1
 in King County, Washington, by Primary Drug and  
 Percent:  2004 
 
Racial Category 
Alcohol 
(n=3,912) 
Cocaine 
(n=1,592) 
Heroin 
(n=2,000) 
Metham-
phetamine 
(n=1,109) 
Marijuana 
(n=2,064) 
Other 
(n=572) 
Percent of 
Total  
Admissions 
by Race 
White 53 37 67 83 46 73 56 
African-American 18 47 17 2 31 9 22 
Asian/Pacific Islander 5 2 2 2 4 4 3 
Native American 7 2 4 2 3 3 4 
Hispanic 10 6 7 5 8 5 8 
Multiple Race 3 3 2 3 6 4 3 
Other 5 3 2 3 2 3 3 
 
1
N=11,249 
SOURCE:  Washington State Treatment and Assessment Report Generation Tool (TARGET) data system—Structured Ad Hoc 
Reporting System 
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Exhibit 3a. Drug Reports
1
 in Drug-Related ED Visits in King and Snohomish Counties, by Drug Category  
 (Unweighted
2
) and Percent:  2004 
 
 
Major 
Sub-
stances 
of Abuse
3
 
Cocaine Heroin Meth Marijuana Rx Opiates 
Anx/Sed/ 
Hyp 
Number of Drug Reports 10,002 2,725 2,171 857 1,160 1,956 1,218 
Type of Case        
Suicide attempt 3.7 1.2 0.5 1.2 2.1 4.6 15.9 
Seeking detox 8.3 9.9 9.5 9.5 5.8 8.4 4.4 
Adverse reaction 0.8 0.1 0.2 0.0 0.2 21.0 11.2 
Overmedication 2.5 0.0 0.0 0.0 0.0 24.7 39.8 
Malicious poisoning 0.1 0.1 0.0 0.0 0.2 0.2 0.1 
Accidental ingestion 0.1 0.0 0.0 0.0 0.0 0.3 0.7 
"Drug Abuse"/Other 80.5 88.7 89.7 89.4 91.8 40.8 27.9 
Gender        
Male 63.6 64.4 60.1 69.8 68.9 47.4 40.8 
Race/Ethnicity        
White 23.8 18.2 32.2 27.7 24.0 23.6 27.4 
Black 8.6 14.9 6.1 3.7 8.8 4.4 2.2 
Hispanic 1.0 1.3 0.9 0.8 1.0 0.8 0.4 
Race/ethnicity NTA 1.6 1.4 1.2 2.8 1.8 1.5 1.1 
Not documented 65.1 64.3 59.6 65.0 64.4 69.6 68.9 
Age Group        
12–17 4.8 1.1 0.3 1.9 10.7 2.4 4.2 
18–20 8.9 3.2 2.9 12.8 15.2 4.6 3.4 
21–24 9.1 6.6 6.8 17.2 13.2 7.1 8.7 
25–29 12.3 10.6 12.6 18.7 13.7 9.5 12.9 
30–34 13.5 14.5 16.1 13.4 14.3 10.2 11.9 
35–44 30.0 37.8 33.3 25.7 20.6 26.3 28.6 
45–54 17.7 22.5 24.3 8.5 9.9 23.8 20.2 
55–64 2.9 3.3 3.2 1.4 1.7 8.0 6.2 
65 and older 0.5 0.3 0.5 0.1 0.5 7.9 3.0 
Chief Complaint        
Overdose 8.5 5.1 9.8 4.1 5.3 17.7 32.7 
Intoxication 7.9 4.7 1.6 4.4 6.6 2.5 5.0 
Seizures 1.2 1.9 0.6 0.7 0.9 0.6 1.1 
Altered mental status 15.7 15.7 9.1 22.8 20.3 15.0 14.8 
Psychiatric condition 18.6 23.6 7.2 23.9 27.0 10.6 18.1 
Withdrawal 2.7 2.3 4.7 1.8 2.0 11.6 4.6 
Seeking detox 5.4 6.4 6.3 6.1 3.9 5.2 2.6 
Accident/injury/assault 3.9 3.6 2.1 3.2 5.3 1.8 1.3 
Abscess/cellulitis/skin/tissue 11.6 7.1 39.1 8.4 1.8 3.9 1.5 
Chest pain 3.8 6.3 1.6 4.8 3.6 1.8 1.4 
Respiratory problems 3.4 4.3 3.2 2.3 3.1 3.1 2.0 
Digestive problems 4.1 4.3 4.2 1.8 4.1 10.6 3.5 
Other 13.2 14.8 10.6 15.6 16.2 15.8 11.3 
Number of Complaints 14,646 3,940 2,891 1,259 1,688 2,909 1,959 
(Continued) 
 
1
Drug-related ED visits often involve multiple drugs (e.g., both cocaine and heroin may be reported for the same visit).  Therefore, 
the number of drug reports will exceed the number of ED visits. 
2
Unweighted data are from 10–13 Seattle EDs reporting to DAWN. All DAWN cases are reviewed for quality control. Based on this 
review, cases may be deleted and corrected and, therefore, are subject to change. Data are duplicated; a person may have used 
multiple drugs. This can lead to odd data, such as suicide attempts that appear to involve marijuana. These data are not estimates 
or rates. 
3
Major Substances include all of the illegal drugs, as well as amphetamine and GHB. 
SOURCE: DAWN Live!, OAS, SAMHSA, updated 5/23/05 
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Exhibit 3a. Drug Reports
1
 in Drug-Related ED Visits in King and Snohomish Counties, by Drug Category  
 (Unweighted
2
) and Percent:  2004 (Continued) 
 
 
Major 
Sub-
stances 
of 
Abuse
3
 
Cocaine Heroin Meth Marijuana Rx Opiates 
Anx/Sed/ 
Hyp 
Patient Disposition        
Discharged home 54.1 49.6 55.5 52.5 58.5 60.7 48.9 
Released to police/jail 2.3 2.6 2.3 3.6 2.2 1.5 1.1 
Referred to detox/treatment 10.2 12.4 6.8 14.6 11.2 7.7 6.2 
Admitted to ICU/Critical care 4.1 4.0 1.6 3.6 4.3 5.5 12.6 
Admitted to surgery 2.1 1.1 6.3 1.3 0.3 0.5 0.2 
Admitted to chem. dependency/detox 2.4 2.8 2.8 1.6 1.6 1.9 1.6 
Admitted to psychiatric unit 4.3 5.7 1.8 4.7 5.3 3.3 7.6 
Admitted to other inpatient unit 9.9 10.6 13.8 7.4 6.1 10.6 11.8 
Transferred 3.4 3.8 1.7 2.8 4.3 4.0 4.5 
Left against medical advice 1.8 1.4 3.0 2.9 0.9 1.3 1.6 
Died 0.0 0.1 0.0 0.0 0.0 0.0 0.0 
Other 2.3 2.6 1.2 2.9 2.8 1.2 1.4 
Not documented 3.1 3.4 3.2 2.1 2.4 1.8 2.4 
Route of Administration        
Oral 19.8 1.8 0.8 2.0 1.7 44.1 49.8 
Injected 18.1 9.7 61.1 17.9 0.3 3.4 1.0 
Inhaled, sniffed, snorted 1.2 2.5 0.6 2.0 0.4 0.4 0.0 
Smoked 7.9 12.7 0.6 7.0 29.4 0.1 0.0 
Other 0.2 0.3 0.2 0.6 0.3 1.6 0.3 
Not documented 52.8 73.0 36.8 70.6 67.9 50.4 48.9 
 
1
Drug-related ED visits often involve multiple drugs (e.g., both cocaine and heroin may be reported for the same visit).  Therefore, 
the number of drug reports will exceed the number of ED visits. 
2
Unweighted data are from 10–13 Seattle EDs reporting to DAWN. All DAWN cases are reviewed for quality control. Based on this 
review, cases may be deleted and corrected and, therefore, are subject to change. Data are duplicated; a person may have used 
multiple drugs. This can lead to odd data, such as suicide attempts that appear to involve marijuana. These data are not estimates 
or rates. 
3
Major Substances include all of the illegal drugs, as well as amphetamine and GHB. 
SOURCE: DAWN Live!, OAS, SAMHSA, updated 5/23/05  
 
 
 
 
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Seattle-King County Area 
 
 
Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005 264
Exhibit 3b. Number of Drug Reports
1
 in Drug-Related ED Visits in King and Snohomish Counties,  by Drug 
 Category (Unweighted
2
):  2004   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
Drug-related ED visits often involve multiple drugs (e.g., both cocaine and heroin may be reported for the same visit).  Therefore, 
the number of drug reports will exceed the number of ED visits. 
2
Unweighted data are from 10–13 Seattle EDs reporting to DAWN. All DAWN cases are reviewed for quality control. Based on this 
review, cases may be deleted and corrected and, therefore, are subject to change. Data are duplicated; a person may have used 
multiple drugs. This can lead to odd data, such as suicide attempts that appear to involve marijuana. These data are not estimates 
or rates. 
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–4/14, 2005
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Exhibit 3c. Characteristics of Drug Abuse/Other Case Type Drug Reports
1 
for Prescription-Type Opiates and  
 Depressants (Unweighted
2
) in King and Snohomish Counties, by Percent:  2004  
 
Rx Opiate Anx/Sed/Hyp 
Characteristic # of Drug Reports 
n=799 n=340 
Gender Male 53 55 
Age 12–17 years 1 2 
 18–20 years 4 3 
 21–24 years 7 8 
 25–29 years 10 12 
 30–34 years 13 14 
 35–44 years 31 31 
 45–54 years 27 22 
 55–64 years 8 6 
 65 years and older 1 1 
Chief Complaint Overdose 8 15 
 Intoxication 3 6 
 Seizures 1 3 
 Altered mental status 15 15 
 Psychiatric condition 14 21 
 Withdrawal 23 13 
 Seeking detox 0 0 
 Accident/injury/assault 2 2 
 Abscess/cellulitis/skin/tissue 4 1 
 Chest pain 2 3 
 Respiratory problems 3 1 
 Digestive problems 9 4 
 Other 16 15 
 Total Complaints (N) 1,205 539 
Patient Disposition Discharged home 62 53 
 Released to police/jail 3 3 
 Referred to detox/treatment 10 13 
 Admitted to ICU/Critical care 3 4 
 Admitted to surgery 1 1 
 Admitted to chemical dependency/detox 2 1 
 Admitted to psychiatric unit 4 4 
 Admitted to other inpatient unit 10 9 
 Transferred 2 4 
 Left against medical advice 2 3 
 Died 0 0 
 Other 1 1 
 Not documented 2 4 
Route Of Administration Oral 33 32 
 Injected 5 1 
 Inhaled, sniffed, snorted 0 0 
 Smoked 0 0 
 Other 1 0 
 Not documented 61 67 
 
1
Drug-related ED visits often involve multiple drugs (e.g., both cocaine and heroin may be reported for the same case).  Therefore, 
the number of drug reports will exceed the number of ED visits. 
2
Unweighted data are from 10–13 Seattle-area EDs reporting to DAWN. All DAWN cases are reviewed for quality control. Based on 
this review, cases may be corrected or deleted and, therefore, are subject to change. These are not estimates or rates. 
SOURCE: DAWN Live!, OAS, SAMHSA, updated 5/23/05 
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Exhibit 4. Illicit Drug Help Line Calls for King County Residents, by Drug and Percent: 2001–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Percent of Adult Calls, by Drug Percent of Youth Calls, by Drug 
Drug 
2001 2002 2003 2004 2001 2002 2003 2004 
RX 9.5 11.0 5.4 4.4 4.1 3.1 3.0 2.4 
Methadone 2.0 2.0 3.2 3.9 0.5 0.0 0.4 0.0 
Other 1.2 1.3 2.2 1.6 0.9 2.0 2.5 1.6 
LSD 0.5 0.1 0.1 0.1 0.0 0.0 0.0 0.5 
Marijuana 21.0 20.3 18.2 20.5 42.3 49.6 52.9 50.6 
Inhalant 0.2 0.3 0.1 0.1 1.0 1.0 0.7 0.2 
Unknown 9.1 11.2 2.5 2.1 11.3 11.0 3.7 3.8 
Heroin 11.2 12.3 16.0 14.8 1.9 1.7 2.5 3.8 
Cocaine 23.5 23.6 32.6 31.6 7.8 9.7 9.8 11.7 
Ecstasy 2.5 1.4 1.0 1.2 8.7 4.9 3.3 4.4 
Hallucinogens 0.6 0.6 0.6 0.8 3.8 1.0 2.5 1.6 
PCP 0.1 0.1 0.1 0.3 0.0 0.0 0.4 0.5 
Methamphetamine 18.2 15.6 17.9 18.4 17.0 15.5 17.3 17.7 
OTC 0.4 0.2 0.3 0.2 0.6 0.6 1.2 0.9 
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
Total Number of Calls 4,639 4,760 3,508 3,978 1,162 711 571 547 
Newer Drug Categories         
OxyContin   20 198   16 9 
Rx Pain Pills   366 397   16 6 
Amphetamine   31 18   2 0 
Benzodiazepine   59 81   1 1 
 
SOURCE:  Washington State 24-Hour Alcohol and Drug Helpline 
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Exhibit 5. Drug Use in Prior 30 Days by 12th Graders in the Seattle Public Schools Communities That Care  
 Survey:  2002 and 2004 
 
Prevalence Response Rate 
2002 2004 Substance 
2002 2004 
% N % N 
Alcohol 47.9 51.1 51.3 1,287 61.0 1,475 
Cigarettes 22.8 16.1 52.0 1,305 61.3 1,481 
Chewing Tobacco 3.9 3.2 51.8 1,301 61.3 1,481 
Inhalants 2.1 1.4 50.0 1,256 60.0 1,451 
Marijuana 27.0 25.4 50.7 1,273 60.6 1,464 
Hallucinogens 3.6 2.5 50.4 1,265 60.5 1,462 
Cocaine 1.7 2.5 50.4 1,266 60.3 1,457 
MDMA (Ecstasy) 3.4 2.8 50.3 1,263 60.4 1,461 
Stimulants (Amphetamines, 
Methamphetamine) 
1.1 2.0 49.8 1,250 59.8 1,445 
 
SOURCE: Communities That Care Survey, http://www.seattleschools.org/area/ctc/survey/survey.xml 
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Exhibit 6. National Forensic Laboratory Information System Drug Test Results for Local Law Enforcement  
 Seizures in Seattle and the State of Washington:  FYs 2003 and 2004 
 
Seattle-Area Lab    WA State Without Seattle-Area Lab  
Substance FY 2003 FY 2004  Substance FY 2003 FY 2004 
Acetaminophen 0.3 0.2  Acetaminophen 0.2 0.1 
Alprazolam** 0.3 0.1  Alprazolam** 0.2 0.2 
Amphetamine 0.3 0.2  Amphetamine 0.3 0.4 
Caffeine 0.3 0.2  Caffeine 0.2 0.2 
Cannabinol     Cannabinol 0.2   
Cannabis 17.2 15.3  Cannabis 15.5 15.6 
Carisoprodol 0.3    Carisoprodol 0.2 0.1 
Cathinone 0.3    Cathinone    
Clonazepam** 0.5 0.3  Clonazepam** 0.3 0.3 
Cocaine 40.5 40.4  Cocaine 20.6 18.2 
Codeine* 0.2    Codeine* 0.2 0.1 
Diazepam** 0.4 0.3  Diazepam** 0.4 0.3 
Heroin 5.0 4.7  Heroin 6.5 4.8 
Hydrocodone* 0.7 0.9  Hydrocodone* 1.1 1.3 
Hydromorphone*  0.1  Hydromorphone*    
Ibuprofen     Ibuprofen  0.1 
Ketamine 0.1    Ketamine    
Lorazepam**  0.1  Lorazepam**    
MDA 0.3 0.3  MDA 0.1   
MDMA 1.4 1.0  MDMA 0.5 0.5 
Methadone* 0.4 0.7  Methadone* 0.4 0.6 
Methamphetamine 27.2 29.4  Methamphetamine 47.8 51.7 
Methandrostenolone 
(Methandienone) 0.1    
Methandrostenolone 
(Methandienone)    
Methylphenidate  0.3  Methylphenidate 0.1 0.1 
Morphine* 0.2 0.3  Morphine* 0.3 0.4 
Non-Controlled Non-Narcotic Drug 0.3 0.3  Non-Controlled Non-Narcotic Drug 0.5 0.7 
Oxycodone* 0.9 1.4  Oxycodone* 1.2 1.1 
PCP 0.9 0.6  PCP    
Propoxyphene*  0.1  Propoxyphene*  0.1 
Pseudoephedrine 0.7 0.4  Pseudoephedrine 0.8 0.7 
Psilocin 0.7 0.6  Psilocin 0.5 0.7 
Psilocybine  0.3  Psilocybine 0.3 0.2 
Sodium Bicarbonate     Sodium Bicarbonate 0.2 0.2 
Total of Top 25 (#) 99.25 
(3,188) 
98.83 
(3,454) 
 Total of Top 25 (#) 98.62 
(12,162) 
98.63 
(11,926) 
Subtotals: *Other opiates 2.43 3.55  Subtotals: *Other opiates 3.25 3.51 
**Benzodiazepines 1.18 0.93  **Benzodiazepines 0.85 0.81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Illicit drugs are italicized. 
Data for cannabinol/cannabis and psilocin/psilocybine may be duplicated. 
SOURCE:  National Forensic Laboratory Information Systems  
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Exhibit 7a. Drug-Involved Deaths
1
 in King County, Washington, Related to Illicit and Prescription Drugs:   
 1997–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug 1997 1998 1999 2000 2001 2002 2003 2004 
Total of 
Each 
Drug 
Cocaine 66 69 76 89 49 79 52 92 572 
Heroin/Opiates/Morphine 111 144 117 102 61 87 62 75 759 
Rx Opiate 28 44 32 50 53 66 84 118 475 
Depressant 45 51 28 33 40 54 71 82 404 
Methamphetamine 3 3 13 10 5 13 18 18 83 
Rx Stimulant 3 0 1 2 0 1 1 4 12 
DXM/MDMA/PCP 2 0 1 2 3 9 11 9 37 
Alcohol 82 103 67 76 50 61 58 71 568 
Total # of Deaths 178 220 196 213 146 195 186 253 1,587 
 
1
Data are duplicated, most deaths involve multiple drugs. 
SOURCE:  Medical Examiners Office, Public Health Seattle & King County.  
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Exhibit 7b. Numbers of Depressant and Prescription-Type Opiate-Involved Deaths in King County,  
 Washington:  1997–2004 
 
Rx Opiates 1997 1998 1999 2000 2001 2002 2003 2004 
Total # of Rx 
Opiates 
Oxycodone 2 5 4 12 18 20 14 32 107 
Methadone 14 20 19 25 24 37 47 67 253 
Hydrocodone 0 3 1 1 4 4 12 14 39 
Other Rx Opiates 18 21 12 17 13 18 20 33 152 
Total # of  
Rx Opiates 
34 49 36 55 59 79 93 146 551 
Total # Deaths 
Involving 
Rx Opiates 
28 44 32 50 53 66 84 118 475 
 
 
         
Depressants 1997 1998 1999 2000 2001 2002 2003 2004 
Total # of 
Depressants 
Diazepam 17 22 10 9 11 23 27 23 142 
Diphenhydramine 11 10 7 6 7 16 25 29 111 
Promethazine  3 3 3 5 5 9 11 39 
Meprobamate 2 5 1 4 6 2 5 7 32 
Alprazolam 1 5 1 3 3 4 5 9 31 
Cyclobenzaprine  3  1 1 3 8 6 22 
Chlordiazepoxide  4 1 2 2 3 4 4 20 
Phenobarbital 4 5 3  1  4 3 20 
Zolpidem 1  1 1 3 3 3 4 16 
Other Depressants 19 10 9 10 12 13 13 17 103 
Total # of  
Depressants 
55 67 36 39 51 72 103 113 536 
Total # of Deaths 
Involving  
Depressants 
45 51 28 33 40 54 71 82 404 
 
SOURCE:  Medical Examiners Office, Public Health Seattle & King County  
 
 
 
Exhibit 7c. Combination Depressant and Prescription-Type Opiate-Involved Deaths in King County,  
 Washington:  1997–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Medical Examiners Office, Public Health Seattle & King County 
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Exhibit 7d. Demographics of Drug-Involved Deaths in King County, Washington:  1997–2004 
 
Demographic 
All 
Drugs 
Cocaine 
Depres- 
sant 
Rx 
Stim. 
Metham. 
DXM/  
MDMA/  
GHB/  
PCP 
Heroin/ 
Opiates/  
Morphine 
Rx 
Opiate 
Oxyco- 
done1 
Metha- 
done1 
Number of Times Identified 1,584 572 404 12 83 37 759 475 107 253 
Percent Male 71 78 57 75 80 57 81 58 60 61 
Average Age 41.6 41.2 43.8 33.8 37.9 36.3 40.6 43 44.7 41.4 
Race/Ethnicity           
White 83 73 88 92 88 81 84 88 89 85 
African-American 11 21 7 0 5 17 10 8 7 12 
Asian/Pacific Islander 1 1 1 0 2 0 0 1 1 1 
Native American 3 2 2 0 2 0 3 2 3 2 
Hispanic 1 1 1 0 0 3 2 0 0 0 
Other/Multiple 1 2 1 8 2 0 2 1 1 0 
Manner of Death           
Accident 81 94 63 92 94 68 92 79 70 90 
Suicide 11 1 24 0 1 11 2 11 22 1 
Homicide 0 0 0 0 0 0 0 0 0 0 
Undetermined 9 5 14 8 5 22 6 11 8 9 
Avg. Number of Drugs2 2.3 2.6 3.5 4.2 2.4 3.4 2.4 3.1 3.2 3.0 
 
1
Oxycodone and Methadone are also included in the Rx Opiate category 
2
Includes Alcohol, Cocaine, Heroin/Op/Mor, Rx Opiates, Depressants, Rx Stimulants, Meth., Hallucinogens. Excludes drugs such as 
NSAIDS and anti-depressants. 
SOURCE: Medical Examiner, Public Health & Seattle-King County. 
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Exhibit 7e. Proportions of King County Deaths
1 
Involving at Least 2 Drugs:  2004  
1
These data are duplicated. A person could have multiple 2-way drug combinations if, for example, they had used heroin, cocaine, a 
prescription-type opiate, and a depressant. 
SOURCE: Medical Examiner’s Office, Public Health-Seattle & King County 
 
 
 
Exhibit 7f. King County Prescription-Type Opiate- and Depressant-Involved Deaths and Proportion of  
 Single-Drug Deaths: 1997–2004 
 
 Depressants 
Prescription-type 
Opiates All Drugs 
 N % N % N % 
No other drugs
1
 26 6% 60 13% 622 29% 
All deaths involving substance 404 25% 475 30%   
Total # of drug involved deaths 1,587  1,587  1,587  
 
1
Other drug=Illegal; prescription: muscle relaxants, opiates, depressants, and diphenhydramine. 
SOURCE:  Medical Examiner- Public Health- Seattle & King County 
 
 
 
Exhibit 7g. Illegal Drug Presence in Prescription-Type Opiate- and Depressant-Involved Deaths in King  
 County: 1997–2004 
 
 Depressants 
Prescription-type 
Opiates All Drugs 
 N % N % N % 
Illegal drugs present
1
 177 44% 164 35% 1056 67% 
All deaths involving substance 404 25% 475 30%   
Total # of drug involved deaths 1,587  1,587  1,587  
 
1
Illegal=Heroin, cocaine, and/or methamphetamine  
SOURCE: Medical Examiner- Public Health- Seattle & King County 
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Exhibit 8. Opiate Substitution Treatment
1
 for King County Residents: 1999–2004 
 
  1999 2000 2001 2002 2003 2004 Total 
Admits 1,333 1,560 1,238 1,175 1,085 1,660 8,051 
Discharges 632 924 890 794 633 743 4,616 
Primary Drug at Admission (%)        
Heroin 94.6 93.3 92.8 90.4 87.7 86.6 90.9 
Prescription-type Opiates 3.0 6.1 6.5 8.8 11.3 11.6 7.9 
 
1
Note-Treatment Capacity Increased by 350 in 2000 and by approximately 200 in 2004. 
SOURCE:  Washington State Treatment and Assessment Report Generation Tool (TARGET) data system—Structured Ad Hoc 
Reporting System Run Date: 05/23/2005 
 
 
 
Exhibit 9. Methadone Waiting List Managed by Syringe Exchange Program, King County:  1997–June 2005
1
 
 
 1997 1998 1999 2000 2001 2002  2003 2004 
June 
2005 
Number on Wait List 198 307 548 624 495 663 638 487 156 
 
1
Note- Figures are for the close of each year. 
SOURCE: Public Health- Seattle & King County, HIV/AIDS Program 
 
 
 
Exhibit 10. Heroin Purity and Street-Level Purchases in the City of Seattle:  1997–June 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data differ from national reports due to exclusion of Tacoma data. 
Each black dot=1 purchase. Purchases totaled 124 for 5 years. 
SOURCE:  Seattle Drug Enforcement Administration (2005), Domestic Monitor Program (used with permission) 
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Exhibit 11. Percent Change in Amount of Prescription Opiates Sold to Hospitals and Pharmacies in the King  
 County Area
1
:  1997–2003 
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1 
Data for ZIP Codes 980xx and 981xx, which approximate King County boundaries. 
SOURCE: Automation of Reports and Consolidated Orders System and DEA, 
http://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.html 
 
 
 
 
Exhibit 12. Percent Change in Amount of Prescription Stimulants Sold to Hospitals and Pharmacies in the  
 King County Area
1
: 1997–2003 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
Data for ZIP Codes 980xx and 981xx, which approximate King County boundaries. 
SOURCE: Automation of Reports and Consolidated Orders System and DEA, 
http://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.html 
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Exhibit 13. Number of Methamphetamine Labs and Dump Sites Reported in King and Neighboring Counties:  
 1990–2004 
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King 6 10 2 7 7 10 23 17 48 107 231 271 241 202 199
Kitsap 1 1 2 1 3 1 21 45 54 60 50 44
Pierce 10 18 18 12 17 17 53 42 129 318 545 589 438 466 541
Snohomish 2 2 2 7 6 5 13 37 69 83 98 101
WA State TOTAL 38 43 40 42 36 54 153 203 349 789 1454 1890 1693 1480 1337
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
 
SOURCE:  Washington State Department of Ecology 
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Exhibit 14. New HIV Infections in King County and Washington State, by Year of Diagnosis and  
 Demographic Characteristics: 1996–2004 
 
 King County WA State 
 2002–2004
1
 Trend
2
 2002–2004
1
 Trend
2
 
 No (%) 1996–2004 No (%) 1996–2004 
 TOTAL 1,006 (100)   1,576 (100)   
 HIV Exposure Category       
MSM 651 (65)  901 (57)  
IDU 67 (7)  153 (10)  
 MSM-IDU 71 (7)  102 (6)  
 Heterosexual contact 109 (11) up 218 (14) up 
 Blood product exposure 3 (0)  6 (0)  
 Perinatal exposure 0 (0)  2 (0)  
 Undetermined
3
 105 (10)   194 (12)   
 Sex & Race/Ethnicity       
 Male 889 (88)  1,319 (84)  
   White Male
4
 571 (57) down 877 (56) down 
   Black Male
4
 155 (15) up 207 (13) up 
   Hispanic Male 103 (10)  149 (9)  
   Other Male
4
 60 (6)  86 (5)  
 Female 117 (12)  257 (16)  
   White Female
4
 33 (3)  103 (7)  
   Black Female
4
 62 (6) up 95 (6)  
   Hispanic Female 8 (1)  25 (2)  
   Other Female
4
 14 (1)   34 (2)   
 Race/Ethnicity       
 White
4
 604 (60) down 980 (62) down 
 Black
4
 217 (22) up 302 (19) up 
 Hispanic 111 (11)  174 (11)  
 Asian & Pacific Islander
4
 33 (3)  56 (4)  
 American Indian/ Alaska Native
4
 21 (2)  40 (3)  
 Multi Race
4
 16 (2) up 16 (1) up 
 Unknown 4 (0)   8 (1)   
 Age at Diagnosis of HIV       
 0–19  10 (1)  19 (1) down 
 20–24  72 (7)  129 (8) up 
 25–29  141 (14) down 218 (14) down 
 30–34  191 (19) down 277 (18) down 
 35–39  244 (24)  343 (22)  
 40–44  173 (17) up 266 (17) up 
 45–49  90 (9)  159 (10)  
 50–54  47 (5)  84 (5)  
 55–59  24 (2) up 47 (3) up 
 60–64  8 (1)  18 (1)  
 65 and older  6 (1)   16 (1)   
 
1
Due to delays in reporting, data from recent years are incomplete 
2
Statistical trends were identified from the chi-square test for trend, calculated for the periods 1996–98, 1999–2001, and 2002–04. 
3
Includes persons for whom exposure information is incomplete (due to death, refusal to be interviewed, or loss to follow-up), pa-
tients still under investigation, patients whose only risk was heterosexual contact and where the risk of the sexual partner(s) was 
(were) undetermined, persons exposed to HIV through their occupation, and patients whose mode of exposure remains undeter-
mined. 
4
And not Hispanic. The groups Asian, Native Hawaiian, and other Pacific Islanders were grouped due to small cell sizes.  All catego-
ries are mutually exclusive. 
SOURCES:  Public Health—Seattle & King County, HIV/AIDS Epidemiology  
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Exhibit 15. Syringes Exchanged and Number of Encounters for King County Syringe Exchanges:   
 2002–2004 
 
 2002 2003 2004 
Syringes Exchanged 1,801,151 1,969,522 2,183,150 
Encounters
1
 73,752 65,593 63,898 
Average Number of Syringes per Encoun-
ter 
24 30 34 
 
1
Encounters are duplicated 
SOURCE: Public Health- Seattle & King County, HIV/AIDS Program 
 
 
Exhibit 16. Trends in Primary Injection Drug in Seattle-Area IDUs Age 18–30 Participating in 4 Studies
1
:  
 1994–2003 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
The number of cases ranged from 27-333 per year, with an average of 164 in each year. 
2
Speedballs refers specifically to the combination of heroin and cocaine. 
SOURCE: Public Health-Seattle & King County, HIV/AIDS Epidemiology Unit 
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Substance Abuse Trends in 
Texas, June 2005 
Jane Carlisle Maxwell, Ph.D.1 
 
ABSTRACT 
Cocaine continues to be readily available, and it is 
the primary illicit drug for which Texans enter 
treatment. It remains a problem on the border with 
Mexico, as documented in the school survey and 
treatment data. Use of crack cocaine continues to 
move beyond Black users to White and Hispanic 
users. Alcohol is the primary drug of abuse in Texas 
in terms of dependence, deaths, and treatment ad-
missions; of minors treated in emergency depart-
ments for a problem with alcohol, some 37–38 per-
cent were younger than 18. Heroin addicts entering 
treatment are primarily injectors. In Texas, hydro-
codone is a much larger problem than oxycodone or 
methadone. Codeine cough syrup, ‘Lean,’ continues 
to be abused. Treatment data show that marijuana 
clients admitted with criminal justice problems are 
less impaired than those who are referred from 
other sources. Methamphetamine is a growing prob-
lem, particularly in north and east Texas, according 
to the indicators, and smoking ice is increasing, 
while the price of the drug continues to drop. Xanax 
and Soma continue to be widely abused pharmaceu-
tical drugs. Club drug users differ in their sociode-
mographic characteristics, just as the properties of 
these drugs differ. Ecstasy use is moving out of the 
White club scene, and indicators increased from 
2003 to 2004. Ketamine continues as a problem. 
GHB, GBL, and similar precursor drugs remain a 
problem, particularly in the Dallas-Fort Worth 
Metroplex area. Although indicators are down, Ro-
hypnol remains a problem along the Texas-Mexico 
border. PCP indicators are mixed; dextromethor-
phan is a problem with adolescents; and carisopro-
dol (Soma) is a growing problem and is often 
abused in combination with other prescription 
drugs. Inhalants remain a problem with different 
types of users. The number of AIDS cases involving 
females and persons of color is growing. The pro-
portion of cases due to the heterosexual mode of 
transmission now exceeds the proportion of cases 
due to injecting drug use.  
                                                 
1 The author is affiliated with the University of Texas at Austin, 
Center for Social Work Research, Austin, Texas. 
INTRODUCTION 
Area Description 
The population of Texas in 2004 is 22,158,126, with 
51 percent White, 12 percent Black, 34 percent His-
panic, and 3 percent “Other.” Illicit drugs continue to 
enter from Mexico through cities such as El Paso, 
Laredo, McAllen, and Brownsville, as well as through 
smaller towns along the border. The drugs then move 
northward for distribution through Dallas-Fort Worth 
and Houston. In addition, drugs move eastward from 
San Diego through Lubbock and from El Paso to 
Amarillo and Dallas-Fort Worth.  
There are multiple routes by which drugs enter 
Texas. The international airports in Houston and 
Dallas-Fort Worth are major ports for the distribu-
tion of drugs into and out of the State, and seaports 
are used to import heroin and cocaine via commer-
cial cargo vessels. Both private and express mail 
companies are used to traffic narcotics and smuggle 
money, and drugs are transported across the border 
by private vehicles and couriers who walk the drugs 
across on their bodies. Another problem is that U.S. 
citizens can buy controlled substances in Mexican 
pharmacies and then bring them into the States.  
Data Sources 
Substance Abuse Trends in Texas is an ongoing se-
ries which is published every 6 months as a report 
for the Community Epidemiology Work Group 
meetings sponsored by the National Institute on 
Drug Abuse (NIDA). This report updates the January 
2005 report. To compare the June 2005 report with 
earlier periods, please access http://www.utexas.edu/ 
research/cswr/gcattc/drugtrends.html. 
 
The information on each drug is discussed in the 
following order of sources:  
• Student substance use data came from the 
Texas School Survey of Substance Abuse: 
Grades 7-12, 2004 and the Texas School Survey 
of Substance Abuse: Grades 4-6, 2004, which 
are published by the Texas Department of State 
Health Services (DSHS), formerly the Texas 
Commission on Alcohol and Drug Abuse. 
• Adult substance use data came from DSHS’s 
2000 Texas Survey of Substance Use Among 
Adults. 
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• Data on use by Texans age 12 and older came 
from the Substance Abuse and Mental Health 
Services Administration’s (SAMHSA) State Es-
timates of Substance Use from the 2002-2003 
National Survey on Drug Use and Health. 
• Poison control center data came from the 
Texas Poison Center Network, DSHS, for 1998–
2004. Analysis was provided by Mathias Forres-
ter, epidemiologist with the Texas Poison Center 
Network, and by the author. In addition, findings 
from four papers authored by Forrester, “Cariso-
prodol Abuse in Texas, 1998-2003,” “Fluni-
trazepam Abuse and Malicious Use in Texas, 
1998-2003,” “Oxycodone Abuse in Texas, 1998-
2003,” and “Methylphenidate Abuse in Texas, 
1998-2004,” were used in this report. 
 
• Emergency department (ED) data were de-
rived for calendar year 2004 from the Drug 
Abuse Warning Network (DAWN) Live! re-
stricted-access online query system administered 
by the Office of Applied Studies (OAS), 
SAMHSA. Eligible hospitals in the Dallas-Fort 
Worth DAWN area totaled 49, with 48 in the 
DAWN sample, and 49 EDs in the sample. Dur-
ing 2004, between 10 and 16 Dallas emergency 
departments reported data each month. Eligible 
hospitals in the Houston DAWN area totaled 44, 
with 37 in the DAWN sample, and 39 EDs in the 
sample. During 2004, between 14 and 15 Hous-
ton EDs reported data each month. The response 
rates in both Dallas and Houston were relatively 
low (exhibit 1). In Houston, this was because it 
was new and, in Dallas, it was because few hos-
pitals agreed to participate. Exhibits in this paper 
reflect cases that were received by DAWN as of 
April 13, 2005 and May 18, 2005. All DAWN 
cases are reviewed for quality control. Based on 
this review, cases may be corrected or deleted. 
Therefore, the data presented in this paper are 
subject to change. Data derived from DAWN 
Live! represent drug reports in drug-related ED 
visits. Drug reports exceed the number of drug 
visits, since a patient may report use of multiple 
drugs (up to six drugs plus alcohol). The DAWN 
Live! data are unweighted and, thus, are not es-
timates for the reporting area. These data cannot 
be compared to DAWN data from 2002 or be-
fore, nor can preliminary data be used for com-
parison with future data. Only weighted DAWN 
data released by SAMHSA can be used for trend 
analysis. A full description of the DAWN system 
can be found at the DAWN Web site: 
<http://dawninfo.samhsa.gov>.  
 
• Treatment data were provided by DSHS’s cli-
ent data system on clients at admission to treat-
ment in DSHS-funded facilities from the first 
quarter of 1987 through December 31, 2004. For 
most drugs, the characteristics of clients entering 
with a primary problem with the drug are dis-
cussed, but in the case of emerging club drugs, 
information is provided on any client with a pri-
mary, secondary, or tertiary problem with that 
drug. Analysis was by the author. 
• Overdose death data statewide on drug over-
dose deaths came from death certificates from 
the Bureau of Vital Statistics, DSHS; analysis 
was by the author. Findings are also presented 
from Maxwell, J.C.; Pullum, T.W.; and Tannert, 
K. “Deaths of Clients in Methadone Treatment in 
Texas: 1994-2002,” Drug and Alcohol Depend-
ence, 78(1); 73-82, 2005. 
• Drug and alcohol arrests data come from the 
Uniform Crime Reports of the Texas Department 
of Public Safety (DPS). 
• Information on drugs identified by laboratory 
tests are from the Texas Department of Public 
Safety, which submitted results from toxicologi-
cal analyses of substances submitted in law en-
forcement operations for 1998 through Decem-
ber 31, 2004, to the National Forensic Labora-
tory Information System (NFLIS) of the Drug 
Enforcement Administration (DEA). Analysis 
was by the author. 
• Price, purity, trafficking, distribution, and 
supply information was provided by first and 
second quarter 2005 reports on trends in traffick-
ing from the Dallas, El Paso, and Houston Field 
Divisions of the DEA and from DEA’s 2003 
Domestic Monitor Program.  
• Reports by users and street outreach workers 
regarding drug trends for 2005 were reported to 
DSHS by workers at local human immunodefi-
ciency syndrome (HIV) counseling and testing 
programs. 
• Acquired immunodeficiency syndrome (AIDS) 
data were provided by DSHS for annual periods 
through December 2004. 
• Hepatitis C (HCV) data were provided by 
DSHS on HCV counseling and testing for the pe-
riod January 1, 2003, to December 31, 2003. 
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DRUG ABUSE PATTERNS AND TRENDS 
Cocaine/Crack 
The Texas School Survey of Substance Abuse: 
Grades 7-12, 2004 reported that lifetime use of pow-
der and crack cocaine had dropped from a high of 9 
percent in 1998 to 8 percent in 2004, while past-
month use dropped from 4 percent in 1998 to 3 per-
cent in 2004. Some 7.0 percent of students in non-
border counties had ever used powder or crack co-
caine, and 2.5 percent had used it in the past month. 
In comparison, students in schools on the Texas bor-
der reported higher levels of cocaine use: 13 percent 
lifetime and 6 percent past-month use (exhibit 2).  
The 2000 Texas Survey of Substance Use Among 
Adults reported 12 percent of Texas adults had ever 
used powder cocaine. Some 2 percent had used it in 
the past year. In 2002–2003, the National Survey on 
Drug Use and Health estimated that 2 percent of 
Texans age 12 and older had used cocaine in the past 
year. Use by age group included 3 percent of those 
age 12–17, 7 percent of those 18–25, and 2 percent 
of those 26 and older. 
Texas Poison Control Center calls involving the use 
of cocaine increased from 503 in 1998 to 1,405 in 
2004. Some 65 percent were male, and the average 
age was 30.  
Cocaine is the major illicit drug in terms of emergency 
department reports. It represented 33 percent of the 
unweighted DAWN ED reports for “major substances 
of abuse” (including alcohol) in Dallas-Fort Worth 
and 38 percent of the reports in Houston. In Dallas, 67 
percent of the patients were male, 36 percent were 
Anglo, 44 percent were Black, and 15 percent were 
Hispanic; 35 percent were age 35–44 and 18 percent 
were 45–54. In Houston, 64 percent of the patients 
were male, 36 percent were Anglo, 42 percent were 
Black, and 19 percent were Hispanic; 33 percent were 
age 35–44 and 17 percent were 45–54. 
Cocaine (crack and powder) together represented 26 
percent of all admissions to DSHS-funded treatment 
programs in 2004. With 18 percent of all admissions, 
crack cocaine is the primary illicit drug problem of 
clients admitted to publicly funded treatment pro-
grams in Texas (exhibit 30). 
Abusers of powder cocaine represented 8 percent of 
all admissions to treatment. Cocaine inhalers were 
the youngest and most likely to be Hispanic and in-
volved in the criminal justice or legal systems. Co-
caine injectors were older than inhalers but younger 
than crack smokers and were most likely to be White 
(exhibit 3). 
The term “lag” refers to the period from first consis-
tent or regular use of a drug to the date of admission 
to treatment. Powder cocaine inhalers average 9 
years between first regular use and entrance to treat-
ment, while injectors average 15 years of use before 
they enter treatment. 
Between 1987 and 2004, the percentage of Hispanic 
treatment admissions using powder cocaine in-
creased from 23 percent to 51 percent, while for 
Whites and Blacks, the proportions dropped from 48 
percent to 36 percent, and from 28 percent to 11 per-
cent, respectively. Exhibit 4 shows these changes by 
route of administration. It also shows that the propor-
tion of Black crack cocaine admissions fell from 75 
percent in 1993 to 49 percent in 2004, while the pro-
portion of Whites increased from 20 percent in 1993 
to 33 percent in 2004. Hispanic admissions rose from 
5 percent to 16 percent in the same time period.  
Cocaine is also a problem on the border. Eighteen per-
cent of treatment admissions on the Texas border in 
2004 were for problems with powder cocaine (86 per-
cent inhaled the drug and 13 percent injected it). An-
other 11 percent of admissions smoked crack cocaine.  
 
The number of deaths statewide in which cocaine 
was mentioned has increased over the years—from 
223 in 1992 to 541 in 2002—but decreased to 477 in 
2003 (exhibit 5). The average age of the decedents 
was 39 in 2003, and 43 percent were White, 25 per-
cent were Hispanic, and 31 percent were Black. 
Eighty percent were male. 
Exhibit 6 shows that the proportion of substances 
identified as cocaine by the DPS labs is decreasing. 
In 1998, cocaine accounted for 40 percent of all 
items examined, compared with 31 percent in 2004.  
In the second quarter of 2005, powder and crack co-
caine were reported by the Dallas DEA Field Division 
as being readily available in the Metroplex, in Lub-
bock, and in small towns and rural communities in 
north Texas. In Dallas, crack was particularly popular 
in the predominantly Black and Hispanic neighbor-
hoods, and it was the most visible drug trafficked in 
Tyler. In Fort Worth, crack and methamphetamine 
were reported as the drugs of choice by young users; 
in Lubbock, crack was used by all ethnic groups, al-
though it was more prevalent in the Black community. 
Both forms of cocaine were readily available in the El 
Paso Field Division. Cocaine availability has re-
mained constant in the Houston Field Division, with 
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availability up in rural areas east of Austin (Elgin and 
Bastrop). Crack availability and use is minimal in 
Laredo. Cocaine is transshipped thorough the Lower 
Rio Grande Valley to large metropolitan centers using 
smaller private vehicles. Vehicle transport fees have 
averaged $500–$700 per kilogram, with a fee of 
$1,000–$1,500 for body carriers. 
In addition to continuing to be readily available, the 
price for a kilogram of powder cocaine remained 
stable at $11,000–$22,500 in the first half of 2005 
(exhibit 7). A gram of powder cocaine costs $50–$80 
in Dallas, $50–$60 in El Paso, and $100 in Amarillo 
and Lubbock. An ounce costs $400–$600 in 
McAllen, $400–$650 in Houston, $500–$600 in 
Austin, $800–$900 in Midland, $500–$600 in El 
Paso, $400–$650 in Houston, $600–$950 in Dallas, 
$600 in Alpine, $500–$700 in Waco, $650–$850 in 
Amarillo, $500–$850 in Lubbock, $300–$750 in 
Tyler, and $600–$750 in Fort Worth. 
Across the State, a rock of crack costs $10–$50, with 
$10–$20 being the most common price. An ounce of 
crack cocaine costs $325–$450 in Houston, $500 in 
Galveston, $400–$600 in San Antonio, $500–$600 in 
Austin, $500–$700 in Waco, $700–$1,100 in Dallas, 
$450–$550 in Tyler, $500–$800 in Beaumont, $450–
$1,000 in Amarillo and Lubbock, $400–$600 in San 
Antonio, $830 in El Paso, $800–$900 in Midland, 
$500 in McAllen, and $650–$750 in Fort Worth. 
In Austin, street outreach workers report crack is 
being sold for $200 per half-ounce or $150 for a 
quarter piece. The quality is reported to be declining, 
and the pieces of crack are becoming smaller and the 
price increasing. A $10-size piece now costs $20. 
Cocaine is being “cut” with baking soda and B-12 
vitamins or a mixture of dishwashing liquid and 
ammonia that is hardened and then combined with 
cocaine to produce crack. BC powder for pain-relief 
is also combined with powder cocaine to produce 
crack. The baking soda and B-12 mixture is reported 
to produce crack of a higher quality. Injecting crack 
users use citric acid break down the crack. They re-
port it is a “clean” shot and is less likely to cause 
abscesses or swollen veins than crack that has been 
dissolved in Kool Aid or lemon juice. Injecting crack 
is also reported in Fort Worth. 
In the Galveston-Brazoria area, powder cocaine use 
is up, but crack is more commonly used, especially 
in situations involving trading sex for drugs. Crack 
cocaine continues to be the most visible drug on the 
street.  
Alcohol 
Alcohol is the primary drug of abuse in Texas. The 
1998 secondary school survey found that 72 percent 
of students had ever drunk alcohol and 38 percent 
had drunk alcohol in the last month. In 2004, 68 per-
cent had ever used alcohol and 33 percent had drunk 
alcohol in the last month.  
Of particular concern is heavy consumption of alco-
hol, or binge drinking, defined as drinking five or 
more drinks at one time. In 2004, 15 percent of all 
secondary students said that when they drank, they 
usually drank five or more beers at one time, and 13 
percent reported binge drinking of liquor. Binge 
drinking increased with grade level. Among seniors, 
27 percent binged on beer and 21 percent on liquor. 
While the percentage binge drinking wine or wine 
coolers has fallen from its peak in 1994, it is still 
higher than in 1988 (exhibit 8). The percentage of 
binge drinking of hard liquor has remained relatively 
stable since 1994.  
Among students in grades 4–6 in 2004, 26 percent 
had ever drunk alcohol and 16 percent had drunk 
alcohol in the past school year. 
The 2000 Texas adult survey found that 50 percent 
of Texas adults reported drinking alcohol in the past 
month. Some 17 percent reported binge drinking, 6 
percent reported heavy drinking in the past month, 
and 5 percent of all adults met the criteria for being 
dependent on alcohol. This estimate was based on 
the Diagnostic and Statistical Manual of Mental Dis-
orders, III-R (DSM III-R). 
The 2002–2003 National Survey on Drug Use and 
Health estimated that 47 percent of Texans age 12 
and older had drunk alcohol in the past month (18 
percent of those age 12–17, 58 percent of those 18–
25, and 50 percent of those 26 and older). Some 24 
percent had drunk five or more drinks on at least 1 
day (binge drinking) in the past month (10 percent of 
those 12–17, 40 percent of those 18–24, and 23 per-
cent of those age 26 and older). Some 8 percent met 
the criteria for alcohol dependence based on the Di-
agnostic and Statistical Manual of Mental Disorders-
IV (DSM-IV). The level of alcohol dependence was 
estimated at 6 percent of those age 12–17, 17 percent 
for those 18–25, and 6 percent of those 26 and older. 
Of all the unweighted DAWN emergency depart-
ment reports for major substances of abuse in 2004, 
26 percent in Dallas-Fort Worth and 27 percent in  
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Houston involved alcohol. In Dallas-Fort Worth, 321 
(4.5 percent) of the reports involved alcohol-only 
among patients younger than 21.  In Houston, 2.6 
percent of the reports involved patients younger than 
21.  In Dallas-Fort Worth, 53 percent of the minors 
were male, 53 percent were Anglo, 6 percent were 
Black, and 30 percent were Hispanic; 63 percent of 
these reports involved youths age 18–20, with 37 
percent being 12–17. In Houston, 62 percent were 
male, 38 percent were White, 8 percent were Black, 
and 47 percent were Hispanic; 61 percent of these 
reports involved youths age 18–20, and 38 percent 
were 12–17. 
In 2004, 27 percent of all clients admitted to publicly 
funded treatment programs had a primary problem 
with alcohol (exhibit 30). They were among the old-
est of the clients (average age of 37), and more likely 
to be male. Of the 14,410 alcohol admissions, 901 (6 
percent) were younger than age 21. Of these minors, 
the average age was 17 and their average age of first 
use was 13. Seventy percent of the minors were 
male, 52 percent were Hispanic, 40 percent were 
White, and 6 percent were Black. Seventy-three per-
cent were referred to treatment by the criminal jus-
tice or legal system; average education was 9.7 
years. In comparison, among adult alcohol clients, 68 
percent were male, 24 percent were Hispanic, 59 
percent were White, and 14 percent were Black. 
Forty-four percent were referred by the criminal jus-
tice or legal system, and average education level was 
12 years. 
Minors entering treatment were more likely to report 
problematic use of other substances: 71 percent re-
ported a second drug of abuse, while among adults, 
50 percent reported a second problem. Marijuana 
was a problem for 48 percent of minors and 14 per-
cent of adults, powder cocaine was a problem for 10 
percent of minors and 12 percent of adults, and crack 
cocaine was a problem for 2 percent of minors and 
15 percent of adults. 
The characteristics of alcohol admissions have 
changed over the years. In 1988, 82 percent of the 
clients were male, compared with 68 percent in 
2004. The proportion of White clients declined from 
63 percent in 1988 to 58 percent in 2004; the propor-
tion of Hispanic clients declined from 28 percent to 
26 percent, while the proportion of Black clients 
increased from 7 percent to 14 percent. The average 
age increased from 35 to 37 years. The proportion of 
alcohol clients reporting no secondary drug problem 
dropped from 67 to 49 percent, while marijuana 
dropped from 18 percent to 16 percent, but stimu- 
 
lants remained level at 4 percent, and cocaine in-
creased from 7 percent to 25 percent. Consuming 
cocaine and alcohol at the same time produces co-
caethylene, which intensifies cocaine's euphoric ef-
fects. 
More Texans are arrested for public intoxication (PI) 
than for any other substance abuse offense, although 
the arrest rate for PI per 100,000 population is de-
creasing. The rates for the other substance abuse 
offenses are fairly level (exhibit 9).  
Heroin 
The proportion of Texas secondary students reporting 
lifetime use of heroin dropped from 2.4 percent in 
1998 to 1.6 percent in 2004. Past-month use dropped 
from 0.7 percent in 1998 to 0.5 percent in 2004. 
The 2000 Texas adult survey found that 1.2 percent 
of adults reported lifetime use of heroin and 0.1 per-
cent reported past-month use. 
Calls to Texas Poison Control Centers involving 
confirmed exposures to heroin ranged from 181 in 
1998 to a high of 296 in 2000 and dropped to 208 in 
2003 and 184 in 2004. In 2004, the average age was 
34, and 60 percent were male. Nine percent of heroin 
exposures involved inhalation (snorting or smoking). 
Heroin represented 5 percent of the unweighted 
DAWN ED reports for major substances of abuse in 
Dallas-Fort Worth and 2 percent of the reports in 
Houston in 2004. In Dallas-Fort Worth, 70 percent of 
the patients were male, 53 percent were Anglo, 28 
percent were Black, and 12 percent were Hispanic; 
22 percent were age 35–44, 19 percent were 45–54, 
and 18 percent were 25–29. In Houston, 68 percent 
were male, 63 percent were Anglo, 10 percent were 
Black, and 23 percent were Hispanic; 36 percent 
were 35–44, 20 percent were 45–54, and 10 percent 
were 25–29 or 30–34. 
Heroin is the primary drug of abuse for 10 percent of 
clients admitted to treatment. The characteristics of 
these addicts vary by route of administration, as ex-
hibit 10 illustrates. Most heroin addicts entering 
treatment inject heroin. While the number of indi-
viduals who inhale heroin is small, it is important to 
note that the lag period from first use and seeking 
treatment is 8 years rather than 16 years for injectors. 
This shorter lag period means that contrary to street 
rumors that “sniffing or inhaling is not addictive,” 
inhalers can become addicted. They will either enter 
treatment sooner while still inhaling or they will shift  
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to injecting, increase their risk of hepatitis C and 
HIV infection, become more impaired, and enter 
treatment later. 
Exhibit 11 shows that the proportion of treatment 
clients who are Hispanic has increased since 1996, 
but there has been little change since 2002. 
There were 278 deaths statewide with a mention of 
heroin or narcotics in 2003 (exhibit 12). Some 56 
percent were White, 33 percent were Hispanic, and 9 
percent were Black; 72 percent were male. The aver-
age age was 39. 
Exhibit 6 shows that the proportion of items identi-
fied as heroin by DPS labs has remained constant at 
1–2 percent over the years. 
The predominant form of heroin in Texas is black 
tar, which has a dark gummy, oily texture that can be 
diluted with water and injected. Exhibit 13 shows the 
decline in price over the years. Depending on the 
location, black tar heroin sells on the street for $10–
$20 per capsule, $50–$350 per gram, $400–$4,500 
per ounce, and $40,000–$80,000 per kilogram. An 
ounce costs $1,000–$1,500 in Dallas, $1,200–$1,700 
in Fort Worth, $1,000–$1,500 in El Paso, $2,100–
$2,200 in Alpine, $1,800–$4,000 in Midland, 
$3,500–$4,500 in Lubbock, $1,200–$1,500 in Hous-
ton, $1,300 in Laredo, $400–$1,500 in McAllen, 
$1,400–$1,600 in Austin, and $1,600–$2,400 in San 
Antonio. 
Mexican brown heroin, which is black tar that has 
been cut with lactose or another substance and then 
turned into a powder to inject or snort, costs $10 per 
cap and $70–$300 per gram. An ounce costs $500–
$800 in San Antonio, $1,100 in McAllen, $800–
$1,600 in Dallas, and $2,200–$3,000 in Lubbock. 
Colombian heroin sells for $10 per cap, $2,000–
$4,000 per ounce, and $65,000–$80,000 per kilogram 
in Dallas and $35,000–$80,000 in Houston. Asian 
heroin costs $200–$350 per gram, $2,000–$4,000 per 
ounce, and $70,000 per kilogram in Dallas.  
In the Dallas area, black tar is readily available and 
Colombian is available in multikilogram quantities. 
Sources report white and beige-colored heroin is 
now being produced in Mexico using Colombian 
production methods, and Colombian heroin organi-
zations are interested in developing a greater market 
presence in the Dallas area. In 2003, 31 exhibits of 
Mexican heroin purchased through the Domestic 
Monitor Program (DMP) were 13.3 percent pure and 
cost $0.98 per milligram pure, compared with 17.2 
percent pure and $0.75 per milligram pure in 2002. 
In El Paso in 2003, heroin was reported by DEA as 
being available, although not plentiful. It could be 
purchased for about $100 per gram. In 2003, 13 
samples of Mexican heroin were purchased under the 
DEA program, and of these, purity averaged 44.7 
percent and cost was $0.40 per milligram pure. The 
price rose from $0.13 and the purity rose from 40.3 
percent in 2002. Colombian heroin is also being 
mentioned in El Paso 
The DEA Houston Field Division reported the sup-
ply of brown and black tar heroin was stable. There 
were 44 DMP purchases of heroin, at a purity of 28.2 
percent and cost of $0.45 per milligram pure in 2003, 
compared with 28.2 percent pure and $0.64 per mil-
ligram pure in 2002. Mexican black tar and brown 
are the primary types seen in the Houston Division, 
although Colombian heroin is transported through 
Houston to the Northeastern United States.  
Street outreach workers in Austin report that heroin 
supplies are plentiful and the drug is cut with lactose, 
brown sugar, and instant coffee. A balloon, which is 
equal to 0.3 gram, costs $15, with two balloons sell-
ing for $30, four selling for $40, and five selling for 
$50. Amarillo street outreach workers report that 
there is an increase in injecting heroin. 
Other Opiates  
This group excludes heroin but includes opiates such 
as methadone, codeine, hydrocodone (Vicodin, Tus-
sionex), oxycodone (OxyContin, Percodan, Percocet-
5, Tylox), d-propoxyphene (Darvon), hydromor-
phone (Dilaudid), morphine, meperidine (Demerol), 
and opium.  
The 2004 Texas secondary school survey found that 
8 percent reported ever having drunk codeine cough 
syrup to get high. Some 9 percent of Black and 
White students reported lifetime use, as did 9 percent 
of Native American students and 5 percent of His-
panic students. There was no difference by gender, 
but lifetime use increased with grade level (from 3 
percent of 7th graders to 11 percent of 12th graders). 
The 2000 Texas adult survey found that lifetime use 
of other opiates was 4 percent, and past-month use 
was 0.5 percent in 2000. Some 2 percent of Texas 
adults in 2000 reported ever having used codeine, 
and 0.7 percent used in the past year. Lifetime use of 
hydrocodone was 0.7 percent, and past-year use was 
0.4 percent. 
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Hydrocodone is a larger problem in Texas than is 
oxycodone, but use of oxycodone is growing, as ex-
hibit 14 shows. Among poison control center cases of 
abuse and misuse, the average age of hydrocodone 
callers was 33 and oxycodone callers was 32. A study 
of oxycodone cases reported through the Texas Poi-
son Center Network found that the proportion of calls 
that involved abuse of the drug more than doubled 
from 1998 to 2003. Oxycodone abuse involved 
males, adolescents, exposures at other residences and 
public areas, referral by the poison center to a health 
care facility, and some sort of clinical effect; one-half 
involved no other substance (Forrester, 2004).  
Cases involving methadone are increasing. Metha-
done is not only used in liquid and 50-milligram 
diskette forms in narcotic treatment programs, but 5- 
and 10-milligram pills are used for pain management. 
The poison control center, death certificate, and fo-
rensic laboratory data usually do not report the form 
of methadone being abused. The form of the drug 
could be an overdose by new patients in narcotic 
treatment programs, liquid methadone which has 
been diverted from treatment, pain pills diverted from 
patients, or overdoses by pain patients who took too 
many of the pills or took other drugs in combination 
with the methadone pills. The number of poison con-
trol center cases involving misuse or abuse of metha-
done increased from 16 in 1998 to 106 in 2004. The 
average age in 2004 was 33. 
The unweighted 2004 DAWN ED reports showed 
598 hydrocodone and hydrocodone combination re-
ports in Dallas-Fort Worth and 664 in Houston. Of 
the reports in Dallas-Fort Worth, 40 percent were 
male, 67 percent were Anglo, 14 percent were Black, 
and 8 percent were Hispanic; 22 percent of the pa-
tients were age 35–44 and 18 percent were 45–54. In 
Houston, 48 percent were male, 67 percent were An-
glo, 13 percent were Black, and 11 percent were His-
panic; 27 percent were age 35-44 and 20 percent 
were 45-54. In comparison, there were 86 oxycodone 
and oxycodone/combination reports in Dallas and 68 
in Houston. Of the oxycodone patients in Dallas-Fort 
Worth, 56 percent were male, 73 percent were Anglo, 
28 percent were age 35–44 and 23 percent were 45–
54. In Houston, 53 percent were male, 74 percent 
were Anglo, 26 percent were 45–54 and 19 percent 
were 25–29. There were also 107 reports of metha-
done in Dallas-Fort Worth and 91 in Houston. Of the 
methadone patients in Dallas-Fort Worth, 48 percent 
were male, 77 percent were Anglo, 31 percent were 
age 35–44, 21 percent were 45–54, and 19 percent 
were 30–34. In Houston, 73 percent were male, 80 
percent were Anglo, 33 percent were age 45–54, and 
23 percent were 35–44. 
Some 5 percent of all clients who entered publicly 
funded treatment during 2004 used opiates other than 
heroin. Of these, 55 used illegal methadone and 
2,759 used other opiates (exhibit 14). Those who 
reported a primary problem with illicit methadone or 
other opiates were different from those who reported 
a problem with heroin. They were much more likely 
to be female, to be White, to have recently visited an 
emergency department, and to report more sickness 
and health problems in the month prior to entering 
treatment.  
Of the hydrocodone deaths statewide, 49 percent 
were male, 90 percent were White, and the average 
age was 42. Of the oxycodone deaths, 67 percent 
were male, 88 percent were White, and the average 
age was 36—younger than the hydrocodone dece-
dents. Of the methadone deaths, 66 percent were 
male, 84 percent were White, and the average age 
was 35. There were 10 deaths with a mention of fen-
tanyl in 2003. 
Narcotic treatment programs are required to report 
deaths of their clients. Between 1994 and 2002, 776 
deaths were reported. Twenty percent died of liver 
disease, 18 percent of cardiovascular disease, and 14 
percent of drug overdose. Compared with the stan-
dardized Texas population, narcotic treatment pa-
tients were 4.6 times more likely to die of a drug 
overdose, 3.4 times more likely to die of liver dis-
ease, 1.7 times more likely to die of a respiratory 
disease, 1.5 times more likely to die of a homicide, 
and 1.4 times more likely to die of AIDS (Maxwell 
et al., 2005). 
In the Dallas DEA Field Division, there has been an 
increase in seizures of codeine cough syrup and in 
Tyler, OxyContin has surpassed hydrocodone as the 
drug of choice among abusers of pharmaceuticals. 
Dilaudid sells for $20–$80 per tablet, and hydro-
codone (Vicodin) sells for $4–$6 per tablet. OxyCon-
tin sells for $1 per milligram. Methadone sells for 
$10 per 10-milligram tablet. Codeine cough syrup is 
mixed with Sprite or 7-Up and drunk in a soda bottle 
to avoid police attention. Promethazine syrup with 
codeine (“lean”) sells for $200–$300 per pint in Dal-
las and $20 per ounce in Fort Worth. In the Houston 
Field Division, hydrocodone, promethazine with co-
deine, and other codeine cough syrups are the most 
commonly abused pharmaceutical drugs. In Houston, 
promethazine or phenergan cough syrup with codeine 
sells for $75–$100 for 4 ounces, $125 for 8 ounces, 
and $1,600 for a gallon. In San Antonio, hydro-
codone sells for $3 per pill and OxyContin costs $1 
per milligram; one OxyContin pill costs $25 in 
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McAllen. Dilaudid sells for $10–$15 per dose in 
McAllen. 
DPS labs report increases in the number of exhibits 
of hydrocodone, oxycodone, and methadone each 
year from 1998 through 2004 (exhibit 14). There 
were 2 fentanyl exhibits in 2003 and 13 in 2004. 
Outreach workers in Fort Worth and Galveston re-
port codeine cough syrup remains a popular drug. 
Marijuana 
The proportion of Texas students in grades 4–6 who 
have ever used marijuana dropped from 2.8 percent 
in 2000 to 2.5 percent in 2004, and use in the past 
school year dropped from 2.1 percent to 1.7 percent. 
Among Texas secondary students (grades 7–12), 30 
percent had ever tried marijuana and 13 percent had 
used in the past month, levels lower than in 2000 
(exhibit 15). 
In comparison, the 2000 Texas adult survey found 
that 37 percent of adults reported lifetime and 4 per-
cent past-month marijuana use, compared with 34 
percent lifetime and 3 percent past-month use in 
1996. The prevalence was much higher among 
younger adults. Thirteen percent of those age 18–24 
reported past-month use, compared with 6 percent of 
those 25–34 and 2 percent of those 35 and older. The 
increase in past-year use between 1996 and 2000 (6 
percent to 7 percent) is statistically significant. 
The 2002–2003 National Survey on Drug Use and 
Health estimated that 4.8 percent of Texans age 12 
and older had used marijuana in the past month, with 
6.4 percent of those 12–17, 12.9 percent of those 18–
25, and 3.0 percent of those 26 and older reporting 
past-month use. 
The Texas Poison Control Centers reported there 
were 135 calls confirming exposure to marijuana in 
1998, compared with 5,060 in 2004. The average age 
was 24.  
Marijuana represented 18 percent of all unweighted 
DAWN ED reports for major substances of abuse in 
Dallas-Fort Worth and 24 percent of the reports in 
Houston. Of the Dallas-Fort Worth patients, 67 per-
cent were male, 45 percent were Anglo, 36 percent 
were Black, and 13 percent were Hispanic; 19 per-
cent were age 35–44, 14 percent were 12–17, and 16 
percent were 21–24. In Houston, 66 percent were 
male, 43 percent were Anglo, 34 percent were Black, 
and 18 percent were Hispanic. Some 17 percent of 
the Houston patients were age 35–44, and another 17 
percent were 21–24. 
Marijuana was the primary problem for 19 percent of 
admissions to treatment programs in 2004 (exhibit 
30). The average age was 22. Some 43 percent were 
Hispanic, 33 percent were White, and 22 percent were 
Black; 53 percent had legal problems or had been re-
ferred from the criminal justice system, and these cli-
ents were less frequent users of marijuana than those 
who came to treatment for other reasons. The criminal 
justice-referred clients reported using marijuana on 
6.6 days in the month prior to admission, compared 
with 11 days for the non-criminal justice referrals. The 
same differences were reported for number of days in 
the past month that a second problem drug was used 
(2.9 vs. 5.5 days) and the number of days a third prob-
lem drug was used (2.5 vs. 4.7 days). All these differ-
ences were significant at p<.0001. Criminal justice 
referrals were more likely to report no second problem 
drug (42 vs. 35 percent for non-criminal justice refer-
rals); 31 percent of the criminal justice and 29 percent 
of the non-criminal justice referrals reported a second 
problem with alcohol; 1.3 percent of criminal justice 
and 6 percent of non-criminal justice referrals had a 
second problem with crack cocaine; and 10 percent of 
criminal justice and 11 percent of non-criminal justice 
referrals had a second problem with powder cocaine.  
The Addiction Severity Index (ASI) scores were 
lower for justice referrals: 30 percent of the criminal 
justice referrals reported employment problems ver-
sus 45 percent non-criminal justice referred clients; 
for sickness or health problems, 14 percent versus 20 
percent; for family problems, 26 percent versus 45 
percent; for social problems with peers, 20 percent 
versus 32 percent; for emotional problems, 18 per-
cent versus 36 percent; and for substance abuse prob-
lems, 37 percent versus 56 percent. These differ-
ences, all of which were significant at p<.0001, indi-
cate that marijuana users who are referred to treat-
ment by the criminal justice system may be more 
appropriate for short-term intervention, with the 
more impaired marijuana users in need of more in-
tensive treatment services. 
Cannabis was identified in 35 percent of all the exhib-
its analyzed by DPS laboratories in 2000, but its rep-
resentation dropped to 27 percent in 2004 (exhibit 6). 
The Houston DEA Field Division reports hydroponic 
marijuana is especially available in Asian communi-
ties and that multi-kilogram amounts are available in 
the Austin area. In the Dallas-Fort Worth area, 
Mexican marijuana is readily available, but there are 
continuing seizures of domestically grown marijuana 
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(both indoor and outdoor grown). Mexican “sin-
semilla” is also plentiful. Marijuana is reported as 
stable in the El Paso Division. In the Dallas Division, 
Mexican marijuana is readily available, along with 
domestically grown marijuana. Prices are reported to 
be dropping to below the cost to dealers because of 
increased availability, and indoor grown marijuana is 
producing THC content as high as 15 percent. 
High quality sinsemilla sells for $900–$1,200 per 
pound in the Dallas-Fort Worth area, $800 per pound 
in Lubbock, and $600 per pound in Houston. Cana-
dian BC Bud sells for $3,300 in Houston. Hydroponic 
sells for $3,500 per pound in Houston, $4,600 in 
McAllen, $3,000 in Austin, and $3,800 in Dallas. The 
average price for a pound of commercial grade mari-
juana is $140–$160 in Laredo, $100–$200 in 
McAllen, $350–$450 in San Antonio, $350–$375 in 
Austin, $350–$425 in Houston, $500 in El Paso, 
$500–$700 in Alpine, $375–$600 in Midland, $350–
$800 in the Dallas-Fort Worth area, $500–$600 in 
Lubbock, and $340–$500 in Tyler. Locally grown 
indoor marijuana sells for $3,800 per pound in Dallas. 
Exhibit 16 shows the decline in prices since 1992. 
Stimulants 
Amphetamine-type substances come in different 
forms and with different names. “Speed” (“meth,” 
“crank”) is a powdered methamphetamine of rela-
tively low purity and is sold in grams or ounces. It 
can be snorted or injected. “Pills” can be pharmaceu-
tical grade stimulants, such as dextroamphetamine, 
Dexedrine, Adderall, or Ritalin (methylphenidate), or 
they can be methamphetamine powder that has been 
pressed into tablets and sold as amphetamines or ec-
stasy. Pills can be taken orally, crushed for inhala-
tion, or dissolved in water for injection. There is also 
a damp, sticky powder of higher purity than “Speed” 
that is known as “Base” in Australia and “Peanut 
Butter” in parts of the United States. “Ice,” also 
known as “Crystal” or “Tina,” is methamphetamine 
that has been “washed” in a solvent to remove impu-
rities; it has longer-lasting physical effects and purity 
levels above 80 percent. Ice can be smoked in a glass 
pipe, “chased” on aluminum foil, mixed with mari-
juana and smoked through a bong, or injected.  
The secondary school survey reported that lifetime 
use of uppers was 8.1 percent in 1998 and 6.0 per-
cent in 2004. Past-month use was 3.1 percent in 1998 
and 2.5 percent in 2004. 
Among Texas adults, 12 percent reported lifetime 
use of uppers and 1 percent reported past-month use 
in 2000. In comparison, lifetime use was 10 percent 
and past-month use was 1 percent in 1996. The dif-
ference in past-year use from 1996 to 2000 (1.1 to 
1.9 percent) was statistically significant. 
There were 144 calls to Texas poison control centers 
involving exposure to methamphetamines in 1998, 
183 in 1999, 264 in 2000, 321 in 2001, 382 in 2002, 
389 in 2003 and 423 in 2004. Of these 2004 calls, 
there were 104 mentions of “ice” or “Crystal.” There 
were also 187 calls involving abuse or misuse of am-
phetamine pills, phentermine, or Adderall, and an-
other 21 calls involving abuse or misuse of Ritalin. 
Forrester’s study of all calls involving Ritalin to poi-
son control centers in Texas between 1998 and 2004 
found that 8.5 percent involved misuse and abuse. Of 
these abuse/misuse calls, 62 percent involved males, 
20 percent were younger than 13, 55 percent were 
age 13–19, and 25 percent were older than 19. 
Ninety-three percent had swallowed the drug, 7 per-
cent had inhaled it, and 67 percent of these 
abuse/misuse calls also had used other substances. As 
compared to non-abuse calls, abusers were signifi-
cantly more likely to be older and to have misused 
the drug while at school and to suffer minor, moder-
ate, or major effects from using the drug. 
 
DAWN ED reports test specifically for amphetamine 
as compared to methamphetamine. In Dallas-Fort 
Worth, methamphetamine represented 8 percent of 
the reports for major substances of abuse, and am-
phetamine accounted for 6 percent of the reports. In 
Houston, methamphetamine represented 1 percent of 
all reports, with amphetamine representing 4 percent. 
Of the methamphetamine patients in Dallas-Fort 
Worth, 66 percent were male, 74 percent were An-
glo, 3 percent were Black, and 13 percent were His-
panic; 22 percent were age 35–44 and 20 percent 
were 25–29. In Houston, 63 percent were male, 75 
percent were Anglo, 7 percent were Black, and 10 
percent were Hispanic; 23 percent were age 21–24 
and 22 percent were 25–29. Patients reporting am-
phetamines were less likely than methamphetamine 
patients to be male: in Dallas-Fort Worth, 58 percent 
were male and in Houston, 57 percent were male. In 
Dallas-Fort Worth, 74 percent were Anglo, 8 percent 
were Black, and 12 percent were Hispanic, but in 
Houston, 60 percent were Anglo, 23 percent were 
Black, and 12 percent were Hispanic. In Dallas-Fort 
Worth, the most common age group was 35–44, (24 
percent of admissions). In Houston, the population 
was younger; 18 percent were 21–24 and 17 percent 
were 25–29. 
Methamphetamine/amphetamine admissions to treat-
ment programs increased from 5 percent of all ad-
missions in 2000 to 10 percent in 2004, and the aver-
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age age of clients admitted for a primary problem 
with stimulants increased. In 1985, the average age 
was 26; in 2004, it was 30. The proportion of White 
clients rose from 80 percent in 1985 to 89 percent in 
2004, while the proportion of Hispanics dropped 
from 11 percent to 8 percent and the proportion of 
Blacks dropped from 9 percent to 1 percent. Unlike 
the other drug categories, more than one-half of 
these clients entering treatment were women (53 
percent) (exhibit 30). The proportion smoking ice 
also increased from less than 1 percent in 1988 to 37 
percent in 2004. The percentage of clients injecting 
methamphetamine dropped from 84 percent in 1988 
to 45 percent in 2004 (exhibit 17). 
Users of amphetamines or methamphetamine tend to 
differ depending on their route of administration, as 
exhibit 18 shows. Those who took the substance 
orally tended to be users of pills. Methamphetamine 
injectors were more likely to have been in treatment 
before (60 percent readmissions) compared with 
amphetamine pill takers (48 percent), ice smokers 
(40 percent), or inhalers (37 percent). 
Statewide, there were 17 deaths in which ampheta-
mines or methamphetamines were mentioned in 
1997, 20 in 1998, 21 in 1999, 39 in 2000, 51 in 2001, 
69 in 2002, and 80 in 2003. Of the decedents in 
2003, 70 percent were male, 84 percent were White, 
and the average age was 35. 
To make methamphetamine, local labs are using the 
“Nazi method,” which includes ephedrine or pseu-
doephedrine, lithium, and anhydrous ammonia, and 
the “cold method,” which uses ephedrine, red phos-
phorus, and iodine crystals. The “Nazi method” is 
the most common method used in North Texas. Be-
fore these methods became common, most illicit labs 
used the “P2P method,” which is based on 1-phenyl-
2-propanone. The most commonly diverted chemi-
cals are 60-milligram pseudoephedrine tablets such 
as Xtreme Relief, Mini-Thins, Zolzina, Two-Way, 
and Ephedrine Release. 
Methamphetamine and amphetamine together repre-
sented 16 percent of all items examined by DPS 
laboratories in 2000, but the percentage increased to 
24 percent in 2004 (exhibit 6). Twenty-three percent 
of the exhibits were methamphetamine, and less than 
1 percent was amphetamine.  
Methamphetamine is more of a problem in the north-
ern half of the State, as exhibit 19 shows. In Abilene, 
54 percent of all of the drug items examined by the 
DPS laboratory were methamphetamine, while in  
 
McAllen and Laredo, only 1 percent were. Labs in 
the northern part of the State were also more likely to 
report analyzing substances that turned out to be 
ammonia or pseudoephedrine, chemicals used in the 
manufacture of methamphetamine. The NFLIS re-
port shows that methamphetamine is also more of a 
problem in the West than in the rest of the country: 
38 percent of all items examined in the western 
United States were methamphetamine, compared 
with 8 percent in the South and the Midwest and less 
than 1 percent in the East.  
The Houston Field Division reports that the avail-
ability of both Mexican and locally produced 
methamphetamine is increasing. Ice comes from 
California via Houston and Dallas. Ice also comes 
from the State of Jalisco, and methamphetamine is 
produced in the States of Aguascalientes, Zacatecas, 
Michoacan, and Guadalajara. Methamphetamine is 
also manufactured in Texas by motorcycle gangs and 
independent producers using small mobile pseu-
doephedrine labs that produce small amounts for 
distribution in the local area.  
The Dallas Field Division reports that the availability 
of methamphetamine, especially ice, is steady or 
rising at the retail level and has emerged as the pri-
mary problem in the Lubbock and Amarillo areas. 
There is continued reporting of use of ice in the club 
and rave scene, with some reports that sales of ice 
rival ecstasy sales. Mexican methamphetamine 
dominates this market, and it is available for pur-
chase in multipound quantities and at a lower price 
than 6 months ago. Mexican ice has a larger profit 
margin than locally produced methamphetamine, so 
low quality methamphetamine may be sold as “ice” 
by some dealers. High-purity methamphetamine is 
primarily distributed by Mexican nationals, but 
Asian gangs are also involved. 
The purity for 1–10 grams has risen from 46 percent 
pure in the Dallas area in 2000 to 65 percent pure in 
2004, according to NFLIS data. At the same time, 
the number of labs seized has risen from 1,707 to 
3,908, yet prices are dropping. The price for a pound 
of methamphetamine was $8,000 in Houston 6 
months ago; now it is $7,000. A pound sells for 
$4,500–$5,500 in Laredo, $6,000–$8,000 in San 
Antonio, $8,000 in Midland, $4,000–$10,000 in Dal-
las and in Fort Worth, and $7,000–$8,000 in Lub-
bock. An ounce of domestic methamphetamine sells 
for $600–$800 in Dallas (it was $700–$1,000 a year 
ago), while an ounce of Mexican sells for $400. An 
ounce of methamphetamine sells for $600 in Fort 
Worth, $600–$1,200 in Tyler, $700 in Lubbock,  
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$960 in El Paso, $600 in Alpine, $700 in Midland, 
$500–$850 in Houston, $700–$1,000 in San Anto-
nio, and $900–$1,250 in Waco.  
The price of ice has dropped even more, from 
$13,000–$17,000 to $8,000–$12,000 in a year in 
Houston. It costs $8,500–$16,000 in Dallas, $9,000–
$10,000 in Fort Worth, and $10,000–$18,000 in Ty-
ler. An ounce of ice sells for $1,000–$1,400 in Dal-
las, $800–$1,000 in Fort Worth, $1,200 in Tyler, 
$700–$1,200 in Houston, and $1,000–$1,500 in San 
Antonio. 
In the Galveston area, outreach workers reported the 
amount of crystal methamphetamine on the street is 
increasing each month, and there is more abuse of 
pseudoephedrine products. In Fort Worth, ice is used 
more often than regular methamphetamine.  
Depressants 
This “downer” category includes three groups of 
drugs: barbiturates, such as phenobarbital and se-
cobarbital (Seconal); nonbarbiturate sedatives, such as 
methaqualone, over-the-counter sleeping aids, chloral 
hydrate, and tranquilizers; and benzodiazepines, such 
as diazepam (Valium), alprazolam (Xanax), fluni-
trazepam (Rohypnol), clonazepam (Klonopin or 
Rivotril), flurazepam (Dalmane), lorazepam (Ativan), 
and chlordiazepoxide (Librium and Librax). Rohypnol 
is discussed separately in the Club Drugs section of 
this report. 
The 2004 secondary school survey reported lifetime 
use of downers decreased from 7.1 percent in 2002 
to 5.9 percent in 2004. Past-year use decreased from 
3.4 percent in 2002 to 2.6 percent in 2004. 
The 2000 adult survey reported lifetime use of 
downers at 6.9 percent and past-month use at 0.6 
percent; in 1996, lifetime use was 6.2 percent and 
past-month use was 0.3 percent. The difference in 
past-year use between 1996 and 2000 (1 percent to 
1.8 percent) was statistically significant. 
About 1 percent of the clients entering treatment in 
2004 had a primary problem with barbiturates, seda-
tives, or tranquilizers. These clients were the most 
likely to be female and highly impaired, based on 
their ASI scores (see exhibit 30).  
Alprazolam, clonazepam, and diazepam are among 
the 15 most commonly identified substances accord-
ing to DPS lab reports, although none of them repre-
sent more than 3 percent of all items examined in a 
year. The proportion of cases that are alprazolam 
(Xanax) continues to increase (exhibit 20). 
Alprazolam sells for $2–$5 in Dallas, Fort Worth, 
and Houston, and for $5–$10 in Tyler. Depending on 
the dosage unit, diazepam sells for $1–$10 in Dallas, 
Fort Worth, and Tyler. 
Street outreach workers in the Galveston area report 
Xanax is becoming more popular with young adults 
Club Drugs and Hallucinogens 
Exhibit 21 shows the demographic characteristics of 
clients entering DSHS-funded treatment programs 
statewide with a problem with a club drug. The row 
“Primary Drug” shows the percentage of clients cit-
ing a primary problem with the club drug shown at 
the top of the column. The rows under the heading 
“Other Primary Drug” show the percentage of clients 
who had a primary problem with another drug, such 
as marijuana, but who had a secondary or tertiary 
problem with one of the club drugs shown at the top 
of the table. Note that the treatment data uses a 
broader category, “Hallucinogens,” that includes ly-
sergic acid diethylamide (LSD), dimethyltryptamine 
(DMT), STP, mescaline, psilocybin, and peyote. 
Excluding ketamine (due to the small number of 
cases), exhibit 21 shows that hallucinogen and Ro-
hypnol admissions are the most likely to be male, 
gamma hydroxybutyrate (GHB) clients are the most 
likely to be White, phencyclidine (PCP) clients are 
the most likely to be Black, Rohypnol clients are the 
youngest, and GHB clients are the oldest. While us-
ers of PCP are the most likely to have a primary 
problem with PCP, users of Rohypnol, ecstasy, and 
hallucinogens are more likely to have primary prob-
lems with marijuana. Users of GHB tend to have a 
primary problem with methamphetamine. 
Exhibit 22 shows the percentage of exhibits identified 
by DPS laboratories that contained various club drugs. 
Only the proportion of PCP exhibits has not decreased 
over time, although the increase in MDMA exhibits 
between 2003 and 2004 is of concern. 
Dextromethorphan 
The most popular dextromethorphan (DXM) prod-
ucts are Robitussin-DM, Tussin, and Coricidin 
Cough and Cold Tablets HBP, which can be pur-
chased over the counter and can produce hallucino-
genic effects if taken in large quantities. Coricidin 
HBP pills are known as “Triple C’s” or “Skittles.” 
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The 2004 Texas school survey reported that 4.3 per-
cent of secondary students indicated they had used 
DXM. Use increased from 2.5 percent in 7th grade to 
5.8 percent in 12th grade. There was no difference 
by gender, but Whites reported higher lifetime use 
(6.1 percent) than Native Americans (5.8 percent), 
Hispanics (3.6 percent), or Blacks (2.4 percent).  
Poison control centers reported the number of abuse 
and misuse cases involving dextromethorphan rose 
from 99 in 1998 to a high of 432 in 2002, and 
dropped to 232 in 2004. Average age was 21.6. The 
number of cases involving abuse or misuse of Cori-
cidin HBP was 7 in 1998 and rose to 268 in 2002 and 
then decreased to 229 cases in 2004. Average age in 
2004 was 16.5 years, which shows that youths can 
easily access and misuse this substance. 
DPS labs examined 2 substances in 1998 that were 
dextromethorphan, 13 in 1999, 36 in 2000, 18 in 
2001, 42 in 2002, 10 in 2003, and 15 in 2004.  
Ecstasy (Methylenedioxymethamphetamine or 
MDMA) 
The 2004 Texas secondary school survey reported 
that lifetime ecstasy use dropped from a high of 8.6 
percent in 2002 to 5.5 percent in 2004, while past-
year use dropped from 3.1 percent to 1.8 percent. 
The 2000 adult survey reported that 3.1 percent had 
ever used ecstasy and 1.0 percent had used in the 
past year. 
Texas Poison Control Centers reported 23 calls involv-
ing misuse or abuse of ecstasy in 1998, 46 in 1999, 119 
in 2000, 155 in 2001, 172 in 2002, 284 in 2003, and 
302 in 2004. In 2004, the average age was 21. 
There were 45 reports in Dallas-Fort Worth and 109 
reports in Houston of ecstasy as one of the major 
substances of abuse recorded in EDS reporting to 
DAWN. In Dallas-Fort Worth, 62 percent of the un-
weighted ecstasy reports involved males, as did 58 
percent of the Houston reports. Anglos accounted for 
38 percent of the Dallas-Fort Worth patients and 44 
percent of the Houston patients, while 27 percent in 
Dallas-Fort Worth were Black, as were 35 percent in 
Houston. Thirteen percent of the patients in Dallas-
Forth Worth and 14 percent of the patients in Hous-
ton were Hispanic. Fifty-eight percent of the patients 
in Dallas-Fort Worth and 56 percent of the patients 
in Houston were age 18–24, with another 13 percent 
in Dallas-Fort Worth and 20 percent in Houston be-
ing 12–17. 
There were 63 admissions for a primary, secondary, 
or tertiary problem with ecstasy in 1998, 114 in 
1999, 199 in 2000, 349 in 2001, 521 in 2002, 502 in 
2003, and 561 in 2004. Approximately 36 percent 
reported marijuana as their primary problem drug, 
compared with 14 percent who reported ecstasy as 
their primary problem drug. Ecstasy has spread out-
side the White club scene and into the Hispanic and 
Black communities, as evidenced by the declining 
proportion of White treatment clients.  
In 1999, there were two deaths that involved ecstasy 
in Texas. There was one death in 2000, five in 2001, 
five in 2002, and two in 2003.  
Exhibit 22 shows the substances identified by DPS 
labs. The labs identified MDMA in 107 exhibits in 
1999, 387 in 2000, 814 in 2001, 503 in 2002, 484 in 
2003, and 691 in 2004. Methylenedioxyampheta-
mine (MDA) was identified in 31 exhibits in 1999, 
27 in 2000, 48 in 2001, 90 in 2002, 94 in 2003, and 
60 in 2004.  
According to the Houston DEA Field Division, ec-
stasy is more available at clubs, raves, and gyms, and 
use is increasing in the Galveston, Beaumont, and 
Fort Hood areas. Logos on the tablets include A&E, 
Blue Dolphins, Bear, Music Notes, Crescent Moon, 
Yellow Dolphins, Aladdin Lamp, Yellow Alligator, 
Yellow Trumpets, Omega, X-5 (BMW), JJ, Spade, 
and Footprints. While most tablets contain MDMA, 
some have high concentrations of caffeine or 
methamphetamine, with traces of ketamine in some 
tablets. Ecstasy is stable in Austin, but use has in-
creased in the Waco area among soldiers stationed at 
Fort Hood.  
The Dallas DEA Field Division reports that ecstasy 
made in Europe is transshipped through other U.S. 
ports into the Metroplex area. The club drug distribu-
tion in the Dallas and Houston Divisions is domi-
nated by Asian traffickers who are also involved 
with hydroponic marijuana and methamphetamine. 
Combinations of drugs mentioned in Dallas include 
“candy flipping” (LSD and MDMA), “hippie flip-
ping” (mushrooms and MDMA), “love flipping” 
(mescaline and MDMA), “robo flipping” (DXM and 
MDMA), and “elephant flipping” (PCP and 
MDMA).  
Single dosage units of ecstasy sell for $6–$20 in Dal-
las, $5–$12.50 in Fort Worth, $12–$25 in Tyler, 
$4.75–$25 in Houston, $20–$30 in McAllen, $20 in 
Laredo, and $11–$20 in San Antonio. Multiple dos-
age units (1,000 tablets) sell for $5,000–$8,000 in 
Houston.  
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Gamma Hydroxybutyrate (GHB), Gamma Butyrate 
Lactone (GBL), 1-4 Butanediol (1,4 BD) 
The 2000 Texas adult survey reported that 0.4 per-
cent had ever used GHB and 0.1 percent had used in 
the past year. 
The number of cases of misuse or abuse of GHB or 
its precursors reported to Texas Poison Control Cen-
ters was 110 in 1998, 150 in 1999, 120 in 2000, 119 
in 2001, 100 in 2002, 66 in 2003, and 84 in 2004. 
The average age of the abusers in 2004 was 26, and 
of the callers whose gender was known, 52 percent 
were male. 
The unweighted DAWN data show there were 41 
GHB reports in Dallas-Fort Worth, and there were 4 
in Houston. Of the patients in Dallas-Fort Worth, 49 
percent were male, 78 percent were Anglo, 27 per-
cent were age 18–24 years old, 39 percent were 25–
34, and 29 percent were 35–54. 
Adult and adolescent clients with a primary, secon-
dary, or tertiary problem with GHB, GBL, or 1,4 
butanediol (1,4 BD) are seen in treatment. In 1998, 2 
were admitted, compared with 17 in 1999, 12 in 
2000, 19 in 2001, 35 in 2002, 31 in 2003, and 45 in 
2004. Clients who used GHB tended to be the oldest 
of all the club drug users (average age 29) and were 
the most likely to be White (89 percent) and female 
(67 percent). GHB users were more likely to have 
used the so-called “hard-core” drugs; 47 percent had 
a history of injecting drug use and 56 percent had a 
primary problem with amphetamines or metham-
phetamine. Because of the sleep-inducing properties 
of GHB, users will also use methamphetamine so 
they can stay awake while they are “high” on GHB 
or they use GHB to “come down” from their use of 
methamphetamine (exhibit 21).  
In 1999, there were three deaths that involved GHB, 
compared with five in 2000, three in 2001, two in 
2002, and two in 2003. 
In 1998, there were 18 items identified by DPS labs 
as being GHB; in 1999 112 were GHB, 4 were GBL, 
and 4 were 1,4 BD (exhibit 22). In 2000, 45 were 
GHB, 7 were GBL, and 4 were 1,4 BD. In 2001, 34 
were GHB, 7 were GBL, and 19 were 1,4 BD. In 
2002, 81 were GHB, 6 were GBL, and 4 were 1,4 
BD. In 2003, 150 were GHB, 5 were GBL, and none 
was 1,4 BD. In 2004, 95 were GHB, 1 was GBL, and 
none was 1,4 BD. In 2004, 96 percent of the GHB 
items were identified in the DPS lab in the Dallas 
area, which shows use of GHB is centered in this 
area of the State. 
In Dallas, the price of GHB had increased from 
$100–$200 per gallon to $250–$500 per gallon. A 
dose of GHB costs $20 in Dallas and $5–$10 in 
Lubbock and San Antonio. A 16-ounce bottle costs 
$100 in San Antonio and two 2-ounce bottles cost 
$110 in Fort Worth. The DEA Field Division in Dal-
las reports that GHB is being manufactured in home 
laboratories where GBL ordered over the Internet is 
mixed with other chemicals and water to produce 
GHB. 
Ketamine 
The 2000 adult survey reported that 0.3 percent had 
ever used ketamine and 0.1 percent had used it in the 
last year. 
Eight cases of misuse or abuse of ketamine were 
reported to Texas Poison Control Centers in 1998, 
compared with 7 in 1999, 15 in 2000, 14 in 2001, 10 
in 2002, 17 in 2003, and 7 in 2004.  
There was one report of ketamine in the unweighted 
2004 Dallas-Fort Worth DAWN emergency depart-
ment reports and zero in Houston. 
Seven clients were admitted to DSHS-funded treat-
ment programs in 2004 with a secondary or tertiary 
problem with ketamine (exhibit 21). Forty-three per-
cent had a history of injecting drug use, and all had 
problems with the legal or criminal justice system. 
There were two deaths in 1999 that involved use of 
ketamine, none in 2000, one in 2001, and one in 
2002. 
In 1999, 25 substances were identified as ketamine 
by DPS labs. There were 29 in 2000, 119 in 2001, 78 
in 2002, 84 in 2003, and 73 in 2004 (exhibit 21).  
Ketamine costs $2,200–$2,500 per liter in Fort 
Worth and $65 per vial in Tyler, with a dose selling 
for $20 per pill or gram. It costs $60 retail for a 10-
milliliter vial and $15–$20 for 0.2 grams of powder. 
LSD and Other Hallucinogens 
The secondary school survey shows that use of hal-
lucinogens (defined as LSD, PCP, mushrooms, etc.) 
continues to decrease. Lifetime use peaked at 7.4 
percent in 1996 and dropped to 4.8 percent by 2004. 
Past-month use dropped from 2.5 percent in 1998 to 
1.6 percent in 2004.  
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The 2000 adult survey reported that 8.8 percent of 
Texas adults had ever used LSD and 0.9 percent had 
used in the past year. 
Texas Poison Control Centers reported 82 mentions 
of abuse or misuse of LSD in 1998, 113 in 1999, 97 
in 2000, 70 in 2001, 129 in 2002, 20 in 2003, and 22 
in 2004. There were also 98 cases of intentional mis-
use or abuse of hallucinogenic mushrooms reported 
in 1998, 73 in 1999, 110 in 2000, 94 in 2001, 151 in 
2002, 130 in 2003, and 172 in 2004. Average age in 
2004 was 21 for the LSD cases and 19.6 for the 
mushroom cases. 
There were 29 unweighted reports in Dallas-Fort 
Worth DAWN and 30 in Houston which involved 
LSD or other hallucinogens. Of the Dallas-Fort 
Worth patients, 76 percent were male, 59 percent 
were Anglo, 7 percent were Black, and 14 percent 
were Hispanic; 10 percent were younger than 18, 66 
percent were 18–24, and 21 percent were 25–34. In 
Houston, 75 percent were male, 43 percent were 
Anglo, 10 percent were Black, and 33 percent were 
Hispanic; 20 percent were younger than 18, 33 per-
cent were 18–24, and 20 percent were 25–34. 
The number of adults and youths with a primary, 
secondary, or tertiary problem with hallucinogens 
entering treatment is decreasing. There were 636 
such admissions in 2000, 486 in 2001, 436 in 2002, 
319 in 2003, and 266 in 2004. Of the admissions in 
2004, the average age was 23, 75 percent were male, 
61 percent were White, 25 percent were Hispanic, 
and 12 percent were Black. Sixty-four percent were 
referred from the criminal justice or legal system, 
and 25 percent had a history of injecting drug use 
(exhibit 21). 
Statewide, there were two deaths in 1999 with a 
mention of LSD. No deaths with a mention of LSD 
have been reported since. 
DPS labs identified 69 substances as LSD in 1998, 
compared with 406 in 1999, 234 in 2000, 122 in 2001, 
10 in 2002, 10 in 2003, and 24 in 2004 (exhibit 22).  
A dosage unit of LSD is selling for $1–$10 in Dallas, 
$5–$10 in Tyler, $6–$10 in Fort Worth, $7 in Lub-
bock, and $8–$12 in San Antonio. A dosage sheet of 
100 sells for $800 in San Antonio.  
Phencyclidine (PCP) 
The 2000 Texas adult survey reported that 0.9 per-
cent of adults had ever used PCP or Angel Dust, and 
0.1 percent had used it in the past year. 
Texas Poison Control Centers reported cases of 
“Fry,” “Amp,” “Water,” “Wack,” or “PCP.” Often, 
marijuana joints are dipped in formaldehyde that 
contains PCP or PCP is sprinkled on the joint. The 
number of cases involving PCP increased from 102 
in 1998 to a high of 237 in 2002 and decreased to 
160 in 2004. There were also 18 cases involving 
misuse or abuse of formaldehyde or formalin in 2003 
and 55 in 2004. These formaldehyde or formalin 
cases may be linked to the use of PCP, but the re-
cords were not clear. 
There were 71 unweighted reports of PCP in Dallas-
Fort Worth DAWN emergency departments and 240 
in Houston in 2004. Of these patients, 82 percent in 
Dallas-Fort Worth and 69 percent in Houston were 
male. Some 63 percent in Dallas-Fort Worth were 
Black, as were 72 percent in Houston. Twenty-five 
percent in Dallas-Fort Worth were Anglo, as were 13 
percent in Houston, and 4 percent in Dallas-Fort 
Worth and 10 percent in Houston were Hispanic. 
PCP patients were not young; only 7 percent in each 
area were younger than 18. Thirty-two percent in 
Dallas-Fort Worth and 42 percent in Houston were 
age 18–24; 39 percent in Dallas-Fort Worth and 40 
percent in Houston were 25–34; and 20 percent in 
Dallas-Fort Worth and 9 percent in Houston were 
35–54. 
Adolescent and adult admissions to treatment with a 
primary, secondary, or tertiary problem with PCP 
have varied over time, rising from 164 in 1998 to 
417 in 2003 and then dropping to 295 in 2004 (ex-
hibit 21). Of these clients in 2004, 81 percent were 
Black, 57 percent were male, 56 percent were in-
volved in the criminal justice system, 22 percent 
were employed, and 14 percent were homeless. 
While 43 percent reported a primary problem with 
PCP, another 30 percent reported a primary problem 
with marijuana, which demonstrates the link between 
these two drugs and “Fry.”  
There were three deaths in 1999, three in 2000, five 
in 2001, eight in 2002, and two in 2003 that involved 
PCP.  
DPS labs identified 10 substances as PCP in 1998, 
84 in 1999, 104 in 2000, 163 in 2001, 95 in 2002, 
143 in 2003, and 161 in 2004 (exhibit 22). 
PCP costs $700–$1,200 per ounce in San Antonio 
and $30 per dosage unit in McAllen. In Dallas, it 
costs $3,800 for a 16-ounce bottle, $375–$450 per 
ounce, $25 per cigarette, and $10 for a piece of a 
"sherm" stick. In Fort Worth, it costs $26,000–
$28,000 per gallon. 
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Street outreach workers in the Galveston/Brazoria 
area report “Water” is a problem. 
Rohypnol 
Rohypnol (flunitrazepam) is a benzodiazepine that 
was never approved for use in the United States. The 
drug is legal in Mexico, but since 1996, it has been 
illegal to bring it into the United States. It continues 
to be a problem along the Texas-Mexico border. As 
shown in exhibit 23, the 2004 secondary school sur-
vey found that students from the border area were 
about three times more likely to report Rohypnol use 
than those living elsewhere in the State (9.1 percent 
vs. 2.5 percent lifetime, and 3.5 percent vs. 2.5 per-
cent current use). Use on both the border and non-
border has declined since its peak in 1998. 
The 2000 Texas adult survey found that 0.8 percent 
reported lifetime use and 0.1 percent reported past-
year use of Rohypnol. 
The number of confirmed exposures to Rohypnol 
reported to the Texas Poison Control Centers peaked 
at 102 in 1998; 62 cases were reported in 2004. The 
average age in 2004 was 17; 52 percent were male; 
and 84 percent lived in counties on the border. A 
study of all the exposure calls between 1998 and 
2003 found a significantly higher proportion of fluni-
trazepam abuse and malicious use calls occurred in 
border counties. The majority of the abuse calls in-
volved males, while the majority of malicious use 
calls involved females. Most abuse calls involved 
adolescents, while the majority of the malicious calls 
involved adults. Abuse cases occurred most fre-
quently at the patient’s own residence or at school, 
while malicious use occurred most often in public 
areas, with the patient’s own residence ranking sec-
ond (Forrester 2004). This analysis provides evi-
dence of two patterns of Rohypnol use: (1) recrea-
tional use and abuse by adolescent males and (2) use 
of the drug with criminal intent on adult women. 
There were no reports of Rohypnol in the Dallas-Fort 
Worth DAWN data in 2004, and there were four in 
Houston. 
The number of youths and adults admitted into 
treatment with a primary, secondary, or tertiary prob-
lem with Rohypnol has varied: 247 in 1998, 364 in 
1999, 324 in 2000, 397 in 2001, 368 in 2002, 331 in 
2003, and 221 in 2004. In 2004, clients abusing Ro-
hypnol were among the youngest of the club drug 
patients (average age 19), and they were predomi-
nately Hispanic (97 percent), which reflects the 
availability and use of this drug along the border 
(exhibit 21). Some 67 percent were involved with the 
criminal justice or legal system. While 13 percent of 
these clients said that Rohypnol was their primary 
problem drug, 48 percent reported a primary problem 
with marijuana. 
DPS lab exhibits for Rohypnol numbered 43 in 1988, 
56 in 1999, 32 in 2000, 35 in 2001, 22 in 2002, 17 in 
2003, and 16 in 2004. The decline in the percentage 
of Rohypnol seizures, as shown in exhibit 22, paral-
lels the declines seen in other indicators. 
Although Roche is reported to no longer be making 
the 2-milligram Rohypnol tablet (a favorite with 
abusers), generic versions are still produced.  The 
blue dye added to the Rohypnol tablet to warn poten-
tial victims is not in the generic version. Unfortu-
nately, the dye is not proving effective, since people 
intent on committing sexual assault may employ blue 
tropical drinks and blue punches into which Rohyp-
nol can be slipped. 
Rohypnol sells for $2–$4 per pill in San Antonio. 
Other Abused Substances 
Inhalants 
The 2004 elementary school survey found that 11 
percent of students in grades 4 to 6 had ever used 
inhalants, and 8 percent had used in the school year. 
The 2004 secondary school survey found that 17 
percent of students in grades 7–12 had ever used 
inhalants and 7 percent had used in the past month.  
Inhalant use exhibits a peculiar age pattern not ob-
served with any other substance. The prevalence of 
lifetime and past-month inhalant use was higher in 
the lower grades and lower in the upper grades (ex-
hibit 24). This decrease in inhalant use as students 
age may be partially related to the fact that inhalant 
users drop out of school early and hence are not in 
school in later grades to respond to school-based 
surveys. 
The 2004 poison control center data show that auto-
motive products such as carburetor cleaner and 
transmission fluid were the inhalants abused or mis-
used the most often, with 67 calls (exhibit 25). Aver-
age age was 29. There were 30 calls of abuse or mis-
use of paint (average age 29), 29 calls of misuse of 
Freon or other propellants (average age 21), 22 calls 
for misuse of air fresheners or dusting sprays (aver-
age age of 18), 21 calls of misuse of gasoline (aver-
age age 24), and 13 calls about abuse of toluene or 
mineral spirits of thinning agents (average age 22).  
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There were 42 unweighted reports of inhalants in 
Dallas-Fort Worth and 52 in Houston in the 2004 
DAWN emergency department reports. In Dallas-
Fort Worth, 71 percent were male, 48 percent were 
Anglo, 21 percent were Black, and 31 percent were 
Hispanic, while in Houston, 71 percent were male, 
31 percent were Anglo, 17 percent were Black, and 
52 percent were Hispanic. In Dallas-Fort Worth, 26 
percent were age 30–34 and 24 percent were younger 
than 21, whereas in Houston, 23 percent were 35–44, 
21 percent were 25–29, and 21 percent were younger 
than 21. 
Inhalant abusers represented 0.2 percent of the ad-
missions to treatment programs in 2004. The clients 
tended to be male (60 percent) and Hispanic (77 per-
cent). The overrepresentation of Hispanics is related 
to the fact that DSHS had developed and funded 
treatment programs targeted specifically to this 
group. The average age of the clients was 22. Sixty-
five percent were involved with the criminal justice 
system; average education level was 8.7 years; 10 
percent were homeless; and 17 percent had a history 
of injection drug use. 
In 2000, there were 12 deaths involving misuse of 
inhalants, compared with 15 in 2001, 8 in 2002, and 
13 in 2003. The categorization of inhalant deaths is 
difficult and leads to underreporting.  However, of 
those reported in 2003, the average age was 34; 85 
percent were male; 69 percent were White; and 31 
percent were Hispanic. 
A new trend in McAllen is the use of “Whip-It” ni-
trous oxide capsules by teenagers. 
Steroids 
The Texas school survey reported that 2 percent of all 
secondary students surveyed in 2004 had ever used 
steroids and that less than 1 percent had used steroids 
during the month before the survey. Although ster-
oids can be bought across the border, the school sur-
vey found lifetime usage lower among border stu-
dents (1.4 percent) than among non-border students 
(2.1 percent). 
There were 17 persons admitted to DSHS-funded 
treatment in 2004 with a primary, secondary, or terti-
ary problem with steroids. Sixty-five percent were 
male, 59 percent were Anglo, and 35 percent were 
Hispanic; the average age was 26. Some 65 percent 
were involved with the criminal justice or legal sys-
tem; 29 percent had a primary problem with alcohol, 
24 percent had a primary problem with marijuana, 
and 18 percent had a primary problem with steroids. 
The NFLIS data for Texas reported testosterone was 
the steroid most likely to be seized and submitted for 
forensic testing.  
Carisoprodol (Soma) 
Poison control centers confirmed exposure cases of 
intentional misuse or abuse of the muscle relaxant 
carisoprodol (Soma) increased from 83 in 1998 to 
298 in 2004. In addition to these abuse and misuse 
cases, there were another 667 cases in which the 
reason for the call was suspected suicide.  
Between 1998 and 2003, 51 percent of these poison 
control center cases involved males and 83 percent 
involved persons older than 19. Carisoprodol is a 
substance that tends to be abused in combination 
with other substances. Only 39 percent of the cases 
involved that one drug; all the others involved com-
binations of drugs (Forrester, 2004). 
The unweighted DAWN emergency department re-
ports showed that in 2004, there were 160 reports of 
Soma in Dallas-Fort Worth and 429 in Houston. In 
Dallas-Fort Worth, 38 percent were male, 78 percent 
were Anglo, 30 percent were age 45–54 and 26 per-
cent were 35–44. In Houston, 46 percent were male, 
75 percent were White, 29 percent were age 35–44, 
10 percent were 45–54, and 18 percent were 30–34. 
In 2003, carisoprodol was mentioned on 51 death 
certificates. Only one of the deaths involved only 
carisoprodol. Hydrocodone, propoxyphene, alcohol, 
and benzodiazepines were also substances that were 
mentioned along with carisoprodol on the other 
death certificates.  
DPS lab exhibits of carisoprodol reported to NFLIS 
increased from 13 in 1998 to 90 in 1999, 153 in 
2000, 202 in 2001, 179 in 2002, 278 in 2003, and 
249 in 2004. 
According to the Dallas DEA Field Division, Soma 
sells for $2–$5 per tablet. 
INFECTIOUS DISEASES RELATED TO DRUG ABUSE 
Hepatitis C 
Exhibit 26 shows that 18 percent of the 8,798 tests 
for HCV exposure given in 2003 were positive. 
Some 41 percent of those with positive tests were 
exposed through injection drug use. The rates were 
higher for males, for American Indians and Blacks, 
and for persons age 40 and older. The highest HCV 
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positivity rates were reported by persons tested at 
sexually transmitted disease clinics and drug treat-
ment centers (22 percent each) and field outreach 
centers and corrections and probation settings (20 
percent each).  
Forty-eight percent of the 200 clients in narcotic 
treatment programs who were interviewed by the 
author as part of NIDA Grant R21 DA014744 said 
they were positive for hepatitis C, and 54 percent 
said a doctor had told them they had liver problems. 
However, only 5 percent reported they were HIV 
positive. 
HIV and AIDS Cases 
In 2004, the percentage of AIDS cases involving 
heterosexual exposures was greater than the percent-
age of cases related to injection drug use (exhibit 
27). The proportion related to heterosexual contact 
rose from 1 percent in 1987 to 26 percent in 2004, 
while the proportion attributed to injection drug use 
was 15 percent in 2004. 
In 1987, 3 percent of the AIDS cases were females 
older than 12; in 2004, 23 percent were female. As 
exhibit 28 shows, the proportion of Whites has 
dropped, while the proportion of Blacks and Hispan-
ics increased. 
The proportion of adult needle users entering DSHS-
funded treatment programs has decreased from 32 
percent in 1988 to 19 percent in 2004. Heroin injec-
tors are most likely to be older, and nearly two-thirds 
are people of color, while injectors of stimulants and 
cocaine are far more likely to be White (exhibit 29). 
 
For inquiries concerning this report, please contact Jane C. Max-
well, Ph.D., Research Professor, Center for Social Work Re-
search, The University of Texas at Austin, Suite 335, 1717 West 
6th Street, Austin, TX 78703, Phone: 512-232-0610, Fax: 512-
232-0617, E-mail: jcmaxwell@sbcglobal.net. 
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Exhibit 1. Dallas/Ft. Worth and Houston ED Data Summary:  2004  
 
No. of EDs Reporting per Month: 
Completeness of Data ( percent)  CEWG Area Total Eligible Hospitals1 
No. of 
Hospitals in 
DAWN Sample 
Total EDs in 
DAWN 
Sample2 90–100 percent 
50–89 
percent 
<50 
percent 
No. of EDs 
Not 
Reporting 
Dallas/ 
Ft. Worth 49 48 49 8–13 0–4 0–2 33–39 
Houston 44 37 39 9–14 0–4 0–1 24–25 
 
1Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association 
Annual Survey. 
2Some hospitals have more than one emergency department. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/13-4/14, 2005 
 
 
 
 
Exhibit 2. Percentage of Border and Nonborder Texas Secondary Students Who Had Ever Used Powder or  
 Crack Cocaine, by Grade:  2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Texas Department of State Health Services 
 
 
 
 
Exhibit 3. Characteristics of Clients Admitted to TDSHS-Funded Treatment with a Primary Problem with  
 Cocaine, by Route of Administration:  2004 
 
Characteristics Crack Cocaine Smoke 
Powder Cocaine 
Inject 
Powder Cocaine 
Inhale Cocaine All
1 
# Admissions 9,131     900     3,256     13,863     
Percent of Cocaine Admissions 66 6 23 100     
Lag-1st Use to Treatment (Years) 12     15     9     11     
Average Age 37     35     29     35     
Percent Male 54     62     54     55     
Percent Black 50     5     13     37     
Percent White 33     63     29     34     
Percent Hispanic 16     29     57     27     
Percent CJ-Involved 36     46     52     41     
Percent Employed 12     13     33     18     
Percent Homeless 18     11     5     14     
 
1Includes clients with “other” routes of administration. 
SOURCE:  Texas Department of State Health Services 
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Exhibit 4. Routes of Administration of Cocaine by Race/Ethnicity from TDSHS Treatment Admissions: 
 1993–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Texas Department of State Health Services 
 
 
 
 
Exhibit 5. Age and Race/Ethnicity of Persons Dying with a Mention of Cocaine in Texas:  1992–2003 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Bureau of Vital Statistics, Texas Department of State Health Services 
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Exhibit 6. Substances Identified by Texas DPS Labs:  1998–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  NFLIS 
 
 
 
 
Exhibit 7. Price of a Kilogram of Cocaine in Texas as Reported by the DEA:  1987–2004  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Prices reported by half year since 1993. 
SOURCE:  DEA 
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Exhibit 8. Percentage of Texas Secondary Students Who Reported They Normally Consumed Five or More  
 Drinks at One Time, by Specific Alcoholic Beverage:  1988–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Texas Department of State Health Services 
 
 
 
 
Exhibit 9. Substance Abuse Arrests Per 100,000 Population in Texas:  1994–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Texas Department of Public Safety 
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Texas 
 
 
Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005 299
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
86 87 88 89 90 91 92 93 94 95 96 97 98 99 00 01 02 03 04
Black White Hispanic
Exhibit 10. Characteristics of Clients Admitted to TDSHS-Funded Treatment with a Primary Problem with 
  Heroin, by Route of Administration:  2004 
 
Characteristic Inject Inhale Smoke All1 
# Admissions 4,651    521    51    5,424    
Percent of Heroin Admissions 86    10    1    100    
Lag-1st Use to Treatment (Years) 16    8    9    15    
Average Age 37    29    30    36    
Percent Male 71    51    51    65    
Percent Black 6    33    16    9    
Percent White 37    16    35    36    
Percent Hispanic 55    49    47    54    
Percent CJ Involved 31    33    20    31    
Percent Employed 12    14    10    13    
Percent Homeless 12    8    8    11    
 
1Includes clients with “other” routes of administration. 
SOURCE:  Texas Department of State Health Services 
 
 
 
Exhibit 11. Heroin Admissions to TDSHS-Funded Treatment by Race/Ethnicity:  1986–2004 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Texas Department of State Health Services 
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Texas 
 
 
Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005 300 
0
50
100
150
200
250
300
350
400
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Nu
mb
er
 of
 D
ea
ths
36
36.5
37
37.5
38
38.5
39
39.5
40
Ag
e (
Ye
ar
s)
Black
Hispanic
White
Age
$-
$1,000
$2,000
$3,000
$4,000
$5,000
$6,000
$7,000
$8,000
$9,000
1987 1989 1991 1h93 1h94 1h95 1h96 1h97 1h98 1h99 1h00 1h01 1h02 1h03 1h04 1h05
Exhibit 12. Age and Race/Ethnicity of Persons Dying with a Mention of Heroin in Texas:  1992–2003 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Texas Department of State Health Services 
 
 
 
 
Exhibit 13. Price1 of an Ounce of Mexican Black Tar Heroin in Texas as Reported by the DEA:  1987–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Prices reported by half year since 1993 
SOURCE:  DEA 
EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Texas 
 
 
Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005 301
0%
5%
10%
15%
20%
1988 1990 1992 1994 1996 1998 2000 2002 2004
Grade 7
Grade 8
Grade 9
Grade 10
Grade 11
Grade 12
Exhibit 14. Hydrocodone, Oxycodone, and Methadone Indicators in Texas:  1998–2004 
 
 
1”Other Opiates” refers to those other than heroin. 
SOURCES:  Texas Poison Center Network, Texas Department of State Health Services, and Texas Department of Public Safety 
 
 
 
 
Exhibit 15. Percentage of Texas Secondary Who Had Used Marijuana in the Past Month, by Grade:   
  1988–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Texas Department of State Health Services 
 
 
 
Indicator 1998 1999 2000 2001 2002 2003 2004 
Poison Control Center Cases of Abuse and Misuse      
Hydrocodone 192 264 286 339 429 414 516 
Oxycodone 12 26 22 34 68 64 77 
Methadone 16 19 21 26 50 41 106 
TDHSH Treatment Admissions        
"Other Opiates"1 542 802 879 1,336 1,752 2,227 2,759 
Methadone 53 68 44 50 63 66 55 
Deaths with Mention of Substance (TDSHS)      
Hydrocodone  25 52 107 168 140  
Oxycodone  8 20 40 56 60  
Methadone 30 36 62 93 131 122  
Drug Exhibits Identified by DPS Laboratories      
Hydrocodone  479 629 771 747 1,212 1,534 
Oxycodone  36 72 115 106 174 241 
Methadone  19 22 42 49 63 116 
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Exhibit 16. Price of a Pound of Commercial Grade Marijuana in Texas, as Reported by the DEA:  1992–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  DEA 
 
 
 
 
Exhibit 17. Route of Administration of Methamphetamine by Clients Admitted to TDSHS-Funded Programs:   
  1988–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Texas Department of State Health Services 
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Exhibit 18. Characteristics of Clients Admitted to TDSHS-Funded Treatment with a Primary Problem of  
  Amphetamines or Methamphetamines, by Route of Administration:  2004 
 
Characteristic Smoke Inject Inhale Oral All1 
# Admissions 1,951    2,363    601    248    5,262 
Percent of Heroin Admissions 37    45    11    5    100    
Lag-1st Use to Treatment (Years) 8    13    9    11    11    
Average Age 28    31    30    31    30    
Percent Male 47    47    45    43    47    
Percent Black 1    0    2    2    1    
Percent White 84    94    87    83    89    
Percent Hispanic 13    4    9    13    8    
Percent CJ Involved 50    52    52    57    52    
Percent Employed 27    18    29    29    23    
Percent Homeless 7    11    6    6    8    
 
1Includes clients with “other” routes of administration. 
SOURCE:  Texas Department of State Health Services 
 
 
 
 
Exhibit 19. Percent of Items Analyzed by Texas DPS Regional Laboratories Identified as Methamphetamine, 
  by Location of Laboratory (County and City):  2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  NFLIS 
 
Location of Laboratory 
County (City) Percent of Items 
Hidalgo (McAllen) 0.5 
Webb (Laredo) 1.1 
El Paso (El Paso) 3.8 
Nueces (Corpus Christi) 11.4 
Harris (Houston) 11.7 
Travis (Austin) 24.1 
McLennan (Waco) 29.3 
Smith (Tyler) 29.0 
Dallas (Dallas) 35.7 
Midland (Odessa) 16.4 
Taylor (Abilene) 54.3 
Lubbock (Lubbock) 26.5 
Potter (Amarillo) 41.3 
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Exhibit 20. Benzodiazepines Identified by DPS Labs in Texas:  1998–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  NFLIS 
 
 
 
 
Exhibit 21. Characteristics of Clients Admitted to TDSHS-Funded Treatment with a Primary, Secondary, or  
  Tertiary Problem with Club Drugs:  2004 
 
Characteristic GHB Hallucinogens Ecstasy PCP Ketamine Rohypnol 
# Admissions 45  266  561  295  7  221  
Percent Male 33  75  54  57  100  75  
Percent White 89  61  55  9  57  1  
Percent Hispanic 4  25  21  10  43  97  
Percent Black 0  12  20  81  0  0  
Average Age (Years) 29  23  23  25  18  19  
Percent Criminal Justice Involved 44  64  63  56  100  67  
Percent History Needle Use 47  25  23  4  43  15  
Percent Primary Drug=Club Drug 24  20  14  43  14  13  
Other Primary Drug       
   Percent Marijuana 2  42  36  30  43  48  
   Percent Alcohol 11  12  8  8  0  9  
   Percent Methamphet/Amphetamines 56  8  16  1  0  1  
   Percent Powder Cocaine 0  7  12  6  14  11  
   Percent Crack Cocaine 2  3  6  10  0  7  
   Percent Heroin 0  2  1  1  8  9  
 
SOURCE:  Texas Department of State Health Services 
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Exhibit 22. Club Drugs Identified by DPS Labs in Texas:  1998–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  NFLIS 
 
 
 
 
Exhibit 23. Percentage of Border and Nonborder Texas Secondary Students Who Had Ever Used Rohypnol,  
  by Grade:  2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Texas Department of State Health Services 
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Exhibit 24. Percentage of Texas Secondary Students Who Had Used Inhalants Ever or in the Past Month, by  
  Grade:  2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Texas Department of State Health Services  
 
 
 
 
Exhibit 25: Exposures Involving Misuse or Abuse of Inhalants:  1998–2004 
 
Product 1998 1999 2000 2001 2002 2003 2004 Total 
Aerosol 4 3 9 3 10 4 22 55 
Amyl/Butyl Nitrite 1 2 1 1   8 2 15 
Carburetor Cleaner, Auto Fluids 11 12 19 30 34 46 67 219 
Freon/Other Propellants 23 24 21 20 23 15 29 155 
Gasoline 24 19 16 18 18 6 21 122 
Lighter Fluid/Propane 19 15 12 5 11 7 8 77 
Nitrous Oxide 4 4 2 5 4 2 7 28 
Paint 46 35 33 26 31 15 31 217 
Toluene/Mineral Spirits 13 25 19 16 14 6 13 106 
Correction Fluid 2 4 3 1 3 2 3 18 
 
SOURCE:  Texas Poison Center Network 
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Exhibit 26. Texas HCV Exposures and Their Demographics:  2004 
 
Demographic Percent 
Overall 17.8 
By Mode of Exposure  
Injection Drug Exposure 40.7 
Medical exposure 13.3 
Tattoo or piercing 5.3 
Occupational 2.8 
Other blood/needle 3.4 
Sexual risk 7.6 
Shared snorting equipment 3.3 
No disclosed risk 5.1 
Gender (%)  
Male 19.3 
Female 15.3 
Race/Ethnicity (%)  
Hispanic 12.1 
Non-Hispanic 20.8 
White 16.8 
Black 20.4 
Age Group (%)  
13–19 2.3 
20–24 6.3 
25–29 11.5 
30–39 23.8 
40 and older 35.3 
 
SOURCE:  Texas Department of State Health Services 
 
 
 
 
Exhibit 27. AIDS Cases1 in Texas by Mode of Exposure:  1987–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Texas Department of State Health Services 
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Exhibit 28. Texas Male and Female AIDS Cases by Race/Ethnicity:  1987–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Texas Department of State Health Services 
 
 
 
 
Exhibit 29. Characteristics of Clients Admitted to TDSHS-Funded Treatment Who Used Needles:  2004 
 
Characteristics   Heroin Cocaine Stimulants 
# Admissions 4,651   900    2,363    
Percent of Needle Admits\Drug 86   6   45    
Lag-1st Use to Treatment (Years)-Yrs. 16   15   13    
Average Age 37   35   31    
Percent Male 71   62   47    
Percent Black 6   5   0    
Percent White 37   63   94    
Percent Hispanic 55   29   4    
Percent CJ Involved 31   46   52    
Percent Employed 12   13   18    
Percent Homeless 12   11   11    
 
SOURCE:  Texas Department of State Health Services 
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Exhibit 30. Adult and Youth Admissions to TDSHS-Funded Programs:  2004 
 
Primary Substance Total Admissions 
% of All 
Admissions Average Age 
Average Age 
1st Use 
Avg. Lag-1st 
Use to 
Admission 
% First 
Treatment 
Percent 
Married 
Total 53,204 100.0 32.5 19.2 14.0 43.8 20.4 
Opiates 8,238 15.5 35.7 22.6 14.0 25.9 19.9 
Alcohol 14,410 27.1 37.2 15.6 23.0 41.4 19.0 
Depressants 706 1.3 28.8 21.8 8.0 42.8 22.0 
Amphetamines 5,268 9.9 29.7 19.7 11.0 50.8 20.3 
Cocaine 4,339 8.2 30.5 20.7 10.0 50.3 23.3 
Marijuana 10,254 19.3 21.6 13.9 8.0 66.9 25.5 
Hallucinogens 180 0.3 25.1 18.9 7.0 38.9 8.3 
Other Drugs 285 0.5 23.7 18.5 6.0 53.0 24.2 
Crack Cocaine 9,524 17.9 37.2 26.0 12.0 31.0 16.4 
 
Primary Substance Percent Male 
% Use 
Needles 
% History of 
IV Drug Use 
Percent 
Black 
Percent 
White 
Percent 
Hispanic 
% Involved 
With CJ or 
Legal 
System 
Total 61.0 19.0 32.7 19.4 48.9 29.7 26.9 
Opiates 57.2 62.8 73.1 8.6 51.6 38.2 12.7 
Alcohol 67.7 5.9 23.1 13.8 57.9 26.1 26.9 
Depressants 37.4 6.5 21.2 5.4 76.2 17.0 22.5 
Amphetamines 46.5 45.5 57.6 0.9 88.9 8.2 23.1 
Cocaine 55.9 21.8 29.9 11.2 36.0 50.8 28.9 
Marijuana 72.3 1.8 6.7 21.9 32.5 43.1 53.1 
Hallucinogens 56.7 6.1 7.8 70.0 19.4 10.6 27.2 
Other Drugs 55.8 9.1 15.8 15.4 35.8 43.5 32.6 
Crack Cocaine 54.2 5.1 29.3 49.0 33.3 16.3 12.2 
 
Primary Substance Percent Employed 
% Employed 
Over Last 12 
Months 
Average 
Education 
(Years) 
Percent 
Homeless 
Average 
Income at 
Admission 
# of Women 
Pregnant at 
Admission 
% On 
Medication 
Total 3.8 48.5 11.3 11.1 $5,716  1,081 21.5 
Opiates 2.9 30.1 11.6 9.5 $4,394  115 34.0 
Alcohol 4.6 45.8 11.9 12.7 $7,250  99 22.5 
Depressants 3.3 44.2 11.5 6.4 $4,823  14 32.2 
Amphetamines 3.8 51.6 11.6 8.4 $5,570  185 17.4 
Cocaine 4.3 50.7 11.2 7.0 $5,986  152 17.0 
Marijuana 4.8 75.7 10.0 7.4 $5,834  242 12.5 
Hallucinogens 3.1 58.9 11.0 9.4 $3,312  8 17.8 
Other Drugs 2.8 62.8 10.3 7.7 $8,495  9 24.2 
Crack Cocaine 2.9 36.4 11.7 17.8 $4,539  257 22.5 
 
(Continued)
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Exhibit 30. Adult and Youth Admissions to TDSHS-Funded Programs:  2004 (Continued) 
 
Primary Substance 
% 
Emergency 
Room Visit 
% Sickness 
or Health 
Problems 
% 
Employment 
Problems 
% Family or 
Marital 
Problems 
% Social/ 
Peer 
Problems 
% Psych/ 
Emotional 
Problems 
% Drug/ 
Alcohol 
Problems 
Total 33.8 24.8 51.2 48.9 39.9 41.6 67.6 
Opiates 40.0 29.5 63.7 60.4 51.9 45.8 84.5 
Alcohol 38.2 26.3 52.0 48.4 40.5 45.9 69.7 
Depressants 46.5 31.0 53.3 55.1 40.5 52.5 71.2 
Amphetamines 40.3 27.3 56.5 56.1 43.6 52.8 73.4 
Cocaine 32.6 21.9 46.5 46.4 34.7 37.5 61.5 
Marijuana 14.9 15.0 33.7 30.4 23.1 22.2 42.0 
Hallucinogens 37.8 18.9 46.1 45.0 33.3 33.9 56.1 
Other Drugs 22.8 20.4 35.1 35.8 28.4 30.9 48.1 
Crack Cocaine 38.8 28.8 57.7 57.0 47.2 47.7 77.2 
 
SOURCE:  Texas Department of State Health Services 
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Patterns and Trends of Drug 
Abuse in Washington, DC 
 
Erin Artigiani, M.A., Margaret Hsu, M.H.S., 
and Eric Wish, Ph.D.1 
 
ABSTRACT 
 
Cocaine/crack, marijuana, and heroin continued to 
be the main illicit drug problems in Washington, DC, 
in 2004, while the use and availability of PCP has 
declined. Although cocaine/crack treatment admis-
sions declined, cocaine remained one of the most se-
rious drugs of abuse in the District as evidenced by 
the fact that more adult arrestees tested positive for 
cocaine than for any other drug in 2004. Pretrial Ser-
vices test results indicate that PCP positives dropped 
sharply during this time. Juvenile arrestees were more 
likely to test positive for marijuana than for any other 
drug, but the percentage testing positive decreased 
slightly. Heroin treatment admissions increased 
slightly. While other parts of the country have seen 
shifts in the use of methamphetamine, use remains 
low and confined to isolated populations in DC.  
 
INTRODUCTION 
 
Area Description 
 
The Nation’s capital is home to approximately 
570,898 people residing in 8 wards that remain 
largely distinguishable by race and economic status 
(U.S. Bureau of the Census, 2001 update). The 
northwest part of the city tends to be home to resi-
dents who are wealthy and White, while the northeast 
and southeast tend to be home to residents who are 
poor and African-American. Slightly more females 
than males live in DC, and the majority of the Dis-
trict’s population continues to be African-American 
(60 percent). Nearly one-third of the population is 
White (31 percent), and the remainder is primarily 
Hispanic and/or Asian (U.S. Bureau of the Census, 
2000 Census). The population of the District is 
slightly older than the general U.S. population. One 
in five residents are younger than 18, and slightly 
more than 12 percent are age 65 and older. More than 
one-third (39.1 percent) of adults age 25 or older 
have at least a bachelor’s degree. (Pach et al. 2002). 
 
                                                 
1The authors are affiliated with the Center for Substance Abuse 
Research, College Park, Maryland.  Some background material 
was taken from prior CEWG reports. 
 
Data from the 2000 census reveal several key demo-
graphic changes since 1990. The total population 
decreased by 5.7 percent during the 1990s, from 
606,900 in 1990 to 572,059 in 2000. The number of 
African-Americans decreased by 14.1 percent, the 
number of Asians grew by 38.6 percent, and the 
number of Hispanic residents grew by 37.4 percent. 
The White population also grew by a much more 
modest 2 percent during this time period (Pach et al. 
2002). 
 
Despite a nationwide economic recession, wealth 
distributions in the District became more polarized 
during 2002. Buoyed by the draw of potential income 
from service employment, government spending, and 
an established technology industry, measures of 
wealth such as median household income ($40,127 in 
the District in 1999) increased in the DC metropoli-
tan region. The percentage of persons living in pov-
erty also increased in many areas in and around 
Washington (Pach et al. 2002). One in five residents 
was living in poverty in 1999 (U.S. Census Bureau). 
 
Alcohol abuse costs the District approximately $700 
million per year, and illicit drug use costs about $500 
million per year. In fiscal year (FY) 2005, the city 
spent approximately $360 million to address the 
problem. Nearly 1 in 10 residents (approximately 
60,000) are addicted to illegal drugs and/or alcohol. 
At least one-half (26,000–42,000) of these individu-
als have co-occurring substance abuse and mental 
health disorders. The DC Household Survey indicates 
that first-time drug use occurs at a younger age in the 
District than in the rest of the Nation (Citywide 
Comprehensive Substance Abuse Strategy for the 
District of Columbia, 2003). 
 
Homicides in the District decreased sharply from 248 
in 2003 to 198 in 2004. Drugs are still listed as one of 
the four most common motives behind these homi-
cides, along with arguments, retaliation, and robberies. 
Narcotic drug law violations account for 32 percent of 
crime in 14 crime HotSpots identified by the Metro-
politan Police Department (MPD 2/1/04–12/29/04). 
 
The major drug problems in the District continue to be 
cocaine/crack, marijuana, and heroin. The use and 
availability of phencyclidine (PCP) increased from 
2000 to 2002 but decreased in 2004. The use of club 
drugs like methylenedioxymethamphetamine (MDMA) 
also appears to be decreasing. 
 
Information from the Department of Justice’s Na-
tional Drug Intelligence Center (NDIC) suggests that 
the District has a wide variety of drug transportation 
options, including an extensive highway system, 
three major airports, and rail and bus systems. While 
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both NDIC and ethnographic information suggest 
that traffickers extensively use all of these options, 
Washington appears to be a secondary drug distribu-
tion center; most drugs intended for distribution in 
DC are distributed first to larger cities, such as New 
York and Miami (Pach et al. 2002). The street-level 
dealing in DC was described as less organized and 
more free-flowing than the organized networks in 
these larger cities. Information from the NDIC sug-
gests that Colombian drug trafficking organizations 
continue to play a major role in supplying opiates and 
cocaine to DC criminal groups of Colombian and Do-
minican descent.  
 
Data Sources  
 
A number of sources were used to obtain compre-
hensive information regarding the drug use trends 
and patterns in Washington, DC. Data for this report 
were obtained from the sources shown below. In ad-
dition, interviews were conducted with a sample of 
substance abuse professionals in the fields of criminal 
justice, public health, and recovery. 
 
• Emergency department (ED) data were de-
rived for 2004 from the Drug Abuse Warning 
Network (DAWN) Live! restricted-access online 
query system administered by the Office of Ap-
plied Studies (OAS), Substance Abuse and Men-
tal Health Services Administration (SAMHSA). 
Eligible hospitals in the Washington, DC, area 
totaled 34; hospitals in the DAWN sample num-
bered 29, with the number of EDs in the sample 
totaling 30.  (Some hospitals have more than one 
emergency department.)  During this 12-month 
period, between 11 and 15 EDs reported data 
each month.  The completeness of data reported 
by participating EDs varied by month (see ex-
hibit 1a).  Exhibits in this paper reflect cases that 
were received by DAWN as of April 13–14, 
2005.  All DAWN cases are reviewed for quality 
control.  Based on this review, cases may be cor-
rected or deleted.  Therefore, the data presented 
in this paper are subject to change.  Data derived 
from DAWN Live! represent drug reports in 
drug-related ED visits.  Drug reports exceed the 
number of ED visits, since a patient may report 
use of multiple drugs (up to six drugs and alco-
hol).  The DAWN Live! data are unweighted 
and, thus, are not estimates for the reporting area. 
These data cannot be compared to DAWN data 
from 2002 and before, nor can preliminary data 
be used for comparison with future data.  Only 
weighted DAWN data released by SAMHSA can 
be used for trend analysis. A full description of 
the DAWN system can be found at the DAWN 
Web site: http://dawninfo.samhsa.gov. 
• Drug-related death data were derived from 
DAWN, OAS, SAMHSA, and annual medical ex-
aminer (ME) data for 1997 to 2003.  Because of 
changes in methodology, DAWN mortality data 
from 2003 cannot be compared to DAWN mortal-
ity data prior to that year. 
 
• Drug treatment data for 2000 to 2003 were ob-
tained from the Treatment Episode Data Set 
(TEDS), OAS, SAMHSA.  
 
• Arrest, crime, and law enforcement action data 
were derived from the Metropolitan Police De-
partment (MPD) crime statistics and press releases 
pertaining to law enforcement action through De-
cember 2004, available at www.mpdc.dc.gov. 
 
• Arrestee urinalysis data were derived from the 
District of Columbia Pretrial Services Agency for 
adult and juvenile arrestees for 2000 to 2004. 
 
• Drug prices and trafficking trends were ob-
tained from the NDIC Narcotics Digest Weekly 
Special Issue: Illicit Drug Prices January 2004-
June 2004 and the Washington-Baltimore High 
Intensity Drug Trafficking Area (HIDTA) “Wash-
ington/Baltimore Threat Assessment” reports re-
leased in 2003 and 2004.  
• General information on drug use was derived 
from the University of Maryland’s Center for 
Substance Abuse Research Drug Early Warning 
System County indicators, DEWS Investigates re-
ports, and CESAR Briefings available at 
www.dewsonline.org and www.cesar.umd.edu.  
 
• Census data for the District of Columbia were 
derived from the “Council of the District of Co-
lumbia; Subcommittee on Labor, Voting Rights, 
and Redistricting; Testimony of the Office of 
Planning/State Data Center on Bill 14-137, The 
Ward Redistricting Amendment Act of 2002.” 
 
• Test results on drug items analyzed by local 
crime lab(s) were obtained from the National Fo-
rensic Laboratory Information System (NFLIS). 
 
• Regional counts on methamphetamine labs 
seized were obtained from the El Paso Intelli-
gence Center’s (EPIC) National Clandestine 
Laboratory Seizure Database. 
 
• Additional information was provided by the 
human immunodeficiency virus (HIV)/acquired 
immunodeficiency syndrome (AIDS) Administra-
tion and members of the DC Epidemiology 
Workgroup. 
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DRUG ABUSE PATTERNS AND TRENDS 
 
Cocaine/Crack 
 
Cocaine, particularly in the form of crack, remains 
the most serious drug of abuse in the District, ac-
counting for more ED reports, adult arrestee positive 
drug tests, and drug-related deaths than any other 
drug. Only heroin has a higher percentage of treat-
ment admissions. Cocaine is most often sold at open-
air markets in the poorer parts of the city and is de-
creasing in price. The NDIC reported that powder 
cocaine sold for $27,500 to $28,000 per kilogram and 
$60 to $100 per gram during the first 6 months of 
2004. Crack sells for slightly more: $28,000 to 
$34,000 per kilogram and $80 to $100 per gram. 
NFLIS data for 2004 show that analyzed drug items 
were more likely to test positive for cocaine than for 
any other drug; cocaine-positive items represented 44 
percent of all items analyzed by NFLIS. Cocaine is 
smuggled into the District from New York, Miami, 
Los Angeles, or Philadelphia. 
 
Unweighted DAWN Live! data show that cocaine 
was the most frequently involved substance in ED 
reports. Of the 2,849 ED reports for cocaine in 2004, 
61 percent were male, 74 percent were Black, and 20 
percent were White (exhibits 1b and 1c). Nearly 
three-quarters (74 percent) were age 35 or older, 19 
percent were age 25–34, and 7 percent were between 
the ages of 18 and 25.  
 
Cocaine-involved deaths totaled 58 in 2002, 27 of 
which were single-drug deaths (exhibit 2a). These 58 
deaths represented an increase from 2001, when the 
total was 42, and from 2000, when the total was 54. 
In 2003, 87 cocaine-related deaths occurred (exhibit 
2b). Due to changes in methodology, however, this 
number cannot be compared to prior years. Nearly 
one-half (43 percent) of these deaths in 2003 were 
single-drug deaths.  
 
In 2003, cocaine was the primary substance of abuse 
among approximately 29 percent of treatment admis-
sions reported to TEDS, with 19 percent reporting 
smoked cocaine (referred to as “crack” here) (exhibit 
3a). The percentage of primary admissions for non-
smoked cocaine (referred to as “powder” here) in-
creased 51 percent from 474 admissions in 2001 to 
717 in 2002, while those for crack decreased 19 per-
cent from 1,450 to 1,172 during this time. In 2003, 
the number of admissions for crack (912) continued 
to decrease. Admissions for powder cocaine de-
creased for the first time since 2000. Treatment ad-
missions in 2003 with powder cocaine and crack co-
caine as the primary drugs of abuse were more likely 
to be male (65.7 and 64.7 percent, respectively) than 
female (exhibit 3b). More than 94 percent of both 
cocaine admissions groups were Black, and more 
than one-half were age 36 to 45. 
 
Reports from the DC Pretrial Services Agency indi-
cate that the percentage of adult arrestees testing 
positive for cocaine has remained about the same 
since 2000 (exhibits 4a and 5). In 2004, 37 percent of 
adult arrestees in DC tested positive for cocaine; in 
2004, 3.3 percent of juveniles tested positive. The 
percentage of juveniles testing positive for cocaine 
appears to have decreased slightly from 2003 to 2004 
(exhibits 4b and 6). 
 
Heroin 
 
Heroin is one of the three leading drug problems in 
the District, along with cocaine and marijuana. The 
MPD describes crack as a weekend drug, but heroin 
as having a more steady ongoing market. The NDIC 
reported that heroin sold for $74,000–$110,000 per 
kilogram and $100–$110 per gram during the first 6 
months of 2004. NFLIS data for 2004 show that ap-
proximately 10 percent of analyzed drug items tested 
positive for heroin. 
 
The number of heroin abusers in the District contin-
ued to increase in 2003, with estimates of 14,000 to 
18,000 abusers according to the Washing-
ton/Baltimore HIDTA. Most heroin is from South 
America, although Southeast Asian and Southwest 
African heroin are still distributed by various groups. 
Purity ranged from 20.8 percent (South American) to 
22.7 percent pure (Southeast Asian). Northwest 
Washington is frequented by White suburban users 
purchasing high-purity heroin, while eastern Wash-
ington is frequented by more well-established sellers 
and long-term addicts. Eastern Washington experi-
ences higher levels of trafficking and associated vio-
lence. 
 
Unweighted DAWN Live! data show that there were 
1,486 heroin ED reports in 2004 (exhibit 1b). Nearly 
two-thirds (65 percent) of these patients were male; 
71 percent were Black and 24 percent were White 
(exhibit 1c). More than three-quarters (78 percent) 
were age 35 or older.  
 
Of the 20 heroin-involved deaths in 2002, 4 were 
single-drug deaths (exhibit 2a). The number of deaths 
in 2002 was substantially lower than in 1997–2000, 
but it was an increase from 2001; deaths peaked at 53 
in 1998.  Eighty-one opiate-related deaths occurred in 
2003 (exhibit 2b); five were specified as heroin. Be-
cause of changes in methodology, however, these 
numbers can not be compared to prior years. All of 
the heroin deaths in 2003 involved multiple drugs.  
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In 2003, heroin was the primary substance of abuse for 
41.9 percent of treatment admissions, a steady increase 
from 2000 (exhibit 3a). Of the 2,023 primary heroin 
admissions in 2003, approximately 72 percent were 
male and 96 percent were Black (exhibit 3b). More 
than three-quarters (84 percent) were age 36–55. 
 
As with cocaine, reports from the DC Pretrial Ser-
vices Agency indicate that the percentage of adult 
arrestees testing positive for opiates has remained 
about the same since 2001 (exhibits 4a and 5). In 
2004, 10 percent of adult arrestees tested positive for 
opiates. Juvenile arrestees were not tested for opiates 
during this time. 
 
Other Opiates/Narcotics 
 
Unweighted DAWN Live! data show 836 ED reports 
for opiates/opioids in 2004. Of these 836 reports, 
oxycodone/combinations accounted for 296 (35 per-
cent) and hydrocodone/combinations accounted for 
78 (9 percent). More than one-quarter (28 percent) of 
opiates/opioids reports were for overmedication, and 
20 percent involved individuals seeking detox. More 
than one-half (53 percent) were designated “other.”   
 
Twenty-six deaths involving narcotic analgesics were 
reported in 2002. This is a substantial increase from 
the 6 in 2001 and the 15–22 reported in the prior 3 
years (exhibit 2a). The number of deaths involving 
methadone in the DC Metropolitan Area increased 
from 15 in 2001 to 18 in 2002. Two of the 2002 
deaths occurred in DC. Eighty-one opiate-related 
deaths occurred in 2003; 20 were specified as metha-
done and 63 were listed as other opiates (exhibit 2b). 
Because of changes in methodology, however, these 
numbers cannot be compared to prior years. Five of 
the methadone deaths in 2003 were single-drug 
deaths. 
 
Other opiates were the primary substance of abuse 
among 0.3 percent of the 4,832 treatment admissions 
in 2003. This percentage has remained about the 
same since 2000 (exhibit 3a). Oxycodone and metha-
done combined accounted for less than 1 percent of 
analyzed drug items reported to NFLIS. 
 
Marijuana 
 
Marijuana is widely used in the District as it is in 
many other jurisdictions. Commercial-grade and 
high-grade marijuana are available for wide ranging, 
but relatively stable, prices. Most of the marijuana is 
transported into the District via package delivery ser-
vices by Mexican and Jamaican trafficking organiza-
tions, according to the most recent NDIC and HIDTA 
threat assessments. Marijuana is most often smoked 
in blunts or joints, which can be combined with rocks 
of cocaine or dipped in liquid PCP. Popular types of 
marijuana in the District and Maryland suburbs in-
clude “chronic,” “kind bud,” “purple haze,” “blue-
berry,” and “orange tulip.” All of these types are re-
puted to have high levels of tetrahydrocannabinol 
(THC). The NDIC reported that commercial grade 
marijuana sold for $1,800 per pound and Hydro sold 
for $5,000 per pound during the first 6 months of 
2004. Joints sold for $5 to $10 during this time. 
NFLIS data for 2004 show that approximately 35 
percent of analyzed drug items tested positive for 
marijuana, which makes marijuana the second most 
frequently found drug. 
 
Unweighted DAWN Live! data show 1,255 ED mari-
juana reports in 2004 (exhibit 1b). More than two-
thirds of these patients were male (68 percent), 58 
percent were Black, and 34 percent were White (ex-
hibit 1c). Twenty-nine percent were patients age 18–
24, 23 percent were patients age 25–34, and 31 per-
cent were those age 35 and older. Seventeen percent 
of the marijuana ED patients were age 12–17. 
 
Marijuana in combination with other drug(s) was 
involved in one death in the District in 2001 and one 
in 2000 (exhibit 2a). No marijuana-involved deaths 
were reported in 2002 or in 2003. 
 
Marijuana was the primary substance of abuse for 7.0 
percent of the 2003 treatment admissions, compared 
with 6.4 percent in 2001 and 8.0 percent in 2000 (ex-
hibit 3a). More than three-quarters of the 336 primary 
marijuana admissions in 2003 were male, and nearly 
87.8 percent were Black (exhibit 3b). Approximately 
one-third (32.7 percent) of these admissions were age 
12–17, and more than one-quarter (28.6 percent) 
were age 18–25. 
 
The DC Pretrial Services Agency does not test adult 
arrestees for marijuana, but more than one-half of 
juveniles tested positive for marijuana each year be-
tween 2000 and 2003. During 2004, 49 percent of 
juveniles tested positive for marijuana (exhibits 4b 
and 6). The proportion of juveniles testing positive 
for marijuana has been decreasing slowly since 1999. 
 
Phencyclidine 
 
According to the MPD, the number of adult arrests 
related to PCP increased 65 percent between 2001 and 
2002 (from 142 to 234). According to the Washing-
ton/Baltimore HIDTA 2003 Threat Assessment, PCP 
was rapidly becoming the drug of choice at raves and 
nightclubs, sometimes used in combination with mari-
juana and/or MDMA (ecstasy). In 2004, however, PCP 
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use began to decline, and PCP use is still well behind 
that of crack and marijuana.  
 
While most PCP is transported to the District from 
southern California, the seizure of precursor chemi-
cals and PCP at a clandestine laboratory in Baltimore 
in 2004 indicates the drug has been produced in the 
region. No clandestine labs have been identified to 
date in the District. NFLIS data for 2004 show that 
approximately 2 percent of analyzed drug items 
tested positive for PCP, making it the fifth most fre-
quently found drug after cocaine, marijuana, heroin, 
and methamphetamine.  
 
According to unweighted DAWN Live! data, there 
were 289 ED PCP reports in 2004 (exhibit 1b).  
 
There were 27 PCP deaths in the metropolitan area in 
2002, including 8 in the District and 14 in Prince 
George’s County, Maryland. The number of deaths in 
the District increased from three in 2001 (data not 
shown). In 2003, the DAWN methodology was 
changed. PCP-related deaths are now only included 
in the hallucinogens category.  There were five hallu-
cinogens-related deaths in 2003. (DAWN Metro Area 
Profiles and Area Spotlights, 2001, 2002, 2003.) 
 
In 2003, PCP was the primary substance of abuse 
among 3.9 percent of treatment admissions, an in-
crease from 2001 (1.8 percent) and 2000 (0.7 per-
cent) (exhibit 3a). Of the 189 primary PCP admis-
sions in 2003, nearly two-thirds were male, and 
nearly all were Black (exhibit 3b). More than one-
half (55 percent) were age 18–25, and one-third (33 
percent) were 26–35. 
 
Data from the DC Pretrial Services Agency show a 
rise in PCP use, from the low single digits in the late 
1990s to the mid-teens (exhibits 5 and 6) in 2002 and 
2003. But PCP use among adult arrestees declined in 
2004 to 6 percent (a steady decrease from 10.6 per-
cent in January to 3 percent in May; for the remain-
der of the year, positives ranged between 4 and 7 
percent). Trend data from 1987 to the present indicate 
that PCP use in the juvenile arrestee population has 
mirrored that of the adult arrestee population (exhib-
its 4a and 4b), with spikes in the late 1980s, mid-
1990s, and again in the current decade.  The propor-
tion of juveniles testing positive for PCP decreased 
from 13.4 percent in 2002 to 1.9 percent in 2004 (ex-
hibits 4b and 6).  
 
Amphetamine/Methamphetamine 
 
Abuse of amphetamines and methamphetamine does 
not appear to be a major problem in the District. Five 
deaths involving amphetamines (2) or methampheta-
mine (3) were reported from 1997 to 2002. One 
methamphetamine-involved death and one ampheta-
mine-involved death were reported in 2002 (exhibit 
2a). Methamphetamine and amphetamine were not 
included in the DAWN 2003 Area Profile.  
 
From 2000 through 2003, amphetamines accounted 
for less than 1 percent of all treatment admissions in 
the District (exhibit 3a). Admissions involving 
methamphetamine as a substance of abuse increased 
steadily from 1 in 1998 to 47 in 2001 (exhibit 3c). In 
2002, only 29 methamphetamine mentions occurred 
among treatment admissions, a decrease of 38 per-
cent from 2001 (exhibit 3c).   
 
Unweighted DAWN Live! data show amphetamine 
ED reports totaled 79 in 2004 and methamphetamine 
ED reports totaled 31 (exhibit 1b).  Nearly two-thirds 
(61 percent) of the methamphetamine patients were 
White and 87 percent were male. Nearly one-third 
(32 percent) of the methamphetamine ED patients 
were age 18–24, 48 percent were 25–34, and 16 per-
cent were 35 and older. Three percent were age 12–
17.  
 
The Washington/Baltimore HIDTA and other mem-
bers of the DC Epidemiological Workgroup report 
that methamphetamine use is established in the ho-
mosexual community. The Whitman Walker Addic-
tion Services Clinic, which specializes in treating the 
gay/lesbian/bisexual/transsexual community, cur-
rently reports that 75 percent of outpatient admissions 
report crystal methamphetamine use. This is an in-
crease from 50–60 percent in 2001 and 35 percent in 
2000. Detectives from the Metropolitan Police De-
partment report that both tablet and powder metham-
phetamine is visible in the Washington, DC, club 
scenes.   
 
NFLIS data for 2004 show that approximately 3 per-
cent of analyzed drug items tested positive for 
methamphetamine, making it the fourth most fre-
quently found drug. The NDIC reported that 
methamphetamine sold for $4,800 per one-half 
pound, and 8-balls sold for $400 during the first 6 
months of 2004. The DC Pre-trial Services Agency 
does not regularly test for methamphetamine, but a 
special study testing for methamphetamine and am-
phetamine found a positive rate of less than 1 percent 
among all specimens tested. 
 
As in the District, the demand for and availability of 
methamphetamine in Maryland is extremely low 
compared to other drugs. Methamphetamine users in 
Maryland tend to be Caucasian males, particularly 
youth, those involved with the rave and club scenes, 
and middle- to lower-class blue collar workers. 
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Methamphetamine use is more prevalent in the rural 
western, eastern, and southern parts of the State. 
From January 2003 to May 2004, law enforcement 
officials report that there were eight methampheta-
mine labs seized in Maryland: two in Garrett, one in 
Washington, three in Charles, one in Prince George's, 
and one in Cecil Counties. Additional information on 
methamphetamine trends in Maryland is available in 
the CESAR Briefing: Methamphetamine in Maryland 
at www.cesar.umd.edu.  
 
Although there is little indication that methampheta-
mine is an emerging problem in the District, there 
have been increases in the number of methampheta-
mine labs seized in several of the States surrounding 
the District. For example, 8 methamphetamine labs 
were seized in Virginia in 1999, compared to 23 in 
2003. In West Virginia and Pennsylvania, the number 
of labs seized has increased even more dramatically 
during this period, from 3 to 52 and 1 to 49, respec-
tively.   
 
The Washington Post reported that nearly all of the 
methamphetamine seized in Virginia in 2004 was 
found in the Shenandoah Valley, and methampheta-
mine is the primary drug seized along the north-south 
corridor between Winchester and Harrisonburg. A 
special report on methamphetamine from the Wash-
ington/Baltimore HIDTA explains this trend further. 
The cities of Harrisonburg and Strasburg, Virginia, in 
particular, are highlighted by law enforcement as 
having a substantial methamphetamine presence. 
According to law enforcement, the primary users in 
these areas are rural, White, working-class adults, 
while the sellers are primarily Latino. Rival Hispanic 
criminal groups such as MS-13 and South Side Locos 
in Strasburg have collaborated in the sale of metham-
phetamine since early 2004, increasing the chance 
that methamphetamine may increase in the area be-
cause of the presence of MS-13 in Maryland.  
 
Prescription Stimulants 
 
Drug Early Warning System (DEWS) staff at 
CESAR recently launched the Student Drug Research 
(SDR) survey, a new tool for monitoring drug trends 
among college students. The SDR survey provides a 
unique opportunity to collect useful and timely in-
formation about emerging drugs and patterns of use 
among college students. A panel of 26 undergraduate 
student reporters (SRs) at the University of Maryland 
College Park has participated in 2 surveys of their 
perceptions of drug availability and use by their 
peers.   
 
In the March and April 2005 surveys, nearly all re-
spondents reported that alcohol, marijuana, and Ad-
derall® were easy or very easy to get around campus. 
Another prescription stimulant, Ritalin®, was rated 
as easy or very easy to get by more than one-half of 
the respondents. Non-medical use of prescription 
stimulants was perceived to be widespread. Prescrip-
tion stimulants were used most often to study for and 
focus on exams. Student reporters rated the use of 
prescription stimulants for studying to be much less 
harmful than using them to party or mix with alcohol 
or other drugs.  
 
The SDR findings are obtained from a panel of stu-
dents oversampled to include students likely to be 
familiar with drug use. They are not representative of 
the general student population. In the coming year, 
DEWS staff plan to expand the sample of SRs to in-
clude “lower risk” students who may have little 
knowledge or experience with drug use. The larger 
sample will enable staff to put the responses from the 
higher risk group into the context of the general stu-
dent population.  Monthly reports are available on the 
CESAR Web site at www.cesar.umd.edu. A DEWS 
Investigates report on these results will also be re-
leased. 
  
Other Drugs 
 
Abuse of club drugs, such as MDMA, gamma 
hydroxybutyrate (GHB), and ketamine, is also 
relatively low in the District. MDMA is the most 
readily available and frequently abused “club drug,” 
selling for $18 to $25 per tablet in the fourth quarter 
of 2002, according to the DEA Washington Division. 
The Washington/Baltimore HIDTA estimated a 
slightly lower range for the cost per dosage unit: $10 
to $20. MDMA is most frequently used and 
distributed by teens and young adults at raves and 
nightclubs. MDMA is typically driven to the District 
from New York, Philadelphia, Orlando, and Miami 
by Dominican and Asian trafficking organizations.  
 
According to unweighted DAWN Live! data, there 
were 83 ED reports for MDMA, 9 for GHB, and 8 for 
lysergic acid diethylamide (LSD) in 2004 (exhibit 
1b). Only one ED report was for ketamine. MDMA 
and methylenedioxyamphetamine (MDA) each ac-
counted for approximately 1 percent of analyzed drug 
items tested through NFLIS in 2004. GHB and keta-
mine were each found in less than 1 percent of ana-
lyzed drug items tested through NFLIS in 2004. No 
drug items tested positive for LSD. No deaths involv-
ing club drugs were reported in the DAWN mortality 
data for 1997–2002 (exhibit 2a). No deaths involving 
club drugs were reported in 2003, but five hallucino-
gen-related deaths were reported. All of these deaths 
involved multiple drugs. Because of changes in 
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methodology, however, these numbers can not be 
compared to prior years.  
 
Benzodiazepines are reported in the DAWN ED and 
mortality reports. In 2004, unweighted DAWN Live! 
data show 549 ED benzodiazepines reports. One death 
in 2001 was attributed solely to benzodiazepines (ex-
hibit 2a); however, in the 1997 to 2000 time period, 
mentions of benzodiazepines in the mortality data 
ranged between 10 and 13. In 2002, four deaths were 
attributed to multiple drugs including benzodiazepines. 
In 2003, five deaths involving benzodiazepines and 
multiple drugs were reported (exhibit 2b). 
 
Unweighted 2004 DAWN Live! data show 2,518 ED 
alcohol reports (exhibit 1b). DAWN mortality data 
show a decrease in mentions of deaths involving alco-
hol in combination with other drugs—from 29 in 1997 
to 17 in 2001, with a peak of 44 in 1998. Alcohol-
involved deaths more than doubled in 2002 to 37 (ex-
hibit 2a). Fifty-one deaths in 2003 involved alcohol 
(exhibit 2b). In 2003, primary alcohol admissions ac-
counted for approximately 18 percent of all treatment 
admissions, a slight decline from 2000 and 2001.  
 
INFECTIOUS DISEASES RELATED TO SUBSTANCE 
ABUSE 
 
The diagnosis of AIDS cases increased rapidly from 
1982 to 1993, when they peaked at 1,342 cases. The 
number of cases decreased 49 percent from 1993 to 
2001, but increased 37.5 percent between 2001 and 
2002. There were 943 diagnosed cases in 2002, the 
last year for which data are available. The number of 
male cases decreased steadily from 1998 to 2001, but 
increased in 2002. Males accounted for 70 percent of 
cases diagnosed in 2002. Almost three-quarters of the 
diagnoses in 2002 occurred among 30–49-year-olds 
(exhibit 7). Almost two-thirds (62 percent) of people 
in DC diagnosed with AIDS in 2002 were Black, and 
about 21 percent had a history of injection drug use. 
The rate of AIDS deaths decreased from 47 per 
100,000 in 1998 to 25 per 100,000 in 2003, according 
to the HIV/AIDS Epidemiologic Profile for the Dis-
trict of Columbia 2004. Of the new AIDS diagnoses 
in 2004, 150 were related to intravenous drug use. 
 
DC EPIDEMIOLOGY WORKGROUP 
 
In 2003, the Mayor’s Interagency Task Force on Sub-
stance Abuse Prevention, Treatment, and Control was 
established and charged with four goals: educate and 
empower DC residents to live healthy and drug-free 
lifestyles; develop and maintain a continuum of care 
that is efficient, effective, and accessible to individuals 
needing treatment; increase the public’s safety and 
improve treatment access for offenders to ensure fair 
and effective administration of justice in the District; 
and encourage a coordinated and focused regional 
response to the problem of substance abuse. The task 
force is chaired by the District’s Addiction Prevention 
and Recovery Administration (APRA) and co-chaired 
by the Metropolitan Police Department.  
 
The first Citywide Comprehensive Substance Abuse 
Strategy was released in 2004 and was updated ear-
lier this year.  To assess progress on implementing 
the strategy and reaching the goals, APRA convened 
the DC Epidemiology workgroup. The Workgroup 
has assessed national and local data sources and iden-
tified more than 40 indicators of the consumption of 
alcohol, tobacco, and other drugs and the health and 
social consequences of drug use. Topics covered in-
clude current use, lifetime use, age of initial use, 
cigarette and ethanol consumption per capita, treat-
ment admissions, drug intoxication deaths, drug law 
violations, AIDS diagnoses related to injection drug 
use, poison center calls, motor vehicle crashes, and 
substance abuse issues in child neglect and abuse 
investigations. The indicators are based on indicators 
developed by the Center for Substance Abuse Pre-
vention (CSAP) as a part of the SPF SIG program 
and indicators monitored by CESAR in Maryland as 
a part of the Drug Early Warning System. Future 
issues of this report will begin to highlight the data 
collected and analyzed by the Workgroup. 
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Exhibit 1a. Data Completeness for Washington, DC, Metropolitan Area DAWN Live! Emergency Depart-
 ments (n=30),1 by Month:  2004 
 
Number of EDs, by Month and Year Data  
Completeness Jan-
04 
Feb-
04 
Mar-
04 
Apr-
04 
May-
04 
Jun-
04 
Jul-
04 
Aug-
04 
Sep-
04 
Oct-
04 
Nov-
04 
Dec-
04 
Basically 
Complete2 9 11 11 12 10 11 13 8 8 9 10 9 
Partially 
Complete3 4 2 2 1 3 2 2 5 3 3 3 4 
Incomplete4 0 0 2 0 0 1 0 2 0 2 0 1 
No Data Reported 17 17 15 17 17 16 15 15 19 16 17 16 
Total EDs in 
Sample5 30 30 30 30 30 30 30 30 30 30 30 30 
 
1Total eligible hospitals in area = 34; Hospitals in DAWN sample = 29; Hospitals not in DAWN Sample = 5.  Tables reflect cases that 
have been received by DAWN as of 4/14/05. 
290%+ Complete; 350% to 89% Complete; 4Less than 50% Complete; 5Some hospitals in the DAWN sample have more than one 
emergency department.  All DAWN cases are reviewed for quality control.  Based on this review, cases may be corrected or de-
leted.  Therefore, these data are subject to change. 
SOURCE:  DAWN Live!, OAS, SAMHSA, update 4/13–4/14/2005 
 
 
 
 
Exhibit 1b. Number of Selected Drug Reports in Washington, DC, Metropolitan Area DAWN EDs 
 (Unweighted1):  2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1The unweighted data are from Washington, DC, metropolitan area hospitals reporting to DAWN.  During calendar year 2004, be-
tween 11 and 15 EDs reported data each month.  All DAWN cases are reviewed for quality control.  Based on this review, cases 
may be corrected or deleted.  Therefore, these data are subject to change. 
2NTA=Not tabulated above. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/13–4/14/2005 
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Exhibit 1c. Demographic Characteristics of Patients Reporting Cocaine, Heroin, and Marijuana Abuse in 
Washington, DC, Metropolitan Area DAWN EDs, by Percent (Unweighted1):  2004 
 
Characteristic Cocaine Reports (n=2,849) 
Heroin Reports 
(n=1,486) 
Marijuana Reports 
(n=1,255) 
Gender    
 Male 61.3 65.0 68.0 
 Female 38.6 35.0 32.0 
Race/Ethnicity    
 White 19.5 23.6 34.2 
 Black 73.6 71.0 58.2 
 Hispanic 1.6 1.1 2.5 
 Race/ethnicity NTA2 0.4 0.7 1.4 
 Not documented 4.8 3.6 3.7 
Age    
 17 and younger 0.7 0.2 17.4 
 18–24 7.1 7.2 28.7 
 25–34 18.5 14.4 23.3 
 35–44 42.8 32.0 19.3 
 45–54 26.3 39.0 9.6 
 55 and older 4.4 7.1 1.9 
 Not documented 0.2 0.1 0.0 
 
1The unweighted data are from Washington, DC, metropolitan area hospitals reporting to DAWN.  During calendar year 
2004, between 11 and 15 EDs reported data each month.  All DAWN cases are reviewed for quality control.  Based on this 
review, cases may be corrected or deleted.  Therefore, these data are subject to change. 
2NTA=Not tabulated above. 
SOURCE:  DAWN Live!, OAS, SAMHSA, updated 4/13–4/14/2005 
 
 
 
 
Exhibit 2a. Drug-Related Deaths in Washington, DC:  1997–2002 
 
Drug 1997 1998 1999 2000 2001 2002 
Single-
Drug 
Deaths, 
2002 
Alcohol-in-Combination 29 44 37 26 17 37 N/A 
Cocaine 33 63 64 54 42 58 27 
Heroin/Morphine 41 53 41 36 15 20 4 
Marijuana – – – 1 1 _ _ 
Amphetamines – – – 1 – 1 _ 
Methamphetamine – 1 – 1 – 1 _ 
Club Drugs1 – – – – – _ _ 
Hallucinogens2 1 – 2 1 3 8 2 
Inhalants – – – – – _ _ 
Narcotic Analgesics3 6 22 15 20 6 26 6 
Other Analgesics 2 3 3 2 1 1 1 
Benzodiazepines 13 13 11 10 1 4 _ 
Antidepressants 4 14 11 4 1 _ _ 
All Other3 7 30 18 10 1 5 1 
Total Drug Deaths 79 145 121 100 53 91 41 
Total Drug Mentions 136 243 202 166 88 161 41 
Total Deaths Certified 1,414 1,607 1,763 1,751 1,582 1,754 N/A 
 
1Includes ecstasy (MDMA), ketamine, GHB-GBL, and Rohypnol®. 
2Includes PCP, LSD, and miscellaneous hallucinogens. 
3Not tabulated above. 
SOURCES: DAWN, OAS, SAMHSA, updated September 2003 
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Exhibit 2b. Multidrug vs. Single-Drug Deaths in Washington, DC:  2003 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  DAWN, 2003: Area Profiles of Drug-Related Mortality 
 
 
 
 
Exhibit 3a. Percentages of Treatment Admissions in Washington, DC, with Abuse of Selected Substances  
 (Primary Substance of Abuse), by Year:  2000–2003 
 
Drug 2000 2001 2002 2003 
Total Admissions (N) (6,025) (5,755) (5,659) (4,832) 
Cocaine (Smoked) 27.0 25.2 20.7 18.9 
Cocaine (Other Form) 7.4 8.2 12.7 9.6 
Heroin 35.2 37.9 39.2 41.9 
Other Opiates 0.2 0.4 0.3 0.3 
Marijuana 8.0 6.4 4.8 7.0 
PCP 0.7 1.8 3.6 3.9 
Alcohol 21.1 19.3 18.4 18.2 
Amphetamines1 0.2 0.6 0.3 0.2 
 
1Amphetamines includes methamphetamines, Benzedrine, Dexedrine, Preludin, Ritalin, and any other amines and related drugs. 
SOURCE:  TEDS, SAMHSA 
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Exhibit 3b. Demographic Characteristics of Treatment Admissions in Washington, DC, by Selected Primary 
Drugs of Abuse and Percent:  20031 
 
Drug Cocaine (Smoked) 
Cocaine 
(Other Form) Heroin Marijuana PCP 
Ampheta-
mines3 
(N=) (912) (466) (2,023) (336) (189) (10) 
Gender 
 Male 
 Female 
 
64.7 
35.3 
 
65.7 
34.3 
 
72.0 
28.0 
 
75.9 
24.1 
 
63.0 
37.0 
 
90.0 
10.0 
Race/Ethnicity 
 Black 
 White 
 Other2 
 
94.8 
1.2 
4.0 
 
94.4 
0.9 
4.8 
 
95.8 
1.8 
2.3 
 
87.8 
0.9 
11.3 
 
98.4 
0 
1.6 
 
10.0 
90.0 
0 
Age Group 
 17 and younger 
 18–25 
 26–35 
 36–45 
 46–55 
 56 and older 
0.2 
2.7 
18.3 
58.2 
18 
2.4 
0 
4.5 
15.8 
54.5 
21.9 
3.2 
0 
1.7 
9.9 
45.6 
38.4 
4.4 
32.7 
28.6 
20.8 
12.2 
5.1 
0.6 
2.1 
55 
32.8 
6.3 
2.7 
1.1 
 
0 
10.0 
30.0 
60.0 
0 
0 
 
1May not add up to 100 percent due to rounding. 
2Primarily Hispanic or Latino. 
3Amphetamines includes methamphetamines, Benzedrine®, Dexedrine®, Preludin®, Ritalin®, and any other amines 
and related drugs. 
SOURCE:  TEDS, SAMHSA 
 
 
 
 
Exhibit 3c. Numbers of Treatment Admissions in Washington, DC, Who Mentioned Methamphetamine as a  
 Substance of Abuse: 1994–2002 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  TEDS, SAMHSA 
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Exhibit 4a. Percentages of Adult Arrestees in Washington, DC, Testing Positive for Selected Drugs: 
 2000–2004 
 
Drug 2000 2001 2002 2003 2004 
(N=) (15,630) (17,350) (17,952) (17,742) (19,531) 
Cocaine 33.6 34.2 35.2 34.8 36.6 
PCP 9.3 12.7 14.2 13.5 6.2 
Opiates 9.5 10.5 10.5 10.0 9.8 
Any Drug 43.2 46.1 48.0 47.3 43.5 
 
SOURCE:  District of Columbia Pretrial Services Agency 
 
 
 
 
Exhibit 4b. Percentages of Juvenile Arrestees in Washington, DC, Testing Positive for Selected Drugs: 
2000–2004 
 
Drug 2000 2001 2002 2003 2004 
(N=) (2,162) (2,165) (1,896) (1,899) (2,001) 
Marijuana 60.7 56.9 54.2 50.8 49 
Cocaine 5.7 4.8 5.5 3.7 3.3 
PCP 9.8 13.5 13.4 11.1 1.9 
Any Drug 62.0 59.1 56.4 53.1 49.6 
 
SOURCE:  District of Columbia Pretrial Services Agency 
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Exhibit 5. Percentages of Washington, DC, Adult Arrestees Testing Positive for Any Drug, Cocaine, PCP,  
 and Opiates: 1984–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE: Adapted by the Center for Substance Abuse Research (CESAR) from data from the District of Columbia Pretrial Services 
Agency 
 
 
 
Exhibit 6.  Percentages of Washington, DC, Juvenile Arrestees Testing Positive for Any Drug,1 Cocaine,  
 PCP, and Marijuana:  1987–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Any Positive includes opiates from 1987 through mid-1994 (<1%) 
SOURCE: Adapted by the Center for Substance Abuse Research (CESAR) from data from the District of Columbia Pretrial Services 
Agency 
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Exhibit 7. District of Columbia Diagnosed AIDS Cases by Gender, Race/Ethnicity, Age, and Exposure:  
 1981–2002 
 
 1998 1999 2000 2001 2002 Cumulative 1981-2002 
Characteristic # % # % # % # % # % # % 
Gender             
 Male 719 72 526 74 471 69 468 68 658 70 12,098 80 
 Female 278 28 188 26 210 31 218 32 285 30 3,034 20 
Total Cases 997  715  681  686  943  15,132  
Race/Ethnicity             
 White 112 11 88 12 68 10 59 9 46 5 2,962 20 
 Black 837 84 591 83 562 83 567 83 584 62 11,286 75 
 Hispanic 42 4 27 4 32 5 28 4 22 2 485 3 
 Asian/Pacific Islander <5 <1 5 <1 <5 <1 <5 <1 <5 <1 48 <1 
 Undisclosed/Unknown <5 <1 <5 <1 15 2 29 4 289 31 351 2 
Age Group             
 0–12 8 <1 <5 <1 0 0 <5 <1 <5 <1 179 1 
 13–19 8 <1 <5 <1 7 1 <5 <1 8 <1 71 <1 
 20–29 120 12 89 12 89 13 75 11 85 9 2,248 15 
 30–39 395 40 265 37 253 97 235 34 319 34 6,327 42 
 40–49 330 33 249 35 231 34 251 37 347 37 4,575 30 
 50-59 107 11 83 12 78 11 94 14 149 16 1,363 9 
 60 and older 29 3 20 3 23 3 26 4 32 3 369 2 
Mode of Exposure             
  MSM 353 35 268 38 200 29 195 28 271 28 7,204 48 
  IDU/MSM 22 2 14 2 14 2 20 3 16 2 673 4 
  IDU 312 31 165 23 163 24 146 21 179 19 3,939 26 
  Heterosexual contact 191 19 169 24 176 26 149 22 253 27 2,095 14 
  Mother with HIV 8 <1 <5 <1 0 0 <5 <1 <5 <1 172 <1 
  Hemophilia 0 0 0 0 0 0 0 0 <5 <1 22 <1 
  Transfusion/transplant <5 <1 <5 <1 <5 <1 <5 <1 <5 <1 104 <1 
 Unknown/other 108 11 90 13 126 19 172 25 219 23 923 6 
Deaths During Period 156  130  89  48  41  6,932  
 
SOURCE:  District of Columbia Department of Health, Division of Epidemiology, Administration for HIV/AIDS 
Panel 
on 
Methamphetamine 
and 
Other 
Stimulant 
Abuse 
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Young 
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Stimulant Abuse in Ohio and 
the Rural South 
 
Robert G. Carlson, Ph.D. 
 
INTRODUCTION 
 
This paper summarizes the methods and findings 
from two NIDA-supported studies of metham-
phetamine (MA) abuse in rural Ohio, Kentucky, and 
Arkansas, conducted by researchers at the Wright 
State University Boonshoft School of Medicine, the 
University of Arkansas for Medical Sciences, and the 
University of Kentucky. In addition, patterns of MA 
abuse among young adult MDMA/ecstasy users in 
urban central Ohio are described. Finally, preliminary 
findings from the Ohio Substance Abuse Monitoring 
Network on trends in methamphetamine abuse in 
Dayton, Ohio, are presented. 
 
SAMPLES AND METHODS 
 
One natural history study focused on “MDMA/Club 
Drug Use and STD/HIV Sex Risk Behavior in Ohio” 
[NIDA grant RO1DA14488; R. Carlson, Principal 
Investigator]. As part of this study, respondents were 
asked about methamphetamine use. The other natural 
history study, “Rural Stimulant Use and Mental 
Health: Services and Outcomes” [RO1DA15363; 
Brenda Booth, PI, Carl Leukefeld, Co-PI; 
R01DA14340; Harvey Siegal/Carlson, PI], focused 
on rural stimulant users and health services needs in 
Ohio, Arkansas, and Kentucky. Finally, funded by 
the Ohio Department of Alcohol and Drug Addiction 
Services, the Ohio Substance Abuse Monitoring 
Network (OSAM), was a targeted study of metham-
phetamine abuse in the first half of 2005; the prelimi-
nary findings are based on research conducted in 
Dayton, Ohio. 
 
For the urban MDMA study, 402 active ecstasy users 
were recruited using respondent-driven sampling 
(RDS) from May 2002 through June 2003. Partici-
pants completed an extensive baseline structured in-
terview, including drug use patterns, mental health, 
adverse consequences, and sex risk behaviors. Eth-
nographic interviews were conducted with a smaller 
sample. For this study, the correlates of MA use were 
examined using logistic regression. 
 
The study on rural methamphetamine abuse was 
based on a sample of 711 active (prior 30-day) stimu-
lant (powder cocaine, crack, methamphetamine) users 
recruited using RDS in rural Ohio, Arkansas, and 
Kentucky. Data were collected from October 2002–
March 2004 (Ohio), June 2003–June 2004 (Arkan-
sas), and July 2003–September 2004 (Kentucky). 
Participants completed an extensive baseline struc-
tured interview focusing on drug use, mental health, 
and health services needs and use. Preliminary analy-
ses were conducted using bivariate statistics. 
 
For the OSAM study, qualitative interviews were 
conducted with a convenience sample of 17 people 
recruited in Dayton, Ohio, who had used metham-
phetamine in the previous 12 months. Interviews fo-
cused on trends in methamphetamine use during the 
first half of 2005, initiation patterns, reasons for use, 
and characteristics of users. 
 
SELECTED FINDINGS 
 
The MDMA Study 
 
Among 402 young adult MDMA users recruited in an 
urban setting in central Ohio, 91 had used metham-
phetamine (MA) in the 6 months prior to the baseline 
interview. Logistic regression revealed that MA users 
were significantly more likely than non-MA users to 
not be enrolled in college and to have used cocaine, 
hallucinogens, and inhalants in the previous 6 
months. Participants who had used MDMA on 50 or 
more lifetime occasions were also more likely to 
have used MA than participants who had used 
MDMA 1–10 times.  
 
The Rural Stimulant Abuse Study 
 
Among the 711 rural stimulant users in Ohio, Arkan-
sas, and Kentucky, 342 (48.1 percent) had used MA 
in the 30 days prior to interview. Compared with co-
caine-only (n=367) and users of both MA and co-
caine (249), MA-only users (93) were more likely to 
be employed and on probation or parole. Cocaine-
only users were more likely to be older, of non-White 
ethnicity, and to have used alcohol in the past 30 
days. Users of both MA and cocaine were more 
likely than the other two groups to have less than a 
high school diploma, to have engaged in illegal acts 
for profit in the past 30 days, and to have used mari-
juana, OxyContin, other non-prescribed analgesics, 
and non-prescribed tranquilizers.  
 
The Ohio Substance Abuse Monitoring  
Network 
 
Ethnographic interviews with 17 recent (past-12 
months) MA users in Dayton revealed that the avail-
ability of MA is increasing. Respondents ranged in 
age from 21 to 57; 10 were men. Five participants 
inhaled MA, seven smoked it, three inhaled and 
smoked, and two injected. Seven were “old gen-
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eration” users who were first introduced to MA about 
15 years ago; 10 were “new generation” users who 
had initiated use 2–5 years ago. Five, sometimes 
overlapping, pathways to MA use were identified 
(powder cocaine to MA, crack to MA, MDMA to 
MA, non-prescribed amphetamines to MA, and mari-
juana to MA).  
 
CONCLUSIONS 
 
Preliminary findings from these diverse studies indi-
cate that there is a wide range of people who abuse 
methamphetamine. MA user groups identified in-
cluded gay men, young Whites, primarily in the 
“party/rave” scene, and young/middle-aged Whites in 
urban and rural settings. Findings from the OSAM 
study suggest that after years of low levels of abuse, 
MA use appears to be increasing in the Dayton area 
among diverse populations. However, these reported 
increases are not yet being observed by treatment 
providers. In summary, the field is confronted with 
multiple methamphetamine epidemics, each with its 
own dynamic trajectory; different kinds of MA users 
have different reasons for use, associated risks, and 
prevention and treatment needs. At the same time, 
barriers to intervention and treatment include para-
noia associated with prolonged MA abuse and fear of 
legal sanctions. 
 
 
Rural Methamphetamine 
Abuse: An Ethnographic  
Perspective 
 
Rocky L. Sexton, Ph.D., and Robert G. 
Carlson, Ph.D. 
INTRODUCTION 
This paper summarizes preliminary ethnographic 
findings from a NIDA-supported study of stimulant 
abuse and health service needs in rural areas 
[RO1DA15363; Brenda Booth, Principal Investiga-
tor]. 
SAMPLE AND METHODS 
All interviewees were part of the larger natural his-
tory study that used respondent-driven sampling to 
select participants in Kentucky and Arkansas. They 
were selected to provide a diversified sample in terms 
of gender, age, ethnicity, primary stimulant used, and 
mode of use.  
Thirty-four persons whose primary stimulant of use 
was methamphetamine (MA) participated in qualita-
tive interviews: 12 men and 9 women from Kentucky 
and 8 women and 5 men from Arkansas. Thirty-two 
participants were White and 2 were African-
American. The average age for men and women was 
32.2 and 29.3, respectively. Most participants earned 
$10,000 per year or less. 
The average age of first MA use for men and women 
was 21.4 and 21.8, respectively. Men had used MA 
for 10.6 years and women 7.6 years. The average 
days of MA use per month was 7.8 for men and 7.9 
for women. Thirty-three participants used other 
drugs, including marijuana, cocaine, and diverted 
prescription-type drugs, and 26 reported regular use 
of alcohol and tobacco. The sample included six 
White MA producers (“cookers”). 
SUMMARY OF SOME KEY FINDINGS 
Small-scale production (“cooking”) of MA using the 
Birch/Nazi method has increased over the last dec-
ade. Primary ingredients like pseudoephedrine pills 
and lithium batteries are obtained through purchases 
or theft by drug users who trade them for MA. The 
volatile chemical fertilizer anhydrous ammonia is 
another key ingredient and is often stolen from farms 
or distribution centers. MA is distributed within rela-
tively small networks through sales, gift-giving, and 
barter for cooking ingredients or other items. Smok-
ing the drug on aluminum foil is the most common 
route of use, followed by injecting, inhaling, and oral 
use. 
The participants identified a variety of reasons for 
using MA, including the following: 
• Peer pressure and regular interactions with 
methamphetamine-using acquaintances 
• Boredom with rural life 
• Availability and flexible distribution mecha-
nisms 
• MA is more cost-effective than other stimulants 
(e.g., cocaine) since its psychoactive effects last 
exponentially longer 
• The psychoactive and physiological effects (e.g., 
enhanced energy, weight loss, enhanced sex) of 
methamphetamine 
Although the sample of African-Americans in this 
study was small, the preliminary findings suggest 
potential barriers to African-American use of MA… 
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• Fear of MA’s ingredients 
• Dislike of MA’s prolonged effects 
• Isolation/avoidance in regard to White-
dominated production and distribution networks 
• Well-established preference for cocaine 
Pathways to limited use of MA by African-
Americans include… 
• Using MA while believing that it is powder co-
caine 
• Situationally substituting MA for cocaine 
• Introduction to MA by a White friend or signifi-
cant other 
• Involvement in a largely White social network 
where MA use is common 
Largely self-reported adverse consequences of MA 
production and use include… 
• Chemical spills from attempts to steal anhydrous 
ammonia, accidents in MA “labs,” and toxic lab 
waste 
• Dependence (e.g. uncontrollable cravings) 
• Paranoia, hallucinations, and violence associated 
with binge use of MA 
• Tremors, feelings of paralysis, and back pain 
caused by improperly prepared MA 
• Risky sexual behaviors 
• Dramatic and unhealthy weight loss 
• Dental problems, respiratory problems, and feel-
ings of poor health in general 
 
Stimulant Use Among New 
York City Area Club-Going 
Young Adults 
 
Brian C. Kelly 
 
INTRODUCTION 
 
This paper presents preliminary findings from two 
NIDA-supported studies [R03-DA016171-01; B. 
Kelly, P.I.] and [R01-DA014925-02; J. Parsons, P.I.] 
 
• The Club Drugs and Health Project (CDHP), 
which focuses on club drug use among young 
adults in the New York City club scene 
 
• The Bridge and Tunnel Project (BTP), which 
focused on club drug use among suburban youth 
who attend clubs in New York City 
 
Brief descriptions and findings from each project are 
presented below. 
 
THE CLUB DRUGS AND HEALTH PROJECT  
 
CDHP was designed to study the patterns and con-
texts of club drug use and its associated risks among 
young adults in the club scene with the intent of gain-
ing data to guide prevention and educational efforts.  
 
Three randomized elements (location, time, and indi-
vidual) were used to select study participants. Inter-
cept survey data from the first 1,828 adults who 
agreed to participate in the screening interview reveal 
that 70.8 percent had ever used (lifetime) any drug - 
not counting alcohol or tobacco. Of the 1,828 partici-
pants, 46.4 percent had used ecstasy, 44.8 percent 
cocaine, 22.0 percent ketamine, 16.6 percent crystal 
methamphetamine (CM), and 11.5 percent gamma 
hydroxybutyrate (GHB). One out of six were active 
club drug users.  
 
Gender differences for CM use were identified 
(males 19.5 percent vs. females 13.7 percent) as were 
sexual orientation differences for CM use 
(gay/bisexual 21.4 percent vs. heterosexual 12.3 per-
cent). The use of CM use among heterosexuals indi-
cates that this phenomenon is not limited to the  
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gay/bisexual community. Racial and ethnic differ-
ences were also identified. White young adults were 
most likely to have used CM (18.9 percent). Differ-
ences in CM use among other racial and ethnic 
groups were 9.3 percent among Black participants, 
13.5 percent among Asian/Pacific Islanders (APIs), 
15.8 percent among participants of "Mixed" ra-
cial/ethnic origin, and 16.5 percent among Latinos.  
 
Cocaine remains more prevalent in New York than 
CM. Unlike CM, cocaine use showed no significant 
gender differences (43.2 vs. 45.7 for females and 
males, respectively). Gay men and women reported 
higher rates of cocaine use, albeit with less statistical 
significance than the CM difference (gay/bisexual 
47.1 percent vs. heterosexual 41.7 percent). Much 
like CM, Whites were significantly more likely to 
have used cocaine (50 percent). Differences among 
other racial and ethnic groups were Blacks 31.5 per-
cent, Latinos 38.8 percent; APIs 27.8 percent and 
Mixed 42.6 percent. 
 
THE BRIDGE AND TUNNEL PROJECT 
 
BTP was an ethnographic research project focused on 
club drug-using suburban youth who attended clubs 
in New York City. All 40 youth participants had used 
ecstasy and 33 reported using some sort of stimulant 
drug, not including ecstasy. The main stimulant drug 
was cocaine. About one-half reported cocaine use, 
almost one-quarter CM use, and approximately one-
third had used prescription (Rx) stimulants non-
medically.  
 
Other than ecstasy, Rx drugs were the most prevalent 
substances among these youth. More than one-third 
of these youth abused Rx stimulants. More than one-
half had used any type of Rx drug; the most popular 
non-stimulants were Vicodin, codeine, Xanax, and 
other benzodiazepines. There were also some youth 
who preloaded or postloaded with SSRIs (Selective 
Serotonin Re-uptake Inhibitors) to reduce or elimi-
nate the post-ecstasy crash, though this use pattern 
appeared to be less frequent than abuse of the other 
Rx drugs. Some youth who would not "use drugs" 
relied on over-the-counter stimulants for the same 
purposes. 
 
Rx stimulants have proliferated because of a "triple-
engine" of availability, reliability, and utility. Rx 
stimulants are widely available to youth. Youth indi-
cate they can more regularly predict the achievement 
of the high they desire with Rx drugs and that Rx 
drugs feel familiar to them. Rx stimulants were 
viewed as very functional drugs by youth in the BTP; 
they perceived Rx stimulants as useful outside the 
partying milieu. 
Increased interest in and use of Rx drugs may be tied 
to shifting ecstasy markets in the Nation. As adultera-
tion of ecstasy increases, youth shift to Rx stimulants. 
The shifts in ecstasy markets relate to other trends 
including those that have allowed some youth to 
"graduate up" to use of other stimulants, such as co-
caine and methamphetamine. The shifting ecstasy 
markets have also enabled the rise of new club drugs 
such as tryptamines, especially 5-methoxy-N,N-
diisopropyltryptamine (5-MeO-DIPT, "foxy," or 
"foxy methoxy") and alpha-methyltryptamine (IT-
290 or "AMT"), both tryptamines with hallucino-
genic and stimulant qualities. 
 
 
Stimulant Use Among Young 
People in Hartford,  
Connecticut 
 
Jean J. Schensul 
 
INTRODUCTION 
 
This paper on stimulant use among urban youth in 
Hartford is based on methods and findings from 
NIDA-supported studies [1R01DA11421 and 
DA01010].  
 
SAMPLES AND METHODS 
 
One study involved polydrug users (n=410); the other 
involved a general population of urban youth 
(n=548). The study methods included participant 
observation, indepth interviews, contextual monitor-
ing, and surveys. The first survey was conducted at 2 
points in time, 15 months apart, and involved 400 
young people age 16–24. The second survey was also 
conducted at 2 points in time, 12 months apart, and 
involved 500 young people age 16–30.  
 
In the study of polydrug users, 70 percent were male, 
38 percent were African-American, and 45 percent 
were Puerto Rican; 62 percent had less than a high 
school education and 57 percent were unemployed. 
This study focused on polydrug and hard drug use; a 
supplemental study focused on the sale and use of 
ecstasy in clubs and other party settings. In the study 
of the general population, 59 percent were male, 37 
percent were African-American, and 47 percent were 
Puerto Rican; 60 percent had less than a high school 
education and 51 percent were unemployed. This 
study focused on club drugs and stimulant use. 
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SUMMARY OF SOME KEY FINDINGS 
 
Ecstasy and cocaine are the primary stimulants used 
among youth in Harford. The media and club-rave 
marketing expanded the market for MDMA, which 
diffused from suburban to urban youth networks 
through urban clubs serving mixed clientele, the first 
of which catered to Latinos. Club closings sent the 
social scene “underground,” but it remained part of 
the youth party drug repertoire. MDMA continues to 
be firmly embedded in urban youth networks and is 
readily available and affordable.  
 
In the polydrug use study, 33 percent of the respon-
dents reported ever using ecstasy, compared with 
nearly 14 percent of 18–25-year-old respondents in 
the 2002 National Survey on Drug Use and Health 
maintained by the Substance Abuse and Mental 
Health Services Administration. These Hartford 
MDMA-using polydrug users were significantly 
more likely than other respondent groups to be La-
tino, have less income and education, to be less opti-
mistic about the future, to take more risks, and to 
bear more legal consequences. In the second study, 
differences between ecstasy users (“ever used”) and 
nonusers showed that one-half of Whites, 25 percent 
of the Latinos, and only 14 percent of African-
Americans reported ever using MDMA (p=.008). 
Ecstasy users tended to be party goers and were sig-
nificantly more likely than non-ecstasy users to fre-
quent clubs, rave-like events, and no-pay parties. 
Users expected ecstasy use to make them feel good, 
enhance their mood, feel less stressed, and feel like 
having sex and also expecting sex; fewer reported 
expecting verbal and physical aggression to be part of 
the ecstasy experience. Ecstasy users were more 
likely than nonusers to be involved in risky sex, to 
deal drugs, and to report negative consequences from 
their drug use.  
 
Other data from the studies show that phencyclidine 
(PCP), alcohol, and marijuana use continue to be 
stable parts of the drug repertories of young people in 
Hartford. In a 1–year followup, alcohol use had in-
creased by 4 percent and marijuana by 3 percent. 
Ecstasy use, on the other hand, had increased by 8.5 
percent; 18.5 percent reported using the drug in the 
30 days prior to interview. Cocaine use decreased.  
 
Continuing at relatively high levels were initiation 
and past 30-day use of “dust” (a PCP derivative or 
substitute of embalming fluid or formaldehyde).  
 
One finding in both studies is that methamphetamine 
use was not reported by these young people. The 
question is: If methamphetamine abuse occurs in 
Hartford, will it follow the same route as MDMA 
(methylenedioxymethamphetamine, commonly re-
ferred to as ecstasy)? 
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Monitoring Drug Abuse 
Trends in Australia  
 
Louisa Degenhardt, Ph.D. 
 
OVERVIEW OF THE DRUG MONITORING SYSTEM  
IN AUSTRALIA 
 
The Illicit Drug Reporting System (IDRS), Austra-
lia’s national drug monitoring system, was estab-
lished in 1996. IRDS is funded by the Australian 
Government Department of Health and Aging and 
the National Drug Law Enforcement Research 
Fund. This paper provides an overview of the sys-
tem used to monitor drug abuse patterns and trends 
in Australia and past and current drug abuse trends. 
  
The IDRS is conducted every year in every State 
and territory by participating research institutions 
and is coordinated by the National Drug and Alco-
hol Research Center. The IRDS monitors the price, 
purity, availability, and patterns of use of illicit 
drugs, and serves as an early warning system for 
identifying and assessing emerging trends in illicit 
drug markets through the triangulation of three data 
sources… 
 
• A qualitative annual survey of approximately 
950 injection drug users (IDUs) who serve as a 
sentinel group for the detection of emerging il-
licit drug use trends 
• A qualitative survey of key experts (KEs) who 
work in the illicit drug field 
• A synthesis of extant indicator data sources 
such as Customs data, drug seizure purity data, 
and arrest data 
One information source, the Party Drugs Initiative 
(PDI) survey targeted to ecstasy users and related 
drug markets, provides data/information on emerg-
ing drug trends in Australia’s illicit drug markets. 
The PDI, like the IDRS, consists of three compo-
nents: interviews with individuals (about 850 ec-
stasy users) in sentinel groups of drug users in 
every capital city; interviews with KEs; and drug 
use indicator data such as numbers of treatment 
admissions, arrests, overdoses, and seizures. 
 
In addition, valuable data are provided through the 
National Drug Strategy Household Survey. In 2004, 
the stratified sample for the household survey in-
volved nearly 30,000 persons age 14 and older. 
 
DRUG ABUSE PATTERNS AND TRENDS 
 
Some major findings from the 2004 Household 
Survey on Australians age 14 and older show 
that… 
• More than 2 million had recently used canna-
bis, 18,000 fewer that in 2004; 1 in 5 teenagers 
had used cannabis in the 12 months prior to the 
2004 survey 
• 17,000 persons reported using cocaine in the 
12 months prior to the 2004 survey 
• 25,800 persons (14,800 males and 11,000 fe-
males) reported use of heroin in the 12 months 
prior to the 2004 survey, approximately 12,000 
fewer than in 2001 
• Nearly 560,000 persons reporting using ec-
stasy at least once in the 12 months prior to the 
2004 survey, roughly 100,000 more than in 
2001  
Past and recent drug abuse trends in Australia show 
that the heroin market increased in scale in the 
1990s. There were approximately 1,000 opioid 
deaths in 1999. A number of steps were taken to 
address the heroin problem including seizures of 
large shipments of heroin destined to Australia, 
arrests of facilitators, and the disruption of heroin 
networks. By 2001, the supply of heroin was cut 
off and there was a growing shortage of the drug. 
The purity of heroin at the street level was halved 
and the price doubled. 
 
Other drug trends identified by IDUs in different 
parts of Australia show… 
 
• Illicit morphine use in the Northern Territory 
• Illicit methadone use in Tasmania 
• Injection of benzodiazepines, particularly in 
Tasmania and Victoria 
• Injection of cocaine in New South Wales 
(2001) 
The most recent trends identified include the fol-
lowing: 
• A stable cannabis market 
• Increased use of psychostimulants including 
ecstasy and crystal methamphetamine, with 
some reports of regular users developing psy-
chotic symptoms 
• Nonmedical use of pharmaceuticals among 
regular IDUs 
• Decreases in heroin overdose and other harm-
ful consequences 
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EMCDDA Report on 
Europe 
 
Paul Griffiths 
 
OVERVIEW OF THE EMCDDA 
 
Established in 1993, the European Monitoring Cen-
tre for Drugs and Drug Addiction (EMCDDA), 
based in Lisbon, Portugal, serves as the central 
reference point for drug information in the Euro-
pean Union (EU). 
 
The EMCDDA collects data/information on the 
drug situation, responses to drug use, and policy 
developments through its Reitox reporting network. 
This report is restricted to the first of these tasks; 
reporting on the drug situation. This network con-
sists of “government nominated” focal points in 
each member State, which are linked to expert 
technical groups. Data are collected on the drug 
situation, responses to drug use, and policy devel-
opment. An additional specific task of the 
EMCDDA is also to coordinate the EU mechanism 
for monitoring the emergence of new synthetic 
drugs that are not currently controlled under inter-
national or European agreements.   
 
Reporting on the drug situation is based on five key 
indicators for epidemiological monitoring. These 
indicators provide a common reporting standard for 
EU member States and methodological guidelines. 
The indicators cover the following topics: 
 
• Prevalence and patterns of drug use in the gen-
eral population, as measured by population 
surveys  
• Problem drug use estimates (statistical esti-
mates of number of long-term and chronic us-
ers of drugs like heroin and cocaine) 
• Drug-related infectious diseases (HIV, HCV, 
HBV) 
• Drug-related mortality of drug users (registry 
data and cohort studies) 
• Demand for treatment (first treatment demands 
and all demands) 
 
In addition to these data, other important sources of 
information for monitoring the drug situation in-
clude statistics on drug law offenses and market 
information, studies of young people and school 
survey data (ESPAD), and reports from the Early 
Warning System on new synthetic drugs.  
 
Data are synthesized into an Annual Report cover-
ing developments across the EU. The system cov-
ers the 25 member States of the European Union 
and Norway, which participates by special agree-
ment. Bulgaria, Romania, and Turkey also now 
provide some data.  
 
SUMMARY OF FINDINGS 
 
Cannabis indicators continue trending upward in 
Europe with some signs of convergence and possi-
bly stabilization among some countries where there 
is a high prevalence of cannabis abuse. Histori-
cally, the United Kingdom (UK) reported the high-
est rates of cannabis use. Currently, cannabis use in 
the UK appears stable and a number of other coun-
tries, notably France, the Czech Republic and 
Spain, report cannabis use similar to that reported 
in the UK, and on some measures, high rates of 
use. Three waves (1996, 1999, and 2003) of the 
school survey data for 15–year-olds from the 
ESPAD are now available for comparison of time 
trends in most European countries. The surveys 
show increases in cannabis prevalence in almost all 
countries between 1996 and 2003, with the greatest 
changes occurring in the 1996 to 1999 period. Can-
nabis issues of concern include the need to better 
assess trends in intensive and regular use, and the 
factors behind reports of rising treatment demands. 
 
Ecstasy indicators also continue to trend upwards 
in most countries. A notably exception is the UK 
where rates are high but stable. Overall, ecstasy has 
replaced amphetamine as Europe’s second most 
commonly used drug.  
 
Currently, significant methamphetamine use is only 
reported from the Czech Republic. The use of 
powder cocaine is increasing in many European 
countries, and in some countries cocaine preva-
lence rates are already high. Estimates of recent use 
(past-year prevalence) of powder cocaine in Spain 
and the UK, for example, are similar to estimates 
reported in the United States, although lifetime 
prevalence estimates remain considerably lower in 
European countries than in the United States. Crack 
cocaine use remains rare with significant use lim-
ited to a few major cities. 
 
In most countries, heroin and injecting indicators 
were stable or decreasing. Opiate-related deaths are 
now declining but are still at historically high lev-
els. The age of heroin-related deaths is also rising 
and the proportion of those younger than 25 has 
decreased substantially, suggesting an aging popu-
lation. This observation does not apply to some of 
the new EU member States where the more limited 
data available suggest that opiate-related deaths are 
representing younger users and the overall trend 
may still be upwards.   
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Surveys of at-risk populations show far higher 
prevalence rates of drug use; however, making 
generalizations from these data is difficult. How-
ever, they do give some indication of the current 
relative popularity of different types of drug. For 
example, a 2004 survey of “clubbers” who were 
regular recreational drug users in the UK found that 
the most commonly used drugs were cannabis, ec-
stasy, and powder cocaine, followed by ampheta-
mine, amyl nitrates, magic mushrooms, and keta-
mine. Much more limited use was reported of other 
substances. (e.g. salvia, GHB [gamma hydroxybu-
tyrate], crack, heroin, methamphetamine, and new 
synthetics). 
 
 
Update of the Epidemi-
ologic Surveillance System 
of Addictions (SISVEA) in 
Mexico: 2004 
 
Roberto Tapia-Conyer, Patricia Cravioto, 
Pablo Kuri, Mario Cortés, Santiago 
Zaragoza,  and Fernando Galván1 
 
ABSTRACT 
 
Alcohol was the most common drug of onset 
among treatment clients at GTCs and NGCs in 
2004, followed by marijuana. Alcohol was also the 
most commonly detected substance among drug-
related decedents in 2004. For the current primary 
drug of abuse, cocaine ranked first at GTCs, while 
crystal (methamphetamine) surpassed heroin as the 
most common current drug of abuse at NGCs in 
2004. Among infractors at Juvenile Detention Cen-
ters in 2004, marijuana was the most common drug 
of abuse, representing 35 percent.  
 
INTRODUCTION   
  
The Epidemiological Surveillance System of Ad-
dictions (SISVEA) is a permanent monitoring sys-
tem of the use and abuse of tobacco, alcohol, and 
medical or illegal drugs, as well as their effects on 
morbidity and mortality and their association with 
juvenile infractors. SISVEA was created in 1990 
by the General Directorate of Epidemiology to in-
vestigate and document drug consumption in Mex-
ico. Originally, SIVEA included eight cities located 
at Mexico’s northern border; currently, SISVEA 
provides information from 31 States of Mexico. 
 
                                                 
1The authors are affiliated with the Ministry of Health of Mex-
ico, Tlanepantla Edo. De Mexico. 
Initially, SISVEA was based conceptually and op-
erationally on three strategies, which have evolved 
and been reinforced to form the present system. 
The five main indicators of the present system give 
continuity to the original model. The indicators and 
data sources are shown below: 
 
• Information on consumption of tobacco, alco-
hol, and medical and illegal drugs is obtained 
from treatment centers. 
 
• Data on diseases and accidental mortality are 
provided by emergency rooms.  
 
• Information on mortality among drug users is 
provided by coroners’ offices. 
 
• Statistics on crimes against health are obtained 
from law enforcement agencies. 
 
• General information on consumption of to-
bacco, alcohol, and medical and illegal drugs in 
the general population and risk groups is ob-
tained from surveys and qualitative studies.  
 
Data Sources 
 
This report includes information on recent activities 
of SISVEA during 2004. The sources of data used 
for this are described below: 
  
• Treatment data are obtained from the govern-
ment treatment centers (the Centers of Juvenile 
Integration) and from the nongovernment treat-
ment centers that participate in SISVEA cities. 
Treatment data cover the characteristics and 
consumption patterns related to the first drug of 
use and primary drug of use for clients for 2004.  
 
• Drug consumption data are reported for the 
general population and for targeted population 
groups. Juvenile arrest data were provided by 
Juvenile Detention Centers for 2004. 
 
• Medical examiner (ME) data are provided 
for 2004 for drug-related deaths, including ac-
cidental or violent deaths (homicides or sui-
cides) in cases in which drug abuse may be the 
direct cause of death or a contributing factor.  
 
DRUG ABUSE PATTERNS AND TRENDS 
 
Marijuana 
 
GTC Data  
 
Marijuana was the second most common drug of 
first choice (11.6 percent) among clients at gov-
ernment treatment centers (GTCs) in 2004. As a 
primary drug, marijuana also ranked second among 
2004 GTC patients (17.7 percent) (exhibit 1).  
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According to GTCs, marijuana users during 2004 
were mostly male (92.1 percent); 27.1 percent were 
age 15–19 (exhibit 2). Forty-six percent had only a 
middle school education; 61.4 percent were single; 
and 49.0 percent came from a middle-low socio-
economic level. The age of onset for 49.1 percent 
of marijuana users occurred between ages 10 and 
14; 43.4 percent began to use between ages 15 and 
19. Two-thirds reported daily use.   
 
Based on natural history data for 2004, 10.4 per-
cent of these marijuana GTC patients were 
monodrug users upon treatment entry, and 89.6 
percent had already begun to use a second drug, 
usually alcohol (32.9 percent) or tobacco (21.4 
percent) (exhibit 3a). Of multiple drug users, 84.8 
percent had advanced to a third drug, usually alco-
hol (24.1 percent), tobacco (21.2 percent), or co-
caine (20.4 percent). 
 
NGC Data 
 
Among patients at nongovernment treatment cen-
ters (NGCs) in 2004, marijuana was the second 
most common drug of first choice (26.6 percent) 
and the fourth most common primary drug of abuse 
(9.9 percent) (exhibit 4). 
 
The overwhelming majority of the marijuana clients 
at NGCs were male (95.6 percent); 24.6 percent 
were age 35 and older (exhibit 5). Forty-one percent 
had a middle school education, and 59.4 percent 
were single. The age of onset for marijuana use 
among these patients was between 10 and 14 for 
48.3 percent, and 82.6 percent reported daily use.  
 
According to the natural history data of marijuana 
consumption for these clients, 12.5 percent were 
still monodrug users upon treatment entry, while 
the remaining 87.5 percent had progressed to a 
second drug, usually cocaine (26.1 percent) or al-
cohol (17.0 percent) (exhibit 3a). Of this group, 
73.6 percent were already using a third drug, 
mainly cocaine (21.9 percent) heroin (18.4 per-
cent), and crystal (15.5 percent).  
 
Juvenile Detention Center Data 
 
Information from the Juvenile Detention Centers 
showed that 34.8 percent of the 10,555 juveniles 
arrested during 2004 had used marijuana (exhibit 6). 
Most of this population were male (95.2 percent); 
52.6 percent had an elementary school education; 
41.6 percent were subemployed; 36.5 percent had a 
tattoo; and 30.2 percent were gang members. Nearly 
one-third (31.6 percent) of the offenses were com-
mitted while the offender was intoxicated, and 44.0 
percent of the offenses were robberies.  
ME Data 
  
ME data indicated that 3.63 percent of deaths re-
ported were associated with marijuana. This dece-
dent group was primarily male; 21.3 percent were 
age 40 and older and 40.0 percent were age 25–34 
(exhibit 7). The main cause of death in these cases 
was asphyxia (20.8 percent), followed by run over 
(12.5 percent). These deaths most commonly oc-
curred on the street (36.1 percent) or at home (25.0 
percent).  
 
Inhalants  
 
GTC Data 
 
During 2004, inhalants ranked as the third most 
commonly reported drug of onset among GTC cli-
ents (7.4 percent) and fourth as a current primary 
drug of abuse (10.6 percent) (exhibit 1).  
 
Inhalant users attending GTCs were mostly male 
(85.1 percent); nearly one-third (31.3 percent) were 
age 15–19 (exhibit 2). Most patients had a middle 
school education (55.3 percent); 76.4 percent were 
single; and 55.1 percent were from a middle-low 
socioeconomic level. Most began to use inhalants 
between ages 10 and 14 (65.9 percent); 42.2 per-
cent used them daily and 41.3 percent used them 
once per week.  
 
GTC data on the natural history of inhalant use 
show that 25.7 percent of these clients were 
monodrug users when they entered treatment; 74.3 
percent were already using a second drug, mainly 
marijuana (33.8 percent), alcohol (22.4 percent), 
and tobacco (20.9 percent). Of the multiple drug 
users, 81.0 percent used a third drug, mainly alco-
hol (27.9 percent), marijuana (20.0 percent), to-
bacco (17.9 percent), or cocaine (13.3 percent) (ex-
hibit 3b).  
 
NGC Data 
 
Inhalants ranked third (11.8 percent) as drug of 
onset and sixth (8.7 percent) as a primary drug 
among clients in NGCs in 2004 (exhibit 4).  
 
NGCs report that of the patients who used inha-
lants, most of them were male (93.2 percent), and 
33.3 percent were age 15–19. Sixty percent had an 
elementary school education, and 72.3 percent 
were single (exhibit 4). More than one-half began 
to use inhalants between ages 10 and 14 (58.5 per-
cent), and 87.0 percent reported daily use.  
 
Regarding the natural history of inhalants users, 
55.0 percent of the patients had progressed to a 
second drug upon treatment entry, which in order 
of importance were marijuana (53.1 percent), alco-
hol (15.5 percent), and other inhalants (7.2 percent) 
(exhibit 3b). Of these patients, 72.2 percent had 
also begun to use a third drug, usually cocaine 
(25.1 percent), marijuana (17.2 percent), or alcohol 
(13.7 percent).  
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Juvenile Detention Center Data 
 
Of the juveniles arrested during 2004, 13.5 percent 
used inhalants (exhibit 6). Most of these juveniles 
were male (95.0 percent), had an elementary school 
education (63.6 percent), and were subemployed 
(46.0 percent). Thirty-nine percent had tattoos, and 
38.8 percent belonged to a gang. More than one-
third (37.6 percent) of these juveniles committed 
their offense while intoxicated, and robbery was 
the most common offense (44.7 percent).  
 
Alcohol  
 
GTC Data 
 
Alcohol was the most commonly reported drug of 
onset (33.3 percent), but it ranked third (17.4 per-
cent) as a primary drug of abuse among GTC pa-
tients in 2004 (exhibit 1).  
 
Of the 3,582 primary alcohol patients attending 
GTCs in 2004, 82.6 percent were male, 24.0 per-
cent were age 15–19, and 20.9 percent were age 35 
or older (exhibit 2). Most had a middle school edu-
cation (41.8 percent); 54.9 percent were single; and 
more than one-half (54.5 percent) were from a 
middle-low socioeconomic level. Nearly one-half 
(47.0 percent) began to use alcohol between ages 
15 and 19; 48.2 percent reported weekly use; and 
31.3 percent reported using alcohol 1–3 times per 
month.  
 
According to the natural history data for alcohol, 
91.4 percent had progressed to a second drug upon 
treatment entry, usually tobacco (57.8 percent), 
marijuana (17.3 percent), and cocaine (13.2 per-
cent) (exhibit 3c). Of the multiple drug user group, 
74.6 percent reported using a third drug, usually 
marijuana (33.1 percent), cocaine (26.6 percent), 
and inhalants (10.5 percent).  
 
NGC Data 
 
Among NGC clients in 2004, alcohol ranked first 
as the drug of onset (30.0 percent) and second as a 
current primary drug (19.5 percent) (exhibit 4).  
 
Most of the 12,360 patients who were alcohol cli-
ents in 2004 were male (92.1 percent); 42.5 percent 
were age 35 or older; and 32.2 percent had only an 
elementary school education (exhibit 5). Forty-
three percent were single, and most (46.5 percent) 
started to use alcohol between ages 15 and 19. 
One-half reported daily use, and 37.2 percent used 
alcohol once per week.  
  
The natural history of alcohol abuse provided by 
NGCs during 2004 shows that 28.7 percent of these 
clients were monodrug users upon treatment entry, 
while the remaining 71.3 percent had progressed to 
a second drug, typically marijuana (36.2 percent), 
cocaine (22.0 percent), and tobacco (14.8 percent) 
(exhibit 3c). Sixty-five percent of these clients had 
progressed to a third drug, usually cocaine (31.5 
percent), marijuana (17.1 percent), and crystal 
(15.1 percent).  
  
Juvenile Detention Center Data 
 
Among juvenile infractors, 14 percent reported 
alcohol abuse (exhibit 6). They were mostly male 
(92.5 percent), and 44.8 percent had an elementary 
school education. Forty percent were subemployed; 
30.2 percent had tattoos; and 24.1 percent were 
gang members. More than one-third of the juve-
niles (44.8 percent) committed the offense while 
intoxicated, and robbery (42.2 percent) was the 
most common offense.  
 
ME Data 
 
According to MEs, the abuse of alcohol is associ-
ated with 83.8 percent of drug-related deaths. Most 
decedents were male (93.8 percent), and 39.4 per-
cent were age 40 or older (exhibit 7). The main 
cause of death was asphyxia (18.2 percent), fol-
lowed by traffic accidents (18.1 percent). Deaths 
typically occurred on the street (39.5 percent) or at 
home (30.4 percent).  
 
Cocaine  
 
Among patients at GTCs in 2004, cocaine ranked 
fourth as the first drug of choice (3.8 percent) and 
first as primary drug of abuse (25.8 percent) (ex-
hibit 1).  
 
GTCs report that cocaine users during 2004 were 
mostly male (78.6 percent); 26.3 percent each were 
age 15–19 and 20–24 (exhibit 2). Nearly one-half 
(45.6 percent) had a middle school education; 51.8 
percent were single; and 26.7 percent were married. 
More than one-half (56.9 percent) were members 
of a middle-low socioeconomic level; 49.3 percent 
initiated cocaine use between ages 15 and 19. 
Forty-two percent reported weekly cocaine use, and 
35.8 percent reported daily use.  
  
The natural history data for GTC cocaine patients 
in 2004 show that 25.7 percent were monodrug 
users upon entering treatment, while the rest were 
already using a second drug, usually alcohol (31.3 
percent), marijuana (20.0 percent), and tobacco 
(18.3 percent) (exhibit 3d). Of the multiple drug 
users, 69.3 percent had started to use a third drug: 
alcohol (28.4 percent), tobacco (26.9 percent), and 
marijuana (19.7 percent).  
 
NGC Data 
 
In 2004, cocaine ranked fourth as the drug of onset 
(5.9 percent) and fourth as current primary drug 
(17.9 percent) among NGC patients (exhibit 4).  
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Ninety-two percent of the cocaine users who at-
tended NGCs in 2004 were male; 24.8 percent were 
age 20–24; 38.6 percent had a middle school edu-
cation; and 30.0 percent had an elementary school 
education (exhibit 5). One-half of these cocaine 
patients were single. Forty-four percent began to 
use cocaine between ages 15 and 19; 60.4 percent 
reported daily use and 29.6 percent reported 
weekly use of the drug.  
 
The natural history of cocaine abuse reported by 
NGCs during 2004 shows that 34.2 percent were 
still monodrug users upon treatment entry, and 65.8 
percent had progressed to a second drug—usually 
marijuana (25.3 percent), crystal (21.0 percent), 
and alcohol (15.4 percent) (exhibit 3d). Of the mul-
tiple drug users, 47.7 percent had started to use a 
third drug, generally crystal (21.7 percent), mari-
juana (17.4 percent), or alcohol (13.3 percent).  
  
Juvenile Detention Center Data 
 
Juvenile Detention Centers reported cocaine use 
among 14.3 percent of these younger arrestees in 
2004 (exhibit 6). They were mostly male (94.3 per-
cent); more than one-half had an elementary school 
education (55.8 percent); and 42.1 percent were 
subemployed. Thirty-six percent had tattoos, and 
30.6 percent were gang members. More than one-
quarter of the juvenile infractors (28.9 percent) 
committed the offense while intoxicated; robbery 
was the most common offense (49.1 percent).  
 
Heroin 
 
GTC Data 
 
Of the patients attending GTCs during 2004, only 
0.1 percent reported heroin as their drug of onset, 
but as primary drug it ranked in fifth place (2.4 
percent) (exhibit 1). 
 
All of the heroin users at GTCs in 2004 were male; 
27.3 percent were age 20–24; and 18.2 percent 
were age 15–19 (exhibit 2). Thirty percent each of 
these patients had an elementary, middle, or high 
school education. Similar proportions (27.3 percent 
each) were single, married, or divorced. Sixty per-
cent were from a middle-low and 30.0 were from a 
low socioeconomic level. The age of onset for 45.5 
percent of heroin users occurred between ages 10 
and 14; 100.0 percent reported daily use.  
 
NGC Data 
 
Among patients at NGCs, heroin as a drug of onset 
has been increasing since 1994; 1.9 percent of pa- 
 
 
 
 
 
tients in 2004 reported heroin as their first drug of 
use (exhibit 4). Heroin ranked third as a primary 
drug of abuse among NGC patients in 2004 (38.4 
percent). 
 
The overwhelming majority of heroin patients at 
NGCs in 2004 were male (91.8 percent), and 43.5 
percent were age 35 and older (exhibit 5). More 
than one-third (37.7 percent) of these patients had 
only a middle school education, and 53.2 percent 
were single. The age of first use of heroin among 
these patients was between 15 and 19 (38.4 per-
cent); 91.7 percent reported daily use.  
 
Juvenile Detention Center Data 
 
Information from the Juvenile Detention Centers 
showed that 0.4 percent of the juveniles arrested 
during 2004 used heroin (exhibit 6). Most of this 
population were male (87.8 percent); 47.5 percent 
had an elementary school education; and 36.6 per-
cent were unemployed. Approximately one-third 
(30.6 percent) had tattoos or were gang members 
(34.1 percent). One-half of the offenses were com-
mitted under intoxication, and robbery was the 
most common offense (58.5 percent).  
 
CONCLUSIONS  
 
Alcohol abuse remains a problem in Mexico. It is 
still the most common drug of onset, although this 
frequency varies in the different regions of the coun-
try. Alcohol is also the most frequently detected drug 
in emergency rooms and by medical examiners. 
Crystal surpassed heroin as the most common pri-
mary drug at NGCs in 2004, while cocaine remained 
the most common primary drug among NGC pa-
tients. The proportion of cocaine patients at NGCs 
has declined, however, since the peak of 40.3 per-
cent in 1998 to 25.8 percent in 2004. 
 
Among offenders at the Juvenile Detention Centers, 
marijuana remains the most frequently abused sub-
stance; it represented 35 percent of the offenders in 
2004. Offenders who abused cocaine, alcohol, and 
inhalants remained at about 14 percent each.  
 
Although SISVEA currently includes 31 States and 
53 cities, the system has to be strengthened and 
expanded to include to the rest of Mexico.  
 
For inquiries concerning this report, please contact Santiago 
Zaragoza, Especialista en Epidemiologia, Direccion General de 
Epidemiologia, Llanura #48 Col. Plazas de la Colina, Tlanep-
antla Edo. De Mexico 54080, Phone: 55-55-93-1011, Fax: 55-
56-51-8338, E-mail: szaragoza@dgepi.salud.gob.mex. 
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Exhibit 1. Comparison Between First Drug of Use and Current Drug of Use Among Patients at  
 Government Treatment Centers, by Percentage:  1991–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  SISVEA—Government treatment centers 
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Exhibit 2. Demographic Characteristics of Government Treatment Center Patients, by First Drug of Use  
 and Percent:  2004 
 
Global Marijuana Inhalants Alcohol Cocaine1 Heroin Tobacco Demographic  
Characteristic N=10,761 n=1,250 n=799 n=3,582 n=404 n=11 n=4,460 
Gender               
 Male 82.4 92.1 85.1 82.6 78.6 100.0 79.3 
 Female 17.6 7.9 14.9 17.4 21.4 0.0 20.7 
Age               
 5–14 Years 8.7 6.6 28.6 7.0 6.5 0.0 7.2 
 15–19 26.8 27.1 31.3 24.0 26.3 18.2 28.3 
 20–24 18.5 19.7 15.3 18.9 26.3 27.3 17.7 
 25–29 15.1 18.0 11.0 16.5 22.1 9.1 13.3 
 30–34 11.1 12.9 6.5 12.7 11.7 0.0 10.2 
 35 and older 19.8 15.8 7.3 20.9 7.1 45.4 23.2 
Schooling               
 Elementary school 19.4 22.9 33.2 16.8 15.9 30.0 18.2 
 Middle school 43.9 46.0 55.3 41.8 45.6 30.0 43.0 
 High school 22.1 21.3 8.1 24.8 25.9 30.0 22.4 
 College studies 9 6.5 0.5 10.3 6.5 10.0 10.4 
 No formal education 0.4 0.5 0.9 0.6 0.3 0.0 0.2 
 Other 5.1 2.7 2.0 5.8 5.8 0.0 5.8 
Marital Status               
 Single 57.9 61.4 76.4 54.9 51.8 27.3 56.6 
 Married 23.4 18.4 10.2 26.2 26.7 27.3 24.8 
 Divorced 2.1 1.8 0.6 2.3 1.6 27.3 2.3 
 Widowed 0.6 0.2 0.0 0.4 0.0 0.0 1.0 
 Living together 10.4 11.9 8.9 10.4 13.7 18.2 10.0 
 Other 5.6 6.3 3.9 5.8 6.2 0.0 5.4 
Socioeconomic Level               
 High, middle-high 15.3 14.0 8.4 15.4 12.2 10.0 16.9 
 Middle-low 54.2 49.0 55.1 54.5 56.9 60.0 54.9 
 Middle 7.4 9.5 4.5 7.6 5.1 0.0 7.4 
 Low 23.2 27.5 32.0 22.5 25.9 30.0 20.7 
Age Of Onset               
 9 and younger 5.2 2.1 6.5 5.2 1.7 0.0 6.1 
 10–14 48.4 49.1 65.9 39.5 29.1 45.5 53.5 
 15–19 40.2 43.4 26.6 47.0 49.3 27.3 35.7 
 20–24 4.3 4.5 0.8 6.1 8.6 18.2 3.2 
 25–29 1.1 0.6 0.1 1.3 7.6 0.0 0.9 
 30–34 0.4 0.2 0.0 0.5 2.3 9.1 0.3 
 35 and older 0.4 0.1 0.0 0.5 1.3 0.0 0.3 
Frequency               
 Daily 53.9 66.1 42.2 16.7 35.8 100.0 79.2 
 Once a Week 27.6 21.1 41.3 48.2 42.3 0.0 12.4 
 1–3 times per month 16.8 11.2 14.6 31.3 20.9 0.0 8.0 
 1–11 times per year 1.7 1.6 1.9 3.8 1.0 0.0 0.4 
 
1Cocaine, basuco, crack 
SOURCE:  SISVEA—Centers for Juvenile Attention (government treatment centers) 
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Exhibit 3a. Natural History of Marijuana Use:  2004 
 
Governmental Centers
89.6% 84.8%
Marijuana Use a 2nd drug Use a 3rd drug 
Alcohol 32.9% Alcohol 24.1%
Tobacco 21.4% Tobacco 21.2%
Cocaine 14.6% Cocaine 20.4%
10.4% Inhalants 11.7% Crack 5.7%
Monodrug users Others 19.4% 15.2% Others 28.6%
Nongovernmental Centers
87.5% 73.6%
Marijuana Use a 2nd drug Use a 3rd drug 
Cocaine 26.1% Cocaine 21.9%
Alcohol 17.0% Heroin 18.4%
Inhalants 14.7% Crystal 15.5%
12.5% Crystal 11.9% Alcohol 9.5%
Monodrug users Tranquilizers 8.1% 26.4% Tranquilizers 7.6%
Others 23.7% Others 25.3%
 
 
SOURCE:  SISVEA—Government and nongovernment treatment centers 
 
 
Exhibit 3b. Natural History of Inhalants Use:  2004 
 
Governmental Centers
74.3% 81.0%
Inhalants Use a 2nd drug Use a 3rd drug 
Marijuana 33.8% Alcohol 27.9%
Alcohol 22.4% Marijuana 20.0%
Tobacco 20.9% Tobacco 17.9%
25.7% Inhalants 11.4% 19.0% Cocaine 13.3%
Monodrug users Others 11.5% Others 20.9%
Nongovernmental Centers
55.0% 72.2%
Inhalants Use a 2nd drug Use a 3rd drug 
Marijuana 53.1% Cocaine 25.1%
Alcohol 15.5% Marijuana 17.2%
Inhalants 7.2% Tranquilizers 11.3%
45.0% Cocaine 6.3% 27.8% Alcohol 13.7%
Monodrug users Tranquilizers 5.8% Heroin 9.4%
Others 11.1% Others 26.3%
 
 
SOURCE:  SISVEA—Government and nongovernment treatment centers 
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Exhibit 3c. Natural History of Alcohol Use:  2004 
 
Governmental Centers
91.4% 74.6%
Alcohol Use a 2nd drug Use a 3rd drug 
Tobacco 57.8% Marijuana 33.1%
Marijuana 17.3% Cocaine 26.6%
Cocaine 13.2% Inhalants 10.5%
8.6% Inhalants 5.2% 25.4% Tobacco 9.6%
Monodrug users Others 6.5% Others 20.2%
Nongovernmental Centers
71.3% 65.0%
Alcohol Use a 2nd drug Use a 3rd drug 
Marijuana 36.2% Cocaine 31.5%
Cocaine 22.0% Marijuana 17.1%
Tobacco 14.8% Crystal 15.1%
28.7% Crystal 5.8% 35.0% Inhalants 6.4%
Monodrug users Inhalants 4.5% Heroin 4.4%
Others 14.6% Others 24.4%
 
 
SOURCE:  SISVEA—Government and nongovernment treatment centers 
 
 
Exhibit 3d. Natural History of Cocaine Use:  2004 
 
Governmental Centers
74.3% 69.3%
Cocaine Use a 2nd drug Use a 3rd drug 
Alcohol 31.3% Alcohol 28.4%
Marijuana 20.0% Tobacco 26.9%
Tobacco 18.3% Marijuana 19.7%
25.7% Crystal 6.0% 30.7% Inhalants 7.2%
Monodrug users Others 24.4% Others 17.8%
Nongovernmental Centers
65.8% 47.7%
Cocaine Use a 2nd drug Use a 3rd drug 
Marijuana 25.3% Crystal 21.7%
Crystal 21.0% Marijuana 17.4%
Alcohol 15.4% Alcohol 13.3%
34.2% Heroin 12.1% 52.3% Heroin 9.2%
Monodrug users Crack 9.3% Inhalants 8.2%
Others 17.7% Others 29.9%
 
 
SOURCE:  SISVEA—Government and nongovernment treatment centers 
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Exhibit 4. Comparison Between First Drug of Use and Current Drug of Use Among Patients at Nongovern- 
 ment Treatment Centers, by Percent:  1994–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  SISVEA—Nongovernment treatment centers 
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Exhibit 5. Demographic Characteristics of Nongovernment Treatment Center Patients, by First Drug of  
 Use and Percent:  2004 
 
Global Marijuana Inhalants Alcohol Cocaine1 Heroin Tobacco Demographic  
Characteristic N=41,135 n=10,927 n=4,857 n=12,360 n=2,447 n=800 n=7,663 
Gender               
 Male 93.1 95.6 93.2 92.1 91.7 91.8 91.5 
 Female 6.9 4.4 6.8 7.9 8.3 8.3 8.5 
Age               
 5–14 Years 2.0 1.6 6.5 0.9 1.3 0.1 1.7 
 15–19 15.7 16.5 33.3 9.2 17.7 3.6 14.4 
 20–24 19.2 21.7 22.9 14.5 24.8 14.9 19.8 
 25–29 18.0 19.3 16.3 16.5 20.8 20.4 18.6 
 30–34 15.7 16.3 9.8 16.4 18.3 17.5 16.2 
 35 and older 29.4 24.6 11.2 42.5 17.2 43.5 29.3 
Schooling               
 Elementary school 36.6 36.6 60.3 32.2 30.0 37.4 34.6 
 Middle school 41.0 41.0 27.1 31.7 38.6 37.7 40.2 
 High school 16.4 16.4 4.6 20.4 23.4 16.7 18.7 
 College studies 2.6 2.6 0.5 9.4 5.8 3.8 3.7 
 No formal education 3.2 3.2 7.5 5.5 1.9 4.3 2.7 
 Other 0.2 0.2   0.7 0.3 0.1 0.2 
Marital Status               
 Single 54.1 59.4 72.3 42.6 50.0 53.2 54.9 
 Married 22.7 18.4 11.7 31.0 28.1 19.7 20.9 
 Divorced 4.1 4.0 1.6 5.2 3.2 4.9 4.3 
 Widowed 6.5 5.9 4.5 7.9 5.6 7.8 6.6 
 Living together 0.9 0.6 0.3 1.6 0.6 1.1 0.9 
 Other 11.7 11.8 9.6 11.6 12.6 13.2 12.4 
Age Of Onset               
 9 and younger 5.6 4.8 8.5 4.4 1.2 0.9 8.8 
 10–14 43.4 48.3 58.5 34.8 20.6 16.2 50.9 
 15–19 40.1 39.8 30.2 46.5 44.0 38.4 35.4 
 20–24 6.7 4.7 2.1 9.3 17.0 20.8 3.7 
 25–29 2.3 1.5 0.5 2.8 9.8 11.2 0.7 
 30–34 1 0.6 0.1 1.2 4.3 6.4 0.3 
 35 and older 0.8 0.4 0.2 0.9 3.2 6.1 0.2 
Frequency               
 Daily 73.2 82.6 87.0 49.8 60.4 91.7 90.9 
 Once a Week 19.5 11.9 9.0 37.2 29.6 5.3 6.7 
 1–3 times per month 5.3 3.4 2.5 10.2 6.9 2.9 1.6 
 1–11 times per year 2.0 2.0 1.5 2.7 3.1 0.1 0.9 
 
1Cocaine, basuco, crack 
SOURCE:  Nongovernment treatment centers  
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Exhibit 6. Social Characteristics and Type of Offense Committed by Juvenile Drug-Using Arrestees, by 
 Percent:  2004 
 
Total Marijuana Inhalants Alcohol Cocaine Heroin 
N=10,555 n=3,671 n=1,429 n=1,473 n=1,505 n=41 
Male 
91.4 
Male 
95.2 
Male 
95.0 
Male 
92.5 
Male 
94.3 
Male 
87.8 
Elementary school 
47.3 
Elementary school 
52.6 
Elementary school 
63.6 
Elementary school 
44.8 
Elementary school 
55.8 
Elementary school 
47.5 
Subemployed 
32.6 
Subemployed 
41.6 
Subemployed 
46.0 
Subemployed 
40.2 
Subemployed 
42.1 
Unemployed 
36.6 
Tattoo 
22.7 
Tattoo 
36.5 
Tattoo 
39.0 
Tattoo 
30.2 
Tattoo 
36.0 
Tattoo 
30.6 
Belong to a gang 
19.8 
Belong to a gang 
30.2 
Belong to a gang 
38.8 
Belong to a gang 
24.1 
Belong to a gang 
30.6 
Belong to a gang 
34.1 
Offense under 
intoxication 
17.8 
Offense under 
intoxication 
31.6 
Offense under 
intoxication 
37.6 
Offense under 
 intoxication 
44.8 
Offense under 
intoxication 
28.9 
Offense under 
intoxication 
50.0 
Frequent Offenses 
Robbery 
Against health 
Injuries 
Damages 
Other 
 
45.2 
14.9 
8.5 
6.3 
25.1 
 
Robbery 
Against health 
Drug 
 Consumption 
Injuries 
Other 
44.0 
27.8 
 
8.8 
3.6 
15.8 
Robbery 
Against health
Drug 
 Consumption
Arms bearing 
Other 
44.7
21.8
12.5
2.7
18.3
Robbery 
Injuries 
Against health
Damages 
Other 
 
42.2
11.1
10.9
6.9 
28.9
 
Robbery 
Against health 
Drug 
 Consumption 
Injuries 
Other 
49.1 
30.0 
 
5.5 
3.6 
11.8 
Robbery 
Against health 
Drug 
 Consumption 
Other 
 
58.5
24.4
2.4
4.9
9.8
 
SOURCE:  SISVEA—Juvenile detention centers  
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Exhibit 7. Type of Death Under Intoxication of Selected Drugs1 in Mexico by Percent:  2004 
 
Total  Alcohol Marijuana Opioids2 Type of Death 
N=2,061 n=1,727 n=75 n=82 
Gender     
 Male 92.2 93.8 93.3 92.7 
 Female 7.8 6.2 6.7 7.3 
Age Group     
 10–14 0.6 0.5 0.0 0.0 
 15–19 8.0 7.6 12.0 9.8 
 20–24 13.0 13.4 17.3 12.2 
 25–29 13.2 13.5 20.0 20.7 
 30–34 13.4 12.9 20.0 23.2 
 35–39 12.6 12.7 9.3 13.4 
 40 and older 39.2 39.4 21.3 20.7 
Cause of Death     
 Run over 12.3 13.6 12.5 0.0 
 Traffic accident 16.2 18.1 11.1 1.2 
 Fall 4.8 5.1 4.2 0.0 
 Electrocuted 0.6 0.5 1.4 0.0 
 Burned 1.2 0.8 0.0 0.0 
 Beaten 2.9 3.2 2.8 0.0 
 Asphyxia 17.2 18.2 20.8 1.2 
 Crushed 0.2 0.2 1.4 0.0 
 Fire arm 8.8 9.4 9.7 1.2 
 Steel knife 4.2 4.8 8.3 0.0 
 Violation 0.1 0.1 0.0 0.0 
 Intoxicated 9.7 6.1 5.6 93.9 
 Poisoned 0.5 0.4 0.0 1.2 
 Other 21.1 19.0 22.2 1.2 
Place of Death     
 Traffic  15.4 16.8 8.3 0.0 
 Home 30.0 30.4 25.0 23.2 
 Street 38.0 39.5 36.1 51.2 
 Public baths 0.1 0.1 1.4 1.2 
 Recreational areas 3.5 3.8 6.9 0.0 
 At work 0.8 0.9 2.8 0.0 
 Service areas 8.4 5.7 8.3 20.7 
 Other 3.7 2.7 11.1 3.7 
 
1Deaths fro all causes totaled 10,304. 
2Indicates opium, morphine, and heroin. 
SOURCE:  SISVEA—Medical examiner 
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Plüddemann, M.A2 
 
ABSTRACT 
 
The Southern African Development Community 
(SADC) Regional Drug Control Program provides 
for the establishment of a regional drug surveil-
lance network (SADC Epidemiology Network on 
Drug Use—SENDU) in the 13 SADC member 
states. At the end of June 2004, data were available 
from 11 countries: Botswana, Lesotho, Malawi, 
Mozambique, Mauritius, Namibia, South Africa, 
Swaziland, Tanzania, Zambia, and Zimbabwe. Dur-
ing this period, data on treatment demand were col-
lected from 98 specialist drug treatment centres and 
psychiatric hospitals in 9 countries and law en-
forcement agencies in 11 countries. Overall, the 
region saw an increase in the demand for treatment 
for substances other than alcohol and cannabis in 
the first half of 2004 compared with the second half 
of 2003 and an increase in police seizures of heroin. 
Seizures of methaqualone (Mandrax), cocaine, and 
amphetamine-type stimulants), however, showed a 
decline. The most alarming findings reported were 
the very high level of HIV/AIDS cases associated 
with intravenous drug use in Mauritius and the 
dramatic increase in treatment demand related to 
methamphetamine use in one of the South Africa 
sites, Cape Town. Among the policy recommenda-
tions requiring urgent attention at national and 
regional levels are the need to (i) increase access to 
substance abuse treatment outside of the psychiatric 
hospital system, (ii) improve the training of person-
nel involved in treatment and prevention, (iii) in-
crease interventions targeting high-risk populations, 
(iv) ensure that law enforcement agencies are ade-
quately equipped to enforce anti-drug legislation, 
and (v) review and, if necessary, update relevant 
legislation.   
 
                                                 
2The authors are affiliated with the Medical Research Council, 
Cape Town, South Africa. 
INTRODUCTION 
 
Background Information on SENDU 
 
The South African Community Epidemiology Net-
work on Drug Use (SACENDU) is an alcohol and 
other drug (AOD) sentinel surveillance system com-
prising a network of researchers, practitioners, and 
policymakers from five sites in South Africa.  The 
network, managed by the Medical Research Council 
(MRC) of South Africa, has been operational since 
July 1996.  In 2000, with funding from the South 
African Development Community (SADC) via the 
European Commission, the MRC was contracted to 
establish sentinel or country surveillance systems in 
the other SADC member states.   
 
The project forms part of the 5-year SADC Drug 
Control Program. The broader (regional) network has 
been named the SADC Epidemiology Network on 
Drug Use (SENDU).  This initiative has been driven 
by the following: (1) the view that the burden of 
harm from AOD use in Southern Africa is likely to 
increase with development; (2) the realization that 
various global, regional, and local factors have high-
lighted the need for monitoring substance use in 
Southern Africa at this time; and (3) the SADC Drug 
Protocol, signed in 1996, which highlights the impor-
tance of information and research to inform interdic-
tion and demand reduction activities. 
 
The overall goal of SENDU is to improve the infor-
mation base for policymakers in SADC member 
states in order to address the health and socioeco-
nomic burden caused by misuse of AODs. SENDU’s 
immediate purpose is to develop, establish, and 
evaluate a substance abuse sentinel surveillance sys-
tem in each of the SADC member states, building on 
the SACENDU model operational in three cities and 
two provinces in South Africa.   
 
The SENDU initiative has the following core compo-
nents: 
 
• Ongoing training and technical support 
 
• site- or country-specific network, and, if possi-
ble, the in (The “basic” system comprises treat-
ment demand data from specialist substance 
abuse treatment facilities [if available] and psy-
chiatric hospitals, as well as information from 
the police on arrests, seizures, and drug prices. 
Additional components might include school 
studies, mortuary or trauma unit studies, etc.) 
 
• Validation and collation of data during 6-month 
country and regional report-back meetings 
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• Dissemination of findings via reports, newslet-
ters, press briefings, and a Web site 
 
Between 2001 and 2004, technical support visits 
were undertaken to all SADC member states. The 
focus of these visits was to learn more about patterns 
of AOD use in the countries, inform government of-
ficials about the SENDU initiative, assist countries in 
developing instruments to collect and collate secon-
dary data on AOD use/associated consequences, pro-
vide technical support in other areas related to estab-
lishing and maintaining an AOD surveillance system, 
support country coordinators in running an initial 
meeting of potential members of an AOD surveil-
lance network, conduct visits to agencies where data 
are to be collected, and identify other areas requiring 
technical or other forms of support. 
 
Area Description 
 
SADC was established in 1992 and comprises 13 
member states (exhibit 1).  These countries differ 
greatly in land area, population, income levels, and 
official languages (exhibit 2). The surveillance sys-
tems in Botswana, Lesotho, Malawi, Mauritius, Na-
mibia, Swaziland, Zambia, and Zimbabwe are coun-
try-level systems.  In Mozambique, the surveillance 
system has been established in Maputo, and in Tan-
zania, systems are established in Dar es Salaam and 
Zanzibar. SACENDU comprises six sentinel sites, 
four of which are large port cities (Cape Town, Dur-
ban, Port Elizabeth, and East London); the other two 
are provinces: Gauteng (a largely urban province 
which includes the cities of Pretoria and Johannes-
burg) and Mpumalanga (a largely rural province bor-
dered by Swaziland and Mozambique).  The South 
African sites cover just over one-third of country’s 
population. 
 
Data Sources 
 
A summary of the data sources accessed in the above 
countries during the first half of 2004 is indicated in 
exhibit 3. The major sources of data are specialist 
treatment centres, psychiatric hospitals, and the po-
lice. With regard to detailed information on treatment 
demand, in the first half of 2004 data were obtained 
from 98 treatment centres/hospitals in 9 countries (on 
8,675 patients), up from 92 treatment centres (and 
7,569 patients) in the second half of 2003. The focus 
of this report is on the findings of Phase 16 of the 
SACENDU Project, Phase 1 of the AOD abuse 
surveillance system established in Zimbabwe, Phase 
2 of the surveillance systems established in Swazi-
land and Zambia, Phase 3 of the surveillance system 
established in Tanzania, Phase 4 of the surveillance 
systems established in Malawi and Mozambique, 
tems established in Malawi and Mozambique, Phase 
5 of the surveillance systems established in Botswana 
and Namibia, and Phase 6 of the AOD abuse surveil-
lance systems established in Lesotho and Mauritius.  
This report covers the period January to June 2004 
and preceding 6-month periods (if applicable). 
DRUG ABUSE PATTERNS AND TRENDS 
 
Treatment Demand Data 
 
Information on primary drug of abuse reported at 
specialist AOD treatment centres3 is provided in ex-
hibits 4 and 5. To facilitate country comparisons, data 
for South Africa are averaged over the six sentinel 
sites in the country, and treatment data for Tanzania 
are averaged over Dar es Salaam and Zanzibar. 
 
In summary, in Mauritius, Mozambique (Maputo), 
Namibia, South Africa, Swaziland, Tanzania, and 
Zambia, there appears to be demand for (and supply 
of) treatment for a greater range of substances of 
abuse than in the other countries (i.e., Botswana, Le-
sotho, and Malawi), where alcohol and cannabis are 
the primary drugs of abuse reported.  Specifically, 
based on treatment demand data, South Africa has a 
greater range of substances available than other 
SADC countries. South Africa also has the largest 
number of treatment centres (in general, and included 
in the SENDU project) and the largest number of 
patients entering substance abuse treatment facilities.   
 
Alcohol is the primary substance of abuse most likely 
to be reported by patients at specialist substance 
abuse treatment centres in six SADC countries; 
among all SADC countries, the proportion of primary 
alcohol admissions ranges from 18 percent in Tanza-
nia to 62 percent in Swaziland. Averaging across the 
nine countries for which data are available, just over 
one-third (38 percent) of patients listed alcohol as a 
primary drug of abuse. This is a decrease of 7 per-
centage points compared with the second half of 
2003. Decreases were noted in six of the nine coun-
tries for which comparative data were available. The 
implication of this is that there is an increase in the 
demand for treatment for substances other than alco-
hol in these countries. 
The proportion of patients entering treatment centres 
with cannabis as their primary drug of abuse varied 
greatly in the first half of 2004, ranging from 7 per-
cent in Mauritius and Namibia to 79 percent in Ma-
lawi.  In the nine countries, just over one-third (37 
percent) of patients had cannabis as a primary drug of 
abuse. This is similar to the previous reporting pe-
                                                 
3 For Botswana, Malawi, Tanzania and Zambia information comes 
from psychiatric hospitals/units only 
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riod. The increase over time reported previously for 
Malawi has not continued; the proportion of cannabis 
admissions there declined from 85 percent in the sec-
ond half of 2003 to 79 percent in the first half of 
2004. An increase in treatment demand for problems 
related to cannabis use was noted in Tanzania during 
the same period (from 39 to 50 percent), while con-
versely a decrease was noted in Swaziland (from 60 
to 36 percent).   
 
Treatment demand for problems related to the use of 
Mandrax (methaqualone) is confined to Namibia and 
South Africa. In the previous reporting period, treat-
ment demand for problems related to Mandrax use 
was noted in Swaziland and Zambia, but this was no 
longer the case in the first half of 2004.  Over the past 
three reporting periods, an increase in treatment de-
mand related to this drug was noted in Namibia, 
whereas in South Africa there appears to be no dis-
cernable trend. 
 
Treatment demand for problems related to the use of 
cocaine is mainly confined to Mozambique, Namibia, 
and South Africa, and to a lesser extent in Swaziland 
and Zambia, with increases being noted in all five 
countries between the second half of 2003 and the 
first half of 2004.  
 
Treatment demand for problems related to the use of 
heroin is confined to Mauritius, Mozambique, South 
Africa, Tanzania, Zambia, and to a much lesser ex-
tent Swaziland, where it appeared in the treatment 
demand data set for the first time since data were 
collected in Swaziland as part of the SENDU project. 
Mauritius has by far the greatest proportion of pa-
tients in treatment whose primary drug of abuse is 
heroin (58.9 percent). Increases in treatment demand 
related to heroin use were noted in all six countries, 
especially in Mauritius, Mozambique, Tanzania, and 
Zambia (by at least five percentage points since the 
second half of 2003).  
Injection use of heroin is extremely high in Mauritius 
(more than 90 percent), but it is also high in the 
South African sites (28 percent in Cape Town, 55 
percent in Gauteng, and 32 percent in Mpumalanga), 
in Maputo, Mozambique (23 percent), and in Tanza-
nia (29 percent). 
 
During the first half of 2004, ecstasy (methylenedi-
oxymethamphetamine) was only reported as a pri-
mary substance of abuse in treatment centres in South 
Africa (0.8 percent). Over-the-counter and prescrip-
tion medicines (primarily benzodiazepines and anal-
gesics) were only reported as primary drugs of abuse 
in Mauritius, South Africa, and Swaziland, ranging 
between 0.5 and 4 percent of admissions. 
 
Other drugs reflected in treatment demand data in-
cluded khat, methcathinone (CAT), lysergic acid di-
ethylamide (LSD), methamphetamine, and inhalants 
(e.g., glue, petrol). A dramatic increase in treatment 
demand for methamphetamine was noted in Cape 
Town (South Africa), especially in the first half of 
2004 and particularly among patients younger than 
20. Almost 4 out of every 10 patients younger than 
20 who attended drug treatment in Cape Town re-
ported methamphetamine as a primary or secondary 
drug of abuse.  
 
Age and Mode of Drug Use 
 
Across countries and sites, the proportion of patients 
in treatment who are younger than 20 averages 12 
percent and ranges from 0.5 percent (Mauritius) to 27 
percent (Zambia). This has declined substantially 
since the last reporting period. With the exception of 
Mauritius, across sites the predominant mode of in-
gesting substances is by swallowing or smoking.  In 
Mauritius, however, more than one-half of persons in 
treatment injected their primary drug of abuse.  Over-
all, only 3 percent of patients in treatment centres in 
the South African sites reported injection as their 
primary mode of ingesting their primary substance. 
The only other countries where intravenous drug use 
was reported were Mozambique, Tanzania, and Zam-
bia. Increases in intravenous drug use were noted in 
Mauritius, South Africa, Tanzania, and Zambia. 
Law Enforcement Data 
 
Arrests  
 
In Botswana and Swaziland, no arrests for drug deal-
ing/trafficking were recorded in the first half of 2004 
(exhibit 6). In Lesotho, Malawi, and Mozambique 
(Maputo) in the first half of 2004, all arrests for drug 
dealing (trafficking) involved cannabis. For South 
Africa, information on cannabis arrests is not avail-
able, but information on police cases (by drug) for 
drugs other than cannabis is available from the police 
forensic science laboratories. The highest number of 
arrests for dealing in cannabis in the first half of 2004 
was noted in Tanzania (2,219), followed by Zambia 
(1,423). Increases in the number of persons arrested  
 
for dealing in cannabis were noted for five of the nine 
countries for which comparative data were available: 
Lesotho, Malawi, Mauritius, Mozambique, and Zam-
bia, but in all cases except Maputo, there was no in-
crease in the proportion of arrests for dealing in can-
nabis in the first half of 2004. Over the eight coun-
tries where arrests were made for dealing in cannabis 
(excluding South Africa), on average 85 percent of 
all arrests for dealing in drugs involved cannabis. 
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Arrests for dealing in Mandrax (methaqualone) were 
only made in Namibia (n=63, including arrests for 
drug possession), South Africa (4,829), and Tanzania 
(1) during this period. The proportion of arrests for 
dealing in this drug stayed much the same in both 
Namibia and South Africa in the last two reporting 
periods. Arrests for dealing in cocaine were made in 
Namibia, South Africa, Tanzania, Zambia, and Zim-
babwe, though in the latter three countries the propor-
tion of arrests for dealing in cocaine represented less 
than 1 percent of all arrests. The largest increase in 
the proportion of cocaine arrests was noted in Na-
mibia, from 2.9 percent of all arrests in the second 
half of 2003 to 12.4 percent in the first half of 2004.  
In Mauritius, more than 6 out of every 10 arrests for 
drug trafficking involved heroin. This is substantially 
greater than for Namibia, South Africa, Tanzania, 
and Zambia, the only other countries where arrests 
for dealing in heroin were recorded.  In these coun-
tries, the corresponding proportions were 0.3 percent, 
3.3 percent, 9.9 percent, and 0.5 percent, respec-
tively.  Increases in the proportion of heroin arrests 
across these five countries ranged from 0.3 percent-
age points in Namibia to 6.3 percentage points in 
Tanzania. 
 
With regard to ecstasy and other amphetamine-type 
stimulants, a substantial number of cases relating to 
dealing in ecstasy and methamphetamine have been 
reported in South Africa over the past five reporting 
periods. They accounted for 21.5 percent of all cases 
(n=1,789) in the first half of 2004. A large increase in 
arrests related to ecstasy dealing/possession was also 
noted in Namibia. Of the 11 countries for which data 
on drug-related arrests were recorded as part of the 
SENDU project in 2004, only in South Africa were 
persons arrested for dealing in LSD  (fewer than 1 
percent in the first half of 2004). Arrests for dealing 
in prescription medicines were noted in Zambia and 
South Africa, and arrests for dealing in khat were 
reported in Tanzania (4 percent of all arrests) and in 
Zambia. 
 
Seizures  
 
The largest amount of cannabis seized during the first 
half of 2004 occurred in Tanzania: 234,045 kilo-
grams. No seizure information regarding cannabis is 
available for South Africa. Increased cannabis sei-
zures were noted in three countries, while decreases 
occurred in four. Heroin seizures were noted in Mau-
ritius, Namibia, South Africa, Swaziland, Tanzania, 
and Zambia. The quantity seized, however, was very 
low in most countries, except for Mauritius, South 
Africa, and Zambia. The amount of heroin seized 
over the 11 countries was 17.5 kilograms, with in-
creases being noted in Mauritius, South Africa, and 
Zambia (off a fairly low base). Seizures of Mandrax 
(methaqualone) were noted in Botswana, Namibia, 
South Africa, and Tanzania, with the equivalent of 
592,968 Mandrax tablets being recorded by the four 
police forensic science laboratories in South Africa. 
Mandrax seizures were down in Namibia and South 
Africa, but they substantially increased in Botswana 
and Tanzania. Cocaine seizures in the region overall 
(67 kilograms) were less than in the previous report-
ing period and totalled more than 10 kilograms in 
only Namibia and South Africa. Seizures of am-
phetamine-type stimulants (mainly ecstasy) were 
noted in four countries (147,809 units in total), with 
the largest seizures being noted in South Africa and 
Zambia. A small quantity of LSD was seized in 
South Africa, and 251 kilograms of khat were seized 
in Tanzania, substantially less than was seized in the 
second half of 2003. 
 
DISCUSSION 
 
Cannabis and alcohol continue to dominate treatment 
demand and community concern in most SADC 
countries. They both represent more than one-third of 
the demand for drug treatment in the region. Across 
the region, there continues to be strong evidence of 
the burden placed by alcohol and cannabis on health 
and law enforcement sectors, and the number of per-
sons arrested for dealing/trafficking in cannabis in-
creased in more than one-half of the countries. There 
is also evidence of substantial use of other drugs such 
as Mandrax (methaqualone), heroin, cocaine, and 
amphetamine-type stimulants in certain countries and 
trafficking of these drugs in many countries (not just 
those where use has been reported).  
 
Heroin use is particularly high in countries in the 
south and east of the region, including South Africa, 
Mozambique, Tanzania, and Mauritius. In addition, 
use of heroin and dealing/trafficking in this drug was 
increasing in the landlocked country of Zambia in the 
first half of 2004. Increases in treatment demand, 
seizures,4 and in the proportion of arrests for deal-
ing/trafficking in this drug were noted in most coun-
tries where heroin use was reported. 
Treatment demand and/or law enforcement indicators 
for cocaine are highest in Mozambique, Namibia, and 
South Africa (i.e., in the coastal countries in the south 
and east of the SADC region). There was an increase 
in problems associated with cocaine in all countries 
where there was a demand for treatment for the drug. 
Regionally, however, there was a decline in seizures 
for cocaine in the first half of 2004. One of the big-
gest changes noted was the increase in the proportion 
                                                 
4 Except Tanzania. In addition it should be noted that the increase 
in heroin seizures in Swaziland was negligible. 
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of arrests related to cocaine relative to other drugs in 
Namibia. 
 
Treatment demand and law enforcement indicators 
related to Mandrax (methaqualone) continue to be 
high in Namibia and South Africa. However, as com-
pared to the previous 6-month period, there appears 
to have been a shift in countries where there is lesser 
evidence of use of Mandrax and/or in dealing in this 
drug, with such evidence no longer being noted in 
Mozambique, Swaziland, and Zambia. Evidence of 
use in Botswana and Tanzania is now apparent. 
Treatment demand and law enforcement indicators 
indicate use of and trafficking in amphetamine-type 
stimulants, especially ecstasy and methamphetamine 
in South Africa.  Trafficking of these substances was 
also noted in Botswana, Namibia and Zambia.  
 
Across sites, just over 1 in 10 patients receiving 
treatment for alcohol or drug related problems is 
younger than 20, but this proportion has decreased 
over time. Drug price information is provided in ex-
hibit 8, and a rough comparison of levels of sub-
stance use and associated consequences to society 
based on treatment demand and law enforcement 
indicators is provided in exhibit 8. 
 
Various policy implications were raised in the coun-
try reports for January–June 2004 and at the sixth 
SENDU Regional Report-Back Meeting.  These are 
indicated below, with reference to specific target 
groups and intervention approaches: 
 
• Primary Prevention 
- Target children at a young age, focusing on 
gateway drugs such as alcohol, tobacco and 
cannabis. 
- Intensify AOD education. 
- Intervene to address the abuse of drugs by 
sex workers. 
- Reduce alcohol-related violence in and 
around liquor outlets, and educate the public 
that abuse of alcohol can put them at risk for 
being a victim of a violent assault. 
 
• Treatment/Rehabilitation 
- Increase the availability of affordable treat-
ment centres, especially outside of the psy-
chiatric system. 
- Provide special facilities for female drug ad-
dicts. 
- Create special interventions that cater to the 
needs of unemployed persons. 
- Increase training in management of sub-
stance abuse and in mental health problems 
to workers in the health and social services. 
- Provide training to emergency/trauma per-
sonnel to ensure that they are equipped to 
deal with cases involving heroin and 
methamphetamine (selected countries). 
- Increase treatment and prevention programs 
aimed at workers.  
- Pilot test harm reduction strategies to reduce 
infections and other problems, such as over-
doses. 
 
• Other 
- Review and increase the enforcement of 
drug trafficking and related legislation. 
- Ensure that police have adequate resources 
to enforce anti-drug legislation. 
 
Across countries, various issues requiring further 
monitoring or more indepth research were also 
raised, including… 
 
• Reasons for use of AODs by youth (Malawi) 
• Impact of AOD use on mental health (Malawi, 
Namibia), violence (Mauritius), overdose deaths 
(Mauritius), and crime (Botswana) 
• Poly-drug use (Mauritius) 
• Strategies to combat inhalant use among children 
(Mauritius) 
• Incidence of human immunodeficiency virus 
(HIV), hepatitis B (HBV), and hepatitis C 
(HCV) among injection drug users (IDUs) and 
non-injection drug users (non-IDUs) (Mauritius) 
• The relationship between drug abuse and 
HIV/AIDS (Swaziland, Zambia) 
• Barriers to treatment for women and other sec-
tors of the population (Mauritius, Namibia, 
South Africa) 
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Seychelles
Mauritius
South Africa
Lesotho
Swaziland
Mozambique
Botswana
Namibia
Zimbabwe
Zambia
Angola
DR Congo
Tanzania
Malawi
• Female drug traffickers (Botswana, Mauritius) 
• Relationship between drug use, tuberculosis 
(TB), and HIV/AIDS (DRC, Swaziland, Zambia) 
• The relationship between patterns of drug abuse 
and expulsions from school (Zimbabwe) 
• Treatment models for resource-poor countries 
 
The first phase of the SENDU project is scheduled to 
be completed at the end of June 2005. By the comple-
tion of this phase, at least one 6-month data collec-
tion period should have been should have been com-
pleted at each site, including the DRC and Angola. 
 
Challenges facing the SENDU project include the 
following: 
 
• Persuading all available treatment centres in the 
sentinel sites to contribute treatment demand 
data and to continue participation in the network 
• Adding additional sources of data to complement 
existing sources (mainly treatment demand and 
law enforcement) 
• Ensuring that data on the links between sub-
stance use and infectious diseases and crime are 
also collected   
• Improving the quality of written and oral reports, 
particularly moving from more descriptive re-
porting to more analytical reporting 
• Getting the SENDU findings to have a greater 
impact on local, national, and regional alco-
hol/drug policy and practice  
• Ensuring the long-term sustainability and matu-
ration of the national networks, as well as 
SENDU as a whole 
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Exhibit 1. Member States of SADC1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1The Seychelles left SADC in 2003. 
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Exhibit 2. Description of SADC Member States, by Selected Indicators 
 
SADC Member 
State 
Land Area 
(sq kms) 
Population 
(2003 est.) 
GDP per 
capita1 Official Language 
Population Age 
14 and Younger 
(%) 
Angola 1,246,700 10,978,552 $1,900 Portuguese 43.5 
Botswana 600,370 1,561,973 $8,800 English 39.2 
Congo (DRC) 2 2,345,410 55,225,478 $590 French - 
Lesotho 30,355 1,865,040 $3,000 English 37.3 
Malawi 118,480 11,906,855 $600 English, Chichewa 46.8 
Mauritius 1,860 1,220,481 $11,400 English 24.8 
Mozambique 801,590 18,811,731 $1,200 Portuguese 43.6 
Namibia 825,418 1,954,033 $7,100 English 42.4 
South Africa 1,219,919 42,718,530 $10,700 11 official languages3 29.5 
Swaziland 17,363 1,169,241 $4,900 English, Swati 41.0 
Tanzania 945,087 36,588,225 $600 English, Swahili 44.2 
Zambia 752,614 10,462,436 $800 English 46.1 
Zimbabwe 390,580 12,671,860 $1,900 English 39.4 
Total 9,296,201 207,134,435    
 
1Purchasing power parity (2003 estimate) 
22002 estimate 
3English predominates 
SOURCE: U.S. Central Intelligence Agency. The World Fact Book 2001. Washington, DC: Author, 2002. 
 
 
 
Exhibit 3. Data Sources, by Sites: January–June 2004 
 
Source 
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Treatment Centres 
(patients in period Jan–Jun 2004) N/A
2 9 (63) 
7 
(556) 
8 
(596) 
5 
(151) 
3 
(54) 
58 
(6,680) 
2 
(223) 
3 
(169) 
3 
(183) N/A 
Police Drug Data/Forensic Y Y Y Y Y Y Y Y Y Y Y 
Psychiatric Hospitals N/A ITC3 ITC Y ITC N/A Y ITC ITC ITC N/A 
Prisons – – – Y – – – – – – - 
Mortuaries – – – – – – Y – – – - 
Orthopedic Unit – – – – – – – – Y – - 
Surveys, Studies – – – – – – Y – – – - 
Other Health Statistics – – – Y – – – – – – - 
Education Ministry – – – – – – – – – – Y 
 
1No data were available as data collection system was being revamped. 
2N/A=Not applicable 
3ITC=Included with treatment centre data 
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Exhibit 4. Treatment Demand Data, by Primary Drug of Abuse1: January 2002–June 2004  
 
Country Period Alco-hol 
Can-
nabis 
Metha-
qualone 
(Mtq) 
Co-
caine Heroin 
Ec-
stasy 
OTC/ 
Rx2 Other N 
# Tx. 
Ctrs 
Jan–Jun ‘02 70.3 23.8 0.5 0.5 0.0 0.0 0.0 4.9 188 9 
Jul–Dec ‘02 69.6 29.0 0.0 0.0 0.0 0.0 0.0 1.5 72 5 
Jan–Jun ‘03 83.6 16.4 0.0 0.0 0.0 0.0 0.0 0.0 73 4 
Jul–Dec ‘03 73.7 26.3 0.0 0.0 0.0 0.0 0.0 0.0 19 4 
Botswana 
Jan–Jun ‘04 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Jul–Dec ‘01 54.3 45.7 0.0 0.0 0.0 0.0 0.0 0.0 45 6 
Jan–Jun ‘02 85.0 15.0 0.0 0.0 0.0 0.0 0.0 0.0 20 5 
Jul–Dec ‘02 97.8 2.2 0.0 0.0 0.0 0.0 0.0 0.0 46 3 
Jan–Jun ‘03 70.2 29.8 0.0 0.0 0.0 0.0 0.0 0.0 67 7 
Jul–Dec ‘03 51.0 49.0 0.0 0.0 0.0 0.0 0.0 0.0 49 6 
Lesotho 
Jan–Jun ‘04 52.4 47.6 0.0 0.0 0.0 0.0 0.0 0.0 63 9 
Jul–Dec ‘02 32.7 67.3 0.0 0.0 0.0 0.0 0.0 0.0 445 3 
Jan–Jun ‘03 19.6 79.8 0.0 0.0 0.0 0.0 0.0 0.6 361 5 
Jul–Dec ‘03 14.9 85.1 0.0 0.0 0.0 0.0 0.0 0.0 417 7 
Malawi 
Jan–Jun ‘04 20.7 79.3 0.0 0.0 0.0 0.0 0.0 0.0 556 7 
Jul–Dec ‘01 21.8 14.1 0.0 0.0 70.7 0.0 1.3 1.5 467 8 
Jan–Jun ‘02 32.7 6.6 0.0 0.0 59.3 0.0 1.1 0.2 452 8 
Jul–Dec ‘02 33.0 10.3 0.0 0.0 52.9 0.0 2.8 0.5 427 8 
Jan–Jun ‘03 36.5 8.2 0.0 0.0 51.7 0.0 3.2 0.4 561 8 
Jul–Dec ‘03 36.7 6.1 0.0 0.0 53.5 0.0 3.2 0.5 591 8 
Mauritius 
Jan–Jun ‘04 28.4 7.4 0.0 0.0 58.9 0.0 4.2 1.2 596 8 
Oct–Dec ‘02 63.7 20.5 0.0 0.9 15.0 0.0 0.0 0.0 234 7 
Jan–Jun ‘03 68.3 20.2 0.0 0.0 10.6 0.0 0.0 1.0 104 4 
Jul–Dec ‘03 54.3 16.5 0.0 3.2 25.2 0.0 0.0 0.8 127 6 
Mozamb. 
Jan–Jun ‘04 39.1 19.2 0.0 8.6 33.1 0.0 0.0 0.0 151 5 
Jan–Jun ‘02 74.0 8.0 12.0 6.0 0.0 0.0 0.0 0.0 50 2 
Jul–Dec ‘02 78.0 8.7 8.7 2.2 0.0 2.2 0.0 0.0 46 3 
Jan–Jun ‘03 82.9 0.0 14.3 2.9 0.0 0.0 0.0 0.0 35 2 
Jul–Dec ‘03 66.7 3.7 22.2 7.4 0.0 0.0 0.0 0.0 54 2 
Namibia 
Jan–Jun ‘04 53.7 7.4 26.0 13.0 0.0 0.0 0.0 0.0 54 3 
Jul–Dec ‘01 52.2 21.4 10.1 5.1 5.1 1.1 3.1 1.6 5,667 48 
Jan–Jun ‘02 54.0 19.3 10.3 5.7 5.3 1.0 3.1 1.2 6,108 50 
Jul–Dec ‘02 54.1 21.0 9.5 5.3 4.6 1.1 2.7 1.7 5,830 50 
Jan–Jun ‘03 51.7 18.2 12.6 5.8 5.5 0.9 3.1 2.1 5,886 52 
Jul–Dec ‘03 48.7 18.9 14.1 6.2 5.2 0.8 2.8 2.3 5,726 50 
South 
Africa 
Jan–Jun ‘04 47.9 16.6 11.9 8.2 6.2 0.8 2.9 5.0 6,680 58 
Jul–Dec ‘03 30.6 59.7 9.7 0.0 0.0 0.0 0.0 0.0 62 2 Swaziland 
Jan–Jun ‘04 61.9 36.3 0.0 0.5 0.5 0.0 0.5 0.5 223 2 
Jul–Dec ‘03 39.1 38.8 0.0 0.0 18.2 0.0 0.0 3.9 330 3 Tanzania 
Jan–Jun ‘04 17.8 50.3 0.0 0.0 30.2 0.0 0.0 1.8 169 3 
Aug–Dec ‘03 34.6 61.8 0.5 0.5 0.5 0.0 1.6 0.5 191 4 Zambia 
Jan–Jun ‘04 24.0 64.5 0.0 1.1 8.2 0.0 0.0 2.2 183 3 
 
1Row percentages add to 100 percent. Information on drug treatment demand is not yet available for Zimbabwe. 
2Includes psychotropic medicines.  
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Exhibit 5. Treatment Demand Data, by Primary or Secondary Drugs of Abuse for Selected Substances and 
  Selected Sites: January–June 2004 
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Exhibit 6.  Police Arrests for Drug Dealing, by Drug1:  January 2002–June 2004 
 
Country Period Cannabis/ Hashish 
Metha-
qualone 
Co-
caine/ 
Crack 
Ec-
stasy/ 
ATS 
Heroin Rx LSD Khat N 
Jan-Jun ‘02 100.0 0.0 0.0 0.0 0.0 0.0 0.0 - 226 
Jul-Dec ‘02 100.0 0.0 0.0 0.0 0.0 0.0 0.0 - 183 
Jan-Jun ‘03 96.5 1.2 1.2 1.2 0.0 0.0 0.0 - 170 
Jul-Dec ‘03 0.0 0.0 0.0 0.0 0.0 0.0 0.0 - 0 
Botswana2 
Jan-Jun ‘04 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0 
Jul-Dec ‘01 100.0 0.0 0.0 0.0 0.0 0.0 0.0 - 108 
Jan-Jun ‘02 100.0 0.0 0.0 0.0 0.0 0.0 0.0 - 87 
Jul-Dec ‘02 100.0 0.0 0.0 0.0 0.0 0.0 0.0 - 93 
Jan-Jun ‘03 100.0 0.0 0.0 0.0 0.0 0.0 0.0 - 103 
Jul-Dec ‘03 100.0 0.0 0.0 0.0 0.0 0.0 0.0 - 56 
Lesotho 
Jan-Jun ‘04 100.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 146 
Jul-Dec ‘02 100.0 0.0 0.0 0.0 0.0 0.0 0.0 - 431 
Jan-Jun ‘03 100.0 0.0 0.0 0.0 0.0 0.0 0.0 - 348 
Jul-Dec ‘03 100.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 182 
Malawi 
Jan-Jun ‘04 100.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 355 
Jul-Dec ‘01 47.0 0.0 0.0 0.0 53.0 0.0 0.0 - 156 
Jan-Jun ‘02 37.0 0.0 0.0 0.0 63.0 0.0 0.0 - 125 
Jul-Dec ‘02 59.1 0.0 0.0 0.0 40.9 0.0 0.0 - 149 
Jan-Jun ‘03 46.0 0.0 0.0 0.0 54.0 0.0 0.0 - 153 
Jul-Dec ‘03 41.0 0.0 0.0 0.0 59.0 0.0 0.0 0.0 122 
Mauritius 
Jan-Jun ‘04 37.2 0.0 0.0 0.0 62.8 0.0 0.0 0.0 199 
Oct-Dec ‘02 N/A N/A N/A N/A N/A N/A N/A - N/A 
Jan-Jun ‘03 100.0 0.0 0.0 0.0 0.0 0.0 0.0 - 4 
Jul-Dec ‘03 0.0 0.0 100.0 0.0 0.0 0.0 0.0 0.0 0 
Mozam-
bique 
(Maputo) 2 
Jan-Jun ‘04 100.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 44 
Jan-Jun ‘02 84.4 14.1 1.0 0.5 0.0 0.0 0.0 - 397 
Jul-Dec ‘02 84.9 9.3 3.5 2.2 0.0 0.0 0.0 - 226 
Jan-Jun ‘03 88.9 9.6 1.0 0.5 0.0 0.0 0.0 - 208 
Jul-Dec ‘03 79.8 16.5 2.9 0.8 0.0 0.0 0.0 0.0 491 
Namibia2 
Jan-Jun ‘04 64.2 17.7 12.4 5.4 0.3 0.0 0.0 0.0 355 
Jul-Dec ‘01 - 65.7 16.2 13.8 3.0 0.0 1.3 - 4,756 
Jan-Jun ‘02 - 60.5 19.1 15.2 4.8 0.0 0.4 - 4,818 
Jul-Dec ‘02 - 61.3 16.5 16.8 4.6 0.0 0.8 - 5,131 
Jan-Jun ‘03 - 66.2 13.5 16.6 2.9 0.0 0.8 - 5,910 
Jul-Dec ‘03 - 59.9 12.0 24.5 3.0 0.0 0.6 0.0 7,373 
South  
Africa3 
Jan-Jun ‘04 - 58.0 16.8 21.5 3.3 0.0 0.4 0.0 8,321 
Jul-Dec ‘03 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0 Swaziland 
Jan-Jun ‘04 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0 
Jan-Jun ‘032 85.8 0.2 0.7 0.0 5.7 0.0 0.0 7.5 2,701 
Jul-Dec ‘03 90.4 0.0 0.0 0.0 3.6 0.0 0.0 6.1 3,418 Tanzania 
Jan-Jun ‘04 85.7 0.04 0.1 0.0 9.9 0.0 0.0 4.2 2,590 
Aug-Dec ‘03 98.0 0.1 0.1 0.0 0.2 1.0 0.0 0.6 1,247 Zambia 
Jan-Jun ‘04 95.7 0.0 0.5 0.0 0.5 2.0 0.0 1.4 1,487 
Zimbabwe2 Jan-Jun ‘04 99.8 0.0 0.2 0.0 0.0 0.0 0.0 0.0 568 
 
1Row percentages add to 100 percent. 
2Including possession.   
3South African data refer to national cases seen by the Forensic Science Laboratory rather than arrests per se.  These laboratories 
do not routinely analyse all cases involving seizures of cannabis. 
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Exhibit 7.  Police Seizures, by Drug: January 2002–June 2004 
 
Country Period Cannabis (kg) 
Metha-
qualone 
(tablets)1 
Cocaine 
(g) 
Ampheta-
mine 
(tablets) 1 
Heroin 
(g) 
LSD 
(units) 
Khat 
(kg) 
Jan-Jun ‘02 1,471 0 0 0 0 0 - 
Jul-Dec ‘02 1,471 0 0 0 0 0 - 
Jan-Jun ‘03 1,189 5 1.77 31 0 0 - 
Jul-Dec ‘03 1,359 0 0 0 0 0 0 
Botswana 
Jan–Jun ‘04 581 2 784 0 29 0 0 0 
Jul-Dec ‘01 19,671 0 0 10 045 0 0 - 
Jan-Jun ‘02 4,154 0 0 0 0 0 - 
Jul-Dec ‘02 4,417 0 0 0 0 0 - 
Jan-Jun ‘03 5,380 0 0 0 0 0 - 
Jul-Dec ‘03 2,020 0 0 0 0 0 0 
Lesotho 
Jan–Jun ‘04 7,349 0 0 0 0 0 0 
Jul-Dec ‘02 4,659 0 0 0 0 0 - 
Jan-Jun –03 6,242 0 0 0 0 0 - 
Jul-Dec ‘03 4,527 0 0 0 0 0 0 
Malawi 
Jan–Jun ‘04 7,808 0 0 0 0 0 0 
Jul-Dec ‘01 30 0 0 0 22 441 0 - 
Jan–Jun ‘02 23 0 0 0 4995 0 - 
Jul-Dec ‘02 44 0 0 0 6 973 0 - 
Jan-Jun ‘03 9 0 0 0 15 432 0 - 
Jul-Dec ‘03 34 0 0 0 517 0 0 
Mauritius 
Jan–Jun ‘04 39 0 0 0 2 357 0 0 
Oct-Dec ‘02 N/A N/A N/A N/A N/A N/A - 
Jan-Jun ‘03 10 0 5 100 0 0 0 - 
Jul-Dec ‘03 23 1 000 9 200 0 15 0 0 
Mozambique 
(Maputo) 
Jan–Jun ‘04 22 0 0 0 0 0 0 
Jan-Jun ‘02 775 9179 78 rocks 10 0 0 - 
Jul-Dec ‘02 147 679 189 rocks 36 0 0 - 
Jan-Jun ‘03 532 2 714 96 rocks 14 0 0 - 
Jul-Dec ‘03 96 6 426 55 162 0 0 0 
Namibia 
Jan–Jun ‘04 434 1 185 15 350 + 141 rocks 169 2 0 0 
Jul-Dec ‘01 N/A 12 872 000 191 143 121 562 1 856 6 632 - 
Jan-Jun ‘02 N/A 2 668 595 375 535 150 324 6 273 322 - 
Jul-Dec ‘02 N/A 750 099 67 148 275 362 77 041 1 303 - 
Jan-Jun ‘03 N/A 630 844 237 728 256 927 16 340 532 - 
Jul-Dec ‘03 N/A 10 935 182 188 298 257 406  2 190 756 0 
South Africa 
Jan-Jun ‘04 N/A 592 968 46 305 76 407 13 655 235  
Jul-Dec ‘03 8,463 473 3 832 0 0.02 0 0 Swaziland 
Jan–Jun ‘04 3,919 0 0 0 0.05 0 0 
Jan-Jun ‘03 413,361 212 1.335 0 2 531 0 1 454 
Jul-Dec ‘03 599,613 0 1 392 0 2 000 0 10 548 Tanzania 
Jan–Jun ‘04 234,043 1000 620 0 10.65 0 251 
Aug-Dec ‘03 1,322 8 0.1 69 152 55.5 0 0 Zambia 
Jan–Jun ‘04 2,510 0 0.7 71 204 1 446 0 0 
Zimbabwe Jan–Jun ‘04 555 0 0.7 0 0 0 0 
 
1Or equivalent (calculated from powder seized): 1g = 2 tablets. 
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 Exhibit 8. Drug Prices in Local Currencies, by Drug: January–June 2004  
 
Country Currency Cannabis (g)1 
Mandrax 
(tablet) 
Cocaine 
(g) 
Crack 
(rock)2 
Ecstasy 
(tablet) 
Heroin 
(g) 
Khat 
(g) 
Speed 
(unit) 
Approx. 
Local 
Currency 
to 1 US$ 
Botswana Pula 2 80 350 100 80 N/A N/A N/A 4.66 
Lesotho Maloti 6–83 N/A N/A N/a N/a N/a N/A N/A 6.28 
Malawi Kwacha 5 N/A N/A N/a N/a N/a N/A N/A 106.33 
Mauritius Rupees 300 N/A N/A N/a N/a 10,000 N/A N/A 26.40 
Mozambique Metical 3,000 N/A 700,000 N/A N/A 600,000 N/A N/A 23,300.00 
Namibia Dollar 5 50 450 150 120 450 N/A N/A 6.28 
Swaziland Lilangeni 0.8 50 212 – – 180 N/A N/A 6.28 
South  
Africa Rands 1–2 28–35 
250–
350 
50–
150 50–80 
180–
200 N/A 3–60 6.28 
Swaziland Emlangeni 0.5 – – – – 455 – – 6.28 
Tanzania Shilling 15 1,000/gm 20,000 N/a N/a 18,000 N/A N/A 1,082.30 
Zambia Kwacha 500 7,000 170,000 – – 140,000 3,500 – 4,675.00 
Zimbabwe Dollar 2,000 50,000 300,000 – 80–100K 250,000 N/a N/A 4,277.10 
 
10.5 g=1 joint. 
2Depends on size. 
3Per small plastic bank bag. 
 
 
 
Exhibit 9. Composite Assessment of the Use of Various Substances per SADC Country and Negative Effect  
 on Health and Social Systems, Based on Treatment Demand (Tx-D) and Law Enforcement (Law-E)  
 Indicators: January–June 2004 
 
 Cannabis Mandrax (methaqualone) Cocaine Heroin ATS 
Country Tx-D Law-E Tx-D Law-E Tx-D Law-E Tx-D Law-E Tx-D Law-E 
Botswana N/A + N/A + N/A - N/A - N/A + 
DRC# ++ + - - - + - + - - 
Lesotho +++ +++ - - - - - - - - 
Malawi +++ +++ - - - - - - - - 
Mauritius + + - - - - +++ ++ - - 
Mozambique ++ ++ - - ++ - +++ - - - 
Namibia + ++ ++ ++ ++ ++ - + - + 
South Africa ++ N/A ++ +++ ++ ++ ++ ++ + ++ 
Swaziland ++ + - - + - + + - - 
Tanzania +++ +++ - + - + +++ ++ - - 
Zambia +++ +++ - - + + ++ ++ + ++ 
Zimbabwe N/A ++ N/A - N/A + N/A - N/A - 
 
- Substance either not used or not showing up substantially on indicators. 
+ Some evidence of use of drug and/or dealing in the country. 
++ Law enforcement and/or treatment demand indicators suggest moderate use of and/or dealing in substance. 
+++ Substantial use and/or negative consequences indicated (e.g., arrests for dealing). 
#From presentation by Mr. Justin Ntambwa on Kinshasa (DRC).
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ABSTRACT 
 
Taiwan encountered the first wave of drug abuse in 
the late nineteenth century, when 6.3 percent of the 
total population consumed opium. The Japanese 
colonial government adopted the ‘gradual prohibi-
tion’ policy to grant an opium quota for addicts. 
The measure is similar to today’s methadone main-
tenance program, and the opium problem was alle-
viated eventually. The second wave of drug abuse in 
Taiwan began in the early 1990s, when metham-
phetamine abuse became prevalent among young-
sters. Methamphetamine and heroin remained the 
two predominant illicit drugs of abuse from 2000 
through 2004. The abuse of club drugs such as 
MDMA and ketamine has been increasing rapidly. 
Cannabis seizures exceeded 100 kilograms per year 
in 2001 and 2003, but cannabis abuse was still a 
minor problem as evidenced by urine testing. A high 
proportion of drug administration through injection 
was observed: 34.7 percent of the drug addicts con-
sumed drugs by injection in 2000, and the percent-
age surged to 63.9 percent in 2004. In addition, the 
percentage of needle sharing among addiction 
treatment admissions increased from 4.0 percent in 
2000 to 15 percent in 2004. In order to prevent the 
spread of infectious diseases such as AIDS and 
hepatitis B and hepatitis C through drug abuse, the 
Department of Health has been implementing harm 
reduction measures, including substitution treat-
ment, education programs for jail inmates, and pos-
sibly needle exchange programs. 
 
INTRODUCTION 
 
Area Description 
 
Located in the West Pacific, Taiwan is separated 
from Mainland China by the Taiwan Strait. Taiwan 
consists of the Taiwan Island proper and some 85 
islets, with a total land area of 36,000 square kilome-
ters (14,400 square miles). Although Taiwan is rela-
                                                 
5The authors are affiliated with the National Bureau of Controlled 
Drugs, Department of Health, Taiwan. 
tively small, it is densely populated, with a popula-
tion of 22,604,550 (2003 census). Such a high popu-
lation density (625 people per square kilometer of 
land area or 3,750 people per square kilometer of 
arable land) has made life on this tiny island very 
crowded and competitive. Nevertheless, the economy 
of Taiwan has been rapidly improved. The per capita 
national income in 2003 was New Taiwan (NT) 
$452,820 (US$13,156), which was a fivefold increase 
over the income of US$2,669 in 1981.6  
 
Brief History of Drug Abuse in Taiwan 
 
In the late nineteenth century, opium smoking was a 
common practice in the Ching Dynasty of China. 
Taiwan, under the reign of Ching Dynasty at that 
time, also suffered from the same problem. After the 
Sino-Japan War, Taiwan was ceded to Japan for 50 
years (1895–1945). Realizing the severe problem of 
opium smoking, the Japanese colonial government 
adopted the “gradual prohibition” policy. Based upon 
the opinion of public physicians, opium addicts were 
issued opium licenses to obtain an opium quota. Ac-
cording to license issuance records, it was estimated 
that there were some 169,000 opium addicts, or ap-
proximately 6.3 percent of the total 2,500,000 inhabi-
tants, in 1900. The opium license system, which is 
similar to today's methadone maintenance program 
except that the opium quota system was distributed 
by the government monopoly, brought a fortune for 
the colonial government and alleviated the problem 
of opium smoking to a manageable situation.7  
 
When the Republic of China reclaimed Taiwan after 
World War II, only 2,000 addicts remained. Chiang 
Kai-Shek, after being defeated by the Chinese Com-
munists, soon retreated with his army and imple-
mented martial law in Taiwan. In the subsequent two 
decades (1940s–1950s), Taiwan was practically a 
drug-free society. However, inhalant abuse (glue 
sniffing) began to emerge among young people in the 
early 1960s. It was not until the 1970s that pentazo-
cine replaced glue as the drug of choice. The abuse of 
pentazocine was eliminated after it was enlisted and 
controlled as a narcotic by the Department of Health. 
In the early 1980s, the trend of abuse switched to 
psychotropic agents. Two barbiturates (secobarbital 
and amobarbital) and methaqualone, all of which 
were legal medicines, became the predominant drugs 
of abuse. This was soon brought under control after 
                                                 
6Accessed June 3, 2005, from “My E-Government” at http://www. 
gov.tw/EBOOKS/TWANNUAL. 
7Li, Jih-Heng (1998). Drug Abuse Situation and Anti-Drug Pro-
grammes in Taiwan, R.O.C., in International Monograph Series 11, 
Report of the Asian Multicity Epidemiology Work Group 1997, 
edited by V. Navaratnam and A.A. Baker, pp151–156. Center for 
Drug Research, Universiti Sains Malaysia, Minden, Pulau Pinang, 
Malaysia. 
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methaqualone was banned and the two barbiturates 
were enlisted as controlled drugs. Although these 
substances were abused during 1960s, 1970s, and 
1980s, drug abuse was not regarded as a serious 
problem in these three decades.8  
 
In 1987, the martial law that had been implemented 
in Taiwan since 1949 was lifted. Being a young 
democratic country with flourishing economy, 
Taiwan has witnessed a deluge of methamphetamine 
and heroin abuse since early 1990s. In the past 
several years, abuse of club drugs such as 
methylenedioxymethamphetamine (MDMA), fluni-
trazepam (FM2, Rohypnol), and ketamine has been 
reported in pubs and karaoke parlors. Facing the 
worsening drug abuse situation, the obsolete “Act for 
Eradication of Illicit Narcotics” was revised into 
“Drugs Hazard Control Act” in 1998. The new act 
states that the “illicit use” of Schedule I and II drugs 
is a criminal offence. A positive result of urine 
testing for Schedule I or II drugs serves as evidence 
of drug use. Once convicted, the penalty for using 
illicit drugs is relatively harsh. The maximum 
penalties for use of Schedule I and II drugs can be 
imprisonment for 5 and 3 years, respectively. Al-
though the first-time offender who is not addicted 
may be released without being indicted, a drug user is 
generally reluctant to reveal his/her drug use 
behaviors to strangers. As a result, the epidemiologic 
data of drug abuse may be underestimated, and this 
should be taken into account.  
Data Sources  
 
For this report, data were collected from the National 
Bureau of Controlled Drugs (NBCD), Department of 
Health. In cooperation with all the incumbent agen-
cies, the NBCD has established a systematic surveil-
lance system to monitor the drug abuse trends and 
situations since 1999. Information from the following 
sources was compiled for the Monthly Drug Abuse 
Report collected and prepared by the NCBD, Febru-
ary 2005: 
 
• Data for court referrals on arrests, seizures, 
and laboratory reports on urine samples of 
drug abusers from 2000 to 2004 were obtained 
from the Investigation Bureau, Ministry of Jus-
tice; the National Police Administration, Minis-
try of Interior; the Military Police Command, 
Ministry of National Defense; the Coastal Guard, 
Executive Yuan; the National Bureau of Con-
trolled Drugs, Department of Health; and all lo-
cal health departments. 
 
                                                 
8Ibid.  
• Information from the Surveillance System of 
Drug Abuse and Addiction Treatment from 
2000 to 2004 was provided by NCBD, Depart-
ment of Health. The Bureau has, in collaboration 
with the designated medical care institutions and 
private institutions for addiction treatment, set up 
the surveillance system. Cases of drug abuse and 
addiction have been reported online since 2002. 
 
• Data on acquired immunodeficiency syndrome 
(AIDS), human immunodeficiency virus (HIV) 
infection, and routes of drug administration 
from December 1984 to December 2004 were ob-
tained from the Center for Disease Control, De-
partment of Health, Taiwan. 
 
DRUG ABUSE PATTERNS AND TRENDS 
 
From 2000 through 2004, methamphetamine and 
heroin were the two most prevalent illicit drugs used 
in Taiwan, while the abuse of club drugs such as 
MDMA and ketamine has been increasing rapidly. 
The drug abuse situation from 2000 through 2004 is 
described in the following sections. 
 
Methamphetamine 
 
An average of 37,500 methamphetamine abusers 
were identified each year during the past 5 years, 
according to the results of urine tests for court refer-
rals, performed by all local health departments, certi-
fied laboratories, National Police Administration, and 
the Investigation Bureau of the Ministry of Justice. 
Methamphetamine was identified in 62.7 percent of 
the total positive cases of urine testing in 2004 (ex-
hibit 1). Methamphetamine seizures have increased 
nearly fourfold since 2000. Methamphetamine re-
mained the most commonly seized drug in 2004 (at 
3,165.5 kilograms), and the quantity has been in-
creasing (exhibit 2). Both the methamphetamine-
positive urines and methamphetamine seizures dem-
onstrate the efforts exerted by the judicial systems to 
identify and combat methamphetamine abuse. 
Among the total treatment admissions from 2000 to 
2004, methamphetamine remained the second most 
commonly reported substance, following only heroin 
(exhibit 3). The wholesale price of methamphetamine 
has increased nearly twofold from NT$310,000 
(US$10,000) per kilogram in 2000 to NT$520,000 
(US$16,774) per kilogram in 2004 (exhibit 4). 
 
Heroin 
 
Among the 51,429 urine tests in 2004, 32,295 (or 
62.8 percent) were positive for morphine (heroin) 
(exhibit 1). The quantity of heroin seized in Taiwan 
increased by 132 percent between 2000 (277 kilo-
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grams) and 2004 (644 kilograms) (exhibit 2). Heroin 
remained the most frequently mentioned drug among 
treatment admissions during the past 5 years. In 
2004, 94 percent of all treatment admissions men-
tioned heroin as a drug of abuse (exhibit 3). The 
wholesale price of heroin has sharply increased, from 
NT$1,270,000 (US$40,968) per kilogram in 2000 to 
NT$2,710,000 (US$87,419) per kilogram in 2004 
(exhibit 4). It is worth noting that most heroin users 
administered the drug by injection, a practice that has 
posed a threat of spreading infectious diseases, such 
as AIDS. 
 
MDMA 
 
The amount of seized MDMA totaled about 5 kilo-
grams in 2000, compared with 303 kilograms in 
2004, thus demonstrating the expanding supply of the 
drug (exhibit 2). MDMA-positive urine cases in-
creased from 266 in 2000 to 2,245 in 2004 (exhibit 
1). Polydrug use is very common among MDMA 
users; since 2001, MDMA-positive urine cases have 
frequently been positive for other substances. 
MDMA abuse cases among treatment admissions 
peaked at 251 in 2002, before declining to 152 in 
2003 and 103 in 2004 (exhibit 3). 
 
Ketamine 
 
The amount of seized ketamine totaled 9.5 kilograms 
in 2001; this increased to 613 kilograms in 2004 (ex-
hibit 2). Ketamine now ranks as the third most com-
monly seized drug in Taiwan. Meanwhile, the com-
bined use of ketamine with methamphetamine, 
MDMA, and FM2 (Rohypnol) has been detected 
among urine tests since 2003. Although the first case 
of ketamine abuse among treatment admissions was 
identified in 2002, ketamine abuse cases increased to 
49 in 2004—thus demonstrating the increasing abuse 
of the drug.  
 
Benzodiazepines 
 
Abuse of depressants is a relatively new concern in 
Taiwan. Triazolam was the predominant drug among 
seized benzodiazepines in 2000, accounting for 92.4 
percent. However, flunitrazepam (Rohypnol, also 
nicknamed as FM2) replaced triazolam as the most 
frequently seized benzodiazepine in 2001, and the 
amounts of seized FM2 have continued to increase. 
In 2003, the amount of seized FM2 totaled 12 kilo-
grams, representing 90.4 percent of total benzodi-
azepines seized. The amount of benzodiazepines 
seized has dramatically increased, from 3.4 kilograms 
in 2000 to 141.3 kilograms in 2004 (exhibit 2); ni-
metazepam replaced FM2 as the most commonly 
seized benzodiazepine in 2004 and represented 97.4 
percent of these seizures. Among addiction treatment 
admissions, the abuse of benzodiazepines has consis-
tently ranked third (exhibit 3), with FM2 being the 
most abused benzodiazepine.  
 
Cannabis 
 
According to the United Nations Office on Drugs and 
Crime (UNODC) 2004 World Drug Report, cannabis 
is the most prevalent drug of abuse in the world. The 
amounts of cannabis seized exceeded 100 kilograms 
each year in 2001 and 2003 (exhibit 2), but cannabis 
does not seem to be a main concern in Taiwan. 
Among the 51,429 drug-positive urine tests in 2004, 
only 119 were positive for cannabis (exhibit 1), and 
only 43 treatment admissions reported cannabis 
abuse in 2004 (exhibit 3).  
 
INFECTIOUS DISEASES RELATED TO SUBSTANCE 
ABUSE 
 
Positive cases of HIV and AIDS increased rapidly in 
Taiwan from December 1984 through December 
2004 (exhibit 5). Between 1984 and 2004, 646 
HIV/AIDS cases in Taiwan (approximately 10 per-
cent) were among injection drug users (IDUs) (ex-
hibit 6). According to reports by addiction treatment 
admissions, 34.7 percent administered drugs by injec-
tion in 2000; this percentage increased to 63.9 per-
cent in 2004 (exhibit 7). In addition, the percentage 
of users sharing needles increased from 4.0 percent in 
2000 to 15 percent in 2004. In response to the new 
drug abuse situation, the Department of Health has 
been implementing harm reduction measures, includ-
ing pilot studies on buprenorphine substitution treat-
ments, education programs for jail inmates, and pos-
sibly needle exchange program through outreach 
groups, to avoid the spread of HIV. 
 
For inquiries concerning this report, please contact Jih-Heng Li, 
Ph.D., Director General, National Bureau of Controlled Drugs, 
Department of Health, No. 6. Linsen South Road, Taipei City 100, 
Taiwan, R.O.C., Phone: 886-2-2-351-7109, Fax: 886-2-2-341-
1635, E-mail: jhli@nbcd.gov.tw. 
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Exhibit 1.  Results of Laboratory Urine Testing in Taiwan: 2000–2004 
 
2000 2001 2002 2003 2004 Drug 
Case % Case % Case % Case % Case % 
All morphine positives 16,655 19.8 21,816 42.8 23,385 52.4 27,741 62.8 32,295 62.8 
All methamphetamine 
positives 71,891 85.5 36,575 71.7 22,567 50.6 24,632 55.7 32,240 62.7 
Morphine-only  2,838 3.4 8,838 17.3 13,341 29.9 13,916 31.5 9,140 17.8 
Methamphetamine-only 45,187 53.8 23,597 46.3 12,523 28.1 10,807 34.5 16,109 31.3 
Methamphetamine and 
Morphine 12,885 15.3 11,706 22.9 8,260 18.5 9,947 22.5 8,849 17.2 
Methamphetamine, Mor-
phine, and other drugs 932 1.1 1,272 2.5 1,784 4.0 3,878 8.8 7,006 13.6 
MDMA 266 0.3 1,388 2.8 4,878 10.9 2,159 4.9 2,245 4.4 
Ketamine 0 0.0 0 0.0 98 0.2 208 0.5 476 0.9 
Cannabis 0 0.0 3 0.0 42 0.1 81 0.2 119 0.2 
Total 84,044 51,017 44,634 44,200  51,429  
 
SOURCES: Certified laboratories for Urine Testing; National Bureau of Controlled Drugs, Department of Health; all local health de-
partments; Investigation Bureau, Ministry of Justice; National Police Administration, Ministry of Interior and Military Police Com-
mand, Ministry of National Defense 
 
 
 
Exhibit 2.  Drug Seizures in Taiwan: 2000–2004 
 
Seizures in Kilograms 
Year 
Heroin Metham-phetamine MDMA (Ecstasy) Cannabis 
Benzo-
diazepines Ketamine 
2000 277.33 836.24 4.93 73.98 3.44 － 
2001 362.50 1,421.01 44.65 106.99 6.51 9.54 
2002 599.09 1,298.06 132.65 11.06 2.54 63.16 
2003 532.64 3,980.51 405.63 121.17 13.40 600.48 
2004 644.50 3,165.51 303.28 38.65 141.28 613.41 
 
SOURCES: Investigation Bureau, Ministry of Justice; Police Administration, Ministry of Interior; Military Police Command, Ministry of 
National Defense; Directorate General of Customs, Ministry of Finance; Coastal Guard, Executive Yuan 
 
 
 
Exhibit 3.  Reported Cases of Drug Addicts Admitted for Treatment in Psychiatric Hospitals/Clinics in  
 Taiwan: 2000–2004 
 
Year Total No. of Cases Heroin 
Metham-
phetamine 
MDMA (Ec-
stasy) Cannabis 
Benzo-
diazepines Ketamine 
2000 2,871 1,513 1,452 9 23 315 0 
2001 3,545 2,265 1,490 164 145 344 0 
2002 7,654 6,233 2,152 251 62 386 18 
2003 8,283 7,353 1,551 152 47 441 42 
2004 12,232 11,479 2,663 103 43 431 49 
 
SOURCE: National Bureau of Controlled Drugs, Department of Health 
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Exhibit 4. Wholesale Prices of Heroin and Methamphetamine in Taiwan: 2000–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE: Investigation Bureau, Ministry of Justice 
 
 
 
 
Exhibit 5. Reported Cases of HIV/AIDS in Taiwan, by Year of Diagnosis: 1984–2004  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE: Center for Disease Control, Department of Health 
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Exhibit 6. Reported Cases of HIV/AIDS in Taiwan, by Exposure Category: 1984–2004 
 
HIV Infection1 AIDS Death 
Exposure Category 
Total % Total % Total % 
Heterosexuals 2,396 35.4 927 49.3 516 50.3 
Homosexuals 2,334 34.5 532 28.3 234 22.8 
Bisexuals 687 10.2 291 15.5 169 16.5 
Hemophiliacs 53 0.8 20 1.1 34 3.3 
Injection Drug Users 603 8.9 43 2.3 25 2.4 
Blood recipients 14 0.2 4 0.2 7 0.7 
Vertical transmission 11 0.2 2 0.1 1 0.1 
Unknown 664 9.8 61 3.2 39 3.8 
Total 6,762 100.0 1,880 100.0 1,025 100.0 
 
1AIDS cases are included; foreigners are not included. 
SOURCE: Center for Disease Control, Department of Health 
 
 
 
 
Exhibit 7. Routes of Drug Administration1 Among Patients Admitted for Addiction Treatment in Psychiatric 
Hospitals/Clinics in Taiwan: 2000–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1A drug user may administer drugs through more than one route. 
SOURCE: National Bureau of Controlled Drugs, Department of Health 
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